<SEC-DOCUMENT>0001551152-22-000017.txt : 20220506
<SEC-HEADER>0001551152-22-000017.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220506125105
ACCESSION NUMBER:		0001551152-22-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220506
DATE AS OF CHANGE:		20220506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbbVie Inc.
		CENTRAL INDEX KEY:			0001551152
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				320375147
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35565
		FILM NUMBER:		22899956

	BUSINESS ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
		BUSINESS PHONE:		(847) 932-7900

	MAIL ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abbv-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:56dec8fe-bb4b-4711-9c82-c533c008edd6,g:2a065e27-cccc-4ae9-a029-5c29f5f60184,d:c89f06320f9c4f57b19c511822f36cac--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:abbv="http://www.abbvie.com/20220331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abbv-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF8xLTEtMS0xLTczMjUz_2f32b1bd-3255-4f21-a632-9c8af16b1cf4">0001551152</ix:nonNumeric><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF8yLTEtMS0xLTczMjUz_1461bdcd-f1c7-45fd-a42c-603d57d93ae0">false</ix:nonNumeric><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF8zLTEtMS0xLTczMjUz_07749f03-cee0-4cdd-a30c-81226c3a085e">December 31</ix:nonNumeric><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF80LTEtMS0xLTczMjUz_ea03aef9-dfb4-4d97-be0d-dd7c0773f7bc">2022</ix:nonNumeric><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF81LTEtMS0xLTczMjUz_0f12976d-b790-4ec4-b2c7-788c50809639">Q1</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xMDAvZnJhZzo1YzRmMGUwYjA3Yzk0MDdkOGFiMzkwMmJjYzlhNWFlMi90YWJsZTo2NWY5YmZiNDZiN2U0OGE3YWI1MTY0NDVjOTExOTQwNi90YWJsZXJhbmdlOjY1ZjliZmI0NmI3ZTQ4YTdhYjUxNjQ0NWM5MTE5NDA2XzEtMS0xLTEtNzMyNTM_32e6e38e-d1ab-4169-aa14-6727c2fdc9d1">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abbv-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe012c9dbd240048d813949942fdca1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1500SeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13386ec6dca24c72873db6a581548a42_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a62f89becf43099721dde7ba0ee70e_I20220427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee167f36562471dab7b2f232caad9ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb1995fa5b74df58173afb77b7e467f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66fe2db515c241c0bb28d212b85279e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e8e05625504d9a944f9bade3f3867c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1feacb1a194c1d9816daa1d27870c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia427e86aee794ddda12fc9e121da41f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6accb844205d4e909ea7d6f406d2b865_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i063a456449f745c98a09be163769f332_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5cf8db55503473d9dd1af8c0d20c48d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e9540820e34b43b3e6ec3daddaa1fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9dace7c91d4297a7aa7f308de3f768_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3023971ae049339d5747605ef52a7c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980dca056e914f6385bbf2d1f0a5c20b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab26cb86a14c46ba9fa64e4b951dfaea_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf70c299b6747128fa4a148bd06c306_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7dd1b7a2964e66b89583f5e940f748_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d21af462c442b5beb00d3ba5c34925_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a07265e199d4b30a14e9e6383620f9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1929ee5ab0f4e8c9347283529630a9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9ff1d5c2f242d3acc07bc91dffb247_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa789cc1b9f041559e83b047a68991b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21ccd46654948208d4f049707193b17_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b37cb73f2d4eacace3c00d60098061_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i207acaa2165d403396ea05f332f5d280_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib201ee2f6aa040aa994d36824861b99b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95c2a9dc2507491cbed7bcc6382ac0bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf65e4946d940d7b337ee6ad83e0838_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613f449aeb814d5eb9f9f5433bf45c4b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72db22a233c742cb9fdaf4ec7205f2f1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3553129a064588b861cbad2e2e642e_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20abf2418b52449bbcdcb69db0df0b34_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9fe4ce1afbad40ee8b142ccdca3cbdf7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757157a6b1f24339a6987f24f728b796_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c90b03e0a9d4b959d426288837a1ac9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9f25b9cf5e4ee0bbe7e382b04feba9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1248f479629473abbdb6ed040285ccc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7189bfa6119440549f13eb789b20c623_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503b434bb2cd4949ab32e3eea0c0a13b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e417e1f49424cb4b129ec6ce7c723da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if70fdebf15534416b657e3efc08cb7de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b131031330347efae33d3283c798c08_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91bb22b751b4f769a3ed871c1a8e163_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6409d59d48544dd3b57e4e907e0daf25_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d0443c07a5417ca515d44ddc962b47_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d7032a627d4586b0df7536454a2953_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6abf8b13366e446b8e4d345e553af9c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id13caefd7d5a471aa354ceb296f2d670_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbf40f3d8814b2cb5a231dbbd3418e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc654c5b431f4e2c81e6d3dc971bbfce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac0e02057646439c9b219a540ab6bba4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d31e315887b49cf9383108785d5b7a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0ea0dc41fe4934b7afc79df8635743_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28ae11319ad4812a556b3a24a0d7eb8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b089c0fc324d5b82b75e000f5fe9cd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c6435c30e6b40489560149b0efd5c0b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2be7d9eaa6f4f369f0de369cbb043f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f0edb319054698965e395df2f44e5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b13ed86da2945de8f2c44a2373537a6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56e369611bfc4546bf3c8e89fd8a3f48_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77324bf397cc41f7a15e4eef24ecff2d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f1ab36dc934e39ae4bfefcbe05705e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714dfb429c6f451eb83c696c0379c6ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5007646043540a1b0e932caf506c8b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8327b6e3b446c39bc4154fdcab2095_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id430b90a4b4b4e00accb2dafe2190824_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f4c4b3745f349e198629a93da34561b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e8c16288ca4a859ec70b21f89ef7a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a368d5034e44f028f602236d3ab8057_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d0578582acc4184bae1fe1a5d03842e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d7cd1d96fd463d81f7b441a15f7907_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e773fb160f4868b7b34f01835f244e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4dcf7772a434cca8535434fc724868d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c27a6d499a4374bb62731e6ee3c5ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea6c9f4ab71401f8e112e105b0a87ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c87abe9559493098137ef93eb16897_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56fd5370a66349abb5a708fcca3df153_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5c418235f74f58be5d142972173da3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i1440f6810115464aaba75d7ad2e205fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e04d5b1b77e42338343cb7a394365ac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1c9540265a40ae89ed8e5bac26055b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0695b54b4eee4244ad7f53879aaf2b88_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3023f47a89be437a8979714fa7aeb5ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae50d2fb61c84091860a38b122dcec5e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3896b7812d9c4f458a6ee1c222fdc5d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf844e180d3a469caf77cbfd640ee06a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278c392732fe405ca9790ebca84a2b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2759b8249f9b4c0abfb4b6e0d5d1f19a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ebd92b09814dbd9c34016fbe056f80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37efff4161cb4c0493595e73c1b6c251_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42302eafa7c143eea1f93c5698a3de9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a96d28015b45949c078f6766332529_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8fe28e93231442a879e677d581e007a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f5ff90441c477985db4a043e94ba99_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i081e9eccbec84d14b3e5e990418ead24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2762b41ed6f34461bfde8f1333fdf996_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6c7748fb844f8387515876c985d86a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i435b30592ac747d989c50678808fe1d0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e7a78e77c640c0978087e1e5aa5365_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20d6c5cd9154d11b748fba274562228_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec68c25a887f49d4b34b8179ed6dda01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24765f81c1fb4287a6f15e1f08b37561_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84610d1bd2b740fb98e00437e286d300_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099396de57cc428db3ba3fa6496e9806_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb723c8d7d94576a2e267ad0bde0d6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84f403b6217414e9c4727bdaddefefa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993003f0c8794563b176024ce0433091_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6856ef91ba4d929d656629013d3068_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie282fe45ad5d4fabb47f2e2e934d4440_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621e08f15f004824aefad73ab5851795_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179bb4a086e74b04bc986f5bbbb847c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed7b475bcdf40e59be351b723196753_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ba58f0b4804781a450e1eafe670429_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a0138eece144c7b6d7536ce561b961_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e338b61d1141f5b8c13e661709f6b5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7bd97603484ae1802843d027d4882c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1681dbbb7fe645d6853c751bdc56bbad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed8d036846c41e7ae1fd8954a4b4f77_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f7ce3635354a61a150bfdfc38169f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id741975d93ce432ca3360bc759262c9c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib000460db5074562808f7f1eb5c6419e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f6fa4fbbe04394a9fe1a7d581eaec0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64b83983f224c629b47278996994efe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ba7efcd0f44228bd851a9cfd907eca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79203b4f0e042919ad95c75b6c9ed1d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3338f9b94ba644cdb8a5bfb1a5c29358_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib576612385b34159a385efbbb44ac312_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2ab8d0faba462a8cdae1d115c9ac72_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859211caa6b54eaa83b28f597db71274_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38e263f9b26407aad657967962464cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab718c63b5884ec79c89e37caa022504_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d51b5f39b30417591b468b9cc37d240_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a1275578fd4eab9c1a98a3a69b8994_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547378d779a94424afb2f81c95c765e8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifced2c43ef9a4921b504c12eeb7b2ef1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0d7604169c4be790295c65966d9417_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ad1758bd2446cea957f2ad4754f617_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e694d0a849640f2baad8365a826d153_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa6a41f682746a8ace32ddbe43016b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af1965f163b48ea903e4c8e2f20baed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if649f364c260430e996cc0e7faf77825_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b425e8bb2fc4bf98f7703e322eb47ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2a58ae48e34c639ba8dc2259cc6bf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib99530b1ca1f4637a531747b189b68e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b92c917f6c46e8bec270fac1ab97be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ad90d3c5e24243a4f6eb626050ecbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c1d4df013d43b6a59943a73db0d1fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e05944c5ce844a18dea78c42fefb97f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2306289346ba4f6eac115558f89ffb15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if76fd003b44e4e00b01dd0219527e8f6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3316afc52f864995939b74f4200c4d5d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41be7ae9a7746e29ab56e1c3957336c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaaf5c1772824540821269f5a7d5d060_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6a0250795b4caeb9007fccb2fb25e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7064869e3d004e11826a6f8e545956e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e23bbc802e473d941d50ddec1eac96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc34b4f0b824400cb3e06c112446fd78_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa6c770a5e4e43219c664f8eeaebc92b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeca827be1174ca8b3b26a2dd3170414_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6e00071bb14c0f9134687f14d184c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f7d8e61c394c11942ca3d90870ce76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36a5db71b7bc44afa79f34197c0d50c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7bbcb6f78a486c9aaaf2cc66ad620a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a58f36c0a0f455fb16aee3fddf5e537_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4ab8ef49f6437ea3dc95bf05981bfc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088dd727214a49e5bdaa60f93779a823_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3155754d608b4eb491cdd36b45bcc5de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86308a2e6f2a4ecfba5255d3af29d432_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9678c4caaf349ba8006f44b404b1b82_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2bc0b8db334803be5cea99172bad7f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc8ba9e255b47fbb82c3c726dd8508a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1455f288cfc245b69c8e6fa1ee29a92c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i653e387441bf474ba40509d89d957072_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d4a0312e1a42c1bbb49eebf6fb2dbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f0399851154ccb8d747ab261a55ff7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e22014612a6456496ade50c3c0e598b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6150f60c782f4bbe93e9e862b343af55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42be951e40b4522978f85dbcf5c6c5f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077c77a1980b4f8fb626087d04f359c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0cf7b896574cd48467e517534d6c7e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f1f25b805ee48a38221900a8f4ec23b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c49899324342418b3c03ecab096e69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c93bb319518438dacf0fb870fcabe09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3079fe6a94b4043bd136bd42880f7e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaafb386815a84014b6e79d88e23df483_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i683f0aac0c634dfca6b9b368ab20372a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb19f61a177a44cc83608f369fc35200_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95aad88173d14db798e85a935c24c68b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>abbv:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i6a1415a76d304bdd903790a631d4b562_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5fd10e4797b4759b2ad9ee884eb18fb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb70f3e9a3064175beb5a4288f9555cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598f780a95a34397b93cc33d29482fbf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if319dff6fb6d4c9b9e70b7590afec644_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24046754e794d98901ac09a9a57728a_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia646a389a6944ee39075a400a0260d9f_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf4aed6ce494fb0b76f1715e4bc5fdb_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d290b478df340cb86cfefef5344e881_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025RefinancedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79841cf14ea346c48bdbc856f1e4b860_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia88ba3758b6c416da9c9db84a7ca5778_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f9a43336ae4b0da381254b468ae09c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7badfe6657634d348d22e9be1faa35ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54988d2c4f2f40c2933727e2b8be27ff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3001aef538c54c44b5812a99e4845adc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf3ce65514c443c8ef37159d35d4a69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e56837ed6bd423c89d802b44906df17_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic438b74601344b28a5a621e09638dfa5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bcd77a684aa4ecf8e6a62f0794f8418_D20220217-20220217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-17</xbrli:startDate><xbrli:endDate>2022-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e438a1448d44f418e9b8f452ccf2783_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2670f469a2ac4a459ccecfc909f364ee_D20210910-20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72db19201e77427a944de55507b7fe80_D20210617-20210617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-17</xbrli:startDate><xbrli:endDate>2021-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300fb3fc7b084fe1ae13da9f57c82d71_D20210218-20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib694cd894894414da5c46138d815dd90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bcc50f777fb4122a035380de5a8418a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30d113b6de524e999e45640992e7d5f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic307ce6fcfdb4b95a357b18194e6695a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4482ed129142548aa3b7aba9e6e05f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b80412b07c14765b60765c6863daf16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i305d5315aa3249959cf54167f51117a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19158d14e728497cbede5b260b0904be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38cbefbb7640470d8912c518f4d612c4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0749feb42e4416b8b7650f417a1131_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8127b3ac3548c3890da55bf63f1701_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice36e374d1fe41cd885017f660510ca7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00bc0c90f91f4af0a5a3a88ab5477eaa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba4be4766064887868cd838db3129a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ba96e9d518432f846efbdefd0568c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfa61ba6e74c4671b7c09c21de67bea5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f7baaa43f94988beb4cab455519ed9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef17bd343cf45f4a0064de2b7b25559_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32fccc997a0749b1bb81108be62eb6e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157ad54cc34c4b9e9f5f62ce15e5c956_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcc473aa8ebe448e985aa0a29dcd7e8c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce7636b82d0488790d551ca1286a964_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0c4dc2984f481b92d6852e941b91b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115d67da01e8464594d5f3097915285d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2a39cd4e914c2baf4e3f7f78e0e037_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93484cb8e084701be386a098217dd41_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac58012cb8394749b3da275880c656bf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8aa0c8a5684d66952c25dc6e509fe7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ce39b3335d40a193f5da7859d3e742_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c8e4e34cdc418dadb3f7f36b8d5041_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2761b85b027474db273e8bb0d34f65a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd179fad6a84747bceee1f796370db1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:NiaspanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>abbv:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="class_action"><xbrli:measure>abbv:class_action</xbrli:measure></xbrli:unit><xbrli:unit id="direct_purchaser"><xbrli:measure>abbv:direct_purchaser</xbrli:measure></xbrli:unit><xbrli:unit id="end_payor_purchaser"><xbrli:measure>abbv:end_payor_purchaser</xbrli:measure></xbrli:unit><xbrli:context id="ie9849c3641274f60b03fcb8763315cdc_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="company"><xbrli:measure>abbv:company</xbrli:measure></xbrli:unit><xbrli:context id="i2876ad381a314d1492fed65c7ba60831_D20190301-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061f6899a2e64d8b9f6710d2ffdaa440_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:BystolicAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b950ca2895a442093c6358346b89e00_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>abbv:claim</xbrli:measure></xbrli:unit><xbrli:context id="i0d6b8a8607154239bab327083f4f2a16_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c041511930545c890fb52c2cac408df_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="investment_fund"><xbrli:measure>abbv:investment_fund</xbrli:measure></xbrli:unit><xbrli:context id="id8b1a9f1c7674ab7b5a46fc570730aa0_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49c8cbd1c924c69b51d6bd1f5088886_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d814e2470641b7adca70c8dfd22826_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7d8cd18e85b4007971cea988abe2864_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86efe50966f24c74849d1de4249000b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1053eda3554c3bb53ea7f9f667809a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8620bf3edb45e497398d57317e67ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151f76a6bb394b0e8dc33fbdabffeef4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9dcf0e2a5bc4237a3420a8ed35591ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a121fb3a1a74d08bb6b193989e4706a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7e3bfd63234b9987cf846478a441fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8267ed584474c71a1ee8dbc54f58ef8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f415caa04a941a3b6c40335ad6d10f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1c4e6bb026457da1f4cdf7df42c5f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38c669542ad4085a09a271f057f90d9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0dfe507ba24433988668a7d003a378c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89a047a7f15451fae62f0586e4244bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4d1ef4d3c3472f8587646493588ca3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06547d54c7744ec59245e1aabe7bb4a9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68fecb4ba92b444e8e7c4082e3cacd88_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c7fad38a034510aef4faf293e98042_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2609235fb4a14a5fa8a9ae2ce41de85d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83dd8a4923b14d1e9444794bdc3c9fa3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839ac535845b43fe8878c6e026ae540d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia88dc4f478b445c989df2931bf4129de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b31104dd4f4b588d5964c0a59fc7d9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0a5001dda54d03b17d99d99907ef72_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc2f01f0a3bc4965baed776f9c1ee2ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd7e7447fe34c6287942f568429ef69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd103eaea8d4b81b307a47031308a2b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21887679ab4450e9854e11b52987fd2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca3b9d904a042d1be012441bfbfbbbc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i646b3499eac046a9a4d0c7b552528647_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d51184fb925493e90b9ff271b8ba444_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf374b782644e749678d1f567eb3bc1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231632e602304cbcbf663af9260ff447_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d97cd1c204d47a0894f071baccfb3dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485c4f314f4d4d4887041a01bca64c2b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia81395f4f3fa48e8826d79041d865c17_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5523e96c483e4a5a83a81a78cfdec571_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bf9f5d90ff4778afcba822173f993c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ccf536e0504054b9c01fbb9c17051f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68379647466f42ac98da932e0ae7ba56_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9a74c5d27b427db7df5b72e0ef9e71_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9886797304fd44789c0dae1792702122_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1192611baa7144ae9f6aa9bd6469b73f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f45042ba49947aea027157aa3e5005e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6297715bc8540428f641904958468e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274365a0958a49bb88080cb48c332ccd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aeec465d3b44d6d836a7f5d22f41e34_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic117a05f0ad047458c3dfdf3d563d985_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0aa0c6e5e8e4e86be8c148b66aedbb6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f1b5410e4a4e8fb9abfa2219b13d78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78f3e2ee61c499ba7cc0746a2385d47_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdbacd087ccb4b378166217f2e6bac38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b0f54b6f66490ea61e7105a06bbd5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff614778cc44cd498c6a9c8964075c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f19775fa7fb4454916890a2d18f7368_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3125d8c421f84befbfdc8c98d0f12733_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c196d5476444949e789bed861f1aa6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d5f22d6d24942c5974fd185d2251f6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf4bed28ef04a34be1be2775ace098f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72f22aa56674f6ea95b38deaf7d7ef0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639f02ea2ac340d384b27444a35f86c5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f9dd7d8685493e9094a8411dc69ba7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5cc0c791ad4deb82c1071bb2540517_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d3e94281d14e1ead6013f512d2ba56_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18fd6150a38a4e9b9bd77ea967639212_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512cec6652ce4f19be4c4e4462feb4e8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b4fe39a35de44ecaa3535608505ded0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeabc0e9b646406e88ddb1c5e1f12518_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12ead842eee42f59b1937c152fb8415_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67b003e0c9d489a93fc432063b0605d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a38522757a47f08bcaaed26cc95890_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b09878f9324ebc81010863a7bb2312_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b43137ee1c4af9956280587d60c83c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae85b406a18e40d7b2917cf2e17d0b83_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741797da087c4ef6a3b16e0b40c35175_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34cab53f8594ff4979a946f5a3fc1f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85cd48264009438ca440c693ab0cf2f1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc8282031784d8caeb6a4ef809f2f50_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a85e57b458b4094a0c62505b2a9799e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50fb763a0f1c482a9572f571170e440e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93307eafe6504d879af164c82b04eda8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46e3aeb263045cfbb0acf95c88c121b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a77a42b923942bfaff4dc08627c3225_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief85b551045345879ed1be64c67a8b4b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf3d5f2dfb344e59a6c9efc465d8f5b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62a015e1747449791ed3c131fc6f351_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf8ded17cba43f7b08f7d24f7aed016_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2c9be5775d49e7af0a83f0b14fce7f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddf6b053a5d4cf1b48234a1c15b6c1a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882c0ed4b6454d5db18fd823a31bcb88_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf25850c2d1c4ceb840ecd9bfee2891c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife17341a39044007bd37eb3dcabab9af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379b152b16b1407985df7a9d9e3ad633_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6df2de6a1db84a14bc36698e3dbcbf51_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a92b2ecc5f4aaf9d8351f86caf7be5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e933b76f7264c7cb306a5779cb4d526_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bf38d011cc4cfd9351b1938594689b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e746d238af04e0fba57b391911704b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59295dec623542dba93f26a4df9b7bf3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieefe0806b5ac487fb58df139e942b4bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic251b48766744736852af8a750fb5fa6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9748feec04436daefd70ed8fde5035_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ca6bfcb2a742d2a419a770b28a65e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ecf09fad83434f8b75838cf1459dde_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6fb7ab9f9404aa4800b094182ef46f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9915235f3a844da69814226e5774c2d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4538d383a2c14cac819e3ce9bc8a27c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531f3349e8c348c39ad330ddd7567561_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a8b6f17bd484927bdf4246fdc7d2e83_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092297541dd04ee2b04cfdcfbb71eef1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143c59ef117840e5b84f10e564ee91c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>abbv:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_5d256177-b7e1-4915-a8f0-e491dbb9f298 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NTA_04ada94e-64b7-459a-a5dd-adeb4f6ea353 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NTg_1139f260-ebf0-4997-a8bf-8e3e9c1797b3 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NjY_34203fed-736d-478f-9829-5ad6abaa8128 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NDQ_7949dad9-89a4-41ee-b66a-7fc7207216bb id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_2255b661-58b9-448c-a8da-5793bd88bc4d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNy0xLTEtNzMyNTM_da5e13a0-ba04-43e2-9ccc-697be415ecf8 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNS0xLTEtNzMyNTM_c3509005-a607-426a-a140-90bfa6a40cdb" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2Ng_339b42bb-9e96-46ac-89bc-283f924a8cbd" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy03LTEtMS03MzI1Mw_e0b01168-ad34-434d-9854-14c860bb3278 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy01LTEtMS03MzI1Mw_5de29469-8128-4032-a9fe-d194d6935866" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwOA_4e00e857-6c03-4577-bf53-0941bd05ee5f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy01LTEtMS03MzI1Mw_dcbb1f13-4991-4b76-b758-f7b88b8d660e id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNS0xLTEtNzMyNTM_5e757465-320d-4d59-890d-c8493a2521aa id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy03LTEtMS03MzI1Mw_a9d9e243-873f-4eef-b19e-5939933a8100 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNy0xLTEtNzMyNTM_9dfa7b53-a718-428a-84f0-a2b6048d47ca id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNS0xLTEtNzMyNTM_f5d8bf1d-c1fd-4481-bde9-f036b794d7e1 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNy0xLTEtNzMyNTM_d33aba04-37d9-4799-8851-d1a29a61115b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0yLTEtMS03MzI1My90ZXh0cmVnaW9uOmQ0MGEzNmJlOGMxYzRjM2RhOTE4ZWYwODI5MTZiYTcwXzI3NDg3NzkwNjk0NDQ_22cd617e-882f-4a62-a3a0-f377e022ebfd id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjgzM2JmZTkxZDBkZDQyMWE5NDI5NmQxMjEyNGE3M2MzXzI3NDg3NzkwNjk0NDQ_274ad924-0f34-4f79-977f-36dc21f67545 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmMzYzcyMDAxZGQyNTQzNTRhYjBjZGRmMzEwOTkxMzQ0XzI3NDg3NzkwNjk0NTA_f621a23b-df7f-4771-a959-3f4a432c6de1 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjc2MzFmNTcxMzBkZTQyZjE4NmQ5MmEwNjk4ODM5MGM1XzI3NDg3NzkwNjk0NTA_6fba84dd-6dc2-4522-a73d-12e386424d43 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS03MzI1Mw_1e8fbd73-3e85-44c5-8cfb-b0e0822a4975 id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmI2ODBhMDkwNGJjZTQ2ZmViMjljYmVjY2Y1NGIzYzMyXzI3NDg3NzkwNjk0NTA_cef10409-9e56-4640-b348-5c474e51230b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ic89f06320f9c4f57b19c511822f36cac_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQw_98c684f0-5d68-4c05-9fb4-d482d42099b2">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUw_b366d782-728e-42cb-a4dd-33c8c4e5b86b">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMjU_e363e7d6-7ae6-44ba-aad3-0a44f7d01a96">March 31, 2022</ix:nonNumeric></span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUx_40be19cc-9daa-420e-a506-194298569fe4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;to </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQx_9cb39a2b-a4dd-4e3d-b534-5907338cba66">001-35565</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><img src="abbv-20220331_g1.jpg" alt="abbv-20220331_g1.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:164px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ0_824631c1-637a-47b6-bd18-d6973a27daa7">AbbVie Inc.</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6ZjBiNmQ0MWIyNjQ2NGRmZjhhY2U2YTE1NjJkNTlmMWUvdGFibGVyYW5nZTpmMGI2ZDQxYjI2NDY0ZGZmOGFjZTZhMTU2MmQ1OWYxZV8xLTAtMS0xLTczMjUz_ff788997-1dd9-48c4-be55-361072a46e57">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6ZjBiNmQ0MWIyNjQ2NGRmZjhhY2U2YTE1NjJkNTlmMWUvdGFibGVyYW5nZTpmMGI2ZDQxYjI2NDY0ZGZmOGFjZTZhMTU2MmQ1OWYxZV8xLTItMS0xLTczMjUz_c8deb2a9-f8fe-46d5-80d3-1f891bffafb9">32-0375147</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. employer identification number)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></div></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ3_9f65a209-5ed8-4087-9578-b2a2ce7fb52a">1 North Waukegan Road</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ1_436136ae-d57a-4cb3-960e-170bbdab9a3c">North Chicago</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUy_f7d2f17b-93c8-4b18-a52e-9a67c370a9f5">Illinois</ix:nonNumeric> <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUz_08defa2b-89ee-484d-88c6-6136da3fe129">60064-6400</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Telephone: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQy_b864d910-1a7e-4f2e-bfd2-28e68e1c6a7b">847</ix:nonNumeric>) <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ4_a6b77ef1-98b3-4290-b63f-bd3f37e2219e">932-7900</ix:nonNumeric> </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQz_e646689c-75b4-4a58-a619-6e7d39aa8e96">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTU0_ab44d58b-fcd9-468c-8b0d-23dda50eec46">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6Y2FkYWY5Mzg1ZWY0NGUxYjg4YzI5OGNkMjYxYmIxMDIvdGFibGVyYW5nZTpjYWRhZjkzODVlZjQ0ZTFiODhjMjk4Y2QyNjFiYjEwMl8wLTAtMS0xLTczMjUz_1472dc24-8c02-4dc4-82e0-43c7951e8f41">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6Y2FkYWY5Mzg1ZWY0NGUxYjg4YzI5OGNkMjYxYmIxMDIvdGFibGVyYW5nZTpjYWRhZjkzODVlZjQ0ZTFiODhjMjk4Y2QyNjFiYjEwMl8xLTMtMS0xLTczMjUz_2395a486-8d1b-454f-acb4-83fcc17cc999">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6Y2FkYWY5Mzg1ZWY0NGUxYjg4YzI5OGNkMjYxYmIxMDIvdGFibGVyYW5nZTpjYWRhZjkzODVlZjQ0ZTFiODhjMjk4Y2QyNjFiYjEwMl8yLTMtMS0xLTczMjUz_7f3accdc-4642-4aaa-beb7-90423b739706">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ5_85120a9e-eb6e-47d4-a780-763d5d45c07f">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTAtMS0xLTczMjUz_024a3240-fef7-46c3-99b5-93815b5a9dfd"><ix:nonNumeric contextRef="iffe012c9dbd240048d813949942fdca1_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTAtMS0xLTczMjUz_a0cead0a-8657-4a4e-ac0b-e3e38f1eef99">Common Stock, par value $0.01 per share</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTItMS0xLTczMjUz_ce10e4c9-4b43-4d4b-972a-579877d6376f"><ix:nonNumeric contextRef="iffe012c9dbd240048d813949942fdca1_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTItMS0xLTczMjUz_dcf6c143-0703-4fe3-b749-3502e796a150">ABBV</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffe012c9dbd240048d813949942fdca1_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTQtMS0xLTczMjUz_6cf3ab2b-ffa4-481b-9e75-3baf482bd6ff">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8yLTQtMS0xLTczMjUz_c51a9dd8-49ef-4029-8b7d-b2fdf836a524">Chicago Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8zLTAtMS0xLTczMjUz_8de0921d-610c-4c7e-9a2a-112814189a93">1.500% Senior Notes due 2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8zLTItMS0xLTczMjUz_da6c4f5b-b837-41db-a0f4-aea2fce3238f">ABBV23B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8zLTQtMS0xLTczMjUz_bff6c4cf-81a9-43ec-bb7e-19224d30c9cb">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl80LTAtMS0xLTczMjUz_8131ca33-47fe-494c-9dd0-b458c5417925">1.375% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl80LTItMS0xLTczMjUz_ca54a00f-dd10-4a63-8741-39d1adb8f637">ABBV24</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl80LTQtMS0xLTczMjUz_82de2794-2685-4dd3-93a4-647e5b1c3dcc">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl81LTAtMS0xLTczMjUz_213ff2ac-b01f-4fb1-9025-9f3f83af2f83">1.250% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl81LTItMS0xLTczMjUz_64ed4422-c691-45fe-8c9a-71f5367447e7">ABBV24B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl81LTQtMS0xLTczMjUz_c48e3414-883d-4e24-9690-4a4b57faeb61">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl82LTAtMS0xLTczMjUz_9cf0fe32-2215-484a-8317-d769db189b0b">0.750% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl82LTItMS0xLTczMjUz_619359a6-93f0-4d17-bbe3-f84029ea30ba">ABBV27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl82LTQtMS0xLTczMjUz_bdebec32-8eab-4ee2-aa2a-cec048d323a5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl83LTAtMS0xLTczMjUz_919d488a-ae2e-4c1e-94a4-c11350aa190d">2.125% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl83LTItMS0xLTczMjUz_fe87b0e7-0f62-4283-961b-00bdff043806">ABBV28</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl83LTQtMS0xLTczMjUz_8e45cd2a-fc10-4f95-a19e-ef4735dfc807">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl84LTAtMS0xLTczMjUz_146c0083-638a-4962-b54f-8ff5203159f6">2.625% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl84LTItMS0xLTczMjUz_fcf2e39d-3e49-4ce8-ad44-b260b02e1d42">ABBV28B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl84LTQtMS0xLTczMjUz_90478eb0-5495-4252-9116-4b31e712942e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl85LTAtMS0xLTczMjUz_9a8281ff-10a3-4631-bee7-aafc3580815d">2.125% Senior Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl85LTItMS0xLTczMjUz_c87b8e02-a187-4a84-abf4-f763d8cb058a">ABBV29</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl85LTQtMS0xLTczMjUz_1d29d022-9105-40a6-9e10-1e57abb51a2e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13386ec6dca24c72873db6a581548a42_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xMC0wLTEtMS03MzI1Mw_a479ec9e-a50f-40e9-a501-6ff6e3482b17">1.250% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13386ec6dca24c72873db6a581548a42_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xMC0yLTEtMS03MzI1Mw_bfb06978-daf0-431b-92c3-00a83b360f8c">ABBV31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13386ec6dca24c72873db6a581548a42_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xMC00LTEtMS03MzI1Mw_3e9f3fc9-c1b6-41d1-8abe-43faa975c980">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of April&#160;27, 2022, AbbVie Inc. had <ix:nonFraction unitRef="shares" contextRef="id0a62f89becf43099721dde7ba0ee70e_I20220427" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMDgy_b1d1ec92-c720-478f-9682-29ac6fd3428e">1,767,110,083</ix:nonFraction> shares of common stock at $0.01 par value outstanding.</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries</span></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_10">PART&#160;I.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_10">FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_13">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_103">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_103">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_103">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_139">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_139">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_139">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_142">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_142">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_142">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_145">PART&#160;II.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_145">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_148">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_148">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_148">35</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_154">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_154">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_154">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_157">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_157">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic89f06320f9c4f57b19c511822f36cac_157">36</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I. FINANCIAL INFORMATION </span></div><div id="ic89f06320f9c4f57b19c511822f36cac_13"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div id="ic89f06320f9c4f57b19c511822f36cac_16"></div><div style="margin-top:3pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries</span></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings (unaudited)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions,&#160;except&#160;per&#160;share&#160;data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMi02LTEtMS03MzI1Mw_1ea9b709-5d26-4b28-acff-0aa6a9ec0628">13,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMi04LTEtMS03MzI1Mw_4b97deba-9eb0-4c71-8642-87fe56902709">13,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNC02LTEtMS03MzI1Mw_0e3cfa95-64c9-439f-833c-cee6ffe28ec1">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNC04LTEtMS03MzI1Mw_f90c9b7c-8f49-4be2-8337-df4f9ad32195">4,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNS02LTEtMS03MzI1Mw_0b4d8aeb-9abd-4b12-83aa-1f89fa80e23e">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNS04LTEtMS03MzI1Mw_d2afea1c-2201-46c3-a71a-00af4157276f">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNi02LTEtMS03MzI1Mw_1c6c7d79-ce85-42b0-ad22-b6d4f55bbc85">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNi04LTEtMS03MzI1Mw_6f254e22-5077-4d46-99bc-6b2911d3f57e">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNy02LTEtMS03MzI1Mw_d3a0d7fb-9152-4301-8443-63aaed03d1ad">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNy04LTEtMS03MzI1Mw_7e528561-c68f-4dbe-901a-09717b6f8c00">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfOS02LTEtMS03MzI1Mw_b185af68-cdaa-4261-8c55-ee3a21ed6fcf">8,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfOS04LTEtMS03MzI1Mw_734845ad-3a60-4f5b-a735-53e2ddcdc639">8,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTAtNi0xLTEtNzMyNTM_1467b817-8a34-4c97-9d87-ca0e047b728b">4,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTAtOC0xLTEtNzMyNTM_e99e3278-993c-4ba8-b2e3-cfadb4935232">4,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTItNi0xLTEtNzMyNTM_6a7c802a-901b-4f40-abd8-43b850233992">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTItOC0xLTEtNzMyNTM_36520dd3-e193-4c95-a8ce-659eb6daadd7">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTMtNi0xLTEtNzMyNTM_c1f21e38-4ecf-47e9-874a-76d7d501bb15">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTMtOC0xLTEtNzMyNTM_0b60e52f-5e8a-4321-9e1c-3888166fa973">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTQtNi0xLTEtNzMyNTM_acc7a249-eb75-4719-a75a-c0ae616fb3a3">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTQtOC0xLTEtNzMyNTM_7e5b3a10-db2f-4675-941b-00eb2f86a320">395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income tax expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTUtNi0xLTEtNzMyNTM_1f521ff4-023e-4eaf-bded-3fcdafd7ede9">4,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTUtOC0xLTEtNzMyNTM_8c73c419-b9bc-4dd2-853e-339e6de88808">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTYtNi0xLTEtNzMyNTM_b0f5ba17-1a9e-4ef1-87fa-0db943e2d278">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTYtOC0xLTEtNzMyNTM_7ae07da7-50da-4855-afbe-2180b417c635">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTctNi0xLTEtNzMyNTM_239139ca-22f5-433c-b154-acc1dc0bded7">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTctOC0xLTEtNzMyNTM_854a3453-e970-46c1-9e52-95b62ecc8d09">3,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTgtNi0xLTEtNzMyNTM_77571f51-7e99-4d81-9fdc-560a71c96392">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTgtOC0xLTEtNzMyNTM_70c73fe4-9bc3-408d-b6bd-d7ddf7505ce8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTktNi0xLTEtNzMyNTM_bfb43cdf-32f7-4e0d-b63e-47171420bef6">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTktOC0xLTEtNzMyNTM_6c4acd5e-e989-4f09-a749-38b57b07efda">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per share data</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjItNi0xLTEtNzMyNTM_ab857fc3-1ff9-491c-8ca9-a8060de0b2e9">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjItOC0xLTEtNzMyNTM_d28524c5-9263-460f-af48-6d9ae0a7c9bf">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjMtNi0xLTEtNzMyNTM_16ff6acc-146c-4494-a4fc-4d3c84b333ff">2.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjMtOC0xLTEtNzMyNTM_e0961706-c156-4b2f-b7ec-d9f9251858cf">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjUtNi0xLTEtNzMyNTM_687c5be5-79f3-497f-b91e-8e74a7c7c243">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjUtOC0xLTEtNzMyNTM_8f078004-9a5f-4e3d-8f18-d13777b8ec11">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjYtNi0xLTEtNzMyNTM_76fe9945-2acd-4f1a-ab58-3983957c3817">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjYtOC0xLTEtNzMyNTM_c8689ae3-d5b2-405a-8476-08cfe2b24e06">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">1</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries <br/>Condensed Consolidated Statements of Comprehensive Income (unaudited)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.705%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMi01LTEtMS03MzI1Mw_e5b2c256-f167-4f33-8e95-738b438d0570">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMi03LTEtMS03MzI1Mw_be1af1e2-9883-4581-8b8a-f1a0da6396a5">3,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net of tax expense (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOmY0ZjEzNDc2NGFjODRhNDY4MjVlYzM1Y2YzOTFkNDI5XzEwNw_0e846dd7-274a-4089-b863-d31d8f2c98aa">7</ix:nonFraction>) for the three months ended March 31, 2022 and $(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOmY0ZjEzNDc2NGFjODRhNDY4MjVlYzM1Y2YzOTFkNDI5XzE1Mw_e8cd5ec1-ebb7-4209-b2a8-99533efcf9bd">25</ix:nonFraction>) for the three months ended March 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC01LTEtMS03MzI1Mw_70dc080a-cb1a-4be7-9da4-db67f848d276">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC03LTEtMS03MzI1Mw_798de2e0-3719-4de0-9729-188832c55c4a">677</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedging activities, net of tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjc5NjA2MjQ4MWI1YjRiZTZiMDk4ZGY5MDNjZDRlYjBhXzk5_28b7d043-e650-41c7-abdc-8b87a4805830">37</ix:nonFraction> for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjc5NjA2MjQ4MWI1YjRiZTZiMDk4ZGY5MDNjZDRlYjBhXzE0NQ_253583b1-c5bc-4253-9944-f64f2fdadb62">103</ix:nonFraction> for the three months ended March 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS01LTEtMS03MzI1Mw_c28da181-5d2e-45a2-a8f1-0f25b9addd76">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS03LTEtMS03MzI1Mw_460fa9c3-1937-4b51-bece-7d37d6569a4f">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-employment benefits, net of tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjBlYWRjMTdhNDExZjRmZTRiZjZiNGVkNWJmYWRlMGY4XzEwMg_b19e5138-7c00-4cbb-8bd5-261772be5129">10</ix:nonFraction> for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjBlYWRjMTdhNDExZjRmZTRiZjZiNGVkNWJmYWRlMGY4XzE0OA_db083b78-e7b9-49d8-9922-8a67833437eb">19</ix:nonFraction> for the three months ended March 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi01LTEtMS03MzI1Mw_0852afd1-ccfe-4252-9886-14736fcf8976">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi03LTEtMS03MzI1Mw_839e17bd-127f-45a0-95fd-bbf7094e3538">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedging activities, net of tax expense (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjEyNTBlM2JlOTgxMzQ0NTRhZjZjYTMxOWY2NWNlYzZmXzk0_6a2f6c77-0238-427b-9d8b-d5577af7ac13">2</ix:nonFraction>) for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjEyNTBlM2JlOTgxMzQ0NTRhZjZjYTMxOWY2NWNlYzZmXzE0MA_a462e94e-e424-4670-b7fc-45d84569ddbf">3</ix:nonFraction> for the three months ended March 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC01LTEtMS03MzI1Mw_6a820093-efec-4899-828f-7fdd15f24551">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC03LTEtMS03MzI1Mw_935e7c51-bdde-4e95-83c0-c0146f465222">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOS01LTEtMS03MzI1Mw_f6dcfc62-adad-4f8f-bcb6-3558f628f51a">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOS03LTEtMS03MzI1Mw_feeeda83-1948-4a60-a8f9-36a6f0c79d29">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTAtNS0xLTEtNzMyNTM_24157632-c44b-4631-a557-d11439da975b">4,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTAtNy0xLTEtNzMyNTM_1a462c34-1e24-47d9-850d-2a2e6989b44a">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTEtNS0xLTEtNzMyNTM_5dce1ca9-b8d9-4882-b4f3-2605b8f24aff">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTEtNy0xLTEtNzMyNTM_3d3580d7-a0d5-40b6-8dbe-42311da99687">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income attributable to AbbVie Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTItNS0xLTEtNzMyNTM_6e5ca759-4a06-45f5-bbd1-fa1646c07d62">4,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTItNy0xLTEtNzMyNTM_e9617d3d-9f0f-4fdf-8f35-6c8ef4799dda">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">2</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries <br/>Condensed Consolidated Balance Sheets</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions,&#160;except&#160;share&#160;data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNC0xLTEtMS03MzI1Mw_8316afbd-0055-4c3d-99a5-e010155aaa37">6,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNC0zLTEtMS03MzI1Mw_c7bb1c16-dc87-4952-9e92-c2f45e4bb6b5">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNS0xLTEtMS03MzI1Mw_f55401f6-4fa9-4e98-95df-89f3e3bc83a8">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNS0zLTEtMS03MzI1Mw_5e828f2a-87f0-469d-9c13-91fd018493e5">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNi0xLTEtMS03MzI1Mw_2bcfeecf-3789-4e26-a973-9c6c2658a108">10,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNi0zLTEtMS03MzI1Mw_2b4ce90d-70d7-4989-afc3-4f90e371fbdc">9,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNy0xLTEtMS03MzI1Mw_29b4a77b-473e-465a-b0c9-081b0a4eba6e">3,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNy0zLTEtMS03MzI1Mw_336e1585-f647-4135-aa66-bb15a4e0bbdf">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOC0xLTEtMS03MzI1Mw_ff7bcbee-26af-419d-8d26-baa81fbde169">4,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOC0zLTEtMS03MzI1Mw_ee90aee1-a3ae-4e46-823a-3c06a7f3ca20">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOS0xLTEtMS03MzI1Mw_fb6d43af-a2f0-4a67-9884-633a821be8e8">26,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOS0zLTEtMS03MzI1Mw_6fd61afb-3843-4a12-943e-1d756adf94c0">27,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTEtMS0xLTEtNzMyNTM_577f6504-c098-48c1-84aa-a9f1f8969df4">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTEtMy0xLTEtNzMyNTM_f9a6a77b-8b60-4c52-a7a3-5b0ae0f7f11e">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTItMS0xLTEtNzMyNTM_9aa46c53-8aeb-4d3f-afab-9b3add98115e">5,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTItMy0xLTEtNzMyNTM_3f320dc6-b648-4487-87a5-01d6dc5a90b8">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTMtMS0xLTEtNzMyNTM_12f3abf4-3aa8-4001-9ffb-9fc27ef4d9a9">73,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTMtMy0xLTEtNzMyNTM_b02db59f-6e3a-4556-b9ff-d2b09ac647ba">75,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTQtMS0xLTEtNzMyNTM_2a97da31-2b0d-46d9-996f-0104083b6bf8">32,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTQtMy0xLTEtNzMyNTM_ad014b88-7067-4de3-ad88-f10d9adaf706">32,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTUtMS0xLTEtNzMyNTM_7276a1d9-fd14-4b76-8dc5-85ec01985fe7">5,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTUtMy0xLTEtNzMyNTM_c7b38354-52cd-4db4-9907-709933592e41">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTYtMS0xLTEtNzMyNTM_f6a09ef9-8206-4732-bedd-3d809ab7963e">143,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTYtMy0xLTEtNzMyNTM_a001d42f-4558-4178-9c9e-d90d688e63bd">146,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjAtMS0xLTEtNzMyNTM_cdb0d5e4-dd17-41c6-a5fe-1e442f01b801">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjAtMy0xLTEtNzMyNTM_e5948576-9323-4dd7-9f12-b48d5f81ecd9">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjEtMS0xLTEtNzMyNTM_bf7b5f59-e58f-4f6b-b883-f4d8aba42b9d">9,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjEtMy0xLTEtNzMyNTM_debd17ca-d32f-4d74-85c0-ccc529b81577">12,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjItMS0xLTEtNzMyNTM_40d9b68d-fdc6-4b5c-bbdc-46cac91adbbe">22,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjItMy0xLTEtNzMyNTM_0af3c78a-bbf1-4a62-a0c3-5713db4ed2d9">22,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjMtMS0xLTEtNzMyNTM_7ffdfa42-c4a5-4704-96d2-83b25cc0903b">32,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjMtMy0xLTEtNzMyNTM_5a3708a9-f49b-4e0a-9b2e-d08efb2a8ca5">35,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjUtMS0xLTEtNzMyNTM_9c4c2dd7-5762-44e2-89ad-08b575e671e3">63,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjUtMy0xLTEtNzMyNTM_c7c9256b-c501-4435-a50e-0f395bcfd1a5">64,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjYtMS0xLTEtNzMyNTM_3f2284c9-a0db-4395-bfcc-cf81b1ded318">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjYtMy0xLTEtNzMyNTM_4d94ecc1-56f6-44ed-ad7c-a72d0eb78f55">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjctMS0xLTEtNzMyNTM_7da6ae52-9067-4f9a-87e5-4bcdf39b3427">28,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjctMy0xLTEtNzMyNTM_f0acfb25-cd5d-4f26-80d5-430906517810">28,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjktMS0xLTEtNzMyNTM_b7cc857a-2e48-437e-8700-e89c51f10679"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjktMy0xLTEtNzMyNTM_46d390b3-d484-40ff-8706-02a079aeb14e"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8xOA_4192cf9d-b0c4-4622-9745-11eae8ef4759"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8xOA_4e098e9d-d53d-40c8-b76b-dd94c11fbf57">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8zMg_b9ab60b0-d780-4de6-ada4-7f93ab3321ae"><ix:nonFraction unitRef="shares" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8zMg_ef34f7b1-6918-4e43-a813-143bb323a9f8">4,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF81NA_c9fda24d-a086-40d8-9a30-97b9fe940fbc">1,811,430,573</ix:nonFraction> shares issued as of March 31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF84NA_43126ee0-8b34-4cb1-97d7-700f5f566268">1,803,195,293</ix:nonFraction> as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMS0xLTEtNzMyNTM_30decaaa-1042-458c-9472-71972581017c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMy0xLTEtNzMyNTM_fd93f7a8-8003-493a-a5c0-8d78f9a74f6f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock held in treasury, at cost, <ix:nonFraction unitRef="shares" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjo3NDRjY2QyZDExZmM0YzZiODhjZTY4YmZmZWNjNmM3M180NA_a7af0163-b2bc-45b7-987e-761a2c523fc0">44,557,588</ix:nonFraction> shares as of March 31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjo3NDRjY2QyZDExZmM0YzZiODhjZTY4YmZmZWNjNmM3M182Nw_fdb31461-60c4-4d48-8d8f-3564908ff517">34,857,597</ix:nonFraction> as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMS0xLTEtNzMyNTM_16c9c040-13b4-4a58-91c9-c1ff7a491b1a">4,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMy0xLTEtNzMyNTM_675da50a-8420-45f7-9dad-49681f47988c">3,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzQtMS0xLTEtNzMyNTM_feef771f-e97c-4ff1-9232-a04e8ece4d2b">18,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzQtMy0xLTEtNzMyNTM_9a64322d-f228-4983-a3f6-58f39b449338">18,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzUtMS0xLTEtNzMyNTM_bd1f6aaa-99ca-4378-a659-cd8daa2ee3bf">5,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzUtMy0xLTEtNzMyNTM_7c896c57-af7c-47cf-80b5-5272dfbe65ee">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzYtMS0xLTEtNzMyNTM_5e9510fd-55ea-4f18-afb9-9c3249690d69">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzYtMy0xLTEtNzMyNTM_2e995146-6538-4980-b3e7-fd84bde81ff7">2,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzctMS0xLTEtNzMyNTM_158bc989-3081-4f29-aa6f-ff9d8e724f49">16,283</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzctMy0xLTEtNzMyNTM_00c22fde-92b6-44d3-b824-f0e8d2d79272">15,408</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzgtMS0xLTEtNzMyNTM_0d003326-ecad-4636-97ed-54f47ff09c9e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzgtMy0xLTEtNzMyNTM_8fbcae41-80fc-47dc-8a87-8e504966dcc5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzktMS0xLTEtNzMyNTM_a3831806-59a8-46d4-aff1-d4f97354fd48">16,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzktMy0xLTEtNzMyNTM_08e93e0d-2e5d-40d3-9a8a-e74aa115c9e9">15,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNDEtMS0xLTEtNzMyNTM_be55db18-1083-4f82-9356-f7f1dc2ca093">143,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNDEtMy0xLTEtNzMyNTM_882253d4-b2f6-479f-93b7-d31f76b08de1">146,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">3</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries <br/>Condensed Consolidated Statements of Equity (unaudited)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xLTEtMS03MzI1Mw_a4e678fd-0fad-4b0a-8413-cfd8c6824a79">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0zLTEtMS03MzI1Mw_eade0620-819d-497f-8b8b-235d0827cf4b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb1995fa5b74df58173afb77b7e467f_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS01LTEtMS03MzI1Mw_a1531eaf-73dd-42f3-9899-c939dc89889a">2,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fe2db515c241c0bb28d212b85279e9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS03LTEtMS03MzI1Mw_c66359e6-ed8b-4687-a8a9-6b6a164e9639">17,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e8e05625504d9a944f9bade3f3867c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS05LTEtMS03MzI1Mw_8f125517-2455-4832-886c-9c99082220dc">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf1feacb1a194c1d9816daa1d27870c0_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xMS0xLTEtNzMyNTM_06f3d593-702a-4709-bd16-4a9d64b3ceb5">3,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia427e86aee794ddda12fc9e121da41f0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xMy0xLTEtNzMyNTM_25a73e1d-0ab5-4acb-bc6f-15796538cc3c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6accb844205d4e909ea7d6f406d2b865_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xNS0xLTEtNzMyNTM_f4db4082-b34c-490d-9bfa-e37c4162a515">13,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0zLTEtMS03MzI1Mw_e3ca5fc4-33e6-43ee-8694-f3b00c8c9248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy01LTEtMS03MzI1Mw_c2c84dbb-ec30-4696-b32a-899d1ec4a593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy03LTEtMS03MzI1Mw_0ab4ac65-6821-4db5-8beb-11159ec2440a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy05LTEtMS03MzI1Mw_e62b6e3f-af5b-4abe-90ae-f8d39ba88c01">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0xMS0xLTEtNzMyNTM_03d8de3b-6caf-4de8-bcf8-9c33389075c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0xMy0xLTEtNzMyNTM_9718d6c0-7f11-406d-94b0-d01b4e84ce92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0xNS0xLTEtNzMyNTM_d4b21536-dc85-46e8-b4e9-9a7359cb3dfb">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0zLTEtMS03MzI1Mw_d106b131-32ad-4b49-a371-66d433850860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC01LTEtMS03MzI1Mw_3803510e-9c05-4f25-98a5-932e352babdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC03LTEtMS03MzI1Mw_6aa53c1e-97ad-486e-a6bc-d5e8c975cb45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC05LTEtMS03MzI1Mw_9d551ec7-48d1-4c32-a2f6-5f21be130c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0xMS0xLTEtNzMyNTM_9cff0b71-47c8-4067-ad5f-53443a4474a9">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0xMy0xLTEtNzMyNTM_80afaaa9-da24-445a-91e5-39658f42dcb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0xNS0xLTEtNzMyNTM_ce54ce16-b4b1-4bc2-ac41-ea5e7e6a8a38">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0zLTEtMS03MzI1Mw_7fc90b72-38c2-41a8-a7d6-3019859cdb2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS01LTEtMS03MzI1Mw_d346eda7-92e2-4c48-b301-6067081462da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS03LTEtMS03MzI1Mw_7467ac60-2df8-4f16-a27f-9caa994a1a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS05LTEtMS03MzI1Mw_f190210a-0aff-4be3-a9f2-1d201350851c">2,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0xMS0xLTEtNzMyNTM_a6d63676-8397-4e0c-8eb1-68cfe500b5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0xMy0xLTEtNzMyNTM_e34905a4-6ef4-44f6-8794-cc9e9baa5cd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0xNS0xLTEtNzMyNTM_746de55a-9e98-4f32-ad84-b9e432db5f1a">2,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xLTEtMS03MzI1Mw_15b11053-6051-4d37-a47e-95a213c3ceac">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0zLTEtMS03MzI1Mw_b3942fac-0ca4-4fb0-b005-aca875bc62f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy01LTEtMS03MzI1Mw_f9009a91-65c6-4b4d-b61b-c4180f4f2f89">787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy03LTEtMS03MzI1Mw_efceb515-9162-4059-958e-9fc4c8e99056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy05LTEtMS03MzI1Mw_65bf7f11-6ed7-4ef5-90ba-dc439addaec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xMS0xLTEtNzMyNTM_c6aff273-6307-475a-9f96-434511770e6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xMy0xLTEtNzMyNTM_96824b9a-cd23-4835-ab9b-011195a2b95b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xNS0xLTEtNzMyNTM_7c69a985-9883-4612-88d1-816f05834349">787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xLTEtMS03MzI1Mw_a0136286-474e-4081-a5ab-badd1abfba22">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0zLTEtMS03MzI1Mw_2ccc3523-3b6f-4741-8b6e-211a231fc25f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC01LTEtMS03MzI1Mw_d7f1e694-e3ad-4ad8-be59-36f054648aba">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC03LTEtMS03MzI1Mw_409986ed-d574-406d-8fe2-a02fc5f386bb">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC05LTEtMS03MzI1Mw_25aa6a27-c9fa-44b4-aa39-8e84a54243a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xMS0xLTEtNzMyNTM_5849e305-8e2e-4e19-9552-f01262642d18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xMy0xLTEtNzMyNTM_82799e9e-4c0a-4550-a4cf-adcef910e6ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xNS0xLTEtNzMyNTM_cf38aadc-e321-40e7-ba16-7f79839d01d4">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0zLTEtMS03MzI1Mw_322023ed-466c-4034-bc7c-6c1f0c4e820c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS01LTEtMS03MzI1Mw_f7adb831-1985-49dc-b801-868806d48470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS03LTEtMS03MzI1Mw_c702255e-291f-417b-bc1c-b0d32612a5a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS05LTEtMS03MzI1Mw_f188eeea-96eb-4b51-88be-d2b90889ea8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0xMS0xLTEtNzMyNTM_2ca9d987-0ba0-48cb-9a58-3dcfa880a9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0xMy0xLTEtNzMyNTM_c90411aa-2729-48ea-b68a-3b3bf2aef917">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0xNS0xLTEtNzMyNTM_f1636c9c-b96c-46b3-92f6-6693e9416e01">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5cf8db55503473d9dd1af8c0d20c48d_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMS0xLTEtNzMyNTM_d48e582b-efd4-4d6b-b9f1-a458b77ab3e5">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cf8db55503473d9dd1af8c0d20c48d_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMy0xLTEtNzMyNTM_b61e1786-bc17-43be-82dd-b94aa55dc2aa">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e9540820e34b43b3e6ec3daddaa1fc_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtNS0xLTEtNzMyNTM_25baf1e2-16ae-4cad-be54-7eed037f54ac">3,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9dace7c91d4297a7aa7f308de3f768_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtNy0xLTEtNzMyNTM_328c177d-be71-4be0-afbe-8cbb50b4ee5e">17,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3023971ae049339d5747605ef52a7c_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtOS0xLTEtNzMyNTM_fb922321-bb0d-4206-a01a-1662090d3849">2,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i980dca056e914f6385bbf2d1f0a5c20b_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMTEtMS0xLTczMjUz_0d7e6e64-3966-40bc-b196-44d53724420f">3,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26cb86a14c46ba9fa64e4b951dfaea_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMTMtMS0xLTczMjUz_696629ae-f3dc-4c3a-a835-b810e51ca727">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf70c299b6747128fa4a148bd06c306_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMTUtMS0xLTczMjUz_5c057a5d-ba73-470e-97c4-2607fd9837fc">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide7dd1b7a2964e66b89583f5e940f748_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMS0xLTEtNzMyNTM_da3a1010-a611-4017-bbb8-623c94357ade">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7dd1b7a2964e66b89583f5e940f748_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMy0xLTEtNzMyNTM_51afcea6-ff15-4089-bcee-25b2537c5745">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d21af462c442b5beb00d3ba5c34925_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItNS0xLTEtNzMyNTM_bfd49c81-dceb-4158-9311-b35ca26d7b27">3,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a07265e199d4b30a14e9e6383620f9f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItNy0xLTEtNzMyNTM_538f06fa-3050-4356-808e-888038c7394c">18,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1929ee5ab0f4e8c9347283529630a9c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItOS0xLTEtNzMyNTM_62ceaf8b-4cea-4d16-b7b3-f11e149f71e6">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e9ff1d5c2f242d3acc07bc91dffb247_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMTEtMS0xLTczMjUz_9b0e8bbd-2b5b-4bfe-aec5-14145f58bada">2,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa789cc1b9f041559e83b047a68991b0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMTMtMS0xLTczMjUz_9f17bc8d-9316-4059-9bda-768cda811235">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMTUtMS0xLTczMjUz_865bc644-144b-48d7-99ff-fb4fb572d3e7">15,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMy0xLTEtNzMyNTM_273ced71-9467-46de-86c8-e2fab61a9d76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtNS0xLTEtNzMyNTM_9ebae2e7-d981-4dd9-bb4e-ab3c751d8a41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtNy0xLTEtNzMyNTM_67e12320-2564-43a4-939d-c4faf061373c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtOS0xLTEtNzMyNTM_fe2a59e8-2a83-4f77-a06b-211ffcb2b53d">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMTEtMS0xLTczMjUz_f6864b29-4af3-4328-b714-c92a37f32812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMTMtMS0xLTczMjUz_327c0758-ecd0-441d-93ed-270cb4d2f2b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMTUtMS0xLTczMjUz_baf6d876-3005-431b-8879-5a5b177e16da">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMy0xLTEtNzMyNTM_175f1a05-7523-48dc-b7bf-4a6bcb3bc39d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtNS0xLTEtNzMyNTM_ac137a3f-510e-4042-97b5-79f74940dc32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtNy0xLTEtNzMyNTM_66a804aa-7f33-4065-9ebb-a20e9508b300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtOS0xLTEtNzMyNTM_a6bfc348-841a-47c7-b05a-1f9bfe166245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMTEtMS0xLTczMjUz_ebe5b4bc-c79b-442c-b8d6-2f0e9eefe083">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMTMtMS0xLTczMjUz_29706705-791a-40cb-9dba-ed39b3526bd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMTUtMS0xLTczMjUz_459a3c18-a423-4bbc-8efb-de606714fd9a">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMy0xLTEtNzMyNTM_d35498b5-f165-4c9d-b295-4c3f30a3167e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtNS0xLTEtNzMyNTM_1bef22c7-0bc7-4673-8bc6-85580b812d86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtNy0xLTEtNzMyNTM_5358e67f-e6b7-473b-b66f-955be4bc964a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtOS0xLTEtNzMyNTM_ecdbcdc3-64a4-497b-b222-bc257030ed12">2,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMTEtMS0xLTczMjUz_6374ec5f-a03d-4f9f-9af8-14437b675659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMTMtMS0xLTczMjUz_f5f5f25a-9def-42ee-920e-b57309c416b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMTUtMS0xLTczMjUz_5d14d7e8-343b-4e31-8a26-7abd7c5ba276">2,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMS0xLTEtNzMyNTM_c9c9f3f9-cdab-4428-86cf-a913664654da">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMy0xLTEtNzMyNTM_37bc470c-91a5-45c8-8a5e-50be070efdb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtNS0xLTEtNzMyNTM_69cba8ce-8a54-4196-bca9-0bdd605c3a4c">1,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtNy0xLTEtNzMyNTM_206ae1ec-81ef-40eb-8700-5b8a4bd78a1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtOS0xLTEtNzMyNTM_5fdb6129-d991-4f98-956a-e48ff8c9dc35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMTEtMS0xLTczMjUz_edec7525-92d0-4218-813c-fd0422d33a5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMTMtMS0xLTczMjUz_c2c8a2c7-65a7-4c4a-9a4a-c1574f0e3937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMTUtMS0xLTczMjUz_0e503333-a9e0-4e27-9c88-b200ba646777">1,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMS0xLTEtNzMyNTM_053f23d8-32e5-4ac3-99bd-0529b34ebf41">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMy0xLTEtNzMyNTM_8cc64268-f982-4e60-a8f7-fad4732574da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktNS0xLTEtNzMyNTM_66ab5441-b1da-467e-8e06-ec7487282db8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktNy0xLTEtNzMyNTM_a90a8739-2ed1-4ab1-bb96-00e721bcd277">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktOS0xLTEtNzMyNTM_866ddb76-ccdb-46b8-ae27-b1ed350ae68d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMTEtMS0xLTczMjUz_8cce41e4-0f7c-4c57-8875-e314714860dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMTMtMS0xLTczMjUz_dbedeb4e-1d69-4915-a355-eb5c1b123888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMTUtMS0xLTczMjUz_326f6111-0cb8-474e-9c7a-e53cff81fcc1">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMy0xLTEtNzMyNTM_71c072a2-a059-454c-b5ea-f71cbb6d68be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtNS0xLTEtNzMyNTM_264d7459-698b-4fcf-ab18-75684d5d0036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtNy0xLTEtNzMyNTM_b940dc32-e641-4d8d-9088-b89b96ee8324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtOS0xLTEtNzMyNTM_8b531163-b2b3-4fa4-bce4-98bb7a3d379a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMTEtMS0xLTczMjUz_ecd0b491-8b9d-4a99-b6c2-608aaf4da37d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMTMtMS0xLTczMjUz_7a79126a-5533-4d55-9ab8-975a5d1313cd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMTUtMS0xLTczMjUz_283d44e7-60fd-4e7e-b4d4-15c33c1c1307">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87b37cb73f2d4eacace3c00d60098061_I20220331" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMS0xLTEtNzMyNTM_cc613c29-90c3-4464-b4bd-73c7f5f5e140">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b37cb73f2d4eacace3c00d60098061_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMy0xLTEtNzMyNTM_b8e6e5a4-bdc9-4405-bca3-3533e34f4f42">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i207acaa2165d403396ea05f332f5d280_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtNS0xLTEtNzMyNTM_fe3686c5-8730-4487-9368-d30720928570">4,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib201ee2f6aa040aa994d36824861b99b_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtNy0xLTEtNzMyNTM_4cbf1be5-b2f4-42f1-bd07-22401cd197a2">18,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c2a9dc2507491cbed7bcc6382ac0bd_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtOS0xLTEtNzMyNTM_97872696-f488-45d0-ba00-6b4ad7175a43">5,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedf65e4946d940d7b337ee6ad83e0838_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMTEtMS0xLTczMjUz_fc9e702b-f530-4dcb-9206-48159e14a476">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613f449aeb814d5eb9f9f5433bf45c4b_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMTMtMS0xLTczMjUz_9ac8621b-1b99-4b62-a123-8063eee1ce10">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMTUtMS0xLTczMjUz_d7af235b-cfd1-405e-8afe-526f41f6a11f">16,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">4</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries<br/>Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)&#160;(brackets&#160;denote&#160;cash&#160;outflows)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMy0xLTEtMS03MzI1Mw_80fac078-8b32-4c80-b927-2dc88edd69e2">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMy0zLTEtMS03MzI1Mw_d500c637-edf9-44ed-950c-68e7039183e0">3,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to net cash from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNS0xLTEtMS03MzI1Mw_24e88413-589b-4601-87b4-f383d75059bf">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNS0zLTEtMS03MzI1Mw_402ad0c7-3ab4-49c3-9a1e-42a4d9c21c06">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNi0xLTEtMS03MzI1Mw_b6f1d8a2-661b-49ce-9ca2-40c1658f2c75">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNi0zLTEtMS03MzI1Mw_2ae0780e-9ef5-4e68-b832-f4ab427bc96d">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNy0xLTEtMS03MzI1Mw_afe54c23-7efd-4a8a-ae0d-6941f1e8fed0">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNy0zLTEtMS03MzI1Mw_f53d41e3-7463-4a58-95ad-07203cbdccc5">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOC0xLTEtMS03MzI1Mw_2d5cf9e2-3f0f-42fa-a775-c11df713c463">748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOC0zLTEtMS03MzI1Mw_60c08583-37e0-4373-95be-5294b7400718">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOS0xLTEtMS03MzI1Mw_c351812c-92d9-4643-9463-79416bd215e4">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOS0zLTEtMS03MzI1Mw_eee48a5d-5d55-462e-a87c-436e7bb9d994">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTAtMS0xLTEtNzMyNTM_5b5af473-f834-4897-9df3-4243c280a524">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTAtMy0xLTEtNzMyNTM_103b95d9-565a-4aa4-85ce-109ea9a96a99">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTQtMS0xLTEtNzMyNTM_f38ff337-003c-4ee4-a3e0-10b605a131b0">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTQtMy0xLTEtNzMyNTM_f83a0448-0a46-4991-8f25-8ccc17145c6b">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTYtMS0xLTEtNzMyNTM_beca9c04-a98b-461a-b2e4-a78761a13587">785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTYtMy0xLTEtNzMyNTM_0528fe90-cf4c-4a9d-8865-74aaec303d09">866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTctMS0xLTEtNzMyNTM_c2f506d5-d282-473d-b6fe-fd4e00a76463">385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTctMy0xLTEtNzMyNTM_3fdcec7f-e492-4ae9-8ad7-585eff445445">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTgtMS0xLTEtNzMyNTM_e00d50e6-cd69-4dbd-ad82-f3ea7101901c">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTgtMy0xLTEtNzMyNTM_f2903eae-8617-4a3e-8863-f79d2ee5ac9d">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTktMS0xLTEtNzMyNTM_c8d318ca-6a71-4359-85ac-1da0811e1fee">258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTktMy0xLTEtNzMyNTM_c28ed7cc-697d-450d-b997-a6fcd587d474">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjAtMS0xLTEtNzMyNTM_ed1ac336-279d-4f7d-8215-f465939cc486">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjAtMy0xLTEtNzMyNTM_93690c4d-33d9-43f7-8b32-5a56aed5d3ff">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjEtMS0xLTEtNzMyNTM_c080bcc5-a3c7-4b09-ad50-96d15c4cf7ea">4,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjEtMy0xLTEtNzMyNTM_8e3fa2e8-f809-41a5-ac21-073b95f6b1c0">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjUtMS0xLTEtNzMyNTM_47c8edbb-989c-43aa-8243-12cc47110b50">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjUtMy0xLTEtNzMyNTM_87b82f96-3f08-4058-83a6-07cdffe36f8e">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjYtMS0xLTEtNzMyNTM_76da0d84-ce07-4933-90ab-36feec3b493b">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjYtMy0xLTEtNzMyNTM_f75c6bb1-4091-420b-a2c3-c4a2bd1b8191">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjctMS0xLTEtNzMyNTM_39eff751-a0ab-45ee-a1f6-8dbf22910720">1,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjctMy0xLTEtNzMyNTM_df0f7ad2-7a21-4e5c-a0cb-36233c36684d">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjgtMS0xLTEtNzMyNTM_1d91aac2-1f44-4648-8a82-d23d28cfb3ce">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjgtMy0xLTEtNzMyNTM_9cf3f9c9-1f5f-43f5-a035-ea10d814879c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzAtMS0xLTEtNzMyNTM_d7bdefaf-3413-4363-9357-b0956913b877">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzAtMy0xLTEtNzMyNTM_6647c99c-aa07-4681-b47e-8a7a59d26c12">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzEtMS0xLTEtNzMyNTM_e87c3884-7c44-437f-b474-0bc0528c238a">1,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzEtMy0xLTEtNzMyNTM_8a85eb77-b547-4add-b2e4-fba617944fef">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzctMS0xLTEtNzMyNTM_1668d5ac-759b-42cf-8d60-3630badbb4d1">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzgtMS0xLTEtNzMyNTM_925d98f6-e312-42b2-b988-4bf7b6b3ca3f">4,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzgtMy0xLTEtNzMyNTM_fe6fef50-6172-452a-b0e6-f38129103e97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDAtMS0xLTEtNzMyNTM_c61925d8-4571-48bc-b518-cbd4952c3b53">2,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDAtMy0xLTEtNzMyNTM_18174dac-bd1c-4579-848f-63f5d711a0b3">2,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDEtMS0xLTEtNzMyNTM_8cdc5087-70d9-459d-b9b9-e84609070fbe">1,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDEtMy0xLTEtNzMyNTM_90c389bf-c744-47fb-b1db-4cda6953aca6">787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDItMS0xLTEtNzMyNTM_721487df-8550-42d9-80c6-9dbebb835857">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDItMy0xLTEtNzMyNTM_89433244-e5dc-441e-830a-fb0fe92daba8">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDMtMS0xLTEtNzMyNTM_31fa4d18-090b-457f-b8c5-a6e8ee0e140d">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDMtMy0xLTEtNzMyNTM_584c8981-5fd9-44f7-9789-9beeab833625">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDQtMS0xLTEtNzMyNTM_21725076-fb18-4bdb-a719-086edb5695bc">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDQtMy0xLTEtNzMyNTM_e96bd76f-24ba-4bea-9fef-42cb0452e9fe">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDUtMS0xLTEtNzMyNTM_a905dc6c-5f2c-426d-8a2f-fcb2e9f75eda">6,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDUtMy0xLTEtNzMyNTM_7aa33fb4-c3a8-4fd6-af39-13183ed1aea9">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDYtMS0xLTEtNzMyNTM_96c7074f-1a3b-4977-bee1-51e3a67cae9b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDYtMy0xLTEtNzMyNTM_e8efbf01-768f-4bfe-95a8-6daa21523d46">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDctMS0xLTEtNzMyNTM_fba706d6-643c-45ca-ac30-2b9689cecb33">3,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDctMy0xLTEtNzMyNTM_c1c38629-d8e2-40b5-b292-fd25d037c7b5">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDgtMS0xLTEtNzMyNTM_123b7522-e492-4684-8b90-7cb48b9689bb">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6accb844205d4e909ea7d6f406d2b865_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDgtMy0xLTEtNzMyNTM_fa43550a-572f-4d30-a73b-6e0786b16210">8,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and equivalents, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNTAtMS0xLTEtNzMyNTM_0099282e-98c8-4836-b09b-881db33ebff0">6,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf70c299b6747128fa4a148bd06c306_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNTAtMy0xLTEtNzMyNTM_4a3d680a-ddd9-46fb-805e-5f623870d6b8">9,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">5</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries</span></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_37"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 1 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zNy9mcmFnOmZkMGM5MjJiNGQ1ZTQ3ZGI4YTQ3ZmE5Mzg4MjUxMmMyL3RleHRyZWdpb246ZmQwYzkyMmI0ZDVlNDdkYjhhNDdmYTkzODgyNTEyYzJfMTg2Nw_8c079f7f-e042-4f01-9385-37c426f57d2e" continuedAt="i40942d3d59074b8ea55cf43884a2ff27" escape="true">Basis of Presentation </ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i40942d3d59074b8ea55cf43884a2ff27" continuedAt="ief6070f2aa2b427ba1975ae4ca7f0ad3">Basis of Historical Presentation </ix:continuation></span></div><ix:continuation id="ief6070f2aa2b427ba1975ae4ca7f0ad3" continuedAt="i1ee4eda7e4bb4836a8e521e10a92c8c1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules&#160;and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company&#8217;s audited consolidated financial statements and notes included in the company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company&#8217;s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ee4eda7e4bb4836a8e521e10a92c8c1">During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&amp;D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&amp;D and milestones expense by $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zNy9mcmFnOmZkMGM5MjJiNGQ1ZTQ3ZGI4YTQ3ZmE5Mzg4MjUxMmMyL3RleHRyZWdpb246ZmQwYzkyMmI0ZDVlNDdkYjhhNDdmYTkzODgyNTEyYzJfMzg0ODI5MDcwMzk4OA_42ce1def-6135-446b-8705-a77bfb198fcf"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zNy9mcmFnOmZkMGM5MjJiNGQ1ZTQ3ZGI4YTQ3ZmE5Mzg4MjUxMmMyL3RleHRyZWdpb246ZmQwYzkyMmI0ZDVlNDdkYjhhNDdmYTkzODgyNTEyYzJfMzg0ODI5MDcwMzk4OA_a6e7375b-84ed-4d73-acf8-ae02b5673c8a">115</ix:nonFraction></ix:nonFraction>&#160;million for the three months ended March 31, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.</ix:continuation> </span></div><div id="ic89f06320f9c4f57b19c511822f36cac_40"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 2 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTky_a67340a9-306f-420d-8872-a32c5ce6d0b1" continuedAt="if0297520cbe94a02b33ee9874e53beb6" escape="true">Supplemental Financial Information</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><ix:continuation id="if0297520cbe94a02b33ee9874e53beb6" continuedAt="i071758f3a20149d999c4a6c5406f7e5b"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTgy_13328d94-63c9-40d2-be37-e768601adc56" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMi02LTEtMS03MzI1Mw_6df3ebf5-89da-4017-b4eb-a66addaedb2e">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMi04LTEtMS03MzI1Mw_79a42790-1bb1-4799-8733-b62ca606e435">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMy02LTEtMS03MzI1Mw_cf2b91cd-306f-4c29-876d-4cfbef4c9bdf">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMy04LTEtMS03MzI1Mw_571f535d-62d7-4cf2-8385-d56738479062">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfNC02LTEtMS03MzI1Mw_effc7d6d-614c-4f21-9787-f80572a57ef9">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfNC04LTEtMS03MzI1Mw_8d2f5397-ab23-4f75-9e01-f5bc4375ea71">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><ix:continuation id="i071758f3a20149d999c4a6c5406f7e5b"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTkw_9227b66f-6914-4b24-9e53-ee4be21a8e0e" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMS0xLTEtMS03MzI1Mw_e195b6b7-c71f-4dde-a55c-9ac423b9cc91">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMS0zLTEtMS03MzI1Mw_5fd14cca-5970-4b67-80a4-471ce809ba27">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMi0xLTEtMS03MzI1Mw_a6c80ffd-50a0-4c0c-98fa-1513502b1b87">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMi0zLTEtMS03MzI1Mw_8f0e37bb-7935-4871-8c1e-604c4da04c73">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMy0xLTEtMS03MzI1Mw_8cb23dbd-f42a-4285-9a7a-f4f04ba0ff67">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMy0zLTEtMS03MzI1Mw_310c45c0-9a12-4227-9eb4-7d68654e6046">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfNC0xLTEtMS03MzI1Mw_b6572eee-fc88-4560-9ad0-ca06a06d11cd">3,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfNC0zLTEtMS03MzI1Mw_1e689099-8e75-4ca4-9396-4651ed5f743a">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTc3_ff373261-3c67-4ae4-805b-73029f5230a7" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMS0xLTEtMS03MzI1Mw_e610d177-eaf8-4328-b627-318d49b6a4b0">10,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMS0zLTEtMS03MzI1Mw_0dbeb4c5-82f7-498c-ad29-63c6e5742d48">10,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMi0xLTEtMS03MzI1Mw_952b0f22-714e-4c37-813f-43eae26ebb6b">5,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMi0zLTEtMS03MzI1Mw_31cc3151-50a4-4415-b539-6d0d43609708">5,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMy0xLTEtMS03MzI1Mw_1c6f2ccd-f5e6-4c66-9047-67147aa3fa7c">5,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMy0zLTEtMS03MzI1Mw_297f9190-21dc-481c-8137-a788c5680950">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTE5_24e88413-589b-4601-87b4-f383d75059bf">198</ix:nonFraction> million for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTU1_402ad0c7-3ab4-49c3-9a1e-42a4d9c21c06">206</ix:nonFraction> million for the three months ended March 31, 2021.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">6</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 3 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RleHRyZWdpb246NjI0MmViNjBmMmNhNGNhNzg5ZTBmYTQxZTgyODE1YTBfNjU2_8133a1ca-6d05-4acf-b8f3-0719081139bd" continuedAt="i4ea65841094a479b9e2fc1a9febdf937" escape="true">Earnings Per Share</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ea65841094a479b9e2fc1a9febdf937" continuedAt="i3fb32f9bda40496faabd7f2d1aa65967">AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.</ix:continuation></span></div><ix:continuation id="i3fb32f9bda40496faabd7f2d1aa65967"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RleHRyZWdpb246NjI0MmViNjBmMmNhNGNhNzg5ZTBmYTQxZTgyODE1YTBfNjUw_00676859-7d33-48e4-859c-3b7e22d8e5bf" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the impact of the two-class method:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMy02LTEtMS03MzI1Mw_5ea84cb7-f8c1-4126-ab24-065cc25b643f">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMy04LTEtMS03MzI1Mw_ffc286d1-92ac-40f0-af96-16d774e7e676">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNC02LTEtMS03MzI1Mw_fd28722b-bb5e-4352-8a69-9f85c18debbb">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNC04LTEtMS03MzI1Mw_572631b0-1926-4446-986d-d849a116fb50">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNS02LTEtMS03MzI1Mw_2d2642d3-cc12-4776-a18e-e6758746805e">4,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNS04LTEtMS03MzI1Mw_b1ebddf7-1878-4df9-be8a-3980c22fc689">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNi02LTEtMS03MzI1Mw_63c1e6da-d80d-4cac-b7f7-eb485dd6172f">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNi04LTEtMS03MzI1Mw_f45594dc-f550-4949-874e-ca9c8f3eea7f">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNy02LTEtMS03MzI1Mw_dc2efae9-c01c-4cd9-9656-ebb26b3abf52">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNy04LTEtMS03MzI1Mw_63ef66bc-5996-4973-9515-fc4333f588e7">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTAtNi0xLTEtNzMyNTM_fe3da331-9e20-46f8-aa4a-684324a4f81d">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTAtOC0xLTEtNzMyNTM_516a8f9e-bf09-4132-ba1f-a5feaf3fe758">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTEtNi0xLTEtNzMyNTM_e2effa79-c3ae-4b3a-813b-2907762fc35b">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTEtOC0xLTEtNzMyNTM_44862c53-8d5d-42f3-b8e4-64d83c555722">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTItNi0xLTEtNzMyNTM_98c973ea-4e40-42f6-baae-639a2113e1fd">4,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTItOC0xLTEtNzMyNTM_7a9ceed3-fdae-40ba-af84-147b9420ead2">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTMtNi0xLTEtNzMyNTM_a9348e89-b9ff-4164-8118-ef1040cfc34c">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTMtOC0xLTEtNzMyNTM_b12e6d43-fb1b-40ac-9baf-3e54dd83e33c">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTQtNi0xLTEtNzMyNTM_14a75b83-f26c-4fbc-84dc-d6eb976200fb">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTQtOC0xLTEtNzMyNTM_1946006e-7c5a-4e19-a293-97a8b2494252">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTUtNi0xLTEtNzMyNTM_39e72f7d-a217-4038-846a-4745696bc91a">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTUtOC0xLTEtNzMyNTM_9297f0cc-580c-4499-9d84-b338b7df9edc">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTYtNi0xLTEtNzMyNTM_ff6ae615-0168-4a48-acfc-eae44cb224c9">2.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTYtOC0xLTEtNzMyNTM_17337729-112a-43c0-bda8-fd904ba80298">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.</span></div></ix:continuation><div id="ic89f06320f9c4f57b19c511822f36cac_49"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfNzMwMg_f66ecb2b-441f-4981-b005-642435d85f25" continuedAt="i86a375476d5b4bf3be7fbd4db900c7bc" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensing, Acquisitions and Other Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><ix:continuation id="i86a375476d5b4bf3be7fbd4db900c7bc"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflows related to acquisitions and investments totaled $<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTg4OQ_b2431296-901c-4f58-9d51-6419e164a0fa">185</ix:nonFraction> million for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTkwNw_34f13724-8ec5-4326-8d15-01caf31738fa">198</ix:nonFraction> million for the three months ended March 31, 2021. AbbVie recorded acquired IPR&amp;D and milestones charges of $<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMjAyMA_d3a0d7fb-9152-4301-8443-63aaed03d1ad">145</ix:nonFraction> million for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMjA5MQ_7e528561-c68f-4dbe-901a-09717b6f8c00">185</ix:nonFraction>&#160;million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Syndesi Therapeutics SA</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i72db22a233c742cb9fdaf4ec7205f2f1_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTA5OTUxMTY0OTU3NA_e6bed5d3-6d28-48fd-857e-0d0b90f2b770">130</ix:nonFraction> million which was recorded to acquired IPR&amp;D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ieb3553129a064588b861cbad2e2e642e_I20220228" decimals="-6" name="abbv:PotentialPaymentsUnderAgreementCertainMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTA5OTUxMTY0OTYxNA_7fcf68ba-d520-42b3-8c2a-535631ddaaf6">870</ix:nonFraction> million upon the achievement of certain development, regulatory and commercial milestones.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">7</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfNDIzNg_9ba26504-47c8-4831-99f2-9ce352b247d6" continuedAt="i1511636aa74744ae96c5e02d71534ecd" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaborations</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended March 31, 2022 and 2021.</span></ix:nonNumeric></div><ix:continuation id="i1511636aa74744ae96c5e02d71534ecd" continuedAt="icd2bf390264c43d2900c71c41a0ccf91"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Janssen Biotech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech,&#160;Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson&#160;&amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton&#8217;s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i20abf2418b52449bbcdcb69db0df0b34_I20220331" decimals="-6" name="abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMTM5OQ_a56564d9-8362-48ab-96c1-35fff7159ec3">200</ix:nonFraction> million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately <ix:nonFraction unitRef="number" contextRef="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331" decimals="2" name="abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMTU3OQ_35405f7a-6b32-4bb2-a58c-4ed19b3101ca">60</ix:nonFraction>% of collaboration development costs and AbbVie is responsible for the remaining <ix:nonFraction unitRef="number" contextRef="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331" decimals="2" name="abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMTY2MQ_75a5f607-5640-4c4f-9b1a-970139eab124">40</ix:nonFraction>% of collaboration development costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i9fe4ce1afbad40ee8b142ccdca3cbdf7_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfNDI0MA_6733a072-32a9-4c46-bfa1-d8e5f9b40dfc" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Janssen's share of profits (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757157a6b1f24339a6987f24f728b796_D20220101-20220331" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMi02LTEtMS03MzI1Mw_58b93f1f-0956-4720-a0e7-cdb12978e2e0">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c90b03e0a9d4b959d426288837a1ac9_D20210101-20210331" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMi04LTEtMS03MzI1Mw_40d1e102-553a-4e2c-857b-ee2a2368bcfb">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International - AbbVie's share of profits (included in net revenues)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9f25b9cf5e4ee0bbe7e382b04feba9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMy02LTEtMS03MzI1Mw_77523dcb-1dca-4a8b-814f-67c11c5f13b7">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1248f479629473abbdb6ed040285ccc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMy04LTEtMS03MzI1Mw_c0404797-473a-4638-9b3c-3f50af1aaca5">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global - AbbVie's share of other costs (included in respective line items)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331" decimals="-6" name="abbv:OtherExpensesFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfNC02LTEtMS03MzI1Mw_5b9896c2-d069-4211-a7ae-1a4cb3be9dd5">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7189bfa6119440549f13eb789b20c623_D20210101-20210331" decimals="-6" name="abbv:OtherExpensesFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfNC04LTEtMS03MzI1Mw_7b628509-f3af-4aa7-8a86-31259dadb6b6">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie&#8217;s receivable from Janssen, included in accounts receivable, net, was $<ix:nonFraction unitRef="usd" contextRef="i20abf2418b52449bbcdcb69db0df0b34_I20220331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjczOQ_997fb397-5c79-47b0-bce7-7801020ee04b">336</ix:nonFraction> million at March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i503b434bb2cd4949ab32e3eea0c0a13b_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjc1Mg_f5a7ed10-7ba1-446a-8a1a-b67b0d594e63">294</ix:nonFraction> million at December 31, 2021. AbbVie&#8217;s payable to Janssen, included in accounts payable and accrued liabilities, was $<ix:nonFraction unitRef="usd" contextRef="i20abf2418b52449bbcdcb69db0df0b34_I20220331" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjg0OQ_62c234a4-10da-4a9b-95c1-c19ad83124a4">401</ix:nonFraction> million at March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i503b434bb2cd4949ab32e3eea0c0a13b_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjg2Mg_9c36f40b-3bd0-4cca-9f33-e51234524f40">509</ix:nonFraction> million at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Genentech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie&#8217;s net revenues. Genentech&#8217;s share of United States profits is included in AbbVie&#8217;s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&amp;A) expenses and global development costs as part of research and development (R&amp;D) expenses, net of Genentech&#8217;s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie&#8217;s cost of products sold.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="icd2bf390264c43d2900c71c41a0ccf91"><ix:nonNumeric contextRef="i7e417e1f49424cb4b129ec6ce7c723da_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfNDIzOA_8a3ef206-6824-47f7-b50f-3e799c9219f3" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Genentech and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech's share of profits, including royalties (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70fdebf15534416b657e3efc08cb7de_D20220101-20220331" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMi02LTEtMS03MzI1Mw_57083e0f-4ae5-4484-85b2-2d1daeaf9290">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b131031330347efae33d3283c798c08_D20210101-20210331" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMi04LTEtMS03MzI1Mw_f2133e4f-ea47-4f21-adfd-53c86d998485">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91bb22b751b4f769a3ed871c1a8e163_D20220101-20220331" decimals="-6" name="abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMy02LTEtMS03MzI1Mw_f3d66a49-4ef0-45c7-85b3-8bc1a231050c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6409d59d48544dd3b57e4e907e0daf25_D20210101-20210331" decimals="-6" name="abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMy04LTEtMS03MzI1Mw_e76f6f95-8b62-4c86-a975-7b54c00c2ce9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of development costs (included in R&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70fdebf15534416b657e3efc08cb7de_D20220101-20220331" decimals="-6" name="abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfNC02LTEtMS03MzI1Mw_4b6a3fc0-2843-4e85-8590-6652f68f26d6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b131031330347efae33d3283c798c08_D20210101-20210331" decimals="-6" name="abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfNC04LTEtMS03MzI1Mw_2860bb34-1669-4399-86df-b629e5bc0350">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="ic89f06320f9c4f57b19c511822f36cac_58"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 6 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIxMw_1bbc4a0f-0118-4290-95ba-1e32b7e75ae8" continuedAt="i0a2d18b46f52425aa68f9ee340226a60" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i0a2d18b46f52425aa68f9ee340226a60" continuedAt="i85d7e10681914c78b2ad8980462a2b47">Goodwill</ix:continuation></span></div><ix:continuation id="i85d7e10681914c78b2ad8980462a2b47"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIwMg_8af45836-2049-4f39-855d-005cf1e6eecf" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjZhMjhmMTEwNmFjMzQyZTNiMjE4ZDFjZDRkOWE5MDFkL3RhYmxlcmFuZ2U6NmEyOGYxMTA2YWMzNDJlM2IyMThkMWNkNGQ5YTkwMWRfMS0xLTEtMS03MzI1Mw_c76b4fe7-6a87-437e-b6bd-e821c498b492">32,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjZhMjhmMTEwNmFjMzQyZTNiMjE4ZDFjZDRkOWE5MDFkL3RhYmxlcmFuZ2U6NmEyOGYxMTA2YWMzNDJlM2IyMThkMWNkNGQ5YTkwMWRfNC0xLTEtMS03MzI1Mw_08467d8a-d66e-4e4d-8668-065794835b89">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjZhMjhmMTEwNmFjMzQyZTNiMjE4ZDFjZDRkOWE5MDFkL3RhYmxlcmFuZ2U6NmEyOGYxMTA2YWMzNDJlM2IyMThkMWNkNGQ5YTkwMWRfNS0xLTEtMS03MzI1Mw_7dd24f25-f89e-4913-aa2c-ee06fcafa4f3">32,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of March 31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMzMy_042753cf-6a11-4355-9825-9266f2f112f6">no</ix:nonFraction> accumulated goodwill impairment losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIxMg_4c6f5c5e-1a98-4d43-9646-1e1d96b9b6c5" escape="true"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIyOQ_d9a84588-4a59-4a4b-8ce6-b5ae2b368ab7" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d0443c07a5417ca515d44ddc962b47_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy0xLTEtMS03MzI1Mw_739e5d82-421a-48ea-a93e-1b7aa567c656">88,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d0443c07a5417ca515d44ddc962b47_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy0zLTEtMS03MzI1Mw_6b27bd28-9930-4664-a146-19480f83ed4f">20,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d0443c07a5417ca515d44ddc962b47_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy01LTEtMS03MzI1Mw_0d0f02b6-a6c3-4343-b8a5-130d29d7133c">68,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy03LTEtMS03MzI1Mw_adb954e7-e01d-4e81-9173-c83c6bb6eda7">88,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy05LTEtMS03MzI1Mw_c40a4540-70c7-4b2c-9bd4-bd4541a7b658">18,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy0xMS0xLTEtNzMyNTM_aa37f470-40cf-4823-aaae-bc6dd3f74cc7">70,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d7032a627d4586b0df7536454a2953_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC0xLTEtMS03MzI1Mw_3070ad73-e52d-4ed6-a946-62bb29f77c42">8,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d7032a627d4586b0df7536454a2953_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC0zLTEtMS03MzI1Mw_4313cddf-4284-4a09-a034-307f3ed69577">3,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d7032a627d4586b0df7536454a2953_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC01LTEtMS03MzI1Mw_b1b5453e-3a7c-4a9b-a6fc-a88eb00bfb6d">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abf8b13366e446b8e4d345e553af9c0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC03LTEtMS03MzI1Mw_1470c6e9-4e5d-4e37-9f98-7df2ed9bbbf1">8,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6abf8b13366e446b8e4d345e553af9c0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC05LTEtMS03MzI1Mw_15245439-750b-447b-b75e-8beb8e5b4a93">3,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abf8b13366e446b8e4d345e553af9c0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC0xMS0xLTEtNzMyNTM_80af6bb4-0d53-4ac6-9bcf-6c810a45195d">4,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS0xLTEtMS03MzI1Mw_07d302e4-cf01-4d3f-8bfc-54dad3f66514">97,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS0zLTEtMS03MzI1Mw_430cd687-4277-4973-bdd4-5fab25d62855">23,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS01LTEtMS03MzI1Mw_32183789-ccf8-4390-a81c-a15e92299fd2">73,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS03LTEtMS03MzI1Mw_b525b944-d971-4c7f-a46d-28e2703dfeeb">97,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS05LTEtMS03MzI1Mw_44984e27-d9a5-4143-a7a0-c2478d5e0a34">22,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS0xMS0xLTEtNzMyNTM_6cd29f98-8939-476e-9a18-64d149ebadb7">75,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi0xLTEtMS03MzI1Mw_cff4191d-b3ef-40ce-9a40-2d773fd723c0">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi01LTEtMS03MzI1Mw_b5c96bfb-348c-411e-9331-7de6f3913cc6">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi03LTEtMS03MzI1Mw_bc8ab582-6b9c-4c68-a21d-dd1ee55f8ea2">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi0xMS0xLTEtNzMyNTM_7d016bfb-99d1-4ff4-8ce6-57c5537bccd9">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy0xLTEtMS03MzI1Mw_e6afaeb4-bd82-482b-b779-f16a88b62722">97,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy0zLTEtMS03MzI1Mw_b749fed3-b1b5-4675-a2db-eb0fc970e709">23,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy01LTEtMS03MzI1Mw_98e19dc6-185b-4d7b-9f72-0e532b684af7">73,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy03LTEtMS03MzI1Mw_e5dbe46c-049a-47b3-8cb7-d7eccdb101c5">98,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy05LTEtMS03MzI1Mw_d78f2269-523e-4b35-9bd7-65c58195c606">22,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy0xMS0xLTEtNzMyNTM_547e5f9b-fec2-45b6-8572-1935bd956d21">75,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfNzgz_3cb31f76-e339-4554-9ea2-56f25b658ff5">1.9</ix:nonFraction> billion for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfODE5_b67eebf2-570d-45ae-9ed6-1dceae33a029">2.0</ix:nonFraction> billion for the three months ended March 31, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.</span></div></ix:continuation><div id="ic89f06320f9c4f57b19c511822f36cac_64"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 7 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAwOQ_8a8fd8c7-fe86-44ca-a9b3-03738467f08d" continuedAt="i734389659f49461f9802524e7e0ef962" escape="true">Integration and Restructuring Plans</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i734389659f49461f9802524e7e0ef962" continuedAt="iaf16704e581b44119f9a68f9c386c880">Allergan Integration Plan </ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf16704e581b44119f9a68f9c386c880" continuedAt="ic5b49503f83443ea9ddc04ba843afaf6">Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $<ix:nonFraction unitRef="usd" contextRef="id13caefd7d5a471aa354ceb296f2d670_I20220331" decimals="-9" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMzEx_bbea9fbb-6a93-4faa-8453-923500b312e4">2</ix:nonFraction> billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ic5b49503f83443ea9ddc04ba843afaf6"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAyNQ_e09fa609-5bf9-489b-b7b7-deef56b2636c" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges associated with the Allergan acquisition integration plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbf40f3d8814b2cb5a231dbbd3418e6_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy05LTEtMS03MzI1Mw_7bf43eb0-b1b2-4399-82e3-5da6189898f6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc654c5b431f4e2c81e6d3dc971bbfce_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy0xMS0xLTEtNzMyNTM_011c9bb1-390a-469e-833e-0c20ca3264aa">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0e02057646439c9b219a540ab6bba4_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy0yMC0xLTEtNzMyNTM_e31712b2-3d62-4198-9d4b-e26d67df5d02">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d31e315887b49cf9383108785d5b7a2_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy0yMi0xLTEtNzMyNTM_16629045-e546-48f5-8e2d-9b9a9bce8d1c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0ea0dc41fe4934b7afc79df8635743_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC05LTEtMS03MzI1Mw_17fafda7-8e08-4800-8519-94a5854da0df">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28ae11319ad4812a556b3a24a0d7eb8_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC0xMS0xLTEtNzMyNTM_d3b46a36-c6f2-4b62-bd25-bf5c202c6c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b089c0fc324d5b82b75e000f5fe9cd_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC0yMC0xLTEtNzMyNTM_a350ce18-4e0e-4120-9288-4be5e511c716">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6435c30e6b40489560149b0efd5c0b_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC0yMi0xLTEtNzMyNTM_34e3ad9e-bb06-4287-9949-4e79e2b0bf8f">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2be7d9eaa6f4f369f0de369cbb043f8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS05LTEtMS03MzI1Mw_b1fa0b8b-f423-4c43-9d42-21b1af0daf05">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f0edb319054698965e395df2f44e5f_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS0xMS0xLTEtNzMyNTM_89f2afa9-f69f-4176-bb67-d1fcfc8e8093">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b13ed86da2945de8f2c44a2373537a6_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS0yMC0xLTEtNzMyNTM_cdc96601-74f8-485c-95b4-0dc54f1d907b">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e369611bfc4546bf3c8e89fd8a3f48_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS0yMi0xLTEtNzMyNTM_2547a9af-442f-48d1-85c8-e27559a97cd4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi05LTEtMS03MzI1Mw_e7b51868-fd5d-431c-9fd5-304ff43d96ec">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77324bf397cc41f7a15e4eef24ecff2d_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi0xMS0xLTEtNzMyNTM_a5e29a83-b30f-47b2-a860-8b6626652bd6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi0yMC0xLTEtNzMyNTM_4e793946-b2aa-4367-83cc-794053862c48">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f1ab36dc934e39ae4bfefcbe05705e_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi0yMi0xLTEtNzMyNTM_c5e3e930-a200-43b2-b58e-0485d79d1126">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAxMg_4a3dac44-80ee-4379-9910-874626f28122" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the recorded liability associated with the integration plan for the three months ended March 31, 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714dfb429c6f451eb83c696c0379c6ab_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMS0xLTEtMS03MzI1Mw_f4056cc2-ff45-460d-8df2-578435740392">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5007646043540a1b0e932caf506c8b2_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMS0zLTEtMS03MzI1Mw_8adae501-dbf6-45c0-94f8-73ebbf1fb1f5">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331" decimals="-6" name="abbv:RestructuringReserveCashSettledRestructuringGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMi0xLTEtMS03MzI1Mw_41317c09-c765-475f-b497-27bb52e01f6d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331" decimals="-6" name="abbv:RestructuringReserveCashSettledRestructuringGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMi0zLTEtMS03MzI1Mw_e1dda12e-53f1-4298-9404-3e68fe298d47">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331" decimals="-6" name="abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNS0xLTEtMS03MzI1Mw_a2cc1610-6eda-40bb-8f28-80758ca7ccd3">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331" decimals="-6" name="abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNS0zLTEtMS03MzI1Mw_6eafc033-57d8-4340-9fa8-ee1b40fd0735">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8327b6e3b446c39bc4154fdcab2095_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNi0xLTEtMS03MzI1Mw_7deed78d-1cd0-4ed3-97dd-ec009bf23675">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id430b90a4b4b4e00accb2dafe2190824_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNi0zLTEtMS03MzI1Mw_f274fcfe-95ba-4b1e-b215-71b2790e9dbb">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Restructuring</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie recorded restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfODUw_7ce8e00f-d9ca-49b0-9bbd-b4b209870933">57</ix:nonFraction> million for the three months ended March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i7f4c4b3745f349e198629a93da34561b_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfOTA0_b05bc93e-bcb8-4fa0-bee3-e62751d0614c">38</ix:nonFraction> million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAyNA_3724d122-3c48-4de5-b1c8-1f9579bde51a" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e8c16288ca4a859ec70b21f89ef7a7_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfMS0xLTEtMS03MzI1Mw_1fcc67f2-9c49-4957-b123-c4d67eec92d4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331" decimals="-6" name="abbv:RestructuringReserveCashSettledRestructuringGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfMi0xLTEtMS03MzI1Mw_53e72d9f-1304-4df0-a253-c935bfed62b5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331" decimals="-6" name="abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfMy0xLTEtMS03MzI1Mw_c421229a-510c-4593-9080-23a0c0eadc44">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a368d5034e44f028f602236d3ab8057_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfNC0xLTEtMS03MzI1Mw_190f62e2-83c1-402a-accd-a83bfdc2d808">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div id="ic89f06320f9c4f57b19c511822f36cac_70"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 8 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:DerivativesAndFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA5OTUxMTY1NTY5OQ_f5b84c9c-1771-46a0-b9c6-81a00e13e3f4" continuedAt="id16b3357b3c9444382c070c9a1d54b9c" escape="true">Financial Instruments and Fair Value Measures</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="id16b3357b3c9444382c070c9a1d54b9c" continuedAt="i8bdbd381e9d84f64ad7af3858f51dcb1">Risk Management Policy</ix:continuation></span></div><ix:continuation id="i8bdbd381e9d84f64ad7af3858f51dcb1" continuedAt="idd6d13563f3c4318845cbf0fb480f4ac"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 to the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie&#8217;s risk management policy and use of derivative instruments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i2d0578582acc4184bae1fe1a5d03842e_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNTM4_7e984bc2-0032-46f2-9ddc-c43ad4af5144">904</ix:nonFraction> million at March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i64d7cd1d96fd463d81f7b441a15f7907_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjE5OTAyMzI3NTk4OA_0bfb1145-2dac-420c-8c45-46dac441b71e">1.1</ix:nonFraction> billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than <ix:nonNumeric contextRef="i85e773fb160f4868b7b34f01835f244e_D20220101-20220331" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNjk3_ccb006f8-97c8-40b1-aa1d-00cc539c1f5c">18</ix:nonNumeric> months. Accumulated gains and losses as of March 31, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding <ix:nonNumeric contextRef="i85e773fb160f4868b7b34f01835f244e_D20220101-20220331" name="us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfODky_9b90ee31-5ade-4391-beb4-3d70c0cd3fed">six months</ix:nonNumeric> from the date of settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="id4dcf7772a434cca8535434fc724868d_I20190930" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA0MA_333ec003-b595-40e5-bbce-29e4f22313ec">10.0</ix:nonFraction> billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive loss. This gain is reclassified to interest expense, net over the term of the related debt. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="idd6d13563f3c4318845cbf0fb480f4ac" continuedAt="i37c6dfcc19ba48d6a45edb0496263c25"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="id7c27a6d499a4374bb62731e6ee3c5ad_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0MQ_b2426b17-156b-4468-bfc5-2c172d2c1229"><ix:nonFraction unitRef="usd" contextRef="i1ea6c9f4ab71401f8e112e105b0a87ea_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0MQ_d748b9f3-f550-4a66-9964-b92f43cab6e3">750</ix:nonFraction></ix:nonFraction> million at March 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i14c87abe9559493098137ef93eb16897_I20220331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjQyMg_b9ede7a2-fb87-416e-b3b6-f0b0f052ec84">7.0</ix:nonFraction> billion at March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i56fd5370a66349abb5a708fcca3df153_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjQzNQ_e01f78ae-f624-47d5-8815-107b9a9edd29">8.2</ix:nonFraction> billion at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling &#8364;<ix:nonFraction unitRef="eur" contextRef="i8e5c418235f74f58be5d142972173da3_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjcxNg_2d490390-e3a3-4757-b063-5a46f43f0fdc"><ix:nonFraction unitRef="eur" contextRef="i1440f6810115464aaba75d7ad2e205fa_I20220331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjcxNg_f6ea4fa2-547b-4389-b71b-29a557ce1739">4.3</ix:nonFraction></ix:nonFraction>&#160;billion at March 31, 2022 and December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of &#8364;<ix:nonFraction unitRef="eur" contextRef="i5e04d5b1b77e42338343cb7a394365ac_I20220331" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjg1MA_04fce40f-facb-4782-914b-fb507f1487a3"><ix:nonFraction unitRef="eur" contextRef="ida1c9540265a40ae89ed8e5bac26055b_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjg1MA_eaa64f96-a3ab-4b87-8245-0612241ca890">5.9</ix:nonFraction></ix:nonFraction> billion at March 31, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i0695b54b4eee4244ad7f53879aaf2b88_I20220331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzM1Mw_25ca30eb-8ac9-4a1e-bfbd-059e11e83f36"><ix:nonFraction unitRef="usd" contextRef="i3023f47a89be437a8979714fa7aeb5ea_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzM1Mw_6fec68bb-b9f4-4828-830f-f9227f10a9e9">4.5</ix:nonFraction></ix:nonFraction> billion at March 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_1bf50e2c-8a3f-4259-a68c-d2537d7710d0"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_4c6a8844-3155-49a5-b49d-2a89afc8f0b3"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_a6f6229d-d536-4eae-8e5c-b80e00813b3f"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_c09d4521-09ef-4f4b-8f08-d912c07d4c2e">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTU_53f9dc5b-fc2a-4088-ae94-e2f7a47dd673" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of AbbVie&#8217;s derivative instruments on the condensed consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211; <br/>Derivatives in asset position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211;<br/>Derivatives&#160;in&#160;liability&#160;position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae50d2fb61c84091860a38b122dcec5e_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy0yLTEtMS03MzI1Mw_05bd43f8-490e-4cba-8c56-d8f81c3903aa">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3896b7812d9c4f458a6ee1c222fdc5d4_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy0zLTEtMS03MzI1Mw_6eac45d5-1237-425e-bf92-b1d028f958d6">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf844e180d3a469caf77cbfd640ee06a_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy02LTEtMS03MzI1Mw_3c6d2c4d-215b-4764-b705-62095d9e0745">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278c392732fe405ca9790ebca84a2b5a_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy03LTEtMS03MzI1Mw_2add260a-a4ab-4cb3-9485-4543083f0780">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2759b8249f9b4c0abfb4b6e0d5d1f19a_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS0yLTEtMS03MzI1Mw_bb62e646-bb56-4758-800d-50526cb54648">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ebd92b09814dbd9c34016fbe056f80_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS0zLTEtMS03MzI1Mw_721d6644-d13d-4f6f-b2ed-81f5242df375">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37efff4161cb4c0493595e73c1b6c251_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS02LTEtMS03MzI1Mw_a46a5b79-2872-43ac-8d56-f20fa8bb99b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42302eafa7c143eea1f93c5698a3de9f_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS03LTEtMS03MzI1Mw_8e0f1d61-5a25-4422-bb73-3590338f624d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a96d28015b45949c078f6766332529_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0yLTEtMS04MDI5Ng_087a6b9c-51e8-45ef-a26d-3fbb70d5db53">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fe28e93231442a879e677d581e007a_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0zLTEtMS03ODM1MQ_a294f124-4f95-483a-b4a0-66144ce5bc96">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f5ff90441c477985db4a043e94ba99_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi02LTEtMS04MDMxMg_49fffed9-f982-4aae-8843-6724860f568b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081e9eccbec84d14b3e5e990418ead24_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi03LTEtMS04MDMxNQ_5514a864-7e6a-4346-8c3d-63887fafe689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2762b41ed6f34461bfde8f1333fdf996_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0yLTEtMS03MzI1Mw_6bc669d7-e7a4-43c8-9a0d-9424d4676f7b">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6c7748fb844f8387515876c985d86a_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0zLTEtMS03MzI1Mw_cc6b3700-c2eb-4835-b1aa-1da6a7d3e917">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435b30592ac747d989c50678808fe1d0_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi02LTEtMS03MzI1Mw_91337926-8ce6-4061-929b-ec746a33ad49">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e7a78e77c640c0978087e1e5aa5365_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi03LTEtMS03MzI1Mw_f264b3da-4d41-4a31-b44d-4091bb0d23f5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20d6c5cd9154d11b748fba274562228_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC0yLTEtMS03MzI1Mw_ee9d473c-0b6c-4c59-8a50-dca2426feea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec68c25a887f49d4b34b8179ed6dda01_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC0zLTEtMS03MzI1Mw_4e2d79a2-b744-45a4-8a27-2add5c169b70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24765f81c1fb4287a6f15e1f08b37561_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC02LTEtMS03MzI1Mw_4d45a2d6-28ef-48a1-a1c5-593e3bd1414c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84610d1bd2b740fb98e00437e286d300_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC03LTEtMS03MzI1Mw_ab48ac2b-a0b9-48dc-92dc-56f386f434fc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099396de57cc428db3ba3fa6496e9806_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtMi0xLTEtNzMyNTM_59f38e48-27bd-404c-8870-2cfe955d7317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb723c8d7d94576a2e267ad0bde0d6a_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtMy0xLTEtNzMyNTM_eaa3336a-0a29-4bf2-a151-f98867a53e90">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84f403b6217414e9c4727bdaddefefa_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtNi0xLTEtNzMyNTM_dcad8185-f3bb-40fd-b768-080583835cf4">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993003f0c8794563b176024ce0433091_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtNy0xLTEtNzMyNTM_053c44c7-1742-42c1-9aa4-790f96f2baae">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItMi0xLTEtNzMyNTM_0c8e3edc-5b93-4d09-8d92-fa4d0a8b0fa2">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItMy0xLTEtNzMyNTM_a1e9a9d4-ac6d-499c-a11d-724c9f8a219d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItNi0xLTEtNzMyNTM_79427a3d-f707-4690-bfc8-1caac4d8d74b">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItNy0xLTEtNzMyNTM_ec03982e-0e72-471b-b234-34d96a927c93">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with the company&#8217;s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i37c6dfcc19ba48d6a45edb0496263c25" continuedAt="ic3a8d7b334ad417381e4c2aaa00d47cc"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDE_09cdfda0-e5a7-4b25-aab7-d360e30ea89f" escape="true"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMzA_ec0bb620-ef75-4536-941b-ecc45f8e3043" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf6856ef91ba4d929d656629013d3068_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfMy02LTEtMS03MzI1Mw_385ec5c6-8df6-40db-a3ca-8e5c6475fb74">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie282fe45ad5d4fabb47f2e2e934d4440_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfMy04LTEtMS03MzI1Mw_9de6fab8-129e-4e53-b7aa-392f21edc1c5">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6856ef91ba4d929d656629013d3068_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNC02LTEtMS03MzI1Mw_12060727-9927-483b-8456-5e9ab0deed03">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie282fe45ad5d4fabb47f2e2e934d4440_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNC04LTEtMS03MzI1Mw_41dfc4e0-f499-42f0-afa7-d9915f95df04">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621e08f15f004824aefad73ab5851795_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNS02LTEtMS03MzI1Mw_b44fe433-bb6a-4e44-8e35-0c7cae8096f2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179bb4a086e74b04bc986f5bbbb847c6_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNS04LTEtMS03MzI1Mw_3c25781a-dfdc-4a06-9c77-0aafeb684adc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="i0ed7b475bcdf40e59be351b723196753_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDIzNQ_49777b53-4953-4b1f-820b-3ee530df7804">52</ix:nonFraction>&#160;million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $<ix:nonFraction unitRef="usd" contextRef="if0ba58f0b4804781a450e1eafe670429_I20220331" decimals="-6" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDI5OQ_59517e26-6648-47b8-a5d5-66cc61d9e096">1</ix:nonFraction> million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="if0ba58f0b4804781a450e1eafe670429_I20220331" decimals="-6" name="abbv:TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDM2OA_5bf27f04-52e7-45b2-bc56-7378bbae3bc5">24</ix:nonFraction> million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to AbbVie&#8217;s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive loss pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="i73a0138eece144c7b6d7536ce561b961_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDYzOA_adce4b49-a22e-40ee-b39b-b1b1c56d0e9f">99</ix:nonFraction>&#160;million for the three months ended March 31, 2022 and pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="ia6e338b61d1141f5b8c13e661709f6b5_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDY3MA_8a56b895-8328-4a49-96ef-91c9654e7a4a">382</ix:nonFraction> million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDQ_b95539fd-da20-4667-aa8d-b2652a132805" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement&#160;of earnings caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7bd97603484ae1802843d027d4882c_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMy03LTEtMS03MzI1Mw_0cb0bea1-24e5-40e3-8bfd-8d2458e45033">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1681dbbb7fe645d6853c751bdc56bbad_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMy05LTEtMS03MzI1Mw_d8917499-82e5-4397-8dfc-20cc3f72e97f">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8d036846c41e7ae1fd8954a4b4f77_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNC03LTEtMS03MzI1Mw_8c468b34-767b-4438-804a-9118565a0750">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f7ce3635354a61a150bfdfc38169f5_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNC05LTEtMS03MzI1Mw_0c4d7810-2dcb-40a7-8ac4-98fd4d7cfd23">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id741975d93ce432ca3360bc759262c9c_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNS03LTEtMS03MzI1Mw_3d5c0c73-31e3-4307-aa58-33ca4e4cdf43">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib000460db5074562808f7f1eb5c6419e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNS05LTEtMS03MzI1Mw_0e0f472a-82bf-4f34-ab04-f8e868d48846">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury rate lock agreements designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f6fa4fbbe04394a9fe1a7d581eaec0_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNi03LTEtMS03MzI1Mw_013212d1-04ae-40dc-8009-2e2f0db68953">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64b83983f224c629b47278996994efe_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNi05LTEtMS03MzI1Mw_02602c5d-26a2-4d1f-96c1-5b37926c4693">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47ba7efcd0f44228bd851a9cfd907eca_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOC03LTEtMS03MzI1Mw_e5121cac-f89a-4001-af69-ddcb87c5eeb0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if79203b4f0e042919ad95c75b6c9ed1d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOC05LTEtMS03MzI1Mw_9fccdeea-6701-4e41-8fa8-61aaaca2748f">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3338f9b94ba644cdb8a5bfb1a5c29358_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOS03LTEtMS03MzI1Mw_a02dce1c-74c9-4023-a5c2-997ce86f63eb">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib576612385b34159a385efbbb44ac312_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOS05LTEtMS03MzI1Mw_f3c726d5-7bec-45f3-bbdb-687d1ec7493b">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as hedged item in fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2ab8d0faba462a8cdae1d115c9ac72_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMTAtNy0xLTEtNzMyNTM_783d6ef0-3f94-4448-b483-86b61e631983">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859211caa6b54eaa83b28f597db71274_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMTAtOS0xLTEtNzMyNTM_6863731a-7c13-4d95-9362-b645f2ce21c3">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 2 &#8211; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 3 &#8211; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company&#8217;s management about the assumptions market participants would use in pricing the asset or liability.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ic3a8d7b334ad417381e4c2aaa00d47cc" continuedAt="i3ced7f853c1c4ae1a585dd65d5426a15"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIwOTM_e53bdd43-136c-42df-b926-56fab805c90c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable <br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy0xLTEtMS03MzI1Mw_7b1af346-6b60-4afe-ad70-649e4551882d">6,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy0zLTEtMS03MzI1Mw_3db9dd1b-1da1-41b0-8918-e8afdb852e58">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy01LTEtMS03MzI1Mw_397f23db-81d3-4c43-ae61-ba928277ebcb">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy03LTEtMS03MzI1Mw_6577533d-eae6-4531-afc3-5de6c4901dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a1275578fd4eab9c1a98a3a69b8994_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC0xLTEtMS03MzI1Mw_3b45f71f-9932-42a7-bb50-3ef82bfa9984">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547378d779a94424afb2f81c95c765e8_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC0zLTEtMS03MzI1Mw_01ffaaeb-6f4e-4421-9c54-f7518f626e8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifced2c43ef9a4921b504c12eeb7b2ef1_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC01LTEtMS03MzI1Mw_49a5a642-84c0-437a-9921-4ed756e32357">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0d7604169c4be790295c65966d9417_I20220331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC03LTEtMS03MzI1Mw_fff10398-75b6-463e-9f76-f8dedad6af83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS0xLTEtMS03MzI1Mw_b850f83a-36a5-4b80-9123-92c1215589c3">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS0zLTEtMS03MzI1Mw_874ac87f-3468-4d66-af4a-fb6ce5adb02d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS01LTEtMS03MzI1Mw_0483490f-fa53-41cb-847f-7836fc72109d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS03LTEtMS03MzI1Mw_26045942-d79b-4551-adf7-5f7da76b3a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi0xLTEtMS03MzI1Mw_5d383c0b-701c-4ae8-9cf8-8a34697d8fd4">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi0zLTEtMS03MzI1Mw_49db4075-9ef8-4cb3-8d68-d4864688f042">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi01LTEtMS03MzI1Mw_8e778f80-a6b9-472d-afd3-23e2ae26deeb">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi03LTEtMS03MzI1Mw_e8282ac4-cc16-4594-83f9-e108938eed27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ad1758bd2446cea957f2ad4754f617_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC0xLTEtMS03MzI1Mw_88004ab2-39f5-467b-aa38-7aea65a00b21">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e694d0a849640f2baad8365a826d153_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC0zLTEtMS03MzI1Mw_84f56ad2-b2f0-45d1-b9d5-996f14ff6244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa6a41f682746a8ace32ddbe43016b7_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC01LTEtMS03MzI1Mw_9c48b418-3f14-4a0a-a9cb-f2c5ee3026cd">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af1965f163b48ea903e4c8e2f20baed_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC03LTEtMS03MzI1Mw_3dcc88ac-c343-4c53-943b-b4b193b6244c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtMS0xLTEtNzMyNTM_55954aab-ae51-4410-98b5-6b6292640ee4">7,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtMy0xLTEtNzMyNTM_0759bc3e-5a02-4b62-a3ee-c4105230f97a">3,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtNS0xLTEtNzMyNTM_bbba2543-0a54-4e22-ac11-ccbe5b21ca64">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtNy0xLTEtNzMyNTM_a40b3004-17e4-4118-a975-2231f1eeae21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItMS0xLTEtNzMyNTM_ec198ca6-e7ca-4ca8-83f4-d54d2aea7962">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItMy0xLTEtNzMyNTM_67fb8181-7d7d-4743-a227-c5855c5324f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItNS0xLTEtNzMyNTM_3ca3d180-ddf3-4aef-9108-0ea1aca467a3">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItNy0xLTEtNzMyNTM_537bdbaa-7879-4120-9542-61c3b065122f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ad1758bd2446cea957f2ad4754f617_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtMS0xLTEtNzMyNTM_47872965-1ecd-4626-877e-b39e96fcb09a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e694d0a849640f2baad8365a826d153_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtMy0xLTEtNzMyNTM_f3988187-cb99-4348-9a39-0923218b3f58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa6a41f682746a8ace32ddbe43016b7_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtNS0xLTEtNzMyNTM_eb1fd52e-074e-4e11-bc7f-08db91db4f0d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af1965f163b48ea903e4c8e2f20baed_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtNy0xLTEtNzMyNTM_1ec79ab3-6082-42d6-9d74-a05a3f92fae9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtMS0xLTEtNzMyNTM_8b9ef945-5ed1-492d-9629-461ea4b6aec3">13,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtMy0xLTEtNzMyNTM_fd291f51-14eb-491b-a375-a142de623dd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtNS0xLTEtNzMyNTM_6c572255-7e81-4c5e-bc68-c27b48b71901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtNy0xLTEtNzMyNTM_d638b04e-76e9-4a9b-ba30-688c529dfd4f">13,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38e263f9b26407aad657967962464cc_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtMS0xLTEtNzMyNTM_7f7c3b55-442a-48f5-b071-f03cc484fd8a">14,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab718c63b5884ec79c89e37caa022504_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtMy0xLTEtNzMyNTM_359a31a3-0140-4e41-ad59-136477d0badd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtNS0xLTEtNzMyNTM_a8c03493-0152-44c6-bc77-6c3de1767703">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtNy0xLTEtNzMyNTM_2baf25d4-3c2f-4a71-97fd-dcb994f46b3b">13,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable<br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy0xLTEtMS03MzI1Mw_a2f3450b-d97b-4c93-b280-f4539b8b6948">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy0zLTEtMS03MzI1Mw_2b54e3ba-2294-4da1-b500-f777557162bb">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy01LTEtMS03MzI1Mw_78a5fd77-c85c-4dd7-b0eb-355ae24a6ce6">5,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy03LTEtMS03MzI1Mw_f72e3675-6df8-457f-82c8-58c702f6c47a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b425e8bb2fc4bf98f7703e322eb47ea_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC0xLTEtMS03MzI1Mw_5e3f2279-d16c-419f-86cb-92bb1820b36e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2a58ae48e34c639ba8dc2259cc6bf8_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC0zLTEtMS03MzI1Mw_10188c07-d41c-4860-a961-f960064fc53c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99530b1ca1f4637a531747b189b68e1_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC01LTEtMS03MzI1Mw_3fa8bad5-a326-43ad-9532-72462249db78">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b92c917f6c46e8bec270fac1ab97be_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC03LTEtMS03MzI1Mw_e09763d9-ccfe-41ec-9417-91c36f74d518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS0xLTEtMS03MzI1Mw_2ef959ad-e53f-44ed-87ff-f399e3fc54ef">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS0zLTEtMS03MzI1Mw_9482f454-42ee-4a6d-9ab6-ef8b5b494fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS01LTEtMS03MzI1Mw_314bc895-2e97-48bb-b711-eebf835e44a8">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS03LTEtMS03MzI1Mw_2c55d62b-bbdd-45b2-9e50-26902c14b7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi0xLTEtMS03MzI1Mw_e1a8d3de-3174-4ce2-913f-10f731262240">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi0zLTEtMS03MzI1Mw_0015bc62-d9d9-45a3-9056-8725ee4fab66">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi01LTEtMS03MzI1Mw_4af78264-b00b-4341-9f4a-aa6c802a2a27">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi03LTEtMS03MzI1Mw_bcff001a-760b-477c-9570-8b3c30cafa77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy0xLTEtMS03MzI1Mw_25607d2c-7295-4d86-8bf9-ffacef8bd111">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy0zLTEtMS03MzI1Mw_9f3a0f60-f481-4edb-9d20-e3a44b2dcd71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy01LTEtMS03MzI1Mw_d325db0e-252d-4adc-820b-abbf846c4d04">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy03LTEtMS03MzI1Mw_339ac371-0314-4401-be84-6db5e7c6d3a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ad90d3c5e24243a4f6eb626050ecbe_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC0xLTEtMS03MzI1Mw_f38f3d0d-ec7f-46e7-9b25-62c5be07af4f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c1d4df013d43b6a59943a73db0d1fc_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC0zLTEtMS03MzI1Mw_34ac3567-513f-4ec0-a22d-0aeb5193947e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e05944c5ce844a18dea78c42fefb97f_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC01LTEtMS03MzI1Mw_da5eb27b-a0b4-40e9-b584-8b0f93fa5bda">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2306289346ba4f6eac115558f89ffb15_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC03LTEtMS03MzI1Mw_19739ae7-eed7-41ef-a382-2d3a2942e887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtMS0xLTEtNzMyNTM_edcc36d0-19e1-43fa-b4a1-0463957e2213">10,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtMy0xLTEtNzMyNTM_da49f0f6-a342-4082-a1c9-bc6af140ca95">4,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtNS0xLTEtNzMyNTM_ee70abd1-c97f-4c9b-bea1-2ee4940783ea">5,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtNy0xLTEtNzMyNTM_84924d73-1989-42d5-960c-68cf624064b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItMS0xLTEtNzMyNTM_df7f0640-fa17-4513-9e7e-63f6c9c27efa">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItMy0xLTEtNzMyNTM_3fd91619-82cb-42aa-9115-9c628298e614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItNS0xLTEtNzMyNTM_882e8e86-3fc9-4077-89c4-e0ec24b7e088">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItNy0xLTEtNzMyNTM_97198781-e44d-4c5a-a6d6-2bd6761340cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ad90d3c5e24243a4f6eb626050ecbe_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtMS0xLTEtNzMyNTM_6f7daaeb-06d9-4d73-91a0-e968a57db3ed">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c1d4df013d43b6a59943a73db0d1fc_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtMy0xLTEtNzMyNTM_20d770c6-8581-48d4-bc69-298c5da76620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e05944c5ce844a18dea78c42fefb97f_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtNS0xLTEtNzMyNTM_4b33ccd3-3c74-4681-a12f-a7246aba7e6a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2306289346ba4f6eac115558f89ffb15_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtNy0xLTEtNzMyNTM_02b7fc5b-e60a-48e3-8f79-414f08b51774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtMS0xLTEtNzMyNTM_872f550f-ebe9-4aa1-b978-3cb8e86b3a53">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtMy0xLTEtNzMyNTM_64cd1b18-bbea-4ffc-93ed-0171c4866d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtNS0xLTEtNzMyNTM_4f18e23d-542d-4dbd-aef2-dbc49719f1ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtNy0xLTEtNzMyNTM_c55aef7d-7b8c-4134-87e4-0b28c0a22ec3">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtMS0xLTEtNzMyNTM_b6c29017-c8fe-4bd1-9798-15145261e8b8">14,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if649f364c260430e996cc0e7faf77825_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtMy0xLTEtNzMyNTM_e57d396e-5112-4854-8ba6-14371266e3bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtNS0xLTEtNzMyNTM_4cbc0d2f-52b6-4585-978f-d2b3b0b98e37">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtNy0xLTEtNzMyNTM_bee800ca-cb65-41f3-a5db-a8481df13dc0">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i3ced7f853c1c4ae1a585dd65d5426a15" continuedAt="i653d992abe1a41be812978532a3d9c4e"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. </span></div><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDU_da4c56ee-ab84-436c-a951-b6b285156327" continuedAt="i59f9e4eefcf5436d81aa9f8e3489dad0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if76fd003b44e4e00b01dd0219527e8f6_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjJlOTI4ZjljOWU4NTRlNWZiMTYwNGY3ODQ4YWRlMTNmXzE2NDkyNjc0NDE2ODQ_d0e959fe-d860-4795-9cc3-b8545de9d413">0.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3316afc52f864995939b74f4200c4d5d_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjJlOTI4ZjljOWU4NTRlNWZiMTYwNGY3ODQ4YWRlMTNmXzE2NDkyNjc0NDE2OTI_9c21d1ed-e8c7-4e75-a080-5a00391862a4">3.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie41be7ae9a7746e29ab56e1c3957336c_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmI2ODBhMDkwNGJjZTQ2ZmViMjljYmVjY2Y1NGIzYzMyXzI3NDg3NzkwNjk0NTA_cef10409-9e56-4640-b348-5c474e51230b">3.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibaaf5c1772824540821269f5a7d5d060_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjRhOWUwNTg1ZjEzODQ1Y2E4NzAzMzliOTdkNzlhOGMzXzI3NDg3NzkwNjk0NTM_65a9005a-a7d0-4fee-b00e-9235bc5a3160">0.2</ix:nonFraction>%- <ix:nonFraction unitRef="number" contextRef="i2e6a0250795b4caeb9007fccb2fb25e6_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjRhOWUwNTg1ZjEzODQ1Y2E4NzAzMzliOTdkNzlhOGMzXzI3NDg3NzkwNjk0NTY_a93bfc2a-eb8e-4cdd-b65f-f9573a7ae001">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7064869e3d004e11826a6f8e545956e8_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjgzM2JmZTkxZDBkZDQyMWE5NDI5NmQxMjEyNGE3M2MzXzI3NDg3NzkwNjk0NDQ_274ad924-0f34-4f79-977f-36dc21f67545">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for unachieved milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0e23bbc802e473d941d50ddec1eac96_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjViYmU5OGFkYWQwZTQ4M2VhMTE0YzQyNmJkOWUwNDhjXzE2NDkyNjc0NDE2ODM_1f720098-413b-4184-9b0d-dcc083ebdb84">89</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="idc34b4f0b824400cb3e06c112446fd78_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjViYmU5OGFkYWQwZTQ4M2VhMTE0YzQyNmJkOWUwNDhjXzI3NDg3NzkwNjk0NzM_df41c27a-8be9-4a76-afd6-6108f0c36160">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa6c770a5e4e43219c664f8eeaebc92b_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmMzYzcyMDAxZGQyNTQzNTRhYjBjZGRmMzEwOTkxMzQ0XzI3NDg3NzkwNjk0NTA_f621a23b-df7f-4771-a959-3f4a432c6de1">91</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifeca827be1174ca8b3b26a2dd3170414_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjUyYjVhYWQ5ZDdjYTRlNWJhMjI0MWI4Y2I2MTQ1Mjk1XzI3NDg3NzkwNjk0NTE_210fd7dc-6734-4f08-8930-315215149d25">89</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4c6e00071bb14c0f9134687f14d184c0_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjUyYjVhYWQ5ZDdjYTRlNWJhMjI0MWI4Y2I2MTQ1Mjk1XzI3NDg3NzkwNjk0NTU_a06df4bd-66c5-42b7-bec1-a1d801b405b0">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40f7d8e61c394c11942ca3d90870ce76_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0yLTEtMS03MzI1My90ZXh0cmVnaW9uOmQ0MGEzNmJlOGMxYzRjM2RhOTE4ZWYwODI5MTZiYTcwXzI3NDg3NzkwNjk0NDQ_22cd617e-882f-4a62-a3a0-f377e022ebfd">90</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for royalties by indication</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36a5db71b7bc44afa79f34197c0d50c0_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NTg_1139f260-ebf0-4997-a8bf-8e3e9c1797b3">56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3b7bbcb6f78a486c9aaaf2cc66ad620a_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NjY_34203fed-736d-478f-9829-5ad6abaa8128">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a58f36c0a0f455fb16aee3fddf5e537_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0">96</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c4ab8ef49f6437ea3dc95bf05981bfc_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NDQ_7949dad9-89a4-41ee-b66a-7fc7207216bb">56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i088dd727214a49e5bdaa60f93779a823_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NTA_04ada94e-64b7-459a-a5dd-adeb4f6ea353">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3155754d608b4eb491cdd36b45bcc5de_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242">96</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86308a2e6f2a4ecfba5255d3af29d432_I20220331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjk3YTdiZDUxZjg2ZjQ5NGJiZjY4YmZkZmVhOGEzMDhlXzI3NDg3NzkwNjk0NjI_3b0ced0f-8f99-4445-907a-3c0d71be910e">2022</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="id9678c4caaf349ba8006f44b404b1b82_I20220331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjk3YTdiZDUxZjg2ZjQ5NGJiZjY4YmZkZmVhOGEzMDhlXzI3NDg3NzkwNjk0NzI_69b5d90e-c630-43e4-b77f-dbe9fdc99247">2034</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d2bc0b8db334803be5cea99172bad7f_I20220331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjc2MzFmNTcxMzBkZTQyZjE4NmQ5MmEwNjk4ODM5MGM1XzI3NDg3NzkwNjk0NTA_6fba84dd-6dc2-4522-a73d-12e386424d43">2027</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdc8ba9e255b47fbb82c3c726dd8508a_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOmU2OTRhY2VkY2VhOTQyMTc5YTIyZDVjNDA4ZTk1ZmMyXzI3NDg3NzkwNjk0NDQ_5fc5885d-234b-4571-8b62-077908990d07">2022</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i1455f288cfc245b69c8e6fa1ee29a92c_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOmU2OTRhY2VkY2VhOTQyMTc5YTIyZDVjNDA4ZTk1ZmMyXzI3NDg3NzkwNjk0NTE_7c73872c-d194-4650-b82e-07c88cc47f6f">2034</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i653e387441bf474ba40509d89d957072_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS03MzI1Mw_1e8fbd73-3e85-44c5-8cfb-b0e0822a4975">2027</ix:nonFraction></span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a" footnoteRole="http://www.xbrl.org/2003/role/footnote">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</ix:footnote></span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b" footnoteRole="http://www.xbrl.org/2003/role/footnote"><ix:continuation id="i59f9e4eefcf5436d81aa9f8e3489dad0">(b) Excluding approved indications, the estimated probability of payment ranged from <ix:nonFraction unitRef="number" contextRef="i01d4a0312e1a42c1bbb49eebf6fb2dbc_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_0f1e56d2-f43a-4f83-bd88-7a819ad1ed4f"><ix:nonFraction unitRef="number" contextRef="ib6f0399851154ccb8d747ab261a55ff7_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_2255b661-58b9-448c-a8da-5793bd88bc4d">56</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i5e22014612a6456496ade50c3c0e598b_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_5d256177-b7e1-4915-a8f0-e491dbb9f298"><ix:nonFraction unitRef="number" contextRef="i6150f60c782f4bbe93e9e862b343af55_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_6cae88be-9805-4211-99eb-5aa8a24bbdff">89</ix:nonFraction></ix:nonFraction>% at March 31, 2022 and December 31, 2021.</ix:continuation> </ix:footnote></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_23556952-0e2b-4c08-99c0-2f6b33baa242"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_a1ddc400-ce0f-422f-8b58-502ad0d49b57"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_af6a8924-aea1-477c-aff9-2976d067f7e6"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_cd407c3f-3b97-4b47-80da-3d25ae11fcb2">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIwOTA_100b962c-957a-43d3-a551-059f15431102" continuedAt="i2e62e9d6612049bf966586cbe30b8cc6" escape="true">The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:</ix:nonNumeric></span><ix:continuation id="i2e62e9d6612049bf966586cbe30b8cc6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfMi0yLTEtMS03MzI1Mw_fce6ad73-5c38-4177-9519-e43dde40a9f1">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6accb844205d4e909ea7d6f406d2b865_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfMi00LTEtMS03MzI1Mw_382bb798-b551-4fda-96c6-4742e882011a">12,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNC0yLTEtMS03MzI1Mw_69b0b4be-0d5c-4446-bbee-159e6cd2147d">748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNC00LTEtMS03MzI1Mw_402c8bb3-37d5-4303-ad01-b5d357d25499">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNS0yLTEtMS03MzI1Mw_ddd6632d-52b8-4685-8f09-71053e6937ec">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNS00LTEtMS03MzI1Mw_507e5aca-753b-4eca-8887-24c735a1ffc0">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNi0yLTEtMS03MzI1Mw_fb7fd865-7fc9-4ae9-9f22-c448c227954e">13,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf70c299b6747128fa4a148bd06c306_I20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNi00LTEtMS03MzI1Mw_9a4f4f93-61f5-4419-9bfc-48b8555f4253">12,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value recognized in net earnings is recorded in other income, net in the condensed consolidated statements of earnings. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial instruments are carried at historical cost or some basis other than fair value. <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDM_910c352f-0926-4622-bb36-74058eab4e5c" continuedAt="ibcb25eeb717e4fc882fb7f8abc22200b" escape="true">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2022 are shown in the table below:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ibcb25eeb717e4fc882fb7f8abc22200b" continuedAt="i9a43199d8d074513b383ff5d2afdb7a3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi0xLTEtMS03MzI1Mw_ec6557c6-4e00-49e1-81e3-3d8e78bb9032">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi0yLTEtMS03MzI1Mw_26abb2c2-8d6f-4b23-8f78-5884b5ada290">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c77a1980b4f8fb626087d04f359c2_I20220331" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi00LTEtMS03MzI1Mw_4edc8536-dbfc-4d47-a360-c1dbf775b231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi02LTEtMS03MzI1Mw_84a5019b-fda2-49c4-beae-82c72713fb14">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi04LTEtMS03MzI1Mw_a93b2245-d4ce-46ff-92d2-ffef3954ffae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy0xLTEtMS03MzI1Mw_84476e5c-8d7c-4829-abc2-5b2abefad4cb">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy0yLTEtMS03MzI1Mw_2d05748d-9d90-4bda-a163-b79dd691ac53">9,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy00LTEtMS03MzI1Mw_8e5f56b3-b846-4db2-81a8-d0a46ca894f6">8,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy02LTEtMS03MzI1Mw_d39416d2-d5dc-4a4e-b778-e83d341839a4">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy04LTEtMS03MzI1Mw_385b0e1d-dd16-4a9e-a97f-0c11faa81e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC0xLTEtMS03MzI1Mw_18332905-2e8b-4488-8522-4f92e26c2e06">63,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC0yLTEtMS03MzI1Mw_98dc593e-30d3-42f3-87ad-743d1255ce0d">65,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC00LTEtMS03MzI1Mw_580f34ac-5a65-413f-a94c-e98086ef8be0">64,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC02LTEtMS03MzI1Mw_e1d8151d-5ef5-46a2-812c-76cc2306d387">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC04LTEtMS03MzI1Mw_3a014d2e-8f45-461e-ad3d-30d5e202d284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS0xLTEtMS03MzI1Mw_b5ec4535-03a9-44c8-ba5c-213b706d3a7f">73,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS0yLTEtMS03MzI1Mw_3ce24172-3512-436b-8cd2-6a96844f948d">75,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS00LTEtMS03MzI1Mw_d9559910-c28d-4090-b849-0bc02256f3cd">73,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS02LTEtMS03MzI1Mw_77c5a49d-c00e-411e-8308-9e31bed78efa">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS04LTEtMS03MzI1Mw_17815096-4c3e-4b4f-a2ae-32b2837f3ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i653d992abe1a41be812978532a3d9c4e"><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i9a43199d8d074513b383ff5d2afdb7a3"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c49899324342418b3c03ecab096e69_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi0xLTEtMS03MzI1Mw_3ea8bba2-220c-4c8f-bc45-6f40036305aa">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi0yLTEtMS03MzI1Mw_10165b74-d3be-402f-a798-ab22fec74d61">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3079fe6a94b4043bd136bd42880f7e2_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi00LTEtMS03MzI1Mw_8401bdd8-e6ba-4ae3-9d19-14252e1f0720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafb386815a84014b6e79d88e23df483_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi02LTEtMS03MzI1Mw_bd649abc-9610-4bba-9fed-c1e33c4212c6">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi04LTEtMS03MzI1Mw_7a2ee053-2092-4357-a168-b009f2343221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c49899324342418b3c03ecab096e69_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy0xLTEtMS03MzI1Mw_e863d395-3e03-4939-a8e1-09b7bb71d98f">12,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy0yLTEtMS03MzI1Mw_911f0c63-673b-462a-86de-546bafb39438">11,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb19f61a177a44cc83608f369fc35200_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy00LTEtMS03MzI1Mw_d1d82fd7-5546-4daa-ac7c-a28e80662c0c">11,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafb386815a84014b6e79d88e23df483_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy02LTEtMS03MzI1Mw_88a73813-5a00-4e32-860a-e73188283410">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy04LTEtMS03MzI1Mw_c55c3667-d87c-4374-841f-4f7722190513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c49899324342418b3c03ecab096e69_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC0xLTEtMS03MzI1Mw_d50e863c-3edb-4679-88a8-de32e17f85b8">64,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC0yLTEtMS03MzI1Mw_d846bc2b-8e9a-415e-b09d-c68a7c1c3bad">71,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb19f61a177a44cc83608f369fc35200_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC00LTEtMS03MzI1Mw_6974b90c-2316-4faf-b7e7-0ee6b474cb5f">70,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafb386815a84014b6e79d88e23df483_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC02LTEtMS03MzI1Mw_560b71b5-1de2-46ef-838e-38343a0ffe61">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC04LTEtMS03MzI1Mw_f1294b3a-c59f-4daa-9318-5ab545c32267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c49899324342418b3c03ecab096e69_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS0xLTEtMS03MzI1Mw_4971d2e4-0359-4820-9b6f-90e7b818b0cd">76,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS0yLTEtMS03MzI1Mw_9bcba3f5-2edd-4014-9ece-72d663988109">83,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb19f61a177a44cc83608f369fc35200_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS00LTEtMS03MzI1Mw_185d839a-d1b3-46bc-9ba8-30f36fcc66f2">82,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafb386815a84014b6e79d88e23df483_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS02LTEtMS03MzI1Mw_6afbfdbc-88a5-49b6-80d2-4204a334b10c">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS04LTEtMS03MzI1Mw_0f30e809-712e-4355-9e87-d25d1a5a6634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTA3MQ_f68f08ac-ad79-4287-a6bd-9521dd11fbdb">147</ix:nonFraction> million as of March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTA4Nw_b215e944-2c71-4796-a771-f3f906066a22">149</ix:nonFraction> million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of total net accounts receivable, <ix:nonFraction unitRef="wholesaler" contextRef="i95aad88173d14db798e85a935c24c68b_D20220101-20220331" decimals="INF" name="abbv:NumberOfPrincipalUSCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTI2NQ_a5b25310-07b4-411f-b9e4-032274334647">three</ix:nonFraction> U.S. wholesalers accounted for <ix:nonFraction unitRef="number" contextRef="i6a1415a76d304bdd903790a631d4b562_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTI5OQ_5d33445e-e46f-4316-87d7-532b0571ebd9">74</ix:nonFraction>% as of March 31, 2022 and <ix:nonFraction unitRef="number" contextRef="ie5fd10e4797b4759b2ad9ee884eb18fb_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTMxNQ_c0a1db7f-bd06-4c2a-97c4-0af505732cb6">75</ix:nonFraction>% as of December 31, 2021, and substantially all of AbbVie&#8217;s pharmaceutical product net revenues in the United States were to these <ix:nonFraction unitRef="wholesaler" contextRef="i95aad88173d14db798e85a935c24c68b_D20220101-20220331" decimals="INF" name="abbv:NumberOfPrincipalUSCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTQxMA_a5b25310-07b4-411f-b9e4-032274334647">three</ix:nonFraction> wholesalers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humira (adalimumab) is AbbVie&#8217;s single largest product and accounted for approximately <ix:nonFraction unitRef="number" contextRef="idb70f3e9a3064175beb5a4288f9555cf_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTUxMw_7808ce34-b29f-4709-83ae-46e43eff3a3e">35</ix:nonFraction>% of AbbVie&#8217;s total net revenues for the three months ended March 31, 2022 and <ix:nonFraction unitRef="number" contextRef="i598f780a95a34397b93cc33d29482fbf_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTU2Mg_917b7ce7-3452-49c4-b914-ec1d6eddfdd6">37</ix:nonFraction>% for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the company repaid $<ix:nonFraction unitRef="usd" contextRef="if319dff6fb6d4c9b9e70b7590afec644_D20220101-20220131" decimals="-8" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzg0ODI5MDcyMjAyMg_9f655c38-f9e0-4c0f-9e6c-171b85fe79ba">2.9</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id24046754e794d98901ac09a9a57728a_I20220131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA5OTUxMTY1OTY4NQ_61f8e13e-05d8-4793-a527-3482e9abff51">3.45</ix:nonFraction>% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the company refinanced its $<ix:nonFraction unitRef="usd" contextRef="ia646a389a6944ee39075a400a0260d9f_I20220228" decimals="-8" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA5OTUxMTY1NTY5Mw_6c281ecd-4bfb-4950-bd00-cd6d64125b93">2.0</ix:nonFraction> billion floating rate <ix:nonNumeric contextRef="iedf4aed6ce494fb0b76f1715e4bc5fdb_D20220201-20220228" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0OTI2NzQ2OTUwOQ_f2dce082-cda0-4d85-94ff-78e1b132304f">five-year</ix:nonNumeric> term loan. As part of the refinancing, the company repaid the existing $<ix:nonFraction unitRef="usd" contextRef="iedf4aed6ce494fb0b76f1715e4bc5fdb_D20220201-20220228" decimals="-8" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0OTI2NzQ2OTU3NA_e8717d41-5c5a-4d99-bf5d-eacfa9e70753">2.0</ix:nonFraction> billion term loan due May 2025 and borrowed $<ix:nonFraction unitRef="usd" contextRef="i5d290b478df340cb86cfefef5344e881_I20220228" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0OTI2NzQ2OTU1OA_20253348-c9b2-427e-9cf5-c90c19f3ad85">2.0</ix:nonFraction> billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.</span></div></ix:continuation><div id="ic89f06320f9c4f57b19c511822f36cac_76"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:PostemploymentBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RleHRyZWdpb246MzBmOWVmMjk3MGRjNDk3NTg5NjZjNDNkZTM1OTc3OWZfMjQ0_edc7fb5f-7c2d-4e7a-943b-743e976a2431" continuedAt="i7cd35ce7cf8d45b791b836a8a6536a1e" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Post-Employment Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RleHRyZWdpb246MzBmOWVmMjk3MGRjNDk3NTg5NjZjNDNkZTM1OTc3OWZfMjQ3_73bb8d3f-d8a6-4688-ba7c-901f4fd7ebae" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost relating to the company&#8217;s defined benefit and other post-employment plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined <br/>benefit&#160;plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;post- <br/>employment&#160;plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy01LTEtMS03MzI1Mw_488dd1c4-fcac-44dd-9935-5adc427c4f1c">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy03LTEtMS03MzI1Mw_0d51ac4d-cc5a-4fd9-b15b-deee1d9ffb74">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy05LTEtMS03MzI1Mw_97b56fd3-7f4e-42ba-b83e-2e5267ecc0be">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy0xMS0xLTEtNzMyNTM_671f4df8-a67d-4a87-859e-ca84e423df81">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC01LTEtMS03MzI1Mw_c7e579ce-a731-45b7-821b-14318b84178b">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC03LTEtMS03MzI1Mw_5ad2697c-86f1-4d42-9ce3-85e0c4a77b4e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC05LTEtMS03MzI1Mw_afbe2674-a3cf-4625-ae85-c20dff5f616e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC0xMS0xLTEtNzMyNTM_e70d36eb-a7a4-4b49-b853-38bc644b8f0f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS01LTEtMS03MzI1Mw_2fcf2d22-9d64-4cc2-8281-d38e9e8b987e">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS03LTEtMS03MzI1Mw_e0c3c265-1736-4ae4-bf59-d05b0658672a">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS05LTEtMS03MzI1Mw_caafee07-dbd1-41cd-9da1-781266df324c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS0xMS0xLTEtNzMyNTM_043cdd3a-76b0-4390-a35a-aec8d8795b79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi01LTEtMS03MzI1Mw_d07abbcd-738d-4ed6-b400-345e7a982614">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi03LTEtMS03MzI1Mw_5868af74-f1ca-48b9-9f3d-e2fa478c0796">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi05LTEtMS03MzI1Mw_4663028c-2c6b-4ecc-a7eb-7991a7c1d27a">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi0xMS0xLTEtNzMyNTM_2bea99c9-92fa-40a1-80ad-30d6361b6993">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy01LTEtMS03MzI1Mw_342d4792-b1f1-4dbd-a881-a75475c86b6d">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy03LTEtMS03MzI1Mw_c3665630-32e5-45b0-b7c4-7c9484eab28b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy05LTEtMS03MzI1Mw_3e8f75c8-4cf7-4175-8c23-da7997a30086">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy0xMS0xLTEtNzMyNTM_b3b361d6-a2b6-404a-909b-5bea4958777e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC01LTEtMS03MzI1Mw_07c564b2-7ddc-44b8-92c4-825f960211b0">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC03LTEtMS03MzI1Mw_9e68bcf6-f68d-4a67-a76c-c1106de49f54">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC05LTEtMS03MzI1Mw_f658938d-68ec-4d89-996a-138a1197afbc">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC0xMS0xLTEtNzMyNTM_29570d0a-0a66-4254-a97d-fc4de62ab605">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7cd35ce7cf8d45b791b836a8a6536a1e">The components of net periodic benefit cost other than service cost are included in other income, net in the condensed consolidated statements of earnings.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">15</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 10 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwMQ_647a1771-735b-4506-b0a5-95143bbe25de" continuedAt="ib646fc8b0806444aa881f041d36654b0" escape="true">Equity</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="ib646fc8b0806444aa881f041d36654b0" continuedAt="i20fa6a6b29fe432293dc90c233bfe75b">Stock-Based Compensation</ix:continuation></span></div><ix:continuation id="i20fa6a6b29fe432293dc90c233bfe75b" continuedAt="i622cdc1d751040dbafda97df89408140"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2NA_a4a4e6a0-1a26-45a7-b9ca-c51c1678f893" continuedAt="i364b730502e54296aa4a668d6128e057" escape="true">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:</ix:nonNumeric></span><ix:continuation id="i364b730502e54296aa4a668d6128e057"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79841cf14ea346c48bdbc856f1e4b860_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMi02LTEtMS03MzI1Mw_ccc8a0d7-a255-46c0-8c21-d5db2870edb9">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88ba3758b6c416da9c9db84a7ca5778_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMi04LTEtMS03MzI1Mw_ba1cba0d-4db2-4283-b027-b53e699209af">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f9a43336ae4b0da381254b468ae09c_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMy02LTEtMS03MzI1Mw_9610329e-e7c6-4798-ac02-a7cf98b279bc">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7badfe6657634d348d22e9be1faa35ea_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMy04LTEtMS03MzI1Mw_4fd7e9ba-9f06-4efd-8570-14b16a0e1486">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54988d2c4f2f40c2933727e2b8be27ff_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNC02LTEtMS03MzI1Mw_3f68270d-d044-4237-ad67-9bdf82e3a6ab">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3001aef538c54c44b5812a99e4845adc_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNC04LTEtMS03MzI1Mw_6a259d62-9ef1-4062-b2b4-18fa1d446484">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNS02LTEtMS03MzI1Mw_4bc27963-ae21-4d83-8e86-bc3433f1ba29">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNS04LTEtMS03MzI1Mw_caeb63a6-cd2f-467b-874d-cd9fac28b578">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNi02LTEtMS03MzI1Mw_566a1e70-5b8f-4390-b16c-dce120b72695">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNi04LTEtMS03MzI1Mw_7f959620-ef5d-404f-8384-9131c6b1871c">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNy02LTEtMS03MzI1Mw_d1151ec7-62c5-4366-b468-5d2de4e9488a">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNy04LTEtMS03MzI1Mw_7cce9d1b-6a90-4c2a-9b9a-bcceccdf42a2">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, primarily in connection with the company's annual grant, AbbVie granted <ix:nonFraction unitRef="shares" contextRef="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfNjM5_6cfa84db-b077-4a76-8c35-be6a353a7a19">0.9</ix:nonFraction>&#160;million stock options with a weighted-average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfNzA1_a2be6f5d-6ea0-401b-aec1-8630750af893">22.83</ix:nonFraction>. As of March 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="icbf3ce65514c443c8ef37159d35d4a69_I20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfNzE5_edcb99ef-15e6-4953-8a25-7705b333973d">15</ix:nonFraction> million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfODQ5_0c6c36dc-7142-4841-8116-fd5a2deb3a98">two years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs and Performance Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, primarily in connection with the company's annual grant, AbbVie granted <ix:nonFraction unitRef="shares" contextRef="i5e56837ed6bd423c89d802b44906df17_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfOTY4_661e766a-c6fa-4471-8ad1-b29ece80f8c5">5.6</ix:nonFraction>&#160;million RSUs and performance shares with a weighted-average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic438b74601344b28a5a621e09638dfa5_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTA0OA_552814b6-7048-48c5-a599-f21a0017f810">145.54</ix:nonFraction>. As of March 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ic438b74601344b28a5a621e09638dfa5_I20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTA2Mg_f51142f9-bd0c-490f-b39e-73842ea982b2">955</ix:nonFraction>&#160;million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="i5e56837ed6bd423c89d802b44906df17_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTIwNg_4b07e495-1675-49f4-bc7b-f808ec978f71">two years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfDividendsPayableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk3Nw_a29c418f-3295-451c-80f6-28f821617c97" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quarterly cash dividends declared during 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/17/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bcd77a684aa4ecf8e6a62f0794f8418_D20220217-20220217" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfMi00LTEtMS03MzI1Mw_4f25a377-5652-41bc-b521-14c47d6f1df9">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e438a1448d44f418e9b8f452ccf2783_D20211029-20211029" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfMi0xMC0xLTEtNzMyNTM_b7f3d94c-d607-427b-a2d2-dce7341ade81">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/10/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2670f469a2ac4a459ccecfc909f364ee_D20210910-20210910" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfMy0xMC0xLTEtNzMyNTM_a8f02438-c7e2-467d-ab5c-412ecffb35a9">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/16/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72db19201e77427a944de55507b7fe80_D20210617-20210617" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfNC0xMC0xLTEtNzMyNTM_9ca16ffc-57cc-49bd-9836-56032288399d">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/14/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i300fb3fc7b084fe1ae13da9f57c82d71_D20210218-20210218" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfNS0xMC0xLTEtNzMyNTM_00b22f3e-6b11-46ad-a647-6b77aee89359">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie repurchased <ix:nonFraction unitRef="shares" contextRef="ib694cd894894414da5c46138d815dd90_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTczNQ_179d288c-4c4b-4176-8afd-d7c1676d3c39">8</ix:nonFraction>&#160;million shares for $<ix:nonFraction unitRef="usd" contextRef="ib694cd894894414da5c46138d815dd90_D20220101-20220331" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTc0OQ_ace58bd0-32f9-4b38-9b4a-feb688038a57">1.1</ix:nonFraction>&#160;billion during the three months ended March 31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i6bcc50f777fb4122a035380de5a8418a_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTc3MA_472345c8-7d01-49d7-9aff-40e3e35ceb0e">5</ix:nonFraction>&#160;million shares for $<ix:nonFraction unitRef="usd" contextRef="i6bcc50f777fb4122a035380de5a8418a_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTc4NA_c73e7f8e-8391-46a6-aed4-3648918de159">550</ix:nonFraction>&#160;million during the three months ended March 31, 2021. AbbVie's remaining stock repurchase authorization was approximately $<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTg3MA_114f1288-7ee2-4d45-8e0e-35269d11d62a">1.4</ix:nonFraction>&#160;billion as of March 31, 2022.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i622cdc1d751040dbafda97df89408140" continuedAt="i8e2925967be2463eaf328135ee6b9ab3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss </span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2MQ_21423e4f-a9b1-4c84-bfca-b2a59f1c6fb0" continuedAt="i65d6407736b0414488df938c58a3eb97" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and post-employment <br/>benefits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30d113b6de524e999e45640992e7d5f9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS0xLTEtMS03MzI1Mw_77f70682-aa47-4061-b81c-c1e5cc33936d">570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic307ce6fcfdb4b95a357b18194e6695a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS0zLTEtMS03MzI1Mw_ed9efadd-0b70-4c28-a654-3ba3fdffec44">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied4482ed129142548aa3b7aba9e6e05f_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS01LTEtMS03MzI1Mw_87a60b0f-b93c-46cf-b77a-d210f3b60ade">2,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b80412b07c14765b60765c6863daf16_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS05LTEtMS03MzI1Mw_fd66df94-3e37-4172-870b-7d694403bb60">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i305d5315aa3249959cf54167f51117a7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS0xMS0xLTEtNzMyNTM_3a7f76fd-01d7-4286-bce0-85eaa3e36fb7">2,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi0xLTEtMS03MzI1Mw_f8b1b970-28c1-417a-a13c-accc19b34ed4">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi0zLTEtMS03MzI1Mw_0c196775-8afa-4e06-abd0-8ac9707cf0a9">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi01LTEtMS03MzI1Mw_4a1d6403-b50c-424e-a577-1329c647cf59">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi05LTEtMS03MzI1Mw_69274530-2b25-41b5-97d3-90492c5cfa64">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi0xMS0xLTEtNzMyNTM_f3bb716e-6c7d-4a47-a30b-e74377f40787">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy0xLTEtMS03MzI1Mw_1298a307-bcbc-447e-837b-437f76c494b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy0zLTEtMS03MzI1Mw_f48164ac-7cd6-43fb-a521-ccce6d9a8f91">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy01LTEtMS03MzI1Mw_8b74cff2-1213-4912-a7bf-6b146f8edcb1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy05LTEtMS03MzI1Mw_dff79d81-9f2f-4fa0-8852-ca8568d86d3d">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy0xMS0xLTEtNzMyNTM_0d3dccb7-f5f7-44a2-b76a-5495135363eb">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC0xLTEtMS03MzI1Mw_298f64df-bbe7-4d83-94c3-58d32b8d3753">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC0zLTEtMS03MzI1Mw_c5a2f653-636f-4547-9735-558b206f4855">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC01LTEtMS03MzI1Mw_36f93c7f-07c3-4763-a333-e296a396fef9">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC05LTEtMS03MzI1Mw_9347fb8c-cdfe-4372-aec8-e495ca7ef79c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC0xMS0xLTEtNzMyNTM_59ef415f-bb77-4dde-aec0-3ce5e3ee7249">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38cbefbb7640470d8912c518f4d612c4_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS0xLTEtMS03MzI1Mw_a2a27db3-fbc3-462c-a009-15a092e1779a">801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0749feb42e4416b8b7650f417a1131_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS0zLTEtMS03MzI1Mw_403a9201-0f5c-4205-aaec-a91ada04e201">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a8127b3ac3548c3890da55bf63f1701_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS01LTEtMS03MzI1Mw_b8a6180b-1cd5-4b51-a6f7-95aa62fc8592">2,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice36e374d1fe41cd885017f660510ca7_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS05LTEtMS03MzI1Mw_92804cbc-58b0-4c67-a080-522492b6e035">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00bc0c90f91f4af0a5a3a88ab5477eaa_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS0xMS0xLTEtNzMyNTM_67f164da-e354-4460-bc13-a1dbc7015a90">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss for the three months ended March 31, 2022 included foreign currency translation adjustments totaling a loss of $<ix:nonFraction unitRef="usd" contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjA2MQ_96e17760-55c4-44a9-8b63-0e567a6341da">231</ix:nonFraction> million and the offsetting impact of net investment hedging activities totaling a gain of $<ix:nonFraction unitRef="usd" contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjE0NA_20b09ab5-2c30-4c26-9dc1-3c6796bbc789">130</ix:nonFraction> million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i65d6407736b0414488df938c58a3eb97"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;<br/>and post-employment <br/>benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba4be4766064887868cd838db3129a4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS0xLTEtMS03MzI1Mw_fe7eb643-5c2e-48ff-b0d7-910749fc9116">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13ba96e9d518432f846efbdefd0568c1_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS0zLTEtMS03MzI1Mw_3b9c3c4c-629d-480e-a9bc-cb6e7730c1a9">790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfa61ba6e74c4671b7c09c21de67bea5_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS01LTEtMS03MzI1Mw_8b1d9b67-75fc-4706-ac89-05607b6fe060">3,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f7baaa43f94988beb4cab455519ed9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS05LTEtMS03MzI1Mw_9e210a6b-a8d7-4be0-bc23-ed4c54775cc6">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef17bd343cf45f4a0064de2b7b25559_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS0xMS0xLTEtNzMyNTM_a8bb977e-b28c-4f5b-bd9a-89e070581d08">3,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi0xLTEtMS03MzI1Mw_5091bf29-43bd-431d-a704-7fb9db81eccd">677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi0zLTEtMS03MzI1Mw_5ecb2c41-ded5-47c1-9456-044ed82eed49">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi01LTEtMS03MzI1Mw_720bf9b4-2c7c-4781-a199-6f2a90a3017d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi05LTEtMS03MzI1Mw_171d1ad6-70f3-410b-a34f-f64b2ae56119">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi0xMS0xLTEtNzMyNTM_f855eef1-8a36-4cf1-80be-dcabedf16dd4">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy0xLTEtMS03MzI1Mw_61d391f1-9d0c-4152-97d2-7f8b158571d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy0zLTEtMS03MzI1Mw_c55f480c-7b37-493b-bbd0-d437c39d8f64">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy01LTEtMS03MzI1Mw_235ef38a-f6ab-43fc-a4c1-c2fe8af5ebb3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy05LTEtMS03MzI1Mw_a2b03e6b-bf89-4c9e-b4b4-d852b838f644">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy0xMS0xLTEtNzMyNTM_0e1bda45-a5a4-42c8-9cbb-929eefa3a23e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC0xLTEtMS03MzI1Mw_e14401c9-dfa9-476c-add1-c1dc16d322af">677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC0zLTEtMS03MzI1Mw_769e6d0e-35c3-4ef5-b0df-64cf7115895c">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC01LTEtMS03MzI1Mw_24867c57-01fa-4dbe-883f-fc6689a9ebf3">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC05LTEtMS03MzI1Mw_447e3161-da5c-40fa-9de3-8e0cbc174251">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC0xMS0xLTEtNzMyNTM_eaf61c04-c54d-4a68-9187-d327530dadb2">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32fccc997a0749b1bb81108be62eb6e8_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS0xLTEtMS03MzI1Mw_f0c16c0e-7b6e-4610-949b-0f71ce370d2e">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157ad54cc34c4b9e9f5f62ce15e5c956_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS0zLTEtMS03MzI1Mw_3a67128c-4e2c-48c8-81f2-2c6e5d5f69f3">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcc473aa8ebe448e985aa0a29dcd7e8c_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS01LTEtMS03MzI1Mw_5120133a-9fb5-43e1-9cbc-40d924229cf5">2,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce7636b82d0488790d551ca1286a964_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS05LTEtMS03MzI1Mw_97434751-500e-4eec-939f-7edc8464e0d7">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe0c4dc2984f481b92d6852e941b91b9_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS0xMS0xLTEtNzMyNTM_a663df18-efbd-4f3f-973a-ce8748b0af62">3,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss for the three months ended March 31, 2021 included foreign currency translation adjustments totaling a loss of $<ix:nonFraction unitRef="usd" contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjQ1Mw_414d4f41-8327-43fc-bdef-4a32becbc3fc">677</ix:nonFraction> million and the offsetting impact of net investment hedging activities totaling a gain of $<ix:nonFraction unitRef="usd" contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjUzNg_a7a98ad9-a4a8-4ce8-bb67-aa673c880201">374</ix:nonFraction>&#160;million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i8e2925967be2463eaf328135ee6b9ab3"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2OQ_f08f215e-185f-43d3-935f-b5ad69422b48" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact on AbbVie&#8217;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) (brackets&#160;denote&#160;gains)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedging activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on derivative amount excluded from effectiveness testing</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy01LTEtMS03MzI1Mw_dcbb1f13-4991-4b76-b758-f7b88b8d660e">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy03LTEtMS03MzI1Mw_a9d9e243-873f-4eef-b19e-5939933a8100">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNC01LTEtMS03MzI1Mw_5f0e1514-67fc-4d20-8b08-68e5c6f4d4f1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNC03LTEtMS03MzI1Mw_77ebe8da-9685-4ffa-8526-61d7c89d48b8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNS01LTEtMS03MzI1Mw_ec404f7b-1deb-4c78-884b-51df5958ad4e">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNS03LTEtMS03MzI1Mw_7044b95b-6116-4e47-a277-d51285f3fb47">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and post-employment benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy01LTEtMS03MzI1Mw_5de29469-8128-4032-a9fe-d194d6935866">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy03LTEtMS03MzI1Mw_e0b01168-ad34-434d-9854-14c860bb3278">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOC01LTEtMS03MzI1Mw_112200b5-9640-4d81-9fee-7db12d22b8a8">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOC03LTEtMS03MzI1Mw_8f879815-e499-4e80-ade5-9e40fe45bc45">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOS01LTEtMS03MzI1Mw_9dd51b1c-5977-4e4e-8c01-6970958c10cf">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOS03LTEtMS03MzI1Mw_d6e3f0b4-65bf-4b59-ba85-79044bab00a6">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedging activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on foreign currency forward exchange contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i115d67da01e8464594d5f3097915285d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNS0xLTEtNzMyNTM_c3509005-a607-426a-a140-90bfa6a40cdb">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2a39cd4e914c2baf4e3f7f78e0e037_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNy0xLTEtNzMyNTM_da5e13a0-ba04-43e2-9ccc-697be415ecf8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on treasury rate lock agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia93484cb8e084701be386a098217dd41_D20220101-20220331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNS0xLTEtNzMyNTM_5e757465-320d-4d59-890d-c8493a2521aa">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac58012cb8394749b3da275880c656bf_D20210101-20210331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNy0xLTEtNzMyNTM_d33aba04-37d9-4799-8851-d1a29a61115b">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on interest rate swap contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8aa0c8a5684d66952c25dc6e509fe7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNS0xLTEtNzMyNTM_f5d8bf1d-c1fd-4481-bde9-f036b794d7e1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ce39b3335d40a193f5da7859d3e742_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNy0xLTEtNzMyNTM_9dfa7b53-a718-428a-84f0-a2b6048d47ca">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense (benefit)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c8e4e34cdc418dadb3f7f36b8d5041_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTQtNS0xLTEtNzMyNTM_d872b70e-3b25-442d-9a78-73c7d69c6ba0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2761b85b027474db273e8bb0d34f65a_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTQtNy0xLTEtNzMyNTM_5319d78c-a45b-46c7-b368-9e3013b38f0a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c8e4e34cdc418dadb3f7f36b8d5041_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTUtNS0xLTEtNzMyNTM_ddf6dd7e-9a94-469b-b583-bf68b1b57af7">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2761b85b027474db273e8bb0d34f65a_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTUtNy0xLTEtNzMyNTM_b0b11797-29bf-4771-bf25-60dd8128fc4f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22" footnoteRole="http://www.xbrl.org/2003/role/footnote">(a)&#160;Amounts are included in interest expense, net (see Note 8)</ix:footnote>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwOA_4e00e857-6c03-4577-bf53-0941bd05ee5f" footnoteRole="http://www.xbrl.org/2003/role/footnote">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</ix:footnote></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2Ng_339b42bb-9e96-46ac-89bc-283f924a8cbd" footnoteRole="http://www.xbrl.org/2003/role/footnote">(c) Amounts are included in cost of products sold (see Note 8).</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="ic89f06320f9c4f57b19c511822f36cac_88"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 11 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfODc2_3cffd7dd-37dd-4a84-81ee-af324be0a3e4" continuedAt="i99cb4b156f08419297b1ad867c8d43ab" escape="true">Income Taxes </ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99cb4b156f08419297b1ad867c8d43ab" continuedAt="i7886cf96252c48d2bd72bf4c5d7cd808">The effective tax rate was <ix:nonFraction unitRef="number" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMzg_95480677-3953-4786-aa98-e1c16c06b125"><ix:nonFraction unitRef="number" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMzg_a5d928bc-8853-4106-a13d-3adbe2389638">9</ix:nonFraction></ix:nonFraction>% for the three months ended March 31, 2022 compared to <ix:nonFraction unitRef="number" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfNjQ_40a93071-68a4-4386-9aa8-1a8d760378c3"><ix:nonFraction unitRef="number" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfNjQ_980de54f-ec99-47f6-ba90-1fb0e3b4ece4">8</ix:nonFraction></ix:nonFraction>% for the three months ended March 31, 2021. The effective tax rate in each period differed from the U.S. statutory tax rate of <ix:nonFraction unitRef="number" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMTYy_342774af-a098-4993-a192-a5e468b13e30"><ix:nonFraction unitRef="number" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMTYy_9d4d592b-3622-4fbb-a18d-cdc5cfadda06">21</ix:nonFraction></ix:nonFraction>% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The increase in the effective tax rate for the three months ended March 31, 2022 over the prior year was primarily due to differences in the company&#8217;s jurisdictional mix of earnings.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7886cf96252c48d2bd72bf4c5d7cd808">Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company&#8217;s gross unrecognized tax benefits balance may change within the next 12 months by up to $<ix:nonFraction unitRef="usd" contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfODcz_24d67e30-c249-4f72-827e-f53b4c88b925">244</ix:nonFraction>&#160;million.</ix:continuation></span></div><div id="ic89f06320f9c4f57b19c511822f36cac_94"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 12 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMTU5MDQ_4c0ad276-1c33-4e3a-a63b-75138bffbe09" continuedAt="idf820d4f97b4411cb498861b357bced4" escape="true">Legal Proceedings and Contingencies </ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf820d4f97b4411cb498861b357bced4" continuedAt="i2eaa16948fae4a78bd89cb9451ab982c">AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management&#8217;s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie&#8217;s consolidated financial position, results of operations or cash flows.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2eaa16948fae4a78bd89cb9451ab982c" continuedAt="i827b9fe08da94ce28fcd2c03aa46d243">Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i827b9fe08da94ce28fcd2c03aa46d243" continuedAt="i495db9e670144528b0827551455b795c"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of <ix:nonFraction unitRef="lawsuit" contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331" decimals="INF" name="abbv:LossContingencyIndividualPlaintiffLawsuitsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjAzMw_5787628e-6f07-4264-aa30-ad6b14497e72">four</ix:nonFraction> individual plaintiff lawsuits and <ix:nonFraction unitRef="class_action" contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331" decimals="INF" name="abbv:LossContingencyPurportedClassActionsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjA3MA_45995349-1a0a-47ca-8a77-5d7f5df40e8c">two</ix:nonFraction> consolidated purported class actions: <ix:nonFraction unitRef="direct_purchaser" contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjExMQ_33823b0e-1fc4-4c5c-a470-3d12bd22c315">one</ix:nonFraction> brought by Niaspan direct purchasers and <ix:nonFraction unitRef="end_payor_purchaser" contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjE1NQ_f45633de-1c5d-4a3f-8084-0ef38c826c91">one</ix:nonFraction> brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Niaspan Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No.&#160;2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney&#8217;s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys&#8217; fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with <ix:nonFraction unitRef="company" contextRef="ie9849c3641274f60b03fcb8763315cdc_D20190801-20190831" decimals="INF" name="abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfNDY2NQ_aa25e41b-bf53-4a5a-a31b-8dc09404aab6">three</ix:nonFraction> generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott&#8217;s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between March and May 2019, <ix:nonFraction unitRef="company" contextRef="i2876ad381a314d1492fed65c7ba60831_D20190301-20190531" decimals="INF" name="abbv:PutativeClassActionLawsuitIndividualNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfNTMyOA_458b4390-3a4a-4239-a538-cf697171a444">12</ix:nonFraction> putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie&#8217;s settlements with biosimilar manufacturers and AbbVie&#8217;s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Humira (Adalimumab) Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices, and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Namenda Indirect Purchaser Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan&#8217;s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with <ix:nonFraction unitRef="company" contextRef="i061f6899a2e64d8b9f6710d2ffdaa440_D20220101-20220331" decimals="INF" name="abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfNzQ2Mg_4ba8e633-fc58-4bcc-8ee8-5bfffb5d90cc">six</ix:nonFraction> generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Bystolic Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately <ix:nonFraction unitRef="claim" contextRef="i1b950ca2895a442093c6358346b89e00_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfODExNQ_3c84c455-296a-473b-8bf5-dee1996e950f">3,146</ix:nonFraction> matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately <ix:nonFraction unitRef="claim" contextRef="i0d6b8a8607154239bab327083f4f2a16_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfODM4OQ_51a4d9ca-a094-49b5-ba2c-ed7909e16509">257</ix:nonFraction> matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i495db9e670144528b0827551455b795c" continuedAt="i41165d3a0cd74222a4ac32e425b3ca37"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In March 2022, Allergan reached settlements with the States of Florida and Rhode Island and their political subdivisions. Allergan previously reached settlements with other plaintiffs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the New Mexico Attorney General filed a lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico&#8217;s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder and Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by <ix:nonFraction unitRef="investment_fund" contextRef="i5c041511930545c890fb52c2cac408df_D20160601-20160630" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfOTIxMg_4b9a294a-6bd8-4bec-bd5e-925e4d42bbbf">five</ix:nonFraction> investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of <ix:nonFraction unitRef="investment_fund" contextRef="id8b1a9f1c7674ab7b5a46fc570730aa0_D20220201-20220228" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfOTYzNA_d11b56cf-06d2-463c-b4f6-23ef529e8f4c">three</ix:nonFraction> investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. <ix:nonFraction unitRef="investment_fund" contextRef="ie49c8cbd1c924c69b51d6bd1f5088886_D20220101-20220131" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfOTc2MA_80e278f6-e0da-4ec5-bd0f-3f6921e4c321">One</ix:nonFraction> of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, a federal securities lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Holwill v. AbbVie Inc., et al</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Allergan plc Securities Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The plaintiffs generally seek compensatory damages and attorneys&#8217; fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability and General Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, a qui tam lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Silbersher v. Allergan Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District Court for the Northern District of Illinois against Alvotech hf. AbbVie alleges defendant&#8217;s proposed biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court denied Defendant&#8217;s motion to dismiss on jurisdictional grounds in the first case; a motion in the second case remains pending. The court has set a trial on a subset of patents for August 2022. The court order provides that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed. In March 2022, the parties settled the case and it was dismissed without prejudice.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41165d3a0cd74222a4ac32e425b3ca37">Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.</ix:continuation> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">21</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 13 <ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RleHRyZWdpb246YWRmOWQwNjFjMDQxNDdhMmE4Y2FhYTcxYzA4NDk4YzFfMTIyNQ_a01029c1-acb2-4324-80fb-b0d9f3987bc5" continuedAt="if12cf0c76d664bb1a83d9efa0003a9ba" escape="true">Segment Information</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if12cf0c76d664bb1a83d9efa0003a9ba" continuedAt="i2986d4963bdf425f863e072a76ea81de">AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i2986d4963bdf425f863e072a76ea81de" continuedAt="id92fcc4540ea400ca8883e907a2ad7f4"><ix:nonNumeric contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RleHRyZWdpb246YWRmOWQwNjFjMDQxNDdhMmE4Y2FhYTcxYzA4NDk4YzFfMTIzMw_32c51bec-a861-4071-b236-e1875aa43e34" continuedAt="icf9070a14c6d4669b7d61d74fb251f20" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.429%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d814e2470641b7adca70c8dfd22826_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNC02LTEtMS03MzI1Mw_36c3bfe8-9650-4555-9459-63295132e331">3,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d8cd18e85b4007971cea988abe2864_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNC04LTEtMS03MzI1Mw_929fc5c8-0534-4b8b-938e-bdd8245084e9">3,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86efe50966f24c74849d1de4249000b9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNS02LTEtMS03MzI1Mw_2a24f481-424e-47e5-9c1b-e3ca9cea3416">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1053eda3554c3bb53ea7f9f667809a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNS04LTEtMS03MzI1Mw_85cb3600-69f7-4b65-9e45-70a17d0c09d7">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8620bf3edb45e497398d57317e67ab_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNi02LTEtMS03MzI1Mw_54002b94-0bd4-4aeb-9b69-56bcf8c8c78f">4,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151f76a6bb394b0e8dc33fbdabffeef4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNi04LTEtMS03MzI1Mw_2641a9b0-3ef3-4582-9bae-12c3a244bd2b">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9dcf0e2a5bc4237a3420a8ed35591ab_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNy02LTEtMS03MzI1Mw_162044ff-fbc3-4ad8-b7f6-a72ff98ab7ab">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a121fb3a1a74d08bb6b193989e4706a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNy04LTEtMS03MzI1Mw_ddf85b60-4824-4dfb-be36-190594c6950e">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7e3bfd63234b9987cf846478a441fd_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOC02LTEtMS03MzI1Mw_6499a3b2-7c7c-4ece-8fc6-d9e76d451169">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8267ed584474c71a1ee8dbc54f58ef8_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOC04LTEtMS03MzI1Mw_518c16b0-8dd8-4197-a15c-326ac85ac06c">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f415caa04a941a3b6c40335ad6d10f0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOS02LTEtMS03MzI1Mw_03042188-9aeb-4ba4-bc81-1b45d1cf0ea2">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1c4e6bb026457da1f4cdf7df42c5f6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOS04LTEtMS03MzI1Mw_5aa32436-4793-4e6b-8872-70789931b376">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38c669542ad4085a09a271f057f90d9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTAtNi0xLTEtNzMyNTM_c4d69af5-a829-45a7-9540-b27d486d3df4">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dfe507ba24433988668a7d003a378c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTAtOC0xLTEtNzMyNTM_f27b2299-fe4b-4669-ac44-b44a59de50bf">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89a047a7f15451fae62f0586e4244bb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTEtNi0xLTEtNzMyNTM_e13db72e-fb4c-4316-b7a8-a4afbbabbf72">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4d1ef4d3c3472f8587646493588ca3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTEtOC0xLTEtNzMyNTM_639016e5-e8f9-4c7b-885b-092f8deeeb6d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06547d54c7744ec59245e1aabe7bb4a9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTItNi0xLTEtNzMyNTM_405092bf-3acd-4a29-ad37-567816952ead">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fecb4ba92b444e8e7c4082e3cacd88_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTItOC0xLTEtNzMyNTM_1da59748-41ab-49d1-b504-3de25de1a323">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c7fad38a034510aef4faf293e98042_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTQtNi0xLTEtNzMyNTM_ee3ab9a4-ad1c-4adc-992a-83b79bd7611d">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609235fb4a14a5fa8a9ae2ce41de85d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTQtOC0xLTEtNzMyNTM_6b42358a-937a-498b-9a59-fc2c81ec2c1b">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83dd8a4923b14d1e9444794bdc3c9fa3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTUtNi0xLTEtNzMyNTM_066cbcc0-a381-4005-99e6-9245e4d8a1ad">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839ac535845b43fe8878c6e026ae540d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTUtOC0xLTEtNzMyNTM_5a601b29-a36d-4b4f-9ebd-27ebc94578fd">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88dc4f478b445c989df2931bf4129de_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTYtNi0xLTEtNzMyNTM_0025c39e-a490-4bde-a247-823399e5217d">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b31104dd4f4b588d5964c0a59fc7d9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTYtOC0xLTEtNzMyNTM_8bf4e65c-57ef-47f6-b085-265597b287be">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0a5001dda54d03b17d99d99907ef72_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTctNi0xLTEtNzMyNTM_7bc08d4b-265a-45ec-999a-5880b7d81bc9">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2f01f0a3bc4965baed776f9c1ee2ee_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTctOC0xLTEtNzMyNTM_60fce076-6160-4caf-87cc-e0583981aac1">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd7e7447fe34c6287942f568429ef69_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTgtNi0xLTEtNzMyNTM_32389218-f067-4d6e-a580-742b7701a81a">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd103eaea8d4b81b307a47031308a2b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTgtOC0xLTEtNzMyNTM_6b3d5f2e-fb4b-4d4b-b2b6-bf0adce3fbeb">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21887679ab4450e9854e11b52987fd2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTktNi0xLTEtNzMyNTM_e7070f5d-8298-426c-9d71-7210a2f9e5fe">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca3b9d904a042d1be012441bfbfbbbc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTktOC0xLTEtNzMyNTM_8dcef4d7-85d6-46b0-8db0-3b79fae3a350">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646b3499eac046a9a4d0c7b552528647_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjEtNi0xLTEtNzMyNTM_73866265-4668-400d-a67d-f7f3f75076e2">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d51184fb925493e90b9ff271b8ba444_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjEtOC0xLTEtNzMyNTM_1ebd005b-4dfe-469b-b721-7756e7b20115">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf374b782644e749678d1f567eb3bc1_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjItNi0xLTEtNzMyNTM_c264426a-4684-4437-8182-33f8b7d452dd">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231632e602304cbcbf663af9260ff447_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjItOC0xLTEtNzMyNTM_442eaa2a-5bc1-4dfc-89fe-02ca33986c62">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d97cd1c204d47a0894f071baccfb3dc_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjMtNi0xLTEtNzMyNTM_62291a29-fb33-4ea7-9dd3-9a1782f9abc2">641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485c4f314f4d4d4887041a01bca64c2b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjMtOC0xLTEtNzMyNTM_fb739af8-6bba-45c1-8b11-01922c4a9043">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81395f4f3fa48e8826d79041d865c17_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjQtNi0xLTEtNzMyNTM_14e65d96-5742-4a2e-9353-b4dc242e06fc">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5523e96c483e4a5a83a81a78cfdec571_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjQtOC0xLTEtNzMyNTM_35fd73b2-36b4-4489-927b-418983fb98ba">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bf9f5d90ff4778afcba822173f993c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjUtNi0xLTEtNzMyNTM_2d73675f-a4dc-4226-92b4-c014f5b1900f">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ccf536e0504054b9c01fbb9c17051f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjUtOC0xLTEtNzMyNTM_2529bfca-3120-4f0e-8b45-d5f9b3f0c389">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68379647466f42ac98da932e0ae7ba56_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjYtNi0xLTEtNzMyNTM_ac4d593e-86fa-43a0-824d-f1199478a40b">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9a74c5d27b427db7df5b72e0ef9e71_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjYtOC0xLTEtNzMyNTM_78ed5b47-b125-4b62-9a16-7f43e4acb843">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9886797304fd44789c0dae1792702122_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjctNi0xLTEtNzMyNTM_ab5f4c59-9bf0-4231-9769-bf405f746840">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1192611baa7144ae9f6aa9bd6469b73f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjctOC0xLTEtNzMyNTM_d1918ce4-e532-4150-b5d2-77cb324c8e5e">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f45042ba49947aea027157aa3e5005e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjgtNi0xLTEtNzMyNTM_b7b6576c-986f-4b54-a6da-7f46e2c52930">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6297715bc8540428f641904958468e5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjgtOC0xLTEtNzMyNTM_5b3719aa-af83-4077-bb5e-beb520b9439c">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274365a0958a49bb88080cb48c332ccd_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjktNi0xLTEtNzMyNTM_5041ce48-e13f-47ff-90fa-c05b5c89533c">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aeec465d3b44d6d836a7f5d22f41e34_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjktOC0xLTEtNzMyNTM_d9223227-4083-4a32-9f50-44d714b8568d">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic117a05f0ad047458c3dfdf3d563d985_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzEtNi0xLTEtNzMyNTM_a14980a4-664b-4ea1-a6f0-365e6cae2a01">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0aa0c6e5e8e4e86be8c148b66aedbb6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzEtOC0xLTEtNzMyNTM_627bf828-6065-419e-8192-900c0845bbd6">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f1b5410e4a4e8fb9abfa2219b13d78_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzItNi0xLTEtNzMyNTM_04926e6a-3715-4def-95f4-9f31abf1cac3">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78f3e2ee61c499ba7cc0746a2385d47_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzItOC0xLTEtNzMyNTM_99f3b4f7-3e67-4b53-88c6-c3ffa1e86380">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdbacd087ccb4b378166217f2e6bac38_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzMtNi0xLTEtNzMyNTM_aae2e661-b438-44c1-9018-01ab05c80024">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b0f54b6f66490ea61e7105a06bbd5f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzMtOC0xLTEtNzMyNTM_e4a24f30-3a05-4de4-940b-12f67c67fb37">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vraylar</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff614778cc44cd498c6a9c8964075c2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzQtNi0xLTEtNzMyNTM_c1fed9b7-0dc1-4f1d-b68a-abcd334da6f1">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f19775fa7fb4454916890a2d18f7368_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzQtOC0xLTEtNzMyNTM_150c33ab-756c-4e02-a022-484ec30d7166">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3125d8c421f84befbfdc8c98d0f12733_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzctNi0xLTEtNzMyNTM_29b75ffb-0381-4970-a9d0-3ada4ae3b464">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c196d5476444949e789bed861f1aa6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzctOC0xLTEtNzMyNTM_ee6fffc4-865e-4ab0-9b8e-12f2347b64d8">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5f22d6d24942c5974fd185d2251f6a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzgtNi0xLTEtNzMyNTM_f566b25d-a465-4361-af44-536ea448062c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf4bed28ef04a34be1be2775ace098f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzgtOC0xLTEtNzMyNTM_4039c928-f5df-4024-8572-a3d4c85a5449">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72f22aa56674f6ea95b38deaf7d7ef0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzktNi0xLTEtNzMyNTM_15774689-14f0-46bb-88e3-bf539fcf6d8a">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639f02ea2ac340d384b27444a35f86c5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzktOC0xLTEtNzMyNTM_17afb34f-3f1b-43ab-9e86-ee9c63a5b746">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f9dd7d8685493e9094a8411dc69ba7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDAtNi0xLTEtNzMyNTM_9e617e15-55ae-4d59-9a31-03d29b13479c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5cc0c791ad4deb82c1071bb2540517_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDAtOC0xLTEtNzMyNTM_66a757f9-b648-4d7c-a0a2-8538d53f748d">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d3e94281d14e1ead6013f512d2ba56_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtNi0xLTEtODE2Njk_d7c0345b-c90d-419b-8d78-c1ffe16d4ba8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fd6150a38a4e9b9bd77ea967639212_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtOC0xLTEtODE2ODI_7783c6ab-c9ef-4120-86b6-49000195aeef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512cec6652ce4f19be4c4e4462feb4e8_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtNi0xLTEtNzMyNTM_cb7d8987-e142-45dd-8a58-885b5bb0ff44">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4fe39a35de44ecaa3535608505ded0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtOC0xLTEtNzMyNTM_da5c2922-dbcc-49f2-a7f1-d1a771183af7">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeabc0e9b646406e88ddb1c5e1f12518_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDQtNi0xLTEtNzMyNTM_e8788858-d899-4db6-aaec-d06cb7ac880c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia12ead842eee42f59b1937c152fb8415_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDQtOC0xLTEtNzMyNTM_d48e3d62-74d7-439f-b248-e3573767dac6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67b003e0c9d489a93fc432063b0605d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDUtNi0xLTEtNzMyNTM_c43e30b9-49b5-46cb-8317-dce2c66c88e2">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a38522757a47f08bcaaed26cc95890_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDUtOC0xLTEtNzMyNTM_06e48134-5cae-4127-9f2a-bf7e134c4e92">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="id92fcc4540ea400ca8883e907a2ad7f4"><ix:continuation id="icf9070a14c6d4669b7d61d74fb251f20"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.429%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b09878f9324ebc81010863a7bb2312_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDctNi0xLTEtNzMyNTM_d2318318-93b2-43da-a67c-dff3909d51a6">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b43137ee1c4af9956280587d60c83c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDctOC0xLTEtNzMyNTM_5743eadd-4e20-403e-9863-6ff734eed9ca">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae85b406a18e40d7b2917cf2e17d0b83_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDgtNi0xLTEtNzMyNTM_8813f64c-9195-4893-8b43-b66f1fabd378">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741797da087c4ef6a3b16e0b40c35175_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDgtOC0xLTEtNzMyNTM_ead8daed-e9d7-493f-af54-6132cade79db">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34cab53f8594ff4979a946f5a3fc1f9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDktNi0xLTEtNzMyNTM_05fa9027-d0cd-4cac-af3b-f71ef87e9cca">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cd48264009438ca440c693ab0cf2f1_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDktOC0xLTEtNzMyNTM_7c681d77-ec0a-41bd-aae3-fcd868aedb4c">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc8282031784d8caeb6a4ef809f2f50_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTAtNi0xLTEtNzMyNTM_55d46e55-341d-43cf-a116-89b43801efcd">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a85e57b458b4094a0c62505b2a9799e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTAtOC0xLTEtNzMyNTM_7bab5c73-9f23-4dc2-9bbf-92388fa89089">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50fb763a0f1c482a9572f571170e440e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTEtNi0xLTEtNzMyNTM_3ea334ee-965e-4608-b89a-4f1eb2db06a3">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93307eafe6504d879af164c82b04eda8_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTEtOC0xLTEtNzMyNTM_1d61a0e4-921f-41f1-9ad6-5ae9811519ca">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46e3aeb263045cfbb0acf95c88c121b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTItNi0xLTEtNzMyNTM_16ef93fd-37c7-4688-9bdb-1a5f802b9c45">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a77a42b923942bfaff4dc08627c3225_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTItOC0xLTEtNzMyNTM_d1625484-50ed-43f3-be25-826a15d39bc7">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief85b551045345879ed1be64c67a8b4b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTMtNi0xLTEtNzMyNTM_53bc52e2-bd4c-4837-ba9c-3c40f70acda8">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf3d5f2dfb344e59a6c9efc465d8f5b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTMtOC0xLTEtNzMyNTM_23e2c35f-3db4-4444-90a4-c3e8cb22efd3">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62a015e1747449791ed3c131fc6f351_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTQtNi0xLTEtNzMyNTM_9a0403a8-91a7-4128-8b45-263a93987573">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf8ded17cba43f7b08f7d24f7aed016_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTQtOC0xLTEtNzMyNTM_af7af429-cb8e-49fa-8159-b65ded5dbcd7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2c9be5775d49e7af0a83f0b14fce7f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTUtNi0xLTEtNzMyNTM_c60990e1-a2a2-4a02-9c3d-490abd0c4f47">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddf6b053a5d4cf1b48234a1c15b6c1a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTUtOC0xLTEtNzMyNTM_6cd9ac42-65ad-4642-a7e3-480dc3c682e2">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882c0ed4b6454d5db18fd823a31bcb88_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTYtNi0xLTEtNzMyNTM_5e161b08-de8e-48dd-bd01-d3e88e3e176b">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf25850c2d1c4ceb840ecd9bfee2891c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTYtOC0xLTEtNzMyNTM_9c030a35-13fd-41e3-ab84-efff01f8f235">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife17341a39044007bd37eb3dcabab9af_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTctNi0xLTEtNzMyNTM_e39d9814-9d7e-4d3f-b4f6-bce26ad8cdb3">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379b152b16b1407985df7a9d9e3ad633_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTctOC0xLTEtNzMyNTM_df937c43-3c35-433e-894d-b3729743f666">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6df2de6a1db84a14bc36698e3dbcbf51_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTgtNi0xLTEtNzMyNTM_b4fd3319-97ce-4b03-807b-e3e658087392">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a92b2ecc5f4aaf9d8351f86caf7be5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTgtOC0xLTEtNzMyNTM_be3abe21-d3be-4f9a-9602-efac9c5f0c15">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e933b76f7264c7cb306a5779cb4d526_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzAtNi0xLTEtNzMyNTM_9152e379-0fc6-4fad-a615-1c6f4467f1e7">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bf38d011cc4cfd9351b1938594689b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzAtOC0xLTEtNzMyNTM_a54130ef-ff84-4355-8b13-997edee68873">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e746d238af04e0fba57b391911704b6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzEtNi0xLTEtNzMyNTM_d3f56cb5-c2bb-4377-ab28-cec53bc7ca50">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59295dec623542dba93f26a4df9b7bf3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzEtOC0xLTEtNzMyNTM_91db4c7b-8ed1-47f2-af88-8c71ffcac031">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieefe0806b5ac487fb58df139e942b4bf_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzItNi0xLTEtNzMyNTM_137adc64-b240-4cbb-b982-d47ea1150d79">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic251b48766744736852af8a750fb5fa6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzItOC0xLTEtNzMyNTM_fa85162e-f767-4553-9b1c-6f8bf43889a0">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9748feec04436daefd70ed8fde5035_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzMtNi0xLTEtNzMyNTM_7a044198-cc03-4d41-a23a-b44a9e180167">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ca6bfcb2a742d2a419a770b28a65e2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzMtOC0xLTEtNzMyNTM_3a9b6290-3743-46e7-b69d-aca39a7363c7">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ecf09fad83434f8b75838cf1459dde_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzctNi0xLTEtNzMyNTM_d91db237-6306-41d3-9027-5189db05b88c">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fb7ab9f9404aa4800b094182ef46f5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzctOC0xLTEtNzMyNTM_4a4787fe-8450-41e4-b2d5-92da5688cefa">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9915235f3a844da69814226e5774c2d7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzgtNi0xLTEtNzMyNTM_0d3b281e-ab0d-45ea-ad80-489e3c75f266">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4538d383a2c14cac819e3ce9bc8a27c4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzgtOC0xLTEtNzMyNTM_e6536072-3b68-4589-857b-80abc79eac26">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531f3349e8c348c39ad330ddd7567561_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzktNi0xLTEtNzMyNTM_27bd77ea-9059-44c3-8a2a-6c60a60af0ca">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a8b6f17bd484927bdf4246fdc7d2e83_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzktOC0xLTEtNzMyNTM_7ac3f90c-6936-448e-bf10-77b7a0ad14e7">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092297541dd04ee2b04cfdcfbb71eef1_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODQtNi0xLTEtNzMyNTM_0abc59f1-4597-4d34-8a52-4eafb5624a34">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143c59ef117840e5b84f10e564ee91c4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODQtOC0xLTEtNzMyNTM_3f9e4b9b-f703-4708-be83-79598895c460">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODUtNi0xLTEtNzMyNTM_3560e8c6-d560-4bf8-9af0-4748f93abd1e">13,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODUtOC0xLTEtNzMyNTM_b38b4100-48f5-49fb-81ff-dac7d1620595">13,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">23</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of March 31, 2022 and December 31, 2021 and the results of operations for the three months ended March 31, 2022 and 2021. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, &#8220;Financial Statements and Supplementary Data.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world&#8217;s most complex and serious diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. Outside the United States, AbbVie sells products primarily to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies. AbbVie has approximately 50,000 employees. AbbVie operates as a single global business segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Strategic Objectives</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie's mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution. AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)&#160;growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)&#160;continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)&#160;expanding operating margins; and (v)&#160;returning cash to shareholders via a strong and growing dividend while also reducing debt. In addition, AbbVie anticipates several regulatory submissions and data readouts from key clinical trials in the next 12 months.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's financial performance for the three months ended March 31, 2022 included delivering worldwide net revenues of $13.5&#160;billion, operating earnings of $4.7&#160;billion, diluted earnings per share of $2.51 and cash flows from operations of $4.9&#160;billion. Worldwide net revenues grew by 4% on a reported basis and 5% on a constant currency basis, reflecting growth across its immunology, neuroscience and aesthetics portfolios.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share was $2.51 for the three months ended March 31, 2022 and included the following after-tax costs:            (i) $1.6&#160;billion related to the amortization of intangible assets; (ii) $148 million for charges related to litigation matters; (iii) $145 million&#160;for acquired IPR&amp;D and milestones; and (iv) $121&#160;million of acquisition and integration expenses. These costs were partially offset by an after-tax benefit of $746&#160;million related to the change in fair value of contingent consideration liabilities. Additionally, financial results reflected continued funding to support all stages of AbbVie&#8217;s pipeline assets and continued investment in AbbVie&#8217;s on-market brands.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. The integration plan is expected to realize approximately $2.5 billion of annual cost synergies in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Global Events</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Russia/Ukraine</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the military conflict between Russia and Ukraine, the United States and other North Atlantic Treaty Organization member states, as well as certain non-member states, announced targeted economic sanctions and export controls on Russia and Belarus. These include restrictions on the export and transfer of products containing certain toxins, including Botox, to Russia and Belarus. With the exception of Botox, AbbVie is not prohibited to continue the sale of essential pharmaceutical products to help ensure patients receive an uninterrupted supply of their medicines. In March 2022, AbbVie announced the suspension of operations for all aesthetics products in Russia. In April 2022, AbbVie also announced that all profits from the sales of essential medicines in Russia will be donated to support direct humanitarian relief efforts in Ukraine. While the company&#8217;s operations in Russia, Belarus and Ukraine are not significant, if the conflict escalates and results in broader economic and political concerns, AbbVie&#8217;s business could be adversely impacted. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the Coronavirus Disease 2019 (COVID-19)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing public health crisis posed by COVID-19, AbbVie continues to focus on ensuring the safety of employees. Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie also continues to closely manage manufacturing and supply chain resources around the world to help ensure that patients continue to receive an uninterrupted supply of their medicines. Clinical trial sites are being monitored locally to protect the safety of study participants, staff and employees. While the impact of COVID-19 on AbbVie's operations to date has not been material, AbbVie continues to experience lower new patient starts in certain products and markets. AbbVie expects this matter could continue to negatively impact its results of operations throughout the duration of the pandemic. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may impact AbbVie's financial condition and results of operations remains uncertain and is dependent on numerous evolving factors, including the measures being taken by authorities to mitigate against the spread of COVID-19, the emergence of new variants and the availability and successful administration of effective vaccines.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and innovation are the cornerstones of AbbVie&#8217;s business as a global biopharmaceutical company. AbbVie&#8217;s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie&#8217;s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care. Of these programs, more than 50 are in mid- and late-stage development. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sections summarize transitions of significant programs from mid-stage development to late-stage development as well as developments in significant late-stage and registration programs. AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Programs and Developments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Skyrizi</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, A</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bbVie announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi for the treatment of adults with active psoriatic arthritis (PsA). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie announced that the FDA has extended the Prescription Drug User Fee Act action date by three months for Skyrizi for the treatment of moderate to severe Crohn&#8217;s disease in patients 16 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rinvoq</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, Abb</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vie announced its submission of a supplemental New Drug Application (sNDA) to the FDA and a marketing authorization application (MAA) to the European Medicines Agency (EMA) for Rinvoq for the treatment of adults with active nr-axSpA with objective signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, Ab</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bVie announced that the FDA approved Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie was notified that the European Commission (EC) is requesting the EMA to assess safety concerns associated with JAK inhibitor products authorized in inflammatory diseases and to evaluate the impact of these events on their benefit-risk balance. The assessment covers all JAK inhibitors approved for use in inflammatory diseases. The request is for an opinion from the EMA by September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie announced top-line results from its second Phase 3 induction study, U-Excel, for Rinvoq in patients with moderate to severe Crohn&#8217;s disease who had an inadequate response or were intolerant to conventional or biologic therapy met the primary and most key secondary endpoints.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, AbbVie announced that the FDA approved Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">In April 2022, AbbVie announced that the FDA approved Rinvoq for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Teliso-V</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Imbruvica</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie submitted an sNDA to the FDA for Imbruvica for the treatment of pediatric and adolescent patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Epcoritamab</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, Genmab A/S (Genmab) announced that FDA granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody-CD3xCD20), for the treatment of follicular lymphoma. Genmab and AbbVie are co-developing epcoritamab and will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">In April 2022, AbbVie and Genmab announced positive topline results from the first cohort of the EPCORE NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20) in patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy. Based on the topline results, the companies will engage global regulatory authorities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aesthetics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Juvederm Collection</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie announced that the FDA approved JUVEDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">BoNTE</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, AbbVie initiated three Phase 3 clinical trials to evaluate the efficacy and safety of BoNTE (AGN-151586) for the treatment of glabellar lines.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuroscience</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vraylar</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie submitted an sNDA to the FDA for Vraylar for the adjunctive treatment of major depressive disorder in patients who are receiving ongoing antidepressant therapy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Qulipta</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, AbbVie announced results from the Phase 3 PROGRESS trial for Qulipta in the preventive treatment of chronic migraine in adults met the primary endpoint and resulted in significant improvements in all secondary endpoints after adjustment for multiple comparisons.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eye Care</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vuity</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">In April 2022, AbbVie announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of Vuity 1.25% in adults with presbyopia met its primary efficacy endpoint. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more comprehensive discussion of AbbVie&#8217;s products and pipeline, see the company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">27</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_115"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year&#8217;s foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company&#8217;s operations and can facilitate analysis of the company&#8217;s results of operations, particularly in evaluating performance from one period to another.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.321%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency&#160;rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenues</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.098%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency rates</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td></tr><tr style="height:14pt"><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;100.0 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;100.0 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vraylar</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.098%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency rates</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n/m &#8211; Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of AbbVie&#8217;s net revenues by product is presented on a constant currency basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Humira sales decreased by 2% for the three months ended March 31, 2022 primarily driven by direct biosimilar competition in certain international markets, partially offset by market growth across therapeutic categories. In the United States, Humira sales increased by 2% for the three months ended March 31, 2022 primarily driven by market growth across all indications. This increase was partially offset by slightly lower market share following corresponding market share gains of Skyrizi and Rinvoq. Internationally, Humira revenues decreased by 18% for the three months ended March 31, 2022 primarily driven by direct biosimilar competition in certain international markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Skyrizi increased by 66% for the three months ended March 31, 2022 primarily driven by continued strong volume and market share uptake since launch as a treatment for plaque psoriasis as well as market growth. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Rinvoq increased by 57% for the three months ended March 31, 2022 primarily driven by continued strong volume and market share uptake since launch for the treatment of moderate to severe rheumatoid arthritis as well as market growth. Net revenues for the three months ended March 31, 2022 were also favorably impacted by recent regulatory approvals and expansion of Rinvoq for the treatment of psoriatic arthritis, atopic dermatitis and ankylosing spondylitis in certain international markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Imbruvica represent product revenues in the United States and collaboration revenues outside of the United States related to AbbVie&#8217;s 50% share of Imbruvica profit. AbbVie's global Imbruvica revenues decreased by 7% for the three months ended March 31, 2022 as a result of lower new patient starts due to the COVID-19 pandemic and share loss in the United States, partially offset by increased collaboration revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Venclexta increased by 21% for the three months ended March 31, 2022 primarily due to continued expansion of Venclexta for the treatment of patients with first-line chronic lymphocytic leukemia (CLL), relapsed/refractory CLL and first-line acute myeloid leukemia.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Botox Cosmetic used in facial aesthetics increased by 37% for the three months ended March 31, 2022 due to increased consumer demand and penetration rates driven by targeted brand investment. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Juvederm Collection (including Juvederm Ultra XC, Juvederm Voluma XC and other Juvederm products) used in facial aesthetics increased by 31% for the three months ended March 31, 2022 due to increased consumer demand and penetration rates driven by targeted brand investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Botox Therapeutic used primarily in neuroscience and urology therapeutic areas increased by 17% for the three months ended March 31, 2022 due to market growth, higher market share and strong market recovery from the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Vraylar for the treatment of schizophrenia, bipolar I disorder and bipolar depression increased by 23% for the three months ended March 31, 2022 due to higher market share and market growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Ubrelvy for the acute treatment of migraine with or without aura in adults increased by 70% for the three months ended March 31, 2022 primarily due to increased market share uptake since launch.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Mavyret decreased by 5% for the three months ended March 31, 2022 driven by the continued disruption of global HCV markets due to the COVID-19 pandemic.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_118"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,797</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as a % of net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percentage of net revenues increased for the three months ended March 31, 2022 compared to the prior year. Gross margin percentage for the three months ended March 31, 2022 was favorably impacted by changes in product mix and lower amortization of intangible assets associated with the Allergan acquisition. </span></div><div id="ic89f06320f9c4f57b19c511822f36cac_121"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,127</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as a % of net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses as a percentage of net revenues increased for the three months ended March 31, 2022 compared to the prior year. SG&amp;A expense percentage for the three months ended March 31, 2022 was unfavorably impacted by litigation reserve charges of $184 million as well as increased brand investment and product launch expenses, partially offset by leverage from revenue growth and increased synergies realized. </span></div><div id="ic89f06320f9c4f57b19c511822f36cac_124"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development and Acquired IPR&amp;D and Milestones</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as a % of net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and milestones</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses as a percentage of net revenues decreased for the three months ended March 31, 2022 compared to the prior year. R&amp;D expense percentage was favorably impacted by the purchase of a priority review voucher from a third party in the first quarter of 2021, increased scale of the combined company and synergies realized as well as lower integration costs related to the acquisition of Allergan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and milestones expense represents upfront and subsequent development milestone payments incurred prior to regulatory approval to acquire rights to in-process R&amp;D projects through R&amp;D collaborations, licensing arrangements or other asset acquisitions. Acquired IPR&amp;D and milestones expense in the three months ended March 31, 2022 included a charge of $130 million as a result of acquiring Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118, which is being evaluated to target nerve terminals to enhance synaptic efficiency. There were no individually significant transactions during the three months ended March 31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">31</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_127"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Expenses (Income)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net decreased for the three months ended March 31, 2022 compared to the prior year primarily due to lower average debt balance due to deleveraging.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net included a benefit related to changes in fair value of contingent consideration liabilities of $748&#160;million for the three months ended March 31, 2022 and $343&#160;million for the three months ended March 31, 2021. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory/commercial milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors. For the three months ended March 31, 2022 and 2021, the change in fair value was driven by higher discount rates partially offset by the passage of time. </span></div><div id="ic89f06320f9c4f57b19c511822f36cac_133"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 9% for the three months ended March 31, 2022 compared to 8% for the three months ended March 31, 2021. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The increase in the effective tax rate for the three months ended March 31, 2022 over the prior year was primarily due to differences in the company&#8217;s jurisdictional mix of earnings.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_136"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,972)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows for the three months ended March 31, 2022 were flat compared to the prior year primarily due to improved results of operations resulting from revenue growth, offset by the timing of working capital cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing cash flows for the three months ended March 31, 2022 included payments made for net purchases of investment securities totaling $1.4&#160;billion, acquisitions and investments of $185&#160;million and capital expenditures of $162&#160;million. Investing cash flows for the three months ended March 31, 2021 included payments made for acquisitions and investments of $198 million, capital expenditures of $188 million and net purchases of investment securities totaling $5&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows for the three months ended March 31, 2022 included an early repayment of $2.9 billion aggregate principal amount of the company&#8217;s 3.45% senior notes. Additionally, financing cash flows included repayment of a $2.0 billion floating rate term loan due May 2025 and issuance of a new $2.0 billion floating rate term loan as part of the term loan refinancing in February 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows also included cash dividend payments of $2.5 billion for the three months ended March 31, 2022 and $2.3 billion for the three months ended March 31, 2021. The increase in cash dividend payments was primarily driven by the increase in the quarterly dividend rate. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;17, 2022, the company announced that its board of directors declared a quarterly cash dividend of $1.41 per share for stockholders of record at the close of business on April&#160;15, 2022, payable on May&#160;16, 2022. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie&#8217;s financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie&#8217;s debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. AbbVie repurchased 8&#160;million shares for $1.1&#160;billion during the three months ended March 31, 2022 and 5&#160;million shares for $550&#160;million during the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance for credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility, Access to Capital and Credit Ratings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie currently has a $4.0 billion five-year revolving credit facility that matures in August 2024. This credit facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At March 31, 2022, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facility as of March 31, 2022 and December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access to Capital</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt. The company&#8217;s ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company&#8217;s products or in the solvency of its customers or suppliers, deterioration in the company&#8217;s key financial ratios or credit ratings or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company&#8217;s growth objectives.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Ratings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Moody&#8217;s Investors Service (Moody&#8217;s) affirmed its Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. At the same time, Moody&#8217;s revised the outlook to positive from stable. Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company&#8217;s ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company&#8217;s outstanding debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company&#8217;s significant accounting policies is included in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in AbbVie's Annual Report on Form&#160;10-K for the year ended December 31, 2021. There have been no significant changes in the company&#8217;s application of its critical accounting policies during the three months ended March 31, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some statements in this quarterly report on Form&#160;10-Q may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.&#160;The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; and similar expressions, among others, generally identify forward-looking statements.&#160;AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.&#160;Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan, failure to promptly and effectively integrate Allergan's businesses, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.&#160;Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie&#8217;s operations is set forth in Item 1A, &#8220;Risk Factors,&#8221; in AbbVie&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021, which has been filed with the Securities and Exchange Commission.&#160;AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_139"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_142"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Chief Executive Officer, Richard A. Gonzalez, and the Chief Financial Officer, Robert A. Michael, evaluated the effectiveness of AbbVie&#8217;s disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie&#8217;s disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules&#160;and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Exchange Act is accumulated and communicated to AbbVie&#8217;s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in AbbVie&#8217;s internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, AbbVie&#8217;s internal control over financial reporting during the quarter ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AbbVie&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie&#8217;s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">34</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_145"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II. OTHER INFORMATION</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_148"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information pertaining to legal proceedings is provided in Note 12 to the Condensed Consolidated Financial Statements and is incorporated by reference herein.</span></div><div id="ic89f06320f9c4f57b19c511822f36cac_154"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:29.25pt"><span><br/></span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)&#160;Total <br/>Number&#160;of <br/>Shares&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Units) <br/>Purchased</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)&#160;Average <br/>Price&#160;Paid <br/>per&#160;Share <br/>(or&#160;Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)&#160;Total&#160;Number <br/>of&#160;Shares&#160;(or <br/>Units)&#160;Purchased <br/>as&#160;Part&#160;of&#160;Publicly <br/>Announced&#160;Plans <br/>or&#160;Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)&#160;Maximum <br/>Number&#160;(or <br/>Approximate <br/>Dollar&#160;Value)&#160;of <br/>Shares&#160;(or&#160;Units) <br/>that&#160;May&#160;Yet&#160;Be <br/>Purchased&#160;Under <br/>the&#160;Plans&#160;or <br/>Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022 - January 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$135.74</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,523,316,993</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2022 - February 28, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,653,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$146.18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,652,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,550,785,350</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022 - March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$149.88</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,393,714,917</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,702,838&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$146.69</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700,791&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,393,714,917</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.92pt">In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan &#8211; 715 in January; 692 in February; and 640 in March.</span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">35</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_157"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be &#8220;filed&#8221; under the Securities Exchange Act of 1934.</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:11.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex101.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex101.htm">Form of AbbVie Inc. Performance-Vested Restricted Stock Unit Agreement*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex102.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex102.htm">Form of AbbVie Inc. Performance Share Award Agreement*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex103.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="abbv-20220331xex103.htm">Form of AbbVie Inc. Non-Employee Director RSU Agreement (US)</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="abbv-20220331xex103.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex104.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="abbv-20220331xex104.htm">Form of AbbVie Inc. Non-Qualified Stock Option Agreement</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="abbv-20220331xex104.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex105.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex105.htm">Form of AbbVie Inc. Retention RSU Agreement &#8211; Ratable Vesting*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex106.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="abbv-20220331xex106.htm">Form of AbbVie Inc. Retention RSU Agreement &#8211; Cliff Vesting with Dividend Equivalent Accrual</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="abbv-20220331xex106.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex311.htm">Certification of Chief Executive Officer Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex312.htm">Certification of Chief Financial Officer Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex321.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220331xex322.htm">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form&#160;10-Q for the quarter ended March 31, 2022, filed on May&#160;6, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)&#160;Condensed Consolidated Statements of Earnings; (ii)&#160;Condensed Consolidated Statements of Comprehensive Income; (iii)&#160;Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)&#160;Condensed Consolidated Statements of Cash Flows; and (vi)&#160;the Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">36</span></div></td></tr></table></div></div></div><div id="ic89f06320f9c4f57b19c511822f36cac_160"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABBVIE INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert A. Michael</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Michael</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chairman, Finance and Commercial Operations and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;6, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220331_g2.gif" alt="abbv-20220331_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">37</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>abbv-20220331xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id79782c9787f433090a52a741124add8_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit&#160;10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ABBVIE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PERFORMANCE-VESTED RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#60;&#60;GRANT DATE </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(MONTH DD, YYYY)&#62;&#62; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), AbbVie Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) hereby grants to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#60;&#60;FIRST NAME&#62;&#62; &#60;&#60;LAST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Employee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) a Performance-Vested Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#60;&#60;TOTAL SHARES GRANTED&#62;&#62; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Units</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The actual number of shares of Company common stock (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus, and the Program administrative rules, the provisions of the Program shall control. </font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The terms and conditions of the Award are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.66pt">Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.24pt"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Performance-Vested Restricted Stock Unit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Unless otherwise defined in the Employee&#8217;s Change in Control Agreement, cause shall mean the following, as determined by the Company in its sole discretion&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">material breach by the Employee of the terms and conditions of the Employee&#8217;s employment, including, but not limited to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  material breach by the Employee of the Code of Business Conduct&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B) material breach by the Employee of the Employee&#8217;s Employee Agreement or employment contract, if any&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C) commission by the Employee of an act of fraud, embezzlement or theft in connection with the Employee&#8217;s duties or in the course of the Employee&#8217;s employment&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D) wrongful disclosure by the Employee of secret processes or confidential information of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E) failure by the Employee to substantially perform the duties of the Employee&#8217;s employment (other than any such failure resulting from the Employee&#8217;s Disability)&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.52pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for the benefit of the Employee or others, in any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">activity, employment or business which is competitive with the Company or any of its Subsidiaries.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.91pt">Change in Control Agreement&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> An agreement regarding Change in Control in effect between the Company (or the Surviving Entity) and the Employee.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Code of Business Conduct</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The Company&#8217;s Code of Business Conduct, as amended from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.01pt">Controlled Group</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; AbbVie Inc. and any corporation, partnership and proprietorship under common control (as defined under the aggregation rules of Code Section 414 (b), (c), or (m)) with AbbVie Inc.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.32pt">Data</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain personal information about the Employee held by the Company and the Subsidiary that employs the Employee (if applicable), including (but not limited to) the Employee&#8217;s name, home address and telephone number, email address, date of birth, social security, passport or other identification number, salary, nationality, job title, any Shares held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.82pt">Disability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sickness or accidental bodily injury, directly and independently of all other causes, that disables the Employee so that the Employee is completely prevented from performing all the duties of his or her occupation or employment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.82pt">Employee Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The Employee Agreement entered into by and between the Company or a Subsidiary and the Employee as it may be amended from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.23pt">Employee&#8217;s Representative</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Employee&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">legal</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">guardian or other legal representative.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.11pt">Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Unless otherwise defined in the Employee&#8217;s Change in Control Agreement, good reason shall mean the occurrence of any of the following circumstances without the Employee&#8217;s express written consent&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">a significant adverse change in the nature, scope or status of the Employee&#8217;s position, authorities or duties from those in effect immediately prior to the Change in Control, including, without limitation, if the Employee was, immediately prior to the Change in Control, an officer of a public company, the Employee ceasing to be an officer of a public company&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.52pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the failure by the Company or a Subsidiary to pay the Employee any portion of the Employee&#8217;s current compensation, or to pay the Employee any portion of any installment of deferred compensation under any deferred compensation program of the Company, within seven days of the date such compensation is due&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-29.27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">a reduction in the Employee&#8217;s annual base salary (or a material change in the frequency of payment) as in effect immediately prior to the Change in Control as the same may be increased from time to time&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-29.18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the failure by the Company or a Subsidiary to award the Employee an annual bonus in any year which is at least equal to the annual bonus awarded to the Employee under the annual bonus plan of the Company or Subsidiary for the year immediately preceding the year of the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.43pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the failure by the Company to award the Employee equity-based incentive compensation (such as stock options, shares of restricted stock, restricted stock units, or other equity-based compensation) on a periodic basis consistent with the Company&#8217;s practices with respect to timing, value and terms prior to the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-29.18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the failure by the Company or a Subsidiary to continue to provide the Employee with the welfare benefits, fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in Control under any of the Company&#8217;s or Subsidiary&#8217;s plans or policies, including, but not limited to, those plans and policies providing pension, life insurance, medical, health and accident, disability and vacation&#59; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.93pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the relocation of the Employee&#8217;s base office to a location that is more than 35 miles from the Employee&#8217;s base office immediately prior to the Change in Control&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-34.68pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">viii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the failure of the Company to obtain a satisfactory agreement from any successor to the Company to assume and agree to perform this Agreement as contemplated in Section 5.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.53pt">Performance Determination Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The date on which the Committee determines whether or to what extent the Performance Vesting Requirements have been achieved.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.23pt">Performance Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The period(s) specified in the attached Schedule, over which achievement of the Performance Vesting Requirements is to be measured.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.49pt">Performance-Vested Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The maximum number of Shares the Employee may receive under this Award based on the extent to which the Performance Vesting Requirements are achieved.  In no event will the number of Performance-Vested Shares exceed 150% of the number of Units set forth in the first paragraph of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.82pt">Performance Vesting Requirements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The performance goals described in the attached Schedule, which must be achieved for Units to vest and the corresponding Shares to be delivered under this Award.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">o.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.83pt">Program</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  The AbbVie Amended and Restated 2013 Incentive Stock Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">p.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.82pt">Retirement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Except as provided under (ii) or (iii) below, Retirement means any of the following&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">age 55 with 10 years of service&#59; or</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">age 60 with five years of service&#59; or</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">age 65 with three years of service.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.52pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">For purposes of calculating service under this Section 1(k), except as otherwise provided by the Committee or its delegate&#58; </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.03pt">service is earned only if performed for a member of the Controlled Group while that Controlled Group member is a part of the Controlled Group as defined in section 1(e) of this Agreement&#59; and </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.33pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">For</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Employees who transferred to the Company directly from Abbott Laboratories during the period from January 1, 2013 through June 30, 2015 either as a result of the Company&#8217;s spin-off from Abbott Laboratories or with the consent of each company&#8217;s head of human resources, service includes service with Abbott Laboratories that is counted for retirement eligibility purposes under applicable law or Company procedures outside the United States the AbbVie Pension Plan, the AbbVie Pension Plan for Former BASF and Former Solvay Employees, or another Company-sponsored pension plan, as applicable.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-29.18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">For Employees who (A) are being credited with service in the AbbVie Pension Plan at the time of a Retirement eligibility determination under this Agreement, and (B) transferred to the Company directly from Abbott Laboratories either as a result of the Company&#8217;s spin-off from Abbott Laboratories or during the period from January 1, 2013 through June 30, 2015 with the consent of each company&#8217;s head of human resources, and (C) were hired into the Abbott Laboratories controlled group prior to January 1, 2004, Retirement means any of the following&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">age 50 with 10 years of service&#59;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">age 65 with at least three years of service&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">age 55 with an age and service combination of 70 points, where each year of age is one point and each year of service is one point.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">q.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.82pt">Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  A severance of employment for any reason (including Retirement) from the Company and all Subsidiaries.  Any Termination shall be effective on the last day the Employee performs services for or on behalf of the Company or its Subsidiary, and employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. Delivery Dates and Shareholder Rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The delivery dates for Shares issuable with respect to the Units are the respective dates on which the Shares are distributable to the Employee if the Restrictions lapse pursuant to Section 4 below (each a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Delivery Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Prior to the Delivery Date(s)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) the Employee shall not be treated as a shareholder as to any Shares issuable under the Agreement, and shall have only a contractual right to receive Shares, unsecured by any assets of the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) the Employee shall not be permitted to vote any Shares issuable under the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) the Employee&#8217;s right to receive such Shares will be subject to the adjustment provisions relating to mergers, reorganizations, and similar events set forth in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the requirements of local law, if any dividend or other distribution is declared and paid on Shares (other than dividends or distributions of securities of the Company which may be issued with respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) while any of the Units remain subject to this Award (meaning that any of the Shares into which Units would be converted are not otherwise issued and outstanding for purposes of the entitlement to the dividend or distribution), then a book account will be maintained for the Employee and credited with a phantom dividend that is equivalent to the actual dividend or distribution that would have been paid on the total number of Performance-Vested Shares that may be distributed under this Award if that number of Shares had been issued and outstanding and entitled to the dividend or distribution.  As any Units vest under this Award, the phantom dividends credited to the book account that are attributable to the Shares issuable with respect to such Units will vest and be distributed to the Employee (in the form in which the actual dividend or distribution was paid to shareholders or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the Shares resulting from the Unit vesting. Any such distribution is subject to the Company&#8217;s collection of withholding taxes applicable to the distribution.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If fewer than all of the Performance-Vested Shares are earned as a result of the application of the vesting requirements or the forfeiture provisions of this Agreement or the Program, then the phantom dividends attributable to the unearned Shares will be cancelled and the Employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will cease to have any right or entitlement to receive any distribution or other amount with respect to such cancelled phantom dividends.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No phantom dividends will be paid or payable to or for the benefit of the Employee with respect to dividends or distributions for which the record date occurs on or after the applicable Delivery Date, the date the Employee has forfeited the Units or, in some cases due to applicable law, the date the Restrictions on the Units have lapsed.  For purposes of compliance with the requirements of Code Section 409A, to the extent applicable, the specified date for payment of any phantom dividend to which the Employee is entitled under this Section 2 is the calendar year in which the corresponding Shares vest and are distributed to the Employee.  The Employee has no right to determine the year in which phantom dividends will be paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. Restrictions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Units (encompassing all of the Performance-Vested Shares) are subject to the forfeiture provisions in Sections 6 and 7 below.  Shares are not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Restrictions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) until an event or combination of events described in subsections 4(a), (b), (c) or (d) or Section 5 occurs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Lapse of Restrictions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The number of Shares that become issuable under this Award, as set forth in this Section 4 and subject to the provisions of Sections 5, 6 and 7 below, will be calculated based on the extent to which the Performance Vesting Requirements described in the attached Schedule are achieved. The Committee may equitably adjust the Performance Vesting Requirements described in the attached Schedule in recognition of unusual or non-recurring events affecting the Company or any Subsidiary or the financial statements of the Company or any Subsidiary, in response to changes in applicable laws or regulations, or to account for items of gain, loss or expense determined to be unusual in nature or infrequent in occurrence or related to the acquisition or disposal of a business or assets or related to a change in accounting principles.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a) Performance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Employee remains employed with the Company or its Subsidiaries as of the applicable vesting date specified below and has not experienced a Termination that triggers forfeiture, then&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) the Restrictions on up to one-third of the total number of Units may lapse on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#60;&#60;VEST DATE PERIOD (MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as determined in accordance with the Schedule</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) the Restrictions on up to an additional one-third of the total number of Units may lapse on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#60;&#60;VEST DATE PERIOD 2 (MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as determined in accordance with the Schedule</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii) the Restrictions on up to an additional one-third of the total number of Units may lapse on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#60;&#60;VEST DATE PERIOD 3 (MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as determined in accordance with the Schedule</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b) Retirement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Restrictions will continue to apply in the event of the Employee&#8217;s Termination due to Retirement, but may lapse thereafter in accordance with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provisions of subsection 4(a) above, in which case any Units not previously settled on a Delivery Date will be settled in the form of Shares on the Delivery Date(s) set forth in subsection 4(a) above occurring after the date of such Termination due to Retirement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c) Death</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Restrictions will lapse on the date of the Employee&#8217;s Termination due to death, and any Units not previously settled on a Delivery Date will be settled (for the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution) in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination due to death.  The extent to which the Restrictions lapse, and the number of Shares to be delivered as a result, will be determined as follows&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) For any Performance Period that has begun but has not been completed as of the date of Termination due to death, the number of Shares to be delivered with respect to the applicable Award tranche will be determined based on the greater of (A) performance through the date of Termination measured against the Performance Vesting Requirements set forth in the Schedule using the most recent earnings information released before the date of Termination, and (B) the target vesting level for the applicable Award tranche.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) For any Performance Period that has not yet begun as of the date of Termination due to death, the number of Shares to be delivered will be determined using the target vesting level for the applicable Award tranche(s).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d) Disability.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Restrictions will lapse on the date of the Employee&#8217;s Termination due to Disability, and any Units not previously settled on a Delivery Date will be settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination due to Disability.  The extent to which the Restrictions lapse, and the number of Shares to be delivered as a result, will be determined as follows&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) For any Performance Period that has begun but has not been completed as of the date of Termination due to Disability, the number of Shares to be delivered with respect to the applicable Award tranche will be determined based on the greater of (A) performance through the date of Termination measured against the Performance Vesting Requirements set forth in the Schedule using the most recent earnings information released before the date of Termination, and (B) the target vesting level for the applicable Award tranche.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) For any Performance Period that has not yet begun as of the date of Termination due to Disability, the number of Shares to be delivered will be determined using the target vesting level for the applicable Award tranche(s).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a Change in Control, the entity surviving such Change in Control or the ultimate parent thereof (referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Surviving Entity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may assume, convert or replace this Award with an award of at least equal value and terms and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conditions not less favorable than the terms and conditions provided in this Agreement, in which case the new award will vest according to the terms of the applicable award agreement.  If the Surviving Entity does not assume, convert or replace this Award, the Restrictions will lapse on the date of the Change in Control, as described below.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Surviving Entity does assume, convert or replace this Award, then in the event the Employee&#8217;s Termination (a) occurs within the time period beginning six months immediately before a Change in Control and ending two years immediately following such Change in Control, and (b) was initiated by the Company (or the Surviving Entity) for a reason other than Cause or was initiated by the Employee for Good Reason, the Restrictions will lapse on the later of the date of the Change in Control and the date of the Employee&#8217;s Termination (referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Applicable Lapse Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The extent to which the Restrictions lapse, and the number of Shares to be delivered as a result, will be determined as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) For any Performance Period that has begun but has not been completed as of the Applicable Lapse Date, the number of Shares to be delivered with respect to the applicable Award tranche will be determined based on the greatest of&#58; (A) performance through the date of the Change in Control measured against the Performance Vesting Requirements set forth in the Schedule using the most recent earnings information released before the date of the Change in Control&#59; (B) performance through the date of the Termination measured against the Performance Vesting Requirements set forth in the Schedule using the most recent earnings information released before the date of the Termination&#59; and (C) the target vesting level for the applicable Award tranche.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) For any Performance Period that has not yet begun as of the Applicable Lapse Date, the number of Shares to be delivered will be determined using the target vesting level for the applicable Award tranche(s).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The provisions of this Section 5 supersede Section 13(a)(iii), (iv) and (v) of the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Effect of Certain Bad Acts</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any Units not previously settled will be cancelled and forfeited immediately if the Employee engages in activity that constitutes Cause, as determined in the sole opinion and discretion of the Committee or its delegate, whether or not the Employee experiences a Termination or remains employed with the Company or a Subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. Forfeiture of Units</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of the Employee&#8217;s Termination for any reason other than those set forth in subsection 4(b), (c) or (d) or Section 5, any Units with respect to which Restrictions have not lapsed as of the date of Termination will be forfeited without consideration to the Employee or the Employee&#8217;s Representative.  In the event that the Employee is terminated by the Company other than for Cause and in a situation not covered by Section 5, the Company may, in its sole discretion, cause some or all of the Units to continue to be subject to the Restrictions, provided such Restrictions may lapse thereafter in accordance with the provisions of subsection 4(a), in which case such Units will be settled in the form of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares on the Delivery Date(s) set forth in subsection 4(a) above as if the Employee had remained employed on such dates.  In accepting this Award, the Employee acknowledges that in the event of Termination (whether or not in breach of local labor laws), the Employee&#8217;s right to vest in the Units, if any, will cease and will not be extended by any notice period mandated under local law (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, active employment does not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law) and that the Company shall have the exclusive discretion to determine when Termination occurs.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. Withholding Taxes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent permitted under applicable law and by the Company, the Employee may satisfy any U.S. or non-U.S. federal, state, local or other applicable taxes arising from the grant of the Award, the lapse of Restrictions or the delivery of Shares pursuant to this Agreement by&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.24pt">tendering a cash payment&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.68pt">having the Company withhold Shares from the Shares to be delivered to satisfy the applicable withholding tax&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.91pt">tendering Shares received in connection with the Award back to the Company&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.68pt">delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount to be withheld.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall have the right and is hereby authorized to withhold from the Shares deliverable to the Employee pursuant to this Agreement or (to the extent permitted by applicable law, including without limitation Code Section 409A) from any other compensation or other amount owing to the Employee, such amount as may be necessary in the opinion of the Company to satisfy all such taxes, requirements and withholding obligations.  If the Company withholds for tax purposes from the Shares otherwise to be delivered to the Employee, the Employee is deemed to have been issued the full number of Shares underlying the Award, subject to the Restrictions set forth in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if the Employee is subject to Section 16(b) of the Exchange Act, the Company will withhold using the method described in subsection 8(b) above unless the use of such withholding method is problematic under applicable laws or has materially adverse accounting consequences, in which case the Committee shall determine which of the other methods described in this Section 8 or in the Program shall be used to satisfy the applicable withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. No Right to Continued Employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Employee&#8217;s participation in the Program do not and shall not be interpreted to&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) form an employment contract or relationship with the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) confer upon the Employee any right to continue in the employ of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) interfere with the ability of the Company or its Subsidiaries to terminate the Employee&#8217;s employment at any time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. Nature of Grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting this Award, the Employee acknowledges and agrees that&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Program is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this Award is a one-time benefit and does not create any contractual or other right to receive future grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have been granted repeatedly in the past&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">all decisions with respect to future Unit grants, if any, and their terms and conditions, will be made by the Company, in its sole discretion&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">nothing contained in this Agreement is intended to create or enlarge any other contractual obligations between the Company and the Employee&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Employee is voluntarily participating in the Program&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Units and Shares subject to the Units are&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Company or its Subsidiaries, and are outside the scope of the Employee&#8217;s employment contract, if any&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not intended to replace any pension rights or compensation&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not part of the Employee&#8217;s normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits, or similar payments and in no event should they be considered as compensation for, or relating in any way to, past services for the Company or any of its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the future value of the Shares underlying the Units is unknown and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in consideration of the Award, no claim or entitlement to compensation or damages shall arise from the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably releases the Company and its Subsidiaries from any such claim that may arise&#59; if any such claim is found by a court of competent jurisdiction to have arisen, then, by signing or electronically accepting this Agreement, the Employee shall be deemed irrevocably to have waived the Employee&#8217;s entitlement to pursue such claim&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Units and the Benefits under the Program, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; and</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)         neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units, the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States Dollar&#47;local currency foreign exchange rate.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11. Data Privacy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) Pursuant to applicable personal data protection laws, the collection, processing and transfer of the Employee&#8217;s personal Data is necessary for the Company&#8217;s administration of the Program and the Employee&#8217;s participation in the Program.  The Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of personal Data may affect his or her ability to participate in the Program.  As such (where required under applicable law), the Employee&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of personal Data as described herein</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Data may be provided by the Employee or collected, where lawful, from third parties, and </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">he Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the exclusive purpose of implementing, administering and managing the Employee&#8217;s participation in the Program.  Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which the Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations in the Employee&#8217;s country of residence.  Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.  The Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and for the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee (if applicable) may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Program.  These recipients may be located throughout the world.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) The Employee may, at any time, exercise his or her rights provided under applicable personal data protection laws, which may include the right to&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.71pt">obtain confirmation as to the existence of the Data&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.19pt">verify the content, origin and accuracy of the Data&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.67pt">request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.75pt">oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and&#47;or operation of the Program and the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Employee may seek to exercise these rights by contacting his or her local human resources manager.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) Upon request of the Company or the Subsidiary that employs the Employee, the Employee agrees to provide an executed data privacy consent form (or any other agreement or consent that may be required by the Company and&#47;or the Subsidiary that employs the Employee) to the Company and&#47;or the Subsidiary that employs the Employee that the Company and&#47;or the Subsidiary that employs the Employee may deem necessary to obtain from the Employee for the purpose of administering his or her participation in the Program in compliance with the data privacy laws in the Employee&#8217;s country, either now or in the future. The Employee understands and agrees that he or she will not be able to participate in the Program if the Employee fails to provide any such requested consent or agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12. Form of Payment.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of a cash payment to the extent settlement in Shares&#58; (a) is prohibited under local law&#59; (b) would require the Employee, the Company and&#47;or its Subsidiaries to obtain the approval of any governmental and&#47;or regulatory body in the Employee&#8217;s country&#59; (c) would result in adverse tax consequences for the Employee or the Company&#59; or (d) is administratively burdensome.  Alternatively, the Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of Shares but require the Employee to sell such Shares immediately or within a specified period of time following the Employee&#8217;s Termination (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Employee&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13. Private Placement. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This Award is not intended to be a public offering of securities in the Employee&#8217;s country.  The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and this Award is not subject to the supervision of the local securities authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14. Exchange Controls.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  As a condition to this Award, the Employee agrees to comply with any applicable foreign exchange rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15. Compliance with Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.97pt">The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company&#8217;s Shares are listed.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.46pt">Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">related to the Employee&#8217;s participation in the Program and legally applicable to the Employee or deemed by the Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by the Company or its Subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Tax-Related Items</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Employee acknowledges that the ultimate liability for all Tax-Related Items is and remains the Employee&#8217;s responsibility and may exceed the amount actually withheld by the Company or its Subsidiaries, if any.  The Employee further acknowledges that the Company and&#47;or its Subsidiaries&#58; (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units, including, but not limited to, the grant, lapse of Restrictions or settlement of the Units, the issuance of Shares upon payment of the Units, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends and&#47;or Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate the Employee&#8217;s liability for Tax-Related Items or achieve any particular tax result.  If the Employee has become subject to tax in more than one jurisdiction between the date of grant and the date of any relevant taxable event, the Employee acknowledges that the Company and&#47;or its Subsidiaries may be required to withhold or account for Tax-Related Items in more than one jurisdiction.  If the Employee relocates to another country, the Company may establish special or alternative terms and conditions as necessary or advisable to comply with local laws, rules or regulations, to facilitate the operation and administration of the Award and the Program and&#47;or to accommodate the Employee&#8217;s relocation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.58pt">The Employee acknowledges that, depending on the Employee&#8217;s or the broker&#8217;s country of residence or where the Shares are listed, the Employee may be subject to insider trading restrictions and&#47;or market abuse laws which may affect his or her ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Units) or rights linked to the value of Shares during such times the Employee is considered to have &#8220;inside information&#8221; regarding the Company as defined in the laws or regulations in his or her country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Employee placed before he or she possessed inside information. Furthermore, the Employee could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. The Employee understands that third parties may include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Employee acknowledges that it is the Employee&#8217;s responsibility to comply with any restrictions and the Employee is advised to speak to his or her personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16. Code Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Payments made pursuant to this Agreement are intended to be exempt from or otherwise comply with the provisions of Code Section 409A to the extent applicable.  The Program and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that any payments under this Agreement are subject to Code Section 409A and this Agreement fails to comply with that section&#8217;s requirements, the Company may, at the Company&#8217;s sole discretion, and without the Employee&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consent, amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section 409A.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent required to avoid accelerated taxation and&#47;or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless the Employee has incurred a &#8220;separation from service&#8221; as defined in Treasury Regulation &#167;1.409A-1(h), and amounts that would otherwise be payable pursuant to this Agreement during the six-month period immediately following the Employee&#8217;s Termination (including Retirement) shall instead be paid on the first business day after the date that is six months following the Employee&#8217;s Termination (or upon the Employee&#8217;s death, if earlier).  For purposes of Code Section 409A, to the extent applicable&#58; (a) all payments provided hereunder shall be treated as a right to a series of separate payments and each separately identified amount to which the Employee is entitled under this Agreement shall be treated as a separate payment&#59; (b) except as otherwise provided in Section 13(a) of the Program, upon the lapse of Restrictions pursuant to Section 5 of this Agreement, any Units not previously settled on a Delivery Date shall be settled as soon as administratively possible after, and effective as of, the date of the Change in Control or the date of the Employee&#8217;s Termination (as applicable)&#59; (c) the term &#8220;as soon as administratively possible&#8221; means a period of time that is within 60 days after the Termination, Disability or Change in Control (as applicable)&#59; and (d) the date of the Employee&#8217;s Disability shall be determined by the Company in its sole discretion.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Although this Agreement and the payments provided hereunder are intended to be exempt from or otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States law.  None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisors shall be liable to the Employee (or any other individual claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to Code Section 409A.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17. No Advice Regarding Grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Award, the Employee&#8217;s participation in the Program or the Employee&#8217;s acquisition or sale of the underlying Shares.  The Employee is hereby advised to consult with the Employee&#8217;s own personal tax, legal and financial advisors regarding participation in the Program before taking any action related to the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18. Imposition of Other Requirements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on the Employee&#8217;s participation in the Program, on the Units and on any Shares acquired under the Program, to the extent the Company or any Subsidiary determines it is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program, and to require the Employee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Employee agrees to take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations in the Employee&#8217;s country.  In addition, the Employee agrees to take any and all actions as may be required to comply with the Employee&#8217;s personal obligations under local laws, rules and regulations in the Employee&#8217;s country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19. Determinations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each decision, determination, interpretation or other action made or taken pursuant to the provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be final, conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20. Electronic Delivery</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Program by electronic means.  The Employee hereby consents to receive such documents by electronic delivery and agrees to participate in the Program through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21. Addendum</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Award shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for the Employee&#8217;s country or jurisdiction.  Moreover, if the Employee relocates to one of the countries or jurisdictions included in the Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).  The Addendum constitutes part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22. Severability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.  To the extent a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23. Entire Agreement.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Agreement and the Program constitute the entire agreement between the Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties regarding the Award.  Except as expressly set forth herein, this Agreement (and any provision of this Agreement) may not be modified, changed or clarified by the parties, except in a writing specifying the modification, change or clarification signed by a duly authorized Company officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24. Succession</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be binding upon and operate for the benefit of the Company and its successors and assigns, and the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25. Language</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Employee acknowledges and agrees that it is the Employee&#8217;s express intent that this Agreement, the Program and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English.  If the Employee is in a country where English is not an official language, the Employee acknowledges that he or she is sufficiently proficient in English or has had the ability to consult with an advisor who is sufficiently proficient in the English language, so as to allow the Employee to understand the terms and conditions of this Agreement, the Program and any other documents related to the Award.  If the Employee has received this Agreement or any other document related to the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26. Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any state&#8217;s conflict of laws principles.  For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed on their behalf.</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ABBVIE INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                                              </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                                            </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMPLOYEE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">By electronically accepting the Award, THE EMPLOYEE agrees that (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) such acceptance constitutes THE EMPLOYEE&#8217;S electronic signature in execution of this Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE agrees to be bound by the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE HAS reviewed the PROGRAM, the Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">and the Addendum in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understands all of the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the PROGRAM&#59; and (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the COMMITTEE OR ITS DULY AUTHORIZED DELEGATE ON any questions arising under the PROGRAM, the Agreement and the Addendum.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SCHEDULE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PERFORMANCE PERIODS AND PERFORMANCE VESTING REQUIREMENTS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any capitalized term used but not defined in this Schedule has the meaning set forth in the Agreement or the Program.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Schedule is subject to, and is to be interpreted in combination with, all of the terms and conditions of the Agreement and the Program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Award Tranches and Performance Periods</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Award is subject to vesting in one-third increments over three years with each vesting tranche tied to the Company&#8217;s return on invested capital (&#8220;ROIC&#8221;) performance for the applicable year (2022, 2023 and 2024), as described in the Agreement and the Performance Vesting Requirements section below.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The vesting tranches and corresponding Performance Periods are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.775%"><tr><td style="width:1.0%"></td><td style="width:29.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Vesting Tranche</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Units Subject to Vesting</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Performance Period</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tranche 1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1&#47;3 of Units</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">January 1-December 31, 2022</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tranche 2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1&#47;3 of Units</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">January 1-December 31, 2023</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tranche 3</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1&#47;3 of Units</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">January 1-December 31, 2024</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Performance Vesting Requirements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The vesting for each tranche will be determined based on the Company&#8217;s ROIC for the applicable Performance Period relative to the ROIC for that period of the companies (other than the Company) that were constituents of either the S&#38;P Pharmaceutical, Biotech, and Life Science Index or the NYSE Arca Pharmaceutical Index on January 1, 2022 and continue to be publicly-traded as of the last day of the applicable Performance Period (the &#8220;Index Companies&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Within sixty-five (65) days after the end of each Performance Period, the Committee will determine the Company&#8217;s relative ROIC percentile rank for the applicable Performance Period.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of determining Performance Period ROIC results, ROIC means non-GAAP (or equivalent) ROIC measured using the annual results disclosed in each company&#8217;s earnings release issued most recently prior to the Performance Determination Date.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If an Index Company has not issued its annual earnings release prior to the Performance Determination Date, then its results shall be based on the most currently available financial information.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s relative ROIC percentile rank for the applicable Performance Period determines the vesting percentage for the Units covered by the applicable tranche, such that&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-22.81pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">A ranking at or above the 85th percentile results in vesting at 200% of target level&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-25.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">A ranking from the 75th percentile up to the 85th percentile results in vesting at 175% of target level&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-27.39pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">A ranking from the 65th percentile up to the 75th percentile results in vesting at 150% of target level&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-27.32pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">A ranking from the 50</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> percentile up to the 65</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> percentile results in vesting at target level&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-25.03pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">A ranking from the 40</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> percentile up to the 50</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> percentile results in vesting at 50% of target level&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-27.32pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">A ranking below the 40th percentile results in 0% vesting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The vesting percentage derived from the ranking determination will be multiplied by the number of Units covered by the applicable tranche and rounded down to the nearest whole share, yielding the number of Shares deliverable under the Agreement as a result of the application of the Performance Vesting Requirements for the applicable Performance Period. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Addendum</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and conditions.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Employee is employed in a country or jurisdiction identified in this Addendum, the additional terms and conditions for such country or jurisdiction will apply.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Employee relocates to one of the countries or jurisdictions identified in this Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All defined terms contained in this Addendum shall have the same meaning as set forth in the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES, SWITZERLAND AND THE UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The following provision replaces Section 11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to applicable personal data protection laws, the Employee is hereby notified of the following in relation to the Employee&#8217;s Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of the Program. The collection, processing and transfer of Personal Data is necessary for the legitimate purpose of the administration of the Program by the Company and the Subsidiary that employs the Employee and the Employee&#8217;s participation in the Program, and the Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect his or her participation in the Program. As such</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by participating in the Program, the Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee understands that the Company and the Subsidiary that employs the Employee may hold certain personally identifiable information about the Employee, specifically his or her name, home address, email address and telephone number, date of birth, social security, passport or other identification number (resident registration number), salary, nationality, job title, any Shares or directorships held in the Company or its Subsidiaries, details of all entitlements to Shares (or cash) granted, awarded, canceled, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Personal Data</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Personal Data may be provided by the Employee or collected, where lawful, from third parties. The Company or the Subsidiary that employs the Employee each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee&#8217;s participation in the P</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rogram and meeting related legal obligations associated with these actions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the employment relationship and for the Employee&#8217;s participation in the Program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company and the Subsidiary that employs the Employee will transfer Personal Data amongst themselves and their affiliates as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee may each further transfer Personal Data to third parties assisting the Company or the Subsidiary that employs the Employer in the implementation, administration and management of the Program, including E*TRADE Financial Corporate Services Inc. and its affiliates (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">E*TRADE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or any successor or other third party that the Company, the Subsidiary that employs the Employee or E*TRADE (or its successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in the EU, EEA, Switzerland, the United Kingdom or elsewhere throughout the world, such as the United States. By participating in the Program, the Employee understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Personal Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further understands that he or she may request a list with the names and addresses of any potential recipients of Personal Data by contacting the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Subsidiary that employs the Employee may provide appropriate safeguards in accordance with EU Standard Contractual Clauses, or other legally binding and permissible arrangements. The Employee may request a copy of such safeguards from the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the extent provided by law, the Employee may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, in any case without cost, by contacting in writing the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. The Employee understands, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units or other equity awards or administer or maintain such awards. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When the Company and the Subsidiary that employs the Employee no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that the Employee can no longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ALGERIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ARGENTINA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Neither the Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">AUSTRALIA</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the Agreement and the Program, the Employee must review the Australian Offer Document for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By accepting the Award, the Employee acknowledges and confirms that the Employee has reviewed the Australian Offer Document.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Program is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">BAHRAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement does not constitute advertising or an offering of securities in Bahrain, nor does it constitute an allotment of securities in Bahrain.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any Shares issued pursuant to the Units under the Program shall be deposited into a brokerage account in the United States.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In no event will Shares be issued or delivered in Bahrain.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The issuance of Shares pursuant to the Units described herein has not and will not be registered in Bahrain and hence, the Shares described herein may not be admitted or used for offering, placement or public circulation in Bahrain.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accordingly, the Employee may not make any public advertising or announcements regarding the Units or Shares in Bahrain, promote these Shares to legal entities or individuals in Bahrain, or sell Shares directly to other legal entities or individuals in Bahrain.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges and agrees that Shares may only be sold outside of Bahrain and on a stock exchange on which AbbVie is traded.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Labor Law Acknowledgment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Employee agrees, for all legal purposes, (i) the Benefits provided under the Agreement and the Program are the result of commercial transactions unrelated to the Employee&#8217;s employment&#59; (ii) the Agreement and the Program are not a part of the terms and conditions of the Employee&#8217;s employment&#59; and (iii) the income from the Units, if any, is not part of the Employee&#8217;s remuneration from employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resale Restriction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is permitted to sell Shares acquired upon settlement of the Units through the designated broker appointed under the Program, provided the resale of Shares acquired under the Program takes place outside of Canada through the facilities of the stock exchange on which the Shares are listed.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Shares are currently listed on the New York Stock Exchange.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following provision supplements Section 7 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of the Units, the Employee&#8217;s employment relationship will be considered terminated as of the date the Employee is no longer actually employed or otherwise rendering services to the Company or, if different, the Subsidiary for which the Employee provides services (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment or other laws or otherwise rendering services or the terms of the Employee&#8217;s Employee Agreement or other service agreement, if any). Unless otherwise extended pursuant to the terms of the Agreement or by the Company, the Employee&#8217;s right to vest in the Units, if any, will terminate as of such date (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Termination Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Termination Date will not be extended by any common law notice period. Notwithstanding the foregoing, however, if applicable employment standards legislation specifically requires continued entitlement to vesting during a statutory notice period, the Employee&#8217;s right to vest in the Units, if any, will be allowed to continue for that minimum notice period but then immediately terminate effective as of the last day of the Employee&#8217;s minimum statutory notice period.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event the date the Employee is no longer providing actual service cannot be reasonably determined under the terms of this Agreement and&#47;or the Program, the Committee or its delegate shall have the exclusive discretion to determine when the Employee is no longer actively providing services for purposes of the Units (including whether the Employee may still be considered to be providing services while on a leave of absence).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise provided in the Agreement or by the Company, any portion of the Units that is not vested on the Termination Date shall terminate immediately and be null and void. Unless the applicable employment standards legislation specifically requires, in the case of the Employee, the Employee will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which his or her employment relationship is terminated (as determined under this provision) nor will the Employee be entitled to any compensation for lost vesting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following provision shall replace Section 13 of the Agreement&#58; </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.69pt">The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to General Ruling no. 336 of the Chilean Commission for the Financial Market&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.23pt">The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.26pt">The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities are not registered with the Chilean Commission for the Financial Market&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.23pt">The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.69pt">La fecha de inicio de la oferta ser&#225; el de la fecha de otorgamiento (o &#8220;Grant Date&#8221;, seg&#250;n este t&#233;rmino se define en el documento denominado &#8220;Agreement&#8221;) y esta oferta se acoge a la norma de Car&#225;cter General n&#176; 336 de la Comisi&#243;n para el Mercado Financiero Chilena&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.23pt">La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la Comisi&#243;n para el Mercado Financiero Chilena, por lo que tales valores no est&#225;n sujetos a la fiscalizaci&#243;n de &#233;sta&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.26pt">Por tratar de valores no inscritos no existe la obligaci&#243;n por parte del emisor de entregar en chile informaci&#243;n p&#250;blica respecto de esos valores&#59; y</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.23pt">Esos valores no podr&#225;n ser objeto de oferta p&#250;blica mientras no sean inscritos en el registro de valores correspondiente.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Control Laws</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The following provisions shall govern the Employee&#8217;s participation in the Program if the Employee is a national of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">China</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) resident in mainland China, or if determined to be necessary or appropriate by the Company in its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee agrees to hold the Shares received upon settlement of the Units and any and all previously granted restricted stock units with the Company&#8217;s designated broker. If the Company changes its designated broker, the Employee acknowledges and agrees that the Company may transfer any Shares issued under the Program to the new designated broker if necessary for legal or administrative reasons. The Employee agrees to sign any documentation necessary to facilitate the transfer. Upon a Termination, the Employee shall be required to sell all Shares issued pursuant to the Units within 180 days (or such shorter period as may be required by the State Administration of Foreign Exchange (&#8220;SAFE&#8221;) or the Company) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company. For purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including procedures whereby the Company may issue sale instructions on behalf of the Employee), and the Employee hereby agrees to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary or advisable for purposes of complying with local laws, rules and regulations in China.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, in the event of the Employee&#8217;s Termination due to Retirement, to comply with the applicable SAFE requirements, any Units outstanding as of the 180th day following the Termination date shall be forfeited on such date (or such earlier date as may be required by the SAFE).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and agrees that dividends issued on Shares and sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the Company on the Employee&#8217;s behalf prior to being delivered to the Employee.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividends and&#47;or sales proceeds may be paid to the Employee in U.S. dollars or local currency at the Company&#8217;s discretion.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If dividends and&#47;or sales proceeds are paid to the Employee in U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so that the dividends or proceeds may be deposited into this account.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If dividends and&#47;or sales proceeds are paid to the Employee in local currency, the Employee acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dividends and&#47;or proceeds to local currency due to exchange control restrictions.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee agrees to bear any currency fluctuation risk between the time dividends are issued or Shares are sold and the net proceeds are converted into local currency and distributed to the Employee.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in the future in order to facilitate compliance with exchange control requirements in China.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges and agrees that the processes and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This provision supplements Section 10 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges that, pursuant to Article 128 of the Colombian Labor Code, the Program and related benefits do not constitute a component of Employee's &#8220;salary&#8221; for any legal purpose. Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and, therefore, the Shares may not be offered to the public in Colombia.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">DENMARK</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">The Act on Stock Options</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the Agreement and the Program, the Employee must review the Employer Information Statement (Denmark) pursuant to the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in the Employment Relationship, as amended as of January 1, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By accepting the Award, the Employee acknowledges having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act, as amended as of January 1, 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything in Section 8 of the Agreement to the contrary, if the Employee is a local national of Finland, any Tax-Related Items shall be withheld only in cash from the Employee&#8217;s regular salary&#47;wages or other amounts payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed under local law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">FRANCE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If, for any reason, Shares are issued to the Employee within six months of the Grant Date, the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary of the Grant Date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IMPORTANT NOTICE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WARNING&#58; The contents of the Agreement, the Addendum, the Program, and all other materials pertaining to the Units and&#47;or the Program have not been reviewed by any regulatory authority in Hong Kong.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is hereby advised to exercise caution in relation to the offer thereunder.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Employee has any doubts about any of the contents of the aforesaid materials, the Employee should obtain independent professional advice.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Units and Shares subject to the Units do not form part of the Employee&#8217;s wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Employee expressly agrees to repatriate all amounts acquired under the Program in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subsidiaries </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be liable for any fines or penalties resulting from the Employee's failure to comply with applicable laws, rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">INDONESIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent to Receive Information in English</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By accepting the grant of the Units, the Employee confirms having read and understood the documents relating to this grant which were provided in the English language and accepts the terms of those documents accordingly and agrees not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Persetujuan untuk Menerima Informasi dalam Bahasa Inggris</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">. Dengan menerima hibah dari Unit Saham Terbatas, Anda mengonfirmasi telah membaca dan memahami dokumen-dokumen yang berkaitan dengan hibah ini (yaitu, Perjanjian Penghargaan, dan LTIP Takeda) yang disediakan dalam bahasa </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Inggris, menerima sesuai dengan dokumen-dokumen tersebut, dan setuju untuk tidak menentang keabsahan dokumen ini berdasarkan Undang-Undang No. 24 tahun 2009 tentang Bendera Nasional, Bahasa, Lambang dan Lagu Kebangsaan atau mengimplementasikan Peraturan Presiden (ketika diterbitkan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ISRAEL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee Arrangement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Employee agrees to hold the Shares received upon settlement of the Units with the Company&#8217;s designated broker. The Employee understands and agrees that upon the Employee&#8217;s sale of Shares, unless otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through a trustee in Israel engaged by the Company (the &#8220;Trustee&#8221;), (b) the Trustee will withhold the requisite tax and other mandatory withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Trustee will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">MALTA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial Relationship</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee expressly acknowledges that the Employee&#8217;s participation in the Program and the Company&#8217;s grant of the Award does not constitute an employment relationship between the Employee and the Company.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee has been granted the Award as a consequence of the commercial relationship between the Company and the Subsidiary in Mexico that employs the Employee, and the Company&#8217;s Subsidiary in Mexico is the Employee&#8217;s sole employer.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on the foregoing&#58; (a) the Employee expressly acknowledges that the Program and the benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in Mexico that employs the Employee&#59; (b) the Program and the benefits derived from participation in the Program are not part of the employment conditions and&#47;or benefits provided by the Subsidiary in Mexico that employs the Employee&#59; and (c) any modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee&#8217;s employment with the Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Extraordinary Item of Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee expressly recognizes and acknowledges that the Employee&#8217;s participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the Employee&#8217;s free and voluntary decision to participate in the Program in accordance with the terms and conditions of the Program, the Agreement and this Addendum.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As such, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Employee acknowledges and agrees that the Company, in its sole discretion, may amend and&#47;or discontinue the Employee&#8217;s participation in the Program at any time and without any liability.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The value of the Units is an extraordinary item of compensation outside the scope of the Employee&#8217;s employment contract, if any.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Units are not part of the Employee&#8217;s regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company&#8217;s Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Units and the Shares offered under the Program have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Program, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to the Employee only because of the Employee's existing relationship with the Company and these materials should not be reproduced or copied in any form.  The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">MOROCCO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">NEPAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Employee waives any and all rights to compensation or damages as a result of a Termination, insofar as those rights result or may result from&#58; (a) the loss or diminution in value of such rights or entitlements under the Program&#59; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under the Program as a result of such Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warning</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement, will be converted into Shares.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares give you a stake in the ownership of AbbVie Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If AbbVie Inc. runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may lose some or all of your investment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This information is designed to help investors make an informed decision.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The usual rules do not apply to this offer because it is made under an employee share purchase scheme.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, you may not be given all the information usually required.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You will also have fewer other legal protections for this investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to the underlying Shares. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Shares are quoted on the New York Stock Exchange.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This means that if you acquire Shares under the Program, you may be able to sell them on the New York Stock Exchange if there are interested buyers.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may get less than you invested.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The price will depend on the demand for the Shares.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.9pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">AbbVie Inc.&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">The AbbVie Amended and Restated 2013 Incentive Stock Program&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Copies of the documents listed above will be sent to you free of charge on written request to&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">PHILIPPINES</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  A Termination shall include </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the situation where the Employee&#8217;s employment contract is terminated by operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of any type.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Employee hereby expressly agrees that this Agreement, the Program </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as well as all documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in the English language. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Angajatul consimte &#238;n mod expres prin prezentul ca acest Contract, Programul precum &#351;i orice alte documente, notific&#259;ri, &#238;n&#351;tiin&#355;&#259;ri legate direct sau indirect de acest Contract s&#259; fie redactate sau efectuate doar</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#238;n limba englez&#259;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale or Transfer of Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Program or the Agreement, the Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee may sell the Shares only through a broker established and operating outside Russia.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any Shares issued upon vesting shall be delivered to the Employee through a brokerage account in the U.S.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee may hold the Shares in his or her brokerage account in the U.S.&#59; however, in no event will Shares issued to the Employee under the Program be delivered to the Employee in Russia.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is not permitted to sell Shares directly to other Russian legal entities or individuals. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee agrees to promptly repatriate proceeds resulting from the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SAUDI ARABIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Qualifying Person Exemption</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The grant of the Award under the Program is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">SFA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accordingly, statutory liability under the SFA in relation to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">content of prospectuses would not apply. The Employee should note that, as a result, the Award is subject to section 257 of the SFA and the Employee will not be able to make&#58; (a) any subsequent sale of the Shares underlying the Award in Singapore&#59; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Control Obligations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is solely responsible for complying with applicable exchange control regulations and rulings (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Exchange Control Regulations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in South Africa.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As the Exchange Control Regulations change frequently and without notice, the Employee should consult the Employee&#8217;s legal advisor prior to the acquisition or sale of Shares under the Program to ensure compliance with current Exchange Control Regulations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws, rules or regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In compliance with South African securities laws, the Employee acknowledges that the documents listed below are available for review at the web addresses listed below&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.68pt">AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee understands that a copy of the above documents will be sent to the Employee free of charge on written request to&#58; Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is advised to carefully read the materials provided before making a decision whether to participate in the Program and to contact the Employee&#8217;s tax advisor for specific information concerning the Employee&#8217;s personal tax situation with regard to Program participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Program&#59; No Vested Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Program to individuals who may be employees of the Company or its Subsidiaries throughout the world.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consequently, the Employee understands that the Units are granted on the assumption and condition that the Units and the Share</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s acquired upon settlement of the Units </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the Employee understands that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this grant would not be made to the Employee but for the assumptions and conditions referenced above&#59; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Section 4 of the Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement to the underlying Shares or to any amount of indemnification in the event of Termination.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges that the Employee has read and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Units.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Program or the Agreement, &#8220;Cause&#8221; shall be as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e., &#8220;despido procedente&#8221;) under Spanish legislation.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory. The Program, the Award, the Agreement, this Addendum and all other materials the Employee may receive regarding the Employee&#8217;s participation in the Program have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Spanish Securities Exchange Commission), and they do not constitute a public offering prospectus.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The following provision shall supplement Section 8 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting the authority of the Company and the Subsidiary that employs the Employee to satisfy their withholding obligations for Tax-Related items as set forth in Section 8 of the Agreement, the Employee authorizes the Company to withhold Shares otherwise deliverable to the Employee upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Subsidiary that employs the Employee has an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither this document nor any other materials relating to the Units</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">FinSA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">person other than an employee of the Company or (iii) has been or will be filed with, approved or</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authority, including the Swiss Financial Market Supervisory Authority (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">FINMA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">TUNISIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">TURKEY</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under Turkish law, the Employee is not permitted to sell any Shares acquired under the Plan in Turkey.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Shares are currently traded on the New York Stock Exchange, which is located outside of Turkey, under the ticker symbol &#8220;ABBV&#8221; and the Shares may be sold through this exchange. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Intermediary Obligation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges that any activity related to investments in foreign securities (e.g., the sale of Shares) should be conducted through a bank or financial intermediary institution licensed by the Turkey Capital Markets Board and should be reported to the Turkish Capital Markets Board.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is solely responsible for complying with this requirement and should consult with a personal legal advisor for further information regarding any obligations in this respect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">UKRAINE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Without limitation to Section 8 of the Agreement, the Employee hereby agrees that the Employee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or (if different) the Subsidiary that employs the Employee or by Her Majesty&#8217;s Revenue &#38; Customs (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HMRC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (or any other tax authority or any other relevant authority).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee also hereby agrees to indemnify and keep indemnified the Company and (if different) the Subsidiary that employs the Employee against any Tax-Related Items that they are required to pay or withhold on the Employee&#8217;s behalf or have paid or will pay on the Employee&#8217;s behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if the Employee is a director or executive officer (as within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that the Employee is a director or executive officer and income tax due is not collected from or paid by the Employee by within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to the Employee on which additional income tax and national insurance contributions may be payable. The Employee acknowledges that the Employee ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Subsidiary that employs the Employee (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Subsidiary that employs the Employee may recover from the Employee at any time thereafter by any of the means referred to in Section 8 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges and agrees that the Employee will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Employee&#8217;s ceasing to have rights under or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or otherwise), or from the loss or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">diminution in value of the Units.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the grant of the Award, the Employee shall be deemed to have waived irrevocably any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Units are granted under the Program only to select Employees and are in the nature of providing employee equity incentives in the United Arab Emirates. The Program and the Agreement are intended for distribution only to such Employees and must not be delivered to, or relied on by, any other person.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prospective acquirors of the securities offered should conduct their own due diligence on the securities.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Employee does not understand the contents of the Program and the Agreement, the Employee should consult an authorized financial adviser. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Program.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Neither the Ministry of Economy nor the Dubai Department of Economic Development has approved the Program or the Agreement nor taken steps to verify the information set out herein, and has no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Without limitation to Section 8 of the Agreement, the Employee hereby agrees that the Employee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or (if different) the Subsidiary that employs the Employee or by Her Majesty&#8217;s Revenue &#38; Customs (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HMRC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (or any other tax authority or any other relevant authority).  The Employee also hereby agrees to indemnify and keep indemnified the Company and (if different) the Subsidiary that employs the Employee against any Tax-Related Items that they are required to pay or withhold on the Employee&#8217;s behalf or have paid or will pay on the Employee&#8217;s behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if the Employee is a director or executive officer (as within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that the Employee is a director or executive officer and income tax due is not collected from or paid by the Employee by within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to the Employee on which additional income tax and national insurance contributions may be payable. The Employee acknowledges that the Employee ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Subsidiary that employs the Employee (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Subsidiary that employs the Employee may recover from the Employee at any time thereafter by any of the means referred to in Section 8 of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">         </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee acknowledges and agrees that the Employee will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Employee&#8217;s ceasing to have rights under or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or otherwise), or from the loss or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">diminution in value of the Units.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the grant of the Award, the Employee shall be deemed to have waived irrevocably any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">VIETNAM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>abbv-20220331xex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id1d8b837354043f7b6e106fc14657d0a_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ABBVIE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PERFORMANCE SHARE AWARD Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#60;&#60;GRANT DATE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), AbbVie Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) hereby grants to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#60;&#60;FIRST NAME&#62;&#62; &#60;&#60;LAST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) a Performance Share Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#60;&#60;TOTAL SHARES GRANTED&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> performance share units (the &#8220;Units&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The actual number of shares of Company common stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In the event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus, and the Program administrative rules, the provisions of the Program shall control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The terms and conditions of the Award are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Performance Share Award Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Cause&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Unless otherwise defined in the Employee&#8217;s Change in Control Agreement, cause shall mean the following, as determined by the Company in its sole discretion&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)         material breach by the Employee of the terms and conditions of the Employee&#8217;s employment, including, but not limited to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(A)       material breach by the Employee of the Code of Business Conduct&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(B)       material breach by the Employee of the Employee&#8217;s Employee Agreement or employment contract, if any&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(C)       commission by the Employee of an act of fraud, embezzlement or theft in connection with the Employee&#8217;s duties or in the course of the Employee&#8217;s employment&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(D)       wrongful disclosure by the Employee of secret processes or confidential information of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(E)       failure by the Employee to substantially perform the duties of the Employee&#8217;s employment (other than any such failure resulting from the Employee&#8217;s Disability)&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for the benefit of the Employee or others, in any activity, employment or business which is competitive with the Company or any of its Subsidiaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> Change in Control Agreement&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">An agreement regarding Change in Control in effect between the Company (or the Surviving Entity) and the Employee.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Code of Business Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The Company&#8217;s Code of Business Conduct, as amended from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Controlled Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58; AbbVie Inc. and any corporation, partnership and proprietorship under common control (as defined under the aggregation rules of Code Section 414 (b), (c), or (m)) with AbbVie Inc.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Certain personal information about the Employee held by the Company and the Subsidiary that employs the Employee (if applicable), including (but not limited to) the Employee&#8217;s name, home address and telephone number, email address, date of birth, social security, passport or other identification number, salary, nationality, job title, any Shares held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Sickness or accidental bodily injury, directly and independently of all other causes, that disables the Employee so that the Employee is completely prevented from performing all the duties of his or her occupation or employment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Employee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The Employee Agreement entered into by and between the Company or a Subsidiary and the Employee as it may be amended from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Employee&#8217;s Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Employee&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">legal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">guardian or other legal representative.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58; Unless otherwise defined in the Employee&#8217;s Change in Control Agreement, good reason shall mean the occurrence of any of the following circumstances without the Employee&#8217;s express written consent&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i) a significant adverse change in the nature, scope or status of the Employee&#8217;s position, authorities or duties from those in effect immediately prior to the Change in Control, including, without limitation, if the Employee was, immediately prior to the Change in Control, an officer of a public company, the Employee ceasing to be an officer of a public company&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii) the failure by the Company or a Subsidiary to pay the Employee any portion of the Employee&#8217;s current compensation, or to pay the Employee any portion of any installment of deferred compensation under any deferred compensation program of the Company, within seven days of the date such compensation is due&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii) a reduction in the Employee&#8217;s annual base salary (or a material change in the frequency of payment) as in effect immediately prior to the Change in Control as the same may be increased from time to time&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv) the failure by the Company or a Subsidiary to award the Employee an annual bonus in any year which is at least equal to the annual bonus awarded to the Employee under the annual bonus plan of the Company or Subsidiary for the year immediately preceding the year of the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(v) the failure by the Company to award the Employee equity-based incentive compensation (such as stock options, shares of restricted stock, restricted stock units, or other equity-based compensation) on a periodic basis consistent with the Company&#8217;s practices with respect to timing, value and terms prior to the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vi) the failure by the Company or a Subsidiary to continue to provide the Employee with the welfare benefits, fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in Control under any of the Company&#8217;s or Subsidiary&#8217;s plans or policies, including, but not limited to, those plans and policies providing pension, life insurance, medical, health and accident, disability and vacation&#59; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vii) the relocation of the Employee&#8217;s base office to a location that is more than 35 miles from the Employee&#8217;s base office immediately prior to the Change in Control&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the Company to assume and agree to perform this Agreement as contemplated in Section 5.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Performance Determination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The date on which the Committee determines whether or to what extent the Performance Vesting Requirements have been achieved.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The period(s) specified in the attached Schedule, over which achievement of the Performance Vesting Requirements is to be measured.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> Performance Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The maximum number of Shares the Employee may receive under this Award based on the extent to which the Performance Vesting Requirements are achieved.  In no event will the number of Performance Shares exceed 250% of the number of Units set forth in the first paragraph of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(n) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Performance Vesting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The performance goals described in the attached Schedule, which must be achieved for Units to vest and the corresponding Shares to be delivered under this Award.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  The AbbVie Amended and Restated 2013 Incentive Stock Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(p) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i) Except as provided under (ii) or (iii) below, Retirement means any of the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">age 55 with 10 years of service&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">age 60 with five years of service&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">age 65 with three years of service.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii) For purposes of calculating service under this Section 1(p), except as otherwise provided by the Committee or its delegate&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">service is earned only if performed for a member of the Controlled Group while that Controlled Group member is a part of the Controlled Group as defined in section 1(e) of this Agreement&#59; and </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">for Employees who transferred to the Company directly from Abbott Laboratories during the period from January 1, 2013 through June 30, 2015 either as a result of the Company&#8217;s spin-off from Abbott Laboratories or with the consent of each company&#8217;s head of human resources, service includes service with Abbott Laboratories that is counted for retirement eligibility purposes under applicable law or Company procedures outside the United States the AbbVie Pension Plan, the AbbVie Pension Plan for Former BASF and Former Solvay Employees, or another Company-sponsored pension plan, as applicable.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii) For Employees who (A) are being credited with service in the AbbVie Pension Plan at the time of a Retirement eligibility determination under this Agreement, and (B) transferred to the Company directly from Abbott Laboratories either as a result of the Company&#8217;s spin-off from Abbott Laboratories or during the period from January 1, 2013 through June 30, 2015 with the consent of each company&#8217;s head of human resources, and (C) were hired into the Abbott Laboratories controlled group prior to January 1, 2004, Retirement means any of the following&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">age 50 with 10 years of service&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">age 65 with at least three years of service&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">age 55 with an age and service combination of 70 points, where each year of age is one point and each year of service is one point.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  A severance of employment for any reason (including Retirement) from the Company and all Subsidiaries.  Any Termination shall be effective on the last day the Employee performs services for or on behalf of the Company or its Subsidiary, and employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">2. Delivery Dates and Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The delivery dates for Shares issuable with respect to the Units are the respective dates on which the Shares are distributable to the Employee if the Units vest pursuant to Section 4 below (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Prior to the Delivery Date(s)&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        the Employee shall not be treated as a shareholder as to any Shares issuable under the Agreement, and shall have only a contractual right to receive Shares, unsecured by any assets of the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        the Employee shall not be permitted to vote any Shares issuable under the Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        the Employee&#8217;s right to receive such Shares will be subject to the adjustment provisions relating to mergers, reorganizations, and similar events set forth in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Subject to the requirements of local law, if any dividend or other distribution is declared and paid on Shares (other than dividends or distributions of securities of the Company which may be issued with respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) while any of the Units remain subject to this Award (meaning that any of the Shares into which Units would be converted are not otherwise issued and outstanding for purposes of the entitlement to the dividend or distribution), then a book account will be maintained for the Employee and credited with a phantom dividend that is equivalent to the actual dividend or distribution that would have been paid on the total number of Performance Shares that may be distributed under this Award if that number of Shares had been issued and outstanding and entitled to the dividend or distribution.  As any Units vest under this Award, the phantom dividends credited to the book account that are attributable to the Shares issuable with respect to such Units will vest and be distributed to the Employee (in the form in which the actual dividend or distribution was paid to shareholders or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the Shares resulting from the Unit vesting. Any such distribution is subject to the Company&#8217;s collection of withholding taxes applicable to the distribution. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">If fewer than all of the Performance Shares are earned as a result of the application of the vesting requirements or the forfeiture provisions of this Agreement or the Program, then the phantom dividends attributable to the unearned Shares will be cancelled and the Employee will cease to have any right or entitlement to receive any distribution or other amount with respect to such cancelled phantom dividends.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">No phantom dividends will be paid or payable to or for the benefit of the Employee with respect to dividends or distributions for which the record date occurs on or after the date the Employee has forfeited the Units, or the date on which vested Units have been settled in Shares.  For purposes of compliance with the requirements of Code Section 409A, to the extent applicable, the specified date for payment of any phantom dividend to which the Employee is entitled under this Section 2 is the calendar year in which the corresponding Shares vest and are distributed to the Employee.  The Employee has no right to determine the year in which phantom dividends will be paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3. Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Units (encompassing all of the Performance Shares) are subject to the forfeiture provisions in Sections 6 and 7 below.  Shares are not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of (collectively, the &#8220;Restrictions&#8221;) until an event or combination of events described in subsections 4(a), (b), (c) or (d) or Section 5 occurs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4. Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The number of Shares that become issuable under this Award, as set forth in this Section 4 and subject to the provisions of Sections 5, 6 and 7 below, will be calculated based on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the extent to which the Performance Vesting Requirements described in the attached Schedule are achieved.  The Committee may equitably adjust the Performance Vesting Requirements described in the attached Schedule in recognition of unusual or non-recurring events affecting the Company or any Subsidiary or the financial statements of the Company or any Subsidiary, in response to changes in applicable laws or regulations, or to account for items of gain, loss or expense determined to be unusual in nature or infrequent in occurrence or related to the acquisition or disposal of a business or assets or related to a change in accounting principles.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(a) Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If the Employee remains employed with the Company or its Subsidiaries as of the vesting date and has not experienced a Termination that triggers forfeiture, then the Units may be earned as described in the Schedule.  The number of Shares deliverable as a result of Units being earned shall be determined in accordance with the Schedule.  The Delivery Date for the Shares to be delivered as a result of Units being earned under this subsection (a) shall be no later than 75 days after the date of the applicable vesting event.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event of the Employee&#8217;s Termination due to Retirement, the Award will remain in effect and any Units not previously vested may vest as set forth in subsection 4(a) above. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event of the Employee&#8217;s Termination due to death, any Units not previously vested will vest and be settled (for the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution) in the form of Shares as soon as administratively possible after, and effective as of, the date of death.  The extent to which the Units vest, and the number of Shares to be delivered as a result, will be determined based on the greater of (A) performance through the date of Termination measured against the Performance Vesting Requirements set forth in the Schedule using, as applicable, adjusted earnings per share calculated through the most recent quarterly earnings release preceding or coinciding with the date of Termination and relative Total Shareholder Return (TSR) calculated as of the date of Termination, and (B) the target vesting level for the Award.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event of the Employee&#8217;s Termination due to Disability, any Units not previously vested will vest and be settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination due to Disability.  The extent to which the Units vest, and the number of Shares to be delivered as a result, will be determined based on the greater of (A) performance through the date of Termination measured against the Performance Vesting Requirements set forth in the Schedule using, as applicable, adjusted earnings per share calculated through the most recent quarterly earnings release preceding or coinciding with the date of Termination and relative TSR calculated as of the date of Termination, and (B) the target vesting level for the Award.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5. Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event of a Change in Control, the entity surviving such Change in Control or the ultimate parent thereof (referred to herein as the &#8220;Surviving Entity&#8221;) may assume, convert or replace this Award with an award of at least equal value and terms and conditions not less favorable than the terms and conditions provided in this Agreement, in which case the new award will vest according to the terms of the applicable award agreement.  If the Surviving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Entity does not assume, convert or replace this Award, the Units will vest on the date of the Change in Control, as described below.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">If the Surviving Entity does assume, convert or replace this Award, then in the event the Employee&#8217;s Termination (a) occurs within the time period beginning six months immediately before a Change in Control and ending two years immediately following such Change in Control, and (b) was initiated by the Company (or the Surviving Entity) for a reason other than Cause or was initiated by the Employee for Good Reason, the Units will vest on the later of the date of the Change in Control and the date of the Employee&#8217;s Termination (referred to herein as the &#8220;Applicable Vesting Date&#8221;).   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The extent to which the Units vest, and the number of Shares to be delivered as a result, will be determined based on the greatest of (A) performance through the date of the Change in Control measured against the Performance Vesting Requirements set forth in the Schedule using the most recent earnings information released before or on the date of the Change in Control and relative TSR calculated immediately before the Change in Control&#59; (B) performance through the date of the Termination measured against the Performance Vesting Requirements set forth in the Schedule using the most recent earnings information released before or on the date of the Termination and relative TSR calculated as of the date of Termination&#59; and (C) the target vesting level for the Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of this Section 5 supersede Section 13(a)(iii), (iv) and (v) of the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">6. Effect of Certain Bad Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Any Units not previously settled will be cancelled and forfeited immediately if the Employee engages in activity that constitutes Cause, as determined in the sole opinion and discretion of the Committee or its delegate, whether or not the Employee experiences a Termination or remains employed with the Company or a Subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">7. Forfeiture of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event of the Employee&#8217;s Termination for any reason other than those set forth in subsections 4(b), (c) or (d) or Section 5, any Units that have not vested as of the date of Termination will be forfeited without consideration to the Employee or the Employee&#8217;s Representative.  In the event that the Employee is terminated by the Company other than for Cause and in a situation not covered by Section 5, the Company may, in its sole discretion, cause some or all of the Units to remain in effect and subject to vesting in accordance with the provisions of subsection 4(a), in which case such Units will be settled in the form of Shares on the Delivery Date(s) set forth in subsection 4(a) above as if the Employee had remained employed on such dates.  In accepting this Award, the Employee acknowledges that in the event of Termination (whether or not in breach of local labor laws), the Employee&#8217;s right to vest in the Units, if any, will cease and will not be extended by any notice period mandated under local law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, active employment does not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law) and that the Company shall have the exclusive discretion to determine when Termination occurs.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">8. Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  To the extent permitted under applicable law and by the Company, the Employee may satisfy any U.S. or non-U.S. federal, state, local or other applicable taxes arising from the grant of the Award, the vesting of Units or the delivery of Shares pursuant to this Agreement by&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a) tendering a cash payment&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b) having the Company withhold Shares from the Shares to be delivered to satisfy the applicable withholding tax&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c) tendering Shares received in connection with the Award back to the Company&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d) delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount to be withheld.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company shall have the right and is hereby authorized to withhold from the Shares deliverable to the Employee pursuant to this Agreement or (to the extent permitted by applicable law, including without limitation Code Section 409A) from any other compensation or other amount owing to the Employee, such amount as may be necessary in the opinion of the Company to satisfy all such taxes, requirements and withholding obligations.  If the Company withholds for tax purposes from the Shares otherwise to be delivered to the Employee, the Employee is deemed to have been issued the full number of Shares underlying the Award, subject to the vesting requirements set forth in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, if the Employee is subject to Section 16(b) of the Exchange Act, the Company will withhold using the method described in subsection 8(b) above unless the use of such withholding method is problematic under applicable laws or has materially adverse accounting consequences, in which case the Committee shall determine which of the other methods described in this Section 8 or in the Program shall be used to satisfy the applicable withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">9. No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement and the Employee&#8217;s participation in the Program do not and shall not be interpreted to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a) form an employment contract or relationship with the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b) confer upon the Employee any right to continue in the employ of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c) interfere with the ability of the Company or its Subsidiaries to terminate the Employee&#8217;s employment at any time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10. Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In accepting this Award, the Employee acknowledges and agrees that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Program is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">this Award is a one-time benefit and does not create any contractual or other right to receive future grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have been granted repeatedly in the past&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">all decisions with respect to future Unit grants, if any, and their terms and conditions, will be made by the Company, in its sole discretion&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">nothing contained in this Agreement is intended to create or enlarge any other contractual obligations between the Company and the Employee&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Employee is voluntarily participating in the Program&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Units and Shares subject to the Units are&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Company or its Subsidiaries, and are outside the scope of the Employee&#8217;s employment contract, if any&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">not part of the Employee&#8217;s normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits, or similar payments and in no event should they be considered as compensation for, or relating in any way to, past services for the Company or any of its Subsidiaries&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the future value of the Shares underlying the Units is unknown and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in consideration of the Award, no claim or entitlement to compensation or damages shall arise from the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably releases the Company and its Subsidiaries from any such claim that may arise&#59; if any such claim is found by a court of competent jurisdiction to have arisen, then, by signing or electronically accepting this Agreement, the Employee shall be deemed irrevocably to have waived the Employee&#8217;s entitlement to pursue such claim&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Units and the Benefits under the Program, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)         neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units, the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States Dollar&#47;local currency foreign exchange rate.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">11. Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a) Pursuant to applicable personal data protection laws, the collection, processing and transfer of the Employee&#8217;s personal Data is necessary for the Company&#8217;s administration of the Program and the Employee&#8217;s participation in the Program.  The Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of personal Data may affect his or her ability to participate in the Program.  As such (where required under applicable law), the Employee&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i) voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of personal Data as described herein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii) authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b) Data may be provided by the Employee or collected, where lawful, from third parties, and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">he Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the exclusive purpose of implementing, administering and managing the Employee&#8217;s participation in the Program.  Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which the Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations in the Employee&#8217;s country of residence.  Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.  The Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and for the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c) The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee (if applicable) may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Program.  These recipients may be located throughout the world.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d) The Employee may, at any time, exercise his or her rights provided under applicable personal data protection laws, which may include the right to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-23.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">obtain confirmation as to the existence of the Data&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">verify the content, origin and accuracy of the Data&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-29.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-29.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and&#47;or operation of the Program and the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Employee may seek to exercise these rights by contacting his or her local human resources manager.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-23.49pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt">Upon request of the Company or the Subsidiary that employs the Employee, the Employee agrees to provide an executed data privacy consent form (or any other agreement or consent that may be required by the Company and&#47;or the Subsidiary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">that employs the Employee) to the Company and&#47;or the Subsidiary that employs the Employee that the Company and&#47;or the Subsidiary that employs the Employee may deem necessary to obtain from the Employee for the purpose of administering his or her participation in the Program in compliance with the data privacy laws in the Employee&#8217;s country, either now or in the future. The Employee understands and agrees that he or she will not be able to participate in the Program if the Employee fails to provide any such requested consent or agreement. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">12. Form of Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of a cash payment to the extent settlement in Shares&#58; (a) is prohibited under local law&#59; (b) would require the Employee, the Company and&#47;or its Subsidiaries to obtain the approval of any governmental and&#47;or regulatory body in the Employee&#8217;s country&#59; (c) would result in adverse tax consequences for the Employee or the Company&#59; or (d) is administratively burdensome.  Alternatively, the Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of Shares but require the Employee to sell such Shares immediately or within a specified period of time following the Employee&#8217;s Termination (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Employee&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13. Private Placement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Award is not intended to be a public offering of securities in the Employee&#8217;s country.  The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and this Award is not subject to the supervision of the local securities authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">14. Exchange Controls.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  As a condition to this Award, the Employee agrees to comply with any applicable foreign exchange rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">15. Compliance with Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a) The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company&#8217;s Shares are listed.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b) Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Employee&#8217;s participation in the Program and legally applicable to the Employee or deemed by the Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by the Company or its Subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), the Employee acknowledges that the ultimate liability for all Tax-Related Items is and remains the Employee&#8217;s responsibility and may exceed the amount actually withheld by the Company or its Subsidiaries, if any.  The Employee further acknowledges that the Company and&#47;or its Subsidiaries&#58; (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units, including, but not limited to, the grant, vesting or settlement of the Units, the issuance of Shares upon payment of the Units, the subsequent sale of Shares </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">acquired pursuant to such issuance and the receipt of any dividends and&#47;or Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate the Employee&#8217;s liability for Tax-Related Items or achieve any particular tax result.  If the Employee has become subject to tax in more than one jurisdiction between the date of grant and the date of any relevant taxable event, the Employee acknowledges that the Company and&#47;or its Subsidiaries may be required to withhold or account for Tax-Related Items in more than one jurisdiction.  If the Employee relocates to another country, the Company may establish special or alternative terms and conditions as necessary or advisable to comply with local laws, rules or regulations, to facilitate the operation and administration of the Award and the Program and&#47;or to accommodate the Employee&#8217;s relocation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c) The Employee acknowledges that, depending on the Employee&#8217;s or the broker&#8217;s country of residence or where the Shares are listed, the Employee may be subject to insider trading restrictions and&#47;or market abuse laws which may affect his or her ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Units) or rights linked to the value of Shares during such times the Employee is considered to have &#8220;inside information&#8221; regarding the Company as defined in the laws or regulations in his or her country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Employee placed before he or she possessed inside information. Furthermore, the Employee could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. The Employee understands that third parties may include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Employee acknowledges that it is the Employee&#8217;s responsibility to comply with any restrictions and the Employee is advised to speak to his or her personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">16. Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Payments made pursuant to this Agreement are intended to be exempt from or otherwise comply with the provisions of Code Section 409A to the extent applicable.  The Program and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that any payments under this Agreement are subject to Code Section 409A and this Agreement fails to comply with that section&#8217;s requirements, the Company may, at the Company&#8217;s sole discretion, and without the Employee&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section 409A.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent required to avoid accelerated taxation and&#47;or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless the Employee has incurred a &#8220;separation from service&#8221; as defined in Treasury Regulation &#167;1.409A-1(h), and amounts that would otherwise be payable pursuant to this Agreement during the six-month period immediately following the Employee&#8217;s Termination (including Retirement) shall instead be paid on the first business day after the date that is six months following the Employee&#8217;s Termination (or upon the Employee&#8217;s death, if earlier).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of Code Section 409A, to the extent applicable&#58; (a) all payments provided hereunder shall be treated as a right to a series of separate payments and each separately identified amount to which the Employee is entitled under this Agreement shall be treated as a separate payment&#59; (b) except as otherwise provided in Section 13(a) of the Program, upon the lapse of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Restrictions pursuant to Section 5 of this Agreement, any Units not previously settled on a Delivery Date shall be settled as soon as administratively possible after, and effective as of, the date of the Change in Control or the date of the Employee&#8217;s Termination (as applicable)&#59; and (c) the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">as soon as administratively possible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a period of time that is within 60 days after the Termination or Change in Control (as applicable).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Although this Agreement and the payments provided hereunder are intended to be exempt from or otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States law.  None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisors shall be liable to the Employee (or any other individual claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">17. No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Award, the Employee&#8217;s participation in the Program or the Employee&#8217;s acquisition or sale of the underlying Shares.  The Employee is hereby advised to consult with the Employee&#8217;s own personal tax, legal and financial advisors regarding participation in the Program before taking any action related to the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">18. Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Company reserves the right to impose other requirements on the Employee&#8217;s participation in the Program, on the Units and on any Shares acquired under the Program, to the extent the Company or any Subsidiary determines it is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program, and to require the Employee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.  The Employee agrees to take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations in the Employee&#8217;s country.  In addition, the Employee agrees to take any and all actions as may be required to comply with the Employee&#8217;s personal obligations under local laws, rules and regulations in the Employee&#8217;s country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">19. Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each decision, determination, interpretation or other action made or taken pursuant to the provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be final, conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">20. Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Program by electronic means.  The Employee hereby consents to receive such documents by electronic delivery and agrees to participate in the Program through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">21. Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Award shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for the Employee&#8217;s country or jurisdiction.  Moreover, if the Employee relocates to one of the countries or jurisdictions included in the Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).  The Addendum constitutes part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">22. Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.  To the extent a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">23. Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  This Agreement and the Program constitute the entire agreement between the Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties regarding the Award.  Except as expressly set forth herein, this Agreement (and any provision of this Agreement) may not be modified, changed or clarified by the parties, except in a writing specifying the modification, change or clarification signed by a duly authorized Company officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">24. Succession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be binding upon and operate for the benefit of the Company and its successors and assigns, and the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">25. Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Employee acknowledges and agrees that it is the Employee&#8217;s express intent that this Agreement, the Program and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English.  If the Employee is in a country where English is not an official language, the Employee acknowledges that he or she is sufficiently proficient in English or has had the ability to consult with an advisor who is sufficiently proficient in the English language, so as to allow the Employee to understand the terms and conditions of this Agreement, the Program and any other documents related to the Award.  If the Employee has received this Agreement or any other document related to the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">26. Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any state&#8217;s conflict of laws principles.  For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">USA, and, if there is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">*</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed on their behalf.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ABBVIE INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">                                                                              </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                            </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMPLOYEE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">By electronically accepting the Award, THE EMPLOYEE agrees that (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) such acceptance constitutes THE EMPLOYEE&#8217;S electronic signature in execution of this Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE agrees to be bound by the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE HAS reviewed the PROGRAM, the Agreement and the Addendum in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understands all of the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the PROGRAM&#59; and (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">) THE EMPLOYEE hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the COMMITTEE OR ITS DULY AUTHORIZED DELEGATE ON any questions arising under the PROGRAM, the Agreement and the Addendum.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">PERFORMANCE PERIODS AND PERFORMANCE VESTING REQUIREMENTS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Any capitalized term used but not defined in this Schedule has the meaning set forth in the Agreement or the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Schedule is subject to, and is to be interpreted in combination with, all of the terms and conditions of the Agreement and the Program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Vesting Steps and Performance Periods</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Award is subject to vesting in two steps as summarized below.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Step 1 is based on the Company&#8217;s adjusted earnings per share (&#8220;EPS&#8221;) performance for the designated Performance Period and Step 2 is based on the Company&#8217;s relative total shareholder return (&#8220;TSR&#8221;) for the designated Performance Period, as described in the Agreement and the Performance Vesting Requirements section below.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The vesting steps and corresponding Performance Periods are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.269%"><tr><td style="width:1.0%"></td><td style="width:36.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Vesting Step</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Performance Period</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Step 1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">January 1-December 31, 2022</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Step 2</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">January 1, 2023-December 31, 2024</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Performance Vesting Requirements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Step 1 </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Step 1 is based on the Company&#8217;s EPS performance for 2022.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Within sixty-five (65) days after the end of the Step 1 Performance Period, the Committee will determine the Company&#8217;s EPS for that Performance Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For purposes of determining such Performance Period EPS results, EPS means non-GAAP EPS disclosed in the Company&#8217;s annual earnings release for the year ended December 31, 2022. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company&#8217;s EPS performance for the Step 1 Performance Period determines the adjustment percentage for Step 1, such that&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">EPS of $14.30 or greater results in an adjustment of 200%&#59;</font></div><div style="padding-left:72pt;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">EPS of $14.10 results in an adjustment of 100%&#59;</font></div><div style="padding-left:72pt;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">EPS of $14.05 results in an adjustment of 50%&#59; and</font></div><div style="padding-left:72pt;text-indent:-27.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">EPS below $14.05 results in an adjustment of 0%.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The adjustment percentages for EPS performance between $14.05 and $14.10 and between $14.10 and $14.30 will be interpolated based on the parameters listed above. The adjustment percentage derived from the EPS performance determination will be multiplied by the number of Units and rounded down to the nearest whole share, yielding an adjusted number of Units (the &#8220;Adjusted Units&#8221;) that will be used in Step 2 below to determine the number of Shares deliverable under the Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Step 2</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Step 2 is based on the Company&#8217;s TSR for 2022-2024 relative to the TSR for the same period of the companies (other than the Company) that were constituents of either the S&#38;P Pharmaceutical, Biotech, and Life Science Index or the NYSE Arca Pharmaceutical Index on January 1, 2022 and continue to be publicly-traded as of the last day of the Step 2 Performance Period (the &#8220;Index Companies&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Within sixty-five (65) days after the end of the Step 2 Performance Period, the Committee will determine performance against the Step 2 Performance Vesting Requirement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Committee will determine the Company&#8217;s 2022-2024 TSR relative to the 2022-2024 TSR of the Index Companies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For the purposes of determining TSR, for each company the beginning stock price will be the closing stock price on December 31, 2021 and the ending stock price will be the closing stock price on December 31, 2024.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The TSR results of the individual Index Companies will be indexed by beginning-of-period market capitalization.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company&#8217;s TSR compared to the Index Companies TSR for the Performance Period determines the adjustment percentage to be applied to the Adjusted Units, such that&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.67pt">Company TSR more than 15 points above the index results in an adjustment of +25%&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.67pt">Company TSR more than 10 points above the index results in an adjustment of +20%&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.23pt">Company TSR more than 5 points above the index results in an adjustment of +15%&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.67pt">Company TSR more than 5 points below the index results in an adjustment of -15%&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.67pt">Company TSR more than 15 points below the index results in an adjustment of -25%.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The adjustment percentage derived from the index comparison will be multiplied by the number of Adjusted Units and rounded down to the nearest whole share, yielding the number of Shares deliverable under the Agreement as a result of the application of the Performance Vesting Requirements.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADDENDUM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee is employed in a country or jurisdiction identified in this Addendum, the additional terms and conditions for such country or jurisdiction will apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee relocates to one of the countries or jurisdictions identified in this Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All defined terms contained in this Addendum shall have the same meaning as set forth in the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES, SWITZERLAND AND UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision replaces Section 11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Pursuant to applicable personal data protection laws, the Employee is hereby notified of the following in relation to the Employee&#8217;s Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of the Program. The collection, processing and transfer of Personal Data is necessary for the legitimate purpose of the administration of the Program by the Company and the Subsidiary that employs the Employee and the Employee&#8217;s participation in the Program, and the Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect his or her participation in the Program. As such</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">by participating in the Program, the Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company and the Subsidiary that employs the Employee may hold certain personally identifiable information about the Employee, specifically his or her name, home address, email address and telephone number, date of birth, social security, passport or other identification number (resident registration number), salary, nationality, job title, any Shares or directorships held in the Company or its Subsidiaries, details of all entitlements to Shares (or cash) granted, awarded, canceled, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Personal Data may be provided by the Employee or collected, where lawful, from third parties. The Company or the Subsidiary that employs the Employee each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee&#8217;s participation in the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and meeting related legal obligations associated with these actions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the employment relationship and for the Employee&#8217;s participation in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company and the Subsidiary that employs the Employee will transfer Personal Data amongst themselves and their affiliates as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee may each further transfer Personal Data to third parties assisting the Company or the Subsidiary that employs the Employer in the implementation, administration and management of the Program, including E*TRADE Financial Corporate Services Inc. and its affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">E*TRADE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) or any successor or other third party that the Company, the Subsidiary that employs the Employee or E*TRADE (or its successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in the EU, EEA, Switzerland, the United Kingdom or elsewhere throughout the world, such as the United States. By participating in the Program, the Employee understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Personal Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further understand that he or she may request a list with the names and addresses of any potential recipients of Personal Data by contacting the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Subsidiary that employs the Employee may provide appropriate safeguards in accordance with EU Standard Contractual Clauses, or other legally binding and permissible arrangements. The Employee may request a copy of such safeguards from the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent provided by law, the Employee may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, in any case without cost, by contacting in writing the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. The Employee understands, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units or other equity awards or administer or maintain such awards. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">When the Company and the Subsidiary that employs the Employee no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that the Employee can no longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ALGERIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Award nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Australian Offer Document for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges and confirms that the Employee has reviewed the Australian Offer Document.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BAHRAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Agreement does not constitute advertising or an offering of securities in Bahrain, nor does it constitute an allotment of securities in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Shares issued pursuant to the Units under the Program shall be deposited into a brokerage account in the United States.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In no event will Shares be issued or delivered in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The issuance of Shares pursuant to the Units described herein has not and will not be registered in Bahrain and hence, the Shares described herein may not be admitted or used for offering, placement or public circulation in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, the Employee may not make any public advertising or announcements regarding the Units or Shares in Bahrain, promote these Shares to legal entities or individuals in Bahrain, or sell Shares directly to other legal entities or individuals in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that Shares may only be sold outside of Bahrain and on a stock exchange on which AbbVie is traded.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Labor Law Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees, for all legal purposes, (i) the Benefits provided under the Agreement and the Program are the result of commercial transactions unrelated to the Employee&#8217;s employment&#59; (ii) the Agreement and the Program are not a part of the terms and conditions of the Employee&#8217;s employment&#59; and (iii) the income from the Units, if any, is not part of the Employee&#8217;s remuneration from employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Resale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee is permitted to sell Shares acquired upon settlement of the Units through the designated broker appointed under the Program, provided the resale of Shares acquired </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">under the Program takes place outside of Canada through the facilities of the stock exchange on which the Shares are listed. The Shares are currently listed on the New York Stock Exchange. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision supplements Section 7 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the Units, the Employee&#8217;s employment relationship will be considered terminated as of the date the Employee is no longer actually employed or otherwise rendering services to the Company or, if different, the Subsidiary for which the Employee provides services (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment or other laws or otherwise rendering services or the terms of the Employee&#8217;s Employee Agreement or other service agreement, if any). Unless otherwise extended pursuant to the terms of the Agreement or by the Company, the Employee&#8217;s right to vest in the Units, if any, will terminate as of such date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Termination Date will not be extended by any common law notice period. Notwithstanding the foregoing, however, if applicable employment standards legislation specifically requires continued entitlement to vesting during a statutory notice period, the Employee&#8217;s right to vest in the Units, if any, will be allowed to continue for that minimum notice period but then immediately terminate effective as of the last day of the Employee&#8217;s minimum statutory notice period.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event the date the Employee is no longer providing actual service cannot be reasonably determined under the terms of this Agreement and&#47;or the Program, the Committee or its delegate shall have the exclusive discretion to determine when the Employee is no longer actively providing services for purposes of the Units (including whether the Employee may still be considered to be providing services while on a leave of absence).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise provided in the Agreement or by the Company, any portion of the Units that is not vested on the Termination Date shall terminate immediately and be null and void. Unless the applicable employment standards legislation specifically requires, in the case of the Employee, the Employee will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which his or her employment relationship is terminated (as determined under this provision) nor will the Employee be entitled to any compensation for lost vesting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision shall replace Section 13 of the Agreement&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to General Ruling no. 336 of the Chilean Commission for the Financial Market&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities are not registered with the Chilean Commission for the Financial Market&#59; and </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Foreign Exchange Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The following provisions shall govern the Employee&#8217;s participation in the Program if the Employee is a national of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) resident in mainland China, or if determined to be necessary or appropriate by the Company in its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to hold the Shares received upon settlement of the Units and any and all previously granted restricted stock units with the Company&#8217;s designated broker. If the Company changes its designated broker, the Employee acknowledges and agrees that the Company may transfer any Shares issued under the Program to the new designated broker if necessary for legal or administrative reasons. The Employee agrees to sign any documentation necessary to facilitate the transfer. Upon a Termination, the Employee shall be required to sell all Shares issued pursuant to the Units within 180 days (or such shorter period as may be required by the State Administration of Foreign Exchange (&#8220;SAFE&#8221;) or the Company) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including procedures whereby the Company may issue sale instructions on behalf of the Employee), and the Employee hereby agrees to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary or advisable for purposes of complying with local laws, rules and regulations in China. Further, in the event of the Employee&#8217;s Termination due to Retirement, to comply with the applicable SAFE requirements, any Units outstanding as of the 180th day following the Termination date shall be forfeited on such date (or such earlier date as may be required by the SAFE).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and agrees that dividends issued on Shares and sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the Company on the Employee&#8217;s behalf prior to being delivered to the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dividends and&#47;or sales proceeds may be paid to the Employee in U.S. dollars or local currency at the Company&#8217;s discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If dividends and&#47;or sales proceeds are paid to the Employee in U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so that the dividends or proceeds may be deposited into this account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If dividends and&#47;or sales proceeds are paid to the Employee in local currency, the Employee acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the dividends and&#47;or proceeds to local currency due to exchange control restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to bear any currency fluctuation risk between the time dividends are issued or Shares are sold and the net proceeds are converted into local currency and distributed to the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in the future in order to facilitate compliance with exchange control requirements in China.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the processes and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This provision supplements Section 10 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that, pursuant to Article 128 of the Colombian Labor Code, the Program and related benefits do not constitute a component of Employee's &#8220;salary&#8221; for any legal purpose. Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) and, therefore, the Shares may not be offered to the public in Colombia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">DENMARK</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">The Act on Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Employer Information Statement (Denmark) pursuant to the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in the Employment Relationship, as amended as of January 1, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act, as amended as of January 1, 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Notwithstanding anything in Section 8 of the Agreement to the contrary, if the Employee is a local national of Finland, any Tax-Related Items shall be withheld only in cash from the Employee&#8217;s regular salary&#47;wages or other amounts payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed under local law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If, for any reason, Shares are issued to the Employee within six months of the Grant Date, the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary of the Grant Date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">IMPORTANT NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WARNING&#58; The contents of the Agreement, the Addendum, the Program, and all other materials pertaining to the Units and&#47;or the Program have not been reviewed by any regulatory authority in Hong Kong.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is hereby advised to exercise caution in relation to the offer thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee has any doubts about any of the contents of the aforesaid materials, the Employee should obtain independent professional advice.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units and Shares subject to the Units do not form part of the Employee&#8217;s wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee expressly agrees to repatriate all amounts acquired under the Program in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subsidiaries </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall be liable for any fines or penalties resulting from the Employee's failure to comply with applicable laws, rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDONESIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Consent to Receive Information in English</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the grant of the Units, the Employee confirms having read and understood the documents relating to this grant which were provided in the English language and accepts the terms of those documents accordingly and agrees not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Persetujuan untuk Menerima Informasi dalam Bahasa Inggris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">. Dengan menerima hibah dari Unit Saham Terbatas, Anda mengonfirmasi telah membaca dan memahami dokumen-dokumen yang berkaitan dengan hibah ini (yaitu, Perjanjian Penghargaan, dan LTIP Takeda) yang disediakan dalam bahasa Inggris, menerima sesuai dengan dokumen-dokumen tersebut, dan setuju untuk tidak menentang keabsahan dokumen ini berdasarkan Undang-Undang No. 24 tahun 2009 tentang Bendera Nasional, Bahasa, Lambang dan Lagu Kebangsaan atau mengimplementasikan Peraturan Presiden (ketika diterbitkan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ISRAEL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Trustee Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees to hold the Shares received upon settlement of the Units with the Company&#8217;s designated broker. The Employee understands and agrees that upon the Employee&#8217;s sale of Shares, unless otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through a trustee in Israel engaged by the Company (the &#8220;Trustee&#8221;), (b) the Trustee will withhold the requisite tax and other mandatory withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Trustee will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MALTA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Commercial Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  The Employee expressly acknowledges that the Employee&#8217;s participation in the Program and the Company&#8217;s grant of the Award does not constitute an employment relationship between the Employee and the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee has been granted the Award as a consequence of the commercial relationship between the Company and the Subsidiary in Mexico that employs the Employee, and the Company&#8217;s Subsidiary in Mexico is the Employee&#8217;s sole employer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Based on the foregoing&#58; (a) the Employee expressly acknowledges that the Program and the benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in Mexico that employs the Employee&#59; (b) the Program and the benefits derived from participation in the Program are not part of the employment conditions and&#47;or benefits provided by the Subsidiary in Mexico that employs the Employee&#59; and (c) any modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee&#8217;s employment with the Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Extraordinary Item of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly recognizes and acknowledges that the Employee&#8217;s participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the Employee&#8217;s free and voluntary decision to participate in the Program in accordance with the terms and conditions of the Program, the Agreement and this Addendum.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As such, the Employee acknowledges and agrees that the Company, in its sole discretion, may amend and&#47;or discontinue the Employee&#8217;s participation in the Program at any time and without any liability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The value of the Units is an extraordinary item of compensation outside the scope of the Employee&#8217;s employment contract, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are not part of the Employee&#8217;s regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company&#8217;s Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Award and the Shares offered under the Program have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Program, the Agreement and any other document relating to the Award may not be publicly distributed in Mexico. These materials are addressed to the Employee only because of the Employee's existing relationship with the Company and these materials should not be reproduced or copied in any form.  The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MOROCCO</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEPAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee waives any and all rights to compensation or damages as a result of a Termination, insofar as those rights result or may result from&#58; (a) the loss or diminution in value of such rights or entitlements under the Program&#59; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under the Program as a result of such Termination.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warning</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement, will be converted into Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares give you a stake in the ownership of AbbVie Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If AbbVie Inc. runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This information is designed to help investors make an informed decision.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The usual rules do not apply to this offer because it is made under an employee share purchase scheme.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a result, you may not be given all the information usually required.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You will also have fewer other legal protections for this investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to the underlying Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are quoted on the New York Stock Exchange.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This means that if you acquire Shares under the Program, you may be able to sell them on the New York Stock Exchange if there are interested buyers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may get less than you invested.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The price will depend on the demand for the Shares.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">The AbbVie 2013 Incentive Stock Program&#58;  This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie 2013 Incentive Stock Program Prospectus&#58;  This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">Copies of the documents listed above will be sent to you free of charge on written request to&#58;  Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">PHILIPPINES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  A Termination shall include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the situation where the Employee&#8217;s employment contract is terminated by operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of any type.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee hereby expressly agrees that this Agreement, the Program as well as all documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in the English language. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Angajatul consimte &#238;n mod expres prin prezentul ca acest Contract, Programul precum &#351;i orice alte documente, notific&#259;ri, &#238;n&#351;tiin&#355;&#259;ri legate direct sau indirect de acest Contract s&#259; fie redactate sau efectuate doar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#238;n limba englez&#259;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sale or Transfer of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, the Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may sell the Shares only through a broker established and operating outside Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Shares issued upon vesting shall be delivered to the Employee through a brokerage account in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may hold the Shares in his or her brokerage account in the U.S.&#59; however, in no event will Shares issued to the Employee under the Program be delivered to the Employee in Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is not permitted to sell Shares directly to other Russian legal entities or individuals.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to promptly repatriate proceeds resulting from the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SAUDI ARABIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Qualifying Person Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Award under the Program is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result, the Award is subject to section 257 of the SFA and the Employee will not be able to make&#58; (a) any subsequent sale of the Shares underlying the Award in Singapore&#59; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exchange Control Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with applicable exchange control regulations and rulings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Exchange Control Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) in South Africa.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As the Exchange Control Regulations change frequently and without notice, the Employee should consult the Employee&#8217;s legal advisor prior to the acquisition or sale of Shares under the Program to ensure compliance with current Exchange Control Regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws, rules or regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In compliance with South African securities laws, the Employee acknowledges that the documents listed below are available for review at the web addresses listed below&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">AbbVie 2013 Amended and Restated Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that copies of the documents listed above will be sent to the Employee free of charge on written request to&#58; Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is advised to carefully read the materials provided before making a decision whether to participate in the Program and to contact the Employee&#8217;s tax advisor for specific information concerning the Employee&#8217;s personal tax situation with regard to Program participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Program&#59; No Vested Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Program to individuals who may be employees of the Company or its Subsidiaries throughout the world.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consequently, the Employee understands that the Units are granted on the assumption and condition that the Units and the Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s acquired upon settlement of the Units </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and conditions referenced above&#59; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Section 4 of the Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement to the underlying Shares or to any amount of indemnification in the event of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that the Employee has read and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Units.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, &#8220;Cause&#8221; shall be as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e., &#8220;despido procedente&#8221;) under Spanish legislation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory. The Program, the Award, the Agreement, this Addendum and all other materials the Employee may receive regarding the Employee&#8217;s participation in the Program have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Spanish Securities Exchange Commission), and they do not constitute a public offering prospectus.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision shall supplement Section 8 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Without limiting the authority of the Company and the Subsidiary that employs the Employee to satisfy their withholding obligations for Tax-Related items as set forth in Section 8 of the Agreement, the Employee authorizes the Company to withhold Shares otherwise deliverable to the Employee upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Subsidiary that employs the Employee has an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWITZERLAND</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Neither this document nor any other materials relating to the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">person other than an employee of the Company or (iii) has been or will be filed with, approved or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">authority, including the Swiss Financial Market Supervisory Authority (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FINMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">TUNISIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Under Turkish law, the Employee is not permitted to sell any Shares acquired under the Plan in Turkey.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are currently traded on the New York Stock Exchange, which is located outside of Turkey, under the ticker symbol &#8220;ABBV&#8221; and the Shares may be sold through this exchange. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Financial Intermediary Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that any activity related to investments in foreign securities (e.g., the sale of Shares) should be conducted through a bank or financial intermediary institution licensed by the Turkey Capital Markets Board and should be reported to the Turkish Capital Markets Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with this requirement and should consult with a personal legal advisor for further information regarding any obligations in this respect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UKRAINE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are granted under the Program only to select Employees and are in the nature of providing employee equity incentives in the United Arab Emirates. The Program and the Agreement are intended for distribution only to such Employees and must not be delivered to, or relied on by, any other person.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prospective acquirors of the securities offered should conduct their own due diligence on the securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee does not understand the contents of the Program and the Agreement, the Employee should consult an authorized financial adviser. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Ministry of Economy nor the Dubai Department of Economic Development has approved the Program or the Agreement nor taken steps to verify the information set out herein, and has no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Without limitation to Section 8 of the Agreement, the Employee hereby agrees that the Employee is liable for all Tax-Related Item</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">s and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or (if different) the Subsidiary that employs the Employee or by Her Majesty&#8217;s Revenue &#38; Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) (or any other tax authority or any other relevant authority).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee also hereby agrees to indemnify and keep indemnified the Company and (if different) the Subsidiary that employs the Employee against any Tax-Related Items that they are required to pay or withhold on the Employee&#8217;s behalf or have paid or will pay on the Employee&#8217;s behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, if the Employee is a director or executive officer (as within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that the Employee is a director or executive officer and income tax due is not collected from or paid by the Employee by within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to the Employee on which additional income tax and national insurance contributions may be payable. The Employee acknowledges that the Employee ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">under the self-assessment regime and for reimbursing the Company or the Subsidiary that employs the Employee (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Subsidiary that employs the Employee may recover from the Employee at any time thereafter by any of the means referred to in Section 8 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the Employee will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Employee&#8217;s ceasing to have rights under or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or otherwise), or from the loss or diminution in value of the Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon the grant of the Award, the Employee shall be deemed to have waived irrevocably any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">VIETNAM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>abbv-20220331xex103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i57d0cac8d7004462bb671eb32d585ab5_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ABBVIE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">On this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;GRANT DATE (MONTH DD, YYYY)&#62;&#62; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">AbbVie Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) hereby grants to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;FIRST NAME&#62;&#62; &#60;&#60;LAST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) a Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;TOTAL SHARES GRANTED&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) representing the right to receive an equal number of Shares on a specified Delivery Date.</font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus, and the Program administrative rules, the provisions of the Program shall control.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The terms and conditions of the Award are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:9.75pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Restricted Stock Unit Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Certain personal information about the Director held by the Company and the Subsidiary for which the Director provides services (if applicable), including (but not limited to) the Director&#8217;s name, home address and telephone number, email address, date of birth, social security, passport or other identification number, salary, nationality, job title, any Shares held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or outstanding in the Director&#8217;s favor, for the purpose of managing and administering the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Director&#8217;s Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58; The Director&#8217;s legal guardian or other legal representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The AbbVie Amended and Restated 2013 Incentive Stock Program.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A termination from service for any reason (including death or retirement) with the Board of Directors of the Company and all Subsidiaries.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2. Delivery Date and Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The delivery dates for Shares underlying the Units is the date on which the Shares are payable to the Director after the Restrictions on such Units lapse pursuant to Section 4 below (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Prior to the Delivery Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Director shall not be treated as a shareholder as to those Shares underlying the Units, and shall have only a contractual right to receive Shares, unsecured by any assets of the Company or its Subsidiaries&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Director shall not be permitted to vote the Shares underlying the Units&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">the Director&#8217;s right to receive such Shares will be subject to the adjustment provisions relating to mergers, reorganizations, and similar events set forth in the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Subject to the requirements of local law, the Director shall receive cash payments equal to the dividends and distributions paid on Shares underlying the Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) (other than dividends or distributions of securities of the Company which may be issued with respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) to the same extent and on the same date as if each Unit were a Share&#59; provided, however, that no Dividend Equivalents shall be payable to or for the benefit of the Director with respect to dividends or distributions the record date for which occurs on or after the applicable Delivery Date, the date the Director has forfeited the Units or, in some cases due to applicable law, the date the Restrictions on the Units have lapsed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of compliance with the requirements of Code Section 409A, to the extent applicable, the specified date for payment of any Dividend Equivalents to which the Director is entitled under this Section 2 is the calendar year during the term of this Agreement in which the associated dividends or distributions are paid on Shares underlying the Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Director shall have no right to determine the year in which Dividend Equivalents will be paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">3. Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Units shall be fully vested as of the Grant Date&#59; provided, however, that the Units will be subject to subsections (3)(a), (b), and (c) below (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) until the earlier to occur of the events described in subsection 4(a) or (b).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Units may not be sold, exchanged, assigned, transferred, pledged, or otherwise disposed of.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Any additional Shares or other securities or property issued with respect to Shares covered by the Units as a result of any stock split, combination, stock dividend or recapitalization, shall be subject to the Restrictions and other provisions of the Program and this Agreement.</font></div><div style="text-align:justify;text-indent:70.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Director shall not be entitled to receive any Shares prior to completion of all actions deemed appropriate by the Company to comply with federal, state or other applicable securities laws and stock exchange requirements.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4. Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Restrictions shall lapse and have no further force or effect and Shares underlying the Units shall be settled upon the earlier of the following events (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#58;</font></div><div style="text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Termination Event.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The date of the Director&#8217;s Termination&#59; or</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The date of occurrence of a Change in Control&#59; provided that the event constituting a Change in Control is a &#8220;change in control event&#8221; as such term is defined in Treasury Regulation &#167; 1.409A-3(i)(5).</font></div><div style="text-align:justify;text-indent:70.55pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">5. Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Director may satisfy any U.S. or non-U.S. federal, state, local or other applicable taxes arising from the grant of the Award, the lapse of Restrictions or the delivery of Shares pursuant to this Agreement by&#58;</font></div><div style="text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">tendering a cash payment&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">having the Company withhold Shares from the Shares to be delivered to satisfy the applicable withholding tax&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">tendering Shares received in connection with the Units back to the Company&#59; or</font></div><div style="text-align:justify;text-indent:70.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount to be withheld.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company shall have the right and is hereby authorized to withhold from the Shares deliverable to the Director pursuant to this Agreement or (to the extent permitted by applicable law, including without limitation Code Section 409A) from any other compensation or other amount owing to the Director, such amount as may be necessary in the opinion of the Company to satisfy all such taxes, requirements and withholding obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">If the Company withholds for tax purposes from the Shares otherwise to be delivered to the Director, the Director is deemed to have been issued the full number of Shares underlying the Units, subject to the Restrictions set forth in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Notwithstanding the foregoing, if the Director is subject to Section 16(b) of the Exchange Act, the Company will withhold using the method described in subsection 5(b) above unless the use of such withholding method is problematic under applicable laws or has materially adverse accounting consequences, in which case the Committee shall determine which of the other methods described in this Section 5 or in the Program shall be used to satisfy the applicable withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">6. No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement and the Director&#8217;s participation in the Program is not and shall not be interpreted to&#58;</font></div><div style="text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">form a contractual or other relationship with the Company or its Subsidiaries&#59;</font></div><div style="text-align:justify;text-indent:70.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">confer upon the Director any right to continue in the service of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">interfere with the ability of the Company or its Subsidiaries to terminate the Director&#8217;s service at any time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">7. No Contract as of Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Award does not create any contractual or other right to receive additional Awards or other Program Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Nothing contained in this Agreement is intended to create or enlarge any other contractual obligations between the Company and the Director.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Future Awards, if any, and their terms and conditions, will be at the sole discretion of the Committee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">8. Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Pursuant to applicable personal data protection laws, the collection, processing and transfer of the Director&#8217;s personal Data is necessary for the Company&#8217;s administration of the Program and the Director&#8217;s participation in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Director&#8217;s denial and&#47;or objection to the collection, processing and transfer of personal Data may affect his or her ability to participate in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">As such (where required under applicable law), the Director&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of personal Data as described herein&#59; and</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for purposes of implementing, administering and managing the Director&#8217;s participation in the Program, including any requisite transfer of such Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Director&#8217;s behalf to a broker or other third party with whom the Director may elect to deposit any Shares acquired pursuant to the Program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data may be provided by the Director or collected, where lawful, from third parties, and the Company will process the Data for the exclusive purpose of implementing, administering and managing the Director&#8217;s participation in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which the Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations in the Director&#8217;s country of residence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and for the Director&#8217;s participation in the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company will transfer Data as necessary for the purpose of implementation, administration and management of the Director&#8217;s participation in the Program, and the Company and the Subsidiary that served by the Director (if applicable) may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">These recipients may be located throughout the world.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Director may, at any time, exercise his or her rights provided under applicable personal data protection laws, which may include the right to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:109.21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">obtain confirmation as to the existence of the Data&#59;</font></div><div style="text-align:justify;text-indent:109.21pt"><font><br></font></div><div style="text-align:justify;text-indent:109.21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">verify the content, origin and accuracy of the Data&#59;</font></div><div style="text-align:justify;text-indent:109.21pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data&#59; and</font></div><div style="text-align:justify;text-indent:109.21pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and&#47;or operation of the Program and the Director&#8217;s participation in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Director may seek to exercise these rights by contacting the Company&#8217;s corporate human resources department.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Upon request of the Company, the Director agrees to provide an executed data privacy consent form (or any other agreement or consent that may be required by the Company) to the Company that the Company may deem necessary to obtain from the Director for the purpose of administering his or her participation in the Program in compliance with the data privacy laws in the Director&#8217;s country, either now or in the future. The Director understands and agrees that he or she will not be able to participate in the Program if the Director fails to provide any such requested consent or agreement. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">9. No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Units, the Director&#8217;s participation in the Program or the Director&#8217;s acquisition or sale of the underlying Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Director is hereby advised to consult with the Director&#8217;s own personal tax, legal and financial advisors regarding participation in the Program before taking any action related to the Program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">10. Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement and the Program constitute the entire agreement between the Director and the Company regarding the Award and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties regarding the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Except as expressly set forth herein, this Agreement (and any provision of this Agreement) may not be modified, changed or clarified by the parties, except in a writing specifying the modification, change or clarification signed by a duly authorized Company officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">11. Succession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement shall be binding upon and operate for the benefit of the Company and its successors and assigns, and the Director, the Director&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">12. Compliance with Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company&#8217;s Shares are listed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Director relocates to another country, the Company may establish special or alternate terms and conditions as necessary or advisable to comply with local laws, rules or regulations, to facilitate the operation and administration of the Award and the Program and&#47;or to accommodate the Director&#8217;s relocation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">13. Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Payments made pursuant to this Agreement are intended to be exempt from or otherwise comply with the provisions of Code Section 409A to the extent applicable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Program and this Agreement shall be administered and interpreted in a manner consistent with this intent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Company determines that any payments under this Agreement are subject to Code Section 409A and this Agreement fails to comply with that section&#8217;s requirements, the Company may, at the Company&#8217;s sole discretion, and without the Director&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent required to avoid accelerated taxation and&#47;or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Director shall not be deemed to have had a Termination unless the Director has incurred a &#8220;separation from service&#8221; as defined in Treasury Regulation &#167;1.409A-1(h), and amounts that would otherwise be payable pursuant to this Agreement during the six-month period immediately following the Director&#8217;s Termination shall instead be paid on the first business day after the date that is six months following the Director&#8217;s Termination (or upon the Director&#8217;s death, if earlier).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of Code Section 409A, to the extent applicable, all payments provided hereunder shall be treated as a right to a series of separate payments and each separately identified amount to which the Director is entitled under this Agreement shall be treated as a separate payment. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Although this Agreement and the payments provided hereunder are intended to be exempt from or otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisers shall be liable to the Director (or any other individual claiming a benefit through the Director) for any tax, interest, or penalties the Director may owe as a result of compensation paid under this Agreement, and the Company and its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Subsidiaries shall have no obligation to indemnify or otherwise protect the Director from the obligation to pay any taxes pursuant to Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">14. Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Each decision, determination, interpretation or other action made or taken pursuant to the provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be final, conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the Director, the Director&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">15. Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">16. Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any state&#8217;s conflict of laws principles. For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed on their behalf.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ABBVIE INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">                                                                              </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                            </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">DIRECTOR</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">By electronically accepting the Award, THE DIRECTOR agrees that (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) such acceptance constitutes THE DIRECTOR&#8217;S electronic signature in execution of this Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE DIRECTOR agrees to be bound by the provisions of the PROGRAM and the Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE director HAS reviewed the PROGRAM and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understands all of the provisions of the PROGRAM and the Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE director HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the PROGRAM&#59; and (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE director hereby agrees to accept as binding, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">conclusive and final all decisions or interpretations of the COMMITTEE OR ITS DULY AUTHORIZED DELEGATE ON any questions arising under the PROGRAM and the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>abbv-20220331xex104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icef0e328dfca44a5beccafb0a6572e5f_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 10.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">ABBVIE INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">NON-QUALIFIED STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:37.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">On this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;GRANT DATE (MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), AbbVie Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">) hereby grants to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;FIRST NAME&#62;&#62; &#60;&#60;LAST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) an Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) to purchase a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;TOTAL SHARES GRANTED&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Shares, at the price of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#60;&#60;OPTION PRICE&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> per Share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), such price being not less than 100% of the Fair Market Value of the Shares on the Grant Date.</font></div><div style="text-align:justify;text-indent:37.45pt"><font><br></font></div><div style="text-align:justify;text-indent:37.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Option is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus, and the Program administrative rules, the provisions of the Program shall control.</font></div><div style="text-align:justify;text-indent:37.45pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The terms and conditions of the Option granted to the Employee are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%;padding-left:9pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(a) Agreement&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">This Non-Qualified Stock Option Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(b) Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">&#58;  Unless otherwise defined in the Employee&#8217;s Change in Control Agreement, cause shall mean the following, as determined by the Company in its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(i) material breach by the Employee of the terms and conditions of the Employee&#8217;s employment, including, but not limited to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(A) material breach by the Employee of the Code of Business Conduct&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(B) material breach by the Employee of the Employee&#8217;s Employee Agreement&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(C) commission by the Employee of an act of fraud, embezzlement or theft in connection with the Employee&#8217;s duties or in the course of the Employee&#8217;s employment&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(D) wrongful disclosure by the Employee of secret processes or confidential information of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(E) failure by the Employee to substantially perform the duties of the Employee&#8217;s employment (other than any such failure resulting from the Employee&#8217;s Disability)&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(ii) to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for the benefit of the Employee or others, in any activity, employment or business which is competitive with the Company or any of its Subsidiaries.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(c) Change in Control Agreement&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> An agreement regarding Change in Control in effect between the Company (or the Surviving Entity) and the Employee.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(d) Code of Business Conduct&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Company&#8217;s Code of Business Conduct, as amended from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(e) Controlled Group&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">AbbVie Inc. and any corporation, partnership and proprietorship under common control (as defined under the aggregation rules of Code Section 414 (b), (c), or (m)) with AbbVie Inc.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(f) Data&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Certain personal information about the Employee held by the Company and the Subsidiary that employs the Employee (if applicable), including (but not limited to) the Employee&#8217;s name, home address and telephone number, email address, date of birth, social security, passport or other identification number, salary, nationality, job title, any Shares held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(g) Disability&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Sickness or accidental bodily injury, directly and independently of all other causes, that disables the Employee so that the Employee is completely prevented from performing all the duties of his or her occupation or employment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(h) Employee Agreement&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> The Employee Agreement entered into by and between the Company or a Subsidiary and the Employee as it may be amended from time to time.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(i) Employee&#8217;s Representative&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Employee&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">legal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">guardian or other legal representative.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(j) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Good Reason&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Unless otherwise defined in the Employee&#8217;s Change in Control Agreement, good reason shall mean the occurrence of any of the following circumstances without the Employee&#8217;s express written consent&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) a significant adverse change in the nature, scope or status of the Employee&#8217;s position, authorities or duties from those in effect immediately prior to the Change in Control, including, without limitation, if the Employee was, immediately prior to the Change in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Control, an officer of a public company, the Employee ceasing to be an officer of a public company&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(ii) the failure by the Company or a Subsidiary to pay the Employee any portion of the Employee&#8217;s current compensation, or to pay the Employee any portion of any installment of deferred compensation under any deferred compensation program of the Company, within seven days of the date such compensation is due&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iii) a reduction in the Employee&#8217;s annual base salary (or a material change in the frequency of payment) as in effect immediately prior to the Change in Control as the same may be increased from time to time&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iv) the failure by the Company or a Subsidiary to award the Employee an annual bonus in any year which is at least equal to the annual bonus awarded to the Employee under the annual bonus plan of the Company or Subsidiary for the year immediately preceding the year of the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(v) the failure by the Company to award the Employee equity-based incentive compensation (such as stock options, shares of restricted stock, restricted stock units, or other equity-based compensation) on a periodic basis consistent with the Company&#8217;s practices with respect to timing, value and terms prior to the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(vi) the failure by the Company or a Subsidiary to continue to provide the Employee with the welfare benefits, fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in Control under any of the Company&#8217;s or Subsidiary&#8217;s plans or policies, including, but not limited to, those plans and policies providing pension, life insurance, medical, health and accident, disability and vacation&#59; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(vii) the relocation of the Employee&#8217;s base office to a location that is more than 35 miles from the Employee&#8217;s base office immediately prior to the Change in Control&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the Company to assume and agree to perform this Agreement as contemplated in Section </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(k) Option&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Non-Qualified Stock Option granted pursuant to this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(l) Program&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The AbbVie Amended and Restated 2013 Incentive Stock Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(m) Retirement&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(i) Except as provided under (ii) or (iii) below, Retirement means either of the following&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:14.15pt">age 55 with 10 years of service&#59; or</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:14.15pt">age 60 with five years of service&#59; or</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:14.15pt">age 65 with at least three years of service.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(ii) For purposes of calculating service under this Section 1(m), except as otherwise provided by the Committee or its delegate&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(A) service is earned only if performed for a member of the Controlled Group while that Controlled Group member is a part of the Controlled Group as defined in section 1(e) of this Agreement&#59; and </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(B) for Employees who transferred to the Company directly from Abbott Laboratories during the period from January 1, 2013 through June 30, 2015 either as a result of the Company&#8217;s spin-off from Abbott Laboratories or with the consent of each company&#8217;s head of human resources, service includes service with Abbott Laboratories that is counted for retirement eligibility purposes under applicable law or Company procedures outside the United States the AbbVie Pension Plan, the AbbVie Pension Plan for Former BASF and Former Solvay Employees, or another Company-sponsored pension plan, as applicable.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iii) For Employees who (A) are being credited with service in the AbbVie Pension Plan at the time of a Retirement eligibility determination under this Agreement, and (B) transferred to the Company directly from Abbott Laboratories either as a result of the Company&#8217;s spin-off from Abbott Laboratories or during the period from January 1, 2013 through June 30, 2015 with the consent of each company&#8217;s head of human resources, and (C) were hired into the Abbott Laboratories controlled group prior to January 1, 2004, Retirement means any of the following&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:14.15pt">age 50 with 10 years of service&#59;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:14.15pt">age 65 with at least three years of service&#59; or</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:14.15pt">age 55 with an age and service combination of 70 points, where each year of age is one point and each year of service is one point.</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">&#8226;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">(n) Termination&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> A severance of employment for any reason (including Retirement) from the Company and all Subsidiaries.  Any Termination shall be effective on the last day the Employee performs services for or on behalf of the Company or its Subsidiary, and employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">2. Term of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  Subject to Sections 5 and 7, the Employee may exercise all or a portion of the vested Option at any time prior to the 10th anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">&#8221;)&#59; provided that the Option may be exercised with respect to whole Shares only.  In no event shall the Option be exercisable on or after the Expiration Date.  To the extent the Option is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">not exercised prior to the Expiration Date (or any earlier expiration of the Option pursuant to Sections 5 and 7), it shall be canceled and forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">3. Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The Option shall vest and become exercisable as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(a) on the first anniversary of the Grant Date, one-third of the total number of Shares may be purchased&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(b) on the second anniversary of the Grant Date, two-thirds of the total number of Shares may be purchased&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(c) on the third anniversary of the Grant Date, the Option may be exercised in full.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Option is not earned and the Employee has no right to purchase the underlying Shares until an event described above occurs.  The vesting described above is cumulative, so that at each vesting date an additional amount of Shares is available for purchase and remains available until the Option&#8217;s Expiration Date or such earlier date determined pursuant to Section 5 or 7 below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">4. Exercise of the Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  To the extent vested, the Option may be exercised in whole or in part as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(a) Who May Hold&#47;Exercise the Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(i) General Rule - Exercise by Employee Only. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> During the lifetime of the Employee, the Option may be exercised only by the Employee or the Employee&#8217;s Representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(ii) Death Exception.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">  If the Employee dies, then the Option may be exercised only by the executor or administrator of the estate of the Employee or the person or persons to whom rights under the Option have passed by will or the laws of descent or distribution.  Such person(s) shall furnish the appropriate tax clearances, proof of the right of such person(s) to exercise the Option, and other pertinent data as the Company may deem necessary.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(iii) Transferability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> Except as otherwise provided by the Committee or its delegate, the Option is not transferable other than by will or the laws of descent and distribution.  It may not be assigned, transferred (except by will or the laws of descent and distribution), pledged or hypothecated in any way, whether by operation of law or otherwise, and shall not be subject to execution, attachment, or similar process.  Any attempt at assignment, transfer, pledge, hypothecation, or other disposition of the Option contrary to the provisions hereof, and the levy of any attachment or similar process upon such Option, shall be null and void.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(b) Method of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  Subject to the requirements of local law, the Option may be exercised only by&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(i) delivery to the designated employee or agent of the Company of a written, electronic, or telephonic notice of exercise, specifying the number of Shares with respect to which the Option is then being exercised, and payment of the full Exercise Price of the Shares being purchased in cash or with other Shares held by the Employee having a then Fair Market Value equal to the Exercise Price&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(ii) delivery of a properly-executed exercise notice together with a copy of irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds to pay the Exercise Price&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iii) a combination of (i) and (ii) above&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iv) any other manner approved by the Committee from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Each method of exercise requires payment of the full amount of any U.S. and non-U.S. federal, state, local or other applicable taxes which the Company believes are required to be withheld and paid with respect to such exercise, as described below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Notwithstanding the foregoing, the Company may require payment in a particular or different method of exercise than those methods specified in Section 4(b)(i) - (iii), may allow the Employee to exercise the Option only by means of a cashless exercise (either a cashless &#8220;sell all&#8221; exercise or a cashless &#8220;sell-to-cover&#8221; exercise) as it shall determine in its sole discretion, or may require the Employee to sell any Shares the Employee acquired under the Program immediately or within a specified period following the Employee&#8217;s Termination (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Employee&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(c) Payment of Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">  To the extent permitted under applicable law and by the Company, the Employee may satisfy any U.S. or non-U.S. federal, state, local or other applicable taxes arising from any transaction related to the exercise of the Option pursuant to this Agreement by&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(i) tendering a cash payment&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(ii) having the Company withhold Shares from the Option exercised to satisfy the applicable withholding tax&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iii) tendering Shares received in connection with the Option back to the Company&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iv) delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount to be withheld.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Company shall have the right and is hereby authorized to withhold from the Shares transferable to the Employee upon any exercise of the Option or (to the extent permitted by applicable law, including without limitation Code Section 409A) from any other compensation or other amount owing to the Employee such amount as may be necessary in the opinion of the Company to satisfy all such tax and withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Notwithstanding the foregoing, if the Employee is subject to Section 16(b) of the Exchange Act, the Company will withhold using the method described in subsection 4(c)(ii) above unless the use of such withholding method is problematic under applicable laws or has materially adverse accounting consequences, in which case the Committee shall determine which of the other methods described in this subsection 4(c) or in the Program shall be used to satisfy the applicable withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">5. Effect of Termination or Death on the Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  By accepting this Option grant, the Employee acknowledges that, except as otherwise provided in this Agreement, in the event of Termination (whether or not in breach of local labor laws), the Employee&#8217;s right to vest in the Option under the Program, if any, will cease and will not be extended by any notice period mandated under local law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">, active employment does not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law) and that the Company shall have the exclusive discretion to determine Termination occurs.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(a) Termination due to Retirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">  Subject to Section 7 below, in the event of Termination due to Retirement, then (regardless of any subsequent death of the Employee) the Option will continue to vest pursuant to Section 3, and the last date on which the Option may be exercised is the day prior to the Expiration Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(b) Termination due to Disability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Subject to Section 7 below, in the event of Termination due to Disability, then (regardless of any subsequent death of the Employee) the Option will continue to vest pursuant to Section 3, and the last date on which the Option may be exercised is the day prior to the Expiration Date.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(c) Termination due to Death of the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">  In the event of the death of the Employee during employment, the Option will continue to vest pursuant to Section 3, and the last date on which the Option may be exercised is the day prior to the Expiration Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(d) Termination for Reason Other than under Subsection 5(a), (b), or (c) or Section 6.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(i) Options Granted Within Nine Months of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">  Any Option granted less than nine months prior to a Termination for any reason other than those set forth in subsections 5(a), (b) or (c) or Section 6 shall be cancelled and forfeited immediately upon such Termination.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">(ii) Options Granted Nine Months or More Prior to Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> Subject to Section 7 below, an Option granted nine months or more prior to a Termination for any reason other than those set forth in subsections 5(a), (b) or (c) or Section 6 will continue to vest and shall be exercisable to the extent permitted by Section 3 for a three-month period after the Employee&#8217;s effective date of Termination, but in no event shall such Option be exercised on or after the Expiration Date.  In the event of the death of the Employee during the three-month period after the Employee&#8217;s effective date of Termination, the Option shall continue to vest and be exercisable for a three-month period measured from the date of death, but in no event shall such Option be exercised on or after the Expiration Date.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">6. Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  In the event of a Change in Control, the entity surviving such Change in Control or the ultimate parent thereof (referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:136%">Surviving Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">&#8221;) may assume, convert or replace this Option with an award of at least equal value and terms and conditions not less favorable than the terms and conditions provided in this Agreement, in which case the new award will vest according to the terms of the applicable award agreement.  If the Surviving Entity does not assume, convert or replace this Option, the Option shall vest on the date of the Change in Control.  If the Surviving Entity does assume, convert or replace this Option, then in the event the Employee&#8217;s Termination (a) occurs within the time period beginning six months immediately before a Change in Control and ending two years immediately following such Change in Control, and (b) was initiated by the Company (or the Surviving Entity) for a reason other than Cause or was initiated by the Employee for Good Reason, the Option will become fully vested and exercisable as of the later of the date of the Change in Control and the date of the Employee&#8217;s Termination.  The provisions of this Section 6 shall supersede Section 13(a)(i) of the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">7. Effect of Certain Bad Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Option shall be cancelled and forfeited immediately if, in the sole opinion and discretion of the Committee or its delegate, the Employee&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(a) commits a material breach of the terms and conditions of the Employee&#8217;s employment, including, but not limited to&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:11.67pt">material breach by the Employee of the Code of Business Conduct&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:8.34pt">material breach by the Employee of the Employee&#8217;s Employee Agreement or employment contract, if any&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:5.01pt">commission by the Employee of an act of fraud, embezzlement or theft in connection with the Employee&#8217;s duties or in the course of the Employee&#8217;s employment&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:5.67pt">wrongful disclosure by the Employee of secret processes or confidential information of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;padding-left:9pt">failure by the Employee to substantially perform the duties of the Employee&#8217;s employment (other than any such failure resulting from the Employee&#8217;s Disability)&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(b) to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for the benefit of the Employee or others, in any activity, employment or business which is competitive with the Company or any of its Subsidiaries.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">8. No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  This Agreement and the Employee&#8217;s participation in the Program do not and shall not be interpreted to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(a) form an employment contract or relationship with the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(b) confer upon the Employee any right to continue in the employ of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(c) interfere with the ability of the Company or its Subsidiaries to terminate the Employee&#8217;s employment at any time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">9. Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  In accepting this Option grant, the Employee acknowledges and agrees that&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a) the Program is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b) this Option grant is a one-time benefit and does not create any contractual or other right to receive future grants of Options, benefits in lieu of Options, or other Program benefits in the future, even if Options have been granted repeatedly in the past&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c) all decisions with respect to future Option grants, if any, and their terms and conditions, will be made by the Company, in its sole discretion&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(d) nothing contained in this Agreement is intended to create or enlarge any other contractual obligations between the Company and the Employee&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e) the Employee is voluntarily participating in the Program&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(f) the Option and Shares subject to the Option are&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Company or its Subsidiaries, and are outside the scope of the Employee&#8217;s employment contract, if any&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(ii) not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iii) not part of the Employee&#8217;s normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits, or similar payments and in no event should they be considered as compensation for, or relating in any way to, past services for the Company or any of its Subsidiaries&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(g) the future value of the Shares underlying the Option is unknown and cannot be predicted with certainty&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(h) in consideration of this Option grant, no claim or entitlement to compensation or damages shall arise from the Option resulting from Termination (for any reason whatsoever) and the Employee irrevocably releases the Company and its Subsidiaries from any such claim that may arise&#59; if any such claim is found by a court of competent jurisdiction to have arisen, then, by signing or electronically accepting this Agreement, the Employee shall be deemed irrevocably to have waived the Employee&#8217;s entitlement to pursue such claim&#59; &#92;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) the Option and the Benefits under the Program, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(j) neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Option, the amount realized upon exercise of the Option or the amount realized upon a subsequent sale of any Shares acquired upon exercise of the Option, resulting from any fluctuation of the United States Dollar&#47;local currency foreign exchange rate.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">10. Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(a) Pursuant to applicable personal data protection laws, the collection, processing and transfer of the Employee&#8217;s personal Data is necessary for the Company&#8217;s administration of the Program and the Employee&#8217;s participation in the Program.  The Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of personal Data may affect his </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">or her ability to participate in the Program.  As such (where required under applicable law), the Employee&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(i) voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of personal Data as described herein&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(ii) authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(b) Data may be provided by the Employee or collected, where lawful, from third parties, and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">he Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the exclusive purpose of implementing, administering and managing the Employee&#8217;s participation in the Program.  Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which the Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations in the Employee&#8217;s country of residence.  Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.  The Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and for the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(c) The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee (if applicable) may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Program.  These recipients may be located throughout the world.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(d) The Employee may, at any time, exercise his or her rights provided under applicable personal data protection laws, which may include the right to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(i) obtain confirmation as to the existence of the Data&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(ii) verify the content, origin and accuracy of the Data&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and&#47;or operation of the Program and the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">The Employee may seek to exercise these rights by contacting his or her local human resources manager.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">(e) Upon request of the Company or the Subsidiary that employs the Employee, the Employee agrees to provide an executed data privacy consent form (or any other agreement or consent that may be required by the Company and&#47;or the Subsidiary that employs the Employee) to the Company and&#47;or the Subsidiary that employs the Employee that the Company and&#47;or the Subsidiary that employs the Employee may deem necessary to obtain from the Employee for the purpose of administering his or her participation in the Program in compliance with the data privacy laws in the Employee&#8217;s country, either now or in the future. The Employee understands and agrees that he or she will not be able to participate in the Program if the Employee fails to provide any such requested consent or agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">11. Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  This Option grant is not intended to be a public offering of securities in the Employee&#8217;s country.  The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and this Option grant is not subject to the supervision of the local securities authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">12. Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  As a condition to this Option grant, the Employee agrees to comply with any applicable foreign exchange rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">13. Compliance with Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a) The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company&#8217;s Shares are listed.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b) Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Employee&#8217;s participation in the Program and legally applicable to the Employee or deemed by the Company or its Subsidiaries to be an appropriate charge to the Employee even if technically </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">due by the Company or its Subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), the Employee acknowledges that the ultimate liability for all Tax-Related Items is and remains the Employee&#8217;s responsibility and may exceed the amount actually withheld by the Company or its Subsidiaries, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee further acknowledges that the Company and&#47;or its Subsidiaries&#58; (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the issuance of Shares upon exercise of the Option, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate the Employee&#8217;s liability for Tax-Related Items or achieve any particular tax result.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee has become subject to tax in more than one jurisdiction between the date of grant and the date of any relevant taxable event, the Employee acknowledges that the Company and&#47;or its Subsidiaries may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee relocates to another country, the Company may establish special or alternative terms and conditions as necessary or advisable to comply with local laws, rules or regulations, to facilitate the operation and administration of the Option and the Program and&#47;or to accommodate the Employee&#8217;s relocation. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c) The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Employee acknowledges that, depending on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Employee&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">or the broker&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">country of residence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">or where the Shares are listed, the Employee may be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">insider trading </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">restrictions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">and&#47;or market abuse laws </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">may affect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> his or her </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ability to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">accept, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">acquire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">sell </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">or otherwise dispose of Shares, rights to Shares (e.g., Options) or rights linked to the value of Shares </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">during such times the Employee is considered to have &#8220;inside information&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">regarding the Company as defined in the laws or regulations in his or her country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Employee placed before he or she possessed inside information. Furthermore, the Employee could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. The Employee understands that third parties may include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Company insider trading policy. The Employee acknowledges that it is the Employee&#8217;s responsibility to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">comply with any restrictions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">and the Employee is advised to speak to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">his or her </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">personal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">legal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">advisor on this matter.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">14. Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The Option is intended to be exempt from the requirements of Code Section 409A.  The Program and this Agreement shall be administered and interpreted in a manner consistent with this intent.  If the Company determines that the Option is subject to Code Section 409A and this Agreement fails to comply with that section&#8217;s requirements, the Company may, at the Company&#8217;s sole discretion, and without the Employee&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section 409A.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Although this Agreement and Benefits provided hereunder are intended to be exempt from the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the Benefits provided hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States law.  None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">15. No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Option, the Employee&#8217;s participation in the Program or the Employee&#8217;s acquisition or sale of the underlying Shares.  The Employee is hereby advised to consult with the Employee&#8217;s own personal tax, legal and financial advisors regarding participation in the Program before taking any action related to the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">16. Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The Company reserves the right to impose other requirements on the Employee&#8217;s participation in the Program, on the Option and on any Shares acquired under the Program, to the extent the Company or any Subsidiary determines it is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Option and the Program, and to require the Employee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.  The Employee agrees to take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations in the Employee&#8217;s country.  In addition, the Employee agrees to take any and all actions as may be required to comply with the Employee&#8217;s personal obligations under local laws, rules and regulations in the Employee&#8217;s country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">17. Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  Each decision, determination, interpretation or other action made or taken pursuant to the provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be final, conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Option have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">18. Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Program by electronic means.  The Employee hereby consents to receive such documents by electronic delivery and agrees to participate in the Program through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">19. Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  This Option grant shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for the Employee&#8217;s country or jurisdiction.  Moreover, if the Employee relocates to one of the countries or jurisdictions included in the Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or facilitate the operation and administration of the Option and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).  The Addendum constitutes part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">20. Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.  To the extent a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">21. Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  This Agreement and the Program constitute the entire agreement between the Employee and the Company regarding the Option and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties regarding the Option.  Except as expressly set forth herein, this Agreement (and any provision of this Agreement) may not be modified, changed or clarified by the parties, except in a writing specifying the modification, change or clarification signed by a duly authorized Company officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">22. Succession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  This Agreement shall be binding upon and operate for the benefit of the Company and its successors and assigns, and the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Option have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">23. Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  The Employee acknowledges and agrees that it is the Employee&#8217;s express intent that this Agreement, the Program and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English. If the Employee is in a country where English is not an official language, the Employee acknowledges that he or she is sufficiently proficient in English or has had the ability to consult with an advisor who is sufficiently proficient in the English language, so as to allow the Employee to understand the terms and conditions of this Agreement, the Program and any other documents related to the Option. If the Employee has received this Agreement or any other document related to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">24. Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any state&#8217;s conflict of laws principles.  For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed on their behalf.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ABBVIE INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">                                                                              </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                            </font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMPLOYEE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">By electronically accepting the OPTION, THE EMPLOYEE agrees that (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) such acceptance constitutes THE EMPLOYEE&#8217;S electronic signature in execution of this Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE EMPLOYEE agrees to be bound by the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE EMPLOYEE HAS reviewed the PROGRAM, the Agreement and the Addendum in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the OPTION and fully understands all of the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE EMPLOYEE HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the PROGRAM&#59; and (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">) THE EMPLOYEE hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the COMMITTEE OR ITS DULY AUTHORIZED DELEGATE ON any questions arising under the PROGRAM, the Agreement and the Addendum.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Addendum to the AbbVie Inc.  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non-Qualified Stock Option Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the terms and conditions set forth in the Agreement, the Option is subject to the following terms and conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee is employed in a country or jurisdiction identified in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Addendum, the additional terms and conditions for such country or jurisdiction will apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee relocates to one of the countries or jurisdictions identified in this Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Option and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All defined terms contained in this Addendum shall have the same meaning as set forth in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES, SWITZERLAND AND THE UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision replaces Section 10 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Pursuant to applicable personal data protection laws, the Employee is hereby notified of the following in relation to the Employee&#8217;s Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of the Program. The collection, processing and transfer of Personal Data is necessary for the legitimate purpose of the administration of the Program by the Company and the Subsidiary that employs the Employee and the Employee&#8217;s participation in the Program, and the Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect his or her participation in the Program. As such</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">by participating in the Program, the Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company and the Subsidiary that employs the Employee may hold certain personally identifiable information about the Employee, specifically his or her name, home address, email address and telephone number, date of birth, social security, passport or other identification number (resident registration number), salary, nationality, job title, any Shares or directorships held in the Company or its Subsidiaries, details of all entitlements to Shares (or cash) granted, awarded, canceled, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Personal Data may be provided by the Employee or collected, where lawful, from third parties. The Company or the Subsidiary that employs the Employee each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee&#8217;s participation in the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and meeting related legal obligations associated with these actions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the employment relationship and for the Employee&#8217;s participation in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company and the Subsidiary that employs the Employee will transfer Personal Data amongst themselves and their affiliates as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee may each further transfer Personal Data to third parties assisting the Company or the Subsidiary that employs the Employee in the implementation, administration and management of the Program, including E*TRADE Financial Corporate Services Inc. and its affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">E*TRADE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) or any successor or other third party that the Company, the Subsidiary that employs the Employee or E*TRADE (or its successor) may engage to assist with the administration of the Program from time to time. These </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">recipients may be located in the EU, EEA, Switzerland, the United Kingdom or elsewhere throughout the world, such as the United States. By participating in the Program, the Employee understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Personal Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further understands that he or she may request a list with the names and addresses of any potential recipients of Personal Data by contacting the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">When transferring Personal Data to these potential recipients, the Company and the Subsidiary that employs the Employee may provide appropriate safeguards in accordance with EU Standard Contractual Clauses, or other legally binding and permissible arrangements. The Employee may request a copy of such safeguards from the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent provided by law, the Employee may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, in any case without cost, by contacting in writing the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. The Employee understands, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Option or other equity awards or administer or maintain such awards. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">When the Company and the Subsidiary that employs the Employee no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that the Employee can no longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Australian Offer Document for additional important information pertaining to the Option.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Option, the Employee acknowledges and confirms that the Employee has reviewed the Australian Offer Document.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) applies (subject to the conditions in that Act). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BAHRAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Agreement does not constitute advertising or an offering of securities in Bahrain, nor does it constitute an allotment of securities in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Shares issued pursuant to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Option under the Program shall be deposited into a brokerage account in the United States.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In no event will Shares be issued or delivered in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The issuance of Shares pursuant to the Option described herein has not and will not be registered in Bahrain and hence, the Shares described herein may not be admitted or used for offering, placement or public circulation in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, the Employee may not make any public advertising or announcements regarding the Option or Shares in Bahrain, promote these Shares to legal entities or individuals in Bahrain, or sell Shares directly to other legal entities or individuals in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that Shares may only be sold outside of Bahrain and on a stock exchange on which AbbVie is traded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Labor Law Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees, for all legal purposes, (i) the Benefits provided under the Agreement and the Program are the result of commercial transactions unrelated to the Employee&#8217;s employment&#59; (ii) the Agreement and the Program are not a part of the terms and conditions of the Employee&#8217;s employment&#59; and (iii) the income from the Option, if any, is not part of the Employee&#8217;s remuneration from employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise of the Option &#8211; No Tendering Previously-Owned Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement or Program to the contrary, if the Employee is resident in Canada, the Employee may not tender Shares that the Employee owns to pay the Exercise Price or taxes in connection with the Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Resale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is permitted to sell Shares acquired upon settlement of the Option through the designated broker appointed under the Program, provided the resale of Shares acquired under the Program takes place outside of Canada through the facilities of the stock exchange on which the Shares are listed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are currently listed on the New York Stock Exchange.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision supplements Sections 3 and 5 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the Option, the Employee&#8217;s employment relationship will be considered terminated as of the date the Employee is no longer actually employed or otherwise rendering services to the Company or, if different, the Subsidiary for which the Employee provides services (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment or other laws or otherwise rendering services or the terms of the Employee&#8217;s Employee Agreement or other service agreement, if any).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise extended pursuant to the terms of the Agreement or by the Company, the Employee&#8217;s right to vest in the Option, if any, will terminate as of such date, and the period (if any) during which the Employee may exercise the Option after termination of the Employee&#8217;s employment will commence on such date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Termination Date will not be extended by any common law notice period. Notwithstanding the foregoing, however, if applicable employment standards legislation specifically requires continued entitlement to vesting during a statutory notice period, the Employee&#8217;s right to vest in the Option, if any, will be allowed to continue for that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">minimum notice period but then immediately terminate effective as of the last day of the Employee&#8217;s minimum statutory notice period.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event the date the Employee is no longer providing actual service cannot be reasonably determined under the terms of this Agreement and&#47;or the Program, the Committee or its delegate shall have the exclusive discretion to determine when the Employee is no longer actively providing services for purposes of the Option (including whether the Employee may still be considered to be providing services while on a leave of absence).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise provided in the Agreement or by the Company, any portion of the Option that is not vested and exercisable on the Termination Date shall terminate immediately and be null and void. Unless the applicable employment standards legislation specifically requires, in the case of the Employee, the Employee will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which his or her employment relationship is terminated (as determined under this provision) nor will the Employee be entitled to any compensation for lost vesting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision shall replace Section 11 of the Agreement&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Option hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt">The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to General Ruling no. 336 of the Chilean Commission for the Financial Market&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt">The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8.67pt">The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities are not registered with the Chilean Commission for the Financial Market&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt">The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provisions shall govern the Employee&#8217;s participation in the Program if the Employee is a national of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) resident in mainland China, or if determined to be necessary or appropriate by the Company in its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Full Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, the Option may be exercised only by using the cashless method, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Only full cashless exercise (net proceeds remitted to the Employee in cash) will be permitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cashless sell-to-cover, or stock swap methods of exercise are prohibited. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Foreign Exchange Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a condition of the Option, the Employee understands and agrees that, due to the exchange control laws in China, the Employee will be required to immediately repatriate the cash proceeds resulting from the cashless exercise of the Option to China.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that the repatriation of sales proceeds may need to be effected through a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and agrees that sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the Company on the Employee&#8217;s behalf prior to being delivered to the Employee. The sales proceeds may be paid to the Employee in U.S. dollars or local currency at the Company&#8217;s discretion. If the sales proceeds are paid to the Employee in U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account. If the sales proceeds are paid to the Employee in local currency, the Employee acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. The Employee agrees to bear any currency fluctuation risk between the time the Shares are sold and the net proceeds are converted into local currency and distributed to the Employee. The Employee further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in the future to facilitate compliance with exchange control requirements in China.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the processes and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, in the event of an Employee&#8217;s Termination other than due to Retirement, the Employee shall be required to exercise the Option (to the extent outstanding, vested and otherwise permitted under the Agreement) and&#47;or sell all Shares issued pursuant to the Program no later than 90 days after the date of Termination (or such shorter period as may be required by the State Administration of Foreign Exchange (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">SAFE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) or the Company), and repatriate the sales proceeds to China in the manner designated by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, in the event of an Employee&#8217;s Termination by reason of Retirement, the Employee shall be required to exercise the Option (to the extent outstanding, vested and otherwise permitted under the Agreement) and&#47;or sell all Shares issued pursuant to the Program no later than 180 days after the date of such Retirement (or such shorter period as may be required by the SAFE or the Company), and repatriate the sales proceeds to China in the manner designated by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Options that remain unexercised after such date shall expire.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Program, the Agreement and the Option in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This provision supplements Section 9 of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that, pursuant to Article 128 of the Colombian Labor Code, the Program and related benefits do not constitute a component of Employee's &#8220;salary&#8221; for any legal purpose. Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) and, therefore, the Shares may not be offered to the public in Colombia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">DENMARK</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">The Act on Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Employer Information Statement (Denmark) pursuant to the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in the Employment Relationship, as amended as of January 1, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act, as amended as of January 1, 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything in Section 4(c) of the Agreement to the contrary, if the Employee is a local national of Finland, any Tax-Related Items shall be withheld only in cash from the Employee&#8217;s regular salary&#47;wages or other amounts payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed under local law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Option is not granted under the French specific regime provided by Articles L.225-177 to L.225-186-1 and Articles L. 22-10-56 to L. 22-10-58 of the French Commercial Code, as amended.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If, for any reason, the Employee exercises the Option within six months of the Grant Date, the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">IMPORTANT NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The contents of the Agreement, the Addendum, the Program, and all other materials pertaining to the Option and&#47;or the Program have not been reviewed by any regulatory authority in Hong Kong.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is hereby advised to exercise caution in relation to the offer thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee has any doubts about any of the contents of the aforesaid materials pertaining to the Option, the Employee should obtain independent professional advice.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Option and Shares underlying the Option do not form part of the Employee&#8217;s wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, the Option may be exercised only by using the cashless method, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Full cashless exercise (net proceeds remitted to the Employee in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">cash) or cashless sell-to-cover will be permitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash and stock swap methods of exercise are prohibited.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly agrees to repatriate all amounts acquired under the Program in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable law, rules and regulations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDONESIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Consent to Receive Information in English</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the grant of the Option, the Employee confirms having read and understood the documents relating to this grant which were provided in the English language and accepts the terms of those documents accordingly and agrees not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Persetujuan untuk Menerima Informasi dalam Bahasa Inggris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">. Dengan menerima hibah dari Option Saham Terbatas, Anda mengonfirmasi telah membaca dan memahami dokumen-dokumen yang berkaitan dengan hibah ini (yaitu, Perjanjian Penghargaan, dan LTIP Takeda) yang disediakan dalam bahasa Inggris, menerima sesuai dengan dokumen-dokumen tersebut, dan setuju untuk tidak menentang keabsahan dokumen ini berdasarkan Undang-Undang No. 24 tahun 2009 tentang Bendera Nasional, Bahasa, Lambang dan Lagu Kebangsaan atau mengimplementasikan Peraturan Presiden (ketika diterbitkan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ISRAEL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Trustee Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees to hold the Shares received upon exercise of the Option with the Company&#8217;s designated broker. The Employee understands and agrees that upon the Employee&#8217;s sale of Shares, unless otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through a trustee in Israel engaged by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), (b) the Trustee will withhold the requisite tax and other mandatory withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Trustee will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ITALY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Full Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, the Option may be exercised only by using the cashless method, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Only full cashless exercise (net proceeds remitted to the Employee in cash) will be permitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cashless sell-to-cover, or stock swap methods of exercise are prohibited.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MALTA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Full Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, the Option may be exercised only by using the cashless method, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Only full cashless exercise (net proceeds remitted to the Employee in cash) will be permitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cashless sell-to-cover, or stock swap methods of exercise are prohibited.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Commercial Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly acknowledges that the Employee&#8217;s participation in the Program and the Company&#8217;s grant of the Option does not constitute an employment relationship between the Employee and the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee has been granted the Option as a consequence of the commercial relationship between the Company and the Company&#8217;s Subsidiary in Mexico that employs the Employee, and the Company&#8217;s Subsidiary in Mexico is the Employee&#8217;s sole employer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Based on the foregoing&#58; (a) the Employee expressly acknowledges that the Program and the benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in Mexico that employs the Employee&#59; (b) the Program and the benefits derived from participation in the Program are not part of the employment conditions and&#47;or benefits provided by the Subsidiary in Mexico that employs the Employee&#59; and (c) any modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee&#8217;s employment with the Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Extraordinary Item of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly recognizes and acknowledges that the Employee&#8217;s participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the Employee&#8217;s free and voluntary decision to participate in the Program in accordance with the terms and conditions of the Program, the Agreement and this Addendum.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As such, the Employee acknowledges and agrees that the Company, in its sole discretion, may amend and&#47;or discontinue the Employee&#8217;s participation in the Program at any time and without any liability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The value of the Option is an extraordinary item of compensation outside the scope of the Employee&#8217;s employment contract, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Option is not part of the Employee&#8217;s regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company&#8217;s Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Option and the Shares offered under the Program have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Program, the Agreement and any other document relating to the Option may not be publicly distributed in Mexico. These materials are addressed to the Employee only because of the Employee's existing relationship with the Company and these materials should not be reproduced or copied in any form.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee waives any and all rights to compensation or damages as a result of a Termination, insofar as those rights result or may result from&#58; (a) the loss or diminution in value of such rights or entitlements under the Program&#59; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any awards, under the Program as a result of such Termination.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warning</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This is an offer of an Option which, upon exercise and settlement in accordance with the terms of the Program and the Agreement, will be converted into Shares. Shares give you a stake in the ownership of AbbVie Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If AbbVie Inc. runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This information is designed to help investors make an informed decision.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The usual rules do not apply to this offer because it is made under an employee share purchase scheme.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a result, you may not be given all the information usually required.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You will also have fewer other legal protections for this investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prior to the exercise and settlement of the Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No interest in any Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are quoted on the New York Stock Exchange.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This means that if you acquire Shares under the Program, you may be able to sell them on the New York Stock Exchange if there are interested buyers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may get less than you invested.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The price will depend on the demand for the Shares.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">The AbbVie Amended and Restated 2013 Incentive Stock Program&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  This document can be accessed in the library section of the E*TRADE website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Amended and Restated 2013 Incentive Stock Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Prospectus&#58;  This document can be accessed in the library section of the E*TRADE website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Copies of the documents listed above will be sent to you free of charge on written request to&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  A Termination shall include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the situation where the Employee&#8217;s employment contract is terminated by operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of any type.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee hereby expressly agrees that this Agreement, the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as well as all documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in the English language. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Angajatul consimte &#238;n mod expres prin prezentul ca acest Contract, Programul precum &#351;i orice alte documente, notific&#259;ri, &#238;n&#351;tiin&#355;&#259;ri legate direct sau indirect de acest Contract s&#259; fie redactate sau efectuate doar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#238;n limba englez&#259;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sale or Transfer of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, the Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Option in Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may sell the Shares only through a broker established and operating outside Russia. Any Shares issued upon exercise of the Option shall be delivered to the Employee through a brokerage account in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may hold the Shares in his or her brokerage account in the U.S.&#59; however, in no event will Shares issued to the Employee under the Program be delivered to the Employee in Russia. The Employee is not permitted to sell Shares directly to other Russian legal entities or individuals.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to promptly repatriate proceeds resulting from the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SAUDI ARABIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Qualifying Person Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Option under the Program is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee should note that, as a result, the Option is subject to section 257 of the SFA and the Employee will not be able to make&#58; (a) any subsequent sale of the Shares in Singapore&#59; or (b) any offer of such subsequent sale of the Shares subject to the Option in Singapore, unless such sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exchange Control Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with applicable exchange control regulations and rulings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Exchange Control Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) in South Africa.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As the Exchange Control Regulations change frequently and without notice, the Employee should consult the Employee&#8217;s legal advisor prior to the acquisition or sale of Shares under the Program to ensure compliance with current Exchange Control Regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In compliance with South African securities laws, the Employee acknowledges that the documents listed below are available for review at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a) AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b) AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that copies of the documents listed above will be sent to the Employee free of charge on written request to&#58; Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is advised to carefully read the materials provided before making a decision whether to participate in the Program and to contact the Employee&#8217;s tax advisor for specific information concerning the Employee&#8217;s personal tax situation with regard to Program participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Program&#59; No Vested Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Option grant, the Employee consents to participation in the Program and acknowledges receipt of a copy of the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Options under the Program to individuals who may be employees of the Company or its Subsidiaries throughout the world.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consequently, the Employee understands that the Option is granted on the assumption and condition that the Option and the Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s acquired upon exercise of the Option </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and conditions referenced above&#59; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Option grant shall be null and void.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that, as a condition of the Option grant, unless otherwise provided in Section 5 of the Agreement, any unvested Option as of the date the Employee ceases active employment, and any vested portion of the Option not exercised within the post-termination exercise period set out in the Agreement, will be forfeited without entitlement to the underlying Shares or to any amount of indemnification in the event of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that the Employee has read and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, &#8220;Cause&#8221; shall be defined as set forth in the applicable Change in Control Agreement, regardless of whether the Termination is considered a fair termination (i.e., &#8220;despido procedente&#8221;) under Spanish legislation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory. The Program, the Award, the Agreement, this Addendum and all other materials the Employee may receive regarding the Employee&#8217;s participation in the Program have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Spanish Securities Exchange Commission), and they do not constitute a public offering prospectus.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision shall supplement Section 4(c) of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Without limiting the authority of the Company and the Subsidiary that employs the Employee to satisfy their withholding obligations for Tax-Related Items as set forth in Section 4(c) of the Agreement, the Employee authorizes the Company to withhold Shares otherwise deliverable to the Employee upon exercise of the Option to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Subsidiary that employs the Employee has an obligation to withhold such Tax-Related Items.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Neither this document nor any other materials relating to the Option (i) constitutes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FINMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Without limitation to Section 4 of the Agreement, the Employee hereby agrees that the Employee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or (if different) the Subsidiary that employs the Employee or by Her Majesty&#8217;s Revenue &#38; Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) (or any other tax authority or any other relevant authority).  The Employee also hereby agrees to indemnify and keep indemnified the Company and (if different) the Subsidiary that employs the Employee against any Tax-Related Items that they are required to pay or withhold on the Employee&#8217;s behalf or have paid or will pay on the Employee&#8217;s behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, if the Employee is a director or executive officer (as within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that the Employee is a director or executive officer and income tax due is not collected from or paid by the Employee by within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to the Employee on which additional income tax and national insurance contributions may be payable. The Employee acknowledges that the Employee ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Subsidiary that employs the Employee (as applicable) for the value of any employee national insurance contributions due on this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">additional benefit, which the Company and&#47;or the Subsidiary that employs the Employee may recover from the Employee at any time thereafter by any of the means referred to in Section 4 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> acknowledges and agrees that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Employee&#8217;s ceasing to have rights under or to be entitled to exercise the Option, whether or not as a result of Termination (whether the Termination is in breach of contract or otherwise), or from the loss or diminution in value of the Option.  Upon the grant of the Option, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> shall be deemed to have waived irrevocably any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">VENEZUELA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Full Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, the Option may be exercised only by using the cashless method, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Only full cashless exercise (net proceeds remitted to the Employee in cash) will be permitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cashless sell-to-cover, or stock swap methods of exercise are prohibited.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">VIETNAM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Full Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, the Option may be exercised only by using the cashless method, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Only full cashless exercise (net proceeds remitted to the Employee in cash) will be permitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cashless sell-to-cover, or stock swap methods of exercise are prohibited.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>abbv-20220331xex105.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icffadc0a1d7a4103854a8abd16a7a83d_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.5</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ABBVIE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">On this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;GRANT DATE (MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">AbbVie Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) hereby grants to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;FIRST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;LAST NAME&#62;&#62; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) a Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;TOTAL SHARES GRANTED&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">representing the right to receive an equal number of Shares on a specified Delivery Date.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus, and the Program administrative rules, the provisions of the Program shall control.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The terms and conditions of the Award are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:9.75pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Restricted Stock Unit Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#58;  Cause shall mean the following, as determined by the Company in its sole discretion&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) material breach by the Employee of the terms and conditions of the Employee&#8217;s employment, including, but not limited to&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">material breach by the Employee of the Code of Business Conduct&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(B) material breach by the Employee of the Employee&#8217;s Employee Agreement or employment contract, if any&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(C) commission by the Employee of an act of fraud, embezzlement or theft in connection with the Employee&#8217;s duties or in the course of the Employee&#8217;s employment&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(D) wrongful disclosure by the Employee of secret processes or confidential information of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(E) failure by the Employee to substantially perform the duties of the Employee&#8217;s employment (other than any such failure resulting from the Employee&#8217;s Disability)&#59; or</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for the benefit of the Employee or others, in any activity, employment or business which is competitive with the Company or any of its Subsidiaries.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Code of Business Conduc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">t&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company&#8217;s Code of Business Conduct, as amended from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Data&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Certain personal information about the Employee held by the Company and he Subsidiary that employs the Employee (if applicable), including (but not limited to) the Employee&#8217;s name, home address and telephone number, email address, date of birth, social security, passport or other identification number, salary, nationality, job title, any Shares held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Disability&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">As of a particular date, the Employee is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of at least six months under (i) the terms of the AbbVie Long Term Disability Plan (the &#8220;LTD Plan&#8221;), or (ii) if the Employee&#8217;s employer does not participate in the LTD Plan, such similar accident and health plan providing replacement benefits in which the Employee&#8217;s employer participates.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Employee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee Agreement entered into by and between the Company or a Subsidiary and the Employee as it may be amended from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(g) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Employee&#8217;s Representative&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee&#8217;s legal guardian or other legal representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The occurrence of any of the following circumstances without the Employee&#8217;s express written consent&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) a significant adverse change in the nature, scope or status of the Employee&#8217;s position, authorities or duties from those in effect immediately prior to the Change in Control, including, without limitation, if the Employee was, immediately prior to the Change in Control, an officer of a public company, the Employee ceasing to be an officer of a public company&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(ii) the failure by the Company or a Subsidiary to pay the Employee any portion of the Employee&#8217;s current compensation, or to pay the Employee any portion of any installment of deferred compensation under any deferred compensation program of the Company, within seven days of the date such compensation is due&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iii) a reduction in the Employee&#8217;s annual base salary (or a material change in the frequency of payment) as in effect immediately prior to the Change in Control as the same may be increased from time to time&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iv) the failure by the Company or a Subsidiary to award the Employee an annual bonus in any year which is at least equal to the annual bonus awarded to the Employee under the annual bonus plan of the Company or Subsidiary for the year immediately preceding the year of the Change in Control&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(v) the failure by the Company to award the Employee equity-based incentive compensation (such as stock options, shares of restricted stock, restricted stock units, or other equity-based compensation) on a periodic basis consistent with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Company&#8217;s practices with respect to timing, value and terms prior to the Change in Control&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(vi) the failure by the Company or a Subsidiary to continue to provide the Employee with the welfare benefits, fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in Control under any of the Company&#8217;s or Subsidiary&#8217;s plans or policies, including, but not limited to, those plans and policies providing pension, life insurance, medical, health and accident, disability and vacation&#59; </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(vii) the relocation of the Employee&#8217;s base office to a location that is more than 35 miles from the Employee&#8217;s base office immediately prior to the Change in Control&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the Company to assume and agree to perform this Agreement as contemplated in Section 5.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Program&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The AbbVie Amended and Restated 2013 Incentive Stock Program.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Termination&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">A severance of employment for any reason (including retirement) from the Company and all Subsidiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Any Termination shall be effective on the last day the Employee performs services for or on behalf of the Company or a Subsidiary, and employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2. Delivery Date and Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The delivery dates for Shares underlying the Units is the date on which the Shares are payable to the Employee after the Restrictions on such Units lapse pursuant to Section 4 below (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Prior to the Delivery Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">the Employee shall not be treated as a shareholder as to those Shares underlying the Units, and shall have only a contractual right to receive Shares, unsecured by any assets of the Company or its Subsidiaries&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">the Employee shall not be permitted to vote the Shares underlying the Units&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">the Employee&#8217;s right to receive such Shares will be subject to the adjustment provisions relating to mergers, reorganizations, and similar events set forth in the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Subject to the requirements of local law, the Employee shall receive cash payments equal to the dividends and distributions paid on Shares underlying the Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) (other than dividends or distributions of securities of the Company which may be issued with respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) to the same extent and on the same date as if each Unit were a Share&#59; provided, however, that no Dividend Equivalents shall be payable to or for the benefit of the Employee with respect to dividends or distributions the record date for which occurs on or after the applicable Delivery Date, the date the Employee has forfeited the Units or, in some cases due to applicable law, the date the Restrictions on the Units have lapsed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">compliance with the requirements of Code Section 409A, to the extent applicable, the specified date for payment of any Dividend Equivalents to which the Employee is entitled under this Section 2 is the calendar year during the term of this Agreement in which the associated dividends or distributions are paid on Shares underlying the Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee shall have no right to determine the year in which Dividend Equivalents will be paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">3. Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Units are subject to the forfeiture provisions in Sections 6 and 7 below.  Units are not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) until the earliest to occur of the events described in subsections 4(a), (b), or (c) or Section 5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">4. Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Subject to Sections 5, 6 and 7 below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">(a) Passage of Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">While the Employee is employed with the Company or its Subsidiaries, the Restrictions on one-third of the Units will lapse on each of the first three anniversaries of the Grant Date (each a &#8220;Delivery Date&#8221;) until, on the third anniversary of the Grant Date, 100% of the Units are no longer subject to Restrictions. Subject to subsections (b) and (c) below, Units for which Restrictions have lapsed, as described in this subsection 4(a), shall be settled in the form of Shares on the Delivery Date(s). Unless indicated otherwise, Shares shall be delivered in an equal number (subject to rounding) as of each Delivery Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">(b) Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Restrictions shall lapse on the date of the Employee&#8217;s Termination due to death, and the Units shall be settled (for the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> in the form of Shares as soon as administratively possible after, and effective as of, the date of death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">(c) Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Restrictions shall lapse on the date of the Employee&#8217;s Disability, and the Units shall be settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Disability.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">5. Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of a Change in Control, the entity surviving such Change in Control or the ultimate parent thereof (referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Surviving Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) may assume, convert or replace this Award with an award of at least equal value and terms and conditions not less favorable than the terms and conditions provided in this Agreement, in which case the new award will vest according to the terms of the applicable award agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Surviving Entity does not assume, convert or replace this Award, the Restrictions shall lapse on the date of the Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Surviving Entity does assume, convert or replace this Award, then in the event the Employee&#8217;s Termination (a) occurs within the time period beginning six months immediately before a Change in Control and ending two years immediately following such Change in Control, and (b) was initiated by the Company (or the Surviving Entity) for a reason other than Cause or was initiated by the Employee for Good Reason,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">the Restrictions shall lapse on the later of the date of the Change in Control and the date of the Employee&#8217;s Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The provisions of this Section 5 shall supersede Section 13(a)(iii) and (v) of the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">6. Effect of Certain Bad Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Any Units not previously settled shall be cancelled and forfeited immediately if the Employee engages in activity that constitutes Cause, as determined in the sole opinion and discretion of the Committee or its delegate, whether or not the Employee experiences a Termination or remains employed with the Company or a Subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">7. Forfeiture of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of the Employee&#8217;s Termination for any reason other than those set forth in subsection 4(b) or Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, any Units with respect to which Restrictions have not lapsed as of the date of Termination shall be forfeited without consideration to the Employee or the Employee&#8217;s Representative.  In the event that the Employee is terminated by the Company other than for Cause and in a situation not covered by Section 5, the Company may, in its sole discretion, cause Restrictions on some or all of the Units not previously settled on a Delivery Date to lapse and be settled in the form of Shares on the Delivery Date set forth in subsection 4(a) above as if the Employee had remained employed on such date.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In accepting this Award, the Employee acknowledges that in the event of Termination (whether or not in breach of local labor laws), the Employee&#8217;s right to vest in the Units, if any, will cease and will not be extended by any notice period mandated under local law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, active employment does not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law) and that the Company shall have the exclusive discretion to determine when Termination occurs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">8. Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent permitted under applicable law and by the Company, the Employee may satisfy any U.S. or non-U.S. federal, state, local or other applicable taxes arising from the grant of the Award, the lapse of Restrictions or the delivery of Shares pursuant to this Agreement by&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a) tendering a cash payment&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b) having the Company withhold Shares from the Shares to be delivered to satisfy the applicable withholding tax&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c) tendering Shares received in connection with the Units back to the Company&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d) delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount to be withheld.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company shall have the right and is hereby authorized to withhold from the Shares deliverable to the Employee pursuant to this Agreement or (to the extent permitted by applicable law, including without limitation Code Section 409A) from any other compensation or other amount owing to the Employee, such amount as may be necessary in the opinion of the Company to satisfy all such taxes, requirements and withholding obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">If the Company withholds for tax purposes from the Shares otherwise to be delivered to the Employee, the Employee is deemed to have been issued the full number of Shares underlying the Units, subject to the Restrictions set forth in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Notwithstanding the foregoing, if the Employee is subject to Section 16(b) of the Exchange Act, the Company will withhold using the method described in subsection 8(b) above unless the use of such withholding method is problematic under applicable laws or has materially adverse accounting consequences, in which case the Committee shall determine which of the other methods described in this Section 8 or in the Program shall be used to satisfy the applicable withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">9. No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement and the Employee&#8217;s participation in the Program do not and shall not be interpreted to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(a) form an employment contract or relationship with the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(b) confer upon the Employee any right to continue in the employ of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(c) interfere with the ability of the Company or its Subsidiaries to terminate the Employee&#8217;s employment at any time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">10. Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In accepting this grant of Units, the Employee acknowledges and agrees that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">the Program is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b) this Award is a one-time benefit and does not create any contractual or other right to receive future grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have been granted repeatedly in the past&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c) all decisions with respect to future Unit grants, if any, and their terms and conditions, will be made by the Company, in its sole discretion&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">nothing contained in this Agreement is intended to create or enlarge any other contractual obligations between the Company and the Employee&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e) the Employee is voluntarily participating in the Program&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(f) the Units and Shares subject to the Units are&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Company or its Subsidiaries, and are outside the scope of the Employee&#8217;s employment contract, if any&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iii) not part of the Employee&#8217;s normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits, or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or its Subsidiaries&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(g) the future value of the Shares underlying the Units is unknown and cannot be predicted with certainty&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(h) in consideration of the Award, no claim or entitlement to compensation or damages shall arise from the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably releases the Company and its Subsidiaries from any such claim that may arise&#59; if any such claim is found by a court of competent jurisdiction to have arisen, then, by signing or electronically accepting this Agreement, the Employee shall be deemed irrevocably to have waived the Employee&#8217;s entitlement to pursue such claim&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) the Units and the Benefits under the Program, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(j) neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units, the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States Dollar&#47;local currency foreign exchange rate.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">11. Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Pursuant to applicable personal data protection laws, the collection, processing and transfer of the Employee&#8217;s personal Data is necessary for the Company&#8217;s administration of the Program and the Employee&#8217;s participation in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of personal Data may affect his or her ability to participate in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">As such (where required under applicable law), the Employee&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i) voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of personal Data as described herein&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b)  Data may be provided by the Employee or collected, where lawful, from third parties, and the Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the exclusive purpose of implementing, administering and managing the Employee&#8217;s participation in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which the Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations in the Employee&#8217;s country of residence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and for the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c) The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee (if applicable) may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">These recipients may be located throughout the world.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d) The Employee may, at any time, exercise his or her rights provided under applicable personal data protection laws, which may include the right to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">obtain confirmation as to the existence of the Data&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">verify the content, origin and accuracy of the Data&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data&#59; and</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and&#47;or operation of the Program and the Employee&#8217;s participation in the Program.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee may seek to exercise these rights by contacting his or her local human resources manager.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e) Upon request of the Company or the Subsidiary that employs the Employee, the Employee agrees to provide an executed data privacy consent form (or any other agreement or consent that may be required by the Company and&#47;or the Subsidiary that employs the Employee) to the Company and&#47;or the Subsidiary that employs the Employee that the Company and&#47;or the Subsidiary that employs the Employee may deem necessary to obtain from the Employee for the purpose of administering his or her participation in the Program in compliance with the data privacy laws in the Employee&#8217;s country, either now or in the future. The Employee understands and agrees that he or she will not be able to participate in the Program if the Employee fails to provide any such requested consent or agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">12. Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of a cash payment to the extent settlement in Shares&#58; (a) is prohibited under local law&#59; (b) would require the Employee, the Company and&#47;or its Subsidiaries to obtain the approval of any governmental and&#47;or regulatory body in the Employee&#8217;s country&#59; (c) would result in adverse tax consequences for the Employee or the Company&#59; or (d) is administratively burdensome.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Alternatively, the Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of Shares but require the Employee to sell such Shares immediately or within a specified period of time following the Employee&#8217;s Termination (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Employee&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">13. Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The grant of this Unit is not intended to be a public offering of securities in the Employee&#8217;s country.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and this grant of Units is not subject to the supervision of the local securities authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">14. Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As a condition to this grant of Units, the Employee agrees to comply with any applicable foreign exchange rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">15. Compliance with Applicable Laws and Regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a) The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company&#8217;s Shares are listed.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b) Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Employee&#8217;s participation in the Program and legally applicable to the Employee or deemed by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">the Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by the Company or its Subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), the Employee acknowledges that the ultimate liability for all Tax-Related Items is and remains the Employee&#8217;s responsibility and may exceed the amount actually withheld by the Company or its Subsidiaries, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee further acknowledges that the Company and&#47;or its Subsidiaries&#58; (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units, including, but not limited to, the grant, lapse of Restriction or settlement of the Units, the issuance of Shares upon payment of the Units, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends and&#47;or any Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate the Employee&#8217;s liability for Tax-Related Items or achieve any particular tax result.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee has become subject to tax in more than one jurisdiction between the date of grant and the date of any relevant taxable event, the Employee acknowledges that the Company and&#47;or its Subsidiaries may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee relocates to another country, the Company may establish special or alternative terms and conditions as necessary or advisable to comply with local laws, rules or regulations, to facilitate the operation and administration of the Award and the Program and&#47;or to accommodate the Employee&#8217;s relocation. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee acknowledges that, depending on the Employee&#8217;s or the broker&#8217;s country of residence or where the Shares are listed, the Employee may be subject to insider trading restrictions and&#47;or market abuse laws which may affect his or her ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Units) or rights linked to the value of Shares during such times the Employee is considered to have &#8220;inside information&#8221; regarding the Company as defined in the laws or regulations in his or her country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Employee placed before he or she possessed inside information. Furthermore, the Employee could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. The Employee understands that third parties may include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Employee acknowledges that it is the Employee&#8217;s responsibility to comply with any restrictions and the Employee is advised to speak to his or her personal legal advisor on this matter.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">16. Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Payments made pursuant to this Agreement are intended to be exempt from or otherwise comply with the provisions of Code Section 409A to the extent applicable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Program and this Agreement shall be administered and interpreted in a manner consistent with this intent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Company determines that any payments under this Agreement are subject to Code Section 409A and this Agreement fails to comply with that section&#8217;s requirements, the Company may, at the Company&#8217;s sole discretion, and without the Employee&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent required to avoid accelerated taxation and&#47;or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless the Employee has incurred a &#8220;separation from service&#8221; as defined in Treasury Regulation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#167;1.409A-1(h), and amounts that would otherwise be payable pursuant to this Agreement during the six-month period immediately following the Employee&#8217;s Termination (including retirement) shall instead be paid on the first business day after the date that is six months following the Employee&#8217;s Termination (or upon the Employee&#8217;s death, if earlier).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of Code Section 409A, to the extent applicable&#58; (a) all payments provided hereunder shall be treated as a right to a series of separate payments and each separately identified amount to which the Employee is entitled under this Agreement shall be treated as a separate payment&#59; (b) except as otherwise provided in Section 13(a) of the Program, upon the lapse of Restrictions pursuant to Section 5 of this Agreement, any Units not previously settled on a Delivery Date shall be settled as soon as administratively possible after, and effective as of, the date of the Change in Control or the date of the Employee&#8217;s Termination (as applicable)&#59; (c) the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">as soon as administratively possible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a period of time that is within 60 days after the Termination, Disability or Change in Control (as applicable)&#59; and (d) the date of the Employee&#8217;s Disability shall be determined by the Company in its sole discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Although this Agreement and the payments provided hereunder are intended to be exempt from or otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">17. No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Units, the Employee&#8217;s participation in the Program or the Employee&#8217;s acquisition or sale of the underlying Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee is hereby advised to consult with the Employee&#8217;s own personal tax, legal and financial advisors regarding participation in the Program before taking any action related to the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">18. Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company reserves the right to impose other requirements on the Employee&#8217;s participation in the Program, on the Units and on any Shares acquired under the Program, to the extent the Company or any Subsidiary determines it is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program, and to require the Employee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee agrees to take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations in the Employee&#8217;s country.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In addition, the Employee agrees to take any and all actions as may be required to comply with the Employee&#8217;s personal obligations under local laws, rules and regulations in the Employee&#8217;s country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">19. Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Each decision, determination, interpretation or other action made or taken pursuant to the provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be final, conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the Employee, the Employee&#8217;s Representative, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">20. Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Program by electronic means.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee hereby consents to receive such documents by electronic delivery and agrees to participate in the Program through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">21. Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This grant of Units shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for the Employee&#8217;s country or jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Moreover, if the Employee relocates to one of the countries or jurisdictions included in the Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Addendum constitutes part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">22. Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">23. Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement and the Program constitute the entire agreement between the Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties regarding the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Except as expressly set forth herein, this Agreement (and any provision of this Agreement) may not be modified, changed or clarified by the parties, except in a writing specifying the modification, change or clarification, signed by a duly authorized Company officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">24. Succession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement shall be binding upon and operate for the benefit of the Company and its successors and assigns, and the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">25. Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee acknowledges and agrees that it is the Employee&#8217;s express intent that this Agreement, the Program and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee is in a country where English is not an official language, the Employee acknowledges that he or she is sufficiently proficient in English or has had the ability to consult with an advisor who is sufficiently proficient in the English language, so as to allow the Employee to understand the terms and conditions of this Agreement, the Program and any other documents related to the Award. If the Employee has received this Agreement or any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">document related to the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">26. Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any state&#8217;s conflict of laws principles.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font></div><div style="text-indent:37.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed on their behalf.</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                                                               &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  </font><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ABBVIE INC.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ABBVIE INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">                                                                              </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                            </font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMPLOYEE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">By electronically accepting the Award, THE EMPLOYEE agrees that (1) such acceptance constitutes THE EMPLOYEE&#8217;S electronic signature in execution of this Agreement&#59; (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">THE EMPLOYEE agrees to be bound by the provisions of the PROGRAM, the Agreement and the Addendum&#59; (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) THE EMPLOYEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> HAS reviewed the PROGRAM, the Agreement and the Addendum in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understands all of the provisions of the PROGRAM, the Agreement and the Addendum&#59; (4) THE EMPLOYEE HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the PROGRAM&#59; and (5) THE EMPLOYEE hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the COMMITTEE OR ITS DULY AUTHORIZED DELEGATE ON any questions arising under the PROGRAM, the Agreement and the Addendum.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Addendum to the AbbVie Inc.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">RESTRICTED STOCK UNIT Agreement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee is employed in a country or jurisdiction identified in this Addendum, the additional terms and conditions for such country or jurisdiction will apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee relocates to one of the countries or jurisdictions identified in this Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All defined terms contained in this Addendum shall have the same meaning as set forth in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES, SWITZERLAND AND THE UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision replaces Section 11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Pursuant to applicable personal data protection laws, the Employee is hereby notified of the following in relation to the Employee&#8217;s Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of the Program. The collection, processing and transfer of Personal Data is necessary for the legitimate purpose of the administration of the Program by the Company and the Subsidiary that employs the Employee and the Employee&#8217;s participation in the Program, and the Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect his or her participation in the Program. As such</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">by participating in the Program, the Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company and the Subsidiary that employs the Employee may hold certain personally identifiable information about the Employee, specifically his or her name, home address, email address and telephone number, date of birth, social security, passport or other identification number (resident registration number), salary, nationality, job title, any Shares or directorships held in the Company or its Subsidiaries, details of all entitlements to Shares (or cash) granted, awarded, canceled, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Personal Data may be provided by the Employee or collected, where lawful, from third parties. The Company or the Subsidiary that employs the Employee each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee&#8217;s participation in the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and meeting related legal obligations associated with these actions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the employment relationship and for the Employee&#8217;s participation in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company and the Subsidiary that employs the Employee will transfer Personal Data amongst themselves and their affiliates as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee may each further transfer Personal Data to third parties assisting the Company or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Subsidiary that employs the Employee in the implementation, administration and management of the Program, including E*TRADE Financial Corporate Services Inc. and its affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">E*TRADE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) or any successor or other third party that the Company, the Subsidiary that employs the Employee or E*TRADE (or its successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in the EU, EEA, Switzerland, the United Kingdom or elsewhere throughout the world, such as the United States. By participating in the Program, the Employee understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Personal Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further understands that he or she may request a list with the names and addresses of any potential recipients of Personal Data by contacting the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Subsidiary that employs the Employee may provide appropriate safeguards in accordance with EU Standard Contractual Clauses, or other legally binding and permissible arrangements. The Employee may request a copy of such safeguards from the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent provided by law, the Employee may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, in any case without cost, by contacting in writing the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. The Employee understands, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units, or other equity awards or administer or maintain such awards. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">When the Company and the Subsidiary that employs the Employee no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that the Employee can no longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ALGERIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Australian Offer Document for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges and confirms that the Employee has reviewed the Australian Offer Document.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BAHRAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Agreement does not constitute advertising or an offering of securities in Bahrain, nor does it constitute an allotment of securities in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Shares issued pursuant to the Units under the Program shall be deposited into a brokerage account in the United States.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In no event will Shares be issued or delivered in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The issuance of Shares pursuant to the Units described herein has not and will not be registered in Bahrain and hence, the Shares described herein may not be admitted or used for offering, placement or public circulation in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, the Employee may not make any public advertising or announcements regarding the Units or Shares in Bahrain, promote these Shares to legal entities or individuals in Bahrain, or sell Shares directly to other legal entities or individuals in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that Shares may only be sold outside of Bahrain and on a stock exchange on which AbbVie is traded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Labor Law Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees, for all legal purposes, (i) the Benefits provided under the Agreement and the Program are the result of commercial transactions unrelated to the Employee&#8217;s employment&#59; (ii) the Agreement and the Program are not a part of the terms and conditions of the Employee&#8217;s employment&#59; and (iii) the income from the Units, if any, is not part of the Employee&#8217;s remuneration from employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Resale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is permitted to sell Shares acquired upon settlement of the Units through the designated broker appointed under the Program, provided the resale of Shares acquired under the Program takes place outside of Canada through the facilities of the stock exchange on which the Shares are listed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are currently listed on the New York Stock Exchange.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision supplements Section 7 of the Agreement&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the Units, the Employee&#8217;s employment relationship will be considered terminated as of the date the Employee is no longer actually employed or otherwise rendering services to the Company or, if different, the Subsidiary for which the Employee provides services (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment or other laws or otherwise rendering services or the terms of the Employee&#8217;s Employee Agreement or other service agreement, if any). Unless otherwise extended pursuant to the terms of the Agreement or by the Company, the Employee&#8217;s right to vest in the Units, if any, will terminate as of such date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Termination Date will not be extended by any common law notice period. Notwithstanding the foregoing, however, if applicable employment standards legislation specifically requires continued entitlement to vesting during a statutory notice period, the Employee&#8217;s right to vest in the Units, if any, will be allowed to continue for that minimum notice period but then immediately terminate effective as of the last day of the Employee&#8217;s minimum statutory notice period.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event the date the Employee is no longer providing actual service cannot be reasonably determined under the terms of this Agreement and&#47;or the Program, the Committee or its delegate shall have the exclusive discretion to determine when the Employee is no longer actively providing services for purposes of the Units (including whether the Employee may still be considered to be providing services while on a leave of absence).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise provided in the Agreement or by the Company, any portion of the Units that is not vested on the Termination Date shall terminate immediately and be null and void. Unless the applicable employment standards legislation specifically requires, in the case of the Employee, the Employee will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which his or her employment relationship is terminated (as determined under this provision) nor will the Employee be entitled to any compensation for lost vesting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision shall replace Section 13 of the Agreement&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to General Ruling no. 336 of the Chilean Commission for the Financial Market&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities are not registered with the Chilean Commission for the Financial Market&#59; and </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Foreign Exchange Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The following provisions shall govern the Employee&#8217;s participation in the Program if the Employee is a national of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) resident in mainland China, or if determined to be necessary or appropriate by the Company in its sole discretion&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to hold the Shares received upon settlement of the Units and any and all previously granted restricted stock units with the Company&#8217;s designated broker. If the Company changes its designated broker, the Employee acknowledges and agrees that the Company may transfer any Shares </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">issued under the Program to the new designated broker if necessary for legal or administrative reasons. The Employee agrees to sign any documentation necessary to facilitate the transfer. Upon a Termination, the Employee shall be required to sell all Shares issued pursuant to the Units within 180 days (or such shorter period as may be required by the State Administration of Foreign Exchange or the Company) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including procedures whereby the Company may issue sale instructions on behalf of the Employee), and the Employee hereby agrees to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary or advisable for purposes of complying with local laws, rules and regulations in China.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and agrees that dividends issued on Shares and sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the Company on the Employee&#8217;s behalf prior to being delivered to the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dividends and&#47;or sales proceeds may be paid to the Employee in U.S. dollars or local currency at the Company&#8217;s discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If dividends and&#47;or sales proceeds are paid to the Employee in U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> so that the dividends or proceeds may be deposited into this account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If dividends and&#47;or sales proceeds are paid to the Employee in local currency, the Employee acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the dividends and&#47;or proceeds to local currency due to exchange control restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to bear any currency fluctuation risk between the time dividends are issued or Shares are sold and the net proceeds are converted into local currency and distributed to the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in the future in order to facilitate compliance with exchange control requirements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the processes and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This provision supplements Section 10 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that, pursuant to Article 128 of the Colombian Labor Code, the Program and related benefits do not constitute a component of Employee's &#8220;salary&#8221; for any legal purpose. Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) and, therefore, the Shares may not be offered to the public in Colombia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">DENMARK</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">The Act on Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Employer Information Statement (Denmark) pursuant to the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in the Employment Relationship, as amended as of January 1, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act, as amended as of January 1, 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Notwithstanding anything in Section 8 of the Agreement to the contrary, if the Employee is a local national of Finland, any Tax-Related Items shall be withheld only in cash from the Employee&#8217;s regular salary&#47;wages or other amounts payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed under local law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If, for any reason, Shares are issued to the Employee within six months of the Grant Date, the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary of the Grant Date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">IMPORTANT NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WARNING&#58; The contents of the Agreement, the Addendum, the Program, and all other materials pertaining to the Units and&#47;or the Program have not been reviewed by any regulatory authority in Hong Kong.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is hereby advised to exercise caution in relation to the offer thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee has any doubts about any of the contents of the aforesaid materials, the Employee should obtain independent professional advice.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units and Shares subject to the Units do not form part of the Employee&#8217;s wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee expressly agrees to repatriate all amounts acquired under the Program in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subsidiaries </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall be liable for any fines or penalties resulting from the Employee's failure to comply with applicable laws, rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDONESIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Consent to Receive Information in English</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the grant of the Units, the Employee confirms having read and understood the documents relating to this grant which were provided in the English language and accepts the terms of those documents accordingly and agrees not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Persetujuan untuk Menerima Informasi dalam Bahasa Inggris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">. Dengan menerima hibah dari Unit Saham Terbatas, Anda mengonfirmasi telah membaca dan memahami dokumen-dokumen yang berkaitan dengan hibah ini (yaitu, Perjanjian Penghargaan, dan LTIP Takeda) yang disediakan dalam bahasa Inggris, menerima sesuai dengan dokumen-dokumen tersebut, dan setuju untuk tidak menentang keabsahan dokumen ini berdasarkan Undang-Undang No. 24 tahun 2009 tentang Bendera Nasional, Bahasa, Lambang dan Lagu Kebangsaan atau mengimplementasikan Peraturan Presiden (ketika diterbitkan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ISRAEL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Trustee Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees to hold the Shares received upon settlement of the Units with the Company&#8217;s designated broker. The Employee understands and agrees that upon the Employee&#8217;s sale of Shares, unless otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through a trustee in Israel engaged by the Company (the &#8220;Trustee&#8221;), (b) the Trustee will withhold the requisite tax and other mandatory withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Trustee will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MALTA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Commercial Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly acknowledges that the Employee&#8217;s participation in the Program and the Company&#8217;s grant of the Award does not constitute an employment relationship between the Employee and the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee has been granted the Award as a consequence of the commercial relationship between the Company and the Subsidiary in Mexico that employs the Employee, and the Company&#8217;s Subsidiary in Mexico is the Employee&#8217;s sole employer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Based on the foregoing&#58; (a) the Employee expressly acknowledges that the Program and the benefits derived from participation in the Program do not establish any rights between the Employee and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Subsidiary in Mexico that employs the Employee&#59; (b) the Program and the benefits derived from participation in the Program are not part of the employment conditions and&#47;or benefits provided by the Subsidiary in Mexico that employs the Employee&#59; and (c) any modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee&#8217;s employment with the Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Extraordinary Item of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly recognizes and acknowledges that the Employee&#8217;s participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the Employee&#8217;s free and voluntary decision to participate in the Program in accordance with the terms and conditions of the Program, the Agreement and this Addendum.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As such, the Employee acknowledges and agrees that the Company, in its sole discretion, may amend and&#47;or discontinue the Employee&#8217;s participation in the Program at any time and without any liability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The value of the Units is an extraordinary item of compensation outside the scope of the Employee&#8217;s employment contract, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are not part of the Employee&#8217;s regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company&#8217;s Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Units and the Shares offered under the Program have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Program, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to the Employee only because of the Employee's existing relationship with the Company and these materials should not be reproduced or copied in any form.  The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MOROCCO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEPAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The Employee waives any and all rights to compensation or damages as a result of a Termination, insofar as those rights result or may result from&#58; (a) the loss or diminution in value of such rights or entitlements under the Program&#59; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under the Program as a result of such Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warning</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement, will be converted into Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares give you a stake in the ownership of AbbVie Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If AbbVie Inc. runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This information is designed to help investors make an informed decision.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The usual rules do not apply to this offer because it is made under an employee share purchase scheme.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a result, you may not be given all the information usually required.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You will also have fewer other legal protections for this investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to the underlying Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are quoted on the New York Stock Exchange.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This means that if you acquire Shares under the Program, you may be able to sell them on the New York Stock Exchange if there are interested buyers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may get less than you invested.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The price will depend on the demand for the Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">The AbbVie Amended and Restated 2013 Incentive Stock Program&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Copies of the documents listed above will be sent to you free of charge on written request to&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">PHILIPPINES</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  A Termination shall include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the situation where the Employee&#8217;s employment contract is terminated by operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of any type.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee hereby expressly agrees that this Agreement, the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as well as all documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in the English language. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Angajatul consimte &#238;n mod expres prin prezentul ca acest Contract, Programul precum &#351;i orice alte documente, notific&#259;ri, &#238;n&#351;tiin&#355;&#259;ri legate direct sau indirect de acest Contract s&#259; fie redactate sau efectuate doar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#238;n limba englez&#259;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sale or Transfer of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, the Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Russia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may sell the Shares only through a broker established and operating outside </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Russia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to promptly repatriate proceeds resulting from the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may sell the Shares only through a broker established and operating outside Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Shares issued upon vesting shall be delivered to the Employee through a brokerage account in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may hold the Shares in his or her brokerage account in the U.S.&#59; however, in no event will Shares issued to the Employee under the Program be delivered to the Employee in Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is not permitted to sell Shares directly to other Russian legal entities or individuals.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SAUDI ARABIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Qualifying Person Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Award under the Program is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result, the Award is subject to section 257 of the SFA and the Employee will not be able to make&#58; (a) any subsequent sale of the Shares underlying the Award in Singapore&#59; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exchange Control Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with applicable exchange control regulations and rulings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Exchange Control Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">South Africa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As the Exchange Control Regulations change frequently and without notice, the Employee should consult the Employee&#8217;s legal advisor prior to the acquisition or sale of Shares under the Program to ensure compliance with current Exchange Control Regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws, rules or regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In compliance with South African securities laws, the Employee acknowledges that the documents listed below are available for review at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.37pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that a copy of the above documents will be sent to the Employee free of charge on written request to&#58; Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is advised to carefully read the materials provided before making a decision whether to participate in the Program and to contact the Employee&#8217;s tax advisor for specific information concerning the Employee&#8217;s personal tax situation with regard to Program participation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SPAIN</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Program&#59; No Vested Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Program to individuals who may be employees of the Company or its Subsidiaries throughout the world.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consequently, the Employee understands that the Units are granted on the assumption and condition that the Units and the Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s acquired upon settlement of the Units </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and conditions referenced above&#59; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Section 4 of the Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement to the underlying Shares or to any amount of indemnification in the event of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that the Employee has read and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Units.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, &#8220;Cause&#8221; shall be as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e., &#8220;despido procedente&#8221;) under Spanish legislation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory. The Program, the Award, the Agreement, this Addendum and all other materials the Employee may receive regarding the Employee&#8217;s participation in the Program have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Spanish Securities Exchange Commission), and they do not constitute a public offering prospectus.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision shall supplement Section 8 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Without limiting the authority of the Company and the Subsidiary that employs the Employee to satisfy their withholding obligations for Tax-Related items as set forth in Section 8 of the Agreement, the Employee authorizes the Company to withhold Shares otherwise deliverable to the Employee upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Subsidiary that employs the Employee has an obligation to withhold such Tax-Related Items.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Neither this document nor any other materials relating to the Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">person other than an employee of the Company or (iii) has been or will be filed with, approved or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">authority, including the Swiss Financial Market Supervisory Authority (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FINMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">TUNISIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Under Turkish law, the Employee is not permitted to sell any Shares acquired under the Plan in Turkey.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are currently traded on the New York Stock Exchange, which is located outside of Turkey, under the ticker symbol &#8220;ABBV&#8221; and the Shares may be sold through this exchange. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Financial Intermediary Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that any activity related to investments in foreign securities (e.g., the sale of Shares) should be conducted through a bank or financial intermediary institution licensed by the Turkey Capital Markets Board and should be reported to the Turkish Capital Markets Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with this requirement and should consult with a personal legal advisor for further information regarding any obligations in this respect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UKRAINE</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are granted under the Program only to select Employees and are in the nature of providing employee equity incentives in the United Arab Emirates. The Program and the Agreement are intended for distribution only to such Employees and must not be delivered to, or relied on by, any other person.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prospective acquirors of the securities offered should conduct their own due diligence on the securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee does not understand the contents of the Program and the Agreement, the Employee should consult an authorized financial adviser. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Ministry of Economy nor the Dubai Department of Economic Development has approved the Program or the Agreement nor taken steps to verify the information set out herein, and has no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Without limitation to Section 8 of the Agreement, the Employee hereby agrees that the Employee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or (if different) the Subsidiary that employs the Employee or by Her Majesty&#8217;s Revenue &#38; Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).  The Employee also hereby agrees to indemnify and keep indemnified the Company and (if different) the Subsidiary that employs the Employee against any Tax-Related Items that they are required to pay or withhold on the Employee&#8217;s behalf or have paid or will pay on the Employee&#8217;s behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, if the Employee is a director or executive officer (as within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that the Employee is a director or executive officer and income tax due is not collected from or paid by the Employee by within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to the Employee on which additional income tax and national insurance contributions may be payable. The Employee acknowledges that the Employee ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Subsidiary that employs the Employee (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Subsidiary that employs the Employee may recover from the Employee at any time thereafter by any of the means referred to in Section 8 of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the Employee will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Employee&#8217;s ceasing to have rights under or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or otherwise), or from the loss or diminution in value of the Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon the grant of the Award, the Employee shall be deemed to have waived irrevocably any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">VIETNAM</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>abbv-20220331xex106.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i35d7d636f8954e87bdf0046169d82ff8_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.6</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ABBVIE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">On this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;GRANT DATE (MONTH DD, YYYY)&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), AbbVie Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) hereby grants to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;FIRST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;LAST NAME&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) a Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#60;&#60;TOTAL SHARES GRANTED&#62;&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) representing the right to receive an equal number of Shares on a specified Delivery Date.</font></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus, and the Program administrative rules, the provisions of the Program shall control.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The terms and conditions of the Award are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:8pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%;padding-left:9pt">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Restricted Stock Unit Agreement.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%;padding-left:9.75pt">Cause&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Cause shall mean the following, as determined by the Company in its sole discretion&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:18pt">material breach by the Employee of the terms and conditions of the Employee&#8217;s employment, including, but not limited to</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(A) material breach by the Employee of the Code of Business Conduct&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(B) material breach by the Employee of the Employee&#8217;s Employee Agreement or employment contract, if any&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(C) commission by the Employee of an act of fraud, embezzlement or theft in connection with the Employee&#8217;s duties or in the course of the Employee&#8217;s employment&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(D) wrongful disclosure by the Employee of secret processes or confidential information of the Company or any of its Subsidiaries&#59; or</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(E) failure by the Employee to substantially perform the duties of the Employee&#8217;s employment (other than any such failure resulting from the Employee&#8217;s Disability)&#59; or</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(ii) to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for the benefit of the Employee or others, in any activity, employment or business which is competitive with the Company or any of its Subsidiaries.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">c. Code of Business Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company&#8217;s Code of Business Conduct, as amended from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">d. Data&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Certain personal information about the Employee held by the Company and the Subsidiary that employs the Employee (if applicable), including (but not limited to) the Employee&#8217;s name, home address and telephone number, email address, date of birth, social security, passport or other identification number, salary, nationality, job title, any Shares held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">purchased, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Disability&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">As of a particular date, the Employee is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of at least six months under (i) the terms of the AbbVie Long Term Disability Plan (the &#8220;LTD Plan&#8221;), or (ii) if the Employee&#8217;s employer does not participate in the LTD Plan, such similar accident and health plan providing replacement benefits in which the Employee&#8217;s employer participates.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">f. Employee Agreement&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee Agreement entered into by and between the Company or a Subsidiary and the Employee as it may be amended from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">g. Employee&#8217;s Representative&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> The Employee&#8217;s legal guardian or other legal representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">h. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The occurrence of any of the following circumstances without the Employee&#8217;s express written consent&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) a significant adverse change in the nature, scope or status of the Employee&#8217;s position, authorities or duties from those in effect immediately prior to the Change in Control, including, without limitation, if the Employee was, immediately prior to the Change in Control, an officer of a public company, the Employee ceasing to be an officer of a public company&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(ii) the failure by the Company or a Subsidiary to pay the Employee any portion of the Employee&#8217;s current compensation, or to pay the Employee any portion of any installment of deferred compensation under any deferred compensation program of the Company, within seven days of the date such compensation is due&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iii) a reduction in the Employee&#8217;s annual base salary (or a material change in the frequency of payment) as in effect immediately prior to the Change in Control as the same may be increased from time to time&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iv) the failure by the Company or a Subsidiary to award the Employee an annual bonus in any year which is at least equal to the annual bonus awarded to the Employee under the annual bonus plan of the Company or Subsidiary for the year immediately preceding the year of the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(v) the failure by the Company to award the Employee equity-based incentive compensation (such as stock options, shares of restricted stock, restricted stock units, or other equity-based compensation) on a periodic basis consistent with the Company&#8217;s practices with respect to timing, value and terms prior to the Change in Control&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(vi) the failure by the Company or a Subsidiary to continue to provide the Employee with the welfare benefits, fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in Control under any of the Company&#8217;s or Subsidiary&#8217;s plans or policies, including, but not limited to, those plans and policies providing pension, life insurance, medical, health and accident, disability and vacation&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(vii) the relocation of the Employee&#8217;s base office to a location that is more than 35 miles from the Employee&#8217;s base office immediately prior to the Change in Control&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the Company to assume and agree to perform this Agreement as contemplated in Section 5.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The AbbVie Amended and Restated 2013 Incentive Stock Program.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">A severance of employment for any reason (including retirement) from the Company and all Subsidiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Any Termination shall be effective on the last day the Employee performs services for or on behalf of the Company or a Subsidiary, and employment shall not be extended by any statutory or common law notice of termination period.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2. Delivery Date and Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The delivery date for Shares underlying the Units is the date on which the Shares are payable to the Employee after the Restrictions on such Units lapse pursuant to Section 4 below (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Prior to the Delivery Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">the Employee shall not be treated as a shareholder as to those Shares underlying the Units, and shall have only a contractual right to receive Shares, unsecured by any assets of the Company or its Subsidiaries&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b) the Employee shall not be permitted to vote the Shares underlying the Units&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c) the Employee&#8217;s right to receive such Shares will be subject to the adjustment provisions relating to mergers, reorganizations, and similar events set forth in the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Subject to the requirements of local law, </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">if any dividend or other distribution is declared and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">paid on Shares underlying the Units (other than dividends or distributions of securities of the Company which may be issued with respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">while any of the Units remain subject to this Award (meaning that any of the Shares into which Units would be converted are not otherwise issued and outstanding for purposes of the entitlement to the dividend or distribution), then a book account will be maintained for the Employee and credited with a phantom dividend that is equivalent to the actual dividend or distribution that would have been paid on the total number of Shares that may be distributed under this Award if that number of Shares had been issued and outstanding and entitled to the dividend or distribution. As any Units vest under this Award, the phantom dividends credited to the book account that are attributable to the Shares issuable with respect to such Units will vest and be distributed to the Employee (in the form in which the actual dividend or distribution was paid to shareholders or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the Shares resulting from the Unit vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Any such distribution is subject to the Company&#8217;s collection of withholding taxes applicable to the distribution.</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If any of the Units are forfeited as a result of the application of the vesting requirements or the forfeiture provisions of this Agreement or the Program, then the phantom dividends attributable to the Shares underlying the forfeited Units will be cancelled and the Employee will cease to have any right or entitlement to receive any distribution or other amount with respect to such cancelled phantom dividends.</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">No phantom dividends will be paid or payable to or for the benefit of the Employee with respect to dividends or distributions for which the record date occurs on or after the date the Employee has forfeited the Units, or the date on which vested Units have been settled in Shares.</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of compliance with the requirements of Code Section 409A, to the extent applicable, the specified date for payment of any phantom dividend to which the Employee is entitled under this Section 2 is the calendar year in which the corresponding Units vest and are distributed to the Employee.</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee has no right to determine the year in which phantom dividends will be paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">3. Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Units are subject to the forfeiture provisions in Sections 6 and 7 below.  Units are not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) until the earliest to occur of the events described in subsections 4(a), (b), or (c) or Section 5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">4. Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Subject to Sections 5, 6 and 7 below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Passage of Time.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">While the Employee is employed with the Company or its Subsidiaries, the Restrictions on 100% of the Units will lapse on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">the third anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Delivery Date&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Subject to subsections (b) and (c) below, Units for which Restrictions have lapsed, as described in this subsection 4(a), shall be settled in the form of Shares on the Delivery Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Restrictions shall lapse on the date of the Employee&#8217;s Termination due to death, and the Units shall be settled (for the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> in the form of Shares as soon as administratively possible after, and effective as of, the date of death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Restrictions shall lapse on the date of the Employee&#8217;s Disability, and the Units shall be settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Disability.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">5. Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of a Change in Control, the entity surviving such Change in Control or the ultimate parent thereof (referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Surviving Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) may assume, convert or replace this Award with an award of at least equal value and terms and conditions not less favorable than the terms and conditions provided in this Agreement, in which case the new award will vest according to the terms of the applicable award agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Surviving Entity does not assume, convert or replace this Award, the Restrictions shall lapse on the date of the Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Surviving Entity does assume, convert or replace this Award, then in the event the Employee&#8217;s Termination (a) occurs within the time period beginning six months immediately before a Change in Control and ending two years immediately following such Change in Control, and (b) was initiated by the Company (or the Surviving Entity) for a reason other than Cause or was initiated by the Employee for Good Reason,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">the Restrictions shall lapse on the later of the date of the Change in Control and the date of the Employee&#8217;s Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The provisions of this Section 5 shall supersede Section 13(a)(iii) and (v) of the Program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">6. Effect of Certain Bad Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Any Units not previously settled shall be cancelled and forfeited immediately if the Employee engages in activity that constitutes Cause, as determined in the sole opinion and discretion of the Committee or its delegate, whether or not the Employee experiences a Termination or remains employed with the Company or a Subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">7. Forfeiture of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the event of the Employee&#8217;s Termination for any reason other than those set forth in subsections 4(b) or (c) or Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, any Units with respect to which Restrictions have not lapsed as of the date of Termination shall be forfeited without consideration to the Employee or the Employee&#8217;s Representative.  In the event that the Employee is terminated by the Company other than for Cause and in a situation not covered by Section 5, the Company may, in its sole discretion, cause Restrictions on some or all of the Units not previously settled to lapse and be settled in the form of Shares on the Delivery Date set forth in subsection 4(a) above as if the Employee had remained employed on such date.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In accepting this Award, the Employee acknowledges that in the event of Termination (whether or not in breach of local labor laws), the Employee&#8217;s right to vest in the Units, if any, will cease and will not be extended by any notice period mandated under local law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, active employment does not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law) and that the Company shall have the exclusive discretion to determine when Termination occurs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">8. Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent permitted under applicable law and by the Company, the Employee may satisfy any U.S. or non-U.S. federal, state, local or other applicable taxes arising from the grant of the Award, the lapse of Restrictions or the delivery of Shares pursuant to this Agreement by&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">tendering a cash payment&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">having the Company withhold Shares from the Shares to be delivered to satisfy the applicable withholding tax&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c) tendering Shares received in connection with the Units back to the Company&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount to be withheld.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company shall have the right and is hereby authorized to withhold from the Shares deliverable to the Employee pursuant to this Agreement or (to the extent permitted by applicable law, including without limitation Code Section 409A) from any other compensation or other amount owing to the Employee, such amount as may be necessary in the opinion of the Company to satisfy all such taxes, requirements and withholding obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">If the Company withholds for tax purposes from the Shares otherwise to be delivered to the Employee, the Employee is deemed to have been issued the full number of Shares underlying the Units, subject to the Restrictions set forth in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Notwithstanding the foregoing, if the Employee is subject to Section 16(b) of the Exchange Act, the Company will withhold using the method described in subsection 8(b) above unless the use of such withholding method is problematic under applicable laws or has materially adverse accounting consequences, in which case the Committee shall determine which of the other methods described in this Section 8 or in the Program shall be used to satisfy the applicable withholding obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">9. No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement and the Employee&#8217;s participation in the Program do not and shall not be interpreted to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(a) form an employment contract or relationship with the Company or its Subsidiaries&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(b) confer upon the Employee any right to continue in the employ of the Company or any of its Subsidiaries&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">(c) interfere with the ability of the Company or its Subsidiaries to terminate the Employee&#8217;s employment at any time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:94%">10. Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:94%">In accepting this grant of Units, the Employee acknowledges and agrees that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a) the Program is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b) this Award is a one-time benefit and does not create any contractual or other right to receive future grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have been granted repeatedly in the past&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c) all decisions with respect to future Unit grants, if any, and their terms and conditions, will be made by the Company, in its sole discretion&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(d) nothing contained in this Agreement is intended to create or enlarge any other contractual obligations between the Company and the Employee&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e) the Employee is voluntarily participating in the Program&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(f) the Units and Shares subject to the Units are&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Company or its Subsidiaries, and are outside the scope of the Employee&#8217;s employment contract, if any&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(ii) not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(iii) not part of the Employee&#8217;s normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits, or similar payments and in no event should they be considered as compensation for, or relating in any way to, past services for the Company or any of its Subsidiaries&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(g) the future value of the Shares underlying the Units is unknown and cannot be predicted with certainty&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(h) in consideration of the Award, no claim or entitlement to compensation or damages shall arise from the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably releases the Company and its Subsidiaries from any such claim that may arise&#59; if any such claim is found by a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">court of competent jurisdiction to have arisen, then, by signing or electronically accepting this Agreement, the Employee shall be deemed irrevocably to have waived the Employee&#8217;s entitlement to pursue such claim&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) the Units and the Benefits under the Program, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(j) neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units, the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States Dollar&#47;local currency foreign exchange rate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">11. Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a) Pursuant to applicable personal data protection laws, the collection, processing and transfer of the Employee&#8217;s personal Data is necessary for the Company&#8217;s administration of the Program and the Employee&#8217;s participation in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of personal Data may affect his or her ability to participate in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">As such (where required under applicable law), the Employee&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i) voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of personal Data as described herein&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii) authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data may be provided by the Employee or collected, where lawful, from third parties, and the Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the exclusive purpose of implementing, administering and managing the Employee&#8217;s participation in the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which the Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations in the Employee&#8217;s country of residence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and for the Employee&#8217;s participation in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c) The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that employs the Employee (if applicable) may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">These recipients may be located throughout the world.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d) The Employee may, at any time, exercise his or her rights provided under applicable personal data protection laws, which may include the right to&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(i) obtain confirmation as to the existence of the Data&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(ii) verify the content, origin and accuracy of the Data&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and&#47;or operation of the Program and the Employee&#8217;s participation in the Program.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Employee may seek to exercise these rights by contacting his or her local human resources manager.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(e) Upon request of the Company or the Subsidiary that employs the Employee, the Employee agrees to provide an executed data privacy consent form (or any other agreement or consent that may be required by the Company and&#47;or the Subsidiary that employs the Employee) to the Company and&#47;or the Subsidiary that employs the Employee that the Company and&#47;or the Subsidiary that employs the Employee may deem necessary to obtain from the Employee for the purpose of administering his or her participation in the Program in compliance with the data privacy laws in the Employee&#8217;s country, either now or in the future. The Employee understands and agrees that he or she will not be able to participate in the Program if the Employee fails to provide any such requested consent or agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">12. Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of a cash payment to the extent settlement in Shares&#58; (a) is prohibited under local law&#59; (b) would require the Employee, the Company and&#47;or its Subsidiaries to obtain the approval of any governmental and&#47;or regulatory body in the Employee&#8217;s country&#59; (c) would result in adverse tax consequences for the Employee or the Company&#59; or (d) is administratively burdensome.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Alternatively, the Company may, in its sole discretion, settle the Employee&#8217;s Units in the form of Shares but require the Employee to sell such Shares immediately or within a specified period of time following the Employee&#8217;s Termination (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Employee&#8217;s behalf).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">13. Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This grant of Units is not intended to be a public offering of securities in the Employee&#8217;s country.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and this grant of Units is not subject to the supervision of the local securities authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">14. Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As a condition to this grant of Units, the Employee agrees to comply with any applicable foreign exchange rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">15. Compliance with Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a) The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company&#8217;s Shares are listed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Employee&#8217;s participation in the Program and legally applicable to the Employee or deemed by the Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by the Company or its Subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), the Employee acknowledges that the ultimate liability for all Tax-Related Items is and remains the Employee&#8217;s responsibility and may exceed the amount actually withheld by the Company or its Subsidiaries, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee further acknowledges that the Company and&#47;or its Subsidiaries&#58; (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units, including, but not limited to, the grant, lapse of Restrictions or settlement of the Units, the issuance of Shares upon payment of the Units, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends, phantom dividends and&#47;or any Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate the Employee&#8217;s liability for Tax-Related Items or achieve any particular tax result.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee has become subject to tax in more than one jurisdiction between the date of grant and the date of any relevant taxable event, the Employee acknowledges that the Company and&#47;or its Subsidiaries may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee relocates to another country, the Company may establish special or alternative terms and conditions as necessary or advisable to comply with local laws, rules or regulations, to facilitate the operation and administration of the Award and the Program and&#47;or to accommodate the Employee&#8217;s relocation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c) The Employee acknowledges that, depending on the Employee&#8217;s or the broker&#8217;s country of residence or where the Shares are listed, the Employee may be subject to insider trading restrictions and&#47;or market abuse laws which may affect his or her ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, Units) or rights linked to the value of Shares during such times the Employee is considered to have &#8220;inside information&#8221; regarding the Company as defined in the laws or regulations in his or her country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Employee placed before he or she possessed inside information. Furthermore, the Employee could be prohibited from (i) disclosing the inside information to any third party (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. The Employee understands that third parties may include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Employee acknowledges that it is the Employee&#8217;s responsibility to comply with any restrictions and the Employee is advised to speak to his or her personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">16. Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Payments made pursuant to this Agreement are intended to be exempt from or otherwise comply with the provisions of Code Section 409A to the extent applicable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Program and this Agreement shall be administered and interpreted in a manner consistent with this intent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Company determines that any payments under this Agreement are subject to Code Section 409A and this Agreement fails to comply with that section&#8217;s requirements, the Company may, at the Company&#8217;s sole discretion, and without the Employee&#8217;s consent, amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent required to avoid accelerated taxation and&#47;or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless the Employee has incurred a &#8220;separation from service&#8221; as defined in Treasury Regulation &#167;1.409A-1(h), and amounts that would otherwise be payable pursuant to this Agreement during the six-month period immediately following the Employee&#8217;s Termination (including retirement) shall instead be paid on the first business day after the date that is six months following the Employee&#8217;s Termination (or upon the Employee&#8217;s death, if earlier).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For purposes of Code Section 409A, to the extent applicable&#58; (a) all payments provided hereunder shall be treated as a right to a series of separate payments and each separately identified amount to which the Employee is entitled under this Agreement shall be treated as a separate payment&#59; (b) except as otherwise provided in Section 13(a) of the Program, upon the lapse of Restrictions pursuant to Section 5 of this Agreement, any Units not previously settled on a Delivery Date shall be settled as soon as administratively possible after, and effective as of, the date of the Change in Control or the date of the Employee&#8217;s Termination (as applicable)&#59; (c) the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">as soon as administratively possible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a period of time that is within 60 days after the Termination, Disability or Change in Control (as applicable)&#59; and (d) the date of the Employee&#8217;s Disability shall be determined by the Company in its sole discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Although this Agreement and the payments provided hereunder are intended to be exempt from or otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">17. No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Units, the Employee&#8217;s participation in the Program or the Employee&#8217;s acquisition or sale of the underlying Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee is hereby advised to consult with the Employee&#8217;s own personal tax, legal and financial advisors regarding participation in the Program before taking any action related to the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">18. Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company reserves the right to impose other requirements on the Employee&#8217;s participation in the Program, on the Units and on any Shares acquired under the Program, to the extent the Company or any Subsidiary determines it is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program, and to require the Employee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee agrees to take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations in the Employee&#8217;s country.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In addition, the Employee agrees to take any and all actions as may be required to comply with the Employee&#8217;s personal obligations under local laws, rules and regulations in the Employee&#8217;s country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">19. Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Each decision, determination, interpretation or other action made or taken pursuant to the provisions of this Agreement by the Company, the Committee or any delegate of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">the Committee shall be final, conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the Employee, the Employee&#8217;s Representative, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">20. Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Program by electronic means.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee hereby consents to receive such documents by electronic delivery and agrees to participate in the Program through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">21. Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This grant of Units shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for the Employee&#8217;s country or jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Moreover, if the Employee relocates to one of the countries or jurisdictions included in the Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and&#47;or regulations or facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Addendum constitutes part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">22. Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">To the extent a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">23. Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement and the Program constitute the entire agreement between the Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties regarding the Award. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Except as expressly set forth herein, this Agreement (and any provision of this Agreement) may not be modified, changed or clarified by the parties, except in a writing specifying the modification, change or clarification, signed by a duly authorized Company officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">24. Succession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Agreement shall be binding upon and operate for the benefit of the Company and its successors and assigns, and the Employee, the Employee&#8217;s Representative, and the person or persons to whom rights under the Award have passed by will or the laws of descent or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">25. Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Employee acknowledges and agrees that it is the Employee&#8217;s express intent that this Agreement, the Program and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee is in a country where English is not an official language, the Employee acknowledges that he or she is sufficiently proficient in English or has had the ability to consult with an advisor who is sufficiently proficient in the English language, so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">as to allow the Employee to understand the terms and conditions of this Agreement, the Program and any other documents related to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If the Employee has received this Agreement or any other document related to the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">26. Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any state&#8217;s conflict of laws principles.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">*</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed on their behalf.</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                                                                  &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ABBVIE INC.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ABBVIE INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">                                                                              </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                            </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMPLOYEE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">SIGNED BY ELECTRONIC SIGNATURE</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">By electronically accepting the Award, THE EMPLOYEE agrees that (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) such acceptance constitutes THE EMPLOYEE&#8217;S electronic signature in execution of this Agreement&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) THE EMPLOYEE agrees to be bound by the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) THE EMPLOYEE HAS reviewed the PROGRAM, the Agreement and the Addendum in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understands all of the provisions of the PROGRAM, the Agreement and the Addendum&#59; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) THE EMPLOYEE HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the PROGRAM&#59; and (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">) THE EMPLOYEE hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the COMMITTEE OR ITS DULY AUTHORIZED DELEGATE ON any questions arising under the PROGRAM, the Agreement and the Addendum.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Addendum to the AbbVie Inc.  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">RESTRICTED STOCK UNIT Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee is employed in a country or jurisdiction identified in this Addendum, the additional terms and conditions for such country or jurisdiction will apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee relocates to one of the countries or jurisdictions identified in this Addendum, the special terms and conditions for such country or jurisdiction will apply to the Employee, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and&#47;or regulations or to facilitate the operation and administration of the Units and the Program (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Employee&#8217;s relocation).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All defined terms contained in this Addendum shall have the same meaning as set forth in the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">EUROPEAN UNION (&#8220;EU&#8221;) &#47; EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) COUNTRIES, SWITZERLAND AND THE UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision replaces Section 11 of the Agreement in its entirety&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Pursuant to applicable personal data protection laws, the Employee is hereby notified of the following in relation to the Employee&#8217;s Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of the Program. The collection, processing and transfer of Personal Data is necessary for the legitimate purpose of the administration of the Program by the Company and the Subsidiary that employs the Employee and the Employee&#8217;s participation in the Program, and the Employee&#8217;s denial and&#47;or objection to the collection, processing and transfer of Personal Data may affect his or her participation in the Program. As such</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">by participating in the Program, the Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company and the Subsidiary that employs the Employee may hold certain personally identifiable information about the Employee, specifically his or her name, home address, email address and telephone number, date of birth, social security, passport or other identification number (resident registration number), salary, nationality, job title, any Shares or directorships held in the Company or its Subsidiaries, details of all entitlements to Shares (or cash) granted, awarded, canceled, vested, unvested or outstanding in the Employee&#8217;s favor, for the purpose of managing and administering the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Personal Data may be provided by the Employee or collected, where lawful, from third parties. The Company or the Subsidiary that employs the Employee each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee&#8217;s participation in the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and meeting related legal obligations associated with these actions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company&#8217;s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the employment relationship and for the Employee&#8217;s participation in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company and the Subsidiary that employs the Employee will transfer Personal Data amongst themselves and their affiliates as necessary for the purpose of implementation, administration and management of the Employee&#8217;s participation in the Program, and the Company and the Subsidiary that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">employs the Employee may each further transfer Personal Data to third parties assisting the Company or the Subsidiary that employs the Employee in the implementation, administration and management of the Program, including E*TRADE Financial Corporate Services Inc. and its affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">E*TRADE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) or any successor or other third party that the Company, the Subsidiary that employs the Employee or E*TRADE (or its successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in the EU, EEA, Switzerland, the United Kingdom or elsewhere throughout the world, such as the United States. By participating in the Program, the Employee understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the Employee&#8217;s participation in the Program, including any requisite transfer of such Personal Data as may be required for the administration of the Program and&#47;or the subsequent holding of Shares on the Employee&#8217;s behalf to a broker or other third party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further understands that he or she may request a list with the names and addresses of any potential recipients of Personal Data by contacting the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Subsidiary that employs the Employee may provide appropriate safeguards in accordance with EU Standard Contractual Clauses, or other legally binding and permissible arrangements. The Employee may request a copy of such safeguards from the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent provided by law, the Employee may, at any time, have the right to request&#58; access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, in any case without cost, by contacting in writing the Employee&#8217;s local Human Resources manager or AbbVie&#8217;s Human Resources Department. The Employee understands, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units or other equity awards or administer or maintain such awards. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">When the Company and the Subsidiary that employs the Employee no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and&#47;or records containing the Personal Data and&#47;or take steps to properly anonymize it so that the Employee can no longer be identified from it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ALGERIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Neither the Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision of such benefit would give rise to a breach of Part 2D.2 of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the Agreement and the Program, the Employee must review the Australian Offer Document for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges and confirms that the Employee has reviewed the Australian Offer Document.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) applies (subject to the conditions in that Act).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BAHRAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Agreement does not constitute advertising or an offering of securities in Bahrain, nor does it constitute an allotment of securities in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any Shares issued pursuant to the Units under the Program shall be deposited into a brokerage account in the United States.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In no event will Shares be issued or delivered in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The issuance of Shares pursuant to the Units described herein has not and will not be registered in Bahrain and hence, the Shares described herein may not be admitted or used for offering, placement or public circulation in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, the Employee may not make any public advertising or announcements regarding the Units or Shares in Bahrain, promote these Shares to legal entities or individuals in Bahrain, or sell Shares directly to other legal entities or individuals in Bahrain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that Shares may only be sold outside of Bahrain and on a stock exchange on which AbbVie is traded.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Labor Law Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees, for all legal purposes, (i) the Benefits provided under the Agreement and the Program are the result of commercial transactions unrelated to the Employee&#8217;s employment&#59; (ii) the Agreement and the Program are not a part of the terms and conditions of the Employee&#8217;s employment&#59; and (iii) the income from the Units, if any, is not part of the Employee&#8217;s remuneration from employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Resale Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is permitted to sell Shares acquired upon settlement of the Units through the designated broker appointed under the Program, provided the resale of Shares acquired under the Program takes place outside of Canada through the facilities of the stock exchange on which the Shares are listed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are currently listed on the New York Stock Exchange.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision supplements Section 7 of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the Units, the Employee&#8217;s employment relationship will be considered terminated as of the date the Employee is no longer actually employed or otherwise rendering services to the Company or, if different, the Subsidiary for which the Employee provides services (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment or other laws or otherwise rendering services or the terms of the Employee&#8217;s Employee Agreement or other service agreement, if any). Unless otherwise extended pursuant to the terms of the Agreement or by the Company, the Employee&#8217;s right to vest in the Units, if any, will terminate as of such date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). The Termination Date will not be extended by any common law notice period. Notwithstanding the foregoing, however, if applicable employment standards legislation specifically requires continued entitlement to vesting during a statutory notice period, the Employee&#8217;s right to vest in the Units, if any, will be allowed to continue for that minimum notice period but then immediately terminate effective as of the last day of the Employee&#8217;s minimum statutory notice period.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event the date the Employee is no longer providing actual service cannot be reasonably determined under the terms of this Agreement and&#47;or the Program, the Committee or its delegate shall have the exclusive discretion to determine when the Employee is no longer actively providing services for purposes of the Units (including whether the Employee may still be considered to be providing services while on a leave of absence).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise provided in the Agreement or by the Company, any portion of the Units that is not vested on the Termination Date shall terminate immediately and be null and void. Unless the applicable employment standards legislation specifically requires, in the case of the Employee, the Employee will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which his or her employment relationship is terminated (as determined under this provision) nor will the Employee be entitled to any compensation for lost vesting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHILE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following provision shall replace Section 13 of the Agreement&#58; </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt">The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to General Ruling no. 336 of the Chilean Commission for the Financial Market&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt">The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8.67pt">The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities are not registered with the Chilean Commission for the Financial Market&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt">The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Foreign Exchange Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The following provisions shall govern the Employee&#8217;s participation in the Program if the Employee is a national of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) resident in mainland China, or if determined to be necessary or appropriate by the Company in its sole discretion&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to hold the Shares received upon settlement of the Units and any and all previously granted restricted stock units with the Company&#8217;s designated broker. If the Company changes its designated broker, the Employee acknowledges and agrees that the Company may transfer any Shares issued under the Program to the new designated broker if necessary for legal or administrative reasons. The Employee agrees to sign any documentation necessary to facilitate the transfer. Upon a Termination, the Employee shall be required to sell all Shares issued pursuant to the Units within 180 days (or such shorter period as may be required by the State Administration of Foreign Exchange or the Company) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including procedures whereby the Company may issue sale instructions on behalf of the Employee), and the Employee hereby agrees to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary or advisable for purposes of complying with local laws, rules and regulations in China.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and agrees that dividends issued on Shares and sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the Company on the Employee&#8217;s behalf prior to being delivered to the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dividends and&#47;or sales proceeds may be paid to the Employee in U.S. dollars or local currency at the Company&#8217;s discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If dividends and&#47;or sales proceeds are paid to the Employee in U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so that the dividends or proceeds may be deposited into this account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If dividends and&#47;or sales proceeds are paid to the Employee in local currency, the Employee acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the dividends and&#47;or proceeds to local currency due to exchange control restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to bear any currency fluctuation risk between the time dividends are issued or Shares are sold and the net proceeds are converted into local currency and distributed to the Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in the future in order to facilitate compliance with exchange control requirements in China.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the processes and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company&#8217;s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This provision supplements Section 10 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that, pursuant to Article 128 of the Colombian Labor Code, the Program and related benefits do not constitute a component of Employee's &#8220;salary&#8221; for any legal purpose. Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares are not and will not be registered with the Colombian registry of publicly held securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) and, therefore, the Shares may not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">be offered to the public in Colombia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing in the Agreement should be construed as making a public offer of securities in Colombia.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">DENMARK</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">The Act on Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon the Employee&#8217;s Termination shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) as in effect at the time of the Employee&#8217;s Termination (as determined by the Company, in its discretion, in consultation with legal counsel). In addition to the Agreement and the Program, the Employee must review the Employer Information Statement (Denmark) pursuant to the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in the Employment Relationship, as amended as of January 1, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) for additional important information pertaining to the Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed via the E*TRADE website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;us.etrade.com&#47;stock-plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee acknowledges having received an &#8220;Employer Information Statement&#8221; in Danish, which is provided to comply with the Stock Option Act, as amended as of January 1, 2019. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Notwithstanding anything in Section 8 of the Agreement to the contrary, if the Employee is a local national of Finland, any Tax-Related Items shall be withheld only in cash from the Employee&#8217;s regular salary&#47;wages or other amounts payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed under local law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nature of the Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The parties to the Agreement acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la pr&#233;sente convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaires intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Award shall be settled only in Shares (and may not be settled in cash).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Lapse of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If, for any reason, Shares are issued to the Employee within six months of the Grant Date, the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary of the Grant Date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">IMPORTANT NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WARNING&#58; The contents of the Agreement, the Addendum, the Program, and all other materials pertaining to the Units and&#47;or the Program have not been reviewed by any regulatory authority in Hong Kong.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is hereby advised to exercise caution in relation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to the offer thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee has any doubts about any of the contents of the aforesaid materials, the Employee should obtain independent professional advice.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Wages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units and Shares subject to the Units do not form part of the Employee&#8217;s wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee expressly agrees to repatriate all amounts acquired under the Program in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subsidiaries </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall be liable for any fines or penalties resulting from the Employee's failure to comply with applicable laws, rules and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">INDONESIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Consent to Receive Information in English</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the grant of the Units, the Employee confirms having read and understood the documents relating to this grant which were provided in the English language and accepts the terms of those documents accordingly and agrees not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Persetujuan untuk Menerima Informasi dalam Bahasa Inggris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">. Dengan menerima hibah dari Unit Saham Terbatas, Anda mengonfirmasi telah membaca dan memahami dokumen-dokumen yang berkaitan dengan hibah ini (yaitu, Perjanjian Penghargaan, dan LTIP Takeda) yang disediakan dalam bahasa Inggris, menerima sesuai dengan dokumen-dokumen tersebut, dan setuju untuk tidak menentang keabsahan dokumen ini berdasarkan Undang-Undang No. 24 tahun 2009 tentang Bendera Nasional, Bahasa, Lambang dan Lagu Kebangsaan atau mengimplementasikan Peraturan Presiden (ketika diterbitkan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the Employee&#8217;s Award shall be settled only in Shares (and may not be settled in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ISRAEL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Trustee Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee agrees to hold the Shares received upon settlement of the Units with the Company&#8217;s designated broker. The Employee understands and agrees that upon the Employee&#8217;s sale of Shares, unless otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through a trustee in Israel engaged by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), (b) the Trustee will withhold the requisite tax and other mandatory withholding (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, National Insurance payments) from the sales proceeds and (c) the Trustee will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the Employee&#8217;s Termination.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MALTA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MEXICO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Commercial Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly acknowledges that the Employee&#8217;s participation in the Program and the Company&#8217;s grant of the Award does not constitute an employment relationship between the Employee and the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee has been granted the Award as a consequence of the commercial relationship between the Company and the Subsidiary in Mexico that employs the Employee, and the Company&#8217;s Subsidiary in Mexico is the Employee&#8217;s sole employer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Based on the foregoing&#58; (a) the Employee expressly acknowledges that the Program and the benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in Mexico that employs the Employee&#59; (b) the Program and the benefits derived from participation in the Program are not part of the employment conditions and&#47;or benefits provided by the Subsidiary in Mexico that employs the Employee&#59; and (c) any modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee&#8217;s employment with the Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Extraordinary Item of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee expressly recognizes and acknowledges that the Employee&#8217;s participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the Employee&#8217;s free and voluntary decision to participate in the Program in accordance with the terms and conditions of the Program, the Agreement and this Addendum.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As such, the Employee acknowledges and agrees that the Company, in its sole discretion, may amend and&#47;or discontinue the Employee&#8217;s participation in the Program at any time and without any liability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The value of the Units is an extraordinary item of compensation outside the scope of the Employee&#8217;s employment contract, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are not part of the Employee&#8217;s regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company&#8217;s Subsidiary in Mexico that employs the Employee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Units and the Shares offered under the Program have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Program, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to the Employee only because of the Employee's existing relationship with the Company and these materials should not be reproduced or copied in any form.  The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MOROCCO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEPAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The Employee waives any and all rights to compensation or damages as a result of a Termination, insofar as those rights result or may result from&#58; (a) the loss or diminution in value of such rights or entitlements under the Program&#59; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under the Program as a result of such Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NEW ZEALAND</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warning</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement, will be converted into Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares give you a stake in the ownership of AbbVie Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may receive a return if dividends are paid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If AbbVie Inc. runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may lose some or all of your investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This information is designed to help investors make an informed decision.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The usual rules do not apply to this offer because it is made under an employee share purchase scheme.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a result, you may not be given all the information usually required.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You will also have fewer other legal protections for this investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ask questions, read all documents carefully, and seek independent financial advice before committing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prior to the vesting and settlement of the Units, you will not have any rights of ownership (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, voting rights) with respect to the underlying Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are quoted on the New York Stock Exchange.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This means that if you acquire Shares under the Program, you may be able to sell them on the New York Stock Exchange if there are interested buyers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may get less than you invested.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The price will depend on the demand for the Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Inc.&#8217;s most recent published financial statements (Form 10-Q or 10-K) and the auditor&#8217;s report on those financial statements&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">The AbbVie Amended and Restated 2013 Incentive Stock Program&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Copies of the documents listed above will be sent to you free of charge on written request to&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">PHILIPPINES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  A Termination shall include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the situation where the Employee&#8217;s employment contract is terminated by operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of any type.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Employee hereby expressly agrees that this Agreement, the Program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as well as all documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in the English language. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Angajatul consimte &#238;n mod expres prin prezentul ca acest Contract, Programul precum &#351;i orice alte documente, notific&#259;ri, &#238;n&#351;tiin&#355;&#259;ri legate direct sau indirect de acest Contract s&#259; fie redactate sau efectuate doar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#238;n limba englez&#259;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sale or Transfer of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, the Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may sell the Shares only through a broker established and operating outside Russia. Any Shares issued upon vesting shall be delivered to the Employee through a brokerage account in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee may hold the Shares in his or her brokerage account in the U.S.&#59; however, in no event will Shares issued to the Employee under the Program be delivered to the Employee in Russia. The Employee is not permitted to sell Shares directly to other Russian legal entities or individuals.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Repatriation Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee agrees to promptly repatriate proceeds resulting from the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SAUDI ARABIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Qualifying Person Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The grant of the Award under the Program is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result, the Award is subject to section 257 of the SFA and the Employee will not be able to make&#58; (a) any subsequent sale of the Shares underlying the Award in Singapore&#59; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SOUTH AFRICA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exchange Control Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with applicable exchange control regulations and rulings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Exchange Control Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) in South Africa.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As the Exchange Control Regulations change frequently and without notice, the Employee should consult the Employee&#8217;s legal advisor prior to the acquisition or sale of Shares under the Program to ensure compliance with current Exchange Control Regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee&#8217;s failure to comply with applicable laws, rules or regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In compliance with South African securities laws, the Employee acknowledges that the documents listed below are available for review at the web addresses listed below&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.37pt">AbbVie Inc.&#8217;s most recent Annual Report (Form 10-K)&#58; https&#58;&#47;&#47;investors.abbvie.com&#47;sec-filings.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">AbbVie Amended and Restated 2013 Incentive Stock Program Prospectus&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This document can be accessed in the library section of the E*TRADE website at https&#58;&#47;&#47;us.etrade.com&#47;stock-plans.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that copies of the documents listed above will be sent to the Employee free of charge on written request to&#58; Executive Compensation, AbbVie Inc., Dept. V58G, Bldg. AP34-2, 1 North Waukegan Road, North Chicago, IL 60064, USA or by email at LTI&#64;abbvie.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is advised to carefully read the materials provided before making a decision whether to participate in the Program and to contact the Employee&#8217;s tax advisor for specific information concerning the Employee&#8217;s personal tax situation with regard to Program participation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SPAIN</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acknowledgement of Discretionary Nature of the Program&#59; No Vested Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the Program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Program to individuals who may be employees of the Company or its Subsidiaries throughout the world.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consequently, the Employee understands that the Units are granted on the assumption and condition that the Units and the Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s acquired upon settlement of the Units </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and conditions referenced above&#59; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Section 4 of the Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement to the underlying Shares or to any amount of indemnification in the event of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that the Employee has read and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Units.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary in the Program or the Agreement, &#8220;Cause&#8221; shall be as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e., &#8220;despido procedente&#8221;) under Spanish legislation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory. The Program, the Award, the Agreement, this Addendum and all other materials the Employee may receive regarding the Employee&#8217;s participation in the Program have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Spanish Securities Exchange Commission), and they do not constitute a public offering prospectus.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The following provision shall supplement Section 8 of the Agreement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Without limiting the authority of the Company and the Subsidiary that employs the Employee to satisfy their withholding obligations for Tax-Related items as set forth in Section 8 of the Agreement, the Employee authorizes the Company to withhold Shares otherwise deliverable to the Employee upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Subsidiary that employs the Employee has an obligation to withhold such Tax-Related Items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Neither this document nor any other materials relating to the Units (i) constitutes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">FINMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">TUNISIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Under Turkish law, the Employee is not permitted to sell any Shares acquired under the Plan in Turkey.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Shares are currently traded on the New York Stock Exchange, which is located outside of Turkey, under the ticker symbol &#8220;ABBV&#8221; and the Shares may be sold through this exchange. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Financial Intermediary Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges that any activity related to investments in foreign securities (e.g., the sale of Shares) should be conducted through a bank or financial intermediary institution licensed by the Turkey Capital Markets Board and should be reported to the Turkish Capital Markets Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee is solely responsible for complying with this requirement and should consult with a personal legal advisor for further information regarding any obligations in this respect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UKRAINE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Securities Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Units are granted under the Program only to select Employees and are in the nature of providing employee equity incentives in the United Arab Emirates. The Program and the Agreement are intended for distribution only to such Employees and must not be delivered to, or relied on by, any other person.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prospective acquirors of the securities offered should conduct their own due diligence on the securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Employee does not understand the contents of the Program and the Agreement, the Employee should consult an authorized financial adviser. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the Ministry of Economy nor the Dubai Department of Economic Development has approved the Program or the Agreement nor taken steps to verify the information set out herein, and has no responsibility for such documents.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Without limitation to Section 8 of the Agreement, the Employee hereby agrees that the Employee is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or (if different) the Subsidiary that employs the Employee or by Her Majesty&#8217;s Revenue &#38; Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) (or any other tax authority or any other relevant authority).  The Employee also hereby agrees to indemnify and keep indemnified the Company and (if different) the Subsidiary that employs the Employee against any Tax-Related Items that they are required to pay or withhold on the Employee&#8217;s behalf or have paid or will pay on the Employee&#8217;s behalf to HMRC (or any other tax authority or any other relevant authority).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, if the Employee is a director or executive officer (as within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that the Employee is a director or executive officer and income tax due is not collected from or paid by the Employee by within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to the Employee on which additional income tax and national insurance contributions may be payable. The Employee acknowledges that the Employee ultimately will be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Subsidiary that employs the Employee (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and&#47;or the Subsidiary that employs the Employee may recover from the Employee at any time thereafter by any of the means referred to in Section 8 of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exclusion of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Employee acknowledges and agrees that the Employee will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Employee&#8217;s ceasing to have rights under or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or otherwise), or from the loss or diminution in value of the Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon the grant of the Award, the Employee shall be deemed to have waived irrevocably any such entitlement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">VIETNAM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement in Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise determined by the Company.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>abbv-20220331xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic365a099312844d48c92eade005145b2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a))</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard A. Gonzalez, certify that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of AbbVie Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for AbbVie and have&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of AbbVie&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in AbbVie&#8217;s internal control over financial reporting that occurred during AbbVie&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie&#8217;s auditors and the audit committee of AbbVie&#8217;s board of directors&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard A. Gonzalez</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard A. Gonzalez, Chairman of the Board</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>abbv-20220331xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idca6348d0c5240419045641eb4538dd8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a))</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert A. Michael, certify that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of AbbVie Inc.&#59;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for AbbVie and have&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of AbbVie&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in AbbVie&#8217;s internal control over financial reporting that occurred during AbbVie&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie&#8217;s auditors and the audit committee of AbbVie&#8217;s board of directors&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert A. Michael</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>abbv-20220331xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i94a7dd17bbcb4e80bc5d0a14be6a059e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of AbbVie Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;),&#160;I, Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard A. Gonzalez</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard A. Gonzalez</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2022</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>abbv-20220331xex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic4625d36e13e486ca7224bbbd7a8de0a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of AbbVie Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;),&#160;I, Robert A. Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert A. Michael</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Michael</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chairman, Finance and Commercial Operations and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2022</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>abbv-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56dec8fe-bb4b-4711-9c82-c533c008edd6,g:2a065e27-cccc-4ae9-a029-5c29f5f60184-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abbv="http://www.abbvie.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abbvie.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.abbvie.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarningsUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEquityUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.abbvie.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.abbvie.com/role/BasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformation" roleURI="http://www.abbvie.com/role/SupplementalFinancialInformation">
        <link:definition>2103102 - Disclosure - Supplemental Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationTables" roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationTables">
        <link:definition>2304301 - Disclosure - Supplemental Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationDetails" roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationDetails">
        <link:definition>2405402 - Disclosure - Supplemental Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.abbvie.com/role/EarningsPerShare">
        <link:definition>2106103 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.abbvie.com/role/EarningsPerShareTables">
        <link:definition>2307302 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.abbvie.com/role/EarningsPerShareDetails">
        <link:definition>2408403 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensingAcquisitionsandOtherArrangements" roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements">
        <link:definition>2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensingAcquisitionsandOtherArrangementsDetails" roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails">
        <link:definition>2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborations" roleURI="http://www.abbvie.com/role/Collaborations">
        <link:definition>2111105 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsTables" roleURI="http://www.abbvie.com/role/CollaborationsTables">
        <link:definition>2312303 - Disclosure - Collaborations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsDetails" roleURI="http://www.abbvie.com/role/CollaborationsDetails">
        <link:definition>2413405 - Disclosure - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssets">
        <link:definition>2114106 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2315304 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillDetails" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails">
        <link:definition>2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails">
        <link:definition>2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntegrationandRestructuringPlans" roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlans">
        <link:definition>2118107 - Disclosure - Integration and Restructuring Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntegrationandRestructuringPlansTables" roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables">
        <link:definition>2319305 - Disclosure - Integration and Restructuring Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntegrationandRestructuringPlansDetails" roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails">
        <link:definition>2420408 - Disclosure - Integration and Restructuring Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasures" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures">
        <link:definition>2121108 - Disclosure - Financial Instruments and Fair Value Measures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresTables" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables">
        <link:definition>2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails">
        <link:definition>2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails">
        <link:definition>2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails">
        <link:definition>2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails">
        <link:definition>2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails">
        <link:definition>2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails">
        <link:definition>2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails">
        <link:definition>2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails">
        <link:definition>2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefits" roleURI="http://www.abbvie.com/role/PostEmploymentBenefits">
        <link:definition>2131109 - Disclosure - Post-Employment Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsTables" roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsTables">
        <link:definition>2332307 - Disclosure - Post-Employment Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsDetails" roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails">
        <link:definition>2433417 - Disclosure - Post-Employment Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.abbvie.com/role/Equity">
        <link:definition>2134110 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.abbvie.com/role/EquityTables">
        <link:definition>2335308 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockBasedCompensationDetails" roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails">
        <link:definition>2436418 - Disclosure - Equity - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockOptionsDetails" roleURI="http://www.abbvie.com/role/EquityStockOptionsDetails">
        <link:definition>2437419 - Disclosure - Equity - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityRSUsandPerformanceSharesDetails" roleURI="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails">
        <link:definition>2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityCashDividendsDetails" roleURI="http://www.abbvie.com/role/EquityCashDividendsDetails">
        <link:definition>2439421 - Disclosure - Equity - Cash Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockRepurchaseProgramDetails" roleURI="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails">
        <link:definition>2440422 - Disclosure - Equity - Stock Repurchase Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.abbvie.com/role/IncomeTaxes">
        <link:definition>2143111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.abbvie.com/role/IncomeTaxesDetails">
        <link:definition>2444425 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsandContingencies" roleURI="http://www.abbvie.com/role/LegalProceedingsandContingencies">
        <link:definition>2145112 - Disclosure - Legal Proceedings and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsandContingenciesDetails" roleURI="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails">
        <link:definition>2446426 - Disclosure - Legal Proceedings and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.abbvie.com/role/SegmentInformation">
        <link:definition>2147113 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.abbvie.com/role/SegmentInformationTables">
        <link:definition>2348309 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>2449427 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDisaggregationofRevenueDetails" roleURI="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails">
        <link:definition>2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" abstract="false" name="CostofGoodsAndServicesSoldFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_PotentialPaymentsUnderAgreementCertainMilestones" abstract="false" name="PotentialPaymentsUnderAgreementCertainMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_OtherKeyProductsMember" abstract="true" name="OtherKeyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PrescriptionDrugAbuseLitigationMember" abstract="true" name="PrescriptionDrugAbuseLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" abstract="false" name="DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" abstract="false" name="CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" abstract="false" name="LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" abstract="false" name="LossContingencyIndividualPlaintiffLawsuitsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_AllerganIntegrationPlanMember" abstract="true" name="AllerganIntegrationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_QuliptaMember" abstract="true" name="QuliptaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherExpensesFromCollaborativeArrangements" abstract="false" name="OtherExpensesFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_UbrelvyMember" abstract="true" name="UbrelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_December2018StockRepurchaseAuthorizationMember" abstract="true" name="December2018StockRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec0.750SeniorNotesDue2027Member" abstract="true" name="Sec0.750SeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" abstract="false" name="CollaborativeArrangementMilestoneMethodPaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" abstract="true" name="AccumulatedNetGainLossFromNetInvestmentHedgesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" abstract="false" name="AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" abstract="false" name="OtherComprehensiveIncomeLossNetInvestmentHedgeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_GenentechInc.Member" abstract="true" name="GenentechInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_KeyProductPortfolioAxis" abstract="true" name="KeyProductPortfolioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" abstract="true" name="ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec2625SeniorNotesDue2028Member" abstract="true" name="Sec2625SeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_BystolicAntitrustLitigationMember" abstract="true" name="BystolicAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherAestheticsMember" abstract="true" name="OtherAestheticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SeniorNotesDue2022At3.450PercentMember" abstract="true" name="SeniorNotesDue2022At3.450PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestasisMember" abstract="true" name="RestasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_JuvedermCollectionMember" abstract="true" name="JuvedermCollectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" abstract="true" name="AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abbv_CreonMember" abstract="true" name="CreonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec1500SeniorNotesDue2023Member" abstract="true" name="Sec1500SeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" abstract="false" name="TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" abstract="false" name="LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" abstract="false" name="ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" abstract="true" name="HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_HUMIRAMember" abstract="true" name="HUMIRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_HematologicOncologyMember" abstract="true" name="HematologicOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" abstract="false" name="ResearchAndDevelopmentExpenseFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" abstract="true" name="AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SupplementalFinancialInformationDisclosureAbstract" abstract="true" name="SupplementalFinancialInformationDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abbv_Sec1250SeniorNotesDue2024Member" abstract="true" name="Sec1250SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec2.125SeniorNotesdue2028Member" abstract="true" name="Sec2.125SeniorNotesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" abstract="false" name="RestructuringReservePeriodCashSettledAndOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_ImbruvicaMember" abstract="true" name="ImbruvicaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" abstract="true" name="PrescriptionDrugAbuseLitigationInStateCourtsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_KeyProductPortfolioDomain" abstract="true" name="KeyProductPortfolioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AlphaganCombiganMember" abstract="true" name="AlphaganCombiganMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_EyeCareMember" abstract="true" name="EyeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AestheticsMember" abstract="true" name="AestheticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_BotoxTherapeuticMember" abstract="true" name="BotoxTherapeuticMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_DuodopaMember" abstract="true" name="DuodopaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PrincipalUSCustomersMember" abstract="true" name="PrincipalUSCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_NumberOfPrincipalUSCustomers" abstract="false" name="NumberOfPrincipalUSCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_ProjectedYearofPaymentsMember" abstract="true" name="ProjectedYearofPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherEyeCareMember" abstract="true" name="OtherEyeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" abstract="false" name="ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" abstract="true" name="FloatingRateTermLoanTrancheDueMay2025RefinancedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LumiganGanfortMember" abstract="true" name="LumiganGanfortMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SyndesiMember" abstract="true" name="SyndesiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SKYRIZIMember" abstract="true" name="SKYRIZIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec1.375SeniorNotesDue2024Member" abstract="true" name="Sec1.375SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abbv_BotoxCosmeticMember" abstract="true" name="BotoxCosmeticMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_FloatingRateTermLoanTrancheDueMay2025Member" abstract="true" name="FloatingRateTermLoanTrancheDueMay2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestrictedStockUnitsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_NiaspanMember" abstract="true" name="NiaspanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LinzessConstellaMember" abstract="true" name="LinzessConstellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestructuringReserveCashSettledRestructuringGainsLosses" abstract="false" name="RestructuringReserveCashSettledRestructuringGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_ProbabilityofPaymentforUnachievedMilestonesMember" abstract="true" name="ProbabilityofPaymentforUnachievedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LossContingencyPurportedClassActionsNumber" abstract="false" name="LossContingencyPurportedClassActionsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" abstract="false" name="LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_MAVYRETMember" abstract="true" name="MAVYRETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_VraylarMember" abstract="true" name="VraylarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec2125SeniorNotesDue2029Member" abstract="true" name="Sec2125SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RINVOQMember" abstract="true" name="RINVOQMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PutativeClassActionLawsuitIndividualNumber" abstract="false" name="PutativeClassActionLawsuitIndividualNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_ElliottAssociatesL.P.Member" abstract="true" name="ElliottAssociatesL.P.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec1.250SeniorNotesdue2031Member" abstract="true" name="Sec1.250SeniorNotesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherRestructuringPlansMember" abstract="true" name="OtherRestructuringPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_VENCLEXTAMember" abstract="true" name="VENCLEXTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" abstract="false" name="CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" abstract="false" name="SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" abstract="true" name="ProbabilityofPaymentforRoyaltiesbyIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>abbv-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56dec8fe-bb4b-4711-9c82-c533c008edd6,g:2a065e27-cccc-4ae9-a029-5c29f5f60184-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofEarningsUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_65570023-4ae0-43a7-ba63-d91f498b334f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_957d1094-5822-45d6-bffb-334117fe3086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_65570023-4ae0-43a7-ba63-d91f498b334f" xlink:to="loc_us-gaap_CostsAndExpenses_957d1094-5822-45d6-bffb-334117fe3086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_18a1e8a0-0e50-4663-bf33-a223e1bc839a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_65570023-4ae0-43a7-ba63-d91f498b334f" xlink:to="loc_us-gaap_Revenues_18a1e8a0-0e50-4663-bf33-a223e1bc839a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e657f325-1759-4dd5-bd4d-9e04489a6205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf478e1f-d73d-46ca-a67a-b0e8abe3af3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e657f325-1759-4dd5-bd4d-9e04489a6205" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf478e1f-d73d-46ca-a67a-b0e8abe3af3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_223454e5-b7ba-44e5-a7d1-785a0fb72c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e657f325-1759-4dd5-bd4d-9e04489a6205" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_223454e5-b7ba-44e5-a7d1-785a0fb72c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_06db3e3e-0c1f-41c7-82a1-fcd21254b2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e657f325-1759-4dd5-bd4d-9e04489a6205" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_06db3e3e-0c1f-41c7-82a1-fcd21254b2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6e5d9ff4-37b0-4365-a0ec-415875b473f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e657f325-1759-4dd5-bd4d-9e04489a6205" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6e5d9ff4-37b0-4365-a0ec-415875b473f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda5b12a-65ac-452f-86f2-a90c7b040f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9ad3a864-c949-4eae-acb2-27c15dce5262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda5b12a-65ac-452f-86f2-a90c7b040f8a" xlink:to="loc_us-gaap_OperatingIncomeLoss_9ad3a864-c949-4eae-acb2-27c15dce5262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f76402dd-ada1-4998-8d46-ddf950ec921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda5b12a-65ac-452f-86f2-a90c7b040f8a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f76402dd-ada1-4998-8d46-ddf950ec921c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d39a3116-db07-452b-b2ce-754097a5df2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda5b12a-65ac-452f-86f2-a90c7b040f8a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d39a3116-db07-452b-b2ce-754097a5df2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1c5c4b41-5a1c-41d0-9430-2c34285572b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda5b12a-65ac-452f-86f2-a90c7b040f8a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1c5c4b41-5a1c-41d0-9430-2c34285572b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e40930b5-d071-4f20-b18b-65f8eb536ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2c9cc1f4-516e-467f-8f96-1bae172fb420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e40930b5-d071-4f20-b18b-65f8eb536ab6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2c9cc1f4-516e-467f-8f96-1bae172fb420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f3d8132-83f2-4e21-b729-4525f056b956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e40930b5-d071-4f20-b18b-65f8eb536ab6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f3d8132-83f2-4e21-b729-4525f056b956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f67464c-64e2-4a92-9910-00c14a122785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_18193ede-28f2-4998-89df-26a9a179b68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7f67464c-64e2-4a92-9910-00c14a122785" xlink:to="loc_us-gaap_ProfitLoss_18193ede-28f2-4998-89df-26a9a179b68b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_acd051a7-551d-4a50-a61c-7995132e3ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7f67464c-64e2-4a92-9910-00c14a122785" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_acd051a7-551d-4a50-a61c-7995132e3ca5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0a3c836f-9112-47ae-b46f-1471eed74eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_830ee9bb-1ab4-4ecf-8e6e-36e1a1ea4db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0a3c836f-9112-47ae-b46f-1471eed74eca" xlink:to="loc_us-gaap_ProfitLoss_830ee9bb-1ab4-4ecf-8e6e-36e1a1ea4db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e0ebc95-9d3c-42bc-b362-1d39a04f3a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0a3c836f-9112-47ae-b46f-1471eed74eca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e0ebc95-9d3c-42bc-b362-1d39a04f3a28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ce913b2-1a1d-4917-8325-27d2accbdd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f6f9f1e3-9cbf-42b9-b798-ecb70114a1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ce913b2-1a1d-4917-8325-27d2accbdd6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f6f9f1e3-9cbf-42b9-b798-ecb70114a1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8c5e7378-da8b-413c-bd87-f611466dee36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ce913b2-1a1d-4917-8325-27d2accbdd6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8c5e7378-da8b-413c-bd87-f611466dee36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7acdb34b-ff97-4504-ad98-90696bdaaffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ce913b2-1a1d-4917-8325-27d2accbdd6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7acdb34b-ff97-4504-ad98-90696bdaaffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_ff833cf2-05ff-435b-8dc2-ff99e61bcd55" xlink:href="abbv-20220331.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ce913b2-1a1d-4917-8325-27d2accbdd6b" xlink:to="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_ff833cf2-05ff-435b-8dc2-ff99e61bcd55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce337f87-1509-44bd-b663-0bdaa454552a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9d481d04-a3cd-4b34-8cc1-3023c6c50dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce337f87-1509-44bd-b663-0bdaa454552a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9d481d04-a3cd-4b34-8cc1-3023c6c50dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bf32d91d-744e-468e-88e3-1e38111d1c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce337f87-1509-44bd-b663-0bdaa454552a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bf32d91d-744e-468e-88e3-1e38111d1c56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_80e0a8fc-198a-4179-99d9-f7b04c616688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_a8895e12-bd74-48d4-89a4-353ff2561049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80e0a8fc-198a-4179-99d9-f7b04c616688" xlink:to="loc_us-gaap_CommonStockValueOutstanding_a8895e12-bd74-48d4-89a4-353ff2561049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d528f58b-7b73-465e-869e-c3f0b1f1295b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80e0a8fc-198a-4179-99d9-f7b04c616688" xlink:to="loc_us-gaap_TreasuryStockValue_d528f58b-7b73-465e-869e-c3f0b1f1295b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_48b617eb-389e-41f8-9a44-2a65eb398343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80e0a8fc-198a-4179-99d9-f7b04c616688" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_48b617eb-389e-41f8-9a44-2a65eb398343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0fa8471-1ed9-4625-88ed-b62e0c6a628e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80e0a8fc-198a-4179-99d9-f7b04c616688" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0fa8471-1ed9-4625-88ed-b62e0c6a628e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc8dbd00-4bbd-4db5-9268-4601e7962eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80e0a8fc-198a-4179-99d9-f7b04c616688" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc8dbd00-4bbd-4db5-9268-4601e7962eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ea235f3-3da1-43b0-9e1e-947328b0355e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:to="loc_us-gaap_AssetsCurrent_2ea235f3-3da1-43b0-9e1e-947328b0355e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_5eef9f43-f1a7-47a6-a1bf-f8faa209594b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:to="loc_us-gaap_LongTermInvestments_5eef9f43-f1a7-47a6-a1bf-f8faa209594b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a00c4875-f406-4712-b6f4-9cda3e59b9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a00c4875-f406-4712-b6f4-9cda3e59b9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f8d79592-bbf5-415e-a3df-ebfac60d3255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f8d79592-bbf5-415e-a3df-ebfac60d3255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d4738cfc-e8cf-48e7-8621-def0bf020b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:to="loc_us-gaap_Goodwill_d4738cfc-e8cf-48e7-8621-def0bf020b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2d355691-3d6b-4b1a-86dc-cb4a9ea801e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6e457cd6-338a-4965-ae4c-f27d151ec431" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2d355691-3d6b-4b1a-86dc-cb4a9ea801e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_81bc4b98-4e61-4a43-a33b-83321bb0c239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:to="loc_us-gaap_LiabilitiesCurrent_81bc4b98-4e61-4a43-a33b-83321bb0c239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4c4a9d8a-05b5-4c3b-9ffc-04a72b9fd522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4c4a9d8a-05b5-4c3b-9ffc-04a72b9fd522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a9ad816-680d-4620-961b-53a14d2d11af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a9ad816-680d-4620-961b-53a14d2d11af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_079abe43-ced3-4a42-b3cb-e6710fad2b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_079abe43-ced3-4a42-b3cb-e6710fad2b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3343ecde-3a03-4669-a260-3aee012f5fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3343ecde-3a03-4669-a260-3aee012f5fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96042146-8876-423e-9365-e4cf9a5dcc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8adc5b7e-8785-4dbb-bc9f-682b073cc0e8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96042146-8876-423e-9365-e4cf9a5dcc7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6cefaadc-e743-4be3-887c-39fbfc19c540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_404955d1-493c-4e60-9e61-9d9041d68255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cefaadc-e743-4be3-887c-39fbfc19c540" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_404955d1-493c-4e60-9e61-9d9041d68255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ea0a10a3-e371-4e32-8e6b-e324f4c41ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cefaadc-e743-4be3-887c-39fbfc19c540" xlink:to="loc_us-gaap_ShortTermInvestments_ea0a10a3-e371-4e32-8e6b-e324f4c41ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f775033f-3781-491c-952b-f94abfe82f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cefaadc-e743-4be3-887c-39fbfc19c540" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f775033f-3781-491c-952b-f94abfe82f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_585f84df-9226-4bd1-9cc7-02402a018d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cefaadc-e743-4be3-887c-39fbfc19c540" xlink:to="loc_us-gaap_InventoryNet_585f84df-9226-4bd1-9cc7-02402a018d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_df40c2eb-315a-457e-b5b4-f310ffdb1686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cefaadc-e743-4be3-887c-39fbfc19c540" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_df40c2eb-315a-457e-b5b4-f310ffdb1686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e46dad1a-9988-4536-bcf4-7e4e20e7d045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_771efa2f-9e56-4b55-8fe8-e613d7e53129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e46dad1a-9988-4536-bcf4-7e4e20e7d045" xlink:to="loc_us-gaap_ShortTermBorrowings_771efa2f-9e56-4b55-8fe8-e613d7e53129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_92b85cfc-1b0f-4b88-b1c9-a8c521c73679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e46dad1a-9988-4536-bcf4-7e4e20e7d045" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_92b85cfc-1b0f-4b88-b1c9-a8c521c73679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ad9bfc8d-0571-49e3-a227-11eb4e9fec73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e46dad1a-9988-4536-bcf4-7e4e20e7d045" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ad9bfc8d-0571-49e3-a227-11eb4e9fec73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b6cddb15-dbe7-48ea-a341-545a32463675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_38f35c78-a996-4d19-bada-f143f37ff334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b6cddb15-dbe7-48ea-a341-545a32463675" xlink:to="loc_us-gaap_StockholdersEquity_38f35c78-a996-4d19-bada-f143f37ff334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_634d5fcd-7a49-4460-b6d2-156d08b71a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b6cddb15-dbe7-48ea-a341-545a32463675" xlink:to="loc_us-gaap_MinorityInterest_634d5fcd-7a49-4460-b6d2-156d08b71a44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5b254aa4-5f03-4c97-a4a0-48c68e3e0c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5b254aa4-5f03-4c97-a4a0-48c68e3e0c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_392f43d8-deda-4e6e-a6b1-9e950655797e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_392f43d8-deda-4e6e-a6b1-9e950655797e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_ea816d47-64be-48cc-967d-ccf34e302b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_ea816d47-64be-48cc-967d-ccf34e302b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3bb761f1-8a6a-4c81-90d6-f2f9d86f5d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3bb761f1-8a6a-4c81-90d6-f2f9d86f5d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_242752a9-239a-42a4-96e6-8ffeba2b745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_242752a9-239a-42a4-96e6-8ffeba2b745e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6168ea7d-2621-4c80-83ec-7fa55045be96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6168ea7d-2621-4c80-83ec-7fa55045be96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_63895c54-75ad-49fd-a7fa-ce535e92cbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_ShareBasedCompensation_63895c54-75ad-49fd-a7fa-ce535e92cbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19125924-152b-4588-97e7-8924a0af8380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19125924-152b-4588-97e7-8924a0af8380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dba6c98e-9b92-469d-bfc9-d183d467a7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dba6c98e-9b92-469d-bfc9-d183d467a7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_60afaf68-7a1d-429d-b858-b98e40f6409c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_60afaf68-7a1d-429d-b858-b98e40f6409c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_46de280c-b0e9-4d49-9fe0-c6c2cea5fd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_ProfitLoss_46de280c-b0e9-4d49-9fe0-c6c2cea5fd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b5307721-d05f-4161-941e-92cc70347582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_Depreciation_b5307721-d05f-4161-941e-92cc70347582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_80bb9f58-c9d6-4d34-a8d5-fb5278fc5796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e1b21cf-a27a-435f-95e5-1637017760e2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_80bb9f58-c9d6-4d34-a8d5-fb5278fc5796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c38e1c43-61e4-4773-a10d-292c7f7973bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_PaymentsOfDividends_c38e1c43-61e4-4773-a10d-292c7f7973bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6c9f611e-10f1-4e5c-bff4-700d9dab5a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6c9f611e-10f1-4e5c-bff4-700d9dab5a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_544bcb31-7c0b-477d-b342-dd6dee09f4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_544bcb31-7c0b-477d-b342-dd6dee09f4d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_645b4ba7-ee59-481c-aafc-63024a45e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_645b4ba7-ee59-481c-aafc-63024a45e0c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_53bd8bd1-f2a7-40de-81e8-9e822a3a53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_53bd8bd1-f2a7-40de-81e8-9e822a3a53a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31309d74-2c52-4227-a90b-e76cb3dff733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31309d74-2c52-4227-a90b-e76cb3dff733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26afa265-8b88-439e-a1c9-d83ef0d1bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c92cb8b-e69a-402c-9ae9-740d202518bb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26afa265-8b88-439e-a1c9-d83ef0d1bfa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_657c448f-b82a-452c-b90b-d453064686a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d9182a5-e378-4b41-aaa0-f4ecfc04fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_657c448f-b82a-452c-b90b-d453064686a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d9182a5-e378-4b41-aaa0-f4ecfc04fb2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f00e911-1cee-43fd-a235-d565790ed74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_657c448f-b82a-452c-b90b-d453064686a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f00e911-1cee-43fd-a235-d565790ed74e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ce0db2a5-7287-41c4-b1ad-445715004707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_657c448f-b82a-452c-b90b-d453064686a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ce0db2a5-7287-41c4-b1ad-445715004707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_466bdfae-c4aa-45e2-bdc4-0074ae9f7dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_657c448f-b82a-452c-b90b-d453064686a2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_466bdfae-c4aa-45e2-bdc4-0074ae9f7dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97818d72-2587-49c7-ba48-67b4b621a7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0fdcded5-3411-4bd9-a77d-5984a8cb0dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97818d72-2587-49c7-ba48-67b4b621a7e5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0fdcded5-3411-4bd9-a77d-5984a8cb0dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5b35a490-df25-44ee-a5ed-9b2069315308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97818d72-2587-49c7-ba48-67b4b621a7e5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5b35a490-df25-44ee-a5ed-9b2069315308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_8dfadd0d-eb41-4bcf-8f57-539675e79ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97818d72-2587-49c7-ba48-67b4b621a7e5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_8dfadd0d-eb41-4bcf-8f57-539675e79ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_608d1414-7f68-4477-b05f-be373e68265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97818d72-2587-49c7-ba48-67b4b621a7e5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_608d1414-7f68-4477-b05f-be373e68265e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_25c9b611-e1f4-4f21-b347-2e50acf3ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97818d72-2587-49c7-ba48-67b4b621a7e5" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_25c9b611-e1f4-4f21-b347-2e50acf3ef21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#SupplementalFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8c56a2ff-d222-4f52-820c-81f372736f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_169a007f-22ec-4ae0-9039-695a6b5afe18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8c56a2ff-d222-4f52-820c-81f372736f1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_169a007f-22ec-4ae0-9039-695a6b5afe18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba96fb90-bec2-47b5-a4d5-3188112bcc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8c56a2ff-d222-4f52-820c-81f372736f1e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba96fb90-bec2-47b5-a4d5-3188112bcc9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_92d38d80-3cd3-4274-910f-4ffbc52b94ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_051db75f-22b1-4ae1-ae92-e05d7b8a79cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_92d38d80-3cd3-4274-910f-4ffbc52b94ea" xlink:to="loc_us-gaap_InterestExpense_051db75f-22b1-4ae1-ae92-e05d7b8a79cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_42770411-3771-404e-b202-8ee9e35e5bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_92d38d80-3cd3-4274-910f-4ffbc52b94ea" xlink:to="loc_us-gaap_InvestmentIncomeInterest_42770411-3771-404e-b202-8ee9e35e5bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_53b816a8-2252-41c8-94b9-cfc163568fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_43222e00-d1c3-4c16-9953-33ad7fdcd567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_53b816a8-2252-41c8-94b9-cfc163568fd3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_43222e00-d1c3-4c16-9953-33ad7fdcd567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6f508e02-87b7-42b7-8fc7-a90c8944c599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_53b816a8-2252-41c8-94b9-cfc163568fd3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6f508e02-87b7-42b7-8fc7-a90c8944c599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8693f926-8dad-4780-8288-05bc4ad10912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_53b816a8-2252-41c8-94b9-cfc163568fd3" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8693f926-8dad-4780-8288-05bc4ad10912" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4014e973-a662-44e1-aa21-8ce8cafa40b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7b49c9e-9aca-4649-837f-91b12e9635c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4014e973-a662-44e1-aa21-8ce8cafa40b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7b49c9e-9aca-4649-837f-91b12e9635c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f377e6dd-9ebd-4133-8feb-3f18862d2175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4014e973-a662-44e1-aa21-8ce8cafa40b1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f377e6dd-9ebd-4133-8feb-3f18862d2175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_74b50174-c329-4d73-91f1-d30cd7ae08a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cd9eacc9-faf4-41fc-8e24-01357895b099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_74b50174-c329-4d73-91f1-d30cd7ae08a2" xlink:to="loc_us-gaap_NetIncomeLoss_cd9eacc9-faf4-41fc-8e24-01357895b099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_7b842c39-c294-41cf-823d-d2e5bf3af1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_74b50174-c329-4d73-91f1-d30cd7ae08a2" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_7b842c39-c294-41cf-823d-d2e5bf3af1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cf4c02d5-9641-45bc-a2ee-8af6aff9f22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_65f6365f-4626-4855-be10-3255da3657f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cf4c02d5-9641-45bc-a2ee-8af6aff9f22e" xlink:to="loc_us-gaap_NetIncomeLoss_65f6365f-4626-4855-be10-3255da3657f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_97550a70-ac68-4524-b4b0-39edf1b02ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cf4c02d5-9641-45bc-a2ee-8af6aff9f22e" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_97550a70-ac68-4524-b4b0-39edf1b02ec0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36eedf5d-915a-43f6-a89f-7935f5f050f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4c63d7cb-7b78-4b7c-8d0e-403048285383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36eedf5d-915a-43f6-a89f-7935f5f050f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4c63d7cb-7b78-4b7c-8d0e-403048285383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5edd63f8-6cd4-438a-a503-5b242bce422b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36eedf5d-915a-43f6-a89f-7935f5f050f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5edd63f8-6cd4-438a-a503-5b242bce422b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7ae0f137-a828-4f44-8cf1-84b771147723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_7971a2df-3cfd-4738-a574-d36e476b688a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_7ae0f137-a828-4f44-8cf1-84b771147723" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_7971a2df-3cfd-4738-a574-d36e476b688a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0cff2b03-bb41-4f7e-a8f1-134510275d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_7ae0f137-a828-4f44-8cf1-84b771147723" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0cff2b03-bb41-4f7e-a8f1-134510275d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a56fa76e-06c0-4531-a2df-dd5e6efb05ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_7ae0f137-a828-4f44-8cf1-84b771147723" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a56fa76e-06c0-4531-a2df-dd5e6efb05ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e4bdccc-5814-4aef-9a7b-c3348f024b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33419642-74ce-4353-acaa-0b5afc1de8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4e4bdccc-5814-4aef-9a7b-c3348f024b11" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33419642-74ce-4353-acaa-0b5afc1de8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd4e53f2-8b77-4a09-a67d-cb405e590882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4e4bdccc-5814-4aef-9a7b-c3348f024b11" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd4e53f2-8b77-4a09-a67d-cb405e590882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_ee6a3b40-f4a0-44f0-afe9-22aade3c4aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4e4bdccc-5814-4aef-9a7b-c3348f024b11" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_ee6a3b40-f4a0-44f0-afe9-22aade3c4aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_b43cad41-214e-47aa-8dc4-ced7ca0c98ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4e4bdccc-5814-4aef-9a7b-c3348f024b11" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_b43cad41-214e-47aa-8dc4-ced7ca0c98ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c519683d-ba11-477f-b45d-334e2c636c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4e4bdccc-5814-4aef-9a7b-c3348f024b11" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c519683d-ba11-477f-b45d-334e2c636c41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e635c1c1-f30d-4bba-8d12-d7f6cb8af48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_776832e9-6192-4506-85ae-4e656f8c84a5" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e635c1c1-f30d-4bba-8d12-d7f6cb8af48a" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_776832e9-6192-4506-85ae-4e656f8c84a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_ca9d31dd-69dd-45f5-bb03-39e04ceb9ca2" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e635c1c1-f30d-4bba-8d12-d7f6cb8af48a" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_ca9d31dd-69dd-45f5-bb03-39e04ceb9ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue_bcce3fa8-be9b-4964-b6ff-2fa25c98fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e635c1c1-f30d-4bba-8d12-d7f6cb8af48a" xlink:to="loc_us-gaap_ShorttermDebtFairValue_bcce3fa8-be9b-4964-b6ff-2fa25c98fe39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#PostEmploymentBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8f3101ea-2b04-4f8e-b317-1903c95eea96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_22aefd5b-4c78-4037-ba96-e1b39aa50bf5" xlink:href="abbv-20220331.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8f3101ea-2b04-4f8e-b317-1903c95eea96" xlink:to="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_22aefd5b-4c78-4037-ba96-e1b39aa50bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_2ffdcde3-9337-4b65-aaf8-a8a3c3f355cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8f3101ea-2b04-4f8e-b317-1903c95eea96" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_2ffdcde3-9337-4b65-aaf8-a8a3c3f355cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_aae4c678-c003-44e1-9a64-0c9ec58c335e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8f3101ea-2b04-4f8e-b317-1903c95eea96" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_aae4c678-c003-44e1-9a64-0c9ec58c335e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_73f614db-e2d9-4272-ab6c-b506f45335a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8f3101ea-2b04-4f8e-b317-1903c95eea96" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_73f614db-e2d9-4272-ab6c-b506f45335a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8f6d6fc1-4671-4089-8f6f-ec78aa35624e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8f3101ea-2b04-4f8e-b317-1903c95eea96" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8f6d6fc1-4671-4089-8f6f-ec78aa35624e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d1523723-38e6-4e47-9404-95fb950acb37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d6705d84-c97e-4bf0-acfd-3e66b617d446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d1523723-38e6-4e47-9404-95fb950acb37" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d6705d84-c97e-4bf0-acfd-3e66b617d446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_39f1951e-e44e-4fe1-b2d0-64ae92096308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d1523723-38e6-4e47-9404-95fb950acb37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_39f1951e-e44e-4fe1-b2d0-64ae92096308" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c8e97469-bcc7-45cb-ac15-881550e5ec39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_97b0d591-6019-440d-a256-173ffde64287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c8e97469-bcc7-45cb-ac15-881550e5ec39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_97b0d591-6019-440d-a256-173ffde64287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1099f76b-d612-4b94-bb8c-9e53bc61627f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c8e97469-bcc7-45cb-ac15-881550e5ec39" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1099f76b-d612-4b94-bb8c-9e53bc61627f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2bceac9d-388c-4b3a-b8f7-48875e3f8f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7a842458-8649-43e5-a942-d27ab45f6445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2bceac9d-388c-4b3a-b8f7-48875e3f8f48" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7a842458-8649-43e5-a942-d27ab45f6445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66108a74-92de-4581-bf89-51b88a6a1e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2bceac9d-388c-4b3a-b8f7-48875e3f8f48" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_66108a74-92de-4581-bf89-51b88a6a1e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0ba22771-d1b4-4c15-b3af-39c1f8ac00e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2bceac9d-388c-4b3a-b8f7-48875e3f8f48" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0ba22771-d1b4-4c15-b3af-39c1f8ac00e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_20c867d1-8c4e-4d02-aef3-fe8658d96510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_74eaa487-61ef-4e2a-8ca7-6c8c6f0b27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_20c867d1-8c4e-4d02-aef3-fe8658d96510" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_74eaa487-61ef-4e2a-8ca7-6c8c6f0b27ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_7fb78d46-ccb0-425f-865e-aceeeeafa676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_20c867d1-8c4e-4d02-aef3-fe8658d96510" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_7fb78d46-ccb0-425f-865e-aceeeeafa676" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>abbv-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56dec8fe-bb4b-4711-9c82-c533c008edd6,g:2a065e27-cccc-4ae9-a029-5c29f5f60184-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="abbv-20220331.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="extended" id="i530a4b47f35844cd88c43825a30222f2_DocumentandEntityInformation">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8d014947-dff8-425d-9083-91d1c75b7408" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentType_8d014947-dff8-425d-9083-91d1c75b7408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_06bc5f17-292b-4eb2-beaa-45833c684d70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentQuarterlyReport_06bc5f17-292b-4eb2-beaa-45833c684d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4bd63c43-e06a-443a-bfaa-c1a4c8ef9795" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentPeriodEndDate_4bd63c43-e06a-443a-bfaa-c1a4c8ef9795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a3f5d213-3054-49c5-ba46-771cb5d30725" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentTransitionReport_a3f5d213-3054-49c5-ba46-771cb5d30725" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_22521a55-628f-45d1-bbdb-b4c41808123e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityFileNumber_22521a55-628f-45d1-bbdb-b4c41808123e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3a2713dc-dac1-431d-96df-65b82f883db0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityRegistrantName_3a2713dc-dac1-431d-96df-65b82f883db0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_74f55100-2711-4cb5-a50b-ef40276c8322" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityCentralIndexKey_74f55100-2711-4cb5-a50b-ef40276c8322" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ef9e4093-4b27-4df3-981a-e14c49115ee8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentFiscalYearFocus_ef9e4093-4b27-4df3-981a-e14c49115ee8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_28183f7b-65bf-4b5c-853a-a1ba02fd0986" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentFiscalPeriodFocus_28183f7b-65bf-4b5c-853a-a1ba02fd0986" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e2eea5ba-b8c9-41b2-8943-5278003264d6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_AmendmentFlag_e2eea5ba-b8c9-41b2-8943-5278003264d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6d2980b4-0e3a-4000-b064-34a6924fd531" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_CurrentFiscalYearEndDate_6d2980b4-0e3a-4000-b064-34a6924fd531" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f9b58a66-3a9f-44fe-97d5-cdaf00582a78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f9b58a66-3a9f-44fe-97d5-cdaf00582a78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e06a3ba7-e10f-47f9-913c-781f292d4578" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityTaxIdentificationNumber_e06a3ba7-e10f-47f9-913c-781f292d4578" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b287d33c-e9ba-49ee-be7e-8765754880d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressAddressLine1_b287d33c-e9ba-49ee-be7e-8765754880d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0c692742-ec6f-4b6c-9a92-c91d487a9604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressCityOrTown_0c692742-ec6f-4b6c-9a92-c91d487a9604" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aafdbe9b-a582-46ec-af60-a5f6630e6831" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressStateOrProvince_aafdbe9b-a582-46ec-af60-a5f6630e6831" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_57237ca4-fb27-434c-8619-a4c1420c7350" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressPostalZipCode_57237ca4-fb27-434c-8619-a4c1420c7350" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ebd24db5-ac20-4bcf-a109-edec366da6c0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_CityAreaCode_ebd24db5-ac20-4bcf-a109-edec366da6c0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f21f7238-0d13-4005-962f-e5b4aad830f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_LocalPhoneNumber_f21f7238-0d13-4005-962f-e5b4aad830f3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_071d612c-7fc9-495f-9a10-444c37c04cc7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityCurrentReportingStatus_071d612c-7fc9-495f-9a10-444c37c04cc7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6bdec3ae-7715-4dc1-9e5f-be17c6b3e9f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityInteractiveDataCurrent_6bdec3ae-7715-4dc1-9e5f-be17c6b3e9f1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c0acc87f-4a8c-4615-8788-e3361af0d620" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityFilerCategory_c0acc87f-4a8c-4615-8788-e3361af0d620" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5b5327c6-c5e6-43a7-a395-e60e1d31e76e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntitySmallBusiness_5b5327c6-c5e6-43a7-a395-e60e1d31e76e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_574017b0-a0b2-43f2-9562-272b67cdabc9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityEmergingGrowthCompany_574017b0-a0b2-43f2-9562-272b67cdabc9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_53d2ecf1-24d2-4342-9e61-d7538c0221dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityShellCompany_53d2ecf1-24d2-4342-9e61-d7538c0221dc" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc89783d-e506-4aca-997a-2acd2b8becd6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_SecurityExchangeName_dc89783d-e506-4aca-997a-2acd2b8becd6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_75dd2544-8eab-4676-94ee-e2c0919bc8c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_Security12bTitle_75dd2544-8eab-4676-94ee-e2c0919bc8c4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8084e4b1-fff0-4051-b599-a11f262a066d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_TradingSymbol_8084e4b1-fff0-4051-b599-a11f262a066d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c33ad587-73e4-4113-a673-aa1cc2b463e5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c33ad587-73e4-4113-a673-aa1cc2b463e5" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:to="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_f5cefcf8-f8f5-461a-9020-db743dbe9f78_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:to="loc_dei_ExchangeDomain_f5cefcf8-f8f5-461a-9020-db743dbe9f78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:to="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_d193ad1f-96ea-410e-b948-8900548208c0" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:to="loc_exch_XNYS_d193ad1f-96ea-410e-b948-8900548208c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_106a1e2a-b7bc-474d-b95d-169bd0ada64d" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XCHI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:to="loc_exch_XCHI_106a1e2a-b7bc-474d-b95d-169bd0ada64d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e89f89f2-9618-4b40-a207-d0aaaf93606a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:to="loc_us-gaap_ClassOfStockDomain_e89f89f2-9618-4b40-a207-d0aaaf93606a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:to="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01b95985-5a7c-4f3b-ac81-fbaa45aa0256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_us-gaap_CommonStockMember_01b95985-5a7c-4f3b-ac81-fbaa45aa0256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member_299f37bc-9f31-408f-b556-ca3014614743" xlink:href="abbv-20220331.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1500SeniorNotesDue2023Member_299f37bc-9f31-408f-b556-ca3014614743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_74e604b3-e80a-451e-a797-5f5e0537a9ad" xlink:href="abbv-20220331.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_74e604b3-e80a-451e-a797-5f5e0537a9ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_fa5f79f0-857b-4b1a-b151-da3787387e2b" xlink:href="abbv-20220331.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_fa5f79f0-857b-4b1a-b151-da3787387e2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_de94130e-0fc8-4b40-bfae-8e5fc79382d0" xlink:href="abbv-20220331.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_de94130e-0fc8-4b40-bfae-8e5fc79382d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_4f0423c2-84d7-45a5-80c9-917e2c00e3ef" xlink:href="abbv-20220331.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_4f0423c2-84d7-45a5-80c9-917e2c00e3ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_384e0566-7981-4b4b-b878-5235206601c4" xlink:href="abbv-20220331.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_384e0566-7981-4b4b-b878-5235206601c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_fdfe52e3-4d9b-4472-88bf-1edead00bd39" xlink:href="abbv-20220331.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_fdfe52e3-4d9b-4472-88bf-1edead00bd39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_9f1055d9-6020-4854-b8c2-8a2534df2472" xlink:href="abbv-20220331.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_9f1055d9-6020-4854-b8c2-8a2534df2472" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="extended" id="idfb6c6d98d854e8d85ea7b62c6b7f60a_CondensedConsolidatedStatementsofEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_12b8376f-9c8b-4f88-88ae-e7357a0e8562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12b8376f-9c8b-4f88-88ae-e7357a0e8562" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3f61d56-263d-4d92-97d3-d16fdfb57989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3f61d56-263d-4d92-97d3-d16fdfb57989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6ab9ee2d-673a-49a7-8b4a-1c5b5db45b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_SharesOutstanding_6ab9ee2d-673a-49a7-8b4a-1c5b5db45b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3843ee64-2f9a-469c-b11d-d2f90f1b333d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_NetIncomeLoss_3843ee64-2f9a-469c-b11d-d2f90f1b333d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19d0d431-11fb-404b-95cb-4ee9775f51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19d0d431-11fb-404b-95cb-4ee9775f51fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7cb5db5e-dd56-4e62-92db-f8465aa2faba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_DividendsCommonStockCash_7cb5db5e-dd56-4e62-92db-f8465aa2faba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_433db83c-2c5e-494b-815c-b0708b407ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_433db83c-2c5e-494b-815c-b0708b407ba8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_be376fb9-6a4b-464b-8432-2203538c9517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_be376fb9-6a4b-464b-8432-2203538c9517" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_face21c2-8798-43b1-a8f4-a23c8a8a1542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_face21c2-8798-43b1-a8f4-a23c8a8a1542" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a0e61201-c379-4f82-bfc9-ef3b8b2f5672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a0e61201-c379-4f82-bfc9-ef3b8b2f5672" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_863849c2-bb7e-49f8-9c19-9a32355ea1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_863849c2-bb7e-49f8-9c19-9a32355ea1af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b27d6d3d-4322-4a75-89e5-317db3018b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_57396afa-d958-45d7-a241-443719f6ef97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_12b8376f-9c8b-4f88-88ae-e7357a0e8562" xlink:to="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8c15386-4577-42bc-ae04-255e3a4fb3fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:to="loc_us-gaap_EquityComponentDomain_d8c15386-4577-42bc-ae04-255e3a4fb3fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:to="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9bd90ce-6035-43cd-8e4a-e2a858405164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_CommonStockMember_e9bd90ce-6035-43cd-8e4a-e2a858405164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b4c3f5e-9ef4-41a9-9f1a-2c28bd45ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_TreasuryStockMember_2b4c3f5e-9ef4-41a9-9f1a-2c28bd45ff77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0b238cd4-133f-448b-9e4a-062c4b117ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0b238cd4-133f-448b-9e4a-062c4b117ee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9197ff93-90dd-488d-ad59-5bf2e01e2365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_RetainedEarningsMember_9197ff93-90dd-488d-ad59-5bf2e01e2365" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3f542ac9-a6e1-407e-8f90-d5260d38fa58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3f542ac9-a6e1-407e-8f90-d5260d38fa58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6b1f62b4-b474-4140-8f12-8a2a1375ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6b1f62b4-b474-4140-8f12-8a2a1375ec5a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#LicensingAcquisitionsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="extended" id="ie1a95bf197c24712ace1667f619fe5aa_LicensingAcquisitionsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_68b26173-d44c-4b05-beaf-40105c24fb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_68b26173-d44c-4b05-beaf-40105c24fb3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0555eb80-98f7-476e-9759-33574b620e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0555eb80-98f7-476e-9759-33574b620e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_262dd832-fe31-497e-a4c5-33d859857037" xlink:href="abbv-20220331.xsd#abbv_PotentialPaymentsUnderAgreementCertainMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_262dd832-fe31-497e-a4c5-33d859857037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02f2e785-430e-48ba-a5f1-34ec87cbddda_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02f2e785-430e-48ba-a5f1-34ec87cbddda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc0838ff-4c28-490c-8a0e-15630c6f1752" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc0838ff-4c28-490c-8a0e-15630c6f1752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SyndesiMember_c23a8cc2-6aaf-4700-9512-1e11fabc9e58" xlink:href="abbv-20220331.xsd#abbv_SyndesiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc0838ff-4c28-490c-8a0e-15630c6f1752" xlink:to="loc_abbv_SyndesiMember_c23a8cc2-6aaf-4700-9512-1e11fabc9e58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92a1bec5-31bc-4802-935e-9f41dd64aa1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92a1bec5-31bc-4802-935e-9f41dd64aa1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14775ee7-7569-4ddf-bb29-9e89bea09157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14775ee7-7569-4ddf-bb29-9e89bea09157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b6da50e0-3caf-4086-86bf-b982458515f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14775ee7-7569-4ddf-bb29-9e89bea09157" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b6da50e0-3caf-4086-86bf-b982458515f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a961665e-ca05-47ad-8510-6a92d9dafb78_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:to="loc_srt_RangeMember_a961665e-ca05-47ad-8510-6a92d9dafb78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec2218c6-2270-4056-8d15-ee7893c1a89d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:to="loc_srt_RangeMember_ec2218c6-2270-4056-8d15-ee7893c1a89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cfdffbb3-f3cd-4d9b-a71c-c871c7d59f2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ec2218c6-2270-4056-8d15-ee7893c1a89d" xlink:to="loc_srt_MaximumMember_cfdffbb3-f3cd-4d9b-a71c-c871c7d59f2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43417ec6-6929-49d7-9c9f-c18982797fc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43417ec6-6929-49d7-9c9f-c18982797fc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8536afa7-7ad9-43cf-bcb6-511cebb8ec44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8536afa7-7ad9-43cf-bcb6-511cebb8ec44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_36daec53-9db5-4b1f-b393-ab138c7b3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8536afa7-7ad9-43cf-bcb6-511cebb8ec44" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_36daec53-9db5-4b1f-b393-ab138c7b3a81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#CollaborationsTables"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/CollaborationsTables" xlink:type="extended" id="i420b338be092447c89a60c4993c628bf_CollaborationsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e87c6f0-649a-4eb8-893f-0dc933d8aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_b5d1b2b5-e7b0-45c4-921f-20febd33757b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e87c6f0-649a-4eb8-893f-0dc933d8aabf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_b5d1b2b5-e7b0-45c4-921f-20febd33757b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e87c6f0-649a-4eb8-893f-0dc933d8aabf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:to="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5017c204-33b6-4562-8e48-1bb7dd3c4b1c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5017c204-33b6-4562-8e48-1bb7dd3c4b1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_d369c64b-b4f8-4184-8971-94347088b62f" xlink:href="abbv-20220331.xsd#abbv_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:to="loc_abbv_JanssenBiotechIncMember_d369c64b-b4f8-4184-8971-94347088b62f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_4a9fa1bf-1bb4-4e6b-9e04-d0f1a7838101" xlink:href="abbv-20220331.xsd#abbv_GenentechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:to="loc_abbv_GenentechInc.Member_4a9fa1bf-1bb4-4e6b-9e04-d0f1a7838101" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#CollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="extended" id="i1c82fb4b2a4e4826b79a31e9f659568f_CollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_b54e3a2d-5c6d-490b-abb8-5aa1ba8b3242" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_b54e3a2d-5c6d-490b-abb8-5aa1ba8b3242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_cc3ccec3-8df0-4599-816a-69c097399b27" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_cc3ccec3-8df0-4599-816a-69c097399b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_f28c62a4-8230-45b9-a3c1-4d956a79b4a4" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_f28c62a4-8230-45b9-a3c1-4d956a79b4a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_887daee4-25fb-421b-a437-f5ea163d5b3c" xlink:href="abbv-20220331.xsd#abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_887daee4-25fb-421b-a437-f5ea163d5b3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_841345e1-fb82-48df-8842-e87fee77780c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_841345e1-fb82-48df-8842-e87fee77780c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherExpensesFromCollaborativeArrangements_592851c1-cee8-4d05-8ea0-12919c137ac6" xlink:href="abbv-20220331.xsd#abbv_OtherExpensesFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_OtherExpensesFromCollaborativeArrangements_592851c1-cee8-4d05-8ea0-12919c137ac6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_612bd560-42cf-4013-9191-53960be617e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_612bd560-42cf-4013-9191-53960be617e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb414fa1-03a5-4661-abd0-9d8da2556418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb414fa1-03a5-4661-abd0-9d8da2556418" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_5d565fba-bf84-44a6-86b0-9a9e07825fb2" xlink:href="abbv-20220331.xsd#abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_5d565fba-bf84-44a6-86b0-9a9e07825fb2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_b58cf2ad-a705-4d7f-9d73-80b220920489" xlink:href="abbv-20220331.xsd#abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_b58cf2ad-a705-4d7f-9d73-80b220920489" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4abcafcb-0078-48f5-a92c-90839ab260e6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4abcafcb-0078-48f5-a92c-90839ab260e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_1e43541b-56a5-409b-aaf4-8a0d2961b691" xlink:href="abbv-20220331.xsd#abbv_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:to="loc_abbv_JanssenBiotechIncMember_1e43541b-56a5-409b-aaf4-8a0d2961b691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_4b438749-c231-4958-a26c-58cba28ad3ab" xlink:href="abbv-20220331.xsd#abbv_GenentechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:to="loc_abbv_GenentechInc.Member_4b438749-c231-4958-a26c-58cba28ad3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0bc18db-4158-4b52-aeb8-5011a8cf91b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0bc18db-4158-4b52-aeb8-5011a8cf91b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a3efe3c-334a-41aa-8aab-ace80e688b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a3efe3c-334a-41aa-8aab-ace80e688b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_53c6dfac-4888-4ad1-8430-5fa1b433b067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a3efe3c-334a-41aa-8aab-ace80e688b00" xlink:to="loc_us-gaap_CollaborativeArrangementMember_53c6dfac-4888-4ad1-8430-5fa1b433b067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eaf8156b-fe8e-47a6-a810-2cebca22a043_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:to="loc_srt_SegmentGeographicalDomain_eaf8156b-fe8e-47a6-a810-2cebca22a043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:to="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_54a5dc8c-99ed-44a9-adde-b648867f0c58" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:to="loc_country_US_54a5dc8c-99ed-44a9-adde-b648867f0c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_8ed7a902-83a8-4221-861f-5c75fe1f5bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:to="loc_us-gaap_NonUsMember_8ed7a902-83a8-4221-861f-5c75fe1f5bdd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="extended" id="if9cb17c2f8ad406e92c9b294f968180a_GoodwillandIntangibleAssetsIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1aedd471-52e7-43d9-9195-35c23c795ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1aedd471-52e7-43d9-9195-35c23c795ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4914c2db-5997-47b4-9b6a-64ef081dd5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4914c2db-5997-47b4-9b6a-64ef081dd5cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9af4351f-0416-4a9b-af15-53bea3897d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9af4351f-0416-4a9b-af15-53bea3897d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e82dabf1-0406-4a94-827b-3acd5481b6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e82dabf1-0406-4a94-827b-3acd5481b6c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b56840d2-ba7a-4c18-b359-3fd9f153b6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b56840d2-ba7a-4c18-b359-3fd9f153b6ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5e972b49-ca0f-4809-840a-cd5b1704ee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5e972b49-ca0f-4809-840a-cd5b1704ee51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9905d461-06da-479d-93c8-0c11cce6f0b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9905d461-06da-479d-93c8-0c11cce6f0b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5efdd12b-7dee-4023-8ef4-60b8ab9a3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5efdd12b-7dee-4023-8ef4-60b8ab9a3bb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3d88affd-9083-4303-8f15-bb87cbb0b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:to="loc_us-gaap_LicensingAgreementsMember_3d88affd-9083-4303-8f15-bb87cbb0b5aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#IntegrationandRestructuringPlansTables"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="extended" id="i7f19fb66415f420a9a1cdf24d211d7ea_IntegrationandRestructuringPlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1fbdf2d5-0c58-4753-b93f-999f04f08591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1fbdf2d5-0c58-4753-b93f-999f04f08591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ad65b25f-a6b4-4a16-9ae8-7ba19f35d2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ad65b25f-a6b4-4a16-9ae8-7ba19f35d2b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:to="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_2e2f5e29-73f2-432f-a86a-719acb47e669_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:to="loc_us-gaap_RestructuringPlanDomain_2e2f5e29-73f2-432f-a86a-719acb47e669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:to="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_2fcdc20c-699c-4b71-9ecd-49fc67a80245" xlink:href="abbv-20220331.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:to="loc_abbv_AllerganIntegrationPlanMember_2fcdc20c-699c-4b71-9ecd-49fc67a80245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_cd2805ca-4461-4474-9105-54bb8547190d" xlink:href="abbv-20220331.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:to="loc_abbv_OtherRestructuringPlansMember_cd2805ca-4461-4474-9105-54bb8547190d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#IntegrationandRestructuringPlansDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="extended" id="i4969a9851cec4a109c428405d31f89a4_IntegrationandRestructuringPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f6cdd7f3-8af4-40fb-a857-4d6170fac64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f6cdd7f3-8af4-40fb-a857-4d6170fac64f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1b650b75-ef9d-42a4-8c78-4fa72ad50787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1b650b75-ef9d-42a4-8c78-4fa72ad50787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7ea3afb2-695c-45db-9d49-dee5e57230e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_us-gaap_RestructuringReserve_7ea3afb2-695c-45db-9d49-dee5e57230e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_cdbf08b9-9122-4443-b350-0b59db47a872" xlink:href="abbv-20220331.xsd#abbv_RestructuringReserveCashSettledRestructuringGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_cdbf08b9-9122-4443-b350-0b59db47a872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_100cd326-d81a-4f43-9566-a94fb46a6adf" xlink:href="abbv-20220331.xsd#abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_100cd326-d81a-4f43-9566-a94fb46a6adf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_278da9e9-888a-424f-927e-4d2fcb6c48a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0f46c812-3cbe-46b7-8a68-7affd74e7d5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:to="loc_us-gaap_RestructuringPlanDomain_0f46c812-3cbe-46b7-8a68-7affd74e7d5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:to="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_06a446dc-dd79-4948-ba05-fba334a16725" xlink:href="abbv-20220331.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:to="loc_abbv_AllerganIntegrationPlanMember_06a446dc-dd79-4948-ba05-fba334a16725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_cd999699-c89a-4511-933c-467d9ba040e7" xlink:href="abbv-20220331.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:to="loc_abbv_OtherRestructuringPlansMember_cd999699-c89a-4511-933c-467d9ba040e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e2d90b66-7646-4e35-b304-c2ca9189ff61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e2d90b66-7646-4e35-b304-c2ca9189ff61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_499e2155-e406-4e3b-945b-5fc340c4619e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_499e2155-e406-4e3b-945b-5fc340c4619e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_4dbad78c-a212-445c-a631-ac9a15420924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:to="loc_us-gaap_OtherRestructuringMember_4dbad78c-a212-445c-a631-ac9a15420924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_abaac714-41e6-4797-bf81-4f6fea384931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_abaac714-41e6-4797-bf81-4f6fea384931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9b71b2a0-eff6-4e07-9081-87f26fc6ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:to="loc_us-gaap_CostOfSalesMember_9b71b2a0-eff6-4e07-9081-87f26fc6ec74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b348e742-8989-4fe0-8568-201269a14df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b348e742-8989-4fe0-8568-201269a14df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_693fc321-1556-40cf-a8c1-59ad8939fe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_693fc321-1556-40cf-a8c1-59ad8939fe9b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="extended" id="i59b00a8617f248408e743071be5a9129_FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_844e42a7-7f55-43c7-89f5-1ccc4cc28b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeNotionalAmount_844e42a7-7f55-43c7-89f5-1ccc4cc28b95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_83c4d0ea-dec7-4159-8f5f-bc41be6dd80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeTermOfContract_83c4d0ea-dec7-4159-8f5f-bc41be6dd80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_cdb0926d-3f4c-4e57-8502-280b2bcc0849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_cdb0926d-3f4c-4e57-8502-280b2bcc0849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fbd7c17e-33de-4c81-9742-b0e0824bdc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fbd7c17e-33de-4c81-9742-b0e0824bdc4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_e89676bd-ba98-4dfb-889a-8eb20912b7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_e89676bd-ba98-4dfb-889a-8eb20912b7a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_139ff5b6-0d38-4853-b6a8-f2a0b5741047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_139ff5b6-0d38-4853-b6a8-f2a0b5741047" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d03611fc-0fc3-48d7-b4bd-51be2603556f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d03611fc-0fc3-48d7-b4bd-51be2603556f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d2428-93b2-4836-a251-8d1231df5e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d2428-93b2-4836-a251-8d1231df5e99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fcddb258-342e-4045-97ef-ae9b728a3c54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:to="loc_us-gaap_HedgingDesignationDomain_fcddb258-342e-4045-97ef-ae9b728a3c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:to="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cb96db0-2114-4d60-bc8a-83e46ce8d6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cb96db0-2114-4d60-bc8a-83e46ce8d6f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2d956806-15f4-4f40-ba3b-9c2b35909c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:to="loc_us-gaap_NondesignatedMember_2d956806-15f4-4f40-ba3b-9c2b35909c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e527a9f6-22f9-42d1-a886-f418279b6c0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e527a9f6-22f9-42d1-a886-f418279b6c0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_784965d4-eadf-4868-93e4-ac4eca18711c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_784965d4-eadf-4868-93e4-ac4eca18711c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_d5c8b715-b2e4-439d-bca5-a2615957d793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:to="loc_us-gaap_TreasuryLockMember_d5c8b715-b2e4-439d-bca5-a2615957d793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5ad6612c-3d4c-464a-b7e7-ce21457a981d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:to="loc_us-gaap_InterestRateSwapMember_5ad6612c-3d4c-464a-b7e7-ce21457a981d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7e854cb3-f3a5-41ea-a1d0-419964c54e6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7e854cb3-f3a5-41ea-a1d0-419964c54e6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bb455877-6f5c-4a2a-9519-c2b61cf1da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:to="loc_us-gaap_CashFlowHedgingMember_bb455877-6f5c-4a2a-9519-c2b61cf1da3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ea867675-f283-4883-9e0d-f93b1570bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ea867675-f283-4883-9e0d-f93b1570bbb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b040b02c-cc46-4dbd-bdee-7003d32ca448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:to="loc_us-gaap_FairValueHedgingMember_b040b02c-cc46-4dbd-bdee-7003d32ca448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5afad1a5-94a7-4646-90c1-f3cac9680ae2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5afad1a5-94a7-4646-90c1-f3cac9680ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b76b51c2-1c24-4853-820e-37587ec4ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b76b51c2-1c24-4853-820e-37587ec4ec9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3bb6498b-f4b0-4bf8-9777-ca9a230f0c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b76b51c2-1c24-4853-820e-37587ec4ec9e" xlink:to="loc_us-gaap_SeniorNotesMember_3bb6498b-f4b0-4bf8-9777-ca9a230f0c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_da3ca75f-0367-4a14-aa85-317869fbe24a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_da3ca75f-0367-4a14-aa85-317869fbe24a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ab825570-74db-4103-b42e-56f52cf2304f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ab825570-74db-4103-b42e-56f52cf2304f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f6f8ec78-e8de-45e5-b47f-37418f24e326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f6f8ec78-e8de-45e5-b47f-37418f24e326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_4e0f1eaf-b27c-4e9d-ae5f-1ece9ba18e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_4e0f1eaf-b27c-4e9d-ae5f-1ece9ba18e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_7ff71237-e47d-447e-bb72-ce76b205627f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_OtherLiabilitiesMember_7ff71237-e47d-447e-bb72-ce76b205627f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="extended" id="i8903d8cd977044619e8b675959304ef0_FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d1b79351-1fe9-48fb-80d4-b587cf642a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d1b79351-1fe9-48fb-80d4-b587cf642a90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_462b7a4d-866a-42a9-9e5a-75a7fedf18e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_462b7a4d-866a-42a9-9e5a-75a7fedf18e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_b0642c77-0e93-40d1-97f2-c6a45ef76a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_b0642c77-0e93-40d1-97f2-c6a45ef76a5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_3eab89f2-8150-4c34-a1da-eccfc60444e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_3eab89f2-8150-4c34-a1da-eccfc60444e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_fd4b4ae4-e565-4191-b6b6-ad6f003d0ad3" xlink:href="abbv-20220331.xsd#abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_fd4b4ae4-e565-4191-b6b6-ad6f003d0ad3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e656c80a-5205-456a-8d19-d694b31b0620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e656c80a-5205-456a-8d19-d694b31b0620" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_ce339923-ad64-4aeb-8ba2-c62a9431df39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_ce339923-ad64-4aeb-8ba2-c62a9431df39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_8fef7cb3-c695-4cd7-9473-5c3590810165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_8fef7cb3-c695-4cd7-9473-5c3590810165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_76a08528-15be-47de-8c85-0757564a95c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:to="loc_us-gaap_InterestRateSwapMember_76a08528-15be-47de-8c85-0757564a95c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_7668dfd4-cafe-4dbc-b0e2-7135b5fd6c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:to="loc_us-gaap_TreasuryLockMember_7668dfd4-cafe-4dbc-b0e2-7135b5fd6c57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_257163c8-0023-4305-b003-2d2e6e566040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:to="loc_us-gaap_HedgingDesignationDomain_257163c8-0023-4305-b003-2d2e6e566040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:to="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa226e21-769c-46f2-8490-25060323e430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa226e21-769c-46f2-8490-25060323e430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_88659b97-d4a9-491e-a855-56880862b003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:to="loc_us-gaap_NondesignatedMember_88659b97-d4a9-491e-a855-56880862b003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_521be55e-bb53-405e-8a01-8a0ff99e1d36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_521be55e-bb53-405e-8a01-8a0ff99e1d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_15738f87-4a50-4935-8215-87c4482f93d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:to="loc_us-gaap_CostOfSalesMember_15738f87-4a50-4935-8215-87c4482f93d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_e4257612-0631-4026-989f-e3c756ce41ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:to="loc_us-gaap_InterestExpenseMember_e4257612-0631-4026-989f-e3c756ce41ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyGainLossMember_66c1f448-fee4-4c39-aceb-ef004394435e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:to="loc_us-gaap_ForeignCurrencyGainLossMember_66c1f448-fee4-4c39-aceb-ef004394435e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_066a1891-dc8e-40a4-82ba-b8d52400f6ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_066a1891-dc8e-40a4-82ba-b8d52400f6ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3007699b-8e8b-4a72-8783-aad30588c519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3007699b-8e8b-4a72-8783-aad30588c519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_397980d1-9545-4ea7-886e-65abaa65af9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3007699b-8e8b-4a72-8783-aad30588c519" xlink:to="loc_us-gaap_SeniorNotesMember_397980d1-9545-4ea7-886e-65abaa65af9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9d233d5f-1918-4ea5-9349-71866934db6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9d233d5f-1918-4ea5-9349-71866934db6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e6f9d834-21a4-431e-9c18-d8c2c78a0fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:to="loc_us-gaap_CashFlowHedgingMember_e6f9d834-21a4-431e-9c18-d8c2c78a0fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_63f73064-bbe1-4663-833e-a78b7df235af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_63f73064-bbe1-4663-833e-a78b7df235af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_9b8f17b8-9dbf-4623-b840-c4e4cdbf972b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:to="loc_us-gaap_FairValueHedgingMember_9b8f17b8-9dbf-4623-b840-c4e4cdbf972b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="extended" id="idc9aee8727044e5a9dc1185ffe98acb2_FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61f84972-eacb-4c72-877f-83cafce138f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61f84972-eacb-4c72-877f-83cafce138f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_99f937b6-871a-4a27-a2e6-c44b99b157c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_99f937b6-871a-4a27-a2e6-c44b99b157c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a072089-3a4e-4437-a48c-903d2551dbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a072089-3a4e-4437-a48c-903d2551dbc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f46d1c65-5402-4990-908f-ae8ed7951061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f46d1c65-5402-4990-908f-ae8ed7951061" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c89c7baa-91fa-4ace-a599-c332fe9ba454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c89c7baa-91fa-4ace-a599-c332fe9ba454" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_29468fc3-abc2-462a-b264-a50819e03a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_29468fc3-abc2-462a-b264-a50819e03a49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ad1c407c-ccef-45bb-8307-c1b873a0919e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ad1c407c-ccef-45bb-8307-c1b873a0919e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b772ccaa-ab86-4cad-9ba8-0cf255051f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b772ccaa-ab86-4cad-9ba8-0cf255051f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d2a5ca31-e50a-4829-8491-30d83524d31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d2a5ca31-e50a-4829-8491-30d83524d31d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a85c360c-d3db-4b9d-83ba-2b3771ef7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a85c360c-d3db-4b9d-83ba-2b3771ef7a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8741a89e-ff06-487e-b00a-3629218ab466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8741a89e-ff06-487e-b00a-3629218ab466" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_52d462ad-a14a-4ab6-9ca4-cda910cb766d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_52d462ad-a14a-4ab6-9ca4-cda910cb766d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2a84712c-1cf8-463a-afab-2412b421bdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2a84712c-1cf8-463a-afab-2412b421bdf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e1e1aea5-a830-4013-881d-f347a377fe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a84712c-1cf8-463a-afab-2412b421bdf1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e1e1aea5-a830-4013-881d-f347a377fe2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0ec18a53-4fba-4c6c-adfd-604cd353b478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0ec18a53-4fba-4c6c-adfd-604cd353b478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a108e7-ef12-4724-b4d0-583d046e0bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a108e7-ef12-4724-b4d0-583d046e0bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_84ac7e32-2915-4c3a-8881-b75b1a1fcb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a108e7-ef12-4724-b4d0-583d046e0bae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_84ac7e32-2915-4c3a-8881-b75b1a1fcb1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b8babb5-ecd4-4b05-bc81-9fd48349565b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b8babb5-ecd4-4b05-bc81-9fd48349565b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6578c5fc-4de9-4056-afe7-1716d0362d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6578c5fc-4de9-4056-afe7-1716d0362d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_838e752f-a59e-424d-bedf-b92443e39951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_838e752f-a59e-424d-bedf-b92443e39951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2b2dc8a9-24a3-4aa2-8e8b-83fb1efd7ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2b2dc8a9-24a3-4aa2-8e8b-83fb1efd7ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_96b78d07-30fa-43df-b7db-0fb58809c2ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_96b78d07-30fa-43df-b7db-0fb58809c2ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_62b18b87-1020-4a1f-a25a-6d70da902912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_62b18b87-1020-4a1f-a25a-6d70da902912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6030c419-f962-4816-ac22-e996a6a41c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_62b18b87-1020-4a1f-a25a-6d70da902912" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6030c419-f962-4816-ac22-e996a6a41c4f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="extended" id="ifc604768d1cb4325b602d2f0b5564a84_FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02047208-1474-42e8-a2e2-1ca7bbc4dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bd83bdd3-ef0a-4360-9697-7893a45da8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02047208-1474-42e8-a2e2-1ca7bbc4dd55" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bd83bdd3-ef0a-4360-9697-7893a45da8bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02047208-1474-42e8-a2e2-1ca7bbc4dd55" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:to="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7039ba95-b80e-464c-b681-965aef4fddd1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:to="loc_srt_RangeMember_7039ba95-b80e-464c-b681-965aef4fddd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:to="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_518a5cf6-d54b-405c-aee8-de4253eb66dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:to="loc_srt_WeightedAverageMember_518a5cf6-d54b-405c-aee8-de4253eb66dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08d2b223-66c1-411a-ba7c-7a7669b2051d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:to="loc_srt_MinimumMember_08d2b223-66c1-411a-ba7c-7a7669b2051d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_16ca6393-ad00-4599-8059-55831be9d288" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:to="loc_srt_MaximumMember_16ca6393-ad00-4599-8059-55831be9d288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_190fd039-3030-4f5b-83a6-31a1ab0168b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_190fd039-3030-4f5b-83a6-31a1ab0168b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b00eaebc-02d1-47de-b513-0433716b7910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b00eaebc-02d1-47de-b513-0433716b7910" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_3f5a2d6b-d84e-4ace-b8c7-bcf7ff26072e" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforUnachievedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_3f5a2d6b-d84e-4ace-b8c7-bcf7ff26072e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_3def7ae9-6f81-4287-8285-35818e124dd7" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_3def7ae9-6f81-4287-8285-35818e124dd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProjectedYearofPaymentsMember_f48f05ac-9282-4e40-8239-41241302bee0" xlink:href="abbv-20220331.xsd#abbv_ProjectedYearofPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProjectedYearofPaymentsMember_f48f05ac-9282-4e40-8239-41241302bee0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a2e3aa89-d458-401b-b71c-5a0ea794e601" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a2e3aa89-d458-401b-b71c-5a0ea794e601" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="extended" id="i4f2f03c0ca9b44e18c3181c8c9b3e62a_FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue_99ef7a71-db6c-4853-84b8-bc6139ea84dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_us-gaap_ShorttermDebtFairValue_99ef7a71-db6c-4853-84b8-bc6139ea84dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_165fe508-3d0f-4bdb-84ee-24a32b6c4f48" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_165fe508-3d0f-4bdb-84ee-24a32b6c4f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_b328a0bb-06f4-49eb-bfba-f2b787d53adb" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_b328a0bb-06f4-49eb-bfba-f2b787d53adb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c067c848-9eef-414c-a481-986bc4b4e914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c067c848-9eef-414c-a481-986bc4b4e914" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_39c0bff2-33e1-408d-9d2f-2c8a994ce428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_39c0bff2-33e1-408d-9d2f-2c8a994ce428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_62a94982-7101-4bd9-905f-4b93461c4c51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_62a94982-7101-4bd9-905f-4b93461c4c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2e87b020-e926-4b3c-b755-1b31f7923206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2e87b020-e926-4b3c-b755-1b31f7923206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9f98b8d9-3db0-4c86-b16c-abbc5bd5983c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9f98b8d9-3db0-4c86-b16c-abbc5bd5983c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c454bb3b-887d-41dc-a14b-48b77b443b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c454bb3b-887d-41dc-a14b-48b77b443b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b335ad60-c347-4e07-89ab-cf5a3860f0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b335ad60-c347-4e07-89ab-cf5a3860f0ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_296971b7-ee44-4697-9068-728514590877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_296971b7-ee44-4697-9068-728514590877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5c417168-7a82-48ce-87c8-fccf4e17935d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5c417168-7a82-48ce-87c8-fccf4e17935d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="extended" id="i1e7067326eb34f7c8601fbffc7c5c8d9_FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NumberOfPrincipalUSCustomers_c9aa957e-498a-4c80-91d6-048e62a0a6a1" xlink:href="abbv-20220331.xsd#abbv_NumberOfPrincipalUSCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:to="loc_abbv_NumberOfPrincipalUSCustomers_c9aa957e-498a-4c80-91d6-048e62a0a6a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1bad1ed0-adb4-4d51-b235-b0a001427f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1bad1ed0-adb4-4d51-b235-b0a001427f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:to="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b96c557-0e81-457d-8117-230e25f57ef8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b96c557-0e81-457d-8117-230e25f57ef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d77c03e4-479c-4ba2-9c4c-9613fd0657bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:to="loc_us-gaap_AccountsReceivableMember_d77c03e4-479c-4ba2-9c4c-9613fd0657bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4302f8ac-fa95-44e2-b166-a505e59cc26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:to="loc_us-gaap_SalesRevenueNetMember_4302f8ac-fa95-44e2-b166-a505e59cc26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_28509239-9fa0-4d5d-bf75-e49d702c1d6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_28509239-9fa0-4d5d-bf75-e49d702c1d6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_e8eeade3-b2b7-49d2-b11d-37404f4452ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_e8eeade3-b2b7-49d2-b11d-37404f4452ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_231e8927-c284-4288-9fd6-c5f4f39856c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_231e8927-c284-4288-9fd6-c5f4f39856c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e03f9d9d-de87-4f76-82fc-3014223d68bc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:to="loc_srt_ProductsAndServicesDomain_e03f9d9d-de87-4f76-82fc-3014223d68bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7622b386-b6c2-4643-b462-d5666a9e3559" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:to="loc_srt_ProductsAndServicesDomain_7622b386-b6c2-4643-b462-d5666a9e3559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_47cd9421-9e99-482f-8e6a-dd312be2b2ae" xlink:href="abbv-20220331.xsd#abbv_HUMIRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7622b386-b6c2-4643-b462-d5666a9e3559" xlink:to="loc_abbv_HUMIRAMember_47cd9421-9e99-482f-8e6a-dd312be2b2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9846d78d-62d6-4553-b820-e38ba5b10b55_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:to="loc_srt_NameOfMajorCustomerDomain_9846d78d-62d6-4553-b820-e38ba5b10b55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b4944d43-838a-4ee5-817a-be93e68d8493" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:to="loc_srt_NameOfMajorCustomerDomain_b4944d43-838a-4ee5-817a-be93e68d8493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrincipalUSCustomersMember_f8111b90-18ef-44bf-b63a-c12ba243a51b" xlink:href="abbv-20220331.xsd#abbv_PrincipalUSCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b4944d43-838a-4ee5-817a-be93e68d8493" xlink:to="loc_abbv_PrincipalUSCustomersMember_f8111b90-18ef-44bf-b63a-c12ba243a51b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="extended" id="i63d4e9a2359f4d18ab3883ef05a8dfc1_FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_a38281cc-26af-458e-98a7-f8bb356a7427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_a38281cc-26af-458e-98a7-f8bb356a7427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a452660-8c83-4a8f-a843-4e055a6c3220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a452660-8c83-4a8f-a843-4e055a6c3220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_e483808d-d840-4f3f-adfc-97461be565b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_e483808d-d840-4f3f-adfc-97461be565b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e89b183a-3dba-49fc-bc4e-75c9eaf2b17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtInstrumentTerm_e89b183a-3dba-49fc-bc4e-75c9eaf2b17a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2695bd79-4b2a-48c5-bcb6-66f7564a5bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_LongTermDebt_2695bd79-4b2a-48c5-bcb6-66f7564a5bef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1768035f-27e4-4a0b-b67d-1260320bc276_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1768035f-27e4-4a0b-b67d-1260320bc276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.450PercentMember_b2c1fe65-92eb-43a5-9b3b-a7ec1ef73cc5" xlink:href="abbv-20220331.xsd#abbv_SeniorNotesDue2022At3.450PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:to="loc_abbv_SeniorNotesDue2022At3.450PercentMember_b2c1fe65-92eb-43a5-9b3b-a7ec1ef73cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_6ae1adc1-794c-44d5-acd3-9b8e0ba481bb" xlink:href="abbv-20220331.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_6ae1adc1-794c-44d5-acd3-9b8e0ba481bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_02e9b48c-1293-4198-aa15-5a86b7016fb9" xlink:href="abbv-20220331.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_02e9b48c-1293-4198-aa15-5a86b7016fb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85abca0f-7dda-4ab6-abef-c97885ca33d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85abca0f-7dda-4ab6-abef-c97885ca33d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a2efc2ee-155a-4a64-b1ae-d531318bca97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:to="loc_us-gaap_SeniorNotesMember_a2efc2ee-155a-4a64-b1ae-d531318bca97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_88955b7a-0e13-4755-9e2c-f297cf0533ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:to="loc_us-gaap_LoansPayableMember_88955b7a-0e13-4755-9e2c-f297cf0533ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#PostEmploymentBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="extended" id="i6eba488c2b6d43bfa2609ba38882bf04_PostEmploymentBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_24f77b13-7c16-4019-9657-130ba12c43ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_24f77b13-7c16-4019-9657-130ba12c43ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_e713f42b-c466-47b1-8179-564a6e92275c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_e713f42b-c466-47b1-8179-564a6e92275c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_94bc429e-b4d1-4595-a711-1221ee61dbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_94bc429e-b4d1-4595-a711-1221ee61dbcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_3501a141-7669-4083-8aa9-91ccf31ec8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_3501a141-7669-4083-8aa9-91ccf31ec8e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_ecae36e4-f9df-4dc8-8507-03f3cbcc3239" xlink:href="abbv-20220331.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_ecae36e4-f9df-4dc8-8507-03f3cbcc3239" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ea8ea1be-173f-4dbf-9115-f4929516c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ea8ea1be-173f-4dbf-9115-f4929516c7cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9d5c3d07-3d7d-4487-9bc0-9e813960628a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9d5c3d07-3d7d-4487-9bc0-9e813960628a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ed5bb012-f5ba-495e-9c6f-84ca8dbeba11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ed5bb012-f5ba-495e-9c6f-84ca8dbeba11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a769f8d-a9f2-4f07-aecb-73eb9f3cb266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a769f8d-a9f2-4f07-aecb-73eb9f3cb266" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="extended" id="ibb0fa1b73cf54748ad02807b493df2f7_EquityStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bf21ca1-72a1-46c2-a6c9-a3ada5f3eaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bf21ca1-72a1-46c2-a6c9-a3ada5f3eaf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_50516cfc-314d-4db4-92ce-03d3bde14ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_50516cfc-314d-4db4-92ce-03d3bde14ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_51d237a4-a686-41e4-983f-b4b7947ee58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_51d237a4-a686-41e4-983f-b4b7947ee58e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_69782dc2-6fb4-447a-a0ec-7df9de71c940_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_69782dc2-6fb4-447a-a0ec-7df9de71c940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b5f92c9b-bd59-4ad0-9d61-c8aacbe2e036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:to="loc_us-gaap_CostOfSalesMember_b5f92c9b-bd59-4ad0-9d61-c8aacbe2e036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5ad7ac8-2add-4d5d-912b-be114d056b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5ad7ac8-2add-4d5d-912b-be114d056b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e83e38e-c162-4410-add5-636d8511913d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e83e38e-c162-4410-add5-636d8511913d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="extended" id="id24a969ae75c4b17a4994dd7cd5e06b2_EquityStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a7003de-20be-439a-8fba-4b3216491f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a7003de-20be-439a-8fba-4b3216491f7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_690c5b8e-c1ef-47b5-b125-80e32a8eda5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_690c5b8e-c1ef-47b5-b125-80e32a8eda5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bdefccb8-5538-4e45-a19e-fe1781b9656d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bdefccb8-5538-4e45-a19e-fe1781b9656d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2d17f0dc-d214-42b1-b6d2-3c6772a1f366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2d17f0dc-d214-42b1-b6d2-3c6772a1f366" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:to="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69536bd1-0ef1-4851-affa-035380f6a6f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69536bd1-0ef1-4851-affa-035380f6a6f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb22c810-9569-42d0-8c28-c54aca8b9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb22c810-9569-42d0-8c28-c54aca8b9aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f6757109-2011-4230-9b5b-b13fa7031982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb22c810-9569-42d0-8c28-c54aca8b9aa8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f6757109-2011-4230-9b5b-b13fa7031982" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityRSUsandPerformanceSharesDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="extended" id="ib5af2fc179b948de8656d86858a1d185_EquityRSUsandPerformanceSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9613d6cf-da42-4587-a1ad-93413f05073b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9613d6cf-da42-4587-a1ad-93413f05073b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1056778f-7dcf-4f50-8e66-5b0bc8f67324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1056778f-7dcf-4f50-8e66-5b0bc8f67324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3cf0b0c-9e99-412e-b3b5-4dad6490b053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3cf0b0c-9e99-412e-b3b5-4dad6490b053" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ad12545a-e1a5-4006-b3f0-178635092869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ad12545a-e1a5-4006-b3f0-178635092869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:to="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_928c476d-8d91-4ea1-9b92-eaa39a27eccd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_928c476d-8d91-4ea1-9b92-eaa39a27eccd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ccb1c33-2f8d-4420-913c-97a7db41e3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ccb1c33-2f8d-4420-913c-97a7db41e3b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_de6f59b0-b270-4c01-9001-bc7f239f8b76" xlink:href="abbv-20220331.xsd#abbv_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ccb1c33-2f8d-4420-913c-97a7db41e3b6" xlink:to="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_de6f59b0-b270-4c01-9001-bc7f239f8b76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockRepurchaseProgramDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="extended" id="i0fad83b23196405da7d2cdeb394357af_EquityStockRepurchaseProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_46ddda24-0c14-4fdc-9b50-69e8624c9aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_46ddda24-0c14-4fdc-9b50-69e8624c9aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_083b6203-c7fb-4b59-abb0-779ceabb2021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_083b6203-c7fb-4b59-abb0-779ceabb2021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6fa6feab-af15-4890-8629-3ced7c980ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6fa6feab-af15-4890-8629-3ced7c980ce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4b628b21-91fb-45f4-a513-9595a07fdb40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4b628b21-91fb-45f4-a513-9595a07fdb40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d1dfacca-94b5-4ec1-997d-03c2dbf8e897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d1dfacca-94b5-4ec1-997d-03c2dbf8e897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_December2018StockRepurchaseAuthorizationMember_a5791ba4-1178-4738-abd0-3c8fab4eaba1" xlink:href="abbv-20220331.xsd#abbv_December2018StockRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_d1dfacca-94b5-4ec1-997d-03c2dbf8e897" xlink:to="loc_abbv_December2018StockRepurchaseAuthorizationMember_a5791ba4-1178-4738-abd0-3c8fab4eaba1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i0bbcb246d7af403099fa4d0077c19ff8_EquityAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ae9dfc8e-68a0-402a-8960-76fe445c0693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ae9dfc8e-68a0-402a-8960-76fe445c0693" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d729ca9b-2f41-4574-baaf-4fa27f78680a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d729ca9b-2f41-4574-baaf-4fa27f78680a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_69c2d229-7987-47bd-a702-ee5538b78789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_69c2d229-7987-47bd-a702-ee5538b78789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f3b14f10-2e6e-48f2-ac43-74346e5265f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f3b14f10-2e6e-48f2-ac43-74346e5265f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e199bbf-9f45-4747-953d-644cde1bf72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e199bbf-9f45-4747-953d-644cde1bf72d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f5996d35-0b3b-4bdd-8ca4-b7b9bf59d6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ae9dfc8e-68a0-402a-8960-76fe445c0693" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2936dfaf-9370-455e-9221-b5508bf012bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:to="loc_us-gaap_EquityComponentDomain_2936dfaf-9370-455e-9221-b5508bf012bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:to="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ce9f095c-fc9b-45b5-9f2b-15629aa69cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ce9f095c-fc9b-45b5-9f2b-15629aa69cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_f9657c56-8fb2-451a-888e-5d3eb2ca4040" xlink:href="abbv-20220331.xsd#abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_f9657c56-8fb2-451a-888e-5d3eb2ca4040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a02f0e25-7f88-48af-b01d-c19add673a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a02f0e25-7f88-48af-b01d-c19add673a08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_586dfdee-a39c-4704-9721-690e3baf9b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_586dfdee-a39c-4704-9721-690e3baf9b3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df657f8-4d55-47b8-96f2-86d922c3a108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df657f8-4d55-47b8-96f2-86d922c3a108" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="if6b4e7ff06d74e519fa6f0093cd98da2_EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_372a8a47-3b5a-43b1-80a6-ef995aaead30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_372a8a47-3b5a-43b1-80a6-ef995aaead30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9cb81636-acad-4de0-bb7e-eaf01352b8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9cb81636-acad-4de0-bb7e-eaf01352b8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9a45fa3-2c48-47b1-a8ef-439693fc06d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_NetIncomeLoss_c9a45fa3-2c48-47b1-a8ef-439693fc06d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_ab9e9924-ba68-41cd-953e-43cd7a3148d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_ab9e9924-ba68-41cd-953e-43cd7a3148d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_86290545-a1c8-4154-badb-ef079d56fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_86290545-a1c8-4154-badb-ef079d56fbe7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_dcb46287-5246-437f-b720-4cccdcf5df3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_dcb46287-5246-437f-b720-4cccdcf5df3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d90ececd-992a-4563-b475-486e2233ce90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d90ececd-992a-4563-b475-486e2233ce90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c1f52a4e-f3e7-48cf-b26e-fc1586170b40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c1f52a4e-f3e7-48cf-b26e-fc1586170b40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_ef76fcbb-dc4b-47c8-9fc9-c0f80b84968e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_ef76fcbb-dc4b-47c8-9fc9-c0f80b84968e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_2d3bc50d-9937-464a-adcc-b7cac0886881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:to="loc_us-gaap_TreasuryLockMember_2d3bc50d-9937-464a-adcc-b7cac0886881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_868bd658-b695-42ce-b9db-d0d04bc35c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:to="loc_us-gaap_InterestRateSwapMember_868bd658-b695-42ce-b9db-d0d04bc35c0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a181ebe3-9892-4f87-acb5-ffbb2131c722_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a181ebe3-9892-4f87-acb5-ffbb2131c722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_48d53c1e-009c-4e0c-88b0-0b5623a7cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_48d53c1e-009c-4e0c-88b0-0b5623a7cd43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9fff4967-fed4-40b3-b5b8-9d643c30a286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_48d53c1e-009c-4e0c-88b0-0b5623a7cd43" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9fff4967-fed4-40b3-b5b8-9d643c30a286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8c769c1b-e300-4ad9-be89-3b298f4b666e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8c769c1b-e300-4ad9-be89-3b298f4b666e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b6de221d-ec8a-4ffd-bee7-09d666fb9c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b6de221d-ec8a-4ffd-bee7-09d666fb9c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_7cd8b856-b938-4480-9169-cd0f9a517aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b6de221d-ec8a-4ffd-bee7-09d666fb9c2b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_7cd8b856-b938-4480-9169-cd0f9a517aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca5e86c0-2724-40bd-97fc-3b89ad325da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:to="loc_us-gaap_EquityComponentDomain_ca5e86c0-2724-40bd-97fc-3b89ad325da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:to="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_82f81e30-2b00-45c2-8747-d92ce2e1fb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_82f81e30-2b00-45c2-8747-d92ce2e1fb57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ba285da0-c164-46b4-9542-e6c6f5a1c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ba285da0-c164-46b4-9542-e6c6f5a1c9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a8a73da9-2ffa-4162-a662-c69883423276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a8a73da9-2ffa-4162-a662-c69883423276" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#LegalProceedingsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="extended" id="ib9971c78a6104fd089437ab2f93aed67_LegalProceedingsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_59deed1f-69ac-46d1-89f0-06118ce17d8a" xlink:href="abbv-20220331.xsd#abbv_LossContingencyIndividualPlaintiffLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_59deed1f-69ac-46d1-89f0-06118ce17d8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyPurportedClassActionsNumber_3907d3a9-aa7b-4a96-b418-958a680d8b1a" xlink:href="abbv-20220331.xsd#abbv_LossContingencyPurportedClassActionsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_LossContingencyPurportedClassActionsNumber_3907d3a9-aa7b-4a96-b418-958a680d8b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c407c1a3-22b1-4cda-9d6a-11aad335fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c407c1a3-22b1-4cda-9d6a-11aad335fd84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_65695876-aa60-4247-91bd-eaaad80a0ac1" xlink:href="abbv-20220331.xsd#abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_65695876-aa60-4247-91bd-eaaad80a0ac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PutativeClassActionLawsuitIndividualNumber_6ee431f1-a981-41fb-83cf-d10e53d2e503" xlink:href="abbv-20220331.xsd#abbv_PutativeClassActionLawsuitIndividualNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_PutativeClassActionLawsuitIndividualNumber_6ee431f1-a981-41fb-83cf-d10e53d2e503" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4afb30f0-0616-43ec-bce8-5bcd9eac2a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4afb30f0-0616-43ec-bce8-5bcd9eac2a3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a70a594c-f208-48e0-8467-1ccd2972b936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a70a594c-f208-48e0-8467-1ccd2972b936" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_7af62fb7-2bce-4607-a8ae-60af3cd7702e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_7af62fb7-2bce-4607-a8ae-60af3cd7702e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:to="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a0545509-926f-437b-a7de-564d3359acc8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:to="loc_srt_LitigationCaseTypeDomain_a0545509-926f-437b-a7de-564d3359acc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:to="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NiaspanMember_c75bce16-dbd7-4d80-a90c-ee1f73d238bf" xlink:href="abbv-20220331.xsd#abbv_NiaspanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_NiaspanMember_c75bce16-dbd7-4d80-a90c-ee1f73d238bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_92564305-36f3-455b-ab84-12d2518e30ab" xlink:href="abbv-20220331.xsd#abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_92564305-36f3-455b-ab84-12d2518e30ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_e13e1837-7480-46f1-8364-47f5db4e6385" xlink:href="abbv-20220331.xsd#abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_e13e1837-7480-46f1-8364-47f5db4e6385" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BystolicAntitrustLitigationMember_9b5ba6c4-10ec-48df-86a8-1a696e3e8631" xlink:href="abbv-20220331.xsd#abbv_BystolicAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_BystolicAntitrustLitigationMember_9b5ba6c4-10ec-48df-86a8-1a696e3e8631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationMember_902deaec-3eda-4c5e-93e1-f6ddbafb0a54" xlink:href="abbv-20220331.xsd#abbv_PrescriptionDrugAbuseLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationMember_902deaec-3eda-4c5e-93e1-f6ddbafb0a54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_afbbb34a-8822-4499-b5a2-655b2aee3941" xlink:href="abbv-20220331.xsd#abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_afbbb34a-8822-4499-b5a2-655b2aee3941" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ElliottAssociatesL.P.Member_7aeaa238-4afb-42aa-bcd7-5005da33026b" xlink:href="abbv-20220331.xsd#abbv_ElliottAssociatesL.P.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_ElliottAssociatesL.P.Member_7aeaa238-4afb-42aa-bcd7-5005da33026b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#SegmentInformationDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="extended" id="ib8e49d340fd1406b98ef3c69190f1732_SegmentInformationDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_96bc86d7-b5fe-4381-822f-67b0793dbde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_96bc86d7-b5fe-4381-822f-67b0793dbde9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fd07ead7-3c00-4eef-b659-24348ad09589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fd07ead7-3c00-4eef-b659-24348ad09589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d9d0d3d-d462-4b4a-95f4-7edebf170c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_Revenues_3d9d0d3d-d462-4b4a-95f4-7edebf170c02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain_dd50e448-8fa4-41d1-8e1f-6366f3c55e93_default" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:to="loc_abbv_KeyProductPortfolioDomain_dd50e448-8fa4-41d1-8e1f-6366f3c55e93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:to="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImmunologyMember_a0fc13f2-1360-4ab8-803b-e84d16696e7d" xlink:href="abbv-20220331.xsd#abbv_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_ImmunologyMember_a0fc13f2-1360-4ab8-803b-e84d16696e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HematologicOncologyMember_171e50fb-dea4-4cf0-b23c-724ebd467e09" xlink:href="abbv-20220331.xsd#abbv_HematologicOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_HematologicOncologyMember_171e50fb-dea4-4cf0-b23c-724ebd467e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AestheticsMember_b97c32c7-483b-4dd0-9e58-3a7e411d40e4" xlink:href="abbv-20220331.xsd#abbv_AestheticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_AestheticsMember_b97c32c7-483b-4dd0-9e58-3a7e411d40e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NeuroscienceMember_74a9b3ad-99be-4fed-ae89-7ac578cfa5d7" xlink:href="abbv-20220331.xsd#abbv_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_NeuroscienceMember_74a9b3ad-99be-4fed-ae89-7ac578cfa5d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_EyeCareMember_36cd3b79-2e00-450c-aab0-a7c305419210" xlink:href="abbv-20220331.xsd#abbv_EyeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_EyeCareMember_36cd3b79-2e00-450c-aab0-a7c305419210" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherKeyProductsMember_4b376299-6b28-4423-9b5b-879ac66253e3" xlink:href="abbv-20220331.xsd#abbv_OtherKeyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_OtherKeyProductsMember_4b376299-6b28-4423-9b5b-879ac66253e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75996820-c755-45db-9354-6702f6bc959b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:to="loc_srt_ProductsAndServicesDomain_75996820-c755-45db-9354-6702f6bc959b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:to="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_37a97594-5a64-412a-91bd-b0495df82605" xlink:href="abbv-20220331.xsd#abbv_HUMIRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_HUMIRAMember_37a97594-5a64-412a-91bd-b0495df82605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SKYRIZIMember_d3057df9-9ef2-4f34-8bf0-70f0cb34916d" xlink:href="abbv-20220331.xsd#abbv_SKYRIZIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_SKYRIZIMember_d3057df9-9ef2-4f34-8bf0-70f0cb34916d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RINVOQMember_5d1a9e2b-08a0-4ac2-8825-29058f3fa9b2" xlink:href="abbv-20220331.xsd#abbv_RINVOQMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_RINVOQMember_5d1a9e2b-08a0-4ac2-8825-29058f3fa9b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImbruvicaMember_782802f5-cde2-4767-bf1b-17c89e163ee3" xlink:href="abbv-20220331.xsd#abbv_ImbruvicaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_ImbruvicaMember_782802f5-cde2-4767-bf1b-17c89e163ee3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VENCLEXTAMember_cca5eceb-0108-4a92-af96-2b4c033918ab" xlink:href="abbv-20220331.xsd#abbv_VENCLEXTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_VENCLEXTAMember_cca5eceb-0108-4a92-af96-2b4c033918ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxCosmeticMember_720b8326-70f3-4623-ba6c-4391152ad819" xlink:href="abbv-20220331.xsd#abbv_BotoxCosmeticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_BotoxCosmeticMember_720b8326-70f3-4623-ba6c-4391152ad819" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvedermCollectionMember_8a2e9fcb-ea70-4822-84e9-903d31dd6041" xlink:href="abbv-20220331.xsd#abbv_JuvedermCollectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_JuvedermCollectionMember_8a2e9fcb-ea70-4822-84e9-903d31dd6041" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherAestheticsMember_e767065e-3e21-4451-9c4a-cdfaf2424b6d" xlink:href="abbv-20220331.xsd#abbv_OtherAestheticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherAestheticsMember_e767065e-3e21-4451-9c4a-cdfaf2424b6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxTherapeuticMember_1c0316ba-ab9f-408b-98f9-1bb92cbb9ee0" xlink:href="abbv-20220331.xsd#abbv_BotoxTherapeuticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_BotoxTherapeuticMember_1c0316ba-ab9f-408b-98f9-1bb92cbb9ee0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VraylarMember_b81ffd0c-0078-46f7-8902-59cb08479449" xlink:href="abbv-20220331.xsd#abbv_VraylarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_VraylarMember_b81ffd0c-0078-46f7-8902-59cb08479449" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DuodopaMember_e7b8a535-4450-41f6-8f97-5145db950f5b" xlink:href="abbv-20220331.xsd#abbv_DuodopaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_DuodopaMember_e7b8a535-4450-41f6-8f97-5145db950f5b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_UbrelvyMember_4e01d9ec-f3a5-4e6e-938c-c1fd0980b578" xlink:href="abbv-20220331.xsd#abbv_UbrelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_UbrelvyMember_4e01d9ec-f3a5-4e6e-938c-c1fd0980b578" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_QuliptaMember_c421269b-1a34-49a6-9011-e0be7e4a0da6" xlink:href="abbv-20220331.xsd#abbv_QuliptaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_QuliptaMember_c421269b-1a34-49a6-9011-e0be7e4a0da6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherNeuroscienceMember_8e48d2ad-63b1-42fd-8bf4-9ce93816e12f" xlink:href="abbv-20220331.xsd#abbv_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherNeuroscienceMember_8e48d2ad-63b1-42fd-8bf4-9ce93816e12f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LumiganGanfortMember_45cbd13a-5239-468f-918b-d319a89aff21" xlink:href="abbv-20220331.xsd#abbv_LumiganGanfortMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_LumiganGanfortMember_45cbd13a-5239-468f-918b-d319a89aff21" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AlphaganCombiganMember_272dd9c4-30f5-44ad-971c-efa23efb7d26" xlink:href="abbv-20220331.xsd#abbv_AlphaganCombiganMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_AlphaganCombiganMember_272dd9c4-30f5-44ad-971c-efa23efb7d26" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestasisMember_cffb6c06-ed0f-4774-bc32-0d43915d064c" xlink:href="abbv-20220331.xsd#abbv_RestasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_RestasisMember_cffb6c06-ed0f-4774-bc32-0d43915d064c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherEyeCareMember_739f71f1-e5c0-43b9-825c-fbb2ef0ae267" xlink:href="abbv-20220331.xsd#abbv_OtherEyeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherEyeCareMember_739f71f1-e5c0-43b9-825c-fbb2ef0ae267" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_MAVYRETMember_afa35d18-a35f-48ef-a334-224975f26137" xlink:href="abbv-20220331.xsd#abbv_MAVYRETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_MAVYRETMember_afa35d18-a35f-48ef-a334-224975f26137" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CreonMember_a05be030-9394-4e1b-a5a8-7347d0e9e775" xlink:href="abbv-20220331.xsd#abbv_CreonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_CreonMember_a05be030-9394-4e1b-a5a8-7347d0e9e775" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LinzessConstellaMember_7573499c-6b5b-4261-a4bb-eb6c01903c4c" xlink:href="abbv-20220331.xsd#abbv_LinzessConstellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_LinzessConstellaMember_7573499c-6b5b-4261-a4bb-eb6c01903c4c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherProductsMember_7651ec3b-76e6-4914-a20e-5e3be5e7a684" xlink:href="abbv-20220331.xsd#abbv_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherProductsMember_7651ec3b-76e6-4914-a20e-5e3be5e7a684" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:to="loc_srt_SegmentGeographicalDomain_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:to="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_57ce3329-ebad-4a03-bb27-c65aea72794c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:to="loc_country_US_57ce3329-ebad-4a03-bb27-c65aea72794c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f018c135-07ea-4732-be51-a6dfae24f229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:to="loc_us-gaap_NonUsMember_f018c135-07ea-4732-be51-a6dfae24f229" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>abbv-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56dec8fe-bb4b-4711-9c82-c533c008edd6,g:2a065e27-cccc-4ae9-a029-5c29f5f60184-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_exch_XCHI_1ea6f4da-0d14-40e5-956a-a2c2b1b25fbc_terseLabel_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC</link:label>
    <link:label id="lab_exch_XCHI_label_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XCHI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XCHI" xlink:to="lab_exch_XCHI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f3b2c19e-48c3-4a2b-8c97-45108d73dd75_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dcc67342-6c39-4fe3-aef8-b733359f358d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProjectedYearofPaymentsMember_4688a7eb-c1eb-4e67-8a4c-6955d674e5cf_terseLabel_en-US" xlink:label="lab_abbv_ProjectedYearofPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected year of payments</link:label>
    <link:label id="lab_abbv_ProjectedYearofPaymentsMember_label_en-US" xlink:label="lab_abbv_ProjectedYearofPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Year of Payments [Member]</link:label>
    <link:label id="lab_abbv_ProjectedYearofPaymentsMember_documentation_en-US" xlink:label="lab_abbv_ProjectedYearofPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents projected year of payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProjectedYearofPaymentsMember" xlink:href="abbv-20220331.xsd#abbv_ProjectedYearofPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProjectedYearofPaymentsMember" xlink:to="lab_abbv_ProjectedYearofPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_f7dfd6c0-072e-4d26-9353-4ebd72b7c962_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings and Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dc6b6225-9a7d-43fe-b149-ae6754046217_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_d3bd35da-c70f-466a-bef9-14aefcb785e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of actuarial losses and other</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_678c9807-7836-44c2-ac86-4bbd1876acde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d28fa352-6a43-42c4-9687-b8edf85e41dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to AbbVie Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f7ab329f-5b1c-4474-be82-b65d3dd9022f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to AbbVie Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_597602e0-b873-4b10-ad8b-557673320889_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9e8f9b5c-2a78-482c-849a-e71dbecb8794_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_0627c58d-bb2b-4d84-8207-929341cc20c1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_826975a7-c7ac-4308-ad94-55472c753b84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad7649c8-c12b-4e1d-ba4f-2307589a5492_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bbc09891-ee65-4ccd-a25a-cef864ab8a5a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_98f238d8-f8ec-4819-84a6-387aff041c0a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_6cf158aa-d79c-4484-ac2a-0ca994aadbeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_c4bafaf5-feb4-4715-8738-806c91c29f4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_3b596cf2-7897-4bb4-9ca5-546e6f0e90c8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1ff67419-d82d-472e-a1cf-9996f7cc6a96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6310dd04-baa8-40ce-a7e7-e759077b25e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dc7807be-464f-4806-85cd-8683aeb71cd5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_d08f61cc-0d08-45b5-8dbc-07bb87df03bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_17ed7421-a953-4b17-94ef-01cd24418bd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets or liabilities between the fair value measurement levels</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_71544cb5-79b0-4445-a82c-0f631cd011a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55f626fd-1751-499c-a20d-f331f87e44db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c9b65a00-4703-4bd6-879a-86292ff54c8a_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_b2c8f6df-ef21-4ca2-9a89-d5be5d7d445d_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D and milestones</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70dd5127-14b0-4e73-9fef-06babcabf981_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_14f736c0-eda8-4e86-8418-69a9778c6499_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_401a1e9e-587c-4813-adb8-80979e52740d_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recognized in net earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_6a958f60-8701-471a-bc84-e1427402c86a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_ef280467-00e4-4097-9480-b6562976a84e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ac044d5f-8ae0-4cdd-bcd4-b95a0b7fb1af_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_abf08e6a-7a44-43de-aadf-5f2947741772_terseLabel_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_label_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029 [Member]</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:href="abbv-20220331.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:to="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_be1fe8c9-3c0b-44a3-8502-b1bc88e84454_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5be2382-aa77-44c4-ad1d-673ae36c8037_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b1a39d7f-6c61-4f30-b4f8-e37233d0fc98_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_381c31e0-60da-45b3-8b1b-a7932e043abf_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_387710a8-1ddb-4c8f-8a32-20dfe554633a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of cash activity in the restructuring reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_f168d4a5-8af8-4d57-9341-08cfa2b967fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining share repurchase authorization amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_DuodopaMember_e45c2dab-b427-4d55-8e97-0213a32fbc62_terseLabel_en-US" xlink:label="lab_abbv_DuodopaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duodopa</link:label>
    <link:label id="lab_abbv_DuodopaMember_label_en-US" xlink:label="lab_abbv_DuodopaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duodopa [Member]</link:label>
    <link:label id="lab_abbv_DuodopaMember_documentation_en-US" xlink:label="lab_abbv_DuodopaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Duodopa, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DuodopaMember" xlink:href="abbv-20220331.xsd#abbv_DuodopaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_DuodopaMember" xlink:to="lab_abbv_DuodopaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_6df63dcc-e8da-4205-b3f4-75e5337956ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4c7dd149-acbd-467e-a1fe-cbaf74b83577_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9e7cef32-6f11-4e81-8b5b-310d4bf0cbca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_5c58e632-f58e-4ea8-908a-6308ae55aebd_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from the assessment of effectiveness for cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_label_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:to="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_878355e0-2cc5-40cf-a313-9f35d6f533d2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_JanssenBiotechIncMember_4511fce3-d63b-4b24-ad8d-e4d8b1050657_terseLabel_en-US" xlink:label="lab_abbv_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:label id="lab_abbv_JanssenBiotechIncMember_label_en-US" xlink:label="lab_abbv_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_abbv_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_abbv_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertains to the entity Janssen Biotech Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember" xlink:href="abbv-20220331.xsd#abbv_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_JanssenBiotechIncMember" xlink:to="lab_abbv_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8317b8a7-13d6-46e5-b372-755bccfab90e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c078c4ae-b4a2-4225-a438-38fd9a6f0c75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_9a91b128-04fe-4316-b6d8-4013625100bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_44b3d21f-738a-408c-8647-aeaec1ca123c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ElliottAssociatesL.P.Member_f1498a15-4117-48af-b45c-cd2973751a91_terseLabel_en-US" xlink:label="lab_abbv_ElliottAssociatesL.P.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elliott Associates, L.P.</link:label>
    <link:label id="lab_abbv_ElliottAssociatesL.P.Member_label_en-US" xlink:label="lab_abbv_ElliottAssociatesL.P.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elliott Associates, L.P. [Member]</link:label>
    <link:label id="lab_abbv_ElliottAssociatesL.P.Member_documentation_en-US" xlink:label="lab_abbv_ElliottAssociatesL.P.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Elliot Associates, LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ElliottAssociatesL.P.Member" xlink:href="abbv-20220331.xsd#abbv_ElliottAssociatesL.P.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ElliottAssociatesL.P.Member" xlink:to="lab_abbv_ElliottAssociatesL.P.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_5b620a66-e6f6-4d8e-a157-4de892e18cfb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International - AbbVie's share of profits (included in net revenues)</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_52bfeeee-c323-4324-aaed-85d6205896d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_2213f90b-7f6c-4ecd-ae96-780538f823d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_21a324b4-8f68-402b-9cb7-974c9918baf0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_ec714dc6-2927-4dfe-bbb9-b859cf5beb8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c4013ca3-47e8-4ddd-b368-655f0911d25b_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential change in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d207f03a-7554-4836-a0ab-3436dd2e043b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_84570155-d175-4a60-9764-ec41d35c01af_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_672222e7-e729-4411-8c25-3c0cf19db236_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_77c22b87-98bb-42ea-8a8c-32cfe2b08751_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cdff64c9-1474-46c8-88ff-425aadb876f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4073fbf6-108f-4cbd-b6af-46d2756bf0b8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b8d52db8-0b42-4e84-a4cc-4c98dda7e91f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_154137f1-b940-4bbd-9dad-94f87b4868e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesAndFairValueTextBlock_1d9e5ed8-fec8-4c1f-8bc6-c63fa5932bd5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesAndFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Fair Value Measures</link:label>
    <link:label id="lab_us-gaap_DerivativesAndFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesAndFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesAndFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesAndFairValueTextBlock" xlink:to="lab_us-gaap_DerivativesAndFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherRestructuringPlansMember_fe0191f2-82fc-46f1-b09c-83fe459bdc28_terseLabel_en-US" xlink:label="lab_abbv_OtherRestructuringPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restructuring</link:label>
    <link:label id="lab_abbv_OtherRestructuringPlansMember_label_en-US" xlink:label="lab_abbv_OtherRestructuringPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Plans [Member]</link:label>
    <link:label id="lab_abbv_OtherRestructuringPlansMember_documentation_en-US" xlink:label="lab_abbv_OtherRestructuringPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents other restructuring plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember" xlink:href="abbv-20220331.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherRestructuringPlansMember" xlink:to="lab_abbv_OtherRestructuringPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0336cbb8-2656-4184-95eb-c5e8b01e3545_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ImbruvicaMember_3e8fb2a7-c935-4f99-ab7e-820f8453fc46_terseLabel_en-US" xlink:label="lab_abbv_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:label id="lab_abbv_ImbruvicaMember_label_en-US" xlink:label="lab_abbv_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica [Member]</link:label>
    <link:label id="lab_abbv_ImbruvicaMember_documentation_en-US" xlink:label="lab_abbv_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Imbruvica, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImbruvicaMember" xlink:href="abbv-20220331.xsd#abbv_ImbruvicaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ImbruvicaMember" xlink:to="lab_abbv_ImbruvicaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8a93ad47-6e46-44a0-83f9-a5829c0f7167_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable input for contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_33e6f448-ce64-40e1-86c0-8796fbb7c8db_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fc5094b-118c-44ad-8510-fb0de0e4379a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_67b72114-4588-4d60-b571-6eb941cc62f8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_195a1b74-5f56-4b22-8450-1cb665445f6b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_7cfeda97-a60f-401d-87a5-c182f7d31adb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_213c2332-9ccd-4377-913b-fc0bde9bdc16_terseLabel_en-US" xlink:label="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual plaintiff lawsuits</link:label>
    <link:label id="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_label_en-US" xlink:label="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Individual Plaintiff Lawsuits Number</link:label>
    <link:label id="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_documentation_en-US" xlink:label="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:href="abbv-20220331.xsd#abbv_LossContingencyIndividualPlaintiffLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:to="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7f25ef9a-518b-45f9-9066-ad75e88c5a5a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_cc6640b2-b78f-4cc6-b8dd-5d9444c125ca_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1b4206de-a7c2-40e6-9208-8ff1c2971114_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_b709513c-b3fc-4f20-9d93-a87977bb3758_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d4947ad0-8aec-4565-961e-3116f843bdc2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and post-employment benefits, net of tax expense (benefit) of $10 for the three months ended March 31, 2022 and $19 for the three months ended March 31, 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_6e7cbf40-f5d3-4604-8ca9-487a7e15f653_terseLabel_en-US" xlink:label="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of generic companies with whom certain litigation related agreements were entered into</link:label>
    <link:label id="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_label_en-US" xlink:label="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws</link:label>
    <link:label id="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_documentation_en-US" xlink:label="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:href="abbv-20220331.xsd#abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:to="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_6b05376d-1d4a-428f-b3f7-fae08f30db3a_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC.</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f6f7dbcb-553e-4a9f-ace6-c2f62d35783c_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_50a82d96-2f71-4af0-8354-1ad478d93d6e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_4f4de933-5df6-45f9-bfd5-d8e2ef83a952_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of collaboration development costs responsible by Janssen (as a percent)</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:to="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b46f63c5-ed17-406d-88e7-596e9f6f231a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_32659c42-c82f-4b10-8894-5840dfb5c447_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of worldwide net revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_11914878-c4e7-4c86-b554-e0fe094c8f04_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2d73725b-c18b-4169-94c1-71e37a143c8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_995baa36-35f1-4a7b-b677-498e80984820_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_MAVYRETMember_16ef80b3-c276-4d86-b0a5-ae77c519e69f_terseLabel_en-US" xlink:label="lab_abbv_MAVYRETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mavyret</link:label>
    <link:label id="lab_abbv_MAVYRETMember_label_en-US" xlink:label="lab_abbv_MAVYRETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAVYRET [Member]</link:label>
    <link:label id="lab_abbv_MAVYRETMember_documentation_en-US" xlink:label="lab_abbv_MAVYRETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to MAVYRET, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_MAVYRETMember" xlink:href="abbv-20220331.xsd#abbv_MAVYRETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_MAVYRETMember" xlink:to="lab_abbv_MAVYRETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member_187c97fc-a300-4883-bcda-e5f233f8eb4c_terseLabel_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating rate notes due 2025</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member_label_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025 [Member]</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member_documentation_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:href="abbv-20220331.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:to="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AllerganIntegrationPlanMember_f51266ce-1915-419d-b349-3df41d7a0461_terseLabel_en-US" xlink:label="lab_abbv_AllerganIntegrationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan integration plan</link:label>
    <link:label id="lab_abbv_AllerganIntegrationPlanMember_label_en-US" xlink:label="lab_abbv_AllerganIntegrationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Integration Plan [Member]</link:label>
    <link:label id="lab_abbv_AllerganIntegrationPlanMember_documentation_en-US" xlink:label="lab_abbv_AllerganIntegrationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Allergan integration plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember" xlink:href="abbv-20220331.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AllerganIntegrationPlanMember" xlink:to="lab_abbv_AllerganIntegrationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_959d2686-6921-4088-ad03-e0978726b0f3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_4325453b-278e-44e5-9a2c-08af1c2e42ae_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value - Derivatives in asset position</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_bfba65a7-b61f-464c-9c96-8d2fa6a5dd23_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_08cf20f7-693f-4bbf-9fdf-fb17ebdfcd91_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of healthcare benefit providers acting as plaintiff in lawsuit</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4171e037-eb5c-4653-a27b-6813950acb26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d298d008-5362-4a72-bd6e-fff66e2c4c94_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c041828b-2577-479c-a60f-744806909c1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_6c4d2909-46a5-4c80-9e59-daf133a0f379_terseLabel_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense from research and development expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense from research and development expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense from research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:href="abbv-20220331.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:to="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_be3ef6b1-7475-44e8-a6de-15d90f8ed3d8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_cec54fe7-b713-4329-9027-8f157be3995b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_cbcaf045-c6c7-4109-b2c0-f8a92ed3824e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt obligations, gross</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_583eafd9-0b1b-4e47-8daf-05c6297ac13f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_85b30c4a-d163-431b-be01-20d8d2386842_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5906ff3a-6f71-45fb-baf8-30921bb6bf70_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d4933120-5028-4530-885b-58bb0dd760d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_3b85585f-08d6-4852-8700-59b29ba34ca7_terseLabel_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_label_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:href="abbv-20220331.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:to="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6e31f174-14dd-4a20-b3ec-0db104107f94_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_de30e84e-342a-42d5-96fb-1dd93b6d88ff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d12d1ae4-03bb-4da5-b0ed-2319b8b807c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months ended March 31, 2022 and $3 for the three months ended March 31, 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_UbrelvyMember_3f8f3a03-5739-4cc5-a1b6-912077fc8e65_terseLabel_en-US" xlink:label="lab_abbv_UbrelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ubrelvy</link:label>
    <link:label id="lab_abbv_UbrelvyMember_label_en-US" xlink:label="lab_abbv_UbrelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ubrelvy [Member]</link:label>
    <link:label id="lab_abbv_UbrelvyMember_documentation_en-US" xlink:label="lab_abbv_UbrelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Ubrelvy, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_UbrelvyMember" xlink:href="abbv-20220331.xsd#abbv_UbrelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_UbrelvyMember" xlink:to="lab_abbv_UbrelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_a06f0f81-65f3-4682-abc7-7c0c863f782c_terseLabel_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription drug abuse litigation in state courts</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_label_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Abuse Litigation In State Courts [Member]</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_documentation_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Abuse Litigation In State Courts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:href="abbv-20220331.xsd#abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:to="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NeuroscienceMember_fabb6896-c5bb-4243-bb06-14a75e286ea1_terseLabel_en-US" xlink:label="lab_abbv_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_abbv_NeuroscienceMember_label_en-US" xlink:label="lab_abbv_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_abbv_NeuroscienceMember_documentation_en-US" xlink:label="lab_abbv_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Neuroscience, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NeuroscienceMember" xlink:href="abbv-20220331.xsd#abbv_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NeuroscienceMember" xlink:to="lab_abbv_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2be2a3f8-ec1e-4e1c-8b10-a3562502318c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a33fd3e-3bd9-4547-b303-39b45158755c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_6b851889-1a2b-4c85-8f84-877238f514e2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and post-employment benefits, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_6734df2b-0ea6-4b78-9608-786a2738feb3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_3a07f482-7b40-49cd-a806-aa18ad8b12b9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_34289d7f-3710-4033-b065-c0c3798e40c2_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as fair value hedges</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_02e24435-f416-4bd1-b489-12f7613904f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherAestheticsMember_7ceb69ca-977a-4c84-b72b-6d88a137b896_terseLabel_en-US" xlink:label="lab_abbv_OtherAestheticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Aesthetics</link:label>
    <link:label id="lab_abbv_OtherAestheticsMember_label_en-US" xlink:label="lab_abbv_OtherAestheticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Aesthetics [Member]</link:label>
    <link:label id="lab_abbv_OtherAestheticsMember_documentation_en-US" xlink:label="lab_abbv_OtherAestheticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Other Aesthetics products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherAestheticsMember" xlink:href="abbv-20220331.xsd#abbv_OtherAestheticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherAestheticsMember" xlink:to="lab_abbv_OtherAestheticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_d76e66a2-ebef-469e-a7fa-e183abe08d9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of liabilities into Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_a533c6ac-d422-45c9-bd3b-dc6dd4bd8784_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve rollforward</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d05237c7-88b8-4340-9b53-14a466450b80_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3bc0f217-8953-46ca-b23e-606b60dd28a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's payable to Janssen</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NiaspanMember_55d13b3a-2610-406f-86d6-d7cdf097d95c_terseLabel_en-US" xlink:label="lab_abbv_NiaspanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Niaspan</link:label>
    <link:label id="lab_abbv_NiaspanMember_label_en-US" xlink:label="lab_abbv_NiaspanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Niaspan [Member]</link:label>
    <link:label id="lab_abbv_NiaspanMember_documentation_en-US" xlink:label="lab_abbv_NiaspanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Niaspan, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NiaspanMember" xlink:href="abbv-20220331.xsd#abbv_NiaspanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NiaspanMember" xlink:to="lab_abbv_NiaspanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_f5ebffa0-a8c5-41c4-8435-184303ab7588_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e7a7c8e1-9230-48ce-8940-0e0823531c40_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2d4f745d-4118-489a-bcc7-0e0d69555fe9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_bb0148d0-30f9-48ae-9768-37bb9035cc38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_61ab5d92-709f-497d-8187-c17ab253e493_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_c7af5eee-5fcc-4b66-a346-b3cbe4d03c1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_b3a1d160-68c6-4b44-b920-6878332269fb_terseLabel_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment for royalties excluding early stage or approved indications</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_label_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Payment for Royalties Excluding Approved Indications [Member]</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_documentation_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents estimated probability of payment for royalties excluding approved indications.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:to="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_758e9402-48e7-45cc-a947-d032c48b2f51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_0b6aad0b-fecc-4fa4-b083-2ec7a0300e1f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3ec2a533-e4c7-4613-8cb3-d02afcf0683e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_52cebf82-f345-47f3-a87c-33367b24f3d0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_720aba27-1ee9-4b71-8575-b1a91523c865_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_117403cf-c039-490c-b55f-0ec264762d7e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6498b471-422b-4ee7-bf73-e27d0f25033e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_389a1f22-4096-4ae5-a52f-98476b04adcc_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_244c60d9-cd15-4478-a258-a137499d24f0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AlphaganCombiganMember_9f25f739-c985-4110-9cbf-a8206702160a_terseLabel_en-US" xlink:label="lab_abbv_AlphaganCombiganMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphagan/Combigan</link:label>
    <link:label id="lab_abbv_AlphaganCombiganMember_label_en-US" xlink:label="lab_abbv_AlphaganCombiganMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphagan/Combigan [Member]</link:label>
    <link:label id="lab_abbv_AlphaganCombiganMember_documentation_en-US" xlink:label="lab_abbv_AlphaganCombiganMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Alphagan/Combigan, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AlphaganCombiganMember" xlink:href="abbv-20220331.xsd#abbv_AlphaganCombiganMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AlphaganCombiganMember" xlink:to="lab_abbv_AlphaganCombiganMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_285ac650-6202-4509-a106-227c4bfa3376_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from the assessment of effectiveness for fair value hedges</link:label>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_label_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:to="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherNeuroscienceMember_d0fd018f-e52c-42e1-9589-ad0ca6ba5bfc_terseLabel_en-US" xlink:label="lab_abbv_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience</link:label>
    <link:label id="lab_abbv_OtherNeuroscienceMember_label_en-US" xlink:label="lab_abbv_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_abbv_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_abbv_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Other Neuroscience products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherNeuroscienceMember" xlink:href="abbv-20220331.xsd#abbv_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherNeuroscienceMember" xlink:to="lab_abbv_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_BotoxTherapeuticMember_6408e971-629a-44bd-bfa5-0ea37565edf6_terseLabel_en-US" xlink:label="lab_abbv_BotoxTherapeuticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Therapeutic</link:label>
    <link:label id="lab_abbv_BotoxTherapeuticMember_label_en-US" xlink:label="lab_abbv_BotoxTherapeuticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Therapeutic [Member]</link:label>
    <link:label id="lab_abbv_BotoxTherapeuticMember_documentation_en-US" xlink:label="lab_abbv_BotoxTherapeuticMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Botox Therapeutic, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxTherapeuticMember" xlink:href="abbv-20220331.xsd#abbv_BotoxTherapeuticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_BotoxTherapeuticMember" xlink:to="lab_abbv_BotoxTherapeuticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_be35a2e8-8ac9-4ad1-b943-e8af5bea75c1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_bd237983-455f-4be9-aff6-f95455258f6a_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued balance beginning of the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_1f6a28a5-1e4e-48f3-b58c-89a8fee9333c_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued balance end of the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fbaffc3c-1b49-4f90-907d-16728a966928_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_3fb6bac0-2793-414f-97c6-e8bd13d02434_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_95868726-d023-4637-bd3e-94847e8c5158_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_3c6377ae-0c6d-4088-b76c-9151987fc421_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_HematologicOncologyMember_b55c49c9-7684-482c-9f0d-38438ab5c943_terseLabel_en-US" xlink:label="lab_abbv_HematologicOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hematologic Oncology</link:label>
    <link:label id="lab_abbv_HematologicOncologyMember_label_en-US" xlink:label="lab_abbv_HematologicOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hematologic Oncology [Member]</link:label>
    <link:label id="lab_abbv_HematologicOncologyMember_documentation_en-US" xlink:label="lab_abbv_HematologicOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HematologicOncologyMember" xlink:href="abbv-20220331.xsd#abbv_HematologicOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_HematologicOncologyMember" xlink:to="lab_abbv_HematologicOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_937ee411-b315-408d-9e4e-f49724ca0a64_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_768ea314-b59f-4ec7-901d-49afe8e3cc36_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_fb46db51-d8af-4c2d-ad5a-f79ef521e03d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other integration</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_03db4b61-2de5-4764-81cb-7b3040becdee_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_b2efbebc-c38a-4dd5-99eb-22309895d575_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_956f85c5-8e60-4075-83a8-c9c53f0e1634_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_be1396c6-05bd-4c8d-8a37-f2b13beb724c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_11e6d6f4-d611-4df0-8dc8-b58b3bfe89e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_cb2df394-f6a8-43f2-9009-2128dcb3b6ae_negatedLabel_en-US" xlink:label="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of actuarial loss</link:label>
    <link:label id="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_label_en-US" xlink:label="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit)</link:label>
    <link:label id="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_documentation_en-US" xlink:label="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:href="abbv-20220331.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:to="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock_dcde958f-a4c8-4e2e-af6f-3d71c7b800ae_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_3f7f2545-d6ab-4bb7-b031-eb5ed7a74f50_terseLabel_en-US" xlink:label="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities</link:label>
    <link:label id="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_label_en-US" xlink:label="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) From Net Investment Hedges [Member]</link:label>
    <link:label id="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_documentation_en-US" xlink:label="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) From Net Investment Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:href="abbv-20220331.xsd#abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:to="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationMember_7e78d8a2-06ad-4bd8-835c-23daeb36dd56_terseLabel_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription drug abuse litigation</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationMember_label_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Abuse Litigation [Member]</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationMember_documentation_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to prescription drug abuse litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationMember" xlink:href="abbv-20220331.xsd#abbv_PrescriptionDrugAbuseLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PrescriptionDrugAbuseLitigationMember" xlink:to="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_67b61028-4556-4748-9d30-e3edd591ddcd_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_050b0fe7-88a8-4fc2-905d-d2324b6251ca_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f565c6cd-a176-4f2a-bb10-a37b99cea5ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_2b227162-a9b4-45cd-ac21-55a73b7db357_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c67427b2-b22a-4446-b930-acb45ace3036_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cedc1263-e642-4e80-ab7a-9f2ec605a707_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of awards vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_5a904490-aa82-4c79-a4cf-e522208ddb31_terseLabel_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023</link:label>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_label_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member" xlink:href="abbv-20220331.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1500SeniorNotesDue2023Member" xlink:to="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6dcc20bf-de97-4f41-a5b3-51f28413ae13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other post-employment plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2825f3e3-e3f2-4bbf-985c-87724fdabb74_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherKeyProductsMember_8dfe46ca-f2d4-428c-8eae-94b9590d9c5d_terseLabel_en-US" xlink:label="lab_abbv_OtherKeyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Key Products</link:label>
    <link:label id="lab_abbv_OtherKeyProductsMember_label_en-US" xlink:label="lab_abbv_OtherKeyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Key Products [Member]</link:label>
    <link:label id="lab_abbv_OtherKeyProductsMember_documentation_en-US" xlink:label="lab_abbv_OtherKeyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to other key products of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherKeyProductsMember" xlink:href="abbv-20220331.xsd#abbv_OtherKeyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherKeyProductsMember" xlink:to="lab_abbv_OtherKeyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b862f9f6-4b16-448e-bc2b-130e8772c67b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_047d411d-e5a5-4a47-9daf-b7ecb02960a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of book values, approximate fair values and bases used to measure certain financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_bc65ad3e-2ba5-4a40-aa86-d85e7eb41766_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Two Class Method [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_27cb03cd-6a2c-4727-8f2d-58d13c320f1b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7970bc6c-bafd-4676-b8dc-1a51290c00af_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_3a72712b-13bb-4a06-97e1-3b8766666a19_terseLabel_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing, Acquisitions, and Other Arrangements</link:label>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_label_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing, Acquisitions, and Other Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:href="abbv-20220331.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:to="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_8892dabe-2664-41c7-a08e-45deae59baf8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HUMIRA</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ddae8a82-a4ff-4c18-b6f7-5e457c76a5c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedging activities, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fddeb1bd-9b17-477c-8a9f-a355af624ea4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_GenentechInc.Member_ff0f99d2-b047-4d40-81d4-d839b08df70c_verboseLabel_en-US" xlink:label="lab_abbv_GenentechInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:label id="lab_abbv_GenentechInc.Member_label_en-US" xlink:label="lab_abbv_GenentechInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. [Member]</link:label>
    <link:label id="lab_abbv_GenentechInc.Member_documentation_en-US" xlink:label="lab_abbv_GenentechInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member" xlink:href="abbv-20220331.xsd#abbv_GenentechInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_GenentechInc.Member" xlink:to="lab_abbv_GenentechInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3f59f146-9f75-44ff-8b8b-869bad0d21a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_30487f88-baec-4c30-9143-7ba518acac58_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LossContingencyPurportedClassActionsNumber_fc788eef-2f13-4c6d-9558-2b4b592ec495_terseLabel_en-US" xlink:label="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purported class actions</link:label>
    <link:label id="lab_abbv_LossContingencyPurportedClassActionsNumber_label_en-US" xlink:label="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Purported Class Actions Number</link:label>
    <link:label id="lab_abbv_LossContingencyPurportedClassActionsNumber_documentation_en-US" xlink:label="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of purported class actions filed, pertaining to a loss contingency during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyPurportedClassActionsNumber" xlink:href="abbv-20220331.xsd#abbv_LossContingencyPurportedClassActionsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LossContingencyPurportedClassActionsNumber" xlink:to="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3798b1fd-e14c-42bf-8674-3c6aa80aff53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c251cf27-6fa7-4828-ae65-25e9c21b6ac5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_91716ea0-4992-4e67-907b-d1415e53ad2b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_b75d6ead-0c57-44d3-9608-7ea64c0e14dd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock held in treasury, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ce44154a-47ce-4744-866b-8d545cecdf18_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_86204e82-4544-4dda-80a8-7f69ec1addab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Long-term Debt and Capital Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ae944595-068d-401e-b3ef-9832caaaab34_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_92b3bf60-3b20-43a9-a093-f8c07ae5b40e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0c171ba3-af61-4997-8e98-65ab6feae884_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f8d000e-4510-45ec-870c-e31651cd55e0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_3f626538-62ba-45c1-858b-a947053b8a99_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_29c3d9fc-0861-4db2-8104-63846dfca33e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_6205424f-6bdd-4e26-84b0-1f0827110959_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_35119394-9b3e-4879-a945-e0779c28a268_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:to="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e93dacf2-09ff-4ceb-87f9-aef804b41ed3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CreonMember_2b63e071-176e-45f7-bc2e-451c6082ce37_terseLabel_en-US" xlink:label="lab_abbv_CreonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creon</link:label>
    <link:label id="lab_abbv_CreonMember_label_en-US" xlink:label="lab_abbv_CreonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creon [Member]</link:label>
    <link:label id="lab_abbv_CreonMember_documentation_en-US" xlink:label="lab_abbv_CreonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Creon, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CreonMember" xlink:href="abbv-20220331.xsd#abbv_CreonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CreonMember" xlink:to="lab_abbv_CreonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5594915d-d7b9-4c19-b775-5488f8206815_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbdc8fb4-830c-4938-8b93-9424b6d5cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_dba647ce-5393-45bb-a464-c1cdf72d1a9b_terseLabel_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating rate notes due 2025, refinanced</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_label_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025, Refinanced [Member]</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_documentation_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025, Refinanced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:href="abbv-20220331.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:to="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a3d922e4-b834-40a1-97f5-6d67ea4ae0dd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e29faa4f-c6aa-4a4e-817e-f5a87c1d9faa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_c897b347-b982-43c0-9f24-632b7fd8b640_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_55e12e0d-1932-4682-b825-bb2099e711f1_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c6fe0f1b-80ad-4276-97eb-d8aab8f30506_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_06af591a-0ed1-42a1-be9e-d357810a596d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d2c76312-cf9a-44a3-bd6c-9330f2d1d5e3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7d5a004a-44f8-4a2c-baa5-49ddb327e01c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ImmunologyMember_621f3426-25dd-4fd4-8834-21cc3f0c99f5_terseLabel_en-US" xlink:label="lab_abbv_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_abbv_ImmunologyMember_label_en-US" xlink:label="lab_abbv_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_abbv_ImmunologyMember_documentation_en-US" xlink:label="lab_abbv_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Immunology, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImmunologyMember" xlink:href="abbv-20220331.xsd#abbv_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ImmunologyMember" xlink:to="lab_abbv_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_167edfa6-a2de-4192-b2f3-49a284c16910_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a79c4fbb-506a-4fe8-b5bc-787ceeebf533_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0e9f115d-5fd0-4c80-b3bd-111176f478de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9bbcd91c-e478-40b0-a45a-36567840e571_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration and Restructuring Plans</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_29350875-e940-4f44-be22-1245dff09a70_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_165a954f-0fc2-40c4-a42f-b3694c03654d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflows related to acquisitions and investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_27bd1fc5-5592-49ca-ab8e-3823e26251db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets out of Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_594729d9-924d-4c1e-b3bf-78f95ae28769_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c41f5842-dd3e-43ab-ae04-49b4320e6294_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_c0a6219a-574b-49d6-8e2a-69a01f374b01_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_dd1077ee-1781-41d6-98b2-963e3b4328f2_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_dea525a4-0f17-4383-9c4f-4efce3cfa55b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SKYRIZIMember_8289a870-9ca4-45bd-ab80-70f1a5ef7d6b_terseLabel_en-US" xlink:label="lab_abbv_SKYRIZIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skyrizi</link:label>
    <link:label id="lab_abbv_SKYRIZIMember_label_en-US" xlink:label="lab_abbv_SKYRIZIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SKYRIZI [Member]</link:label>
    <link:label id="lab_abbv_SKYRIZIMember_documentation_en-US" xlink:label="lab_abbv_SKYRIZIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to SKYRIZI, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SKYRIZIMember" xlink:href="abbv-20220331.xsd#abbv_SKYRIZIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SKYRIZIMember" xlink:to="lab_abbv_SKYRIZIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_1e9edcf1-acbd-4421-9da6-27fe819bf44d_terseLabel_en-US" xlink:label="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</link:label>
    <link:label id="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General And Administrative Expense From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:href="abbv-20220331.xsd#abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:to="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_606f3509-817e-4a40-a61a-382509a4807b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_8c653cd4-eaf1-4052-a097-60dad509b111_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d85065f2-9dc7-4237-b9a7-559470301bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_ad2e088d-9b4b-48aa-912b-0f8ce394780c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ef466f3e-bdd2-4d95-a2b4-92f014f053e9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_44d6ad51-836d-4cf3-842b-0a881790dc78_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D and milestones</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_17a9acab-714e-4c98-a78e-b8c3b10be005_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3456855-ea0a-4876-b776-6211d718c615_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_29bc6995-5706-4917-be0c-09c47452256e_terseLabel_en-US" xlink:label="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months</link:label>
    <link:label id="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:label id="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_documentation_en-US" xlink:label="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:href="abbv-20220331.xsd#abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:to="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1ac2d862-09dd-4cc4-995d-5e9509be4e17_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_ab15becd-382a-4143-99b7-586d06092537_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_4a686cbd-f76c-4c34-863c-bb84d9e9e446_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of profit and cost sharing relationship</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LumiganGanfortMember_7eebe3c2-c9b6-41d4-8f44-8ffe61686d2e_terseLabel_en-US" xlink:label="lab_abbv_LumiganGanfortMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumigan/Ganfort</link:label>
    <link:label id="lab_abbv_LumiganGanfortMember_label_en-US" xlink:label="lab_abbv_LumiganGanfortMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumigan/Ganfort [Member]</link:label>
    <link:label id="lab_abbv_LumiganGanfortMember_documentation_en-US" xlink:label="lab_abbv_LumiganGanfortMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Lumigan/Ganfort, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LumiganGanfortMember" xlink:href="abbv-20220331.xsd#abbv_LumiganGanfortMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LumiganGanfortMember" xlink:to="lab_abbv_LumiganGanfortMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_8f35a419-cdc6-41d1-8312-0ccae0440e55_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_86f482f3-922c-4de3-b14d-356c9fc50188_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_44893205-904f-42f8-ae05-d9f78e06894f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_31796079-1bda-4ec9-bdad-de0702e45b0e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShorttermDebtFairValue_77db101d-bf8e-48af-bc2d-72e49d11c241_terseLabel_en-US" xlink:label="lab_us-gaap_ShorttermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ShorttermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_ShorttermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShorttermDebtFairValue" xlink:to="lab_us-gaap_ShorttermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_8128bfcf-31fe-43ec-82d8-dcb7e9ab85a6_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Milestone Method Payments Receivable</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:to="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a683bcf6-f84d-4301-8fd6-a620542944dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29ac0a33-e003-460d-b0db-47fd08219308_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f32d403a-9185-453a-8675-dd17871a039b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_74b6244d-85a2-404c-be17-db03470143fd_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AestheticsMember_4d6a3b7d-1e6b-4bf7-8be9-a6f701c462b0_terseLabel_en-US" xlink:label="lab_abbv_AestheticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aesthetics</link:label>
    <link:label id="lab_abbv_AestheticsMember_label_en-US" xlink:label="lab_abbv_AestheticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aesthetics [Member]</link:label>
    <link:label id="lab_abbv_AestheticsMember_documentation_en-US" xlink:label="lab_abbv_AestheticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Aesthetics, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AestheticsMember" xlink:href="abbv-20220331.xsd#abbv_AestheticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AestheticsMember" xlink:to="lab_abbv_AestheticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d0130d5b-94e4-40af-a977-75419a0d6b90_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDividendsPayableTextBlock_abebc8f4-461e-4431-96cf-201a2269a426_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of quarterly cash dividends</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDividendsPayableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dividends Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDividendsPayableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_55498842-d131-4cb5-a8e6-a7b69d83f8fc_terseLabel_en-US" xlink:label="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.</link:label>
    <link:label id="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_label_en-US" xlink:label="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member]</link:label>
    <link:label id="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_documentation_en-US" xlink:label="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:href="abbv-20220331.xsd#abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:to="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1f10a75e-e0a4-4d9c-8545-5b0af0dc8561_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7f8e0045-aefc-41b1-8f6f-474f58ad38dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4973418f-cbe4-4481-9025-c02e85906581_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes in balances of each component of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_79e7459e-e84e-4bb3-9e84-927771cb296f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_308975e4-a922-456a-bb37-ad2b5743b635_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_7c3a5bc0-2112-46b0-8d10-32e9332c310e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_197b84d2-4c4d-4cc7-8ee5-e1a71f72f65f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_20889c49-7de9-458a-bad7-db5178249157_terseLabel_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities, net of tax expense (benefit) of $37 for the three months ended March 31, 2022 and $103 for the three months ended March 31, 2021</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_label_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_documentation_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:href="abbv-20220331.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:to="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bedde9ee-3ce6-4187-a40b-562ec5e5a38f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ad74ce34-cc4e-46eb-9d14-99775de72f34_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of unsecured senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c0adcc63-3a46-4fbd-beb1-511aadaec9c7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_687fcd5b-1a74-4977-b95d-7020859195e7_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_30c5d9c2-1aa8-412c-be15-e5fc6ecc2054_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_cd651c45-a8a5-477d-a353-40baed86126d_terseLabel_en-US" xlink:label="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)</link:label>
    <link:label id="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods And Services Sold From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:href="abbv-20220331.xsd#abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:to="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_JuvedermCollectionMember_7642d0eb-816b-4a12-83b7-6ab226fe9bb7_terseLabel_en-US" xlink:label="lab_abbv_JuvedermCollectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvederm Collection</link:label>
    <link:label id="lab_abbv_JuvedermCollectionMember_label_en-US" xlink:label="lab_abbv_JuvedermCollectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvederm Collection [Member]</link:label>
    <link:label id="lab_abbv_JuvedermCollectionMember_documentation_en-US" xlink:label="lab_abbv_JuvedermCollectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Juvederm Collection, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvedermCollectionMember" xlink:href="abbv-20220331.xsd#abbv_JuvedermCollectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_JuvedermCollectionMember" xlink:to="lab_abbv_JuvedermCollectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_98a2f868-c0f1-444d-92fd-f22e05894b81_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_daf7f01d-3107-4ac7-b3c5-18488faf8201_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dfebde7f-f1c0-41c9-96bb-6d7257c435c6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0aed3bd6-c0a8-4b88-a420-1c9020d1c64d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_dc550f7e-052d-40e8-849d-171f89dea9c9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e74e06b6-736a-4131-8271-f286066eec07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_129de860-1742-4d5c-aa23-4cf41695f0a8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments, notional amount and fair value</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d2c931c3-c26b-4c23-8551-2775b3608f5d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_020c7795-5629-4c2b-9390-8e0b0950e02d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_466fd05c-344a-40de-8462-3a67d2e387ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherExpensesFromCollaborativeArrangements_36e56090-0f23-42a4-a249-9099ac3fcb42_terseLabel_en-US" xlink:label="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global - AbbVie's share of other costs (included in respective line items)</link:label>
    <link:label id="lab_abbv_OtherExpensesFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_OtherExpensesFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherExpensesFromCollaborativeArrangements" xlink:href="abbv-20220331.xsd#abbv_OtherExpensesFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherExpensesFromCollaborativeArrangements" xlink:to="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1294bc92-5839-409a-b11d-873e2b94930f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_59b520da-0695-4e82-8784-f478d9972a94_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_b633bae7-9d96-49f8-9c2e-39dbc47c7676_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6c1ccf02-8ae5-4aea-9e6d-04ce76eac062_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate fair value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_d5aedb7c-9068-4ada-be0b-b573a4c8805b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_85134054-2e99-4e53-bdfe-ff9d4efab7f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in fair value of Level 3 inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_659689f4-0608-41ae-bd9a-0c29361fdb84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_02eaeeb0-cc24-41f0-bb9d-8accfe52841d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7e904a64-94c4-4655-9f25-c960c9e7738b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_30be9028-5871-46e1-8da3-8a531b839d6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_cebec24e-e4d4-4045-b38d-4b1009f59254_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4d2d5b9c-d144-43e9-bfd6-e9c9ebd7e5a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fce02458-be12-4735-b5b6-b74f62fd114b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75443b4e-df0a-4e5d-8ef4-48a707218e49_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_312b7510-e3b4-45e2-ab6b-10cf45881051_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4e41fb57-5572-4166-a6bc-a17902ad7604_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4935928d-6641-4450-910b-8ce2b8951c07_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_d30d527c-7c60-40ad-85ec-a893f6fe7016_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0208a595-e16b-4082-9636-215099d7c1cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e480e65e-2fe6-406e-bdbd-eda135fe78d1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's receivable from Janssen</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6cb0f04c-4e49-4ccc-a33c-aa2398f9a8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_2cc0dcd6-658e-4a0c-b6c9-7db565ba6dfe_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiff claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_aaea9ac5-1204-4404-80d7-17c246e466c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f41474cf-5f76-4abc-bf1e-ed9871383ee5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c58a5456-fb85-4f54-a62d-f39723e97cd7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_c23efaf3-5adb-4d60-9fec-e93ced54c0f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c50a80bf-626b-4ca5-8195-8fe735997e0a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherProductsMember_6ea586db-f2b6-43e8-af62-e001660231b1_terseLabel_en-US" xlink:label="lab_abbv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_abbv_OtherProductsMember_label_en-US" xlink:label="lab_abbv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_abbv_OtherProductsMember_documentation_en-US" xlink:label="lab_abbv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to other products of the entity not specified anywhere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherProductsMember" xlink:href="abbv-20220331.xsd#abbv_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherProductsMember" xlink:to="lab_abbv_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_227418aa-47f7-4051-bcab-09418faf7509_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_2efcfcb0-0b2b-4560-9fbe-34f577d7a59a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_61686048-d990-4537-a550-825ed8d6ff91_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_5a13dc84-7d91-45d5-9bc1-16cb474a9221_verboseLabel_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and finance lease obligations, excluding fair value hedges</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_label_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Fair Value Disclosure</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_documentation_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:to="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_85b998b6-95df-40f8-8d26-c3a69a8faace_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_20a92be2-784f-4d5d-b264-e8db4d5bdc40_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6963269a-da51-42e7-904e-7d6ebbd8e586_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e04cf22d-30f4-47aa-b537-e1c96ec7d7ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, asset and liability measures</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_392014e0-7b7f-4e89-bdeb-d36251a05d42_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bases used to measure the approximate fair values of the financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a192c657-3208-4b6a-a3fe-89316ced4ed4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_5e26dc30-09a9-4bee-8903-88e91d70a107_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net of tax expense (benefit) of $(7) for the three months ended March 31, 2022 and $(25) for the three months ended March 31, 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SupplementalFinancialInformationDisclosureAbstract_d4c2316a-8971-4414-bef6-28ac902994c4_terseLabel_en-US" xlink:label="lab_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_abbv_SupplementalFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:href="abbv-20220331.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:to="lab_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4c5d4e5d-4b87-4c74-8b3a-58e949229877_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_bcf943c7-b047-4cda-9a44-b5fe0abc0e42_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e6f06353-cc1c-4e76-9bd0-e5caf4e90484_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c2fb30a1-7b78-4a32-a4a9-08ca9e4afb28_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_5885bf3d-f93c-4891-a6c3-b7add1b51c26_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_802ea456-d35e-487d-bb77-2e65a0903564_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_2227f791-3c4e-4d1f-8c4d-ffbb65bc1c0d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_14addc83-b5ca-4211-aad6-580a3d1cdfdd_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of investments in equity securities that do not have readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestasisMember_c4a94cf5-6fc6-4337-a186-646efc373e74_terseLabel_en-US" xlink:label="lab_abbv_RestasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restasis</link:label>
    <link:label id="lab_abbv_RestasisMember_label_en-US" xlink:label="lab_abbv_RestasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restasis [Member]</link:label>
    <link:label id="lab_abbv_RestasisMember_documentation_en-US" xlink:label="lab_abbv_RestasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Restasis, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestasisMember" xlink:href="abbv-20220331.xsd#abbv_RestasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestasisMember" xlink:to="lab_abbv_RestasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_05dfd937-07ea-4140-9b22-99e6f1de21cf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryLockMember_045d6b22-eb8e-4db1-b931-7d440089f811_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury rate lock agreements</link:label>
    <link:label id="lab_us-gaap_TreasuryLockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Lock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryLockMember" xlink:to="lab_us-gaap_TreasuryLockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_bb08332c-7530-4f45-8e06-825ce7eff4c9_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9b3e053f-78b8-4f00-b287-fdbeddfde54a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of the stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_84bb5bde-9036-4e33-be4a-1118a7b484a2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_578b1e21-3581-4e3f-a222-1b2535cf680d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation plans and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_f32d6432-81b5-4cf4-98d8-1b8e4e440ca4_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3cbc69e3-6fe0-4f4d-88c3-b2b176c86368_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_7b2683ca-5678-4382-a1df-31573422c18c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_11093b9a-6038-45f6-93b8-444567cf34b1_terseLabel_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment for unachieved milestones</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_label_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Payment for Unachieved Milestones [Member]</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_documentation_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the probability of payment for unachieved milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforUnachievedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:to="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_a0c5e00b-d83a-45d7-b4fd-7bf7f18ead83_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges associated with integration or restructuring plans</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_15c7d06a-a2ed-4424-a996-6f9f677e9e1c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_d3917ae9-7615-4bc9-b2c9-ea94a650d167_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7328824-94dc-4b3f-80bb-cf50fd793f11_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_70b47d0b-05f3-4ff5-81cb-82f67fddd6da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e1ede848-e7b2-45b0-bb29-f5be1a7ceda0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_148bc6f4-9670-4e80-bc7a-5b4a9cd6e3be_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_236b0784-efea-452c-95f6-0ef08a159d0c_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9307c3d9-e0fe-4e04-aeb0-c39eb0b44ca0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5ed4e6f9-f194-4ceb-be6e-0349836221ba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.450PercentMember_d1f35fc5-139a-4b9c-96f4-d804787a5641_terseLabel_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% senior notes due 2022</link:label>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.450PercentMember_label_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 At 3.450 Percent [Member]</link:label>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.450PercentMember_documentation_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 At 3.450 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:href="abbv-20220331.xsd#abbv_SeniorNotesDue2022At3.450PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:to="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c93265a-6c16-4df4-9547-29088449cae4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_1e7d9f6e-48dc-41d2-8284-17866ff40460_terseLabel_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:href="abbv-20220331.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6725f50e-3be1-457e-80c2-9e6012ac7d9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LinzessConstellaMember_b8c7f87b-ff7c-4ef1-8799-ffabf7e9ba6d_terseLabel_en-US" xlink:label="lab_abbv_LinzessConstellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Linzess/Constella</link:label>
    <link:label id="lab_abbv_LinzessConstellaMember_label_en-US" xlink:label="lab_abbv_LinzessConstellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Linzess/Constella [Member]</link:label>
    <link:label id="lab_abbv_LinzessConstellaMember_documentation_en-US" xlink:label="lab_abbv_LinzessConstellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Linzess/Constella, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LinzessConstellaMember" xlink:href="abbv-20220331.xsd#abbv_LinzessConstellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LinzessConstellaMember" xlink:to="lab_abbv_LinzessConstellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_e32eb875-24c3-4466-bde5-cf3b186d98ec_terseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_b8ec03fa-f673-4719-9fb7-e91f8f223b28_verboseLabel_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:to="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_165018df-f8e9-459a-bfbe-7abc719ce90b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_30552746-3491-4f72-a400-f57dca8cd60e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_a981def2-4c4e-46bc-bd2b-b045be95b585_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a52fe7a8-e914-4c88-bae1-dabc8160ef17_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_ab7458be-cf77-441f-92bf-2a096a321e3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0590c265-a847-4c58-93a4-cf928e5af7d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_33735c25-9ab5-4b14-8e2c-73e0f159c2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of basic and diluted earnings per share, impact of two-class method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1bf366c7-9d44-47d2-b1a4-672237fe460c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3ad72fcb-b8ee-4cae-9eef-ab0dcc774af3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_34b69511-9a7d-4fe1-906d-61ea6588987b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_QuliptaMember_51042e5a-707a-4711-b712-84b0078b0230_terseLabel_en-US" xlink:label="lab_abbv_QuliptaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qulipta</link:label>
    <link:label id="lab_abbv_QuliptaMember_label_en-US" xlink:label="lab_abbv_QuliptaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qulipta [Member]</link:label>
    <link:label id="lab_abbv_QuliptaMember_documentation_en-US" xlink:label="lab_abbv_QuliptaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qulipta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_QuliptaMember" xlink:href="abbv-20220331.xsd#abbv_QuliptaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_QuliptaMember" xlink:to="lab_abbv_QuliptaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_94187773-c822-46c7-b026-33dfbad02d0b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Two Class Method [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicTwoClassMethodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_f6ded069-7e5e-4d91-9514-935ecd9dd243_terseLabel_en-US" xlink:label="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's share of development costs (included in R&amp;D)</link:label>
    <link:label id="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:href="abbv-20220331.xsd#abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:to="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9f785b80-cea6-4b89-967e-641009aa258e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3ce1d6d5-a24e-4802-b9db-8f8a03d5f0d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_b7ab4039-8cd3-44e1-a36d-a948194d3526_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration related costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_566a4178-4947-4a66-88bd-68eb3962e350_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5278d589-c9c4-4cca-a134-8d1a4e437973_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3fe30605-9eb6-4b03-9d45-1293081e0646_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_aa9a732a-30a2-4b60-80a0-bea1a93b635a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ecb4cd7f-78b7-4599-b389-2503bc01657f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and post-employment benefits</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_98540a5a-f589-456e-9e3b-205d6d232d7e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9397b7be-6107-4d12-a8a7-46ca28ec0289_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_cc5f19e5-2b88-40e0-9968-12b4f8eeec97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ca56c2b2-f4fe-49b0-9b99-5a75a58ec418_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_aebdceaa-702e-4b42-a871-24d1c1ddd84b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e0bef713-d937-4efd-a931-2813e27bc64e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_90d699f4-3b0f-4212-9db6-2cb8119164c6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3528afdc-70bf-4f09-bfac-d874926f3c9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_121ff4f8-9ad7-4283-a189-ccd63d6af2d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_40567d88-f03b-4f0f-8a3f-c20dbd44eb2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e30eba7-7286-4cb1-9aa2-106ba52f2fb4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_50135996-08c9-4f30-bb27-53f3003f2987_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PutativeClassActionLawsuitIndividualNumber_5793bef5-521d-4c87-879e-38675d87134b_terseLabel_en-US" xlink:label="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual putative class action lawsuits</link:label>
    <link:label id="lab_abbv_PutativeClassActionLawsuitIndividualNumber_label_en-US" xlink:label="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Putative Class Action Lawsuit Individual Number</link:label>
    <link:label id="lab_abbv_PutativeClassActionLawsuitIndividualNumber_documentation_en-US" xlink:label="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents number of the number of individual putative class action lawsuit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:href="abbv-20220331.xsd#abbv_PutativeClassActionLawsuitIndividualNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:to="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember_cd85d329-a497-4b4b-a0ab-0e612ec0635a_terseLabel_en-US" xlink:label="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and Performance Shares</link:label>
    <link:label id="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember_label_en-US" xlink:label="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance Shares [Member]</link:label>
    <link:label id="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="abbv-20220331.xsd#abbv_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:to="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06c76937-291c-4d98-bf7d-2c00aa0b8507_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_faa9b8f1-32db-4c2e-bb6b-2373378966ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Credit Facilities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ea0b4de0-fb08-4af7-a295-464a383343b0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1e34ec97-77d3-402f-9081-6e86ac383b53_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_e8df98b0-674f-458d-8098-cd77799220f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of liabilities out of Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a627b91b-de68-41a0-a16d-5de6607f930b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e39df46-7712-464a-bd7b-72136a987692_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4c690a8f-652e-428d-b431-1e0a37aa995a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_84e5d8ed-d01c-43e0-8763-06787f840665_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_cd79db60-4f39-4c46-a529-352d110c1d93_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_102c100d-94c5-4f89-a4dc-b7061de008f0_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b1e06338-0a46-4b22-9754-f1d998253293_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_6cfcad16-8eb0-40a0-966f-0cc80006525c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_0a877389-b942-4d72-b93d-753c8367a0ac_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3219a916-396a-430a-a887-33e834a6de23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d1739018-ddd0-4c04-8ce7-c72fb6d4e434_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a2caaf06-43ee-44f9-94c6-6de06c99368c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to AbbVie Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_271cd899-90e8-4386-b8be-f9bdf843bef8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_dafa8c02-8e96-4975-9ff8-f0efcd013aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_483bae90-50fb-487b-9e1d-54ac35f594d9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_77ac9abe-6d43-453c-8e44-5ca7b16253db_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock held in treasury, at cost, 44,557,588 shares as of March 31, 2022 and 34,857,597 as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RINVOQMember_acfe3a6a-82d2-4962-91c5-fae4536ba7d9_terseLabel_en-US" xlink:label="lab_abbv_RINVOQMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rinvoq</link:label>
    <link:label id="lab_abbv_RINVOQMember_label_en-US" xlink:label="lab_abbv_RINVOQMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RINVOQ [Member]</link:label>
    <link:label id="lab_abbv_RINVOQMember_documentation_en-US" xlink:label="lab_abbv_RINVOQMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to RINVOQ, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RINVOQMember" xlink:href="abbv-20220331.xsd#abbv_RINVOQMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RINVOQMember" xlink:to="lab_abbv_RINVOQMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_BystolicAntitrustLitigationMember_feb7918b-1dcd-4dde-bb5f-dfecfff6aff0_terseLabel_en-US" xlink:label="lab_abbv_BystolicAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bystolic antitrust litigation</link:label>
    <link:label id="lab_abbv_BystolicAntitrustLitigationMember_label_en-US" xlink:label="lab_abbv_BystolicAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bystolic Antitrust Litigation [Member]</link:label>
    <link:label id="lab_abbv_BystolicAntitrustLitigationMember_documentation_en-US" xlink:label="lab_abbv_BystolicAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Bystolic antitrust litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BystolicAntitrustLitigationMember" xlink:href="abbv-20220331.xsd#abbv_BystolicAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_BystolicAntitrustLitigationMember" xlink:to="lab_abbv_BystolicAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_15cb11e7-509f-4fce-b96e-65b5376f5ad0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_779b5d9a-1904-4653-bfc8-be2c3f6525e9_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_188a72be-69eb-425b-be37-7ac616359efd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_dfc035da-653e-4ee8-8df7-05820f0cd300_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a583114f-9385-4a20-8081-135eca96afd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_ad39d756-f8dc-43c2-a786-2305896b0627_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ffa9b52d-87ec-46b4-aeeb-b668f620a25b_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherEyeCareMember_bae9662a-5df6-4974-90ae-dde1866ff611_terseLabel_en-US" xlink:label="lab_abbv_OtherEyeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Eye Care</link:label>
    <link:label id="lab_abbv_OtherEyeCareMember_label_en-US" xlink:label="lab_abbv_OtherEyeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Eye Care [Member]</link:label>
    <link:label id="lab_abbv_OtherEyeCareMember_documentation_en-US" xlink:label="lab_abbv_OtherEyeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Other Eye Care products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherEyeCareMember" xlink:href="abbv-20220331.xsd#abbv_OtherEyeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherEyeCareMember" xlink:to="lab_abbv_OtherEyeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_BotoxCosmeticMember_9424d3f4-3f77-4e39-bb5c-9ef772640045_terseLabel_en-US" xlink:label="lab_abbv_BotoxCosmeticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Cosmetic</link:label>
    <link:label id="lab_abbv_BotoxCosmeticMember_label_en-US" xlink:label="lab_abbv_BotoxCosmeticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Cosmetic [Member]</link:label>
    <link:label id="lab_abbv_BotoxCosmeticMember_documentation_en-US" xlink:label="lab_abbv_BotoxCosmeticMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Botox Cosmetic, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxCosmeticMember" xlink:href="abbv-20220331.xsd#abbv_BotoxCosmeticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_BotoxCosmeticMember" xlink:to="lab_abbv_BotoxCosmeticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a1b0063-7ea5-4a03-8d3d-92c5399eefc8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_37f8ac57-881c-4004-bbeb-91c3668055cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2d66d608-3b96-4a5e-8b4b-be114c54b754_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of charges associated with integration plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_93b3968d-67ee-4d30-9536-b283da2fec8a_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of collaboration development costs responsible by the entity (as a percent)</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Percentage Of Share Of Development Costs</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:to="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_536bcbd4-84fb-4902-a645-d7b3bb949b00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets into Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_99bd9854-c325-4ed2-8215-0afc4d9798d1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_6a61b9c7-0700-4eb2-a987-1c55e2ab7238_terseLabel_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing, Acquisitions, and Other Arrangements</link:label>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_label_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Collaborations and Other Arrangements Disclosure [Text Block]</link:label>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for acquisitions, collaborations and other arrangements of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:href="abbv-20220331.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:to="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_KeyProductPortfolioAxis_7aba9add-cdc6-43c2-a38e-d71b8b3c48be_terseLabel_en-US" xlink:label="lab_abbv_KeyProductPortfolioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Axis]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioAxis_label_en-US" xlink:label="lab_abbv_KeyProductPortfolioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Axis]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioAxis_documentation_en-US" xlink:label="lab_abbv_KeyProductPortfolioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information concerning the company's portfolios of key products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioAxis" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_KeyProductPortfolioAxis" xlink:to="lab_abbv_KeyProductPortfolioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_00b4ba6a-2491-4a4b-9d90-ca5ac4382582_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3db8b161-f721-44d3-8b15-f6f62864f0b7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_16f9809b-5b79-415a-889c-aef40187ed21_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses (gains) on foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_80572a86-7622-4d0a-a5dd-7797bacc3731_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_KeyProductPortfolioDomain_a55740be-1f7e-49fd-bfd7-e558d5ad32b0_terseLabel_en-US" xlink:label="lab_abbv_KeyProductPortfolioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Domain]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioDomain_label_en-US" xlink:label="lab_abbv_KeyProductPortfolioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Domain]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioDomain_documentation_en-US" xlink:label="lab_abbv_KeyProductPortfolioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Information concerning the company's portfolios of key products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_KeyProductPortfolioDomain" xlink:to="lab_abbv_KeyProductPortfolioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_31c71e65-63da-496e-9c6c-2ff8302d8cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PrincipalUSCustomersMember_27a19b06-6fff-4a84-8f86-4b444e94fb39_terseLabel_en-US" xlink:label="lab_abbv_PrincipalUSCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal US customers</link:label>
    <link:label id="lab_abbv_PrincipalUSCustomersMember_label_en-US" xlink:label="lab_abbv_PrincipalUSCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal US Customers [Member]</link:label>
    <link:label id="lab_abbv_PrincipalUSCustomersMember_documentation_en-US" xlink:label="lab_abbv_PrincipalUSCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal US Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrincipalUSCustomersMember" xlink:href="abbv-20220331.xsd#abbv_PrincipalUSCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PrincipalUSCustomersMember" xlink:to="lab_abbv_PrincipalUSCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_HUMIRAMember_924cbbf9-c6a8-4484-bb7d-970162a0fae4_terseLabel_en-US" xlink:label="lab_abbv_HUMIRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira</link:label>
    <link:label id="lab_abbv_HUMIRAMember_label_en-US" xlink:label="lab_abbv_HUMIRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H U M I R A [Member]</link:label>
    <link:label id="lab_abbv_HUMIRAMember_documentation_en-US" xlink:label="lab_abbv_HUMIRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to HUMIRA, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember" xlink:href="abbv-20220331.xsd#abbv_HUMIRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_HUMIRAMember" xlink:to="lab_abbv_HUMIRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_621a9844-3194-4df4-bcc8-626d99e43dd5_terseLabel_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:href="abbv-20220331.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7abeb02c-4b56-4cf8-a8f7-301cfe4de352_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_dfe17789-d41a-4c70-be8f-67adda96ef32_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_e283322a-a0e5-409c-b3f8-09440ee92e3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan credit agreement term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_51b61635-ecb0-4b0d-a3c0-fa2a02a31d46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_5ee37714-46f4-40d3-8652-dff7deb0b381_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds and time deposits</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d2354e66-a833-49d8-8cce-cc01d50de3c3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings and Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_fab8b8fb-e6ed-4f84-a381-ba00fbd107e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b9e1261f-9bf5-4ff4-b233-54bfed84cf0e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_22551513-a6da-42c8-9f26-f0d93b36da58_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3a170bab-c2ce-4c88-800f-6c1729156ef3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f91adc8f-657a-40f0-b0d9-40977394a620_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_b20734c2-6342-4b81-83d2-ba40d232c4d9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0d7f9387-ce70-4edf-8e72-d60c6589362f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Credit Facilities [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_cf04b45c-3751-45cf-8184-3fd4548e3adf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_773fb763-d2ea-473e-b324-2e03686ff1a9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_7104307e-65a2-4e1f-8300-251963aff971_negatedLabel_en-US" xlink:label="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_label_en-US" xlink:label="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Period Cash Settled and Other Adjustments</link:label>
    <link:label id="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_documentation_en-US" xlink:label="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:href="abbv-20220331.xsd#abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:to="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d169cb7a-9581-49c3-8f5a-1fa24f65fbd8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9e302a0c-bfc5-491a-a659-689506c78a6e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_84364666-0a0c-4c8f-b943-e2fe7536b3c0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_67a60e16-57fb-4bcc-bee6-bfaa163deeae_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_2dc73586-82d0-4b42-aac4-aab35ff5985f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedging activities</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_01e39a9c-9830-4bab-bf2a-3906b1d3350f_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses (gains) reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c603a822-f215-428f-8a0c-51a972be395b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_3ed03517-ee4f-4702-93db-8963247cdf1d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_54894210-5bec-407a-9f05-96c2ef7e82b5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4118ddd6-55d5-4064-b84c-75513e2c3bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_6fbec4d5-f122-4cb8-b245-71ae8d5bae59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_219ba282-74e1-49d1-9616-1dc3a49a4d8d_terseLabel_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment for royalties by indication</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_label_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Payment for Royalties by Indication [Member]</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_documentation_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents probability of payment for royalties by indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:to="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_bbb42371-7120-4b0f-a189-18df066be2df_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c392a70c-e600-42f0-81e0-d6a88b01364d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0afad4e8-b8b5-4708-aec3-f4355efceb6f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share data</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9bb1b7a0-dfe1-45b6-80aa-545003ffa6f8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_984a8bef-cd76-4323-acf2-eaf8196a4ab2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5b02827c-aa6d-4958-89a5-8179e57d8a41_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_db0f82aa-9634-4604-8db4-146db0d1bd72_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5d025063-36fe-4465-ae17-73a4d18acd06_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d25a8c5e-c14f-4139-82e8-87580332ccfa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_862b8bfb-2d50-4ea0-ba10-6b0a32fcd0fd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_008b623d-d39f-4a6b-b2ab-a33edc1e53cf_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ffba3ad-02be-4cce-a15f-8907b66f8d12_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e35768be-b1ea-41a2-beef-615c513856aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_83819b40-83d1-4d96-8229-d894a02df57b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_833d2b53-7b40-415d-a264-a090c04cc1de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_a916cc35-dcb7-4c43-b71c-489c2f3bd4ac_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_11bd53cc-acc7-4cba-aa37-0d8493fb7666_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit and other post-employment plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_0e7d4d62-d89e-4e76-be55-65db3b3b44a6_terseLabel_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_label_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:href="abbv-20220331.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:to="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7d38f8ce-a01d-4ed1-a71a-28d0efa96bf4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7b861360-6b53-4ad4-8218-b7a8a0dabe03_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d061676d-f919-43a5-9ef5-84c0705df658_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f0aef366-2ea3-4d21-8d74-a8ac91f24eb0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_a51834ac-9a41-4058-93a2-959bf785cd6b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8ecaa330-c4da-4768-9233-2f5485368317_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_d1179647-c733-404a-afec-ed1c65b2cd74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4d4f00e3-0f4c-4c1c-a40d-b175a6ac2865_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5b56e159-cd79-4d44-b661-17df5bab3a72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a6aabbb7-f213-44a6-b177-c5134bb4b151_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_a7ce207d-5fe8-480a-9607-41246ebda394_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8fcd33e6-cf97-4fd9-92ec-663029e4aa0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NumberOfPrincipalUSCustomers_04f07b50-a701-4f1e-ba01-504721a11a2d_terseLabel_en-US" xlink:label="lab_abbv_NumberOfPrincipalUSCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of principal customers</link:label>
    <link:label id="lab_abbv_NumberOfPrincipalUSCustomers_label_en-US" xlink:label="lab_abbv_NumberOfPrincipalUSCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Principal US Customers</link:label>
    <link:label id="lab_abbv_NumberOfPrincipalUSCustomers_documentation_en-US" xlink:label="lab_abbv_NumberOfPrincipalUSCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of principal U.S. customers of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NumberOfPrincipalUSCustomers" xlink:href="abbv-20220331.xsd#abbv_NumberOfPrincipalUSCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NumberOfPrincipalUSCustomers" xlink:to="lab_abbv_NumberOfPrincipalUSCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_992720f4-dfea-4c0f-9a94-6461a38a1156_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_312171d3-f31c-49e1-9a8b-27de76f7611d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c31e490-f30f-4653-b0cb-891c9c79ee32_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b68696b3-bec2-4e13-b8a3-bce35b8a8402_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ee3b4442-70bf-4d2f-941d-e50b3df9ddca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_VraylarMember_096785d1-9153-4d3a-a260-103ba747fbd2_terseLabel_en-US" xlink:label="lab_abbv_VraylarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vraylar</link:label>
    <link:label id="lab_abbv_VraylarMember_label_en-US" xlink:label="lab_abbv_VraylarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vraylar [Member]</link:label>
    <link:label id="lab_abbv_VraylarMember_documentation_en-US" xlink:label="lab_abbv_VraylarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Vraylar, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VraylarMember" xlink:href="abbv-20220331.xsd#abbv_VraylarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_VraylarMember" xlink:to="lab_abbv_VraylarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a9b0767c-5f79-46bc-ba05-01270f8b7199_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_46bdb99c-c9e7-413c-a3e0-181850d4079e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_11c91abe-e681-4945-ab81-61dd3b24d275_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_234b6308-4e22-4e77-924e-9882ae6e8d0c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueOrExpenseNetAbstract_eaf26673-e42f-43df-9e1c-b5dd747c8302_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Net</link:label>
    <link:label id="lab_us-gaap_InterestRevenueOrExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Revenue (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueOrExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:to="lab_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementsAbstract_6dea4645-14ca-48c4-bea5-a5ad964cdaf6_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementsAbstract" xlink:to="lab_abbv_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SyndesiMember_40135fb2-2005-4d69-bb13-321b1ef436b5_terseLabel_en-US" xlink:label="lab_abbv_SyndesiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndesi</link:label>
    <link:label id="lab_abbv_SyndesiMember_label_en-US" xlink:label="lab_abbv_SyndesiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndesi [Member]</link:label>
    <link:label id="lab_abbv_SyndesiMember_documentation_en-US" xlink:label="lab_abbv_SyndesiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndesi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SyndesiMember" xlink:href="abbv-20220331.xsd#abbv_SyndesiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SyndesiMember" xlink:to="lab_abbv_SyndesiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_6930ee46-d9bf-4dd9-8642-9bde5bcba62a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_dc4166b9-157b-44ec-8521-c67708c3c671_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_48b857a3-593e-4d38-ba49-d4fb3e8111e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_f1d671d9-db3c-45f0-96ca-ffe9ed5b55f7_terseLabel_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_label_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:href="abbv-20220331.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:to="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyGainLossMember_4452b182-153d-45cd-8934-5c770a2c2b09_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyGainLossMember_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Gain (Loss) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyGainLossMember" xlink:to="lab_us-gaap_ForeignCurrencyGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_995326fa-7129-499f-922d-b5f693bdc80e_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_6bb358d3-fa6c-4ad2-b505-b599a4881d83_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedges</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2713fc5-eed8-4faf-8a25-cebba5577626_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b729383f-ea49-48c7-95fd-e309db96f7d6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1981843b-9b65-4e24-a598-5cf3580321c4_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at fair value measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b604e60-9d98-49bf-9bf3-f44b312f0118_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f79e9c76-f108-43bb-8629-0d94d5445424_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_73d120fc-78e5-45c7-97c3-8f5697253f45_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_78fb1dbb-e5cf-4ce4-9ea8-88cc601627c8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_7a02f865-2ff0-4fbf-8764-a72cdd422046_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_26e3c7f8-b8ff-47c5-be6f-558fa4c33b18_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_11d1d09d-b4cf-45c0-aa48-633cbde8cc8c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant amounts reclassified out of each component of AOCI</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5cc378bb-8894-448f-9077-cb89948c6941_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds and time deposits</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_c6c0b27b-d302-424f-9c8f-47a9d2c0e055_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_1cce97d2-6cde-46ed-99aa-d97ade1fc92c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_December2018StockRepurchaseAuthorizationMember_116f106d-eb61-4cdc-bdb3-f249c141bf70_terseLabel_en-US" xlink:label="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Repurchase Authorization</link:label>
    <link:label id="lab_abbv_December2018StockRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Repurchase Authorization [Member]</link:label>
    <link:label id="lab_abbv_December2018StockRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_December2018StockRepurchaseAuthorizationMember" xlink:href="abbv-20220331.xsd#abbv_December2018StockRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_December2018StockRepurchaseAuthorizationMember" xlink:to="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_54e155e8-2aee-4835-a7d2-efd4a9a2e5a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_c6460e85-25f3-4a7c-a12b-8517845f16fb_terseLabel_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense to IPR&amp;D and milestones expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_label_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense to IPR&amp;D and milestones expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_documentation_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&amp;D and milestones expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:href="abbv-20220331.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:to="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_241a3a4f-a2fb-4dac-b28a-035e1ca19503_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e1f7e612-467c-4883-9890-d3d527eb770f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_778bfd61-f7b5-4173-874c-dbc568752844_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d0d1e1a7-2436-4102-9717-77494dc9bfc9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_97d14eb1-455c-4e00-878a-1c95d8436d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6b76efba-df58-408a-8a3c-9fad01087663_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_8dba0acb-8de3-416e-8604-8cb559ef84b2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties to lawsuit (in investment funds)</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ad48f9fd-d959-4193-b01f-e2ac359908f2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones_a5fca564-77d9-4c1d-aab3-2e1dafc0823d_terseLabel_en-US" xlink:label="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payments under agreement certain milestones</link:label>
    <link:label id="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones_label_en-US" xlink:label="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payments under Agreement Certain Milestones</link:label>
    <link:label id="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones_documentation_en-US" xlink:label="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:href="abbv-20220331.xsd#abbv_PotentialPaymentsUnderAgreementCertainMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:to="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_869f16e6-a948-4ded-a614-c6eebad30bbd_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value - Derivatives in liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_8b06d8bc-59f4-4f2c-97e2-cff3c8139aff_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e2b61d41-8040-4808-a6db-f68bd381f190_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_bea0fe7f-162c-494f-96d6-f9cf6bf95c16_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d281cb12-f62f-4954-b1bc-951ad45be135_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9ac3770b-c951-4cf9-a78d-ab22a51859a5_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_12e54aa1-42ff-4851-b16c-0816a34384d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_efcf7325-2845-4aa8-a93d-7500ccb53df9_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d21903ba-ddc7-435d-9aae-01f00ea68959_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_7f613647-4cbb-4c2d-8e64-5a87a81f3b00_terseLabel_en-US" xlink:label="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation</link:label>
    <link:label id="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_label_en-US" xlink:label="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Antitrust Litigation, In re: Humira (Adalimumab) Antitrust Litigation [Member]</link:label>
    <link:label id="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_documentation_en-US" xlink:label="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to lawsuits filed alleging that AbbVie&#8217;s settlements with biosimilar manufacturers and AbbVie&#8217;s Humira patent portfolio violated state and federal antitrust laws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:href="abbv-20220331.xsd#abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:to="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_26912884-8871-469f-8e37-03ce24072aae_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bbc50c48-866e-4149-8319-c4a764fc39b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant level 3 unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_28f82230-9cfc-4235-96b7-ed8397a68a63_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_VENCLEXTAMember_8a1905a4-cabb-47b2-adeb-302b9f0d736a_terseLabel_en-US" xlink:label="lab_abbv_VENCLEXTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Venclexta</link:label>
    <link:label id="lab_abbv_VENCLEXTAMember_label_en-US" xlink:label="lab_abbv_VENCLEXTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VENCLEXTA [Member]</link:label>
    <link:label id="lab_abbv_VENCLEXTAMember_documentation_en-US" xlink:label="lab_abbv_VENCLEXTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to VENCLEXTA, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VENCLEXTAMember" xlink:href="abbv-20220331.xsd#abbv_VENCLEXTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_VENCLEXTAMember" xlink:to="lab_abbv_VENCLEXTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_19a94b1a-6a10-439b-a38b-3981d120958b_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time Hedged in Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:to="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_631b2102-079a-4720-bfd8-0ffede07bea8_terseLabel_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_label_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_documentation_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:href="abbv-20220331.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:to="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_a54943fa-3b6e-4ac3-8e31-15c5ecd6c85e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_34c0456f-5322-4322-8e4d-354fbe1686a3_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_1b2184bb-2e52-46bb-94c1-ec6417287beb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,811,430,573 shares issued as of March 31, 2022 and 1,803,195,293 as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0ec0fc4b-9def-4b85-b530-2bced0ddc728_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of amounts and location of derivatives on the condensed consolidated balance sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4525c52a-399d-4c52-9578-427aacac74f1_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_EyeCareMember_64840ce1-bcbe-413a-a1e0-022d51cb23ee_terseLabel_en-US" xlink:label="lab_abbv_EyeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eye Care</link:label>
    <link:label id="lab_abbv_EyeCareMember_label_en-US" xlink:label="lab_abbv_EyeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eye Care [Member]</link:label>
    <link:label id="lab_abbv_EyeCareMember_documentation_en-US" xlink:label="lab_abbv_EyeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Eye Care, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_EyeCareMember" xlink:href="abbv-20220331.xsd#abbv_EyeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_EyeCareMember" xlink:to="lab_abbv_EyeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b6c98182-81ae-4f7f-bd9c-4db3b3654fe1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_ed1a2f32-17ba-49d1-b46b-fc8f0f3e17ef_verboseLabel_en-US" xlink:label="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_label_en-US" xlink:label="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Cash Settled Restructuring Gains (Losses)</link:label>
    <link:label id="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_documentation_en-US" xlink:label="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:href="abbv-20220331.xsd#abbv_RestructuringReserveCashSettledRestructuringGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:to="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_ab18278a-052f-4298-9ac9-c9688c9603aa_terseLabel_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities, tax expense (benefit)</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_label_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Tax</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_documentation_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:href="abbv-20220331.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:to="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47a84a94-d5c3-4143-b2c9-9c87f56fbdcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8df42d90-19c9-4a61-8187-db024f65a16c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and license agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a1fc1d0b-b275-4d22-b949-68e327eef22d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cced752c-084c-484f-86b5-a888edb12963_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>abbv-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56dec8fe-bb4b-4711-9c82-c533c008edd6,g:2a065e27-cccc-4ae9-a029-5c29f5f60184-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="abbv-20220331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f05b2126-b0b2-4f7c-a1db-60fe20e572cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f05b2126-b0b2-4f7c-a1db-60fe20e572cc" xlink:to="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:to="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_f5cefcf8-f8f5-461a-9020-db743dbe9f78" xlink:to="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_d193ad1f-96ea-410e-b948-8900548208c0" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:to="loc_exch_XNYS_d193ad1f-96ea-410e-b948-8900548208c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_106a1e2a-b7bc-474d-b95d-169bd0ada64d" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XCHI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_0cad15df-4c2f-4cdc-ae6a-ac8e69785b49" xlink:to="loc_exch_XCHI_106a1e2a-b7bc-474d-b95d-169bd0ada64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e89f89f2-9618-4b40-a207-d0aaaf93606a" xlink:to="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01b95985-5a7c-4f3b-ac81-fbaa45aa0256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_us-gaap_CommonStockMember_01b95985-5a7c-4f3b-ac81-fbaa45aa0256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member_299f37bc-9f31-408f-b556-ca3014614743" xlink:href="abbv-20220331.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1500SeniorNotesDue2023Member_299f37bc-9f31-408f-b556-ca3014614743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_74e604b3-e80a-451e-a797-5f5e0537a9ad" xlink:href="abbv-20220331.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_74e604b3-e80a-451e-a797-5f5e0537a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_fa5f79f0-857b-4b1a-b151-da3787387e2b" xlink:href="abbv-20220331.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_fa5f79f0-857b-4b1a-b151-da3787387e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_de94130e-0fc8-4b40-bfae-8e5fc79382d0" xlink:href="abbv-20220331.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_de94130e-0fc8-4b40-bfae-8e5fc79382d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_4f0423c2-84d7-45a5-80c9-917e2c00e3ef" xlink:href="abbv-20220331.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_4f0423c2-84d7-45a5-80c9-917e2c00e3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_384e0566-7981-4b4b-b878-5235206601c4" xlink:href="abbv-20220331.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_384e0566-7981-4b4b-b878-5235206601c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_fdfe52e3-4d9b-4472-88bf-1edead00bd39" xlink:href="abbv-20220331.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_fdfe52e3-4d9b-4472-88bf-1edead00bd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_9f1055d9-6020-4854-b8c2-8a2534df2472" xlink:href="abbv-20220331.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3d1dc128-73c9-4c02-a5bc-aa898ae2c4e1" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_9f1055d9-6020-4854-b8c2-8a2534df2472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b77eb68c-2c24-4d6e-9183-d876e3259122" xlink:to="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8d014947-dff8-425d-9083-91d1c75b7408" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentType_8d014947-dff8-425d-9083-91d1c75b7408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_06bc5f17-292b-4eb2-beaa-45833c684d70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentQuarterlyReport_06bc5f17-292b-4eb2-beaa-45833c684d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4bd63c43-e06a-443a-bfaa-c1a4c8ef9795" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentPeriodEndDate_4bd63c43-e06a-443a-bfaa-c1a4c8ef9795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a3f5d213-3054-49c5-ba46-771cb5d30725" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentTransitionReport_a3f5d213-3054-49c5-ba46-771cb5d30725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_22521a55-628f-45d1-bbdb-b4c41808123e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityFileNumber_22521a55-628f-45d1-bbdb-b4c41808123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3a2713dc-dac1-431d-96df-65b82f883db0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityRegistrantName_3a2713dc-dac1-431d-96df-65b82f883db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_74f55100-2711-4cb5-a50b-ef40276c8322" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityCentralIndexKey_74f55100-2711-4cb5-a50b-ef40276c8322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ef9e4093-4b27-4df3-981a-e14c49115ee8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentFiscalYearFocus_ef9e4093-4b27-4df3-981a-e14c49115ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_28183f7b-65bf-4b5c-853a-a1ba02fd0986" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_DocumentFiscalPeriodFocus_28183f7b-65bf-4b5c-853a-a1ba02fd0986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e2eea5ba-b8c9-41b2-8943-5278003264d6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_AmendmentFlag_e2eea5ba-b8c9-41b2-8943-5278003264d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6d2980b4-0e3a-4000-b064-34a6924fd531" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_CurrentFiscalYearEndDate_6d2980b4-0e3a-4000-b064-34a6924fd531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f9b58a66-3a9f-44fe-97d5-cdaf00582a78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f9b58a66-3a9f-44fe-97d5-cdaf00582a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e06a3ba7-e10f-47f9-913c-781f292d4578" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityTaxIdentificationNumber_e06a3ba7-e10f-47f9-913c-781f292d4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b287d33c-e9ba-49ee-be7e-8765754880d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressAddressLine1_b287d33c-e9ba-49ee-be7e-8765754880d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0c692742-ec6f-4b6c-9a92-c91d487a9604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressCityOrTown_0c692742-ec6f-4b6c-9a92-c91d487a9604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aafdbe9b-a582-46ec-af60-a5f6630e6831" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressStateOrProvince_aafdbe9b-a582-46ec-af60-a5f6630e6831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_57237ca4-fb27-434c-8619-a4c1420c7350" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityAddressPostalZipCode_57237ca4-fb27-434c-8619-a4c1420c7350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ebd24db5-ac20-4bcf-a109-edec366da6c0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_CityAreaCode_ebd24db5-ac20-4bcf-a109-edec366da6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f21f7238-0d13-4005-962f-e5b4aad830f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_LocalPhoneNumber_f21f7238-0d13-4005-962f-e5b4aad830f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_071d612c-7fc9-495f-9a10-444c37c04cc7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityCurrentReportingStatus_071d612c-7fc9-495f-9a10-444c37c04cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6bdec3ae-7715-4dc1-9e5f-be17c6b3e9f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityInteractiveDataCurrent_6bdec3ae-7715-4dc1-9e5f-be17c6b3e9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c0acc87f-4a8c-4615-8788-e3361af0d620" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityFilerCategory_c0acc87f-4a8c-4615-8788-e3361af0d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5b5327c6-c5e6-43a7-a395-e60e1d31e76e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntitySmallBusiness_5b5327c6-c5e6-43a7-a395-e60e1d31e76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_574017b0-a0b2-43f2-9562-272b67cdabc9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityEmergingGrowthCompany_574017b0-a0b2-43f2-9562-272b67cdabc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_53d2ecf1-24d2-4342-9e61-d7538c0221dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityShellCompany_53d2ecf1-24d2-4342-9e61-d7538c0221dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc89783d-e506-4aca-997a-2acd2b8becd6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_SecurityExchangeName_dc89783d-e506-4aca-997a-2acd2b8becd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_75dd2544-8eab-4676-94ee-e2c0919bc8c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_Security12bTitle_75dd2544-8eab-4676-94ee-e2c0919bc8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8084e4b1-fff0-4051-b599-a11f262a066d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_TradingSymbol_8084e4b1-fff0-4051-b599-a11f262a066d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c33ad587-73e4-4113-a673-aa1cc2b463e5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_658298a9-5043-41e8-955b-7be8a9d18820" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c33ad587-73e4-4113-a673-aa1cc2b463e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofEarningsUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5262ac65-4718-472e-8a99-e9709911bfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_Revenues_5262ac65-4718-472e-8a99-e9709911bfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fac3d497-c2cd-48a0-a618-b7796a79f70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fac3d497-c2cd-48a0-a618-b7796a79f70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c94049ed-71b6-451c-af95-a7cc77b255f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c94049ed-71b6-451c-af95-a7cc77b255f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3dea659b-2f1d-46ce-9e93-4c2604e2490b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3dea659b-2f1d-46ce-9e93-4c2604e2490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1451f1fd-8279-456e-a434-fa4ab5bdf733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1451f1fd-8279-456e-a434-fa4ab5bdf733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8103e8c4-766f-473f-bfa2-fa2192be6cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_CostsAndExpenses_8103e8c4-766f-473f-bfa2-fa2192be6cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f2856042-a78b-4cf8-805e-f9b833d801a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_OperatingIncomeLoss_f2856042-a78b-4cf8-805e-f9b833d801a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_367c97a7-d238-421e-bf06-b8c20b5c301d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_367c97a7-d238-421e-bf06-b8c20b5c301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2085031b-4575-447f-b913-62ce749fb04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2085031b-4575-447f-b913-62ce749fb04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8b534911-a52e-4f55-89b7-71b4c1338947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8b534911-a52e-4f55-89b7-71b4c1338947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11c2edd4-3cd7-41a6-9382-6b9e299dc642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11c2edd4-3cd7-41a6-9382-6b9e299dc642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a6db49db-bebd-4a00-a6a5-eab4ac7068dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a6db49db-bebd-4a00-a6a5-eab4ac7068dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a8f84616-5afa-4fc4-be3c-eadd09fc3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_ProfitLoss_a8f84616-5afa-4fc4-be3c-eadd09fc3b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cfc41038-bb24-4a32-99d5-980adf453eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cfc41038-bb24-4a32-99d5-980adf453eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b58450b6-7398-477c-a98a-e0325f94c246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_NetIncomeLoss_b58450b6-7398-477c-a98a-e0325f94c246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40920fe2-1c1c-41d4-9b82-203136de247d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40920fe2-1c1c-41d4-9b82-203136de247d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_110002e4-17cc-49a0-a702-4677ed94de68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40920fe2-1c1c-41d4-9b82-203136de247d" xlink:to="loc_us-gaap_EarningsPerShareBasic_110002e4-17cc-49a0-a702-4677ed94de68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b726be98-4086-467f-aa4b-8f2607681e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40920fe2-1c1c-41d4-9b82-203136de247d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b726be98-4086-467f-aa4b-8f2607681e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ce5b07cb-b6b2-4adb-aeda-ba8c1cc0a8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ce5b07cb-b6b2-4adb-aeda-ba8c1cc0a8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d2db6b6c-04a2-4b5f-8afc-391d0b0ba7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53bd47b9-be2c-43b9-9845-68006d831ed7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d2db6b6c-04a2-4b5f-8afc-391d0b0ba7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_828953c7-5906-406b-870f-f2731c7bc720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_ProfitLoss_828953c7-5906-406b-870f-f2731c7bc720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_05e7c330-8acd-4899-bf7b-e57b56e3ffce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_05e7c330-8acd-4899-bf7b-e57b56e3ffce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_f895dc50-0ccc-4a13-95b0-18e93d6102c7" xlink:href="abbv-20220331.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_f895dc50-0ccc-4a13-95b0-18e93d6102c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_874b0b03-790c-40b5-aa87-efb5830bcd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_874b0b03-790c-40b5-aa87-efb5830bcd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d6cc5d02-2b96-493b-8d2c-6f15a5c756ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d6cc5d02-2b96-493b-8d2c-6f15a5c756ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e922df7e-e840-4295-8a9c-264be40cef58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e922df7e-e840-4295-8a9c-264be40cef58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a447aff7-9779-470d-b12e-d22057cc09ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a447aff7-9779-470d-b12e-d22057cc09ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c752c7aa-8a1b-4432-80af-6e28dfaa3a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c752c7aa-8a1b-4432-80af-6e28dfaa3a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_93fef7bc-4bd2-4c41-b79f-6602df4ef4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ca4e68a-2be8-4c39-8385-0ae0142f8b2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_93fef7bc-4bd2-4c41-b79f-6602df4ef4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_03498f77-dbed-4282-a8f4-94076ecd637a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_3445a21b-bee8-40ba-944d-082707a87485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_03498f77-dbed-4282-a8f4-94076ecd637a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_3445a21b-bee8-40ba-944d-082707a87485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_427abb33-74d4-466a-8622-4f9e3bd98e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_3445a21b-bee8-40ba-944d-082707a87485" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_427abb33-74d4-466a-8622-4f9e3bd98e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_bce86634-08a5-4486-953f-bdd4ba6a09c8" xlink:href="abbv-20220331.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_3445a21b-bee8-40ba-944d-082707a87485" xlink:to="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_bce86634-08a5-4486-953f-bdd4ba6a09c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_b019b412-40c0-4e2f-b6f8-edfed4bc7cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_3445a21b-bee8-40ba-944d-082707a87485" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_b019b412-40c0-4e2f-b6f8-edfed4bc7cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_71586ce3-a794-4029-8295-0287dba472bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_3445a21b-bee8-40ba-944d-082707a87485" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_71586ce3-a794-4029-8295-0287dba472bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f94c070a-3784-433d-acea-91826599f98c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f94c070a-3784-433d-acea-91826599f98c" xlink:to="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ca5adc4-7520-430f-a3dc-2640e703c85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ca5adc4-7520-430f-a3dc-2640e703c85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c247a981-fbad-48a2-9429-382d5c52e31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:to="loc_us-gaap_ShortTermInvestments_c247a981-fbad-48a2-9429-382d5c52e31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c22ac7a-45ea-4ba2-8093-2807b6b34376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c22ac7a-45ea-4ba2-8093-2807b6b34376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_45ff2cda-3e19-4ed8-83b4-07be4370549c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:to="loc_us-gaap_InventoryNet_45ff2cda-3e19-4ed8-83b4-07be4370549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_48119c86-2606-4356-b0db-2b2f50a21d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_48119c86-2606-4356-b0db-2b2f50a21d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d7db85fd-00eb-422f-b176-5a10fb93fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d96b5fe3-b8c5-4658-8918-ae59169ac17a" xlink:to="loc_us-gaap_AssetsCurrent_d7db85fd-00eb-422f-b176-5a10fb93fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_db67d1c1-8322-437a-a20c-392eab5bae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_LongTermInvestments_db67d1c1-8322-437a-a20c-392eab5bae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_198debec-fb4d-401e-8597-fc99b4f510f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_198debec-fb4d-401e-8597-fc99b4f510f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_48b8ea9b-cbdc-4aa4-89d6-8fb6e5b8d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_48b8ea9b-cbdc-4aa4-89d6-8fb6e5b8d66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_29f6b6ed-91a5-4de3-9552-f49bc4f8c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_Goodwill_29f6b6ed-91a5-4de3-9552-f49bc4f8c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cab13378-9877-4114-b759-8cccc0423378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cab13378-9877-4114-b759-8cccc0423378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b557f403-ed34-4c5c-9d45-4c68ca016cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04b6e6e9-bc5f-443d-a5a1-23032af1babd" xlink:to="loc_us-gaap_Assets_b557f403-ed34-4c5c-9d45-4c68ca016cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f94c070a-3784-433d-acea-91826599f98c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6b794a8d-547f-4c0a-9f77-d17db44afc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6b794a8d-547f-4c0a-9f77-d17db44afc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_eea34494-3a62-47db-9315-20faf7d04098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b794a8d-547f-4c0a-9f77-d17db44afc76" xlink:to="loc_us-gaap_ShortTermBorrowings_eea34494-3a62-47db-9315-20faf7d04098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de0ebf33-fe7e-4a27-a116-88552a22e064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b794a8d-547f-4c0a-9f77-d17db44afc76" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de0ebf33-fe7e-4a27-a116-88552a22e064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_88b50788-b8ea-46da-95ed-bd71441e210a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b794a8d-547f-4c0a-9f77-d17db44afc76" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_88b50788-b8ea-46da-95ed-bd71441e210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9c1c5181-fcad-44f4-b2fa-fa470b5fc599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b794a8d-547f-4c0a-9f77-d17db44afc76" xlink:to="loc_us-gaap_LiabilitiesCurrent_9c1c5181-fcad-44f4-b2fa-fa470b5fc599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ef2db62-fe6d-404a-8d53-7a2c67157a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ef2db62-fe6d-404a-8d53-7a2c67157a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_70a13095-66e3-41ce-9487-d1a7c4f1edc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_70a13095-66e3-41ce-9487-d1a7c4f1edc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_249a7899-0145-4138-a22c-87500990fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_249a7899-0145-4138-a22c-87500990fd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_41142d37-783c-4c6d-b231-e905b43c37b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_41142d37-783c-4c6d-b231-e905b43c37b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_31926eb1-158d-4467-8830-ca916f86f49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_31926eb1-158d-4467-8830-ca916f86f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ded43482-7294-4e8e-96ff-59647c96f84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:to="loc_us-gaap_TreasuryStockValue_ded43482-7294-4e8e-96ff-59647c96f84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5b100db0-0ce7-456e-b9b1-0eac4292be4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5b100db0-0ce7-456e-b9b1-0eac4292be4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_302383d1-1c3c-414f-982e-2db47a841cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_302383d1-1c3c-414f-982e-2db47a841cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a6412b68-0a2a-4b7c-98de-f4121597c7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a6412b68-0a2a-4b7c-98de-f4121597c7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71201f37-0833-48d5-b11a-41facc27e348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_079a272e-58a5-4c4f-8139-b78b3c8c8b9c" xlink:to="loc_us-gaap_StockholdersEquity_71201f37-0833-48d5-b11a-41facc27e348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b4565670-8a3a-42eb-8342-d84247e2c557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_MinorityInterest_b4565670-8a3a-42eb-8342-d84247e2c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16fb24af-fa35-4b67-b66b-501d6cf5aa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16fb24af-fa35-4b67-b66b-501d6cf5aa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f45d5e36-93c5-4a2c-87e9-7c261e9d8e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e65d383-7a28-4f68-a91a-238c838ff5e5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f45d5e36-93c5-4a2c-87e9-7c261e9d8e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cb47fb62-c9b4-48fc-ad7c-b68807e01fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_858d92bb-6597-4d2d-99b7-8f2251e2c50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cb47fb62-c9b4-48fc-ad7c-b68807e01fe2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_858d92bb-6597-4d2d-99b7-8f2251e2c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99818948-430c-4263-82a7-226cad38ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cb47fb62-c9b4-48fc-ad7c-b68807e01fe2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_99818948-430c-4263-82a7-226cad38ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_09f021d2-635a-4a12-bdfd-f13940ce5821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cb47fb62-c9b4-48fc-ad7c-b68807e01fe2" xlink:to="loc_us-gaap_CommonStockSharesIssued_09f021d2-635a-4a12-bdfd-f13940ce5821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_051b0f59-3170-4317-976d-78accac6e5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cb47fb62-c9b4-48fc-ad7c-b68807e01fe2" xlink:to="loc_us-gaap_TreasuryStockShares_051b0f59-3170-4317-976d-78accac6e5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bc2c92d1-5703-4fb7-b6f3-e95902097e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bc2c92d1-5703-4fb7-b6f3-e95902097e9a" xlink:to="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8c15386-4577-42bc-ae04-255e3a4fb3fd" xlink:to="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9bd90ce-6035-43cd-8e4a-e2a858405164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_CommonStockMember_e9bd90ce-6035-43cd-8e4a-e2a858405164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b4c3f5e-9ef4-41a9-9f1a-2c28bd45ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_TreasuryStockMember_2b4c3f5e-9ef4-41a9-9f1a-2c28bd45ff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0b238cd4-133f-448b-9e4a-062c4b117ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0b238cd4-133f-448b-9e4a-062c4b117ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9197ff93-90dd-488d-ad59-5bf2e01e2365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_RetainedEarningsMember_9197ff93-90dd-488d-ad59-5bf2e01e2365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3f542ac9-a6e1-407e-8f90-d5260d38fa58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3f542ac9-a6e1-407e-8f90-d5260d38fa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6b1f62b4-b474-4140-8f12-8a2a1375ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86e6b572-5ee5-4241-9878-eab2018997d2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6b1f62b4-b474-4140-8f12-8a2a1375ec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_12b8376f-9c8b-4f88-88ae-e7357a0e8562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54b6d0c6-b3c7-446e-8566-da0e86c1e152" xlink:to="loc_us-gaap_StatementLineItems_12b8376f-9c8b-4f88-88ae-e7357a0e8562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12b8376f-9c8b-4f88-88ae-e7357a0e8562" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3f61d56-263d-4d92-97d3-d16fdfb57989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3f61d56-263d-4d92-97d3-d16fdfb57989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6ab9ee2d-673a-49a7-8b4a-1c5b5db45b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_SharesOutstanding_6ab9ee2d-673a-49a7-8b4a-1c5b5db45b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3843ee64-2f9a-469c-b11d-d2f90f1b333d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_NetIncomeLoss_3843ee64-2f9a-469c-b11d-d2f90f1b333d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19d0d431-11fb-404b-95cb-4ee9775f51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19d0d431-11fb-404b-95cb-4ee9775f51fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7cb5db5e-dd56-4e62-92db-f8465aa2faba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_DividendsCommonStockCash_7cb5db5e-dd56-4e62-92db-f8465aa2faba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_433db83c-2c5e-494b-815c-b0708b407ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_433db83c-2c5e-494b-815c-b0708b407ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_be376fb9-6a4b-464b-8432-2203538c9517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_be376fb9-6a4b-464b-8432-2203538c9517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_face21c2-8798-43b1-a8f4-a23c8a8a1542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_face21c2-8798-43b1-a8f4-a23c8a8a1542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a0e61201-c379-4f82-bfc9-ef3b8b2f5672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a0e61201-c379-4f82-bfc9-ef3b8b2f5672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_863849c2-bb7e-49f8-9c19-9a32355ea1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_863849c2-bb7e-49f8-9c19-9a32355ea1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b27d6d3d-4322-4a75-89e5-317db3018b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b27d6d3d-4322-4a75-89e5-317db3018b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_57396afa-d958-45d7-a241-443719f6ef97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f76e27e1-7ab2-46d8-9b9b-0160176c5e4b" xlink:to="loc_us-gaap_SharesOutstanding_57396afa-d958-45d7-a241-443719f6ef97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="abbv-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_387cbd0f-7129-4322-8e67-7bf4eebc07b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_ProfitLoss_387cbd0f-7129-4322-8e67-7bf4eebc07b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2c919ca3-9af7-4d76-9592-56cd4efe8e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2c919ca3-9af7-4d76-9592-56cd4efe8e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2c919ca3-9af7-4d76-9592-56cd4efe8e11" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4750be13-27e3-42e2-a7e2-9fc8c013fb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_Depreciation_4750be13-27e3-42e2-a7e2-9fc8c013fb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a4e5afd5-087b-45f0-a740-3e1479ef4a10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a4e5afd5-087b-45f0-a740-3e1479ef4a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a1ff8317-e6f6-48a6-8088-cb5cb583c8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a1ff8317-e6f6-48a6-8088-cb5cb583c8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8a0aa873-8ba8-4775-9804-8c8f3024f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8a0aa873-8ba8-4775-9804-8c8f3024f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8d5f90d0-0c2d-4a4a-a092-e5da28716008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_ShareBasedCompensation_8d5f90d0-0c2d-4a4a-a092-e5da28716008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0a7d6395-bc58-4771-9f69-1ea249fc18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0a7d6395-bc58-4771-9f69-1ea249fc18b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0fcb7b76-67fd-4f49-aaaf-510ab8ecc2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0fcb7b76-67fd-4f49-aaaf-510ab8ecc2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14c84b1-83b1-48d2-8bac-6799eb310389" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e9c526c4-8d5e-482c-90a2-6a9bb69d9e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e9c526c4-8d5e-482c-90a2-6a9bb69d9e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c171aa73-eba7-4a47-b9df-33fd4bbe9928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c171aa73-eba7-4a47-b9df-33fd4bbe9928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0fc65a28-4197-4ce7-a419-e3022f9a0c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0fc65a28-4197-4ce7-a419-e3022f9a0c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f85de6b5-cb10-40b4-a57f-421479f53135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f85de6b5-cb10-40b4-a57f-421479f53135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_f32f149e-2d0e-491f-8358-b88254d63ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a4e96b6f-027b-4726-975e-18040c80e56d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_f32f149e-2d0e-491f-8358-b88254d63ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cc2eb6e-14ae-4f34-a219-d570f618e0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2c919ca3-9af7-4d76-9592-56cd4efe8e11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cc2eb6e-14ae-4f34-a219-d570f618e0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_785c5991-3894-48dd-a501-fe03c5d6b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_785c5991-3894-48dd-a501-fe03c5d6b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4831e548-4aa6-476a-b57b-f164a8df5624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4831e548-4aa6-476a-b57b-f164a8df5624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8dc9ce3e-a3fe-4c85-90e4-02a5c30f5c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8dc9ce3e-a3fe-4c85-90e4-02a5c30f5c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_32543c9d-8a23-423b-a410-a8c31d289d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_32543c9d-8a23-423b-a410-a8c31d289d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_eb3186bd-f44c-4177-a7d9-a9929e74ff27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_eb3186bd-f44c-4177-a7d9-a9929e74ff27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7582a80-c0e7-416b-996c-92cc92826742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1f10dfd6-eb2f-4b29-ad3e-84eba26c8d23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7582a80-c0e7-416b-996c-92cc92826742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8441f264-56d2-4a50-bbe6-673735bee3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8441f264-56d2-4a50-bbe6-673735bee3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_2cef9efc-d186-4fe4-91e5-f67286f6fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_2cef9efc-d186-4fe4-91e5-f67286f6fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_e7d693f6-db79-4a39-97d2-10b565f4f64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_PaymentsOfDividends_e7d693f6-db79-4a39-97d2-10b565f4f64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_acbedbc3-3629-4c2c-962f-c0d8b5d78c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_acbedbc3-3629-4c2c-962f-c0d8b5d78c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_88a202e4-cfbe-43e1-b42a-0e4cdabdce72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_88a202e4-cfbe-43e1-b42a-0e4cdabdce72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b62793dc-7c84-484e-be28-94d7052fbf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b62793dc-7c84-484e-be28-94d7052fbf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0b52317a-04b1-43df-963d-3deb782cd262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0b52317a-04b1-43df-963d-3deb782cd262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3fd18c4-bc0c-436d-b8b2-1a565a64f726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2333eb89-59ba-40ca-ad7c-df596652b0cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3fd18c4-bc0c-436d-b8b2-1a565a64f726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_bc9e1716-c869-458f-b084-8fd6c69507ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_bc9e1716-c869-458f-b084-8fd6c69507ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12b863b7-8d42-4f9f-8f32-60ef14674a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12b863b7-8d42-4f9f-8f32-60ef14674a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f9ea3de-433f-4a9a-8812-42cb5bd66c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f9ea3de-433f-4a9a-8812-42cb5bd66c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7aea1934-cb48-4d1b-bad2-9773ed666530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce65793f-7285-43b8-b3dc-309252d44aa7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7aea1934-cb48-4d1b-bad2-9773ed666530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/BasisofPresentation" xlink:type="simple" xlink:href="abbv-20220331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28975918-d3d6-4273-892c-5e7cf2ffe260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_377a53df-942e-44f8-bd1f-e349b44f6826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28975918-d3d6-4273-892c-5e7cf2ffe260" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_377a53df-942e-44f8-bd1f-e349b44f6826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c583446b-dd52-4fd7-bb82-d32ad2291a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_640da35d-d4f0-467d-9200-0e14be4cfd66" xlink:href="abbv-20220331.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c583446b-dd52-4fd7-bb82-d32ad2291a6c" xlink:to="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_640da35d-d4f0-467d-9200-0e14be4cfd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_b2d0415a-82a5-4fc7-952f-81812fe824fa" xlink:href="abbv-20220331.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c583446b-dd52-4fd7-bb82-d32ad2291a6c" xlink:to="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_b2d0415a-82a5-4fc7-952f-81812fe824fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformation" xlink:type="simple" xlink:href="abbv-20220331.xsd#SupplementalFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_a7d2d074-82e7-41cd-bf5e-f87d230aaff8" xlink:href="abbv-20220331.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9f0b2c23-64cb-4b2a-b71c-a09b536745ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_a7d2d074-82e7-41cd-bf5e-f87d230aaff8" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9f0b2c23-64cb-4b2a-b71c-a09b536745ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#SupplementalFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_d4c15246-d3d5-4681-abbd-03cae05c8172" xlink:href="abbv-20220331.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_f31511c5-a661-43c4-b314-9b68af460f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_d4c15246-d3d5-4681-abbd-03cae05c8172" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_f31511c5-a661-43c4-b314-9b68af460f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bfc700ac-47bd-4f54-8663-9d7c82d3e94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_d4c15246-d3d5-4681-abbd-03cae05c8172" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bfc700ac-47bd-4f54-8663-9d7c82d3e94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7dfe004b-a1b5-4ac9-a80d-083853370779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_d4c15246-d3d5-4681-abbd-03cae05c8172" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7dfe004b-a1b5-4ac9-a80d-083853370779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#SupplementalFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_6d670088-129c-4b09-8139-19a18cdf4f1f" xlink:href="abbv-20220331.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_dbe17932-6612-4c51-8e5b-302889e07d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueOrExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_6d670088-129c-4b09-8139-19a18cdf4f1f" xlink:to="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_dbe17932-6612-4c51-8e5b-302889e07d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6bffcbf1-7330-4982-868b-3d6a7e754ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_dbe17932-6612-4c51-8e5b-302889e07d2f" xlink:to="loc_us-gaap_InterestExpense_6bffcbf1-7330-4982-868b-3d6a7e754ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f53e7462-4a61-46dc-bd48-8c0e993915a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_dbe17932-6612-4c51-8e5b-302889e07d2f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f53e7462-4a61-46dc-bd48-8c0e993915a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a96826be-d0f1-4610-9a70-4e72cf0f4230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_dbe17932-6612-4c51-8e5b-302889e07d2f" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a96826be-d0f1-4610-9a70-4e72cf0f4230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_193521f8-9957-4540-b536-4b5b62cb7d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_6d670088-129c-4b09-8139-19a18cdf4f1f" xlink:to="loc_us-gaap_InventoryNetAbstract_193521f8-9957-4540-b536-4b5b62cb7d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_424a5133-2228-490e-a42d-980403c70dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_193521f8-9957-4540-b536-4b5b62cb7d3e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_424a5133-2228-490e-a42d-980403c70dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4b9ff862-3982-4186-a2e9-a944f4b53abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_193521f8-9957-4540-b536-4b5b62cb7d3e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4b9ff862-3982-4186-a2e9-a944f4b53abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c5de399e-9ef7-453d-a3a7-91cba28443b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_193521f8-9957-4540-b536-4b5b62cb7d3e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c5de399e-9ef7-453d-a3a7-91cba28443b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cb215411-e68c-4f77-89c4-6ef2318bfaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_193521f8-9957-4540-b536-4b5b62cb7d3e" xlink:to="loc_us-gaap_InventoryNet_cb215411-e68c-4f77-89c4-6ef2318bfaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_98778bd7-c00b-4fa4-b4ee-5f721b872de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_6d670088-129c-4b09-8139-19a18cdf4f1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_98778bd7-c00b-4fa4-b4ee-5f721b872de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1f8e55d8-7727-42b1-a42d-817466e09381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_98778bd7-c00b-4fa4-b4ee-5f721b872de8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1f8e55d8-7727-42b1-a42d-817466e09381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc2b4bc0-bb3f-42de-ae2d-0aa5cd3e92f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_98778bd7-c00b-4fa4-b4ee-5f721b872de8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc2b4bc0-bb3f-42de-ae2d-0aa5cd3e92f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d8e8a1c2-b433-46aa-8ba5-197bacf77ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_98778bd7-c00b-4fa4-b4ee-5f721b872de8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d8e8a1c2-b433-46aa-8ba5-197bacf77ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a38bf3b2-f5b0-4f28-81ff-ca576c095537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_98778bd7-c00b-4fa4-b4ee-5f721b872de8" xlink:to="loc_us-gaap_Depreciation_a38bf3b2-f5b0-4f28-81ff-ca576c095537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShare" xlink:type="simple" xlink:href="abbv-20220331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_421e857a-fcc5-40e6-ad7c-4c823eb910bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5a524587-c49e-446f-b152-3a0bbd3ee92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_421e857a-fcc5-40e6-ad7c-4c823eb910bf" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5a524587-c49e-446f-b152-3a0bbd3ee92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d4db8dd6-6969-477c-9b01-e1240e1de364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f3e7dd6c-5351-4ce5-b20d-6df38d01fda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4db8dd6-6969-477c-9b01-e1240e1de364" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f3e7dd6c-5351-4ce5-b20d-6df38d01fda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f5d27690-4b1d-4076-8212-f6d0e03ba354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicTwoClassMethodAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5d27690-4b1d-4076-8212-f6d0e03ba354" xlink:to="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7235a63a-4809-4ef5-b603-5ec1332e9bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:to="loc_us-gaap_NetIncomeLoss_7235a63a-4809-4ef5-b603-5ec1332e9bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_b9f2dca6-b7f5-4d22-a97c-96663a931e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_b9f2dca6-b7f5-4d22-a97c-96663a931e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7acaf5f1-f480-4017-aa6a-ff0082896688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7acaf5f1-f480-4017-aa6a-ff0082896688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_29a8df10-be5c-43ab-8d31-39bf0d2656ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_29a8df10-be5c-43ab-8d31-39bf0d2656ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_32d2ef90-bc0c-4a84-9783-96e202695114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_628b398b-7ce3-4dc5-a596-1fcfe63da2dc" xlink:to="loc_us-gaap_EarningsPerShareBasic_32d2ef90-bc0c-4a84-9783-96e202695114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5d27690-4b1d-4076-8212-f6d0e03ba354" xlink:to="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ef37c4c-e3fb-4022-b4d8-8f75f949f099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_NetIncomeLoss_3ef37c4c-e3fb-4022-b4d8-8f75f949f099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_8197b0e1-fd07-4bb3-85c5-74c0a1a2f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_8197b0e1-fd07-4bb3-85c5-74c0a1a2f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_85f7d6e9-1a85-4ee0-b9a3-91bdcc691c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_85f7d6e9-1a85-4ee0-b9a3-91bdcc691c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa656217-2dd2-4d24-a492-70fd9613384d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa656217-2dd2-4d24-a492-70fd9613384d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_58b63b38-e2bb-4c4f-b896-fefede8bf6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_58b63b38-e2bb-4c4f-b896-fefede8bf6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52c424e3-d97d-4cc3-9fb0-0d3d0e449f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52c424e3-d97d-4cc3-9fb0-0d3d0e449f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eee18f3c-17d9-4557-95a6-f6c61862cc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_8739369f-26d9-47bb-bc09-0ce84c130e12" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eee18f3c-17d9-4557-95a6-f6c61862cc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements" xlink:type="simple" xlink:href="abbv-20220331.xsd#LicensingAcquisitionsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_eee4964d-37d0-432a-a4f9-4273f8fd4b43" xlink:href="abbv-20220331.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_2e478dd5-489f-4b9f-8bcf-1bb3e75c3240" xlink:href="abbv-20220331.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_eee4964d-37d0-432a-a4f9-4273f8fd4b43" xlink:to="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_2e478dd5-489f-4b9f-8bcf-1bb3e75c3240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#LicensingAcquisitionsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_1a72fb50-b8e6-435e-bd58-9514c0989839" xlink:href="abbv-20220331.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_1a72fb50-b8e6-435e-bd58-9514c0989839" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc0838ff-4c28-490c-8a0e-15630c6f1752" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_02f2e785-430e-48ba-a5f1-34ec87cbddda" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc0838ff-4c28-490c-8a0e-15630c6f1752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SyndesiMember_c23a8cc2-6aaf-4700-9512-1e11fabc9e58" xlink:href="abbv-20220331.xsd#abbv_SyndesiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc0838ff-4c28-490c-8a0e-15630c6f1752" xlink:to="loc_abbv_SyndesiMember_c23a8cc2-6aaf-4700-9512-1e11fabc9e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14775ee7-7569-4ddf-bb29-9e89bea09157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92a1bec5-31bc-4802-935e-9f41dd64aa1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14775ee7-7569-4ddf-bb29-9e89bea09157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b6da50e0-3caf-4086-86bf-b982458515f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14775ee7-7569-4ddf-bb29-9e89bea09157" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b6da50e0-3caf-4086-86bf-b982458515f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec2218c6-2270-4056-8d15-ee7893c1a89d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a961665e-ca05-47ad-8510-6a92d9dafb78" xlink:to="loc_srt_RangeMember_ec2218c6-2270-4056-8d15-ee7893c1a89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cfdffbb3-f3cd-4d9b-a71c-c871c7d59f2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ec2218c6-2270-4056-8d15-ee7893c1a89d" xlink:to="loc_srt_MaximumMember_cfdffbb3-f3cd-4d9b-a71c-c871c7d59f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8536afa7-7ad9-43cf-bcb6-511cebb8ec44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43417ec6-6929-49d7-9c9f-c18982797fc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8536afa7-7ad9-43cf-bcb6-511cebb8ec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_36daec53-9db5-4b1f-b393-ab138c7b3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8536afa7-7ad9-43cf-bcb6-511cebb8ec44" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_36daec53-9db5-4b1f-b393-ab138c7b3a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f51e781-f9e4-4f68-ae37-6760c17a40ef" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_68b26173-d44c-4b05-beaf-40105c24fb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_68b26173-d44c-4b05-beaf-40105c24fb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0555eb80-98f7-476e-9759-33574b620e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0555eb80-98f7-476e-9759-33574b620e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_262dd832-fe31-497e-a4c5-33d859857037" xlink:href="abbv-20220331.xsd#abbv_PotentialPaymentsUnderAgreementCertainMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7633033-88a7-4b69-87e7-1acd50153255" xlink:to="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_262dd832-fe31-497e-a4c5-33d859857037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/Collaborations" xlink:type="simple" xlink:href="abbv-20220331.xsd#Collaborations"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/Collaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract_626c3c90-f2fa-4bd3-b035-affe2021dc45" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_76939771-e83a-42a3-bee5-6bfdac95ecea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_CollaborativeArrangementsAbstract_626c3c90-f2fa-4bd3-b035-affe2021dc45" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_76939771-e83a-42a3-bee5-6bfdac95ecea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#CollaborationsTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CollaborationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract_e0fbf831-e802-475c-89d4-4c78dcc4e19d" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_CollaborativeArrangementsAbstract_e0fbf831-e802-475c-89d4-4c78dcc4e19d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:to="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5017c204-33b6-4562-8e48-1bb7dd3c4b1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_d369c64b-b4f8-4184-8971-94347088b62f" xlink:href="abbv-20220331.xsd#abbv_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:to="loc_abbv_JanssenBiotechIncMember_d369c64b-b4f8-4184-8971-94347088b62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_4a9fa1bf-1bb4-4e6b-9e04-d0f1a7838101" xlink:href="abbv-20220331.xsd#abbv_GenentechInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe88446a-bd96-48f8-a6ad-7f023ab60ac1" xlink:to="loc_abbv_GenentechInc.Member_4a9fa1bf-1bb4-4e6b-9e04-d0f1a7838101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e87c6f0-649a-4eb8-893f-0dc933d8aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d6b4d503-9267-4329-981a-1baf8c3a7460" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e87c6f0-649a-4eb8-893f-0dc933d8aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_b5d1b2b5-e7b0-45c4-921f-20febd33757b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e87c6f0-649a-4eb8-893f-0dc933d8aabf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_b5d1b2b5-e7b0-45c4-921f-20febd33757b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#CollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract_1f050450-b7a4-42d1-bda2-8afc4b4c4197" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_CollaborativeArrangementsAbstract_1f050450-b7a4-42d1-bda2-8afc4b4c4197" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4abcafcb-0078-48f5-a92c-90839ab260e6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_1e43541b-56a5-409b-aaf4-8a0d2961b691" xlink:href="abbv-20220331.xsd#abbv_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:to="loc_abbv_JanssenBiotechIncMember_1e43541b-56a5-409b-aaf4-8a0d2961b691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_4b438749-c231-4958-a26c-58cba28ad3ab" xlink:href="abbv-20220331.xsd#abbv_GenentechInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79cdb0-4704-4517-ba51-3392bd9dde30" xlink:to="loc_abbv_GenentechInc.Member_4b438749-c231-4958-a26c-58cba28ad3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a3efe3c-334a-41aa-8aab-ace80e688b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e0bc18db-4158-4b52-aeb8-5011a8cf91b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a3efe3c-334a-41aa-8aab-ace80e688b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_53c6dfac-4888-4ad1-8430-5fa1b433b067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a3efe3c-334a-41aa-8aab-ace80e688b00" xlink:to="loc_us-gaap_CollaborativeArrangementMember_53c6dfac-4888-4ad1-8430-5fa1b433b067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_eaf8156b-fe8e-47a6-a810-2cebca22a043" xlink:to="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_54a5dc8c-99ed-44a9-adde-b648867f0c58" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:to="loc_country_US_54a5dc8c-99ed-44a9-adde-b648867f0c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_8ed7a902-83a8-4221-861f-5c75fe1f5bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9b689c5-719b-43cb-9dd5-9172e2924b0c" xlink:to="loc_us-gaap_NonUsMember_8ed7a902-83a8-4221-861f-5c75fe1f5bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93e4b8a3-183f-4fca-86a2-be79952548b1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_b54e3a2d-5c6d-490b-abb8-5aa1ba8b3242" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_b54e3a2d-5c6d-490b-abb8-5aa1ba8b3242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_cc3ccec3-8df0-4599-816a-69c097399b27" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_cc3ccec3-8df0-4599-816a-69c097399b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_f28c62a4-8230-45b9-a3c1-4d956a79b4a4" xlink:href="abbv-20220331.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_f28c62a4-8230-45b9-a3c1-4d956a79b4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_887daee4-25fb-421b-a437-f5ea163d5b3c" xlink:href="abbv-20220331.xsd#abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_887daee4-25fb-421b-a437-f5ea163d5b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_841345e1-fb82-48df-8842-e87fee77780c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_841345e1-fb82-48df-8842-e87fee77780c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherExpensesFromCollaborativeArrangements_592851c1-cee8-4d05-8ea0-12919c137ac6" xlink:href="abbv-20220331.xsd#abbv_OtherExpensesFromCollaborativeArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_OtherExpensesFromCollaborativeArrangements_592851c1-cee8-4d05-8ea0-12919c137ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_612bd560-42cf-4013-9191-53960be617e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_612bd560-42cf-4013-9191-53960be617e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb414fa1-03a5-4661-abd0-9d8da2556418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb414fa1-03a5-4661-abd0-9d8da2556418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_5d565fba-bf84-44a6-86b0-9a9e07825fb2" xlink:href="abbv-20220331.xsd#abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_5d565fba-bf84-44a6-86b0-9a9e07825fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_b58cf2ad-a705-4d7f-9d73-80b220920489" xlink:href="abbv-20220331.xsd#abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_992d4172-cc70-49dd-9b77-ce2000343333" xlink:to="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_b58cf2ad-a705-4d7f-9d73-80b220920489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="abbv-20220331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8fb125a-0706-4965-9f3b-a46ff1d21700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5092f2ff-f850-4a2b-9af8-d6440ead0c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8fb125a-0706-4965-9f3b-a46ff1d21700" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5092f2ff-f850-4a2b-9af8-d6440ead0c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a0dcc633-835c-44a8-beaf-5817e3c26c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ebdd44c8-e16a-4b17-8f00-79b96d8b82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a0dcc633-835c-44a8-beaf-5817e3c26c98" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ebdd44c8-e16a-4b17-8f00-79b96d8b82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c0265e3a-5c98-4c26-a80b-45a4d031f330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a0dcc633-835c-44a8-beaf-5817e3c26c98" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c0265e3a-5c98-4c26-a80b-45a4d031f330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_bdffc461-8a1f-4667-87a7-5f117f030cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a0dcc633-835c-44a8-beaf-5817e3c26c98" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_bdffc461-8a1f-4667-87a7-5f117f030cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5986e2ac-4067-4fa8-9725-30a81ecf209e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3856805d-ee25-4715-af01-7bf45fdc3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5986e2ac-4067-4fa8-9725-30a81ecf209e" xlink:to="loc_us-gaap_GoodwillRollForward_3856805d-ee25-4715-af01-7bf45fdc3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2aba83f6-4065-4bcd-a8f0-229f6b99b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3856805d-ee25-4715-af01-7bf45fdc3a09" xlink:to="loc_us-gaap_Goodwill_2aba83f6-4065-4bcd-a8f0-229f6b99b5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_3cd01334-0d15-491f-932b-a875a4250294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3856805d-ee25-4715-af01-7bf45fdc3a09" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_3cd01334-0d15-491f-932b-a875a4250294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5230a8ac-836d-488c-afea-ee8b5b3821b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3856805d-ee25-4715-af01-7bf45fdc3a09" xlink:to="loc_us-gaap_Goodwill_5230a8ac-836d-488c-afea-ee8b5b3821b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_e9b16f6c-82a5-4543-988f-281f67dc6c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5986e2ac-4067-4fa8-9725-30a81ecf209e" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_e9b16f6c-82a5-4543-988f-281f67dc6c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_93e9816a-de7e-4f7e-a33c-03013ece2c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_e9b16f6c-82a5-4543-988f-281f67dc6c61" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_93e9816a-de7e-4f7e-a33c-03013ece2c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05686d61-d433-49d8-955a-8727407490e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05686d61-d433-49d8-955a-8727407490e2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9905d461-06da-479d-93c8-0c11cce6f0b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5efdd12b-7dee-4023-8ef4-60b8ab9a3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5efdd12b-7dee-4023-8ef4-60b8ab9a3bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3d88affd-9083-4303-8f15-bb87cbb0b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4fbfb7c-a281-44df-9252-c1d4da4e90ce" xlink:to="loc_us-gaap_LicensingAgreementsMember_3d88affd-9083-4303-8f15-bb87cbb0b5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5768bb58-b15e-4fe5-8d73-22f0c06ee04b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1aedd471-52e7-43d9-9195-35c23c795ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1aedd471-52e7-43d9-9195-35c23c795ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4914c2db-5997-47b4-9b6a-64ef081dd5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4914c2db-5997-47b4-9b6a-64ef081dd5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9af4351f-0416-4a9b-af15-53bea3897d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9af4351f-0416-4a9b-af15-53bea3897d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e82dabf1-0406-4a94-827b-3acd5481b6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e82dabf1-0406-4a94-827b-3acd5481b6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b56840d2-ba7a-4c18-b359-3fd9f153b6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b56840d2-ba7a-4c18-b359-3fd9f153b6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5e972b49-ca0f-4809-840a-cd5b1704ee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ca0acb77-8634-4884-9ed2-f302868447af" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5e972b49-ca0f-4809-840a-cd5b1704ee51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c86037ed-fc7c-442c-a5f9-4a30662e2f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05686d61-d433-49d8-955a-8727407490e2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c86037ed-fc7c-442c-a5f9-4a30662e2f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlans" xlink:type="simple" xlink:href="abbv-20220331.xsd#IntegrationandRestructuringPlans"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b70e364f-5244-4c02-b63f-796515061f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_dd84916e-5987-44f6-9b81-431d30acb4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b70e364f-5244-4c02-b63f-796515061f8a" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_dd84916e-5987-44f6-9b81-431d30acb4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#IntegrationandRestructuringPlansTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1d994d52-add2-4f34-b3db-7848cf9d9338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1d994d52-add2-4f34-b3db-7848cf9d9338" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:to="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_2e2f5e29-73f2-432f-a86a-719acb47e669" xlink:to="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_2fcdc20c-699c-4b71-9ecd-49fc67a80245" xlink:href="abbv-20220331.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:to="loc_abbv_AllerganIntegrationPlanMember_2fcdc20c-699c-4b71-9ecd-49fc67a80245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_cd2805ca-4461-4474-9105-54bb8547190d" xlink:href="abbv-20220331.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d7b620da-9fdf-4b22-a858-efef589b603d" xlink:to="loc_abbv_OtherRestructuringPlansMember_cd2805ca-4461-4474-9105-54bb8547190d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab915ff7-3b03-4681-acf5-62afe88b9053" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1fbdf2d5-0c58-4753-b93f-999f04f08591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1fbdf2d5-0c58-4753-b93f-999f04f08591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ad65b25f-a6b4-4a16-9ae8-7ba19f35d2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ab4e85e9-5b82-4730-8dfb-3e5a146b701c" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ad65b25f-a6b4-4a16-9ae8-7ba19f35d2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#IntegrationandRestructuringPlansDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_52f816c2-20a1-4b34-a0c3-828ff8db8016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_52f816c2-20a1-4b34-a0c3-828ff8db8016" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_0f46c812-3cbe-46b7-8a68-7affd74e7d5a" xlink:to="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_06a446dc-dd79-4948-ba05-fba334a16725" xlink:href="abbv-20220331.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:to="loc_abbv_AllerganIntegrationPlanMember_06a446dc-dd79-4948-ba05-fba334a16725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_cd999699-c89a-4511-933c-467d9ba040e7" xlink:href="abbv-20220331.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cd4e521-cb60-464e-a04b-d101c5caba92" xlink:to="loc_abbv_OtherRestructuringPlansMember_cd999699-c89a-4511-933c-467d9ba040e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e2d90b66-7646-4e35-b304-c2ca9189ff61" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_499e2155-e406-4e3b-945b-5fc340c4619e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_499e2155-e406-4e3b-945b-5fc340c4619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_4dbad78c-a212-445c-a631-ac9a15420924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b0785f99-fe3c-479c-828d-ddf2af1e2f2b" xlink:to="loc_us-gaap_OtherRestructuringMember_4dbad78c-a212-445c-a631-ac9a15420924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abaac714-41e6-4797-bf81-4f6fea384931" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9b71b2a0-eff6-4e07-9081-87f26fc6ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:to="loc_us-gaap_CostOfSalesMember_9b71b2a0-eff6-4e07-9081-87f26fc6ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b348e742-8989-4fe0-8568-201269a14df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b348e742-8989-4fe0-8568-201269a14df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_693fc321-1556-40cf-a8c1-59ad8939fe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d494913-756e-4411-a627-3dea9a21d9fc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_693fc321-1556-40cf-a8c1-59ad8939fe9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f8b9bb53-0803-451f-87a1-48747a322117" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f6cdd7f3-8af4-40fb-a857-4d6170fac64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f6cdd7f3-8af4-40fb-a857-4d6170fac64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1b650b75-ef9d-42a4-8c78-4fa72ad50787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1b650b75-ef9d-42a4-8c78-4fa72ad50787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_30ddf16c-b462-4534-9085-f28f26417eaf" xlink:to="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7ea3afb2-695c-45db-9d49-dee5e57230e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_us-gaap_RestructuringReserve_7ea3afb2-695c-45db-9d49-dee5e57230e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_cdbf08b9-9122-4443-b350-0b59db47a872" xlink:href="abbv-20220331.xsd#abbv_RestructuringReserveCashSettledRestructuringGainsLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_cdbf08b9-9122-4443-b350-0b59db47a872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_100cd326-d81a-4f43-9566-a94fb46a6adf" xlink:href="abbv-20220331.xsd#abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_100cd326-d81a-4f43-9566-a94fb46a6adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_278da9e9-888a-424f-927e-4d2fcb6c48a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7779759f-2a46-4491-9bd1-9c4ab630ebfb" xlink:to="loc_us-gaap_RestructuringReserve_278da9e9-888a-424f-927e-4d2fcb6c48a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasures"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_815b6388-566a-4a76-be6f-5bf60d332272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesAndFairValueTextBlock_a1c1f3ea-8e03-4a70-a40b-3d2b9d224495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_815b6388-566a-4a76-be6f-5bf60d332272" xlink:to="loc_us-gaap_DerivativesAndFairValueTextBlock_a1c1f3ea-8e03-4a70-a40b-3d2b9d224495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4e7be23d-1d6b-47c7-bb50-b136f943970f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4e7be23d-1d6b-47c7-bb50-b136f943970f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8c6e8ea7-58de-47e7-acbe-0bc06acc96f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8c6e8ea7-58de-47e7-acbe-0bc06acc96f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9739cb43-dd2a-452b-9935-8df160140be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9739cb43-dd2a-452b-9935-8df160140be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8e580c66-ada7-447b-b667-67c2d508bf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8e580c66-ada7-447b-b667-67c2d508bf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1e9cae4e-a885-4596-a347-7615c3d24ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1e9cae4e-a885-4596-a347-7615c3d24ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fc117edf-2932-44ce-8dc1-9191bc8fd6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fc117edf-2932-44ce-8dc1-9191bc8fd6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_756c641d-7967-4bcf-a143-9d386bbe8f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_756c641d-7967-4bcf-a143-9d386bbe8f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_94729dc7-6bcf-407f-b63f-edeff0a09fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fdd28b27-9b9b-4cad-af16-18759710dfbf" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_94729dc7-6bcf-407f-b63f-edeff0a09fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7bb0f963-7298-439d-b9c7-352523be120b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7bb0f963-7298-439d-b9c7-352523be120b" xlink:to="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_fcddb258-342e-4045-97ef-ae9b728a3c54" xlink:to="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cb96db0-2114-4d60-bc8a-83e46ce8d6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cb96db0-2114-4d60-bc8a-83e46ce8d6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2d956806-15f4-4f40-ba3b-9c2b35909c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_87216495-1959-4761-b897-b3e673490725" xlink:to="loc_us-gaap_NondesignatedMember_2d956806-15f4-4f40-ba3b-9c2b35909c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e527a9f6-22f9-42d1-a886-f418279b6c0c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_784965d4-eadf-4868-93e4-ac4eca18711c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_784965d4-eadf-4868-93e4-ac4eca18711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_d5c8b715-b2e4-439d-bca5-a2615957d793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:to="loc_us-gaap_TreasuryLockMember_d5c8b715-b2e4-439d-bca5-a2615957d793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5ad6612c-3d4c-464a-b7e7-ce21457a981d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_03a4d2c9-9b45-4941-83cc-0acfd8ee9bf8" xlink:to="loc_us-gaap_InterestRateSwapMember_5ad6612c-3d4c-464a-b7e7-ce21457a981d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7e854cb3-f3a5-41ea-a1d0-419964c54e6d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bb455877-6f5c-4a2a-9519-c2b61cf1da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:to="loc_us-gaap_CashFlowHedgingMember_bb455877-6f5c-4a2a-9519-c2b61cf1da3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ea867675-f283-4883-9e0d-f93b1570bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ea867675-f283-4883-9e0d-f93b1570bbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b040b02c-cc46-4dbd-bdee-7003d32ca448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b16d3ead-ae34-4cec-b21e-e73c02dcdec7" xlink:to="loc_us-gaap_FairValueHedgingMember_b040b02c-cc46-4dbd-bdee-7003d32ca448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b76b51c2-1c24-4853-820e-37587ec4ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5afad1a5-94a7-4646-90c1-f3cac9680ae2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b76b51c2-1c24-4853-820e-37587ec4ec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3bb6498b-f4b0-4bf8-9777-ca9a230f0c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b76b51c2-1c24-4853-820e-37587ec4ec9e" xlink:to="loc_us-gaap_SeniorNotesMember_3bb6498b-f4b0-4bf8-9777-ca9a230f0c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_da3ca75f-0367-4a14-aa85-317869fbe24a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ab825570-74db-4103-b42e-56f52cf2304f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ab825570-74db-4103-b42e-56f52cf2304f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f6f8ec78-e8de-45e5-b47f-37418f24e326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f6f8ec78-e8de-45e5-b47f-37418f24e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_4e0f1eaf-b27c-4e9d-ae5f-1ece9ba18e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_4e0f1eaf-b27c-4e9d-ae5f-1ece9ba18e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_7ff71237-e47d-447e-bb72-ce76b205627f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d99acbf2-738d-4d76-af6e-e7fe7b457089" xlink:to="loc_us-gaap_OtherLiabilitiesMember_7ff71237-e47d-447e-bb72-ce76b205627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0854bf67-4256-4e46-aa71-36ffbec2fb02" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_844e42a7-7f55-43c7-89f5-1ccc4cc28b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeNotionalAmount_844e42a7-7f55-43c7-89f5-1ccc4cc28b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_83c4d0ea-dec7-4159-8f5f-bc41be6dd80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeTermOfContract_83c4d0ea-dec7-4159-8f5f-bc41be6dd80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_cdb0926d-3f4c-4e57-8502-280b2bcc0849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_cdb0926d-3f4c-4e57-8502-280b2bcc0849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fbd7c17e-33de-4c81-9742-b0e0824bdc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fbd7c17e-33de-4c81-9742-b0e0824bdc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_e89676bd-ba98-4dfb-889a-8eb20912b7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_e89676bd-ba98-4dfb-889a-8eb20912b7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_139ff5b6-0d38-4853-b6a8-f2a0b5741047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_139ff5b6-0d38-4853-b6a8-f2a0b5741047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d03611fc-0fc3-48d7-b4bd-51be2603556f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d03611fc-0fc3-48d7-b4bd-51be2603556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d2428-93b2-4836-a251-8d1231df5e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_01e51eb5-dfb5-4bb9-b49d-4a26932f2e7f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d2428-93b2-4836-a251-8d1231df5e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83f19994-e1e3-4089-b3f1-897ae3801bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83f19994-e1e3-4089-b3f1-897ae3801bd2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fd0110c2-a9a3-4a8f-b1d8-73a6fee7a297" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_8fef7cb3-c695-4cd7-9473-5c3590810165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_8fef7cb3-c695-4cd7-9473-5c3590810165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_76a08528-15be-47de-8c85-0757564a95c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:to="loc_us-gaap_InterestRateSwapMember_76a08528-15be-47de-8c85-0757564a95c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_7668dfd4-cafe-4dbc-b0e2-7135b5fd6c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_807af97c-8328-4598-b65a-a10e9fa7c6d9" xlink:to="loc_us-gaap_TreasuryLockMember_7668dfd4-cafe-4dbc-b0e2-7135b5fd6c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_257163c8-0023-4305-b003-2d2e6e566040" xlink:to="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa226e21-769c-46f2-8490-25060323e430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa226e21-769c-46f2-8490-25060323e430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_88659b97-d4a9-491e-a855-56880862b003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f46800df-4676-40d5-a006-e6af16f37b3a" xlink:to="loc_us-gaap_NondesignatedMember_88659b97-d4a9-491e-a855-56880862b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_521be55e-bb53-405e-8a01-8a0ff99e1d36" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_15738f87-4a50-4935-8215-87c4482f93d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:to="loc_us-gaap_CostOfSalesMember_15738f87-4a50-4935-8215-87c4482f93d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_e4257612-0631-4026-989f-e3c756ce41ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:to="loc_us-gaap_InterestExpenseMember_e4257612-0631-4026-989f-e3c756ce41ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyGainLossMember_66c1f448-fee4-4c39-aceb-ef004394435e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_980ad14a-130b-49e3-97aa-e8f2dcbdfbeb" xlink:to="loc_us-gaap_ForeignCurrencyGainLossMember_66c1f448-fee4-4c39-aceb-ef004394435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3007699b-8e8b-4a72-8783-aad30588c519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_066a1891-dc8e-40a4-82ba-b8d52400f6ad" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3007699b-8e8b-4a72-8783-aad30588c519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_397980d1-9545-4ea7-886e-65abaa65af9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3007699b-8e8b-4a72-8783-aad30588c519" xlink:to="loc_us-gaap_SeniorNotesMember_397980d1-9545-4ea7-886e-65abaa65af9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9d233d5f-1918-4ea5-9349-71866934db6f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e6f9d834-21a4-431e-9c18-d8c2c78a0fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:to="loc_us-gaap_CashFlowHedgingMember_e6f9d834-21a4-431e-9c18-d8c2c78a0fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_63f73064-bbe1-4663-833e-a78b7df235af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_63f73064-bbe1-4663-833e-a78b7df235af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_9b8f17b8-9dbf-4623-b840-c4e4cdbf972b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_09a1dd63-1cb6-4de7-8772-f7b29f32fa5b" xlink:to="loc_us-gaap_FairValueHedgingMember_9b8f17b8-9dbf-4623-b840-c4e4cdbf972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_81d396df-9b8d-423a-9ea7-ead7cf2bb36e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d1b79351-1fe9-48fb-80d4-b587cf642a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d1b79351-1fe9-48fb-80d4-b587cf642a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_462b7a4d-866a-42a9-9e5a-75a7fedf18e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_462b7a4d-866a-42a9-9e5a-75a7fedf18e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_b0642c77-0e93-40d1-97f2-c6a45ef76a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_b0642c77-0e93-40d1-97f2-c6a45ef76a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_3eab89f2-8150-4c34-a1da-eccfc60444e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_3eab89f2-8150-4c34-a1da-eccfc60444e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_fd4b4ae4-e565-4191-b6b6-ad6f003d0ad3" xlink:href="abbv-20220331.xsd#abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_fd4b4ae4-e565-4191-b6b6-ad6f003d0ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e656c80a-5205-456a-8d19-d694b31b0620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e656c80a-5205-456a-8d19-d694b31b0620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_ce339923-ad64-4aeb-8ba2-c62a9431df39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aec23d64-e544-4ef5-8e24-850856390010" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_ce339923-ad64-4aeb-8ba2-c62a9431df39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a17048e9-3d94-443d-bd27-517d57cef653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a17048e9-3d94-443d-bd27-517d57cef653" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2a84712c-1cf8-463a-afab-2412b421bdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_52d462ad-a14a-4ab6-9ca4-cda910cb766d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2a84712c-1cf8-463a-afab-2412b421bdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e1e1aea5-a830-4013-881d-f347a377fe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a84712c-1cf8-463a-afab-2412b421bdf1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e1e1aea5-a830-4013-881d-f347a377fe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a108e7-ef12-4724-b4d0-583d046e0bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec18a53-4fba-4c6c-adfd-604cd353b478" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a108e7-ef12-4724-b4d0-583d046e0bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_84ac7e32-2915-4c3a-8881-b75b1a1fcb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a108e7-ef12-4724-b4d0-583d046e0bae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_84ac7e32-2915-4c3a-8881-b75b1a1fcb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b8babb5-ecd4-4b05-bc81-9fd48349565b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6578c5fc-4de9-4056-afe7-1716d0362d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6578c5fc-4de9-4056-afe7-1716d0362d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_838e752f-a59e-424d-bedf-b92443e39951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_838e752f-a59e-424d-bedf-b92443e39951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2b2dc8a9-24a3-4aa2-8e8b-83fb1efd7ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715ced23-c437-46e7-a774-38e41d825006" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2b2dc8a9-24a3-4aa2-8e8b-83fb1efd7ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_62b18b87-1020-4a1f-a25a-6d70da902912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_96b78d07-30fa-43df-b7db-0fb58809c2ea" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_62b18b87-1020-4a1f-a25a-6d70da902912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6030c419-f962-4816-ac22-e996a6a41c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_62b18b87-1020-4a1f-a25a-6d70da902912" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6030c419-f962-4816-ac22-e996a6a41c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abcb566d-8d65-4cf0-a823-0c3732be075d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61f84972-eacb-4c72-877f-83cafce138f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61f84972-eacb-4c72-877f-83cafce138f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_99f937b6-871a-4a27-a2e6-c44b99b157c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_99f937b6-871a-4a27-a2e6-c44b99b157c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a072089-3a4e-4437-a48c-903d2551dbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a072089-3a4e-4437-a48c-903d2551dbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f46d1c65-5402-4990-908f-ae8ed7951061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f46d1c65-5402-4990-908f-ae8ed7951061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c89c7baa-91fa-4ace-a599-c332fe9ba454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c89c7baa-91fa-4ace-a599-c332fe9ba454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_29468fc3-abc2-462a-b264-a50819e03a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_29468fc3-abc2-462a-b264-a50819e03a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ad1c407c-ccef-45bb-8307-c1b873a0919e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2fadc31d-fc01-4c70-8e6d-5b0f8aff971e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ad1c407c-ccef-45bb-8307-c1b873a0919e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e21052b-9d96-47da-af69-142f2d563898" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b772ccaa-ab86-4cad-9ba8-0cf255051f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b772ccaa-ab86-4cad-9ba8-0cf255051f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d2a5ca31-e50a-4829-8491-30d83524d31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d2a5ca31-e50a-4829-8491-30d83524d31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a85c360c-d3db-4b9d-83ba-2b3771ef7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a85c360c-d3db-4b9d-83ba-2b3771ef7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8741a89e-ff06-487e-b00a-3629218ab466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c5c9a24e-66b9-44c1-a6c9-bb1d587ca89c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8741a89e-ff06-487e-b00a-3629218ab466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_467efe47-80d8-4079-b29e-6e7143dc213d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_467efe47-80d8-4079-b29e-6e7143dc213d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:to="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7039ba95-b80e-464c-b681-965aef4fddd1" xlink:to="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_518a5cf6-d54b-405c-aee8-de4253eb66dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:to="loc_srt_WeightedAverageMember_518a5cf6-d54b-405c-aee8-de4253eb66dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08d2b223-66c1-411a-ba7c-7a7669b2051d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:to="loc_srt_MinimumMember_08d2b223-66c1-411a-ba7c-7a7669b2051d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_16ca6393-ad00-4599-8059-55831be9d288" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcf00260-2f78-4b60-a92f-d75404cbe95e" xlink:to="loc_srt_MaximumMember_16ca6393-ad00-4599-8059-55831be9d288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_190fd039-3030-4f5b-83a6-31a1ab0168b7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b00eaebc-02d1-47de-b513-0433716b7910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b00eaebc-02d1-47de-b513-0433716b7910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_3f5a2d6b-d84e-4ace-b8c7-bcf7ff26072e" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforUnachievedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_3f5a2d6b-d84e-4ace-b8c7-bcf7ff26072e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_3def7ae9-6f81-4287-8285-35818e124dd7" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_3def7ae9-6f81-4287-8285-35818e124dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProjectedYearofPaymentsMember_f48f05ac-9282-4e40-8239-41241302bee0" xlink:href="abbv-20220331.xsd#abbv_ProjectedYearofPaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProjectedYearofPaymentsMember_f48f05ac-9282-4e40-8239-41241302bee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a2e3aa89-d458-401b-b71c-5a0ea794e601" xlink:href="abbv-20220331.xsd#abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8da4cbb6-ad61-40a8-bc29-7268e23aa33a" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a2e3aa89-d458-401b-b71c-5a0ea794e601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02047208-1474-42e8-a2e2-1ca7bbc4dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bf9f355-7ca5-43f2-922d-11ddc1e36094" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02047208-1474-42e8-a2e2-1ca7bbc4dd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bd83bdd3-ef0a-4360-9697-7893a45da8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02047208-1474-42e8-a2e2-1ca7bbc4dd55" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bd83bdd3-ef0a-4360-9697-7893a45da8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4073c8b0-444a-4fbb-94c1-8802abd992ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_5e2cab9e-0de1-4dde-9177-d81610100c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4073c8b0-444a-4fbb-94c1-8802abd992ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_5e2cab9e-0de1-4dde-9177-d81610100c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_c3fb3aa7-0c26-49c6-9ba7-13e122f56b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_5e2cab9e-0de1-4dde-9177-d81610100c52" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_c3fb3aa7-0c26-49c6-9ba7-13e122f56b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a09718fd-f7eb-452e-b490-7cf153fec516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_5e2cab9e-0de1-4dde-9177-d81610100c52" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a09718fd-f7eb-452e-b490-7cf153fec516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_b6d13e41-7246-4d9a-a44c-a733d1e01f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4073c8b0-444a-4fbb-94c1-8802abd992ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_b6d13e41-7246-4d9a-a44c-a733d1e01f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_6adb1512-2486-4384-a09a-3453d5f5a44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_b6d13e41-7246-4d9a-a44c-a733d1e01f0f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_6adb1512-2486-4384-a09a-3453d5f5a44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_b04b61e3-0400-4470-ad73-796944b9c3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_b6d13e41-7246-4d9a-a44c-a733d1e01f0f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_b04b61e3-0400-4470-ad73-796944b9c3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7a0b2cde-1e77-4ca5-95f7-0ecb0c4d0dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4073c8b0-444a-4fbb-94c1-8802abd992ab" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7a0b2cde-1e77-4ca5-95f7-0ecb0c4d0dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_329bda2c-bab5-47e4-b93f-1bba9dadfc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7a0b2cde-1e77-4ca5-95f7-0ecb0c4d0dbd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_329bda2c-bab5-47e4-b93f-1bba9dadfc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6eac73e9-70d0-427d-9aa6-4253843e0806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7a0b2cde-1e77-4ca5-95f7-0ecb0c4d0dbd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6eac73e9-70d0-427d-9aa6-4253843e0806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0c6bfaac-9571-442e-bb96-815d2ca504d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7a0b2cde-1e77-4ca5-95f7-0ecb0c4d0dbd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0c6bfaac-9571-442e-bb96-815d2ca504d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1fcb2e31-fa24-42ca-af35-a1fa669a450f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7a0b2cde-1e77-4ca5-95f7-0ecb0c4d0dbd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1fcb2e31-fa24-42ca-af35-a1fa669a450f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e6fe92d4-8abe-45c5-8ff0-c7f8c28d2d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e6fe92d4-8abe-45c5-8ff0-c7f8c28d2d79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_62a94982-7101-4bd9-905f-4b93461c4c51" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2e87b020-e926-4b3c-b755-1b31f7923206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2e87b020-e926-4b3c-b755-1b31f7923206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9f98b8d9-3db0-4c86-b16c-abbc5bd5983c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9f98b8d9-3db0-4c86-b16c-abbc5bd5983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c454bb3b-887d-41dc-a14b-48b77b443b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_390f2b61-0282-44e8-9889-2893c4884556" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c454bb3b-887d-41dc-a14b-48b77b443b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bda1fc7-10b1-467a-ad4d-e0969cf3cf4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b335ad60-c347-4e07-89ab-cf5a3860f0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b335ad60-c347-4e07-89ab-cf5a3860f0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_296971b7-ee44-4697-9068-728514590877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_296971b7-ee44-4697-9068-728514590877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5c417168-7a82-48ce-87c8-fccf4e17935d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed895435-cc64-4f9c-ac27-c36407098a72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5c417168-7a82-48ce-87c8-fccf4e17935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7394608-a7e3-4fcc-8c9e-efc2e23746f3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue_99ef7a71-db6c-4853-84b8-bc6139ea84dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_us-gaap_ShorttermDebtFairValue_99ef7a71-db6c-4853-84b8-bc6139ea84dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_165fe508-3d0f-4bdb-84ee-24a32b6c4f48" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_165fe508-3d0f-4bdb-84ee-24a32b6c4f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_b328a0bb-06f4-49eb-bfba-f2b787d53adb" xlink:href="abbv-20220331.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_b328a0bb-06f4-49eb-bfba-f2b787d53adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c067c848-9eef-414c-a481-986bc4b4e914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_50765a02-a2f7-4ed8-b308-5d37bfd32c71" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c067c848-9eef-414c-a481-986bc4b4e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_39c0bff2-33e1-408d-9d2f-2c8a994ce428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a3ace4e-7d1f-462e-b726-e20df1a42fe0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_39c0bff2-33e1-408d-9d2f-2c8a994ce428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a96cf854-4a16-4c1a-ad58-3437b24cfab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a96cf854-4a16-4c1a-ad58-3437b24cfab4" xlink:to="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2b96c557-0e81-457d-8117-230e25f57ef8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d77c03e4-479c-4ba2-9c4c-9613fd0657bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:to="loc_us-gaap_AccountsReceivableMember_d77c03e4-479c-4ba2-9c4c-9613fd0657bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4302f8ac-fa95-44e2-b166-a505e59cc26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d98bb8a-eb42-4113-be66-bf97bf682bfd" xlink:to="loc_us-gaap_SalesRevenueNetMember_4302f8ac-fa95-44e2-b166-a505e59cc26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_28509239-9fa0-4d5d-bf75-e49d702c1d6d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_e8eeade3-b2b7-49d2-b11d-37404f4452ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_e8eeade3-b2b7-49d2-b11d-37404f4452ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_231e8927-c284-4288-9fd6-c5f4f39856c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78b4a03d-7ce4-4094-9ecf-700c80747398" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_231e8927-c284-4288-9fd6-c5f4f39856c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7622b386-b6c2-4643-b462-d5666a9e3559" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e03f9d9d-de87-4f76-82fc-3014223d68bc" xlink:to="loc_srt_ProductsAndServicesDomain_7622b386-b6c2-4643-b462-d5666a9e3559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_47cd9421-9e99-482f-8e6a-dd312be2b2ae" xlink:href="abbv-20220331.xsd#abbv_HUMIRAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7622b386-b6c2-4643-b462-d5666a9e3559" xlink:to="loc_abbv_HUMIRAMember_47cd9421-9e99-482f-8e6a-dd312be2b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b4944d43-838a-4ee5-817a-be93e68d8493" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9846d78d-62d6-4553-b820-e38ba5b10b55" xlink:to="loc_srt_NameOfMajorCustomerDomain_b4944d43-838a-4ee5-817a-be93e68d8493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrincipalUSCustomersMember_f8111b90-18ef-44bf-b63a-c12ba243a51b" xlink:href="abbv-20220331.xsd#abbv_PrincipalUSCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b4944d43-838a-4ee5-817a-be93e68d8493" xlink:to="loc_abbv_PrincipalUSCustomersMember_f8111b90-18ef-44bf-b63a-c12ba243a51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_fcdde1e9-1016-4eaf-9c90-0153a169530c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NumberOfPrincipalUSCustomers_c9aa957e-498a-4c80-91d6-048e62a0a6a1" xlink:href="abbv-20220331.xsd#abbv_NumberOfPrincipalUSCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:to="loc_abbv_NumberOfPrincipalUSCustomers_c9aa957e-498a-4c80-91d6-048e62a0a6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1bad1ed0-adb4-4d51-b235-b0a001427f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_120bfd4c-e4ae-426a-9ab6-386637dcb3f8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1bad1ed0-adb4-4d51-b235-b0a001427f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a3360c73-f0f2-417c-8c0e-722fecea825f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a3360c73-f0f2-417c-8c0e-722fecea825f" xlink:to="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1768035f-27e4-4a0b-b67d-1260320bc276" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.450PercentMember_b2c1fe65-92eb-43a5-9b3b-a7ec1ef73cc5" xlink:href="abbv-20220331.xsd#abbv_SeniorNotesDue2022At3.450PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:to="loc_abbv_SeniorNotesDue2022At3.450PercentMember_b2c1fe65-92eb-43a5-9b3b-a7ec1ef73cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_6ae1adc1-794c-44d5-acd3-9b8e0ba481bb" xlink:href="abbv-20220331.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_6ae1adc1-794c-44d5-acd3-9b8e0ba481bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_02e9b48c-1293-4198-aa15-5a86b7016fb9" xlink:href="abbv-20220331.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c518dcec-a6d1-4541-9111-8f9bef9d717b" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_02e9b48c-1293-4198-aa15-5a86b7016fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85abca0f-7dda-4ab6-abef-c97885ca33d6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a2efc2ee-155a-4a64-b1ae-d531318bca97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:to="loc_us-gaap_SeniorNotesMember_a2efc2ee-155a-4a64-b1ae-d531318bca97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_88955b7a-0e13-4755-9e2c-f297cf0533ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fe36fd56-77d3-4cad-834e-972a1703c16d" xlink:to="loc_us-gaap_LoansPayableMember_88955b7a-0e13-4755-9e2c-f297cf0533ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7fa3cd4-e49b-45ab-a4b8-b41a69c6a22c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_a38281cc-26af-458e-98a7-f8bb356a7427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_a38281cc-26af-458e-98a7-f8bb356a7427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a452660-8c83-4a8f-a843-4e055a6c3220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a452660-8c83-4a8f-a843-4e055a6c3220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_e483808d-d840-4f3f-adfc-97461be565b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_e483808d-d840-4f3f-adfc-97461be565b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e89b183a-3dba-49fc-bc4e-75c9eaf2b17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_DebtInstrumentTerm_e89b183a-3dba-49fc-bc4e-75c9eaf2b17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2695bd79-4b2a-48c5-bcb6-66f7564a5bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4641393-706b-4cd1-b2f8-a464bc3fca0a" xlink:to="loc_us-gaap_LongTermDebt_2695bd79-4b2a-48c5-bcb6-66f7564a5bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefits" xlink:type="simple" xlink:href="abbv-20220331.xsd#PostEmploymentBenefits"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_46c247f8-c638-4372-b223-c136b363aeff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock_2f0cbe8d-6efb-4ee5-a45d-5f5ebae5fd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_46c247f8-c638-4372-b223-c136b363aeff" xlink:to="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock_2f0cbe8d-6efb-4ee5-a45d-5f5ebae5fd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#PostEmploymentBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_b2daf78b-3800-464b-8f0a-84a68dd3de81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_6bc7b9e1-5a15-4833-a7bd-25d4d94a3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_b2daf78b-3800-464b-8f0a-84a68dd3de81" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_6bc7b9e1-5a15-4833-a7bd-25d4d94a3d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#PostEmploymentBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_cc4d22ec-1004-44fc-b229-c84c314a4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_cc4d22ec-1004-44fc-b229-c84c314a4ce4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9d5c3d07-3d7d-4487-9bc0-9e813960628a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ed5bb012-f5ba-495e-9c6f-84ca8dbeba11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ed5bb012-f5ba-495e-9c6f-84ca8dbeba11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a769f8d-a9f2-4f07-aecb-73eb9f3cb266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_67d38be9-9207-406a-b1ed-6c342532531e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a769f8d-a9f2-4f07-aecb-73eb9f3cb266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55eee29e-d07e-44c8-87b2-287205d03918" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_24f77b13-7c16-4019-9657-130ba12c43ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_24f77b13-7c16-4019-9657-130ba12c43ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_e713f42b-c466-47b1-8179-564a6e92275c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_e713f42b-c466-47b1-8179-564a6e92275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_94bc429e-b4d1-4595-a711-1221ee61dbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_94bc429e-b4d1-4595-a711-1221ee61dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_3501a141-7669-4083-8aa9-91ccf31ec8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_3501a141-7669-4083-8aa9-91ccf31ec8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_ecae36e4-f9df-4dc8-8507-03f3cbcc3239" xlink:href="abbv-20220331.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_ecae36e4-f9df-4dc8-8507-03f3cbcc3239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ea8ea1be-173f-4dbf-9115-f4929516c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_073ef4ed-235e-46ce-bf61-672e1cfeff2b" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ea8ea1be-173f-4dbf-9115-f4929516c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/Equity" xlink:type="simple" xlink:href="abbv-20220331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_74f15934-9bc9-48ff-bee4-9fa16bd1f033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_067da296-c706-41bf-bea5-0d79de7f1af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_74f15934-9bc9-48ff-bee4-9fa16bd1f033" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_067da296-c706-41bf-bea5-0d79de7f1af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d9c22a2c-4a7a-47d5-b210-c38549830223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a9a80cd3-ecf3-4153-a012-6cf1620c1da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d9c22a2c-4a7a-47d5-b210-c38549830223" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a9a80cd3-ecf3-4153-a012-6cf1620c1da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDividendsPayableTextBlock_ed717d10-5b9e-4ce5-8d19-c01983db22e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDividendsPayableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d9c22a2c-4a7a-47d5-b210-c38549830223" xlink:to="loc_us-gaap_ScheduleOfDividendsPayableTextBlock_ed717d10-5b9e-4ce5-8d19-c01983db22e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_da3dbe9c-51d8-472c-8a5a-130747ae43ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d9c22a2c-4a7a-47d5-b210-c38549830223" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_da3dbe9c-51d8-472c-8a5a-130747ae43ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_bfc9e586-da42-4ff9-ac5a-48a53c02bded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d9c22a2c-4a7a-47d5-b210-c38549830223" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_bfc9e586-da42-4ff9-ac5a-48a53c02bded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4bb15781-09dc-434d-a8c7-9f454851530e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4bb15781-09dc-434d-a8c7-9f454851530e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69782dc2-6fb4-447a-a0ec-7df9de71c940" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b5f92c9b-bd59-4ad0-9d61-c8aacbe2e036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:to="loc_us-gaap_CostOfSalesMember_b5f92c9b-bd59-4ad0-9d61-c8aacbe2e036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5ad7ac8-2add-4d5d-912b-be114d056b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5ad7ac8-2add-4d5d-912b-be114d056b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e83e38e-c162-4410-add5-636d8511913d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19702819-30c8-46ed-ad8d-923395ba7e41" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e83e38e-c162-4410-add5-636d8511913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddac7eb2-4a85-47ae-890d-df4baa8b4706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bf21ca1-72a1-46c2-a6c9-a3ada5f3eaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bf21ca1-72a1-46c2-a6c9-a3ada5f3eaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_50516cfc-314d-4db4-92ce-03d3bde14ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_50516cfc-314d-4db4-92ce-03d3bde14ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_51d237a4-a686-41e4-983f-b4b7947ee58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fbeff04-9033-4598-8969-11783b6ee36d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_51d237a4-a686-41e4-983f-b4b7947ee58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_63090436-9d17-4613-947f-7b08db0389ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_63090436-9d17-4613-947f-7b08db0389ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:to="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb22c810-9569-42d0-8c28-c54aca8b9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_69536bd1-0ef1-4851-affa-035380f6a6f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb22c810-9569-42d0-8c28-c54aca8b9aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f6757109-2011-4230-9b5b-b13fa7031982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb22c810-9569-42d0-8c28-c54aca8b9aa8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f6757109-2011-4230-9b5b-b13fa7031982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a1e1ea7-3ae5-41bc-8c4c-9b3b890a90d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a7003de-20be-439a-8fba-4b3216491f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a7003de-20be-439a-8fba-4b3216491f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_690c5b8e-c1ef-47b5-b125-80e32a8eda5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_690c5b8e-c1ef-47b5-b125-80e32a8eda5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bdefccb8-5538-4e45-a19e-fe1781b9656d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bdefccb8-5538-4e45-a19e-fe1781b9656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2d17f0dc-d214-42b1-b6d2-3c6772a1f366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9daf846-3e04-4371-bb1c-8df94e1b1e48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2d17f0dc-d214-42b1-b6d2-3c6772a1f366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityRSUsandPerformanceSharesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_64c2cba5-b50d-4b4e-9871-ef1ea34f59a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64c2cba5-b50d-4b4e-9871-ef1ea34f59a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:to="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ccb1c33-2f8d-4420-913c-97a7db41e3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_928c476d-8d91-4ea1-9b92-eaa39a27eccd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ccb1c33-2f8d-4420-913c-97a7db41e3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_de6f59b0-b270-4c01-9001-bc7f239f8b76" xlink:href="abbv-20220331.xsd#abbv_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ccb1c33-2f8d-4420-913c-97a7db41e3b6" xlink:to="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_de6f59b0-b270-4c01-9001-bc7f239f8b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e5a3df-53f8-4d38-82e5-e8dfa9dee14e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9613d6cf-da42-4587-a1ad-93413f05073b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9613d6cf-da42-4587-a1ad-93413f05073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1056778f-7dcf-4f50-8e66-5b0bc8f67324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1056778f-7dcf-4f50-8e66-5b0bc8f67324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3cf0b0c-9e99-412e-b3b5-4dad6490b053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3cf0b0c-9e99-412e-b3b5-4dad6490b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ad12545a-e1a5-4006-b3f0-178635092869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8cd2110-3e91-4afa-bbc2-5d9a47793f3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ad12545a-e1a5-4006-b3f0-178635092869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityCashDividendsDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityCashDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityCashDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_99e5a14b-63aa-4564-b680-fe733f6f9a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_9ae1f025-6ac5-4d55-beae-a1f5d23b6715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_99e5a14b-63aa-4564-b680-fe733f6f9a78" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_9ae1f025-6ac5-4d55-beae-a1f5d23b6715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityStockRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_33b48766-79b6-47f7-ad42-85e4cd9a0371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_33b48766-79b6-47f7-ad42-85e4cd9a0371" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d1dfacca-94b5-4ec1-997d-03c2dbf8e897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4b628b21-91fb-45f4-a513-9595a07fdb40" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d1dfacca-94b5-4ec1-997d-03c2dbf8e897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_December2018StockRepurchaseAuthorizationMember_a5791ba4-1178-4738-abd0-3c8fab4eaba1" xlink:href="abbv-20220331.xsd#abbv_December2018StockRepurchaseAuthorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_d1dfacca-94b5-4ec1-997d-03c2dbf8e897" xlink:to="loc_abbv_December2018StockRepurchaseAuthorizationMember_a5791ba4-1178-4738-abd0-3c8fab4eaba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_65036ea8-e19f-47a3-bd0d-e68509805f02" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_46ddda24-0c14-4fdc-9b50-69e8624c9aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_46ddda24-0c14-4fdc-9b50-69e8624c9aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_083b6203-c7fb-4b59-abb0-779ceabb2021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_083b6203-c7fb-4b59-abb0-779ceabb2021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6fa6feab-af15-4890-8629-3ced7c980ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_266d810c-c23a-43c2-b4c0-8e4d787cd7db" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6fa6feab-af15-4890-8629-3ced7c980ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c2e5f07c-8420-4501-97d7-2f43c0f06d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c2e5f07c-8420-4501-97d7-2f43c0f06d0b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2936dfaf-9370-455e-9221-b5508bf012bd" xlink:to="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ce9f095c-fc9b-45b5-9f2b-15629aa69cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ce9f095c-fc9b-45b5-9f2b-15629aa69cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_f9657c56-8fb2-451a-888e-5d3eb2ca4040" xlink:href="abbv-20220331.xsd#abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_f9657c56-8fb2-451a-888e-5d3eb2ca4040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a02f0e25-7f88-48af-b01d-c19add673a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a02f0e25-7f88-48af-b01d-c19add673a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_586dfdee-a39c-4704-9721-690e3baf9b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_586dfdee-a39c-4704-9721-690e3baf9b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df657f8-4d55-47b8-96f2-86d922c3a108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_06cecf84-e599-4fb0-a951-c47b4522ab90" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df657f8-4d55-47b8-96f2-86d922c3a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ae9dfc8e-68a0-402a-8960-76fe445c0693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_309218dd-0553-49bc-b57b-f5d6f8a3c3bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ae9dfc8e-68a0-402a-8960-76fe445c0693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ae9dfc8e-68a0-402a-8960-76fe445c0693" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d729ca9b-2f41-4574-baaf-4fa27f78680a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d729ca9b-2f41-4574-baaf-4fa27f78680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_69c2d229-7987-47bd-a702-ee5538b78789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_69c2d229-7987-47bd-a702-ee5538b78789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f3b14f10-2e6e-48f2-ac43-74346e5265f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f3b14f10-2e6e-48f2-ac43-74346e5265f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e199bbf-9f45-4747-953d-644cde1bf72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e199bbf-9f45-4747-953d-644cde1bf72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f5996d35-0b3b-4bdd-8ca4-b7b9bf59d6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc1f990f-4749-4c1b-ad0f-8e0cc6447443" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f5996d35-0b3b-4bdd-8ca4-b7b9bf59d6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2ecfaa77-117a-4683-817e-1fd3fcf13693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2ecfaa77-117a-4683-817e-1fd3fcf13693" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c1f52a4e-f3e7-48cf-b26e-fc1586170b40" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_ef76fcbb-dc4b-47c8-9fc9-c0f80b84968e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_ef76fcbb-dc4b-47c8-9fc9-c0f80b84968e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_2d3bc50d-9937-464a-adcc-b7cac0886881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:to="loc_us-gaap_TreasuryLockMember_2d3bc50d-9937-464a-adcc-b7cac0886881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_868bd658-b695-42ce-b9db-d0d04bc35c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0edf3b31-83f2-45ac-a37a-fb8dc5997aca" xlink:to="loc_us-gaap_InterestRateSwapMember_868bd658-b695-42ce-b9db-d0d04bc35c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_48d53c1e-009c-4e0c-88b0-0b5623a7cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a181ebe3-9892-4f87-acb5-ffbb2131c722" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_48d53c1e-009c-4e0c-88b0-0b5623a7cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9fff4967-fed4-40b3-b5b8-9d643c30a286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_48d53c1e-009c-4e0c-88b0-0b5623a7cd43" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9fff4967-fed4-40b3-b5b8-9d643c30a286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b6de221d-ec8a-4ffd-bee7-09d666fb9c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8c769c1b-e300-4ad9-be89-3b298f4b666e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b6de221d-ec8a-4ffd-bee7-09d666fb9c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_7cd8b856-b938-4480-9169-cd0f9a517aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b6de221d-ec8a-4ffd-bee7-09d666fb9c2b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_7cd8b856-b938-4480-9169-cd0f9a517aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca5e86c0-2724-40bd-97fc-3b89ad325da8" xlink:to="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_82f81e30-2b00-45c2-8747-d92ce2e1fb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_82f81e30-2b00-45c2-8747-d92ce2e1fb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ba285da0-c164-46b4-9542-e6c6f5a1c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ba285da0-c164-46b4-9542-e6c6f5a1c9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a8a73da9-2ffa-4162-a662-c69883423276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7cfb533b-4906-4ff5-88db-1e0c16b9e050" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a8a73da9-2ffa-4162-a662-c69883423276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d612600c-c9d0-45b2-bead-3b7244c5ae65" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_372a8a47-3b5a-43b1-80a6-ef995aaead30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_372a8a47-3b5a-43b1-80a6-ef995aaead30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9cb81636-acad-4de0-bb7e-eaf01352b8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9cb81636-acad-4de0-bb7e-eaf01352b8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9a45fa3-2c48-47b1-a8ef-439693fc06d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_NetIncomeLoss_c9a45fa3-2c48-47b1-a8ef-439693fc06d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_ab9e9924-ba68-41cd-953e-43cd7a3148d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_ab9e9924-ba68-41cd-953e-43cd7a3148d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_86290545-a1c8-4154-badb-ef079d56fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_86290545-a1c8-4154-badb-ef079d56fbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_dcb46287-5246-437f-b720-4cccdcf5df3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_dcb46287-5246-437f-b720-4cccdcf5df3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d90ececd-992a-4563-b475-486e2233ce90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_35915600-75e7-47b3-a614-9ae6f3f2cb3c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d90ececd-992a-4563-b475-486e2233ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IncomeTaxes" xlink:type="simple" xlink:href="abbv-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4440d096-b49a-4e2e-9654-494ab3d96655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3d760d6a-0893-4232-9b6c-67c129d8d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4440d096-b49a-4e2e-9654-494ab3d96655" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3d760d6a-0893-4232-9b6c-67c129d8d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_deba8ec5-9721-4b9d-b2af-e4045dfe6c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1fdc05d-990d-4da6-911d-912a05f9d9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_deba8ec5-9721-4b9d-b2af-e4045dfe6c4b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1fdc05d-990d-4da6-911d-912a05f9d9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_674f93a5-5e06-4655-8f89-245aa26d5ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_deba8ec5-9721-4b9d-b2af-e4045dfe6c4b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_674f93a5-5e06-4655-8f89-245aa26d5ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_0fc5d284-32de-4b41-8545-da6f4788d301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_deba8ec5-9721-4b9d-b2af-e4045dfe6c4b" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_0fc5d284-32de-4b41-8545-da6f4788d301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LegalProceedingsandContingencies" xlink:type="simple" xlink:href="abbv-20220331.xsd#LegalProceedingsandContingencies"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LegalProceedingsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d367864-acaa-4f4f-9bd3-932fbe7d6fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_5ec036bf-5ad7-44c6-827f-7f1970eb1a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d367864-acaa-4f4f-9bd3-932fbe7d6fdb" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_5ec036bf-5ad7-44c6-827f-7f1970eb1a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#LegalProceedingsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89955c97-1908-4956-83b6-48c9a7805059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89955c97-1908-4956-83b6-48c9a7805059" xlink:to="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:to="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a0545509-926f-437b-a7de-564d3359acc8" xlink:to="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NiaspanMember_c75bce16-dbd7-4d80-a90c-ee1f73d238bf" xlink:href="abbv-20220331.xsd#abbv_NiaspanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_NiaspanMember_c75bce16-dbd7-4d80-a90c-ee1f73d238bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_92564305-36f3-455b-ab84-12d2518e30ab" xlink:href="abbv-20220331.xsd#abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_92564305-36f3-455b-ab84-12d2518e30ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_e13e1837-7480-46f1-8364-47f5db4e6385" xlink:href="abbv-20220331.xsd#abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_e13e1837-7480-46f1-8364-47f5db4e6385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BystolicAntitrustLitigationMember_9b5ba6c4-10ec-48df-86a8-1a696e3e8631" xlink:href="abbv-20220331.xsd#abbv_BystolicAntitrustLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_BystolicAntitrustLitigationMember_9b5ba6c4-10ec-48df-86a8-1a696e3e8631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationMember_902deaec-3eda-4c5e-93e1-f6ddbafb0a54" xlink:href="abbv-20220331.xsd#abbv_PrescriptionDrugAbuseLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationMember_902deaec-3eda-4c5e-93e1-f6ddbafb0a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_afbbb34a-8822-4499-b5a2-655b2aee3941" xlink:href="abbv-20220331.xsd#abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_afbbb34a-8822-4499-b5a2-655b2aee3941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ElliottAssociatesL.P.Member_7aeaa238-4afb-42aa-bcd7-5005da33026b" xlink:href="abbv-20220331.xsd#abbv_ElliottAssociatesL.P.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ffc988be-0321-4633-bec3-136560fc39ae" xlink:to="loc_abbv_ElliottAssociatesL.P.Member_7aeaa238-4afb-42aa-bcd7-5005da33026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5e893cd2-12ee-4138-b475-4ac28643c28e" xlink:to="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_59deed1f-69ac-46d1-89f0-06118ce17d8a" xlink:href="abbv-20220331.xsd#abbv_LossContingencyIndividualPlaintiffLawsuitsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_59deed1f-69ac-46d1-89f0-06118ce17d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyPurportedClassActionsNumber_3907d3a9-aa7b-4a96-b418-958a680d8b1a" xlink:href="abbv-20220331.xsd#abbv_LossContingencyPurportedClassActionsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_LossContingencyPurportedClassActionsNumber_3907d3a9-aa7b-4a96-b418-958a680d8b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c407c1a3-22b1-4cda-9d6a-11aad335fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c407c1a3-22b1-4cda-9d6a-11aad335fd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_65695876-aa60-4247-91bd-eaaad80a0ac1" xlink:href="abbv-20220331.xsd#abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_65695876-aa60-4247-91bd-eaaad80a0ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PutativeClassActionLawsuitIndividualNumber_6ee431f1-a981-41fb-83cf-d10e53d2e503" xlink:href="abbv-20220331.xsd#abbv_PutativeClassActionLawsuitIndividualNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_abbv_PutativeClassActionLawsuitIndividualNumber_6ee431f1-a981-41fb-83cf-d10e53d2e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4afb30f0-0616-43ec-bce8-5bcd9eac2a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4afb30f0-0616-43ec-bce8-5bcd9eac2a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a70a594c-f208-48e0-8467-1ccd2972b936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a70a594c-f208-48e0-8467-1ccd2972b936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_7af62fb7-2bce-4607-a8ae-60af3cd7702e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_15697895-45ba-4203-82bb-3513f86bc5fd" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_7af62fb7-2bce-4607-a8ae-60af3cd7702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformation" xlink:type="simple" xlink:href="abbv-20220331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c0f353db-5078-4e4b-bdfa-1ce8c9fbe394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_0cba3cc6-e77c-4a56-808f-940663f9a75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0f353db-5078-4e4b-bdfa-1ce8c9fbe394" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_0cba3cc6-e77c-4a56-808f-940663f9a75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="abbv-20220331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e8a25a16-065e-4f52-9dd4-4da8e0d8c27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_42ba0d01-81ea-4c29-a76c-cc67c13ed582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8a25a16-065e-4f52-9dd4-4da8e0d8c27f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_42ba0d01-81ea-4c29-a76c-cc67c13ed582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_84f5cb15-71e7-4521-aae8-13728c7e34d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c351e0ac-df93-49c8-a322-6f71872c2121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_84f5cb15-71e7-4521-aae8-13728c7e34d5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c351e0ac-df93-49c8-a322-6f71872c2121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="abbv-20220331.xsd#SegmentInformationDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f86e8b7f-1520-486b-9501-0767c02fa79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f86e8b7f-1520-486b-9501-0767c02fa79f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:href="abbv-20220331.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioAxis_dd50e448-8fa4-41d1-8e1f-6366f3c55e93" xlink:to="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImmunologyMember_a0fc13f2-1360-4ab8-803b-e84d16696e7d" xlink:href="abbv-20220331.xsd#abbv_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_ImmunologyMember_a0fc13f2-1360-4ab8-803b-e84d16696e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HematologicOncologyMember_171e50fb-dea4-4cf0-b23c-724ebd467e09" xlink:href="abbv-20220331.xsd#abbv_HematologicOncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_HematologicOncologyMember_171e50fb-dea4-4cf0-b23c-724ebd467e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AestheticsMember_b97c32c7-483b-4dd0-9e58-3a7e411d40e4" xlink:href="abbv-20220331.xsd#abbv_AestheticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_AestheticsMember_b97c32c7-483b-4dd0-9e58-3a7e411d40e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NeuroscienceMember_74a9b3ad-99be-4fed-ae89-7ac578cfa5d7" xlink:href="abbv-20220331.xsd#abbv_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_NeuroscienceMember_74a9b3ad-99be-4fed-ae89-7ac578cfa5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_EyeCareMember_36cd3b79-2e00-450c-aab0-a7c305419210" xlink:href="abbv-20220331.xsd#abbv_EyeCareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_EyeCareMember_36cd3b79-2e00-450c-aab0-a7c305419210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherKeyProductsMember_4b376299-6b28-4423-9b5b-879ac66253e3" xlink:href="abbv-20220331.xsd#abbv_OtherKeyProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_e0e476d2-a75b-4c7f-a0c1-c32417b4944a" xlink:to="loc_abbv_OtherKeyProductsMember_4b376299-6b28-4423-9b5b-879ac66253e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_75996820-c755-45db-9354-6702f6bc959b" xlink:to="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_37a97594-5a64-412a-91bd-b0495df82605" xlink:href="abbv-20220331.xsd#abbv_HUMIRAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_HUMIRAMember_37a97594-5a64-412a-91bd-b0495df82605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SKYRIZIMember_d3057df9-9ef2-4f34-8bf0-70f0cb34916d" xlink:href="abbv-20220331.xsd#abbv_SKYRIZIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_SKYRIZIMember_d3057df9-9ef2-4f34-8bf0-70f0cb34916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RINVOQMember_5d1a9e2b-08a0-4ac2-8825-29058f3fa9b2" xlink:href="abbv-20220331.xsd#abbv_RINVOQMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_RINVOQMember_5d1a9e2b-08a0-4ac2-8825-29058f3fa9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImbruvicaMember_782802f5-cde2-4767-bf1b-17c89e163ee3" xlink:href="abbv-20220331.xsd#abbv_ImbruvicaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_ImbruvicaMember_782802f5-cde2-4767-bf1b-17c89e163ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VENCLEXTAMember_cca5eceb-0108-4a92-af96-2b4c033918ab" xlink:href="abbv-20220331.xsd#abbv_VENCLEXTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_VENCLEXTAMember_cca5eceb-0108-4a92-af96-2b4c033918ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxCosmeticMember_720b8326-70f3-4623-ba6c-4391152ad819" xlink:href="abbv-20220331.xsd#abbv_BotoxCosmeticMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_BotoxCosmeticMember_720b8326-70f3-4623-ba6c-4391152ad819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvedermCollectionMember_8a2e9fcb-ea70-4822-84e9-903d31dd6041" xlink:href="abbv-20220331.xsd#abbv_JuvedermCollectionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_JuvedermCollectionMember_8a2e9fcb-ea70-4822-84e9-903d31dd6041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherAestheticsMember_e767065e-3e21-4451-9c4a-cdfaf2424b6d" xlink:href="abbv-20220331.xsd#abbv_OtherAestheticsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherAestheticsMember_e767065e-3e21-4451-9c4a-cdfaf2424b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxTherapeuticMember_1c0316ba-ab9f-408b-98f9-1bb92cbb9ee0" xlink:href="abbv-20220331.xsd#abbv_BotoxTherapeuticMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_BotoxTherapeuticMember_1c0316ba-ab9f-408b-98f9-1bb92cbb9ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VraylarMember_b81ffd0c-0078-46f7-8902-59cb08479449" xlink:href="abbv-20220331.xsd#abbv_VraylarMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_VraylarMember_b81ffd0c-0078-46f7-8902-59cb08479449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DuodopaMember_e7b8a535-4450-41f6-8f97-5145db950f5b" xlink:href="abbv-20220331.xsd#abbv_DuodopaMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_DuodopaMember_e7b8a535-4450-41f6-8f97-5145db950f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_UbrelvyMember_4e01d9ec-f3a5-4e6e-938c-c1fd0980b578" xlink:href="abbv-20220331.xsd#abbv_UbrelvyMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_UbrelvyMember_4e01d9ec-f3a5-4e6e-938c-c1fd0980b578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_QuliptaMember_c421269b-1a34-49a6-9011-e0be7e4a0da6" xlink:href="abbv-20220331.xsd#abbv_QuliptaMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_QuliptaMember_c421269b-1a34-49a6-9011-e0be7e4a0da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherNeuroscienceMember_8e48d2ad-63b1-42fd-8bf4-9ce93816e12f" xlink:href="abbv-20220331.xsd#abbv_OtherNeuroscienceMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherNeuroscienceMember_8e48d2ad-63b1-42fd-8bf4-9ce93816e12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LumiganGanfortMember_45cbd13a-5239-468f-918b-d319a89aff21" xlink:href="abbv-20220331.xsd#abbv_LumiganGanfortMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_LumiganGanfortMember_45cbd13a-5239-468f-918b-d319a89aff21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AlphaganCombiganMember_272dd9c4-30f5-44ad-971c-efa23efb7d26" xlink:href="abbv-20220331.xsd#abbv_AlphaganCombiganMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_AlphaganCombiganMember_272dd9c4-30f5-44ad-971c-efa23efb7d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestasisMember_cffb6c06-ed0f-4774-bc32-0d43915d064c" xlink:href="abbv-20220331.xsd#abbv_RestasisMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_RestasisMember_cffb6c06-ed0f-4774-bc32-0d43915d064c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherEyeCareMember_739f71f1-e5c0-43b9-825c-fbb2ef0ae267" xlink:href="abbv-20220331.xsd#abbv_OtherEyeCareMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherEyeCareMember_739f71f1-e5c0-43b9-825c-fbb2ef0ae267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_MAVYRETMember_afa35d18-a35f-48ef-a334-224975f26137" xlink:href="abbv-20220331.xsd#abbv_MAVYRETMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_MAVYRETMember_afa35d18-a35f-48ef-a334-224975f26137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CreonMember_a05be030-9394-4e1b-a5a8-7347d0e9e775" xlink:href="abbv-20220331.xsd#abbv_CreonMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_CreonMember_a05be030-9394-4e1b-a5a8-7347d0e9e775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LinzessConstellaMember_7573499c-6b5b-4261-a4bb-eb6c01903c4c" xlink:href="abbv-20220331.xsd#abbv_LinzessConstellaMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_LinzessConstellaMember_7573499c-6b5b-4261-a4bb-eb6c01903c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherProductsMember_7651ec3b-76e6-4914-a20e-5e3be5e7a684" xlink:href="abbv-20220331.xsd#abbv_OtherProductsMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa7a461d-c612-4891-8ce7-86c66eadaabf" xlink:to="loc_abbv_OtherProductsMember_7651ec3b-76e6-4914-a20e-5e3be5e7a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_caaff6ef-d2b2-4131-8b9c-3e7734b0fc61" xlink:to="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_57ce3329-ebad-4a03-bb27-c65aea72794c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:to="loc_country_US_57ce3329-ebad-4a03-bb27-c65aea72794c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f018c135-07ea-4732-be51-a6dfae24f229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c2dbfbd6-e568-47c5-83a1-cf91a9e328a1" xlink:to="loc_us-gaap_NonUsMember_f018c135-07ea-4732-be51-a6dfae24f229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f2966f42-21dc-4f4b-a9d6-4996cf40c236" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_96bc86d7-b5fe-4381-822f-67b0793dbde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_96bc86d7-b5fe-4381-822f-67b0793dbde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fd07ead7-3c00-4eef-b659-24348ad09589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fd07ead7-3c00-4eef-b659-24348ad09589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d9d0d3d-d462-4b4a-95f4-7edebf170c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98af9a90-ef17-4732-99ee-947c13576f1f" xlink:to="loc_us-gaap_Revenues_3d9d0d3d-d462-4b4a-95f4-7edebf170c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>abbv-20220331_g1.jpg
<TEXT>
begin 644 abbv-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$!&0$9  #__@ R35),3%]'4D%02$E#4SI;04)"5DE%
M74%"0E9)15]53D-/051?4$U37TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ . %$ P$B  (1
M 0,1 ?_$ !\   (" P # 0$            *"0L"!P@!!08$ __$ $T0   &
M 0," P((!PH/ 0    $" P0%!@< " D1$@H3(10Q%1HB05%88=<6,G%R@9&8
M%Q@C)S-)E[&RLSE"4E598G:)E*&WR-'3\(?_Q  < 0 " P$! 0$
M   &!P,$!0((  '_Q  _$0 " @(! P($! ,#"0D    ! @,$!1$& !(A$S$'
M(D%1%",R815Q@4)RH187,U1C@I&4\$-%559B9972U/_:  P# 0 "$0,1 #\
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MMIA'(M): LE<P[B^4B91@N & J[9VV3,)%"*(KI"HW<)JH*JIFM L/6Y[?\
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MK.%RM>% 2\LV.MQ1J -DM(\*JH \[) UU)#F<18<1P93'32,0%CBNUI'8DZ
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M_?2]^M6E'A6SD_DVK;S-PS<[PHD]D1!W!Y:FE4FRH>9[2N+-=9$0)Y+=8!,
M0>[Z.%'D'XWVQ,K7NIL;KC"N/$7B>X# <[.3\%2722Y 8/[0)XRN7_&2OFG0
M!O8)");UU!VLDT2M7MJB2*EK/KUDU"Q%BB92!GXN.FX2;CGL1,P\NQ;2<3+Q
M,DV49R,5*QSQ-5I(QDBT66:/V#M)5J\:JJMW"9TE#%&]COBGR>M.C7Y:^4K$
M@3035J\#-&?U".6M%%V.1[%TE3P.Y#U5N?#SC\T3"E'-CK !,4\,\TG8_P!"
MRS.[,ON-!T]SH])#<"7B ;],9 HNQ_?7='5Q;7-Y'4[ FX2SNDSV>.M"I!:P
M6,LNS3@Y%;0UM"Y6\12\@OQ5LC>QK,J];7,RVF&4W#O$'$!2.(?Y!OL^8?>
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M#V\[RC/T$MS5<<,A9L9 Q-HR".U(L,8'L9&+N%+;"+WN5;04KE83\(_O-N<
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MV5)&P3U#)X@Z&?P_+OO?;ODBD5DK#0IEH4A^\%F$U@;&R[ _=VE[3JDZE.0
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M._53?_M X)^]?1\7>YG?JIO_ -H'!/WKZM* ,F/N,0?R"4?ZM>?D?ZO_ "T
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M40B*BCHT-3_A-RHGW&CX%R<R:9S1K%Y#=@XG0FNX3$86K86(D,F/2/W^YKM
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MA],"A(\JRL =E>UCOJ,*F;T>938\5SCB)RSO<PFTJZ!&BF/\CUB^RD-66H)
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M7&QDN0MM<Q/N(JTA6UEF,;G_ &FO;O;*U)Q)CD.FY;V[%)"V>,AGWR3&A[W
M5Y8JP&1>PY52_*-&I>$<OS%22+!.U>[C)>Y5K7H3.(%8@LD+"1"(VV?RG,D0
M))5%)),?*^-8RRK98+-5OHT8-BI*(6DV0H:4=C!G ]G 5C_:+#QU]9#<X'-K
MC,48IQN>S415NP"/3:9&PI09^1!!JX$AEUE;CB125=OR+I';N)-VNX>',55!
MPN=0#@'T'Q@[FP^LU8/V;\*?=%HT:>$6#X_,BR/Q[!%G\L?X54\G:CZQD_\
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92?U7,$?=)(B-(YTFV=M#N8[.SKR3OK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>abbv-20220331_g2.gif
<TEXT>
begin 644 abbv-20220331_g2.gif
M1TE&.#EA9  3 (0  $56=^_Q]-#4W<'&T39(:Z*JNN#CZ&1RCB8Y8)*<KU5D
M@G2 F;&XQN'DZ>OM\-_BZ.;H[>/EZN+EZN#BZ.+DZ>7H[!<K5(..I <=2?__
M_P                       "'_"TY%5%-#05!%,BXP P$!   A^00
M "P     9  3   (_P S"!Q(L&!! P(,*BPX(,#"AQ C2IQ(,<,%# <J"L1@
MP8#&CP(9 "@ LJ3 BP ^8L PP&1%E"Y!PM2XLF5,B0P()+@YT$&$!PT@+)PI
MT"=0H0IK$C0:E.=$ID@7%E! 8*55"P N>!R(,D " !:LKD2@H(##@34''*@J
M%NL"CP8L6,@X<8%< Q<L,"#H%0 "L59'$A3 %G!;DB<Q( AK6"R"A!L5-P9\
M(0.#E0LD)EBY]Z*"@0,83UY9.4, Q@<:$AR0@+'-BRLM7+ I,,  NQRWBCW
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<->VO"T%5D;E/_=0410;$>FX%$DP % 51!00 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171817000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AbbVie Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001551152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0375147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 North Waukegan Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">North Chicago<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60064-6400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">932-7900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,767,110,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.500 Senior Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.500% Senior Notes due 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV23B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.375 Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Senior Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.250 Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 0.750 Senior Notes Due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.750% Senior Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 2.125 Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 2.625 Senior Notes Due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.625% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 2.125 Senior Notes Due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.250 Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XCHI', window );">CHICAGO STOCK EXCHANGE, INC | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">CHX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XCHI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XCHI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424180799144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues</a></td>
<td class="nump">$ 13,538<span></span>
</td>
<td class="nump">$ 13,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">4,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,127<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">8,821<span></span>
</td>
<td class="nump">8,907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings</a></td>
<td class="nump">4,717<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange loss</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(776)<span></span>
</td>
<td class="num">(395)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before income tax expense</a></td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">4,493<span></span>
</td>
<td class="nump">3,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net earnings attributable to noncontrolling interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">$ 4,490<span></span>
</td>
<td class="nump">$ 3,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per share data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424180775224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">$ 4,493<span></span>
</td>
<td class="nump">$ 3,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments, net of tax expense (benefit) of $(7) for the three months ended March 31, 2022 and $(25) for the three months ended March 31, 2021</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax', window );">Net investment hedging activities, net of tax expense (benefit) of $37 for the three months ended March 31, 2022 and $103 for the three months ended March 31, 2021</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Pension and post-employment benefits, net of tax expense (benefit) of $10 for the three months ended March 31, 2022 and $19 for the three months ended March 31, 2021</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months ended March 31, 2022 and $3 for the three months ended March 31, 2021</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">4,408<span></span>
</td>
<td class="nump">3,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to AbbVie Inc.</a></td>
<td class="nump">$ 4,405<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176235480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, tax expense (benefit)</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax', window );">Net investment hedging activities, tax expense (benefit)</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Pension and post-employment benefits, tax expense (benefit)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Cash flow hedging activities, tax expense (benefit)</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181988376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 6,098<span></span>
</td>
<td class="nump">$ 9,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">10,733<span></span>
</td>
<td class="nump">9,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,483<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">4,721<span></span>
</td>
<td class="nump">4,993<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">26,509<span></span>
</td>
<td class="nump">27,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,075<span></span>
</td>
<td class="nump">5,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">73,986<span></span>
</td>
<td class="nump">75,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,298<span></span>
</td>
<td class="nump">32,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,083<span></span>
</td>
<td class="nump">4,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,211<span></span>
</td>
<td class="nump">146,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt and finance lease obligations</a></td>
<td class="nump">9,940<span></span>
</td>
<td class="nump">12,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">22,569<span></span>
</td>
<td class="nump">22,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,521<span></span>
</td>
<td class="nump">35,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt and finance lease obligations</a></td>
<td class="nump">63,522<span></span>
</td>
<td class="nump">64,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">28,023<span></span>
</td>
<td class="nump">28,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,811,430,573 shares issued as of March 31, 2022 and 1,803,195,293 as of December 31, 2021</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common stock held in treasury, at cost, 44,557,588 shares as of March 31, 2022 and 34,857,597 as of December 31, 2021</a></td>
<td class="num">(4,585)<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">18,731<span></span>
</td>
<td class="nump">18,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">5,103<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,984)<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,283<span></span>
</td>
<td class="nump">15,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">16,314<span></span>
</td>
<td class="nump">15,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 143,211<span></span>
</td>
<td class="nump">$ 146,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424179019896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="nump">4,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,811,430,573<span></span>
</td>
<td class="nump">1,803,195,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common stock held in treasury, at cost (in shares)</a></td>
<td class="nump">44,557,588<span></span>
</td>
<td class="nump">34,857,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424172388888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Equity (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 13,097<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (2,264)<span></span>
</td>
<td class="nump">$ 17,384<span></span>
</td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="num">$ (3,117)<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">3,553<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,553<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(178)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(2,316)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,316)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(787)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(787)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation plans and other</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">13,733<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(3,017)<span></span>
</td>
<td class="nump">17,712<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
<td class="num">(3,295)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">15,436<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
<td class="nump">18,305<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">4,490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(2,514)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,514)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(1,470)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation plans and other</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 16,314<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (4,585)<span></span>
</td>
<td class="nump">$ 18,731<span></span>
</td>
<td class="nump">$ 5,103<span></span>
</td>
<td class="num">$ (2,984)<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424269672456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">$ 4,493<span></span>
</td>
<td class="nump">$ 3,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liabilities</a></td>
<td class="num">(748)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">128<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(785)<span></span>
</td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(385)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="num">(258)<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income tax assets and liabilities, net</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">4,908<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Acquisitions and investments</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisitions of property and equipment</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investment securities</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales and maturities of investment securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows from investing activities</a></td>
<td class="num">(1,591)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt and finance lease obligations</a></td>
<td class="num">(4,879)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(2,526)<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,470)<span></span>
</td>
<td class="num">(787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows from financing activities</a></td>
<td class="num">(6,972)<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and equivalents</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and equivalents</a></td>
<td class="num">(3,648)<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents, beginning of period</a></td>
<td class="nump">9,746<span></span>
</td>
<td class="nump">8,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents, end of period</a></td>
<td class="nump">$ 6,098<span></span>
</td>
<td class="nump">$ 9,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424175975288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation Basis of Historical Presentation <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules&#160;and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company&#8217;s audited consolidated financial statements and notes included in the company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company&#8217;s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. </span></div>During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&amp;D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&amp;D and milestones expense by $115&#160;million for the three months ended March 31, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424177023048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_SupplementalFinancialInformationDisclosureAbstract', window );"><strong>Supplemental Financial Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Supplemental Financial Information</a></td>
<td class="text">Supplemental Financial Information<span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $198 million for the three months ended March 31, 2022 and $206 million for the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_SupplementalFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_SupplementalFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424177030008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the impact of the two-class method:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176147864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing, Acquisitions and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract', window );"><strong>Licensing, Acquisitions, and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock', window );">Licensing, Acquisitions, and Other Arrangements</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensing, Acquisitions and Other Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflows related to acquisitions and investments totaled $185 million for the three months ended March 31, 2022 and $198 million for the three months ended March 31, 2021. AbbVie recorded acquired IPR&amp;D and milestones charges of $145 million for the three months ended March 31, 2022 and $185&#160;million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Syndesi Therapeutics SA</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&amp;D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for acquisitions, collaborations and other arrangements of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176145368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaborations</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended March 31, 2022 and 2021.</span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Janssen Biotech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech,&#160;Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson&#160;&amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton&#8217;s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Janssen's share of profits (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International - AbbVie's share of profits (included in net revenues)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global - AbbVie's share of other costs (included in respective line items)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie&#8217;s receivable from Janssen, included in accounts receivable, net, was $336 million at March 31, 2022 and $294 million at December 31, 2021. AbbVie&#8217;s payable to Janssen, included in accounts payable and accrued liabilities, was $401 million at March 31, 2022 and $509 million at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Genentech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie&#8217;s net revenues. Genentech&#8217;s share of United States profits is included in AbbVie&#8217;s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&amp;A) expenses and global development costs as part of research and development (R&amp;D) expenses, net of Genentech&#8217;s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie&#8217;s cost of products sold.</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Genentech and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech's share of profits, including royalties (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of development costs (included in R&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176134424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsGoodwill<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of March 31, 2022, there were no accumulated goodwill impairment losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,988)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $1.9 billion for the three months ended March 31, 2022 and $2.0 billion for the three months ended March 31, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424175937736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Integration and Restructuring Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Integration and Restructuring Plans</a></td>
<td class="text">Integration and Restructuring PlansAllergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges associated with the Allergan acquisition integration plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the recorded liability associated with the integration plan for the three months ended March 31, 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Restructuring</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie recorded restructuring charges of $57 million for the three months ended March 31, 2022 and $38 million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176115208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Financial Instruments and Fair Value Measures</a></td>
<td class="text">Financial Instruments and Fair Value MeasuresRisk Management Policy<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 to the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie&#8217;s risk management policy and use of derivative instruments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $904 million at March 31, 2022 and $1.1 billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of March 31, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive loss. This gain is reclassified to interest expense, net over the term of the related debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $750 million at March 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.0 billion at March 31, 2022 and $8.2 billion at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling &#8364;4.3&#160;billion at March 31, 2022 and December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of &#8364;5.9 billion at March 31, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.5 billion at March 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of AbbVie&#8217;s derivative instruments on the condensed consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211; <br/>Derivatives in asset position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211;<br/>Derivatives&#160;in&#160;liability&#160;position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with the company&#8217;s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $52&#160;million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $1 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to AbbVie&#8217;s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive loss pre-tax gains of $99&#160;million for the three months ended March 31, 2022 and pre-tax gains of $382 million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement&#160;of earnings caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury rate lock agreements designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as hedged item in fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 2 &#8211; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 3 &#8211; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company&#8217;s management about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable <br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,871&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable<br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 3.6%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%- 2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for unachieved milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for royalties by indication</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034 </span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at March 31, 2022 and December 31, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value recognized in net earnings is recorded in other income, net in the condensed consolidated statements of earnings. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2022 are shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $147 million as of March 31, 2022 and $149 million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of total net accounts receivable, three U.S. wholesalers accounted for 74% as of March 31, 2022 and 75% as of December 31, 2021, and substantially all of AbbVie&#8217;s pharmaceutical product net revenues in the United States were to these three wholesalers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humira (adalimumab) is AbbVie&#8217;s single largest product and accounted for approximately 35% of AbbVie&#8217;s total net revenues for the three months ended March 31, 2022 and 37% for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the company repaid $2.9 billion aggregate principal amount of 3.45% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176124328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock', window );">Post-Employment Benefits</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Post-Employment Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost relating to the company&#8217;s defined benefit and other post-employment plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined <br/>benefit&#160;plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;post- <br/>employment&#160;plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>The components of net periodic benefit cost other than service cost are included in other income, net in the condensed consolidated statements of earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176085656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">EquityStock-Based Compensation<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, primarily in connection with the company's annual grant, AbbVie granted 0.9&#160;million stock options with a weighted-average grant-date fair value of $22.83. As of March 31, 2022, $15 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs and Performance Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, primarily in connection with the company's annual grant, AbbVie granted 5.6&#160;million RSUs and performance shares with a weighted-average grant-date fair value of $145.54. As of March 31, 2022, $955&#160;million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quarterly cash dividends declared during 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/17/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/10/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/16/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/14/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie repurchased 8&#160;million shares for $1.1&#160;billion during the three months ended March 31, 2022 and 5&#160;million shares for $550&#160;million during the three months ended March 31, 2021. AbbVie's remaining stock repurchase authorization was approximately $1.4&#160;billion as of March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and post-employment <br/>benefits</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,899)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss for the three months ended March 31, 2022 included foreign currency translation adjustments totaling a loss of $231 million and the offsetting impact of net investment hedging activities totaling a gain of $130 million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;<br/>and post-employment <br/>benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,295)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss for the three months ended March 31, 2021 included foreign currency translation adjustments totaling a loss of $677 million and the offsetting impact of net investment hedging activities totaling a gain of $374&#160;million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact on AbbVie&#8217;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) (brackets&#160;denote&#160;gains)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedging activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on derivative amount excluded from effectiveness testing</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and post-employment benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedging activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on foreign currency forward exchange contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on treasury rate lock agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on interest rate swap contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense (benefit)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Amounts are included in interest expense, net (see Note 8).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Amounts are included in cost of products sold (see Note 8).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176098872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The effective tax rate was 9% for the three months ended March 31, 2022 compared to 8% for the three months ended March 31, 2021. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The increase in the effective tax rate for the three months ended March 31, 2022 over the prior year was primarily due to differences in the company&#8217;s jurisdictional mix of earnings.Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company&#8217;s gross unrecognized tax benefits balance may change within the next 12 months by up to $244&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424175977448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings and Contingencies</a></td>
<td class="text">Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management&#8217;s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie&#8217;s consolidated financial position, results of operations or cash flows.Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Niaspan Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No.&#160;2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney&#8217;s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys&#8217; fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott&#8217;s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie&#8217;s settlements with biosimilar manufacturers and AbbVie&#8217;s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Humira (Adalimumab) Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices, and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Namenda Indirect Purchaser Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan&#8217;s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Bystolic Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,146 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 257 matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In March 2022, Allergan reached settlements with the States of Florida and Rhode Island and their political subdivisions. Allergan previously reached settlements with other plaintiffs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the New Mexico Attorney General filed a lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico&#8217;s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder and Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. One of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, a federal securities lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Holwill v. AbbVie Inc., et al</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Allergan plc Securities Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The plaintiffs generally seek compensatory damages and attorneys&#8217; fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability and General Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, a qui tam lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Silbersher v. Allergan Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District Court for the Northern District of Illinois against Alvotech hf. AbbVie alleges defendant&#8217;s proposed biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court denied Defendant&#8217;s motion to dismiss on jurisdictional grounds in the first case; a motion in the second case remains pending. The court has set a trial on a subset of patents for August 2022. The court order provides that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed. In March 2022, the parties settled the case and it was dismissed without prejudice.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.</span></div>Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424175939384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vraylar</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424269641192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_SupplementalFinancialInformationDisclosureAbstract', window );"><strong>Supplemental Financial Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of interest expense, net</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_SupplementalFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_SupplementalFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176008488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted earnings per share, impact of two-class method</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the impact of the two-class method:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181904216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of profit and cost sharing relationship</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Janssen's share of profits (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International - AbbVie's share of profits (included in net revenues)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global - AbbVie's share of other costs (included in respective line items)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of profit and cost sharing relationship</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Genentech and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech's share of profits, including royalties (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of development costs (included in R&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424180058648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of changes in the carrying amount of goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of definite-lived intangible assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,988)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of indefinite-lived intangible assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,988)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176223672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Integration and Restructuring Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of charges associated with integration plan</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges associated with the Allergan acquisition integration plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of cash activity in the restructuring reserve</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the recorded liability associated with the integration plan for the three months ended March 31, 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember', window );">Other restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of cash activity in the restructuring reserve</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171734744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of amounts and location of derivatives on the condensed consolidated balance sheets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of AbbVie&#8217;s derivative instruments on the condensed consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211; <br/>Derivatives in asset position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211;<br/>Derivatives&#160;in&#160;liability&#160;position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement&#160;of earnings caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury rate lock agreements designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as hedged item in fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable <br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,871&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable<br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of significant level 3 unobservable inputs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 3.6%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%- 2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for unachieved milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for royalties by indication</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034 </span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</span></div>(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at March 31, 2022 and December 31, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in fair value of Level 3 inputs</a></td>
<td class="text">The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of book values, approximate fair values and bases used to measure certain financial instruments</a></td>
<td class="text">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2022 are shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176101656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost relating to the company&#8217;s defined benefit and other post-employment plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined <br/>benefit&#160;plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;post- <br/>employment&#160;plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424177140520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of share-based compensation expense</a></td>
<td class="text">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDividendsPayableTextBlock', window );">Summary of quarterly cash dividends</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quarterly cash dividends declared during 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/17/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/10/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/16/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/14/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of changes in balances of each component of accumulated other comprehensive loss</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and post-employment <br/>benefits</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,899)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;<br/>and post-employment <br/>benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,295)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact on AbbVie&#8217;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) (brackets&#160;denote&#160;gains)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedging activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on derivative amount excluded from effectiveness testing</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and post-employment benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedging activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on foreign currency forward exchange contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on treasury rate lock agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on interest rate swap contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense (benefit)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Amounts are included in interest expense, net (see Note 8).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Amounts are included in cost of products sold (see Note 8).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDividendsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDividendsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424175907592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of worldwide net revenues</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vraylar</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424176058232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense', window );">Reclassification of development milestone expense to IPR&amp;D and milestones expense</a></td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense', window );">Reclassification of development milestone expense from research and development expense</a></td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of development milestone expense from research and development expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&amp;D and milestones expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181284344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueOrExpenseNetAbstract', window );"><strong>Interest Expense, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">10,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(5,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,617)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueOrExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueOrExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171661288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract', window );"><strong>Basic EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">$ 4,490<span></span>
</td>
<td class="nump">$ 3,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Earnings allocated to participating securities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Earnings available to common shareholders</a></td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 3,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract', window );"><strong>Diluted EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">$ 4,490<span></span>
</td>
<td class="nump">$ 3,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted', window );">Earnings allocated to participating securities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Earnings available to common shareholders</a></td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 3,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicTwoClassMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424182027144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing, Acquisitions and Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Cash outflows related to acquisitions and investments</a></td>
<td class="num">$ (185)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_SyndesiMember', window );">Syndesi | Collaborative arrangement | Acquired IPR&amp;D and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_SyndesiMember', window );">Syndesi | Collaborative arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_PotentialPaymentsUnderAgreementCertainMilestones', window );">Potential payments under agreement certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_PotentialPaymentsUnderAgreementCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_PotentialPaymentsUnderAgreementCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_SyndesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_SyndesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424170425208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">AbbVie's receivable from Janssen</a></td>
<td class="nump">$ 10,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">AbbVie's payable to Janssen</a></td>
<td class="nump">22,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable', window );">Milestone payments</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty', window );">Share of collaboration development costs responsible by Janssen (as a percent)</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts', window );">Share of collaboration development costs responsible by the entity (as a percent)</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_OtherExpensesFromCollaborativeArrangements', window );">Global - AbbVie's share of other costs (included in respective line items)</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">AbbVie's receivable from Janssen</a></td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">AbbVie's payable to Janssen</a></td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Collaborative arrangement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements', window );">Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Collaborative arrangement | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">International - AbbVie's share of profits (included in net revenues)</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member', window );">Genentech, Inc. | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements', window );">Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements', window );">AbbVie's share of development costs (included in R&amp;D)</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member', window );">Genentech, Inc. | Collaborative arrangement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements', window );">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_OtherExpensesFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_OtherExpensesFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424179157224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 32,379,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Foreign currency translation adjustments</a></td>
<td class="num">(81,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">32,298,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract', window );"><strong>Accumulated goodwill impairment losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424172244440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 97,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(23,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">73,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets gross carrying amount</a></td>
<td class="nump">97,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">73,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">88,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(20,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,463)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">68,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">8,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(3,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,688)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181108472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Integration and Restructuring Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Integration related costs</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring reserve rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance beginning of the period</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses', window );">Restructuring charges</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance end of the period</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring reserve rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance beginning of the period</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses', window );">Restructuring charges</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance end of the period</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember', window );">Other restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring reserve rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance beginning of the period</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses', window );">Restructuring charges</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance end of the period</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_RestructuringReserveCashSettledRestructuringGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424170810664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Financial Instruments (Details)<br> &#8364; in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet', window );">Amount excluded from the assessment of effectiveness for cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet', window );">Amount excluded from the assessment of effectiveness for fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">186,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Net investment hedges | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of unsecured senior notes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">$ 904,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Duration of forward exchange contracts</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1', window );">Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">173,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Foreign currency forward exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) relating to components of the gain (loss) on the cash flow hedging instrument excluded from the assessment of cash flow hedge effectiveness. Recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181127128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet', window );">Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense, net | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1', window );">Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Designated as hedging instrument | Cost of products sold | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Designated as hedging instrument | Interest expense, net | Net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Not designated as hedges | Net foreign exchange loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Designated as fair value hedges | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember', window );">Treasury rate lock agreements | Designated as hedging instrument | Interest expense, net | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ForeignCurrencyGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ForeignCurrencyGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171383528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">73,765<span></span>
</td>
<td class="nump">82,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">6,098<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">7,871<span></span>
</td>
<td class="nump">10,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">13,818<span></span>
</td>
<td class="nump">14,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">14,031<span></span>
</td>
<td class="nump">14,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">3,417<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,498<span></span>
</td>
<td class="nump">4,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1) | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant other observable inputs (Level&#160;2) | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">13,818<span></span>
</td>
<td class="nump">14,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">13,818<span></span>
</td>
<td class="nump">14,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant unobservable inputs (Level&#160;3) | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring | Significant other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424182105400">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)<br></strong></div></th>
<th class="th" colspan="2"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Probability of payment for unachieved milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.91<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Probability of payment for royalties by indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Projected year of payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.009<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Probability of payment for unachieved milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Probability of payment for royalties by indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Projected year of payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Probability of payment for royalties excluding early stage or approved indications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.036<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Probability of payment for unachieved milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Probability of payment for royalties by indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Projected year of payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Probability of payment for royalties excluding early stage or approved indications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at March 31, 2022 and December 31, 2021.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforUnachievedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforUnachievedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProjectedYearofPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProjectedYearofPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424177656744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract', window );"><strong>Transfers of assets or liabilities between the fair value measurement levels</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers of assets into Level 3 of the fair value hierarchy</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers of assets out of Level 3 of the fair value hierarchy</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract', window );"><strong>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers of liabilities into Level 3 of the fair value hierarchy</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers of liabilities out of Level 3 of the fair value hierarchy</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">14,887,000,000<span></span>
</td>
<td class="nump">$ 12,997,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in net earnings</a></td>
<td class="num">(748,000,000)<span></span>
</td>
<td class="num">(343,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(321,000,000)<span></span>
</td>
<td class="num">(132,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 13,818,000,000<span></span>
</td>
<td class="nump">$ 12,522,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424182087752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying amount of investments in equity securities that do not have readily determinable fair values</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">8,851<span></span>
</td>
<td class="nump">11,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">64,914<span></span>
</td>
<td class="nump">70,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">73,765<span></span>
</td>
<td class="nump">82,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">9,922<span></span>
</td>
<td class="nump">12,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">63,634<span></span>
</td>
<td class="nump">64,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">73,568<span></span>
</td>
<td class="nump">76,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">9,208<span></span>
</td>
<td class="nump">11,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">65,790<span></span>
</td>
<td class="nump">71,810<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">75,010<span></span>
</td>
<td class="nump">83,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value | Significant other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181043544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_NumberOfPrincipalUSCustomers', window );">Number of principal customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable, net | Geographic risk | Principal US customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk (as a percent)</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Total revenues | HUMIRA | Humira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk (as a percent)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_NumberOfPrincipalUSCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of principal U.S. customers of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_NumberOfPrincipalUSCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=abbv_PrincipalUSCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=abbv_PrincipalUSCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_HUMIRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_HUMIRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171713784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.450PercentMember', window );">3.45% senior notes due 2022 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025Member', window );">Floating rate notes due 2025 | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Aggregate principal amount outstanding</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term loan credit agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember', window );">Floating rate notes due 2025, refinanced | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt obligations, gross</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt, including capital lease obligations and mandatory redeemable capital securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.450PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.450PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181950488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined benefit and other post-employment plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost (credit)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit', window );">Amortization of actuarial loss</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other post-employment plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined benefit and other post-employment plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost (credit)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit', window );">Amortization of actuarial loss</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424181044264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">After-tax compensation expense</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171771528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock Options (Details) - Stock Options<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares) | shares</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of the stock options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized compensation cost</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424179013320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares) | shares</a></td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Fair market value of awards vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 145.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized compensation cost</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abbv_RestrictedStockUnitsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abbv_RestrictedStockUnitsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424172325656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Cash Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424170367000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock Repurchase Program (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Payment for shares repurchased</a></td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining share repurchase authorization amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=abbv_December2018StockRepurchaseAuthorizationMember', window );">December 2018 Stock Repurchase Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Payment for shares repurchased</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=abbv_December2018StockRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=abbv_December2018StockRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424170698264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 15,436<span></span>
</td>
<td class="nump">$ 13,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">16,314<span></span>
</td>
<td class="nump">13,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(570)<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(801)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember', window );">Net investment hedging activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Pension and post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,546)<span></span>
</td>
<td class="num">(3,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,518)<span></span>
</td>
<td class="num">(2,988)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Cash flow hedging activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,899)<span></span>
</td>
<td class="num">(3,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (2,984)<span></span>
</td>
<td class="num">$ (3,295)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424170501528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">436<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,490)<span></span>
</td>
<td class="num">(3,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Losses (gains) on foreign currency forward exchange contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">4,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Pension and post-employment benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amortization of actuarial losses and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Losses (gains) on foreign currency forward exchange contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember', window );">Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(a)&#160;Amounts are included in interest expense, net (see Note 8)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">(c) Amounts are included in cost of products sold (see Note 8).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424177109032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Potential change in unrecognized tax benefits</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424171263224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>investment_fund</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>investment_fund</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>company</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>investment_fund</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>lawsuit </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>claim </div>
<div>class_action</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>claim </div>
<div>direct_purchaser</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>claim </div>
<div>end_payor_purchaser</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>claim </div>
<div>company</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>company</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_NiaspanMember', window );">Niaspan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber', window );">Number of individual plaintiff lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyPurportedClassActionsNumber', window );">Number of purported class actions | class_action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of healthcare benefit providers acting as plaintiff in lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember', window );">AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws', window );">Number of generic companies with whom certain litigation related agreements were entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember', window );">Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_PutativeClassActionLawsuitIndividualNumber', window );">Number of individual putative class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember', window );">Bystolic antitrust litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws', window );">Number of generic companies with whom certain litigation related agreements were entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember', window );">Prescription drug abuse litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember', window );">Prescription drug abuse litigation in state courts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member', window );">Elliott Associates, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of parties to lawsuit (in investment funds) | investment_fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of plaintiff claims dismissed | investment_fund</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LossContingencyIndividualPlaintiffLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LossContingencyPurportedClassActionsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purported class actions filed, pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LossContingencyPurportedClassActionsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_PutativeClassActionLawsuitIndividualNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of the number of individual putative class action lawsuit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_PutativeClassActionLawsuitIndividualNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_NiaspanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_NiaspanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424177022488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140424169045576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="nump">$ 13,538<span></span>
</td>
<td class="nump">$ 13,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abbv_OtherProductsMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Humira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">4,736<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Humira | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,993<span></span>
</td>
<td class="nump">3,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Humira | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Skyrizi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Skyrizi | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Skyrizi | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Rinvoq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Rinvoq | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Rinvoq | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Imbruvica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Imbruvica | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Imbruvica | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Venclexta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Venclexta | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Venclexta | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Botox Cosmetic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Botox Cosmetic | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Botox Cosmetic | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Juvederm Collection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Juvederm Collection | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Juvederm Collection | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Other Aesthetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Other Aesthetics | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Other Aesthetics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Botox Therapeutic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Botox Therapeutic | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Botox Therapeutic | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Vraylar | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Duodopa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Duodopa | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Duodopa | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Ubrelvy | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Qulipta | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Other Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Other Neuroscience | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Other Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Lumigan/Ganfort</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Lumigan/Ganfort | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Lumigan/Ganfort | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Alphagan/Combigan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Alphagan/Combigan | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Alphagan/Combigan | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Restasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Restasis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Restasis | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Other Eye Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Other Eye Care | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Other Eye Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Mavyret</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Mavyret | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Mavyret | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Creon | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Linzess/Constella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Linzess/Constella | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Linzess/Constella | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_HUMIRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_HUMIRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_SKYRIZIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_SKYRIZIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_RINVOQMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_RINVOQMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_ImbruvicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_ImbruvicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_VENCLEXTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_VENCLEXTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_AestheticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_BotoxCosmeticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_BotoxCosmeticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_JuvedermCollectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_JuvedermCollectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherAestheticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherAestheticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_BotoxTherapeuticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_BotoxTherapeuticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_VraylarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_VraylarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_DuodopaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_DuodopaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_UbrelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_UbrelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_QuliptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_QuliptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_EyeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_LumiganGanfortMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_LumiganGanfortMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_AlphaganCombiganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_AlphaganCombiganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_RestasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_RestasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherEyeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherEyeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_MAVYRETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_MAVYRETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_CreonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_CreonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_LinzessConstellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_LinzessConstellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>abbv-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abbv="http://www.abbvie.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:exch="http://xbrl.sec.gov/exch/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abbv-20220331.xsd" xlink:type="simple"/>
    <context id="icf2f690357b3411ab045058c62c6b838_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iffe012c9dbd240048d813949942fdca1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1500SeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13386ec6dca24c72873db6a581548a42_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id0a62f89becf43099721dde7ba0ee70e_I20220427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2022-04-27</instant>
        </period>
    </context>
    <context id="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ee167f36562471dab7b2f232caad9ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cb1995fa5b74df58173afb77b7e467f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66fe2db515c241c0bb28d212b85279e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6e8e05625504d9a944f9bade3f3867c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf1feacb1a194c1d9816daa1d27870c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia427e86aee794ddda12fc9e121da41f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6accb844205d4e909ea7d6f406d2b865_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d02525654584e2f9f785b90b9913777_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i063a456449f745c98a09be163769f332_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5cf8db55503473d9dd1af8c0d20c48d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6e9540820e34b43b3e6ec3daddaa1fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0f9dace7c91d4297a7aa7f308de3f768_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9a3023971ae049339d5747605ef52a7c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i980dca056e914f6385bbf2d1f0a5c20b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab26cb86a14c46ba9fa64e4b951dfaea_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3cf70c299b6747128fa4a148bd06c306_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ide7dd1b7a2964e66b89583f5e940f748_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03d21af462c442b5beb00d3ba5c34925_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a07265e199d4b30a14e9e6383620f9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1929ee5ab0f4e8c9347283529630a9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e9ff1d5c2f242d3acc07bc91dffb247_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa789cc1b9f041559e83b047a68991b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie21ccd46654948208d4f049707193b17_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87b37cb73f2d4eacace3c00d60098061_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i207acaa2165d403396ea05f332f5d280_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib201ee2f6aa040aa994d36824861b99b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95c2a9dc2507491cbed7bcc6382ac0bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iedf65e4946d940d7b337ee6ad83e0838_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i613f449aeb814d5eb9f9f5433bf45c4b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i72db22a233c742cb9fdaf4ec7205f2f1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb3553129a064588b861cbad2e2e642e_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i20abf2418b52449bbcdcb69db0df0b34_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9fe4ce1afbad40ee8b142ccdca3cbdf7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i757157a6b1f24339a6987f24f728b796_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c90b03e0a9d4b959d426288837a1ac9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f9f25b9cf5e4ee0bbe7e382b04feba9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if1248f479629473abbdb6ed040285ccc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7189bfa6119440549f13eb789b20c623_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i503b434bb2cd4949ab32e3eea0c0a13b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e417e1f49424cb4b129ec6ce7c723da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if70fdebf15534416b657e3efc08cb7de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b131031330347efae33d3283c798c08_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia91bb22b751b4f769a3ed871c1a8e163_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6409d59d48544dd3b57e4e907e0daf25_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6d0443c07a5417ca515d44ddc962b47_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85d7032a627d4586b0df7536454a2953_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6abf8b13366e446b8e4d345e553af9c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id13caefd7d5a471aa354ceb296f2d670_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9dbf40f3d8814b2cb5a231dbbd3418e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icc654c5b431f4e2c81e6d3dc971bbfce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iac0e02057646439c9b219a540ab6bba4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d31e315887b49cf9383108785d5b7a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7b0ea0dc41fe4934b7afc79df8635743_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie28ae11319ad4812a556b3a24a0d7eb8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4b089c0fc324d5b82b75e000f5fe9cd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c6435c30e6b40489560149b0efd5c0b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic2be7d9eaa6f4f369f0de369cbb043f8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib7f0edb319054698965e395df2f44e5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b13ed86da2945de8f2c44a2373537a6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i56e369611bfc4546bf3c8e89fd8a3f48_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77324bf397cc41f7a15e4eef24ecff2d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92f1ab36dc934e39ae4bfefcbe05705e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i714dfb429c6f451eb83c696c0379c6ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5007646043540a1b0e932caf506c8b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae8327b6e3b446c39bc4154fdcab2095_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id430b90a4b4b4e00accb2dafe2190824_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f4c4b3745f349e198629a93da34561b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6e8c16288ca4a859ec70b21f89ef7a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a368d5034e44f028f602236d3ab8057_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d0578582acc4184bae1fe1a5d03842e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i64d7cd1d96fd463d81f7b441a15f7907_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85e773fb160f4868b7b34f01835f244e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id4dcf7772a434cca8535434fc724868d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id7c27a6d499a4374bb62731e6ee3c5ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ea6c9f4ab71401f8e112e105b0a87ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i14c87abe9559493098137ef93eb16897_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i56fd5370a66349abb5a708fcca3df153_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e5c418235f74f58be5d142972173da3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1440f6810115464aaba75d7ad2e205fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e04d5b1b77e42338343cb7a394365ac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida1c9540265a40ae89ed8e5bac26055b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0695b54b4eee4244ad7f53879aaf2b88_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3023f47a89be437a8979714fa7aeb5ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae50d2fb61c84091860a38b122dcec5e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3896b7812d9c4f458a6ee1c222fdc5d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf844e180d3a469caf77cbfd640ee06a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i278c392732fe405ca9790ebca84a2b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2759b8249f9b4c0abfb4b6e0d5d1f19a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i21ebd92b09814dbd9c34016fbe056f80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37efff4161cb4c0493595e73c1b6c251_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42302eafa7c143eea1f93c5698a3de9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45a96d28015b45949c078f6766332529_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8fe28e93231442a879e677d581e007a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21f5ff90441c477985db4a043e94ba99_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i081e9eccbec84d14b3e5e990418ead24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2762b41ed6f34461bfde8f1333fdf996_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9d6c7748fb844f8387515876c985d86a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i435b30592ac747d989c50678808fe1d0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i47e7a78e77c640c0978087e1e5aa5365_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic20d6c5cd9154d11b748fba274562228_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec68c25a887f49d4b34b8179ed6dda01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24765f81c1fb4287a6f15e1f08b37561_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i84610d1bd2b740fb98e00437e286d300_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i099396de57cc428db3ba3fa6496e9806_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6bb723c8d7d94576a2e267ad0bde0d6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if84f403b6217414e9c4727bdaddefefa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i993003f0c8794563b176024ce0433091_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf6856ef91ba4d929d656629013d3068_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie282fe45ad5d4fabb47f2e2e934d4440_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i621e08f15f004824aefad73ab5851795_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i179bb4a086e74b04bc986f5bbbb847c6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0ed7b475bcdf40e59be351b723196753_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if0ba58f0b4804781a450e1eafe670429_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i73a0138eece144c7b6d7536ce561b961_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6e338b61d1141f5b8c13e661709f6b5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a7bd97603484ae1802843d027d4882c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1681dbbb7fe645d6853c751bdc56bbad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaed8d036846c41e7ae1fd8954a4b4f77_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52f7ce3635354a61a150bfdfc38169f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id741975d93ce432ca3360bc759262c9c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib000460db5074562808f7f1eb5c6419e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9f6fa4fbbe04394a9fe1a7d581eaec0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib64b83983f224c629b47278996994efe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i47ba7efcd0f44228bd851a9cfd907eca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if79203b4f0e042919ad95c75b6c9ed1d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3338f9b94ba644cdb8a5bfb1a5c29358_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib576612385b34159a385efbbb44ac312_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaa2ab8d0faba462a8cdae1d115c9ac72_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i859211caa6b54eaa83b28f597db71274_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia38e263f9b26407aad657967962464cc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab718c63b5884ec79c89e37caa022504_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d51b5f39b30417591b468b9cc37d240_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9a1275578fd4eab9c1a98a3a69b8994_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i547378d779a94424afb2f81c95c765e8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifced2c43ef9a4921b504c12eeb7b2ef1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ied0d7604169c4be790295c65966d9417_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia5ad1758bd2446cea957f2ad4754f617_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2e694d0a849640f2baad8365a826d153_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idfa6a41f682746a8ace32ddbe43016b7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2af1965f163b48ea903e4c8e2f20baed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i626df6b5d80b4e98b0edeaa02ad00831_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if649f364c260430e996cc0e7faf77825_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b425e8bb2fc4bf98f7703e322eb47ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e2a58ae48e34c639ba8dc2259cc6bf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib99530b1ca1f4637a531747b189b68e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75b92c917f6c46e8bec270fac1ab97be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87ad90d3c5e24243a4f6eb626050ecbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1c1d4df013d43b6a59943a73db0d1fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e05944c5ce844a18dea78c42fefb97f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2306289346ba4f6eac115558f89ffb15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if76fd003b44e4e00b01dd0219527e8f6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3316afc52f864995939b74f4200c4d5d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie41be7ae9a7746e29ab56e1c3957336c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibaaf5c1772824540821269f5a7d5d060_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e6a0250795b4caeb9007fccb2fb25e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7064869e3d004e11826a6f8e545956e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0e23bbc802e473d941d50ddec1eac96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc34b4f0b824400cb3e06c112446fd78_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa6c770a5e4e43219c664f8eeaebc92b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifeca827be1174ca8b3b26a2dd3170414_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c6e00071bb14c0f9134687f14d184c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40f7d8e61c394c11942ca3d90870ce76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36a5db71b7bc44afa79f34197c0d50c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3b7bbcb6f78a486c9aaaf2cc66ad620a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4a58f36c0a0f455fb16aee3fddf5e537_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c4ab8ef49f6437ea3dc95bf05981bfc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i088dd727214a49e5bdaa60f93779a823_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3155754d608b4eb491cdd36b45bcc5de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86308a2e6f2a4ecfba5255d3af29d432_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id9678c4caaf349ba8006f44b404b1b82_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6d2bc0b8db334803be5cea99172bad7f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifdc8ba9e255b47fbb82c3c726dd8508a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1455f288cfc245b69c8e6fa1ee29a92c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i653e387441bf474ba40509d89d957072_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01d4a0312e1a42c1bbb49eebf6fb2dbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6f0399851154ccb8d747ab261a55ff7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e22014612a6456496ade50c3c0e598b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6150f60c782f4bbe93e9e862b343af55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if42be951e40b4522978f85dbcf5c6c5f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i077c77a1980b4f8fb626087d04f359c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c0cf7b896574cd48467e517534d6c7e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0f1f25b805ee48a38221900a8f4ec23b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib6c49899324342418b3c03ecab096e69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c93bb319518438dacf0fb870fcabe09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3079fe6a94b4043bd136bd42880f7e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaafb386815a84014b6e79d88e23df483_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i683f0aac0c634dfca6b9b368ab20372a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb19f61a177a44cc83608f369fc35200_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95aad88173d14db798e85a935c24c68b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a1415a76d304bdd903790a631d4b562_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5fd10e4797b4759b2ad9ee884eb18fb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb70f3e9a3064175beb5a4288f9555cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i598f780a95a34397b93cc33d29482fbf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if319dff6fb6d4c9b9e70b7590afec644_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="id24046754e794d98901ac09a9a57728a_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ia646a389a6944ee39075a400a0260d9f_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="iedf4aed6ce494fb0b76f1715e4bc5fdb_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i5d290b478df340cb86cfefef5344e881_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025RefinancedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i79841cf14ea346c48bdbc856f1e4b860_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia88ba3758b6c416da9c9db84a7ca5778_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26f9a43336ae4b0da381254b468ae09c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7badfe6657634d348d22e9be1faa35ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i54988d2c4f2f40c2933727e2b8be27ff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3001aef538c54c44b5812a99e4845adc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icbf3ce65514c443c8ef37159d35d4a69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e56837ed6bd423c89d802b44906df17_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic438b74601344b28a5a621e09638dfa5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4bcd77a684aa4ecf8e6a62f0794f8418_D20220217-20220217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="i5e438a1448d44f418e9b8f452ccf2783_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i2670f469a2ac4a459ccecfc909f364ee_D20210910-20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="i72db19201e77427a944de55507b7fe80_D20210617-20210617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="i300fb3fc7b084fe1ae13da9f57c82d71_D20210218-20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="ib694cd894894414da5c46138d815dd90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6bcc50f777fb4122a035380de5a8418a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30d113b6de524e999e45640992e7d5f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic307ce6fcfdb4b95a357b18194e6695a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied4482ed129142548aa3b7aba9e6e05f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b80412b07c14765b60765c6863daf16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i305d5315aa3249959cf54167f51117a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19158d14e728497cbede5b260b0904be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38cbefbb7640470d8912c518f4d612c4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d0749feb42e4416b8b7650f417a1131_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a8127b3ac3548c3890da55bf63f1701_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ice36e374d1fe41cd885017f660510ca7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i00bc0c90f91f4af0a5a3a88ab5477eaa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idba4be4766064887868cd838db3129a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13ba96e9d518432f846efbdefd0568c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfa61ba6e74c4671b7c09c21de67bea5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85f7baaa43f94988beb4cab455519ed9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ef17bd343cf45f4a0064de2b7b25559_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i32fccc997a0749b1bb81108be62eb6e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i157ad54cc34c4b9e9f5f62ce15e5c956_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibcc473aa8ebe448e985aa0a29dcd7e8c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ce7636b82d0488790d551ca1286a964_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibe0c4dc2984f481b92d6852e941b91b9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i115d67da01e8464594d5f3097915285d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d2a39cd4e914c2baf4e3f7f78e0e037_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia93484cb8e084701be386a098217dd41_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iac58012cb8394749b3da275880c656bf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5f8aa0c8a5684d66952c25dc6e509fe7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5ce39b3335d40a193f5da7859d3e742_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i18c8e4e34cdc418dadb3f7f36b8d5041_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie2761b85b027474db273e8bb0d34f65a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idfd179fad6a84747bceee1f796370db1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:NiaspanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie9849c3641274f60b03fcb8763315cdc_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i2876ad381a314d1492fed65c7ba60831_D20190301-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i061f6899a2e64d8b9f6710d2ffdaa440_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:BystolicAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b950ca2895a442093c6358346b89e00_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0d6b8a8607154239bab327083f4f2a16_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c041511930545c890fb52c2cac408df_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="id8b1a9f1c7674ab7b5a46fc570730aa0_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ie49c8cbd1c924c69b51d6bd1f5088886_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="id3d814e2470641b7adca70c8dfd22826_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie7d8cd18e85b4007971cea988abe2864_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i86efe50966f24c74849d1de4249000b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icf1053eda3554c3bb53ea7f9f667809a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d8620bf3edb45e497398d57317e67ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i151f76a6bb394b0e8dc33fbdabffeef4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9dcf0e2a5bc4237a3420a8ed35591ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a121fb3a1a74d08bb6b193989e4706a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ief7e3bfd63234b9987cf846478a441fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8267ed584474c71a1ee8dbc54f58ef8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7f415caa04a941a3b6c40335ad6d10f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f1c4e6bb026457da1f4cdf7df42c5f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia38c669542ad4085a09a271f057f90d9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia0dfe507ba24433988668a7d003a378c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia89a047a7f15451fae62f0586e4244bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa4d1ef4d3c3472f8587646493588ca3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06547d54c7744ec59245e1aabe7bb4a9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i68fecb4ba92b444e8e7c4082e3cacd88_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63c7fad38a034510aef4faf293e98042_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2609235fb4a14a5fa8a9ae2ce41de85d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i83dd8a4923b14d1e9444794bdc3c9fa3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i839ac535845b43fe8878c6e026ae540d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia88dc4f478b445c989df2931bf4129de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if8b31104dd4f4b588d5964c0a59fc7d9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa0a5001dda54d03b17d99d99907ef72_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc2f01f0a3bc4965baed776f9c1ee2ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8fd7e7447fe34c6287942f568429ef69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iffd103eaea8d4b81b307a47031308a2b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia21887679ab4450e9854e11b52987fd2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ca3b9d904a042d1be012441bfbfbbbc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i646b3499eac046a9a4d0c7b552528647_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d51184fb925493e90b9ff271b8ba444_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9cf374b782644e749678d1f567eb3bc1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i231632e602304cbcbf663af9260ff447_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3d97cd1c204d47a0894f071baccfb3dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i485c4f314f4d4d4887041a01bca64c2b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia81395f4f3fa48e8826d79041d865c17_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5523e96c483e4a5a83a81a78cfdec571_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie2bf9f5d90ff4778afcba822173f993c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id8ccf536e0504054b9c01fbb9c17051f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i68379647466f42ac98da932e0ae7ba56_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b9a74c5d27b427db7df5b72e0ef9e71_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9886797304fd44789c0dae1792702122_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1192611baa7144ae9f6aa9bd6469b73f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f45042ba49947aea027157aa3e5005e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6297715bc8540428f641904958468e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i274365a0958a49bb88080cb48c332ccd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8aeec465d3b44d6d836a7f5d22f41e34_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic117a05f0ad047458c3dfdf3d563d985_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0aa0c6e5e8e4e86be8c148b66aedbb6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie0f1b5410e4a4e8fb9abfa2219b13d78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic78f3e2ee61c499ba7cc0746a2385d47_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibdbacd087ccb4b378166217f2e6bac38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2b0f54b6f66490ea61e7105a06bbd5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9ff614778cc44cd498c6a9c8964075c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f19775fa7fb4454916890a2d18f7368_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3125d8c421f84befbfdc8c98d0f12733_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if1c196d5476444949e789bed861f1aa6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3d5f22d6d24942c5974fd185d2251f6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibdf4bed28ef04a34be1be2775ace098f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia72f22aa56674f6ea95b38deaf7d7ef0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i639f02ea2ac340d384b27444a35f86c5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0f9dd7d8685493e9094a8411dc69ba7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb5cc0c791ad4deb82c1071bb2540517_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if3d3e94281d14e1ead6013f512d2ba56_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i18fd6150a38a4e9b9bd77ea967639212_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i512cec6652ce4f19be4c4e4462feb4e8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b4fe39a35de44ecaa3535608505ded0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifeabc0e9b646406e88ddb1c5e1f12518_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia12ead842eee42f59b1937c152fb8415_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia67b003e0c9d489a93fc432063b0605d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45a38522757a47f08bcaaed26cc95890_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0b09878f9324ebc81010863a7bb2312_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67b43137ee1c4af9956280587d60c83c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iae85b406a18e40d7b2917cf2e17d0b83_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i741797da087c4ef6a3b16e0b40c35175_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic34cab53f8594ff4979a946f5a3fc1f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i85cd48264009438ca440c693ab0cf2f1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5fc8282031784d8caeb6a4ef809f2f50_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a85e57b458b4094a0c62505b2a9799e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50fb763a0f1c482a9572f571170e440e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i93307eafe6504d879af164c82b04eda8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia46e3aeb263045cfbb0acf95c88c121b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a77a42b923942bfaff4dc08627c3225_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ief85b551045345879ed1be64c67a8b4b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cf3d5f2dfb344e59a6c9efc465d8f5b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic62a015e1747449791ed3c131fc6f351_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7bf8ded17cba43f7b08f7d24f7aed016_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iea2c9be5775d49e7af0a83f0b14fce7f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ddf6b053a5d4cf1b48234a1c15b6c1a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i882c0ed4b6454d5db18fd823a31bcb88_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf25850c2d1c4ceb840ecd9bfee2891c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ife17341a39044007bd37eb3dcabab9af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i379b152b16b1407985df7a9d9e3ad633_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6df2de6a1db84a14bc36698e3dbcbf51_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58a92b2ecc5f4aaf9d8351f86caf7be5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e933b76f7264c7cb306a5779cb4d526_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9bf38d011cc4cfd9351b1938594689b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e746d238af04e0fba57b391911704b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59295dec623542dba93f26a4df9b7bf3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieefe0806b5ac487fb58df139e942b4bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic251b48766744736852af8a750fb5fa6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ife9748feec04436daefd70ed8fde5035_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72ca6bfcb2a742d2a419a770b28a65e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2ecf09fad83434f8b75838cf1459dde_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6fb7ab9f9404aa4800b094182ef46f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9915235f3a844da69814226e5774c2d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4538d383a2c14cac819e3ce9bc8a27c4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i531f3349e8c348c39ad330ddd7567561_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a8b6f17bd484927bdf4246fdc7d2e83_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i092297541dd04ee2b04cfdcfbb71eef1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i143c59ef117840e5b84f10e564ee91c4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="wholesaler">
        <measure>abbv:wholesaler</measure>
    </unit>
    <unit id="lawsuit">
        <measure>abbv:lawsuit</measure>
    </unit>
    <unit id="class_action">
        <measure>abbv:class_action</measure>
    </unit>
    <unit id="direct_purchaser">
        <measure>abbv:direct_purchaser</measure>
    </unit>
    <unit id="end_payor_purchaser">
        <measure>abbv:end_payor_purchaser</measure>
    </unit>
    <unit id="company">
        <measure>abbv:company</measure>
    </unit>
    <unit id="claim">
        <measure>abbv:claim</measure>
    </unit>
    <unit id="investment_fund">
        <measure>abbv:investment_fund</measure>
    </unit>
    <unit id="segment">
        <measure>abbv:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF8xLTEtMS0xLTczMjUz_2f32b1bd-3255-4f21-a632-9c8af16b1cf4">0001551152</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF8yLTEtMS0xLTczMjUz_1461bdcd-f1c7-45fd-a42c-603d57d93ae0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF8zLTEtMS0xLTczMjUz_07749f03-cee0-4cdd-a30c-81226c3a085e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF80LTEtMS0xLTczMjUz_ea03aef9-dfb4-4d97-be0d-dd7c0773f7bc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180L2ZyYWc6YzNhM2I4ZWVhZmUyNDNlY2FjNGEyZmMyYTBiZWNkMGYvdGFibGU6NjZjZjk5YTQ2MmI4NGU2YTk3ZWZlNGQ3MzRkMjQ2MmQvdGFibGVyYW5nZTo2NmNmOTlhNDYyYjg0ZTZhOTdlZmU0ZDczNGQyNDYyZF81LTEtMS0xLTczMjUz_0f12976d-b790-4ec4-b2c7-788c50809639">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:NumberOfOperatingSegments
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xMDAvZnJhZzo1YzRmMGUwYjA3Yzk0MDdkOGFiMzkwMmJjYzlhNWFlMi90YWJsZTo2NWY5YmZiNDZiN2U0OGE3YWI1MTY0NDVjOTExOTQwNi90YWJsZXJhbmdlOjY1ZjliZmI0NmI3ZTQ4YTdhYjUxNjQ0NWM5MTE5NDA2XzEtMS0xLTEtNzMyNTM_32e6e38e-d1ab-4169-aa14-6727c2fdc9d1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQw_98c684f0-5d68-4c05-9fb4-d482d42099b2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUw_b366d782-728e-42cb-a4dd-33c8c4e5b86b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMjU_e363e7d6-7ae6-44ba-aad3-0a44f7d01a96">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUx_40be19cc-9daa-420e-a506-194298569fe4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQx_9cb39a2b-a4dd-4e3d-b534-5907338cba66">001-35565</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ0_824631c1-637a-47b6-bd18-d6973a27daa7">AbbVie Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6ZjBiNmQ0MWIyNjQ2NGRmZjhhY2U2YTE1NjJkNTlmMWUvdGFibGVyYW5nZTpmMGI2ZDQxYjI2NDY0ZGZmOGFjZTZhMTU2MmQ1OWYxZV8xLTAtMS0xLTczMjUz_ff788997-1dd9-48c4-be55-361072a46e57">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6ZjBiNmQ0MWIyNjQ2NGRmZjhhY2U2YTE1NjJkNTlmMWUvdGFibGVyYW5nZTpmMGI2ZDQxYjI2NDY0ZGZmOGFjZTZhMTU2MmQ1OWYxZV8xLTItMS0xLTczMjUz_c8deb2a9-f8fe-46d5-80d3-1f891bffafb9">32-0375147</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ3_9f65a209-5ed8-4087-9578-b2a2ce7fb52a">1 North Waukegan Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ1_436136ae-d57a-4cb3-960e-170bbdab9a3c">North Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUy_f7d2f17b-93c8-4b18-a52e-9a67c370a9f5">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTUz_08defa2b-89ee-484d-88c6-6136da3fe129">60064-6400</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQy_b864d910-1a7e-4f2e-bfd2-28e68e1c6a7b">847</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ4_a6b77ef1-98b3-4290-b63f-bd3f37e2219e">932-7900</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQz_e646689c-75b4-4a58-a619-6e7d39aa8e96">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTU0_ab44d58b-fcd9-468c-8b0d-23dda50eec46">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6Y2FkYWY5Mzg1ZWY0NGUxYjg4YzI5OGNkMjYxYmIxMDIvdGFibGVyYW5nZTpjYWRhZjkzODVlZjQ0ZTFiODhjMjk4Y2QyNjFiYjEwMl8wLTAtMS0xLTczMjUz_1472dc24-8c02-4dc4-82e0-43c7951e8f41">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6Y2FkYWY5Mzg1ZWY0NGUxYjg4YzI5OGNkMjYxYmIxMDIvdGFibGVyYW5nZTpjYWRhZjkzODVlZjQ0ZTFiODhjMjk4Y2QyNjFiYjEwMl8xLTMtMS0xLTczMjUz_2395a486-8d1b-454f-acb4-83fcc17cc999">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6Y2FkYWY5Mzg1ZWY0NGUxYjg4YzI5OGNkMjYxYmIxMDIvdGFibGVyYW5nZTpjYWRhZjkzODVlZjQ0ZTFiODhjMjk4Y2QyNjFiYjEwMl8yLTMtMS0xLTczMjUz_7f3accdc-4642-4aaa-beb7-90423b739706">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMTQ5_85120a9e-eb6e-47d4-a780-763d5d45c07f">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTAtMS0xLTczMjUz_024a3240-fef7-46c3-99b5-93815b5a9dfd">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="iffe012c9dbd240048d813949942fdca1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTAtMS0xLTczMjUz_a0cead0a-8657-4a4e-ac0b-e3e38f1eef99">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTItMS0xLTczMjUz_ce10e4c9-4b43-4d4b-972a-579877d6376f">ABBV</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="iffe012c9dbd240048d813949942fdca1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTItMS0xLTczMjUz_dcf6c143-0703-4fe3-b749-3502e796a150">ABBV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iffe012c9dbd240048d813949942fdca1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xLTQtMS0xLTczMjUz_6cf3ab2b-ffa4-481b-9e75-3baf482bd6ff">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="ic7b03101ef58492ca9192ba750dbd681_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8yLTQtMS0xLTczMjUz_c51a9dd8-49ef-4029-8b7d-b2fdf836a524">CHX</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8zLTAtMS0xLTczMjUz_8de0921d-610c-4c7e-9a2a-112814189a93">1.500% Senior Notes due 2023</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8zLTItMS0xLTczMjUz_da6c4f5b-b837-41db-a0f4-aea2fce3238f">ABBV23B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i80b5d238bb8e41cca471222ecd0792da_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8zLTQtMS0xLTczMjUz_bff6c4cf-81a9-43ec-bb7e-19224d30c9cb">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl80LTAtMS0xLTczMjUz_8131ca33-47fe-494c-9dd0-b458c5417925">1.375% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl80LTItMS0xLTczMjUz_ca54a00f-dd10-4a63-8741-39d1adb8f637">ABBV24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2d28e73ff9804c2ba49fd0a53b2e8e80_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl80LTQtMS0xLTczMjUz_82de2794-2685-4dd3-93a4-647e5b1c3dcc">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl81LTAtMS0xLTczMjUz_213ff2ac-b01f-4fb1-9025-9f3f83af2f83">1.250% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl81LTItMS0xLTczMjUz_64ed4422-c691-45fe-8c9a-71f5367447e7">ABBV24B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib20f829371cc40dabd2a3c59b1f1a0fb_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl81LTQtMS0xLTczMjUz_c48e3414-883d-4e24-9690-4a4b57faeb61">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl82LTAtMS0xLTczMjUz_9cf0fe32-2215-484a-8317-d769db189b0b">0.750% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl82LTItMS0xLTczMjUz_619359a6-93f0-4d17-bbe3-f84029ea30ba">ABBV27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i21ebb248bd964f8fa03fbfc9e37742b5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl82LTQtMS0xLTczMjUz_bdebec32-8eab-4ee2-aa2a-cec048d323a5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl83LTAtMS0xLTczMjUz_919d488a-ae2e-4c1e-94a4-c11350aa190d">2.125% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl83LTItMS0xLTczMjUz_fe87b0e7-0f62-4283-961b-00bdff043806">ABBV28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8ec6ad1bebd34f3bb53e7507c29a99ae_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl83LTQtMS0xLTczMjUz_8e45cd2a-fc10-4f95-a19e-ef4735dfc807">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl84LTAtMS0xLTczMjUz_146c0083-638a-4962-b54f-8ff5203159f6">2.625% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl84LTItMS0xLTczMjUz_fcf2e39d-3e49-4ce8-ad44-b260b02e1d42">ABBV28B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib84804f5ed9046c8ad2c59ea3175685c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl84LTQtMS0xLTczMjUz_90478eb0-5495-4252-9116-4b31e712942e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl85LTAtMS0xLTczMjUz_9a8281ff-10a3-4631-bee7-aafc3580815d">2.125% Senior Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl85LTItMS0xLTczMjUz_c87b8e02-a187-4a84-abf4-f763d8cb058a">ABBV29</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1583bfe6b33a4f04a6bafb359ac40353_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl85LTQtMS0xLTczMjUz_1d29d022-9105-40a6-9e10-1e57abb51a2e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i13386ec6dca24c72873db6a581548a42_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xMC0wLTEtMS03MzI1Mw_a479ec9e-a50f-40e9-a501-6ff6e3482b17">1.250% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i13386ec6dca24c72873db6a581548a42_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xMC0yLTEtMS03MzI1Mw_bfb06978-daf0-431b-92c3-00a83b360f8c">ABBV31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i13386ec6dca24c72873db6a581548a42_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGFibGU6MzM0N2JlMTdmYjcyNDI4NGE0NWNhNGViMmI5Y2M0YmIvdGFibGVyYW5nZTozMzQ3YmUxN2ZiNzI0Mjg0YTQ1Y2E0ZWIyYjljYzRiYl8xMC00LTEtMS03MzI1Mw_3e9f3fc9-c1b6-41d1-8abe-43faa975c980">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id0a62f89becf43099721dde7ba0ee70e_I20220427"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xL2ZyYWc6OGQwMjM0NjQ1ZWYzNDliZTliMDI3MDZmMzQzZGMxOGIvdGV4dHJlZ2lvbjo4ZDAyMzQ2NDVlZjM0OWJlOWIwMjcwNmYzNDNkYzE4Yl8yMDgy_b1d1ec92-c720-478f-9682-29ac6fd3428e"
      unitRef="shares">1767110083</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMi02LTEtMS03MzI1Mw_1ea9b709-5d26-4b28-acff-0aa6a9ec0628"
      unitRef="usd">13538000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMi04LTEtMS03MzI1Mw_4b97deba-9eb0-4c71-8642-87fe56902709"
      unitRef="usd">13010000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNC02LTEtMS03MzI1Mw_0e3cfa95-64c9-439f-833c-cee6ffe28ec1"
      unitRef="usd">4052000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNC04LTEtMS03MzI1Mw_f90c9b7c-8f49-4be2-8337-df4f9ad32195"
      unitRef="usd">4213000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNS02LTEtMS03MzI1Mw_0b4d8aeb-9abd-4b12-83aa-1f89fa80e23e"
      unitRef="usd">3127000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNS04LTEtMS03MzI1Mw_d2afea1c-2201-46c3-a71a-00af4157276f"
      unitRef="usd">2842000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNi02LTEtMS03MzI1Mw_1c6c7d79-ce85-42b0-ad22-b6d4f55bbc85"
      unitRef="usd">1497000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNi04LTEtMS03MzI1Mw_6f254e22-5077-4d46-99bc-6b2911d3f57e"
      unitRef="usd">1667000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNy02LTEtMS03MzI1Mw_d3a0d7fb-9152-4301-8443-63aaed03d1ad"
      unitRef="usd">145000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfNy04LTEtMS03MzI1Mw_7e528561-c68f-4dbe-901a-09717b6f8c00"
      unitRef="usd">185000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:CostsAndExpenses
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfOS02LTEtMS03MzI1Mw_b185af68-cdaa-4261-8c55-ee3a21ed6fcf"
      unitRef="usd">8821000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfOS04LTEtMS03MzI1Mw_734845ad-3a60-4f5b-a735-53e2ddcdc639"
      unitRef="usd">8907000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTAtNi0xLTEtNzMyNTM_1467b817-8a34-4c97-9d87-ca0e047b728b"
      unitRef="usd">4717000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTAtOC0xLTEtNzMyNTM_e99e3278-993c-4ba8-b2e3-cfadb4935232"
      unitRef="usd">4103000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTItNi0xLTEtNzMyNTM_6a7c802a-901b-4f40-abd8-43b850233992"
      unitRef="usd">-539000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTItOC0xLTEtNzMyNTM_36520dd3-e193-4c95-a8ce-659eb6daadd7"
      unitRef="usd">-622000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTMtNi0xLTEtNzMyNTM_c1f21e38-4ecf-47e9-874a-76d7d501bb15"
      unitRef="usd">-25000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTMtOC0xLTEtNzMyNTM_0b60e52f-5e8a-4321-9e1c-3888166fa973"
      unitRef="usd">-9000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTQtNi0xLTEtNzMyNTM_acc7a249-eb75-4719-a75a-c0ae616fb3a3"
      unitRef="usd">776000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTQtOC0xLTEtNzMyNTM_7e5b3a10-db2f-4675-941b-00eb2f86a320"
      unitRef="usd">395000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTUtNi0xLTEtNzMyNTM_1f521ff4-023e-4eaf-bded-3fcdafd7ede9"
      unitRef="usd">4929000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTUtOC0xLTEtNzMyNTM_8c73c419-b9bc-4dd2-853e-339e6de88808"
      unitRef="usd">3867000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTYtNi0xLTEtNzMyNTM_b0f5ba17-1a9e-4ef1-87fa-0db943e2d278"
      unitRef="usd">436000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTYtOC0xLTEtNzMyNTM_7ae07da7-50da-4855-afbe-2180b417c635"
      unitRef="usd">312000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTctNi0xLTEtNzMyNTM_239139ca-22f5-433c-b154-acc1dc0bded7"
      unitRef="usd">4493000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTctOC0xLTEtNzMyNTM_854a3453-e970-46c1-9e52-95b62ecc8d09"
      unitRef="usd">3555000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTgtNi0xLTEtNzMyNTM_77571f51-7e99-4d81-9fdc-560a71c96392"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTgtOC0xLTEtNzMyNTM_70c73fe4-9bc3-408d-b6bd-d7ddf7505ce8"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTktNi0xLTEtNzMyNTM_bfb43cdf-32f7-4e0d-b63e-47171420bef6"
      unitRef="usd">4490000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMTktOC0xLTEtNzMyNTM_6c4acd5e-e989-4f09-a749-38b57b07efda"
      unitRef="usd">3553000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjItNi0xLTEtNzMyNTM_ab857fc3-1ff9-491c-8ca9-a8060de0b2e9"
      unitRef="usdPerShare">2.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjItOC0xLTEtNzMyNTM_d28524c5-9263-460f-af48-6d9ae0a7c9bf"
      unitRef="usdPerShare">2.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjMtNi0xLTEtNzMyNTM_16ff6acc-146c-4494-a4fc-4d3c84b333ff"
      unitRef="usdPerShare">2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjMtOC0xLTEtNzMyNTM_e0961706-c156-4b2f-b7ec-d9f9251858cf"
      unitRef="usdPerShare">1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjUtNi0xLTEtNzMyNTM_687c5be5-79f3-497f-b91e-8e74a7c7c243"
      unitRef="shares">1771000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjUtOC0xLTEtNzMyNTM_8f078004-9a5f-4e3d-8f18-d13777b8ec11"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjYtNi0xLTEtNzMyNTM_76fe9945-2acd-4f1a-ab58-3983957c3817"
      unitRef="shares">1778000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xNi9mcmFnOjcyNzlmNmY4NGY5ZTQ4MmQ4NGFjMDk3NmYxZmIzNjQxL3RhYmxlOjA5MjQ1YjFhYTJlNzQwMThiYmE3MjlkMzE1ZDVjODg4L3RhYmxlcmFuZ2U6MDkyNDViMWFhMmU3NDAxOGJiYTcyOWQzMTVkNWM4ODhfMjYtOC0xLTEtNzMyNTM_c8689ae3-d5b2-405a-8476-08cfe2b24e06"
      unitRef="shares">1775000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMi01LTEtMS03MzI1Mw_e5b2c256-f167-4f33-8e95-738b438d0570"
      unitRef="usd">4493000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMi03LTEtMS03MzI1Mw_be1af1e2-9883-4581-8b8a-f1a0da6396a5"
      unitRef="usd">3555000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOmY0ZjEzNDc2NGFjODRhNDY4MjVlYzM1Y2YzOTFkNDI5XzEwNw_0e846dd7-274a-4089-b863-d31d8f2c98aa"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOmY0ZjEzNDc2NGFjODRhNDY4MjVlYzM1Y2YzOTFkNDI5XzE1Mw_e8cd5ec1-ebb7-4209-b2a8-99533efcf9bd"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC01LTEtMS03MzI1Mw_70dc080a-cb1a-4be7-9da4-db67f848d276"
      unitRef="usd">-231000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNC03LTEtMS03MzI1Mw_798de2e0-3719-4de0-9729-188832c55c4a"
      unitRef="usd">-677000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjc5NjA2MjQ4MWI1YjRiZTZiMDk4ZGY5MDNjZDRlYjBhXzk5_28b7d043-e650-41c7-abdc-8b87a4805830"
      unitRef="usd">37000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjc5NjA2MjQ4MWI1YjRiZTZiMDk4ZGY5MDNjZDRlYjBhXzE0NQ_253583b1-c5bc-4253-9944-f64f2fdadb62"
      unitRef="usd">103000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS01LTEtMS03MzI1Mw_c28da181-5d2e-45a2-a8f1-0f25b9addd76"
      unitRef="usd">130000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNS03LTEtMS03MzI1Mw_460fa9c3-1937-4b51-bece-7d37d6569a4f"
      unitRef="usd">374000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjBlYWRjMTdhNDExZjRmZTRiZjZiNGVkNWJmYWRlMGY4XzEwMg_b19e5138-7c00-4cbb-8bd5-261772be5129"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjBlYWRjMTdhNDExZjRmZTRiZjZiNGVkNWJmYWRlMGY4XzE0OA_db083b78-e7b9-49d8-9922-8a67833437eb"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi01LTEtMS03MzI1Mw_0852afd1-ccfe-4252-9886-14736fcf8976"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfNi03LTEtMS03MzI1Mw_839e17bd-127f-45a0-95fd-bbf7094e3538"
      unitRef="usd">-79000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjEyNTBlM2JlOTgxMzQ0NTRhZjZjYTMxOWY2NWNlYzZmXzk0_6a2f6c77-0238-427b-9d8b-d5577af7ac13"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC0wLTEtMS03MzI1My90ZXh0cmVnaW9uOjEyNTBlM2JlOTgxMzQ0NTRhZjZjYTMxOWY2NWNlYzZmXzE0MA_a462e94e-e424-4670-b7fc-45d84569ddbf"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC01LTEtMS03MzI1Mw_6a820093-efec-4899-828f-7fdd15f24551"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOC03LTEtMS03MzI1Mw_935e7c51-bdde-4e95-83c0-c0146f465222"
      unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOS01LTEtMS03MzI1Mw_f6dcfc62-adad-4f8f-bcb6-3558f628f51a"
      unitRef="usd">-85000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfOS03LTEtMS03MzI1Mw_feeeda83-1948-4a60-a8f9-36a6f0c79d29"
      unitRef="usd">-178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTAtNS0xLTEtNzMyNTM_24157632-c44b-4631-a557-d11439da975b"
      unitRef="usd">4408000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTAtNy0xLTEtNzMyNTM_1a462c34-1e24-47d9-850d-2a2e6989b44a"
      unitRef="usd">3377000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTEtNS0xLTEtNzMyNTM_5dce1ca9-b8d9-4882-b4f3-2605b8f24aff"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTEtNy0xLTEtNzMyNTM_3d3580d7-a0d5-40b6-8dbe-42311da99687"
      unitRef="usd">2000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTItNS0xLTEtNzMyNTM_6e5ca759-4a06-45f5-bbd1-fa1646c07d62"
      unitRef="usd">4405000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18xOS9mcmFnOmNlMTMyMzJhOTk3YTQ0ZGVhODgzNzY5NWQwMDQxZGYwL3RhYmxlOjNlOWQ3ZTkzYzJjNTRlNDJiYWVhMTEwZDllNjRiNjgwL3RhYmxlcmFuZ2U6M2U5ZDdlOTNjMmM1NGU0MmJhZWExMTBkOWU2NGI2ODBfMTItNy0xLTEtNzMyNTM_e9617d3d-9f0f-4fdf-8f35-6c8ef4799dda"
      unitRef="usd">3375000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNC0xLTEtMS03MzI1Mw_8316afbd-0055-4c3d-99a5-e010155aaa37"
      unitRef="usd">6098000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNC0zLTEtMS03MzI1Mw_c7bb1c16-dc87-4952-9e92-c2f45e4bb6b5"
      unitRef="usd">9746000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNS0xLTEtMS03MzI1Mw_f55401f6-4fa9-4e98-95df-89f3e3bc83a8"
      unitRef="usd">1474000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNS0zLTEtMS03MzI1Mw_5e828f2a-87f0-469d-9c13-91fd018493e5"
      unitRef="usd">84000000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNi0xLTEtMS03MzI1Mw_2bcfeecf-3789-4e26-a973-9c6c2658a108"
      unitRef="usd">10733000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNi0zLTEtMS03MzI1Mw_2b4ce90d-70d7-4989-afc3-4f90e371fbdc"
      unitRef="usd">9977000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNy0xLTEtMS03MzI1Mw_29b4a77b-473e-465a-b0c9-081b0a4eba6e"
      unitRef="usd">3483000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNy0zLTEtMS03MzI1Mw_336e1585-f647-4135-aa66-bb15a4e0bbdf"
      unitRef="usd">3128000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOC0xLTEtMS03MzI1Mw_ff7bcbee-26af-419d-8d26-baa81fbde169"
      unitRef="usd">4721000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOC0zLTEtMS03MzI1Mw_ee90aee1-a3ae-4e46-823a-3c06a7f3ca20"
      unitRef="usd">4993000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOS0xLTEtMS03MzI1Mw_fb6d43af-a2f0-4a67-9884-633a821be8e8"
      unitRef="usd">26509000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfOS0zLTEtMS03MzI1Mw_6fd61afb-3843-4a12-943e-1d756adf94c0"
      unitRef="usd">27928000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTEtMS0xLTEtNzMyNTM_577f6504-c098-48c1-84aa-a9f1f8969df4"
      unitRef="usd">260000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTEtMy0xLTEtNzMyNTM_f9a6a77b-8b60-4c52-a7a3-5b0ae0f7f11e"
      unitRef="usd">277000000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTItMS0xLTEtNzMyNTM_9aa46c53-8aeb-4d3f-afab-9b3add98115e"
      unitRef="usd">5075000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTItMy0xLTEtNzMyNTM_3f320dc6-b648-4487-87a5-01d6dc5a90b8"
      unitRef="usd">5110000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTMtMS0xLTEtNzMyNTM_12f3abf4-3aa8-4001-9ffb-9fc27ef4d9a9"
      unitRef="usd">73986000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTMtMy0xLTEtNzMyNTM_b02db59f-6e3a-4556-b9ff-d2b09ac647ba"
      unitRef="usd">75951000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTQtMS0xLTEtNzMyNTM_2a97da31-2b0d-46d9-996f-0104083b6bf8"
      unitRef="usd">32298000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTQtMy0xLTEtNzMyNTM_ad014b88-7067-4de3-ad88-f10d9adaf706"
      unitRef="usd">32379000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTUtMS0xLTEtNzMyNTM_7276a1d9-fd14-4b76-8dc5-85ec01985fe7"
      unitRef="usd">5083000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTUtMy0xLTEtNzMyNTM_c7b38354-52cd-4db4-9907-709933592e41"
      unitRef="usd">4884000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTYtMS0xLTEtNzMyNTM_f6a09ef9-8206-4732-bedd-3d809ab7963e"
      unitRef="usd">143211000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMTYtMy0xLTEtNzMyNTM_a001d42f-4558-4178-9c9e-d90d688e63bd"
      unitRef="usd">146529000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjAtMS0xLTEtNzMyNTM_cdb0d5e4-dd17-41c6-a5fe-1e442f01b801"
      unitRef="usd">12000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjAtMy0xLTEtNzMyNTM_e5948576-9323-4dd7-9f12-b48d5f81ecd9"
      unitRef="usd">14000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjEtMS0xLTEtNzMyNTM_bf7b5f59-e58f-4f6b-b883-f4d8aba42b9d"
      unitRef="usd">9940000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjEtMy0xLTEtNzMyNTM_debd17ca-d32f-4d74-85c0-ccc529b81577"
      unitRef="usd">12481000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjItMS0xLTEtNzMyNTM_40d9b68d-fdc6-4b5c-bbdc-46cac91adbbe"
      unitRef="usd">22569000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjItMy0xLTEtNzMyNTM_0af3c78a-bbf1-4a62-a0c3-5713db4ed2d9"
      unitRef="usd">22699000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjMtMS0xLTEtNzMyNTM_7ffdfa42-c4a5-4704-96d2-83b25cc0903b"
      unitRef="usd">32521000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjMtMy0xLTEtNzMyNTM_5a3708a9-f49b-4e0a-9b2e-d08efb2a8ca5"
      unitRef="usd">35194000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjUtMS0xLTEtNzMyNTM_9c4c2dd7-5762-44e2-89ad-08b575e671e3"
      unitRef="usd">63522000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjUtMy0xLTEtNzMyNTM_c7c9256b-c501-4435-a50e-0f395bcfd1a5"
      unitRef="usd">64189000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjYtMS0xLTEtNzMyNTM_3f2284c9-a0db-4395-bfcc-cf81b1ded318"
      unitRef="usd">2831000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjYtMy0xLTEtNzMyNTM_4d94ecc1-56f6-44ed-ad7c-a72d0eb78f55"
      unitRef="usd">3009000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjctMS0xLTEtNzMyNTM_7da6ae52-9067-4f9a-87e5-4bcdf39b3427"
      unitRef="usd">28023000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjctMy0xLTEtNzMyNTM_f0acfb25-cd5d-4f26-80d5-430906517810"
      unitRef="usd">28701000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjktMS0xLTEtNzMyNTM_b7cc857a-2e48-437e-8700-e89c51f10679"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMjktMy0xLTEtNzMyNTM_46d390b3-d484-40ff-8706-02a079aeb14e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8xOA_4192cf9d-b0c4-4622-9745-11eae8ef4759"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8xOA_4e098e9d-d53d-40c8-b76b-dd94c11fbf57"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8zMg_b9ab60b0-d780-4de6-ada4-7f93ab3321ae"
      unitRef="shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF8zMg_ef34f7b1-6918-4e43-a813-143bb323a9f8"
      unitRef="shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF81NA_c9fda24d-a086-40d8-9a30-97b9fe940fbc"
      unitRef="shares">1811430573</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjoyZDAxYzUwMTQ5NWU0N2EwOTMxMzhhNGQ3ZDMyZGEyMF84NA_43126ee0-8b34-4cb1-97d7-700f5f566268"
      unitRef="shares">1803195293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMS0xLTEtNzMyNTM_30decaaa-1042-458c-9472-71972581017c"
      unitRef="usd">18000000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzItMy0xLTEtNzMyNTM_fd93f7a8-8003-493a-a5c0-8d78f9a74f6f"
      unitRef="usd">18000000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:TreasuryStockShares
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjo3NDRjY2QyZDExZmM0YzZiODhjZTY4YmZmZWNjNmM3M180NA_a7af0163-b2bc-45b7-987e-761a2c523fc0"
      unitRef="shares">44557588</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMC0xLTEtNzMyNTMvdGV4dHJlZ2lvbjo3NDRjY2QyZDExZmM0YzZiODhjZTY4YmZmZWNjNmM3M182Nw_fdb31461-60c4-4d48-8d8f-3564908ff517"
      unitRef="shares">34857597</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMS0xLTEtNzMyNTM_16c9c040-13b4-4a58-91c9-c1ff7a491b1a"
      unitRef="usd">4585000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzMtMy0xLTEtNzMyNTM_675da50a-8420-45f7-9dad-49681f47988c"
      unitRef="usd">3143000000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzQtMS0xLTEtNzMyNTM_feef771f-e97c-4ff1-9232-a04e8ece4d2b"
      unitRef="usd">18731000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzQtMy0xLTEtNzMyNTM_9a64322d-f228-4983-a3f6-58f39b449338"
      unitRef="usd">18305000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzUtMS0xLTEtNzMyNTM_bd1f6aaa-99ca-4378-a659-cd8daa2ee3bf"
      unitRef="usd">5103000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzUtMy0xLTEtNzMyNTM_7c896c57-af7c-47cf-80b5-5272dfbe65ee"
      unitRef="usd">3127000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzYtMS0xLTEtNzMyNTM_5e9510fd-55ea-4f18-afb9-9c3249690d69"
      unitRef="usd">-2984000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzYtMy0xLTEtNzMyNTM_2e995146-6538-4980-b3e7-fd84bde81ff7"
      unitRef="usd">-2899000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzctMS0xLTEtNzMyNTM_158bc989-3081-4f29-aa6f-ff9d8e724f49"
      unitRef="usd">16283000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzctMy0xLTEtNzMyNTM_00c22fde-92b6-44d3-b824-f0e8d2d79272"
      unitRef="usd">15408000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzgtMS0xLTEtNzMyNTM_0d003326-ecad-4636-97ed-54f47ff09c9e"
      unitRef="usd">31000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzgtMy0xLTEtNzMyNTM_8fbcae41-80fc-47dc-8a87-8e504966dcc5"
      unitRef="usd">28000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzktMS0xLTEtNzMyNTM_a3831806-59a8-46d4-aff1-d4f97354fd48"
      unitRef="usd">16314000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfMzktMy0xLTEtNzMyNTM_08e93e0d-2e5d-40d3-9a8a-e74aa115c9e9"
      unitRef="usd">15436000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNDEtMS0xLTEtNzMyNTM_be55db18-1083-4f82-9356-f7f1dc2ca093"
      unitRef="usd">143211000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yNS9mcmFnOjc2MjJlNGFlYjUzNjRhZGU5NTI4NjgwMmRkYTdkNzM2L3RhYmxlOjEzMWEyOTMyMWFmYjRiNGI4MjNiYjI5ZWEyODMyYjI5L3RhYmxlcmFuZ2U6MTMxYTI5MzIxYWZiNGI0YjgyM2JiMjllYTI4MzJiMjlfNDEtMy0xLTEtNzMyNTM_882253d4-b2f6-479f-93b7-d31f76b08de1"
      unitRef="usd">146529000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xLTEtMS03MzI1Mw_a4e678fd-0fad-4b0a-8413-cfd8c6824a79"
      unitRef="shares">1765000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0zLTEtMS03MzI1Mw_eade0620-819d-497f-8b8b-235d0827cf4b"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4cb1995fa5b74df58173afb77b7e467f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS01LTEtMS03MzI1Mw_a1531eaf-73dd-42f3-9899-c939dc89889a"
      unitRef="usd">-2264000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66fe2db515c241c0bb28d212b85279e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS03LTEtMS03MzI1Mw_c66359e6-ed8b-4687-a8a9-6b6a164e9639"
      unitRef="usd">17384000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6e8e05625504d9a944f9bade3f3867c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS05LTEtMS03MzI1Mw_8f125517-2455-4832-886c-9c99082220dc"
      unitRef="usd">1055000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf1feacb1a194c1d9816daa1d27870c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xMS0xLTEtNzMyNTM_06f3d593-702a-4709-bd16-4a9d64b3ceb5"
      unitRef="usd">-3117000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia427e86aee794ddda12fc9e121da41f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xMy0xLTEtNzMyNTM_25a73e1d-0ab5-4acb-bc6f-15796538cc3c"
      unitRef="usd">21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6accb844205d4e909ea7d6f406d2b865_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMS0xNS0xLTEtNzMyNTM_f4db4082-b34c-490d-9bfa-e37c4162a515"
      unitRef="usd">13097000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0zLTEtMS03MzI1Mw_e3ca5fc4-33e6-43ee-8694-f3b00c8c9248"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy01LTEtMS03MzI1Mw_c2c84dbb-ec30-4696-b32a-899d1ec4a593"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy03LTEtMS03MzI1Mw_0ab4ac65-6821-4db5-8beb-11159ec2440a"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy05LTEtMS03MzI1Mw_e62b6e3f-af5b-4abe-90ae-f8d39ba88c01"
      unitRef="usd">3553000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0xMS0xLTEtNzMyNTM_03d8de3b-6caf-4de8-bcf8-9c33389075c5"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0xMy0xLTEtNzMyNTM_9718d6c0-7f11-406d-94b0-d01b4e84ce92"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMy0xNS0xLTEtNzMyNTM_d4b21536-dc85-46e8-b4e9-9a7359cb3dfb"
      unitRef="usd">3553000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0zLTEtMS03MzI1Mw_d106b131-32ad-4b49-a371-66d433850860"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC01LTEtMS03MzI1Mw_3803510e-9c05-4f25-98a5-932e352babdf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC03LTEtMS03MzI1Mw_6aa53c1e-97ad-486e-a6bc-d5e8c975cb45"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC05LTEtMS03MzI1Mw_9d551ec7-48d1-4c32-a2f6-5f21be130c09"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0xMS0xLTEtNzMyNTM_9cff0b71-47c8-4067-ad5f-53443a4474a9"
      unitRef="usd">-178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0xMy0xLTEtNzMyNTM_80afaaa9-da24-445a-91e5-39658f42dcb0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNC0xNS0xLTEtNzMyNTM_ce54ce16-b4b1-4bc2-ac41-ea5e7e6a8a38"
      unitRef="usd">-178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0zLTEtMS03MzI1Mw_7fc90b72-38c2-41a8-a7d6-3019859cdb2f"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS01LTEtMS03MzI1Mw_d346eda7-92e2-4c48-b301-6067081462da"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS03LTEtMS03MzI1Mw_7467ac60-2df8-4f16-a27f-9caa994a1a65"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS05LTEtMS03MzI1Mw_f190210a-0aff-4be3-a9f2-1d201350851c"
      unitRef="usd">2316000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0xMS0xLTEtNzMyNTM_a6d63676-8397-4e0c-8eb1-68cfe500b5de"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0xMy0xLTEtNzMyNTM_e34905a4-6ef4-44f6-8794-cc9e9baa5cd7"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNS0xNS0xLTEtNzMyNTM_746de55a-9e98-4f32-ad84-b9e432db5f1a"
      unitRef="usd">2316000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xLTEtMS03MzI1Mw_15b11053-6051-4d37-a47e-95a213c3ceac"
      unitRef="shares">7000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0zLTEtMS03MzI1Mw_b3942fac-0ca4-4fb0-b005-aca875bc62f4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy01LTEtMS03MzI1Mw_f9009a91-65c6-4b4d-b61b-c4180f4f2f89"
      unitRef="usd">787000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy03LTEtMS03MzI1Mw_efceb515-9162-4059-958e-9fc4c8e99056"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy05LTEtMS03MzI1Mw_65bf7f11-6ed7-4ef5-90ba-dc439addaec7"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xMS0xLTEtNzMyNTM_c6aff273-6307-475a-9f96-434511770e6d"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xMy0xLTEtNzMyNTM_96824b9a-cd23-4835-ab9b-011195a2b95b"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfNy0xNS0xLTEtNzMyNTM_7c69a985-9883-4612-88d1-816f05834349"
      unitRef="usd">787000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xLTEtMS03MzI1Mw_a0136286-474e-4081-a5ab-badd1abfba22"
      unitRef="shares">8000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0zLTEtMS03MzI1Mw_2ccc3523-3b6f-4741-8b6e-211a231fc25f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC01LTEtMS03MzI1Mw_d7f1e694-e3ad-4ad8-be59-36f054648aba"
      unitRef="usd">34000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC03LTEtMS03MzI1Mw_409986ed-d574-406d-8fe2-a02fc5f386bb"
      unitRef="usd">328000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC05LTEtMS03MzI1Mw_25aa6a27-c9fa-44b4-aa39-8e84a54243a2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xMS0xLTEtNzMyNTM_5849e305-8e2e-4e19-9552-f01262642d18"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xMy0xLTEtNzMyNTM_82799e9e-4c0a-4550-a4cf-adcef910e6ec"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOC0xNS0xLTEtNzMyNTM_cf38aadc-e321-40e7-ba16-7f79839d01d4"
      unitRef="usd">362000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i0bd6e7e0203e48078669ad3bde0d5c7d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0zLTEtMS03MzI1Mw_322023ed-466c-4034-bc7c-6c1f0c4e820c"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i0d02525654584e2f9f785b90b9913777_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS01LTEtMS03MzI1Mw_f7adb831-1985-49dc-b801-868806d48470"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i063a456449f745c98a09be163769f332_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS03LTEtMS03MzI1Mw_c702255e-291f-417b-bc1c-b0d32612a5a2"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ia0872c55f62b455494f25c4d7b92ca72_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS05LTEtMS03MzI1Mw_f188eeea-96eb-4b51-88be-d2b90889ea8f"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i022758431fdb43f8b4df8421bb21711f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0xMS0xLTEtNzMyNTM_2ca9d987-0ba0-48cb-9a58-3dcfa880a9e1"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i2c3f47fb5c714936a77899d22ef47d49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0xMy0xLTEtNzMyNTM_c90411aa-2729-48ea-b68a-3b3bf2aef917"
      unitRef="usd">2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfOS0xNS0xLTEtNzMyNTM_f1636c9c-b96c-46b3-92f6-6693e9416e01"
      unitRef="usd">2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="id5cf8db55503473d9dd1af8c0d20c48d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMS0xLTEtNzMyNTM_d48e582b-efd4-4d6b-b9f1-a458b77ab3e5"
      unitRef="shares">1766000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5cf8db55503473d9dd1af8c0d20c48d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMy0xLTEtNzMyNTM_b61e1786-bc17-43be-82dd-b94aa55dc2aa"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6e9540820e34b43b3e6ec3daddaa1fc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtNS0xLTEtNzMyNTM_25baf1e2-16ae-4cad-be54-7eed037f54ac"
      unitRef="usd">-3017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f9dace7c91d4297a7aa7f308de3f768_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtNy0xLTEtNzMyNTM_328c177d-be71-4be0-afbe-8cbb50b4ee5e"
      unitRef="usd">17712000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a3023971ae049339d5747605ef52a7c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtOS0xLTEtNzMyNTM_fb922321-bb0d-4206-a01a-1662090d3849"
      unitRef="usd">2292000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i980dca056e914f6385bbf2d1f0a5c20b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMTEtMS0xLTczMjUz_0d7e6e64-3966-40bc-b196-44d53724420f"
      unitRef="usd">-3295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab26cb86a14c46ba9fa64e4b951dfaea_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMTMtMS0xLTczMjUz_696629ae-f3dc-4c3a-a835-b810e51ca727"
      unitRef="usd">23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cf70c299b6747128fa4a148bd06c306_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTAtMTUtMS0xLTczMjUz_5c057a5d-ba73-470e-97c4-2607fd9837fc"
      unitRef="usd">13733000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ide7dd1b7a2964e66b89583f5e940f748_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMS0xLTEtNzMyNTM_da3a1010-a611-4017-bbb8-623c94357ade"
      unitRef="shares">1768000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide7dd1b7a2964e66b89583f5e940f748_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMy0xLTEtNzMyNTM_51afcea6-ff15-4089-bcee-25b2537c5745"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03d21af462c442b5beb00d3ba5c34925_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItNS0xLTEtNzMyNTM_bfd49c81-dceb-4158-9311-b35ca26d7b27"
      unitRef="usd">-3143000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a07265e199d4b30a14e9e6383620f9f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItNy0xLTEtNzMyNTM_538f06fa-3050-4356-808e-888038c7394c"
      unitRef="usd">18305000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1929ee5ab0f4e8c9347283529630a9c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItOS0xLTEtNzMyNTM_62ceaf8b-4cea-4d16-b7b3-f11e149f71e6"
      unitRef="usd">3127000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e9ff1d5c2f242d3acc07bc91dffb247_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMTEtMS0xLTczMjUz_9b0e8bbd-2b5b-4bfe-aec5-14145f58bada"
      unitRef="usd">-2899000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa789cc1b9f041559e83b047a68991b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMTMtMS0xLTczMjUz_9f17bc8d-9316-4059-9bda-768cda811235"
      unitRef="usd">28000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTItMTUtMS0xLTczMjUz_865bc644-144b-48d7-99ff-fb4fb572d3e7"
      unitRef="usd">15436000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMy0xLTEtNzMyNTM_273ced71-9467-46de-86c8-e2fab61a9d76"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtNS0xLTEtNzMyNTM_9ebae2e7-d981-4dd9-bb4e-ab3c751d8a41"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtNy0xLTEtNzMyNTM_67e12320-2564-43a4-939d-c4faf061373c"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtOS0xLTEtNzMyNTM_fe2a59e8-2a83-4f77-a06b-211ffcb2b53d"
      unitRef="usd">4490000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMTEtMS0xLTczMjUz_f6864b29-4af3-4328-b714-c92a37f32812"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMTMtMS0xLTczMjUz_327c0758-ecd0-441d-93ed-270cb4d2f2b1"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTQtMTUtMS0xLTczMjUz_baf6d876-3005-431b-8879-5a5b177e16da"
      unitRef="usd">4490000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMy0xLTEtNzMyNTM_175f1a05-7523-48dc-b7bf-4a6bcb3bc39d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtNS0xLTEtNzMyNTM_ac137a3f-510e-4042-97b5-79f74940dc32"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtNy0xLTEtNzMyNTM_66a804aa-7f33-4065-9ebb-a20e9508b300"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtOS0xLTEtNzMyNTM_a6bfc348-841a-47c7-b05a-1f9bfe166245"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMTEtMS0xLTczMjUz_ebe5b4bc-c79b-442c-b8d6-2f0e9eefe083"
      unitRef="usd">-85000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMTMtMS0xLTczMjUz_29706705-791a-40cb-9dba-ed39b3526bd3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTUtMTUtMS0xLTczMjUz_459a3c18-a423-4bbc-8efb-de606714fd9a"
      unitRef="usd">-85000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMy0xLTEtNzMyNTM_d35498b5-f165-4c9d-b295-4c3f30a3167e"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtNS0xLTEtNzMyNTM_1bef22c7-0bc7-4673-8bc6-85580b812d86"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtNy0xLTEtNzMyNTM_5358e67f-e6b7-473b-b66f-955be4bc964a"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtOS0xLTEtNzMyNTM_ecdbcdc3-64a4-497b-b222-bc257030ed12"
      unitRef="usd">2514000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMTEtMS0xLTczMjUz_6374ec5f-a03d-4f9f-9af8-14437b675659"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMTMtMS0xLTczMjUz_f5f5f25a-9def-42ee-920e-b57309c416b6"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTYtMTUtMS0xLTczMjUz_5d14d7e8-343b-4e31-8a26-7abd7c5ba276"
      unitRef="usd">2514000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMS0xLTEtNzMyNTM_c9c9f3f9-cdab-4428-86cf-a913664654da"
      unitRef="shares">10000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMy0xLTEtNzMyNTM_37bc470c-91a5-45c8-8a5e-50be070efdb3"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtNS0xLTEtNzMyNTM_69cba8ce-8a54-4196-bca9-0bdd605c3a4c"
      unitRef="usd">1470000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtNy0xLTEtNzMyNTM_206ae1ec-81ef-40eb-8700-5b8a4bd78a1e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtOS0xLTEtNzMyNTM_5fdb6129-d991-4f98-956a-e48ff8c9dc35"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMTEtMS0xLTczMjUz_edec7525-92d0-4218-813c-fd0422d33a5e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMTMtMS0xLTczMjUz_c2c8a2c7-65a7-4c4a-9a4a-c1574f0e3937"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTgtMTUtMS0xLTczMjUz_0e503333-a9e0-4e27-9c88-b200ba646777"
      unitRef="usd">1470000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMS0xLTEtNzMyNTM_053f23d8-32e5-4ac3-99bd-0529b34ebf41"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMy0xLTEtNzMyNTM_8cc64268-f982-4e60-a8f7-fad4732574da"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktNS0xLTEtNzMyNTM_66ab5441-b1da-467e-8e06-ec7487282db8"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktNy0xLTEtNzMyNTM_a90a8739-2ed1-4ab1-bb96-00e721bcd277"
      unitRef="usd">426000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktOS0xLTEtNzMyNTM_866ddb76-ccdb-46b8-ae27-b1ed350ae68d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMTEtMS0xLTczMjUz_8cce41e4-0f7c-4c57-8875-e314714860dc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMTMtMS0xLTczMjUz_dbedeb4e-1d69-4915-a355-eb5c1b123888"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMTktMTUtMS0xLTczMjUz_326f6111-0cb8-474e-9c7a-e53cff81fcc1"
      unitRef="usd">454000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i029e4a4f41224ff9bf2006f28fa206ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMy0xLTEtNzMyNTM_71c072a2-a059-454c-b5ea-f71cbb6d68be"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ie21ccd46654948208d4f049707193b17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtNS0xLTEtNzMyNTM_264d7459-698b-4fcf-ab18-75684d5d0036"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i31fbe96bedc549d2b2b83439135cb5b0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtNy0xLTEtNzMyNTM_b940dc32-e641-4d8d-9088-b89b96ee8324"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i4eb84aa68550418ebde877bd62bbcda0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtOS0xLTEtNzMyNTM_8b531163-b2b3-4fa4-bce4-98bb7a3d379a"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i76fbe238f3894a0eb179d09b47890654_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMTEtMS0xLTczMjUz_ecd0b491-8b9d-4a99-b6c2-608aaf4da37d"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i1baefcb501194b7fb536593a1a2bd9ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMTMtMS0xLTczMjUz_7a79126a-5533-4d55-9ab8-975a5d1313cd"
      unitRef="usd">3000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjAtMTUtMS0xLTczMjUz_283d44e7-60fd-4e7e-b4d4-15c33c1c1307"
      unitRef="usd">3000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i87b37cb73f2d4eacace3c00d60098061_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMS0xLTEtNzMyNTM_cc613c29-90c3-4464-b4bd-73c7f5f5e140"
      unitRef="shares">1767000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87b37cb73f2d4eacace3c00d60098061_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMy0xLTEtNzMyNTM_b8e6e5a4-bdc9-4405-bca3-3533e34f4f42"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i207acaa2165d403396ea05f332f5d280_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtNS0xLTEtNzMyNTM_fe3686c5-8730-4487-9368-d30720928570"
      unitRef="usd">-4585000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib201ee2f6aa040aa994d36824861b99b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtNy0xLTEtNzMyNTM_4cbf1be5-b2f4-42f1-bd07-22401cd197a2"
      unitRef="usd">18731000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95c2a9dc2507491cbed7bcc6382ac0bd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtOS0xLTEtNzMyNTM_97872696-f488-45d0-ba00-6b4ad7175a43"
      unitRef="usd">5103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedf65e4946d940d7b337ee6ad83e0838_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMTEtMS0xLTczMjUz_fc9e702b-f530-4dcb-9206-48159e14a476"
      unitRef="usd">-2984000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i613f449aeb814d5eb9f9f5433bf45c4b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMTMtMS0xLTczMjUz_9ac8621b-1b99-4b62-a123-8063eee1ce10"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18yOC9mcmFnOjAwYzE2ZWNlNjBjYTQ3OTU4YmI2NjEzM2JiOTUxMWViL3RhYmxlOjVlMjIxODc1ZDgyMTRkZDNhMTgwZTQ4NWJkYTRiY2YzL3RhYmxlcmFuZ2U6NWUyMjE4NzVkODIxNGRkM2ExODBlNDg1YmRhNGJjZjNfMjEtMTUtMS0xLTczMjUz_d7af235b-cfd1-405e-8afe-526f41f6a11f"
      unitRef="usd">16314000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMy0xLTEtMS03MzI1Mw_80fac078-8b32-4c80-b927-2dc88edd69e2"
      unitRef="usd">4493000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMy0zLTEtMS03MzI1Mw_d500c637-edf9-44ed-950c-68e7039183e0"
      unitRef="usd">3555000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNS0xLTEtMS03MzI1Mw_24e88413-589b-4601-87b4-f383d75059bf"
      unitRef="usd">198000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNS0zLTEtMS03MzI1Mw_402ad0c7-3ab4-49c3-9a1e-42a4d9c21c06"
      unitRef="usd">206000000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNi0xLTEtMS03MzI1Mw_b6f1d8a2-661b-49ce-9ca2-40c1658f2c75"
      unitRef="usd">1855000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNi0zLTEtMS03MzI1Mw_2ae0780e-9ef5-4e68-b832-f4ab427bc96d"
      unitRef="usd">2009000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNy0xLTEtMS03MzI1Mw_afe54c23-7efd-4a8a-ae0d-6941f1e8fed0"
      unitRef="usd">-194000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNy0zLTEtMS03MzI1Mw_f53d41e3-7463-4a58-95ad-07203cbdccc5"
      unitRef="usd">-28000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOC0xLTEtMS03MzI1Mw_2d5cf9e2-3f0f-42fa-a775-c11df713c463"
      unitRef="usd">-748000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOC0zLTEtMS03MzI1Mw_60c08583-37e0-4373-95be-5294b7400718"
      unitRef="usd">-343000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOS0xLTEtMS03MzI1Mw_c351812c-92d9-4643-9463-79416bd215e4"
      unitRef="usd">306000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfOS0zLTEtMS03MzI1Mw_eee48a5d-5d55-462e-a87c-436e7bb9d994"
      unitRef="usd">269000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTAtMS0xLTEtNzMyNTM_5b5af473-f834-4897-9df3-4243c280a524"
      unitRef="usd">145000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTAtMy0xLTEtNzMyNTM_103b95d9-565a-4aa4-85ce-109ea9a96a99"
      unitRef="usd">185000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTQtMS0xLTEtNzMyNTM_f38ff337-003c-4ee4-a3e0-10b605a131b0"
      unitRef="usd">-128000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTQtMy0xLTEtNzMyNTM_f83a0448-0a46-4991-8f25-8ccc17145c6b"
      unitRef="usd">20000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTYtMS0xLTEtNzMyNTM_beca9c04-a98b-461a-b2e4-a78761a13587"
      unitRef="usd">785000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTYtMy0xLTEtNzMyNTM_0528fe90-cf4c-4a9d-8865-74aaec303d09"
      unitRef="usd">866000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTctMS0xLTEtNzMyNTM_c2f506d5-d282-473d-b6fe-fd4e00a76463"
      unitRef="usd">385000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTctMy0xLTEtNzMyNTM_3fdcec7f-e492-4ae9-8ad7-585eff445445"
      unitRef="usd">187000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTgtMS0xLTEtNzMyNTM_e00d50e6-cd69-4dbd-ad82-f3ea7101901c"
      unitRef="usd">285000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTgtMy0xLTEtNzMyNTM_f2903eae-8617-4a3e-8863-f79d2ee5ac9d"
      unitRef="usd">330000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTktMS0xLTEtNzMyNTM_c8d318ca-6a71-4359-85ac-1da0811e1fee"
      unitRef="usd">-258000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMTktMy0xLTEtNzMyNTM_c28ed7cc-697d-450d-b997-a6fcd587d474"
      unitRef="usd">236000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjAtMS0xLTEtNzMyNTM_ed1ac336-279d-4f7d-8215-f465939cc486"
      unitRef="usd">438000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjAtMy0xLTEtNzMyNTM_93690c4d-33d9-43f7-8b32-5a56aed5d3ff"
      unitRef="usd">191000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjEtMS0xLTEtNzMyNTM_c080bcc5-a3c7-4b09-ad50-96d15c4cf7ea"
      unitRef="usd">4908000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjEtMy0xLTEtNzMyNTM_8e3fa2e8-f809-41a5-ac21-073b95f6b1c0"
      unitRef="usd">4877000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjUtMS0xLTEtNzMyNTM_47c8edbb-989c-43aa-8243-12cc47110b50"
      unitRef="usd">185000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjUtMy0xLTEtNzMyNTM_87b82f96-3f08-4058-83a6-07cdffe36f8e"
      unitRef="usd">198000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjYtMS0xLTEtNzMyNTM_76da0d84-ce07-4933-90ab-36feec3b493b"
      unitRef="usd">162000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjYtMy0xLTEtNzMyNTM_f75c6bb1-4091-420b-a2c3-c4a2bd1b8191"
      unitRef="usd">188000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjctMS0xLTEtNzMyNTM_39eff751-a0ab-45ee-a1f6-8dbf22910720"
      unitRef="usd">1406000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjctMy0xLTEtNzMyNTM_df0f7ad2-7a21-4e5c-a0cb-36233c36684d"
      unitRef="usd">16000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjgtMS0xLTEtNzMyNTM_1d91aac2-1f44-4648-8a82-d23d28cfb3ce"
      unitRef="usd">8000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMjgtMy0xLTEtNzMyNTM_9cf3f9c9-1f5f-43f5-a035-ea10d814879c"
      unitRef="usd">11000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzAtMS0xLTEtNzMyNTM_d7bdefaf-3413-4363-9357-b0956913b877"
      unitRef="usd">-154000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzAtMy0xLTEtNzMyNTM_6647c99c-aa07-4681-b47e-8a7a59d26c12"
      unitRef="usd">-49000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzEtMS0xLTEtNzMyNTM_e87c3884-7c44-437f-b474-0bc0528c238a"
      unitRef="usd">-1591000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzEtMy0xLTEtNzMyNTM_8a85eb77-b547-4add-b2e4-fba617944fef"
      unitRef="usd">-342000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzctMS0xLTEtNzMyNTM_1668d5ac-759b-42cf-8d60-3630badbb4d1"
      unitRef="usd">2000000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzgtMS0xLTEtNzMyNTM_925d98f6-e312-42b2-b988-4bf7b6b3ca3f"
      unitRef="usd">4879000000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfMzgtMy0xLTEtNzMyNTM_fe6fef50-6172-452a-b0e6-f38129103e97"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:PaymentsOfDividends
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDAtMS0xLTEtNzMyNTM_c61925d8-4571-48bc-b518-cbd4952c3b53"
      unitRef="usd">2526000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDAtMy0xLTEtNzMyNTM_18174dac-bd1c-4579-848f-63f5d711a0b3"
      unitRef="usd">2322000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDEtMS0xLTEtNzMyNTM_8cdc5087-70d9-459d-b9b9-e84609070fbe"
      unitRef="usd">1470000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDEtMy0xLTEtNzMyNTM_90c389bf-c744-47fb-b1db-4cda6953aca6"
      unitRef="usd">787000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDItMS0xLTEtNzMyNTM_721487df-8550-42d9-80c6-9dbebb835857"
      unitRef="usd">128000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDItMy0xLTEtNzMyNTM_89433244-e5dc-441e-830a-fb0fe92daba8"
      unitRef="usd">71000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDMtMS0xLTEtNzMyNTM_31fa4d18-090b-457f-b8c5-a6e8ee0e140d"
      unitRef="usd">246000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDMtMy0xLTEtNzMyNTM_584c8981-5fd9-44f7-9789-9beeab833625"
      unitRef="usd">132000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDQtMS0xLTEtNzMyNTM_21725076-fb18-4bdb-a719-086edb5695bc"
      unitRef="usd">21000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDQtMy0xLTEtNzMyNTM_e96bd76f-24ba-4bea-9fef-42cb0452e9fe"
      unitRef="usd">-4000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDUtMS0xLTEtNzMyNTM_a905dc6c-5f2c-426d-8a2f-fcb2e9f75eda"
      unitRef="usd">-6972000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDUtMy0xLTEtNzMyNTM_7aa33fb4-c3a8-4fd6-af39-13183ed1aea9"
      unitRef="usd">-3174000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDYtMS0xLTEtNzMyNTM_96c7074f-1a3b-4977-bee1-51e3a67cae9b"
      unitRef="usd">7000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDYtMy0xLTEtNzMyNTM_e8efbf01-768f-4bfe-95a8-6daa21523d46"
      unitRef="usd">-55000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDctMS0xLTEtNzMyNTM_fba706d6-643c-45ca-ac30-2b9689cecb33"
      unitRef="usd">-3648000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDctMy0xLTEtNzMyNTM_c1c38629-d8e2-40b5-b292-fd25d037c7b5"
      unitRef="usd">1306000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDgtMS0xLTEtNzMyNTM_123b7522-e492-4684-8b90-7cb48b9689bb"
      unitRef="usd">9746000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6accb844205d4e909ea7d6f406d2b865_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNDgtMy0xLTEtNzMyNTM_fa43550a-572f-4d30-a73b-6e0786b16210"
      unitRef="usd">8449000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNTAtMS0xLTEtNzMyNTM_0099282e-98c8-4836-b09b-881db33ebff0"
      unitRef="usd">6098000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cf70c299b6747128fa4a148bd06c306_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zMS9mcmFnOjdlMjg4ZWViZTFkZDQ2YzFiNGRlMzg2YzRjZjhkZjRhL3RhYmxlOjI4NjUzZWQzN2RlZjQ1MzBiM2Y1Y2ZiNTc3NjExZmFmL3RhYmxlcmFuZ2U6Mjg2NTNlZDM3ZGVmNDUzMGIzZjVjZmI1Nzc2MTFmYWZfNTAtMy0xLTEtNzMyNTM_4a3d680a-ddd9-46fb-805e-5f623870d6b8"
      unitRef="usd">9755000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zNy9mcmFnOmZkMGM5MjJiNGQ1ZTQ3ZGI4YTQ3ZmE5Mzg4MjUxMmMyL3RleHRyZWdpb246ZmQwYzkyMmI0ZDVlNDdkYjhhNDdmYTkzODgyNTEyYzJfMTg2Nw_8c079f7f-e042-4f01-9385-37c426f57d2e">Basis of Presentation Basis of Historical Presentation &lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules&#160;and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company&#x2019;s audited consolidated financial statements and notes included in the company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is management&#x2019;s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company&#x2019;s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. &lt;/span&gt;&lt;/div&gt;During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&amp;amp;D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&amp;amp;D and milestones expense by $115&#160;million for the three months ended March 31, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zNy9mcmFnOmZkMGM5MjJiNGQ1ZTQ3ZGI4YTQ3ZmE5Mzg4MjUxMmMyL3RleHRyZWdpb246ZmQwYzkyMmI0ZDVlNDdkYjhhNDdmYTkzODgyNTEyYzJfMzg0ODI5MDcwMzk4OA_42ce1def-6135-446b-8705-a77bfb198fcf"
      unitRef="usd">115000000</abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense>
    <abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY18zNy9mcmFnOmZkMGM5MjJiNGQ1ZTQ3ZGI4YTQ3ZmE5Mzg4MjUxMmMyL3RleHRyZWdpb246ZmQwYzkyMmI0ZDVlNDdkYjhhNDdmYTkzODgyNTEyYzJfMzg0ODI5MDcwMzk4OA_a6e7375b-84ed-4d73-acf8-ae02b5673c8a"
      unitRef="usd">115000000</abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTky_a67340a9-306f-420d-8872-a32c5ce6d0b1">Supplemental Financial Information&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $198 million for the three months ended March 31, 2022 and $206 million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTgy_13328d94-63c9-40d2-be37-e768601adc56">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMi02LTEtMS03MzI1Mw_6df3ebf5-89da-4017-b4eb-a66addaedb2e"
      unitRef="usd">548000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMi04LTEtMS03MzI1Mw_79a42790-1bb1-4799-8733-b62ca606e435"
      unitRef="usd">632000000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMy02LTEtMS03MzI1Mw_cf2b91cd-306f-4c29-876d-4cfbef4c9bdf"
      unitRef="usd">9000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfMy04LTEtMS03MzI1Mw_571f535d-62d7-4cf2-8385-d56738479062"
      unitRef="usd">10000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfNC02LTEtMS03MzI1Mw_effc7d6d-614c-4f21-9787-f80572a57ef9"
      unitRef="usd">-539000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjMwOGM5OGQ4Y2YzZDRkYjhiMTIzMDBlZmM0YTRlMjE3L3RhYmxlcmFuZ2U6MzA4Yzk4ZDhjZjNkNGRiOGIxMjMwMGVmYzRhNGUyMTdfNC04LTEtMS03MzI1Mw_8d2f5397-ab23-4f75-9e01-f5bc4375ea71"
      unitRef="usd">-622000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTkw_9227b66f-6914-4b24-9e53-ee4be21a8e0e">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMS0xLTEtMS03MzI1Mw_e195b6b7-c71f-4dde-a55c-9ac423b9cc91"
      unitRef="usd">1220000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMS0zLTEtMS03MzI1Mw_5fd14cca-5970-4b67-80a4-471ce809ba27"
      unitRef="usd">932000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMi0xLTEtMS03MzI1Mw_a6c80ffd-50a0-4c0c-98fa-1513502b1b87"
      unitRef="usd">1235000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMi0zLTEtMS03MzI1Mw_8f0e37bb-7935-4871-8c1e-604c4da04c73"
      unitRef="usd">1193000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMy0xLTEtMS03MzI1Mw_8cb23dbd-f42a-4285-9a7a-f4f04ba0ff67"
      unitRef="usd">1028000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfMy0zLTEtMS03MzI1Mw_310c45c0-9a12-4227-9eb4-7d68654e6046"
      unitRef="usd">1003000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfNC0xLTEtMS03MzI1Mw_b6572eee-fc88-4560-9ad0-ca06a06d11cd"
      unitRef="usd">3483000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjI4OTVlMmU3MmFiNTRkMGFiMmQxMDk3MDJiZTJjZjE1L3RhYmxlcmFuZ2U6Mjg5NWUyZTcyYWI1NGQwYWIyZDEwOTcwMmJlMmNmMTVfNC0zLTEtMS03MzI1Mw_1e689099-8e75-4ca4-9396-4651ed5f743a"
      unitRef="usd">3128000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTc3_ff373261-3c67-4ae4-805b-73029f5230a7">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMS0xLTEtMS03MzI1Mw_e610d177-eaf8-4328-b627-318d49b6a4b0"
      unitRef="usd">10879000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMS0zLTEtMS03MzI1Mw_0dbeb4c5-82f7-498c-ad29-63c6e5742d48"
      unitRef="usd">10727000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMi0xLTEtMS03MzI1Mw_952b0f22-714e-4c37-813f-43eae26ebb6b"
      unitRef="usd">5804000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMi0zLTEtMS03MzI1Mw_31cc3151-50a4-4415-b539-6d0d43609708"
      unitRef="usd">5617000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMy0xLTEtMS03MzI1Mw_1c6f2ccd-f5e6-4c66-9047-67147aa3fa7c"
      unitRef="usd">5075000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RhYmxlOjdhOTJiNzc5NjllYjQyZThhODg0YzQxYzBlYmIyMDQ0L3RhYmxlcmFuZ2U6N2E5MmI3Nzk2OWViNDJlOGE4ODRjNDFjMGViYjIwNDRfMy0zLTEtMS03MzI1Mw_297f9190-21dc-481c-8137-a788c5680950"
      unitRef="usd">5110000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTE5_24e88413-589b-4601-87b4-f383d75059bf"
      unitRef="usd">198000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180MC9mcmFnOmQwYzliNDYwMTAxMDQ2ZGJiYzFmZmFmMDEwYjdlYTY5L3RleHRyZWdpb246ZDBjOWI0NjAxMDEwNDZkYmJjMWZmYWYwMTBiN2VhNjlfMTU1_402ad0c7-3ab4-49c3-9a1e-42a4d9c21c06"
      unitRef="usd">206000000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RleHRyZWdpb246NjI0MmViNjBmMmNhNGNhNzg5ZTBmYTQxZTgyODE1YTBfNjU2_8133a1ca-6d05-4acf-b8f3-0719081139bd">Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the impact of the two-class method:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RleHRyZWdpb246NjI0MmViNjBmMmNhNGNhNzg5ZTBmYTQxZTgyODE1YTBfNjUw_00676859-7d33-48e4-859c-3b7e22d8e5bf">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the impact of the two-class method:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMy02LTEtMS03MzI1Mw_5ea84cb7-f8c1-4126-ab24-065cc25b643f"
      unitRef="usd">4490000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMy04LTEtMS03MzI1Mw_ffc286d1-92ac-40f0-af96-16d774e7e676"
      unitRef="usd">3553000000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNC02LTEtMS03MzI1Mw_fd28722b-bb5e-4352-8a69-9f85c18debbb"
      unitRef="usd">22000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNC04LTEtMS03MzI1Mw_572631b0-1926-4446-986d-d849a116fb50"
      unitRef="usd">24000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNS02LTEtMS03MzI1Mw_2d2642d3-cc12-4776-a18e-e6758746805e"
      unitRef="usd">4468000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNS04LTEtMS03MzI1Mw_b1ebddf7-1878-4df9-be8a-3980c22fc689"
      unitRef="usd">3529000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNi02LTEtMS03MzI1Mw_63c1e6da-d80d-4cac-b7f7-eb485dd6172f"
      unitRef="shares">1771000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNi04LTEtMS03MzI1Mw_f45594dc-f550-4949-874e-ca9c8f3eea7f"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNy02LTEtMS03MzI1Mw_dc2efae9-c01c-4cd9-9656-ebb26b3abf52"
      unitRef="usdPerShare">2.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfNy04LTEtMS03MzI1Mw_63ef66bc-5996-4973-9515-fc4333f588e7"
      unitRef="usdPerShare">2.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTAtNi0xLTEtNzMyNTM_fe3da331-9e20-46f8-aa4a-684324a4f81d"
      unitRef="usd">4490000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTAtOC0xLTEtNzMyNTM_516a8f9e-bf09-4132-ba1f-a5feaf3fe758"
      unitRef="usd">3553000000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTEtNi0xLTEtNzMyNTM_e2effa79-c3ae-4b3a-813b-2907762fc35b"
      unitRef="usd">22000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTEtOC0xLTEtNzMyNTM_44862c53-8d5d-42f3-b8e4-64d83c555722"
      unitRef="usd">24000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTItNi0xLTEtNzMyNTM_98c973ea-4e40-42f6-baae-639a2113e1fd"
      unitRef="usd">4468000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTItOC0xLTEtNzMyNTM_7a9ceed3-fdae-40ba-af84-147b9420ead2"
      unitRef="usd">3529000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTMtNi0xLTEtNzMyNTM_a9348e89-b9ff-4164-8118-ef1040cfc34c"
      unitRef="shares">1771000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTMtOC0xLTEtNzMyNTM_b12e6d43-fb1b-40ac-9baf-3e54dd83e33c"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTQtNi0xLTEtNzMyNTM_14a75b83-f26c-4fbc-84dc-d6eb976200fb"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTQtOC0xLTEtNzMyNTM_1946006e-7c5a-4e19-a293-97a8b2494252"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTUtNi0xLTEtNzMyNTM_39e72f7d-a217-4038-846a-4745696bc91a"
      unitRef="shares">1778000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTUtOC0xLTEtNzMyNTM_9297f0cc-580c-4499-9d84-b338b7df9edc"
      unitRef="shares">1775000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTYtNi0xLTEtNzMyNTM_ff6ae615-0168-4a48-acfc-eae44cb224c9"
      unitRef="usdPerShare">2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180Ni9mcmFnOjYyNDJlYjYwZjJjYTRjYTc4OWUwZmE0MWU4MjgxNWEwL3RhYmxlOmQ3YTBjZTY1MTViOTQyZmI5ZDg5MWRjZjg1MDMwNGUwL3RhYmxlcmFuZ2U6ZDdhMGNlNjUxNWI5NDJmYjlkODkxZGNmODUwMzA0ZTBfMTYtOC0xLTEtNzMyNTM_17337729-112a-43c0-bda8-fd904ba80298"
      unitRef="usdPerShare">1.99</us-gaap:EarningsPerShareDiluted>
    <abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfNzMwMg_f66ecb2b-441f-4981-b005-642435d85f25">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Licensing, Acquisitions and Other Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash outflows related to acquisitions and investments totaled $185 million for the three months ended March 31, 2022 and $198 million for the three months ended March 31, 2021. AbbVie recorded acquired IPR&amp;amp;D and milestones charges of $145 million for the three months ended March 31, 2022 and $185&#160;million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Syndesi Therapeutics SA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&amp;amp;D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones.&lt;/span&gt;&lt;/div&gt;</abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTg4OQ_b2431296-901c-4f58-9d51-6419e164a0fa"
      unitRef="usd">185000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTkwNw_34f13724-8ec5-4326-8d15-01caf31738fa"
      unitRef="usd">198000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMjAyMA_d3a0d7fb-9152-4301-8443-63aaed03d1ad"
      unitRef="usd">145000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMjA5MQ_7e528561-c68f-4dbe-901a-09717b6f8c00"
      unitRef="usd">185000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i72db22a233c742cb9fdaf4ec7205f2f1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTA5OTUxMTY0OTU3NA_e6bed5d3-6d28-48fd-857e-0d0b90f2b770"
      unitRef="usd">130000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <abbv:PotentialPaymentsUnderAgreementCertainMilestones
      contextRef="ieb3553129a064588b861cbad2e2e642e_I20220228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY180OS9mcmFnOjRkZGVhYjRiNmM4YjQ4M2RhM2E4YTFmOTQ3ZjdmOGU1L3RleHRyZWdpb246NGRkZWFiNGI2YzhiNDgzZGEzYThhMWY5NDdmN2Y4ZTVfMTA5OTUxMTY0OTYxNA_7fcf68ba-d520-42b3-8c2a-535631ddaaf6"
      unitRef="usd">870000000</abbv:PotentialPaymentsUnderAgreementCertainMilestones>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfNDIzNg_9ba26504-47c8-4831-99f2-9ce352b247d6">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Collaborations&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended March 31, 2022 and 2021.&lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration with Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech,&#160;Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson&#160;&amp;amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton&#x2019;s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Janssen and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Janssen's share of profits (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International - AbbVie's share of profits (included in net revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global - AbbVie's share of other costs (included in respective line items)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie&#x2019;s receivable from Janssen, included in accounts receivable, net, was $336 million at March 31, 2022 and $294 million at December 31, 2021. AbbVie&#x2019;s payable to Janssen, included in accounts payable and accrued liabilities, was $401 million at March 31, 2022 and $509 million at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration with Genentech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie&#x2019;s net revenues. Genentech&#x2019;s share of United States profits is included in AbbVie&#x2019;s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&amp;amp;A) expenses and global development costs as part of research and development (R&amp;amp;D) expenses, net of Genentech&#x2019;s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie&#x2019;s cost of products sold.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Genentech and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Genentech's share of profits, including royalties (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;amp;A)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of development costs (included in R&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable
      contextRef="i20abf2418b52449bbcdcb69db0df0b34_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMTM5OQ_a56564d9-8362-48ab-96c1-35fff7159ec3"
      unitRef="usd">200000000</abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable>
    <abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty
      contextRef="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMTU3OQ_35405f7a-6b32-4bb2-a58c-4ed19b3101ca"
      unitRef="number">0.60</abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty>
    <abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts
      contextRef="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMTY2MQ_75a5f607-5640-4c4f-9b1a-970139eab124"
      unitRef="number">0.40</abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i9fe4ce1afbad40ee8b142ccdca3cbdf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfNDI0MA_6733a072-32a9-4c46-bfa1-d8e5f9b40dfc">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Janssen and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Janssen's share of profits (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International - AbbVie's share of profits (included in net revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global - AbbVie's share of other costs (included in respective line items)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i757157a6b1f24339a6987f24f728b796_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMi02LTEtMS03MzI1Mw_58b93f1f-0956-4720-a0e7-cdb12978e2e0"
      unitRef="usd">408000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i7c90b03e0a9d4b959d426288837a1ac9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMi04LTEtMS03MzI1Mw_40d1e102-553a-4e2c-857b-ee2a2368bcfb"
      unitRef="usd">465000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i1f9f25b9cf5e4ee0bbe7e382b04feba9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMy02LTEtMS03MzI1Mw_77523dcb-1dca-4a8b-814f-67c11c5f13b7"
      unitRef="usd">299000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if1248f479629473abbdb6ed040285ccc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfMy04LTEtMS03MzI1Mw_c0404797-473a-4638-9b3c-3f50af1aaca5"
      unitRef="usd">269000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <abbv:OtherExpensesFromCollaborativeArrangements
      contextRef="i1e7da2bc9100421a9871b5285fd9fa10_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfNC02LTEtMS03MzI1Mw_5b9896c2-d069-4211-a7ae-1a4cb3be9dd5"
      unitRef="usd">64000000</abbv:OtherExpensesFromCollaborativeArrangements>
    <abbv:OtherExpensesFromCollaborativeArrangements
      contextRef="i7189bfa6119440549f13eb789b20c623_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOjRjODRmMjI1MWU4YzQ3OTU4MTEwNDIyYzA1MzYwNjA0L3RhYmxlcmFuZ2U6NGM4NGYyMjUxZThjNDc5NTgxMTA0MjJjMDUzNjA2MDRfNC04LTEtMS03MzI1Mw_7b628509-f3af-4aa7-8a86-31259dadb6b6"
      unitRef="usd">70000000</abbv:OtherExpensesFromCollaborativeArrangements>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i20abf2418b52449bbcdcb69db0df0b34_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjczOQ_997fb397-5c79-47b0-bce7-7801020ee04b"
      unitRef="usd">336000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i503b434bb2cd4949ab32e3eea0c0a13b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjc1Mg_f5a7ed10-7ba1-446a-8a1a-b67b0d594e63"
      unitRef="usd">294000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i20abf2418b52449bbcdcb69db0df0b34_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjg0OQ_62c234a4-10da-4a9b-95c1-c19ad83124a4"
      unitRef="usd">401000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i503b434bb2cd4949ab32e3eea0c0a13b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfMjg2Mg_9c36f40b-3bd0-4cca-9f33-e51234524f40"
      unitRef="usd">509000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i7e417e1f49424cb4b129ec6ce7c723da_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RleHRyZWdpb246NTE3NTIyNTIyYTJkNDlkMWI2ZTMyNDU0MDBiZDRiZjRfNDIzOA_8a3ef206-6824-47f7-b50f-3e799c9219f3">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Genentech and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Genentech's share of profits, including royalties (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;amp;A)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of development costs (included in R&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="if70fdebf15534416b657e3efc08cb7de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMi02LTEtMS03MzI1Mw_57083e0f-4ae5-4484-85b2-2d1daeaf9290"
      unitRef="usd">178000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i9b131031330347efae33d3283c798c08_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMi04LTEtMS03MzI1Mw_f2133e4f-ea47-4f21-adfd-53c86d998485"
      unitRef="usd">159000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
      contextRef="ia91bb22b751b4f769a3ed871c1a8e163_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMy02LTEtMS03MzI1Mw_f3d66a49-4ef0-45c7-85b3-8bc1a231050c"
      unitRef="usd">12000000</abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements>
    <abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
      contextRef="i6409d59d48544dd3b57e4e907e0daf25_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfMy04LTEtMS03MzI1Mw_e76f6f95-8b62-4c86-a975-7b54c00c2ce9"
      unitRef="usd">11000000</abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements>
    <abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements
      contextRef="if70fdebf15534416b657e3efc08cb7de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfNC02LTEtMS03MzI1Mw_4b6a3fc0-2843-4e85-8590-6652f68f26d6"
      unitRef="usd">27000000</abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements>
    <abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements
      contextRef="i9b131031330347efae33d3283c798c08_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181NS9mcmFnOjUxNzUyMjUyMmEyZDQ5ZDFiNmUzMjQ1NDAwYmQ0YmY0L3RhYmxlOmNkNTNlOTU4Yzc5MjRiNmFiZTg3MzczYmRiZWRhMWU3L3RhYmxlcmFuZ2U6Y2Q1M2U5NThjNzkyNGI2YWJlODczNzNiZGJlZGExZTdfNC04LTEtMS03MzI1Mw_2860bb34-1669-4399-86df-b629e5bc0350"
      unitRef="usd">42000000</abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIxMw_1bbc4a0f-0118-4290-95ba-1e32b7e75ae8">Goodwill and Intangible AssetsGoodwill&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of March 31, 2022, there were no accumulated goodwill impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Definite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $1.9 billion for the three months ended March 31, 2022 and $2.0 billion for the three months ended March 31, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIwMg_8af45836-2049-4f39-855d-005cf1e6eecf">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjZhMjhmMTEwNmFjMzQyZTNiMjE4ZDFjZDRkOWE5MDFkL3RhYmxlcmFuZ2U6NmEyOGYxMTA2YWMzNDJlM2IyMThkMWNkNGQ5YTkwMWRfMS0xLTEtMS03MzI1Mw_c76b4fe7-6a87-437e-b6bd-e821c498b492"
      unitRef="usd">32379000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjZhMjhmMTEwNmFjMzQyZTNiMjE4ZDFjZDRkOWE5MDFkL3RhYmxlcmFuZ2U6NmEyOGYxMTA2YWMzNDJlM2IyMThkMWNkNGQ5YTkwMWRfNC0xLTEtMS03MzI1Mw_08467d8a-d66e-4e4d-8668-065794835b89"
      unitRef="usd">-81000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjZhMjhmMTEwNmFjMzQyZTNiMjE4ZDFjZDRkOWE5MDFkL3RhYmxlcmFuZ2U6NmEyOGYxMTA2YWMzNDJlM2IyMThkMWNkNGQ5YTkwMWRfNS0xLTEtMS03MzI1Mw_7dd24f25-f89e-4913-aa2c-ee06fcafa4f3"
      unitRef="usd">32298000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMzMy_042753cf-6a11-4355-9825-9266f2f112f6"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIxMg_4c6f5c5e-1a98-4d43-9646-1e1d96b9b6c5">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfMTIyOQ_d9a84588-4a59-4a4b-8ce6-b5ae2b368ab7">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if6d0443c07a5417ca515d44ddc962b47_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy0xLTEtMS03MzI1Mw_739e5d82-421a-48ea-a93e-1b7aa567c656"
      unitRef="usd">88811000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if6d0443c07a5417ca515d44ddc962b47_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy0zLTEtMS03MzI1Mw_6b27bd28-9930-4664-a146-19480f83ed4f"
      unitRef="usd">20095000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if6d0443c07a5417ca515d44ddc962b47_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy01LTEtMS03MzI1Mw_0d0f02b6-a6c3-4343-b8a5-130d29d7133c"
      unitRef="usd">68716000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy03LTEtMS03MzI1Mw_adb954e7-e01d-4e81-9173-c83c6bb6eda7"
      unitRef="usd">88945000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy05LTEtMS03MzI1Mw_c40a4540-70c7-4b2c-9bd4-bd4541a7b658"
      unitRef="usd">18463000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6d4ad2d90a3249b7ab95933f6531b3bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfMy0xMS0xLTEtNzMyNTM_aa37f470-40cf-4823-aaae-bc6dd3f74cc7"
      unitRef="usd">70482000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i85d7032a627d4586b0df7536454a2953_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC0xLTEtMS03MzI1Mw_3070ad73-e52d-4ed6-a946-62bb29f77c42"
      unitRef="usd">8493000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i85d7032a627d4586b0df7536454a2953_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC0zLTEtMS03MzI1Mw_4313cddf-4284-4a09-a034-307f3ed69577"
      unitRef="usd">3893000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i85d7032a627d4586b0df7536454a2953_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC01LTEtMS03MzI1Mw_b1b5453e-3a7c-4a9b-a6fc-a88eb00bfb6d"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6abf8b13366e446b8e4d345e553af9c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC03LTEtMS03MzI1Mw_1470c6e9-4e5d-4e37-9f98-7df2ed9bbbf1"
      unitRef="usd">8487000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6abf8b13366e446b8e4d345e553af9c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC05LTEtMS03MzI1Mw_15245439-750b-447b-b75e-8beb8e5b4a93"
      unitRef="usd">3688000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6abf8b13366e446b8e4d345e553af9c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNC0xMS0xLTEtNzMyNTM_80af6bb4-0d53-4ac6-9bcf-6c810a45195d"
      unitRef="usd">4799000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS0xLTEtMS03MzI1Mw_07d302e4-cf01-4d3f-8bfc-54dad3f66514"
      unitRef="usd">97304000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS0zLTEtMS03MzI1Mw_430cd687-4277-4973-bdd4-5fab25d62855"
      unitRef="usd">23988000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS01LTEtMS03MzI1Mw_32183789-ccf8-4390-a81c-a15e92299fd2"
      unitRef="usd">73316000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS03LTEtMS03MzI1Mw_b525b944-d971-4c7f-a46d-28e2703dfeeb"
      unitRef="usd">97432000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS05LTEtMS03MzI1Mw_44984e27-d9a5-4143-a7a0-c2478d5e0a34"
      unitRef="usd">22151000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNS0xMS0xLTEtNzMyNTM_6cd29f98-8939-476e-9a18-64d149ebadb7"
      unitRef="usd">75281000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi0xLTEtMS03MzI1Mw_cff4191d-b3ef-40ce-9a40-2d773fd723c0"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi01LTEtMS03MzI1Mw_b5c96bfb-348c-411e-9331-7de6f3913cc6"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi03LTEtMS03MzI1Mw_bc8ab582-6b9c-4c68-a21d-dd1ee55f8ea2"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNi0xMS0xLTEtNzMyNTM_7d016bfb-99d1-4ff4-8ce6-57c5537bccd9"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy0xLTEtMS03MzI1Mw_e6afaeb4-bd82-482b-b779-f16a88b62722"
      unitRef="usd">97974000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy0zLTEtMS03MzI1Mw_b749fed3-b1b5-4675-a2db-eb0fc970e709"
      unitRef="usd">23988000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy01LTEtMS03MzI1Mw_98e19dc6-185b-4d7b-9f72-0e532b684af7"
      unitRef="usd">73986000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy03LTEtMS03MzI1Mw_e5dbe46c-049a-47b3-8cb7-d7eccdb101c5"
      unitRef="usd">98102000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy05LTEtMS03MzI1Mw_d78f2269-523e-4b35-9bd7-65c58195c606"
      unitRef="usd">22151000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RhYmxlOjA1MmNkZjQwMDE1NDQzZGY5MDg5ZjQ2MzYyMmE2ZTEzL3RhYmxlcmFuZ2U6MDUyY2RmNDAwMTU0NDNkZjkwODlmNDYzNjIyYTZlMTNfNy0xMS0xLTEtNzMyNTM_547e5f9b-fec2-45b6-8572-1935bd956d21"
      unitRef="usd">75951000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfNzgz_3cb31f76-e339-4554-9ea2-56f25b658ff5"
      unitRef="usd">1900000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY181OC9mcmFnOmQ1NzIwMTg4N2VhNjQwMGQ4ZDAwNWJmMWRkZjdiZWU2L3RleHRyZWdpb246ZDU3MjAxODg3ZWE2NDAwZDhkMDA1YmYxZGRmN2JlZTZfODE5_b67eebf2-570d-45ae-9ed6-1dceae33a029"
      unitRef="usd">2000000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAwOQ_8a8fd8c7-fe86-44ca-a9b3-03738467f08d">Integration and Restructuring PlansAllergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges associated with the Allergan acquisition integration plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the recorded liability associated with the integration plan for the three months ended March 31, 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie recorded restructuring charges of $57 million for the three months ended March 31, 2022 and $38 million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="id13caefd7d5a471aa354ceb296f2d670_I20220331"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMzEx_bbea9fbb-6a93-4faa-8453-923500b312e4"
      unitRef="usd">2000000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAyNQ_e09fa609-5bf9-489b-b7b7-deef56b2636c">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges associated with the Allergan acquisition integration plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9dbf40f3d8814b2cb5a231dbbd3418e6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy05LTEtMS03MzI1Mw_7bf43eb0-b1b2-4399-82e3-5da6189898f6"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="icc654c5b431f4e2c81e6d3dc971bbfce_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy0xMS0xLTEtNzMyNTM_011c9bb1-390a-469e-833e-0c20ca3264aa"
      unitRef="usd">6000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iac0e02057646439c9b219a540ab6bba4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy0yMC0xLTEtNzMyNTM_e31712b2-3d62-4198-9d4b-e26d67df5d02"
      unitRef="usd">30000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5d31e315887b49cf9383108785d5b7a2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfMy0yMi0xLTEtNzMyNTM_16629045-e546-48f5-8e2d-9b9a9bce8d1c"
      unitRef="usd">15000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7b0ea0dc41fe4934b7afc79df8635743_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC05LTEtMS03MzI1Mw_17fafda7-8e08-4800-8519-94a5854da0df"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie28ae11319ad4812a556b3a24a0d7eb8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC0xMS0xLTEtNzMyNTM_d3b46a36-c6f2-4b62-bd25-bf5c202c6c60"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if4b089c0fc324d5b82b75e000f5fe9cd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC0yMC0xLTEtNzMyNTM_a350ce18-4e0e-4120-9288-4be5e511c716"
      unitRef="usd">6000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5c6435c30e6b40489560149b0efd5c0b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNC0yMi0xLTEtNzMyNTM_34e3ad9e-bb06-4287-9949-4e79e2b0bf8f"
      unitRef="usd">51000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic2be7d9eaa6f4f369f0de369cbb043f8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS05LTEtMS03MzI1Mw_b1fa0b8b-f423-4c43-9d42-21b1af0daf05"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib7f0edb319054698965e395df2f44e5f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS0xMS0xLTEtNzMyNTM_89f2afa9-f69f-4176-bb67-d1fcfc8e8093"
      unitRef="usd">17000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5b13ed86da2945de8f2c44a2373537a6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS0yMC0xLTEtNzMyNTM_cdc96601-74f8-485c-95b4-0dc54f1d907b"
      unitRef="usd">66000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i56e369611bfc4546bf3c8e89fd8a3f48_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNS0yMi0xLTEtNzMyNTM_2547a9af-442f-48d1-85c8-e27559a97cd4"
      unitRef="usd">50000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi05LTEtMS03MzI1Mw_e7b51868-fd5d-431c-9fd5-304ff43d96ec"
      unitRef="usd">8000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i77324bf397cc41f7a15e4eef24ecff2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi0xMS0xLTEtNzMyNTM_a5e29a83-b30f-47b2-a860-8b6626652bd6"
      unitRef="usd">23000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi0yMC0xLTEtNzMyNTM_4e793946-b2aa-4367-83cc-794053862c48"
      unitRef="usd">102000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i92f1ab36dc934e39ae4bfefcbe05705e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmM0NzUyNmFhYjc3ODRiZjg4ZjdmZDUwNzlkN2Q4NTMwL3RhYmxlcmFuZ2U6YzQ3NTI2YWFiNzc4NGJmODhmN2ZkNTA3OWQ3ZDg1MzBfNi0yMi0xLTEtNzMyNTM_c5e3e930-a200-43b2-b58e-0485d79d1126"
      unitRef="usd">116000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAxMg_4a3dac44-80ee-4379-9910-874626f28122">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the recorded liability associated with the integration plan for the three months ended March 31, 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i714dfb429c6f451eb83c696c0379c6ab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMS0xLTEtMS03MzI1Mw_f4056cc2-ff45-460d-8df2-578435740392"
      unitRef="usd">222000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie5007646043540a1b0e932caf506c8b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMS0zLTEtMS03MzI1Mw_8adae501-dbf6-45c0-94f8-73ebbf1fb1f5"
      unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <abbv:RestructuringReserveCashSettledRestructuringGainsLosses
      contextRef="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMi0xLTEtMS03MzI1Mw_41317c09-c765-475f-b497-27bb52e01f6d"
      unitRef="usd">8000000</abbv:RestructuringReserveCashSettledRestructuringGainsLosses>
    <abbv:RestructuringReserveCashSettledRestructuringGainsLosses
      contextRef="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfMi0zLTEtMS03MzI1Mw_e1dda12e-53f1-4298-9404-3e68fe298d47"
      unitRef="usd">98000000</abbv:RestructuringReserveCashSettledRestructuringGainsLosses>
    <abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i20b7593516564b7588f173a9d381ac8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNS0xLTEtMS03MzI1Mw_a2cc1610-6eda-40bb-8f28-80758ca7ccd3"
      unitRef="usd">22000000</abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i7e5e0d98c3744bdb9096abdccc0ad91a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNS0zLTEtMS03MzI1Mw_6eafc033-57d8-4340-9fa8-ee1b40fd0735"
      unitRef="usd">98000000</abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="iae8327b6e3b446c39bc4154fdcab2095_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNi0xLTEtMS03MzI1Mw_7deed78d-1cd0-4ed3-97dd-ec009bf23675"
      unitRef="usd">208000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id430b90a4b4b4e00accb2dafe2190824_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmY3YzZlMWUxYzEyNjQxYzc5ODRhMzVkYzhiZTg0YzEwL3RhYmxlcmFuZ2U6ZjdjNmUxZTFjMTI2NDFjNzk4NGEzNWRjOGJlODRjMTBfNi0zLTEtMS03MzI1Mw_f274fcfe-95ba-4b1e-b215-71b2790e9dbb"
      unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfODUw_7ce8e00f-d9ca-49b0-9bbd-b4b209870933"
      unitRef="usd">57000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7f4c4b3745f349e198629a93da34561b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfOTA0_b05bc93e-bcb8-4fa0-bee3-e62751d0614c"
      unitRef="usd">38000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RleHRyZWdpb246ODQwNzQ2MGM4MzRjNGU0ZWE0MTBjMDI5NWViN2FlODJfMTAyNA_3724d122-3c48-4de5-b1c8-1f9579bde51a">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="if6e8c16288ca4a859ec70b21f89ef7a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfMS0xLTEtMS03MzI1Mw_1fcc67f2-9c49-4957-b123-c4d67eec92d4"
      unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <abbv:RestructuringReserveCashSettledRestructuringGainsLosses
      contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfMi0xLTEtMS03MzI1Mw_53e72d9f-1304-4df0-a253-c935bfed62b5"
      unitRef="usd">48000000</abbv:RestructuringReserveCashSettledRestructuringGainsLosses>
    <abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i35524fcc0d8743e3af6573cf03287f13_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfMy0xLTEtMS03MzI1Mw_c421229a-510c-4593-9080-23a0c0eadc44"
      unitRef="usd">9000000</abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="i5a368d5034e44f028f602236d3ab8057_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY182NC9mcmFnOjg0MDc0NjBjODM0YzRlNGVhNDEwYzAyOTVlYjdhZTgyL3RhYmxlOmRkZGU5ZjJmY2JhNzRhODRiOWI5ZGMwNzI1MzQzOGRiL3RhYmxlcmFuZ2U6ZGRkZTlmMmZjYmE3NGE4NGI5YjlkYzA3MjUzNDM4ZGJfNC0xLTEtMS03MzI1Mw_190f62e2-83c1-402a-accd-a83bfdc2d808"
      unitRef="usd">72000000</us-gaap:RestructuringReserve>
    <us-gaap:DerivativesAndFairValueTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA5OTUxMTY1NTY5OQ_f5b84c9c-1771-46a0-b9c6-81a00e13e3f4">Financial Instruments and Fair Value MeasuresRisk Management Policy&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 11 to the company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie&#x2019;s risk management policy and use of derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $904 million at March 31, 2022 and $1.1 billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of March 31, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive loss. This gain is reclassified to interest expense, net over the term of the related debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $750 million at March 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.0 billion at March 31, 2022 and $8.2 billion at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling &#x20ac;4.3&#160;billion at March 31, 2022 and December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of &#x20ac;5.9 billion at March 31, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.5 billion at March 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts and location of AbbVie&#x2019;s derivative instruments on the condensed consolidated balance sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013; &lt;br/&gt;Derivatives in asset position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013;&lt;br/&gt;Derivatives&#160;in&#160;liability&#160;position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain derivatives are subject to netting arrangements with the company&#x2019;s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $52&#160;million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $1 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to AbbVie&#x2019;s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive loss pre-tax gains of $99&#160;million for the three months ended March 31, 2022 and pre-tax gains of $382 million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement&#160;of earnings caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net foreign exchange loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury rate lock agreements designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt designated as hedged item in fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt"&gt;Level 1 &#x2013; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt"&gt;Level 2 &#x2013; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt"&gt;Level 3 &#x2013; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company&#x2019;s management about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable &lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable&lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9% - 3.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%- 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for unachieved milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for royalties by indication&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at March 31, 2022 and December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in fair value recognized in net earnings is recorded in other income, net in the condensed consolidated statements of earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2022 are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $147 million as of March 31, 2022 and $149 million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of total net accounts receivable, three U.S. wholesalers accounted for 74% as of March 31, 2022 and 75% as of December 31, 2021, and substantially all of AbbVie&#x2019;s pharmaceutical product net revenues in the United States were to these three wholesalers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Humira (adalimumab) is AbbVie&#x2019;s single largest product and accounted for approximately 35% of AbbVie&#x2019;s total net revenues for the three months ended March 31, 2022 and 37% for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt and Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the company repaid $2.9 billion aggregate principal amount of 3.45% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2d0578582acc4184bae1fe1a5d03842e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNTM4_7e984bc2-0032-46f2-9ddc-c43ad4af5144"
      unitRef="usd">904000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i64d7cd1d96fd463d81f7b441a15f7907_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjE5OTAyMzI3NTk4OA_0bfb1145-2dac-420c-8c45-46dac441b71e"
      unitRef="usd">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i85e773fb160f4868b7b34f01835f244e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNjk3_ccb006f8-97c8-40b1-aa1d-00cc539c1f5c">P18M</us-gaap:DerivativeTermOfContract>
    <us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1
      contextRef="i85e773fb160f4868b7b34f01835f244e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfODky_9b90ee31-5ade-4391-beb4-3d70c0cd3fed">P6M</us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id4dcf7772a434cca8535434fc724868d_I20190930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA0MA_333ec003-b595-40e5-bbce-29e4f22313ec"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id7c27a6d499a4374bb62731e6ee3c5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0MQ_b2426b17-156b-4468-bfc5-2c172d2c1229"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1ea6c9f4ab71401f8e112e105b0a87ea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0MQ_d748b9f3-f550-4a66-9964-b92f43cab6e3"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i14c87abe9559493098137ef93eb16897_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjQyMg_b9ede7a2-fb87-416e-b3b6-f0b0f052ec84"
      unitRef="usd">7000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i56fd5370a66349abb5a708fcca3df153_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjQzNQ_e01f78ae-f624-47d5-8815-107b9a9edd29"
      unitRef="usd">8200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8e5c418235f74f58be5d142972173da3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjcxNg_2d490390-e3a3-4757-b063-5a46f43f0fdc"
      unitRef="eur">4300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1440f6810115464aaba75d7ad2e205fa_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjcxNg_f6ea4fa2-547b-4389-b71b-29a557ce1739"
      unitRef="eur">4300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5e04d5b1b77e42338343cb7a394365ac_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjg1MA_04fce40f-facb-4782-914b-fb507f1487a3"
      unitRef="eur">5900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ida1c9540265a40ae89ed8e5bac26055b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjg1MA_eaa64f96-a3ab-4b87-8245-0612241ca890"
      unitRef="eur">5900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0695b54b4eee4244ad7f53879aaf2b88_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzM1Mw_25ca30eb-8ac9-4a1e-bfbd-059e11e83f36"
      unitRef="usd">4500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3023f47a89be437a8979714fa7aeb5ea_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzM1Mw_6fec68bb-b9f4-4828-830f-f9227f10a9e9"
      unitRef="usd">4500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_1bf50e2c-8a3f-4259-a68c-d2537d7710d0"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_4c6a8844-3155-49a5-b49d-2a89afc8f0b3"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_a6f6229d-d536-4eae-8e5c-b80e00813b3f"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzYyNQ_c09d4521-09ef-4f4b-8f08-d912c07d4c2e"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTU_53f9dc5b-fc2a-4088-ae94-e2f7a47dd673">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts and location of AbbVie&#x2019;s derivative instruments on the condensed consolidated balance sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013; &lt;br/&gt;Derivatives in asset position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013;&lt;br/&gt;Derivatives&#160;in&#160;liability&#160;position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iae50d2fb61c84091860a38b122dcec5e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy0yLTEtMS03MzI1Mw_05bd43f8-490e-4cba-8c56-d8f81c3903aa"
      unitRef="usd">28000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3896b7812d9c4f458a6ee1c222fdc5d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy0zLTEtMS03MzI1Mw_6eac45d5-1237-425e-bf92-b1d028f958d6"
      unitRef="usd">51000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="idf844e180d3a469caf77cbfd640ee06a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy02LTEtMS03MzI1Mw_3c6d2c4d-215b-4764-b705-62095d9e0745"
      unitRef="usd">6000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i278c392732fe405ca9790ebca84a2b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMy03LTEtMS03MzI1Mw_2add260a-a4ab-4cb3-9485-4543083f0780"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2759b8249f9b4c0abfb4b6e0d5d1f19a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS0yLTEtMS03MzI1Mw_bb62e646-bb56-4758-800d-50526cb54648"
      unitRef="usd">48000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i21ebd92b09814dbd9c34016fbe056f80_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS0zLTEtMS03MzI1Mw_721d6644-d13d-4f6f-b2ed-81f5242df375"
      unitRef="usd">149000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i37efff4161cb4c0493595e73c1b6c251_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS02LTEtMS03MzI1Mw_a46a5b79-2872-43ac-8d56-f20fa8bb99b3"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i42302eafa7c143eea1f93c5698a3de9f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNS03LTEtMS03MzI1Mw_8e0f1d61-5a25-4422-bb73-3590338f624d"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i45a96d28015b45949c078f6766332529_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0yLTEtMS04MDI5Ng_087a6b9c-51e8-45ef-a26d-3fbb70d5db53"
      unitRef="usd">47000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id8fe28e93231442a879e677d581e007a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0zLTEtMS03ODM1MQ_a294f124-4f95-483a-b4a0-66144ce5bc96"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i21f5ff90441c477985db4a043e94ba99_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi02LTEtMS04MDMxMg_49fffed9-f982-4aae-8843-6724860f568b"
      unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i081e9eccbec84d14b3e5e990418ead24_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi03LTEtMS04MDMxNQ_5514a864-7e6a-4346-8c3d-63887fafe689"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2762b41ed6f34461bfde8f1333fdf996_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0yLTEtMS03MzI1Mw_6bc669d7-e7a4-43c8-9a0d-9424d4676f7b"
      unitRef="usd">63000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i9d6c7748fb844f8387515876c985d86a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi0zLTEtMS03MzI1Mw_cc6b3700-c2eb-4835-b1aa-1da6a7d3e917"
      unitRef="usd">26000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i435b30592ac747d989c50678808fe1d0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi02LTEtMS03MzI1Mw_91337926-8ce6-4061-929b-ec746a33ad49"
      unitRef="usd">29000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i47e7a78e77c640c0978087e1e5aa5365_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfNi03LTEtMS03MzI1Mw_f264b3da-4d41-4a31-b44d-4091bb0d23f5"
      unitRef="usd">13000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic20d6c5cd9154d11b748fba274562228_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC0yLTEtMS03MzI1Mw_ee9d473c-0b6c-4c59-8a50-dca2426feea5"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iec68c25a887f49d4b34b8179ed6dda01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC0zLTEtMS03MzI1Mw_4e2d79a2-b744-45a4-8a27-2add5c169b70"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i24765f81c1fb4287a6f15e1f08b37561_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC02LTEtMS03MzI1Mw_4d45a2d6-28ef-48a1-a1c5-593e3bd1414c"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i84610d1bd2b740fb98e00437e286d300_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfOC03LTEtMS03MzI1Mw_ab48ac2b-a0b9-48dc-92dc-56f386f434fc"
      unitRef="usd">7000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i099396de57cc428db3ba3fa6496e9806_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtMi0xLTEtNzMyNTM_59f38e48-27bd-404c-8870-2cfe955d7317"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6bb723c8d7d94576a2e267ad0bde0d6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtMy0xLTEtNzMyNTM_eaa3336a-0a29-4bf2-a151-f98867a53e90"
      unitRef="usd">26000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if84f403b6217414e9c4727bdaddefefa_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtNi0xLTEtNzMyNTM_dcad8185-f3bb-40fd-b768-080583835cf4"
      unitRef="usd">173000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i993003f0c8794563b176024ce0433091_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTEtNy0xLTEtNzMyNTM_053c44c7-1742-42c1-9aa4-790f96f2baae"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItMi0xLTEtNzMyNTM_0c8e3edc-5b93-4d09-8d92-fa4d0a8b0fa2"
      unitRef="usd">186000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItMy0xLTEtNzMyNTM_a1e9a9d4-ac6d-499c-a11d-724c9f8a219d"
      unitRef="usd">267000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItNi0xLTEtNzMyNTM_79427a3d-f707-4690-bfc8-1caac4d8d74b"
      unitRef="usd">213000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmFlOTczNDI2NTUyOTRmYTU4N2VjNGE3OGVlZjExN2FlL3RhYmxlcmFuZ2U6YWU5NzM0MjY1NTI5NGZhNTg3ZWM0YTc4ZWVmMTE3YWVfMTItNy0xLTEtNzMyNTM_ec03982e-0e72-471b-b234-34d96a927c93"
      unitRef="usd">37000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDE_09cdfda0-e5a7-4b25-aab7-d360e30ea89f">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMzA_ec0bb620-ef75-4536-941b-ecc45f8e3043">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="idf6856ef91ba4d929d656629013d3068_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfMy02LTEtMS03MzI1Mw_385ec5c6-8df6-40db-a3ca-8e5c6475fb74"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie282fe45ad5d4fabb47f2e2e934d4440_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfMy04LTEtMS03MzI1Mw_9de6fab8-129e-4e53-b7aa-392f21edc1c5"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="idf6856ef91ba4d929d656629013d3068_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNC02LTEtMS03MzI1Mw_12060727-9927-483b-8456-5e9ab0deed03"
      unitRef="usd">82000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie282fe45ad5d4fabb47f2e2e934d4440_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNC04LTEtMS03MzI1Mw_41dfc4e0-f499-42f0-afa7-d9915f95df04"
      unitRef="usd">99000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i621e08f15f004824aefad73ab5851795_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNS02LTEtMS03MzI1Mw_b44fe433-bb6a-4e44-8e35-0c7cae8096f2"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i179bb4a086e74b04bc986f5bbbb847c6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjM1ZTQ5NjA0N2UwYzQzMTFiNGQ0MmY3NmY1Zjc1Y2FiL3RhYmxlcmFuZ2U6MzVlNDk2MDQ3ZTBjNDMxMWI0ZDQyZjc2ZjVmNzVjYWJfNS04LTEtMS03MzI1Mw_3c25781a-dfdc-4a06-9c77-0aafeb684adc"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i0ed7b475bcdf40e59be351b723196753_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDIzNQ_49777b53-4953-4b1f-820b-3ee530df7804"
      unitRef="usd">52000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="if0ba58f0b4804781a450e1eafe670429_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDI5OQ_59517e26-6648-47b8-a5d5-66cc61d9e096"
      unitRef="usd">-1000000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <abbv:TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet
      contextRef="if0ba58f0b4804781a450e1eafe670429_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDM2OA_5bf27f04-52e7-45b2-bc56-7378bbae3bc5"
      unitRef="usd">24000000</abbv:TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i73a0138eece144c7b6d7536ce561b961_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDYzOA_adce4b49-a22e-40ee-b39b-b1b1c56d0e9f"
      unitRef="usd">99000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia6e338b61d1141f5b8c13e661709f6b5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNDY3MA_8a56b895-8328-4a49-96ef-91c9654e7a4a"
      unitRef="usd">382000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDQ_b95539fd-da20-4667-aa8d-b2652a132805">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement&#160;of earnings caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net foreign exchange loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury rate lock agreements designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt designated as hedged item in fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3a7bd97603484ae1802843d027d4882c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMy03LTEtMS03MzI1Mw_0cb0bea1-24e5-40e3-8bfd-8d2458e45033"
      unitRef="usd">8000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i1681dbbb7fe645d6853c751bdc56bbad_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMy05LTEtMS03MzI1Mw_d8917499-82e5-4397-8dfc-20cc3f72e97f"
      unitRef="usd">-12000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="iaed8d036846c41e7ae1fd8954a4b4f77_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNC03LTEtMS03MzI1Mw_8c468b34-767b-4438-804a-9118565a0750"
      unitRef="usd">14000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i52f7ce3635354a61a150bfdfc38169f5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNC05LTEtMS03MzI1Mw_0c4d7810-2dcb-40a7-8ac4-98fd4d7cfd23"
      unitRef="usd">4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="id741975d93ce432ca3360bc759262c9c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNS03LTEtMS03MzI1Mw_3d5c0c73-31e3-4307-aa58-33ca4e4cdf43"
      unitRef="usd">-41000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib000460db5074562808f7f1eb5c6419e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNS05LTEtMS03MzI1Mw_0e0f472a-82bf-4f34-ab04-f8e868d48846"
      unitRef="usd">-25000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ie9f6fa4fbbe04394a9fe1a7d581eaec0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNi03LTEtMS03MzI1Mw_013212d1-04ae-40dc-8009-2e2f0db68953"
      unitRef="usd">6000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib64b83983f224c629b47278996994efe_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfNi05LTEtMS03MzI1Mw_02602c5d-26a2-4d1f-96c1-5b37926c4693"
      unitRef="usd">6000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i47ba7efcd0f44228bd851a9cfd907eca_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOC03LTEtMS03MzI1Mw_e5121cac-f89a-4001-af69-ddcb87c5eeb0"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if79203b4f0e042919ad95c75b6c9ed1d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOC05LTEtMS03MzI1Mw_9fccdeea-6701-4e41-8fa8-61aaaca2748f"
      unitRef="usd">-7000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3338f9b94ba644cdb8a5bfb1a5c29358_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOS03LTEtMS03MzI1Mw_a02dce1c-74c9-4023-a5c2-997ce86f63eb"
      unitRef="usd">-184000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib576612385b34159a385efbbb44ac312_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfOS05LTEtMS03MzI1Mw_f3c726d5-7bec-45f3-bbdb-687d1ec7493b"
      unitRef="usd">-57000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1
      contextRef="iaa2ab8d0faba462a8cdae1d115c9ac72_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMTAtNy0xLTEtNzMyNTM_783d6ef0-3f94-4448-b483-86b61e631983"
      unitRef="usd">184000000</us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1>
    <us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1
      contextRef="i859211caa6b54eaa83b28f597db71274_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjUwYTk1NmRjZGQyNTQ4YjBiNGE5ZDRjNjc1OTE2MDMxL3RhYmxlcmFuZ2U6NTBhOTU2ZGNkZDI1NDhiMGI0YTlkNGM2NzU5MTYwMzFfMTAtOS0xLTEtNzMyNTM_6863731a-7c13-4d95-9362-b645f2ce21c3"
      unitRef="usd">57000000</us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIwOTM_e53bdd43-136c-42df-b926-56fab805c90c">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable &lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable&lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy0xLTEtMS03MzI1Mw_7b1af346-6b60-4afe-ad70-649e4551882d"
      unitRef="usd">6098000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy0zLTEtMS03MzI1Mw_3db9dd1b-1da1-41b0-8918-e8afdb852e58"
      unitRef="usd">3417000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy01LTEtMS03MzI1Mw_397f23db-81d3-4c43-ae61-ba928277ebcb"
      unitRef="usd">2681000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMy03LTEtMS03MzI1Mw_6577533d-eae6-4531-afc3-5de6c4901dd1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic9a1275578fd4eab9c1a98a3a69b8994_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC0xLTEtMS03MzI1Mw_3b45f71f-9932-42a7-bb50-3ef82bfa9984"
      unitRef="usd">1445000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i547378d779a94424afb2f81c95c765e8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC0zLTEtMS03MzI1Mw_01ffaaeb-6f4e-4421-9c54-f7518f626e8d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifced2c43ef9a4921b504c12eeb7b2ef1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC01LTEtMS03MzI1Mw_49a5a642-84c0-437a-9921-4ed756e32357"
      unitRef="usd">1445000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ied0d7604169c4be790295c65966d9417_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNC03LTEtMS03MzI1Mw_fff10398-75b6-463e-9f76-f8dedad6af83"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS0xLTEtMS03MzI1Mw_b850f83a-36a5-4b80-9123-92c1215589c3"
      unitRef="usd">42000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS0zLTEtMS03MzI1Mw_874ac87f-3468-4d66-af4a-fb6ce5adb02d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS01LTEtMS03MzI1Mw_0483490f-fa53-41cb-847f-7836fc72109d"
      unitRef="usd">42000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNS03LTEtMS03MzI1Mw_26045942-d79b-4551-adf7-5f7da76b3a5a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi0xLTEtMS03MzI1Mw_5d383c0b-701c-4ae8-9cf8-8a34697d8fd4"
      unitRef="usd">100000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi0zLTEtMS03MzI1Mw_49db4075-9ef8-4cb3-8d68-d4864688f042"
      unitRef="usd">81000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi01LTEtMS03MzI1Mw_8e778f80-a6b9-472d-afd3-23e2ae26deeb"
      unitRef="usd">19000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfNi03LTEtMS03MzI1Mw_e8282ac4-cc16-4594-83f9-e108938eed27"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia5ad1758bd2446cea957f2ad4754f617_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC0xLTEtMS03MzI1Mw_88004ab2-39f5-467b-aa38-7aea65a00b21"
      unitRef="usd">186000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2e694d0a849640f2baad8365a826d153_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC0zLTEtMS03MzI1Mw_84f56ad2-b2f0-45d1-b9d5-996f14ff6244"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="idfa6a41f682746a8ace32ddbe43016b7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC01LTEtMS03MzI1Mw_9c48b418-3f14-4a0a-a9cb-f2c5ee3026cd"
      unitRef="usd">186000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2af1965f163b48ea903e4c8e2f20baed_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfOC03LTEtMS03MzI1Mw_3dcc88ac-c343-4c53-943b-b4b193b6244c"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtMS0xLTEtNzMyNTM_55954aab-ae51-4410-98b5-6b6292640ee4"
      unitRef="usd">7871000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtMy0xLTEtNzMyNTM_0759bc3e-5a02-4b62-a3ee-c4105230f97a"
      unitRef="usd">3498000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtNS0xLTEtNzMyNTM_bbba2543-0a54-4e22-ac11-ccbe5b21ca64"
      unitRef="usd">4373000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTAtNy0xLTEtNzMyNTM_a40b3004-17e4-4118-a975-2231f1eeae21"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItMS0xLTEtNzMyNTM_ec198ca6-e7ca-4ca8-83f4-d54d2aea7962"
      unitRef="usd">174000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItMy0xLTEtNzMyNTM_67fb8181-7d7d-4743-a227-c5855c5324f0"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItNS0xLTEtNzMyNTM_3ca3d180-ddf3-4aef-9108-0ea1aca467a3"
      unitRef="usd">174000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTItNy0xLTEtNzMyNTM_537bdbaa-7879-4120-9542-61c3b065122f"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia5ad1758bd2446cea957f2ad4754f617_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtMS0xLTEtNzMyNTM_47872965-1ecd-4626-877e-b39e96fcb09a"
      unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2e694d0a849640f2baad8365a826d153_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtMy0xLTEtNzMyNTM_f3988187-cb99-4348-9a39-0923218b3f58"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="idfa6a41f682746a8ace32ddbe43016b7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtNS0xLTEtNzMyNTM_eb1fd52e-074e-4e11-bc7f-08db91db4f0d"
      unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2af1965f163b48ea903e4c8e2f20baed_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTMtNy0xLTEtNzMyNTM_1ec79ab3-6082-42d6-9d74-a05a3f92fae9"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtMS0xLTEtNzMyNTM_8b9ef945-5ed1-492d-9629-461ea4b6aec3"
      unitRef="usd">13818000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtMy0xLTEtNzMyNTM_fd291f51-14eb-491b-a375-a142de623dd6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtNS0xLTEtNzMyNTM_6c572255-7e81-4c5e-bc68-c27b48b71901"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTUtNy0xLTEtNzMyNTM_d638b04e-76e9-4a9b-ba30-688c529dfd4f"
      unitRef="usd">13818000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia38e263f9b26407aad657967962464cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtMS0xLTEtNzMyNTM_7f7c3b55-442a-48f5-b071-f03cc484fd8a"
      unitRef="usd">14031000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iab718c63b5884ec79c89e37caa022504_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtMy0xLTEtNzMyNTM_359a31a3-0140-4e41-ad59-136477d0badd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8d51b5f39b30417591b468b9cc37d240_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtNS0xLTEtNzMyNTM_a8c03493-0152-44c6-bc77-6c3de1767703"
      unitRef="usd">213000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibdce0bbf0ade46c2bcb9b28658b93b26_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjBjYjRjMDMwNzY4ODRhODM4ZmM1MzBmNDk0NWMyNmY1L3RhYmxlcmFuZ2U6MGNiNGMwMzA3Njg4NGE4MzhmYzUzMGY0OTQ1YzI2ZjVfMTYtNy0xLTEtNzMyNTM_2baf25d4-3c2f-4a71-97fd-dcb994f46b3b"
      unitRef="usd">13818000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy0xLTEtMS03MzI1Mw_a2f3450b-d97b-4c93-b280-f4539b8b6948"
      unitRef="usd">9746000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy0zLTEtMS03MzI1Mw_2b54e3ba-2294-4da1-b500-f777557162bb"
      unitRef="usd">4451000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy01LTEtMS03MzI1Mw_78a5fd77-c85c-4dd7-b0eb-355ae24a6ce6"
      unitRef="usd">5295000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMy03LTEtMS03MzI1Mw_f72e3675-6df8-457f-82c8-58c702f6c47a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1b425e8bb2fc4bf98f7703e322eb47ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC0xLTEtMS03MzI1Mw_5e3f2279-d16c-419f-86cb-92bb1820b36e"
      unitRef="usd">45000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7e2a58ae48e34c639ba8dc2259cc6bf8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC0zLTEtMS03MzI1Mw_10188c07-d41c-4860-a961-f960064fc53c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib99530b1ca1f4637a531747b189b68e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC01LTEtMS03MzI1Mw_3fa8bad5-a326-43ad-9532-72462249db78"
      unitRef="usd">45000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i75b92c917f6c46e8bec270fac1ab97be_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNC03LTEtMS03MzI1Mw_e09763d9-ccfe-41ec-9417-91c36f74d518"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS0xLTEtMS03MzI1Mw_2ef959ad-e53f-44ed-87ff-f399e3fc54ef"
      unitRef="usd">46000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS0zLTEtMS03MzI1Mw_9482f454-42ee-4a6d-9ab6-ef8b5b494fc0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS01LTEtMS03MzI1Mw_314bc895-2e97-48bb-b711-eebf835e44a8"
      unitRef="usd">46000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNS03LTEtMS03MzI1Mw_2c55d62b-bbdd-45b2-9e50-26902c14b7cb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi0xLTEtMS03MzI1Mw_e1a8d3de-3174-4ce2-913f-10f731262240"
      unitRef="usd">121000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi0zLTEtMS03MzI1Mw_0015bc62-d9d9-45a3-9056-8725ee4fab66"
      unitRef="usd">100000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi01LTEtMS03MzI1Mw_4af78264-b00b-4341-9f4a-aa6c802a2a27"
      unitRef="usd">21000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNi03LTEtMS03MzI1Mw_bcff001a-760b-477c-9570-8b3c30cafa77"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy0xLTEtMS03MzI1Mw_25607d2c-7295-4d86-8bf9-ffacef8bd111"
      unitRef="usd">26000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy0zLTEtMS03MzI1Mw_9f3a0f60-f481-4edb-9d20-e3a44b2dcd71"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy01LTEtMS03MzI1Mw_d325db0e-252d-4adc-820b-abbf846c4d04"
      unitRef="usd">26000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfNy03LTEtMS03MzI1Mw_339ac371-0314-4401-be84-6db5e7c6d3a8"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i87ad90d3c5e24243a4f6eb626050ecbe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC0xLTEtMS03MzI1Mw_f38f3d0d-ec7f-46e7-9b25-62c5be07af4f"
      unitRef="usd">241000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id1c1d4df013d43b6a59943a73db0d1fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC0zLTEtMS03MzI1Mw_34ac3567-513f-4ec0-a22d-0aeb5193947e"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5e05944c5ce844a18dea78c42fefb97f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC01LTEtMS03MzI1Mw_da5eb27b-a0b4-40e9-b584-8b0f93fa5bda"
      unitRef="usd">241000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2306289346ba4f6eac115558f89ffb15_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfOC03LTEtMS03MzI1Mw_19739ae7-eed7-41ef-a382-2d3a2942e887"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtMS0xLTEtNzMyNTM_edcc36d0-19e1-43fa-b4a1-0463957e2213"
      unitRef="usd">10225000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtMy0xLTEtNzMyNTM_da49f0f6-a342-4082-a1c9-bc6af140ca95"
      unitRef="usd">4551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtNS0xLTEtNzMyNTM_ee70abd1-c97f-4c9b-bea1-2ee4940783ea"
      unitRef="usd">5674000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTAtNy0xLTEtNzMyNTM_84924d73-1989-42d5-960c-68cf624064b5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItMS0xLTEtNzMyNTM_df7f0640-fa17-4513-9e7e-63f6c9c27efa"
      unitRef="usd">22000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItMy0xLTEtNzMyNTM_3fd91619-82cb-42aa-9115-9c628298e614"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItNS0xLTEtNzMyNTM_882e8e86-3fc9-4077-89c4-e0ec24b7e088"
      unitRef="usd">22000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTItNy0xLTEtNzMyNTM_97198781-e44d-4c5a-a6d6-2bd6761340cc"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i87ad90d3c5e24243a4f6eb626050ecbe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtMS0xLTEtNzMyNTM_6f7daaeb-06d9-4d73-91a0-e968a57db3ed"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id1c1d4df013d43b6a59943a73db0d1fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtMy0xLTEtNzMyNTM_20d770c6-8581-48d4-bc69-298c5da76620"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5e05944c5ce844a18dea78c42fefb97f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtNS0xLTEtNzMyNTM_4b33ccd3-3c74-4681-a12f-a7246aba7e6a"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2306289346ba4f6eac115558f89ffb15_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTMtNy0xLTEtNzMyNTM_02b7fc5b-e60a-48e3-8f79-414f08b51774"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtMS0xLTEtNzMyNTM_872f550f-ebe9-4aa1-b978-3cb8e86b3a53"
      unitRef="usd">14887000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtMy0xLTEtNzMyNTM_64cd1b18-bbea-4ffc-93ed-0171c4866d60"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtNS0xLTEtNzMyNTM_4f18e23d-542d-4dbd-aef2-dbc49719f1ab"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTUtNy0xLTEtNzMyNTM_c55aef7d-7b8c-4134-87e4-0b28c0a22ec3"
      unitRef="usd">14887000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i626df6b5d80b4e98b0edeaa02ad00831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtMS0xLTEtNzMyNTM_b6c29017-c8fe-4bd1-9798-15145261e8b8"
      unitRef="usd">14924000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if649f364c260430e996cc0e7faf77825_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtMy0xLTEtNzMyNTM_e57d396e-5112-4854-8ba6-14371266e3bb"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7f48fccb6a964533ad0a2bc9fa1b69d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtNS0xLTEtNzMyNTM_4cbc0d2f-52b6-4585-978f-d2b3b0b98e37"
      unitRef="usd">37000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ida5d7c1351314f0aa35ce7a44c4a1460_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjA0NWE5ZmUyZWI0MjQzMThhMDM3YjAwYTk1NjhhYmFkL3RhYmxlcmFuZ2U6MDQ1YTlmZTJlYjQyNDMxOGEwMzdiMDBhOTU2OGFiYWRfMTYtNy0xLTEtNzMyNTM_bee800ca-cb65-41f3-a5db-a8481df13dc0"
      unitRef="usd">14887000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDU_da4c56ee-ab84-436c-a951-b6b285156327">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9% - 3.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%- 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for unachieved milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for royalties by indication&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.&lt;/span&gt;&lt;/div&gt;(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at March 31, 2022 and December 31, 2021.</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if76fd003b44e4e00b01dd0219527e8f6_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjJlOTI4ZjljOWU4NTRlNWZiMTYwNGY3ODQ4YWRlMTNmXzE2NDkyNjc0NDE2ODQ_d0e959fe-d860-4795-9cc3-b8545de9d413"
      unitRef="number">0.009</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3316afc52f864995939b74f4200c4d5d_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjJlOTI4ZjljOWU4NTRlNWZiMTYwNGY3ODQ4YWRlMTNmXzE2NDkyNjc0NDE2OTI_9c21d1ed-e8c7-4e75-a080-5a00391862a4"
      unitRef="number">0.036</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie41be7ae9a7746e29ab56e1c3957336c_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmI2ODBhMDkwNGJjZTQ2ZmViMjljYmVjY2Y1NGIzYzMyXzI3NDg3NzkwNjk0NTA_cef10409-9e56-4640-b348-5c474e51230b"
      unitRef="number">0.030</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ibaaf5c1772824540821269f5a7d5d060_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjRhOWUwNTg1ZjEzODQ1Y2E4NzAzMzliOTdkNzlhOGMzXzI3NDg3NzkwNjk0NTM_65a9005a-a7d0-4fee-b00e-9235bc5a3160"
      unitRef="number">0.002</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i2e6a0250795b4caeb9007fccb2fb25e6_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjRhOWUwNTg1ZjEzODQ1Y2E4NzAzMzliOTdkNzlhOGMzXzI3NDg3NzkwNjk0NTY_a93bfc2a-eb8e-4cdd-b65f-f9573a7ae001"
      unitRef="number">0.026</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i7064869e3d004e11826a6f8e545956e8_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjgzM2JmZTkxZDBkZDQyMWE5NDI5NmQxMjEyNGE3M2MzXzI3NDg3NzkwNjk0NDQ_274ad924-0f34-4f79-977f-36dc21f67545"
      unitRef="number">0.017</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib0e23bbc802e473d941d50ddec1eac96_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjViYmU5OGFkYWQwZTQ4M2VhMTE0YzQyNmJkOWUwNDhjXzE2NDkyNjc0NDE2ODM_1f720098-413b-4184-9b0d-dcc083ebdb84"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="idc34b4f0b824400cb3e06c112446fd78_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjViYmU5OGFkYWQwZTQ4M2VhMTE0YzQyNmJkOWUwNDhjXzI3NDg3NzkwNjk0NzM_df41c27a-8be9-4a76-afd6-6108f0c36160"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ifa6c770a5e4e43219c664f8eeaebc92b_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmMzYzcyMDAxZGQyNTQzNTRhYjBjZGRmMzEwOTkxMzQ0XzI3NDg3NzkwNjk0NTA_f621a23b-df7f-4771-a959-3f4a432c6de1"
      unitRef="number">0.91</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ifeca827be1174ca8b3b26a2dd3170414_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjUyYjVhYWQ5ZDdjYTRlNWJhMjI0MWI4Y2I2MTQ1Mjk1XzI3NDg3NzkwNjk0NTE_210fd7dc-6734-4f08-8930-315215149d25"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4c6e00071bb14c0f9134687f14d184c0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjUyYjVhYWQ5ZDdjYTRlNWJhMjI0MWI4Y2I2MTQ1Mjk1XzI3NDg3NzkwNjk0NTU_a06df4bd-66c5-42b7-bec1-a1d801b405b0"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i40f7d8e61c394c11942ca3d90870ce76_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0yLTEtMS03MzI1My90ZXh0cmVnaW9uOmQ0MGEzNmJlOGMxYzRjM2RhOTE4ZWYwODI5MTZiYTcwXzI3NDg3NzkwNjk0NDQ_22cd617e-882f-4a62-a3a0-f377e022ebfd"
      unitRef="number">0.90</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i36a5db71b7bc44afa79f34197c0d50c0_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NTg_1139f260-ebf0-4997-a8bf-8e3e9c1797b3"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3b7bbcb6f78a486c9aaaf2cc66ad620a_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NjY_34203fed-736d-478f-9829-5ad6abaa8128"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4a58f36c0a0f455fb16aee3fddf5e537_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0"
      unitRef="number">0.96</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i1c4ab8ef49f6437ea3dc95bf05981bfc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NDQ_7949dad9-89a4-41ee-b66a-7fc7207216bb"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i088dd727214a49e5bdaa60f93779a823_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NTA_04ada94e-64b7-459a-a5dd-adeb4f6ea353"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3155754d608b4eb491cdd36b45bcc5de_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242"
      unitRef="number">0.96</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i86308a2e6f2a4ecfba5255d3af29d432_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjk3YTdiZDUxZjg2ZjQ5NGJiZjY4YmZkZmVhOGEzMDhlXzI3NDg3NzkwNjk0NjI_3b0ced0f-8f99-4445-907a-3c0d71be910e"
      unitRef="number">2022</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id9678c4caaf349ba8006f44b404b1b82_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjk3YTdiZDUxZjg2ZjQ5NGJiZjY4YmZkZmVhOGEzMDhlXzI3NDg3NzkwNjk0NzI_69b5d90e-c630-43e4-b77f-dbe9fdc99247"
      unitRef="number">2034</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6d2bc0b8db334803be5cea99172bad7f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjc2MzFmNTcxMzBkZTQyZjE4NmQ5MmEwNjk4ODM5MGM1XzI3NDg3NzkwNjk0NTA_6fba84dd-6dc2-4522-a73d-12e386424d43"
      unitRef="number">2027</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ifdc8ba9e255b47fbb82c3c726dd8508a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOmU2OTRhY2VkY2VhOTQyMTc5YTIyZDVjNDA4ZTk1ZmMyXzI3NDg3NzkwNjk0NDQ_5fc5885d-234b-4571-8b62-077908990d07"
      unitRef="number">2022</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i1455f288cfc245b69c8e6fa1ee29a92c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS03MzI1My90ZXh0cmVnaW9uOmU2OTRhY2VkY2VhOTQyMTc5YTIyZDVjNDA4ZTk1ZmMyXzI3NDg3NzkwNjk0NTE_7c73872c-d194-4650-b82e-07c88cc47f6f"
      unitRef="number">2034</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i653e387441bf474ba40509d89d957072_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS03MzI1Mw_1e8fbd73-3e85-44c5-8cfb-b0e0822a4975"
      unitRef="number">2027</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i01d4a0312e1a42c1bbb49eebf6fb2dbc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_0f1e56d2-f43a-4f83-bd88-7a819ad1ed4f"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib6f0399851154ccb8d747ab261a55ff7_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_2255b661-58b9-448c-a8da-5793bd88bc4d"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i5e22014612a6456496ade50c3c0e598b_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_5d256177-b7e1-4915-a8f0-e491dbb9f298"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6150f60c782f4bbe93e9e862b343af55_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_6cae88be-9805-4211-99eb-5aa8a24bbdff"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_23556952-0e2b-4c08-99c0-2f6b33baa242"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_a1ddc400-ce0f-422f-8b58-502ad0d49b57"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_af6a8924-aea1-477c-aff9-2976d067f7e6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfNzkyNw_cd407c3f-3b97-4b47-80da-3d25ae11fcb2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIwOTA_100b962c-957a-43d3-a551-059f15431102">The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfMi0yLTEtMS03MzI1Mw_fce6ad73-5c38-4177-9519-e43dde40a9f1"
      unitRef="usd">14887000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6accb844205d4e909ea7d6f406d2b865_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfMi00LTEtMS03MzI1Mw_382bb798-b551-4fda-96c6-4742e882011a"
      unitRef="usd">12997000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNC0yLTEtMS03MzI1Mw_69b0b4be-0d5c-4446-bbee-159e6cd2147d"
      unitRef="usd">748000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNC00LTEtMS03MzI1Mw_402c8bb3-37d5-4303-ad01-b5d357d25499"
      unitRef="usd">343000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNS0yLTEtMS03MzI1Mw_ddd6632d-52b8-4685-8f09-71053e6937ec"
      unitRef="usd">321000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNS00LTEtMS03MzI1Mw_507e5aca-753b-4eca-8887-24c735a1ffc0"
      unitRef="usd">132000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNi0yLTEtMS03MzI1Mw_fb7fd865-7fc9-4ae9-9f22-c448c227954e"
      unitRef="usd">13818000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3cf70c299b6747128fa4a148bd06c306_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmNhMDVlMjFjZjQ3ZjQ4YTk4YmY2YzcwMWQwNTk5NmI5L3RhYmxlcmFuZ2U6Y2EwNWUyMWNmNDdmNDhhOThiZjZjNzAxZDA1OTk2YjlfNi00LTEtMS03MzI1Mw_9a4f4f93-61f5-4419-9bfc-48b8555f4253"
      unitRef="usd">12522000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDM_910c352f-0926-4622-bb36-74058eab4e5c">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2022 are shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi0xLTEtMS03MzI1Mw_ec6557c6-4e00-49e1-81e3-3d8e78bb9032"
      unitRef="usd">12000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi0yLTEtMS03MzI1Mw_26abb2c2-8d6f-4b23-8f78-5884b5ada290"
      unitRef="usd">12000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i077c77a1980b4f8fb626087d04f359c2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi00LTEtMS03MzI1Mw_4edc8536-dbfc-4d47-a360-c1dbf775b231"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi02LTEtMS03MzI1Mw_84a5019b-fda2-49c4-beae-82c72713fb14"
      unitRef="usd">12000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNi04LTEtMS03MzI1Mw_a93b2245-d4ce-46ff-92d2-ffef3954ffae"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy0xLTEtMS03MzI1Mw_84476e5c-8d7c-4829-abc2-5b2abefad4cb"
      unitRef="usd">9922000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy0yLTEtMS03MzI1Mw_2d05748d-9d90-4bda-a163-b79dd691ac53"
      unitRef="usd">9208000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy00LTEtMS03MzI1Mw_8e5f56b3-b846-4db2-81a8-d0a46ca894f6"
      unitRef="usd">8851000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy02LTEtMS03MzI1Mw_d39416d2-d5dc-4a4e-b778-e83d341839a4"
      unitRef="usd">357000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfNy04LTEtMS03MzI1Mw_385b0e1d-dd16-4a9e-a97f-0c11faa81e4b"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC0xLTEtMS03MzI1Mw_18332905-2e8b-4488-8522-4f92e26c2e06"
      unitRef="usd">63634000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC0yLTEtMS03MzI1Mw_98dc593e-30d3-42f3-87ad-743d1255ce0d"
      unitRef="usd">65790000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC00LTEtMS03MzI1Mw_580f34ac-5a65-413f-a94c-e98086ef8be0"
      unitRef="usd">64914000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC02LTEtMS03MzI1Mw_e1d8151d-5ef5-46a2-812c-76cc2306d387"
      unitRef="usd">876000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOC04LTEtMS03MzI1Mw_3a014d2e-8f45-461e-ad3d-30d5e202d284"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i044a3d7ac50441e494f6a05e1c9a61b5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS0xLTEtMS03MzI1Mw_b5ec4535-03a9-44c8-ba5c-213b706d3a7f"
      unitRef="usd">73568000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if42be951e40b4522978f85dbcf5c6c5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS0yLTEtMS03MzI1Mw_3ce24172-3512-436b-8cd2-6a96844f948d"
      unitRef="usd">75010000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8a0fb1ead0c4427aa4a771f260c12ddb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS00LTEtMS03MzI1Mw_d9559910-c28d-4090-b849-0bc02256f3cd"
      unitRef="usd">73765000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9c0cf7b896574cd48467e517534d6c7e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS02LTEtMS03MzI1Mw_77c5a49d-c00e-411e-8308-9e31bed78efa"
      unitRef="usd">1245000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0f1f25b805ee48a38221900a8f4ec23b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmYxZTNmOGY0YTdhNjRjYzE4YThmODA4OTQwYzFmNjQ1L3RhYmxlcmFuZ2U6ZjFlM2Y4ZjRhN2E2NGNjMThhOGY4MDg5NDBjMWY2NDVfOS04LTEtMS03MzI1Mw_17815096-4c3e-4b4f-a2ae-32b2837f3ff2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ShorttermDebtFairValue
      contextRef="ib6c49899324342418b3c03ecab096e69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi0xLTEtMS03MzI1Mw_3ea8bba2-220c-4c8f-bc45-6f40036305aa"
      unitRef="usd">14000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi0yLTEtMS03MzI1Mw_10165b74-d3be-402f-a798-ab22fec74d61"
      unitRef="usd">14000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="ie3079fe6a94b4043bd136bd42880f7e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi00LTEtMS03MzI1Mw_8401bdd8-e6ba-4ae3-9d19-14252e1f0720"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="iaafb386815a84014b6e79d88e23df483_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi02LTEtMS03MzI1Mw_bd649abc-9610-4bba-9fed-c1e33c4212c6"
      unitRef="usd">14000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNi04LTEtMS03MzI1Mw_7a2ee053-2092-4357-a168-b009f2343221"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="ib6c49899324342418b3c03ecab096e69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy0xLTEtMS03MzI1Mw_e863d395-3e03-4939-a8e1-09b7bb71d98f"
      unitRef="usd">12455000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy0yLTEtMS03MzI1Mw_911f0c63-673b-462a-86de-546bafb39438"
      unitRef="usd">11830000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="icb19f61a177a44cc83608f369fc35200_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy00LTEtMS03MzI1Mw_d1d82fd7-5546-4daa-ac7c-a28e80662c0c"
      unitRef="usd">11329000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="iaafb386815a84014b6e79d88e23df483_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy02LTEtMS03MzI1Mw_88a73813-5a00-4e32-860a-e73188283410"
      unitRef="usd">501000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfNy04LTEtMS03MzI1Mw_c55c3667-d87c-4374-841f-4f7722190513"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="ib6c49899324342418b3c03ecab096e69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC0xLTEtMS03MzI1Mw_d50e863c-3edb-4679-88a8-de32e17f85b8"
      unitRef="usd">64113000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC0yLTEtMS03MzI1Mw_d846bc2b-8e9a-415e-b09d-c68a7c1c3bad"
      unitRef="usd">71810000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="icb19f61a177a44cc83608f369fc35200_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC00LTEtMS03MzI1Mw_6974b90c-2316-4faf-b7e7-0ee6b474cb5f"
      unitRef="usd">70757000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="iaafb386815a84014b6e79d88e23df483_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC02LTEtMS03MzI1Mw_560b71b5-1de2-46ef-838e-38343a0ffe61"
      unitRef="usd">1053000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOC04LTEtMS03MzI1Mw_f1294b3a-c59f-4daa-9318-5ab545c32267"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib6c49899324342418b3c03ecab096e69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS0xLTEtMS03MzI1Mw_4971d2e4-0359-4820-9b6f-90e7b818b0cd"
      unitRef="usd">76582000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5c93bb319518438dacf0fb870fcabe09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS0yLTEtMS03MzI1Mw_9bcba3f5-2edd-4014-9ece-72d663988109"
      unitRef="usd">83654000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icb19f61a177a44cc83608f369fc35200_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS00LTEtMS03MzI1Mw_185d839a-d1b3-46bc-9ba8-30f36fcc66f2"
      unitRef="usd">82086000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iaafb386815a84014b6e79d88e23df483_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS02LTEtMS03MzI1Mw_6afbfdbc-88a5-49b6-80d2-4204a334b10c"
      unitRef="usd">1568000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i683f0aac0c634dfca6b9b368ab20372a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOmIyNzFmMmM3NTZjNTQxZjM5YmY1YjNlMTg4YjJkNWNjL3RhYmxlcmFuZ2U6YjI3MWYyYzc1NmM1NDFmMzliZjViM2UxODhiMmQ1Y2NfOS04LTEtMS03MzI1Mw_0f30e809-712e-4355-9e87-d25d1a5a6634"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTA3MQ_f68f08ac-ad79-4287-a6bd-9521dd11fbdb"
      unitRef="usd">147000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i3ee167f36562471dab7b2f232caad9ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTA4Nw_b215e944-2c71-4796-a771-f3f906066a22"
      unitRef="usd">149000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <abbv:NumberOfPrincipalUSCustomers
      contextRef="i95aad88173d14db798e85a935c24c68b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTI2NQ_a5b25310-07b4-411f-b9e4-032274334647"
      unitRef="wholesaler">3</abbv:NumberOfPrincipalUSCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6a1415a76d304bdd903790a631d4b562_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTI5OQ_5d33445e-e46f-4316-87d7-532b0571ebd9"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie5fd10e4797b4759b2ad9ee884eb18fb_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTMxNQ_c0a1db7f-bd06-4c2a-97c4-0af505732cb6"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <abbv:NumberOfPrincipalUSCustomers
      contextRef="i95aad88173d14db798e85a935c24c68b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTQxMA_a5b25310-07b4-411f-b9e4-032274334647"
      unitRef="wholesaler">3</abbv:NumberOfPrincipalUSCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb70f3e9a3064175beb5a4288f9555cf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTUxMw_7808ce34-b29f-4709-83ae-46e43eff3a3e"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i598f780a95a34397b93cc33d29482fbf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfOTU2Mg_917b7ce7-3452-49c4-b914-ec1d6eddfdd6"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="if319dff6fb6d4c9b9e70b7590afec644_D20220101-20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMzg0ODI5MDcyMjAyMg_9f655c38-f9e0-4c0f-9e6c-171b85fe79ba"
      unitRef="usd">-2900000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id24046754e794d98901ac09a9a57728a_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA5OTUxMTY1OTY4NQ_61f8e13e-05d8-4793-a527-3482e9abff51"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="ia646a389a6944ee39075a400a0260d9f_I20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTA5OTUxMTY1NTY5Mw_6c281ecd-4bfb-4950-bd00-cd6d64125b93"
      unitRef="usd">2000000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentTerm
      contextRef="iedf4aed6ce494fb0b76f1715e4bc5fdb_D20220201-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0OTI2NzQ2OTUwOQ_f2dce082-cda0-4d85-94ff-78e1b132304f">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="iedf4aed6ce494fb0b76f1715e4bc5fdb_D20220201-20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0OTI2NzQ2OTU3NA_e8717d41-5c5a-4d99-bf5d-eacfa9e70753"
      unitRef="usd">-2000000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:LongTermDebt
      contextRef="i5d290b478df340cb86cfefef5344e881_I20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTY0OTI2NzQ2OTU1OA_20253348-c9b2-427e-9cf5-c90c19f3ad85"
      unitRef="usd">2000000000</us-gaap:LongTermDebt>
    <us-gaap:PostemploymentBenefitsDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RleHRyZWdpb246MzBmOWVmMjk3MGRjNDk3NTg5NjZjNDNkZTM1OTc3OWZfMjQ0_edc7fb5f-7c2d-4e7a-943b-743e976a2431">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Post-Employment Benefits&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes net periodic benefit cost relating to the company&#x2019;s defined benefit and other post-employment plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined &lt;br/&gt;benefit&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;post- &lt;br/&gt;employment&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;The components of net periodic benefit cost other than service cost are included in other income, net in the condensed consolidated statements of earnings.</us-gaap:PostemploymentBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RleHRyZWdpb246MzBmOWVmMjk3MGRjNDk3NTg5NjZjNDNkZTM1OTc3OWZfMjQ3_73bb8d3f-d8a6-4688-ba7c-901f4fd7ebae">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes net periodic benefit cost relating to the company&#x2019;s defined benefit and other post-employment plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined &lt;br/&gt;benefit&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;post- &lt;br/&gt;employment&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy01LTEtMS03MzI1Mw_488dd1c4-fcac-44dd-9935-5adc427c4f1c"
      unitRef="usd">116000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy03LTEtMS03MzI1Mw_0d51ac4d-cc5a-4fd9-b15b-deee1d9ffb74"
      unitRef="usd">112000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy05LTEtMS03MzI1Mw_97b56fd3-7f4e-42ba-b83e-2e5267ecc0be"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfMy0xMS0xLTEtNzMyNTM_671f4df8-a67d-4a87-859e-ca84e423df81"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC01LTEtMS03MzI1Mw_c7e579ce-a731-45b7-821b-14318b84178b"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC03LTEtMS03MzI1Mw_5ad2697c-86f1-4d42-9ce3-85e0c4a77b4e"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC05LTEtMS03MzI1Mw_afbe2674-a3cf-4625-ae85-c20dff5f616e"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNC0xMS0xLTEtNzMyNTM_e70d36eb-a7a4-4b49-b853-38bc644b8f0f"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS01LTEtMS03MzI1Mw_2fcf2d22-9d64-4cc2-8281-d38e9e8b987e"
      unitRef="usd">180000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS03LTEtMS03MzI1Mw_e0c3c265-1736-4ae4-bf59-d05b0658672a"
      unitRef="usd">166000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS05LTEtMS03MzI1Mw_caafee07-dbd1-41cd-9da1-781266df324c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNS0xMS0xLTEtNzMyNTM_043cdd3a-76b0-4390-a35a-aec8d8795b79"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi01LTEtMS03MzI1Mw_d07abbcd-738d-4ed6-b400-345e7a982614"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi03LTEtMS03MzI1Mw_5868af74-f1ca-48b9-9f3d-e2fa478c0796"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi05LTEtMS03MzI1Mw_4663028c-2c6b-4ecc-a7eb-7991a7c1d27a"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNi0xMS0xLTEtNzMyNTM_2bea99c9-92fa-40a1-80ad-30d6361b6993"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy01LTEtMS03MzI1Mw_342d4792-b1f1-4dbd-a881-a75475c86b6d"
      unitRef="usd">-57000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy03LTEtMS03MzI1Mw_c3665630-32e5-45b0-b7c4-7c9484eab28b"
      unitRef="usd">-70000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy05LTEtMS03MzI1Mw_3e8f75c8-4cf7-4175-8c23-da7997a30086"
      unitRef="usd">-7000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfNy0xMS0xLTEtNzMyNTM_b3b361d6-a2b6-404a-909b-5bea4958777e"
      unitRef="usd">-8000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC01LTEtMS03MzI1Mw_07c564b2-7ddc-44b8-92c4-825f960211b0"
      unitRef="usd">68000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia3cf0076169046e2a8a90c274b32e1a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC03LTEtMS03MzI1Mw_9e68bcf6-f68d-4a67-a76c-c1106de49f54"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id8f119ab76784686b6ca0d67fd748f1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC05LTEtMS03MzI1Mw_f658938d-68ec-4d89-996a-138a1197afbc"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i336829d47f964430a3f3ec676b1093ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183Ni9mcmFnOjMwZjllZjI5NzBkYzQ5NzU4OTY2YzQzZGUzNTk3NzlmL3RhYmxlOmJlOTk0Mzk2NWM2NTRmYTk4YTA2MjRkZGI2YWM5NzNjL3RhYmxlcmFuZ2U6YmU5OTQzOTY1YzY1NGZhOThhMDYyNGRkYjZhYzk3M2NfOC0xMS0xLTEtNzMyNTM_29570d0a-0a66-4254-a97d-fc4de62ab605"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwMQ_647a1771-735b-4506-b0a5-95143bbe25de">EquityStock-Based Compensation&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, primarily in connection with the company's annual grant, AbbVie granted 0.9&#160;million stock options with a weighted-average grant-date fair value of $22.83. As of March 31, 2022, $15 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RSUs and Performance Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, primarily in connection with the company's annual grant, AbbVie granted 5.6&#160;million RSUs and performance shares with a weighted-average grant-date fair value of $145.54. As of March 31, 2022, $955&#160;million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quarterly cash dividends declared during 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/17/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/16/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/29/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/15/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/10/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/15/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/17/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/16/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/18/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/14/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie repurchased 8&#160;million shares for $1.1&#160;billion during the three months ended March 31, 2022 and 5&#160;million shares for $550&#160;million during the three months ended March 31, 2021. AbbVie's remaining stock repurchase authorization was approximately $1.4&#160;billion as of March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss for the three months ended March 31, 2022 included foreign currency translation adjustments totaling a loss of $231 million and the offsetting impact of net investment hedging activities totaling a gain of $130 million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#x2019;s Euro-denominated assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;br/&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss for the three months ended March 31, 2021 included foreign currency translation adjustments totaling a loss of $677 million and the offsetting impact of net investment hedging activities totaling a gain of $374&#160;million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#x2019;s Euro-denominated assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the impact on AbbVie&#x2019;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions) (brackets&#160;denote&#160;gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension and post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial losses and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses (gains) on foreign currency forward exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on treasury rate lock agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on interest rate swap contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&#160;Amounts are included in interest expense, net (see Note 8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) Amounts are included in cost of products sold (see Note 8).&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2NA_a4a4e6a0-1a26-45a7-b9ca-c51c1678f893">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79841cf14ea346c48bdbc856f1e4b860_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMi02LTEtMS03MzI1Mw_ccc8a0d7-a255-46c0-8c21-d5db2870edb9"
      unitRef="usd">19000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia88ba3758b6c416da9c9db84a7ca5778_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMi04LTEtMS03MzI1Mw_ba1cba0d-4db2-4283-b027-b53e699209af"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26f9a43336ae4b0da381254b468ae09c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMy02LTEtMS03MzI1Mw_9610329e-e7c6-4798-ac02-a7cf98b279bc"
      unitRef="usd">107000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7badfe6657634d348d22e9be1faa35ea_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfMy04LTEtMS03MzI1Mw_4fd7e9ba-9f06-4efd-8570-14b16a0e1486"
      unitRef="usd">87000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54988d2c4f2f40c2933727e2b8be27ff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNC02LTEtMS03MzI1Mw_3f68270d-d044-4237-ad67-9bdf82e3a6ab"
      unitRef="usd">180000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3001aef538c54c44b5812a99e4845adc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNC04LTEtMS03MzI1Mw_6a259d62-9ef1-4062-b2b4-18fa1d446484"
      unitRef="usd">162000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNS02LTEtMS03MzI1Mw_4bc27963-ae21-4d83-8e86-bc3433f1ba29"
      unitRef="usd">306000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNS04LTEtMS03MzI1Mw_caeb63a6-cd2f-467b-874d-cd9fac28b578"
      unitRef="usd">269000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNi02LTEtMS03MzI1Mw_566a1e70-5b8f-4390-b16c-dce120b72695"
      unitRef="usd">56000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNi04LTEtMS03MzI1Mw_7f959620-ef5d-404f-8384-9131c6b1871c"
      unitRef="usd">48000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNy02LTEtMS03MzI1Mw_d1151ec7-62c5-4366-b468-5d2de4e9488a"
      unitRef="usd">250000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjI2YWRhNTY0NjUzMTRhZGQ5MGY2MGEyZDBiOTUwMDNjL3RhYmxlcmFuZ2U6MjZhZGE1NjQ2NTMxNGFkZDkwZjYwYTJkMGI5NTAwM2NfNy04LTEtMS03MzI1Mw_7cce9d1b-6a90-4c2a-9b9a-bcceccdf42a2"
      unitRef="usd">221000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfNjM5_6cfa84db-b077-4a76-8c35-be6a353a7a19"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfNzA1_a2be6f5d-6ea0-401b-aec1-8630750af893"
      unitRef="usdPerShare">22.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="icbf3ce65514c443c8ef37159d35d4a69_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfNzE5_edcb99ef-15e6-4953-8a25-7705b333973d"
      unitRef="usd">15000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfODQ5_0c6c36dc-7142-4841-8116-fd5a2deb3a98">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5e56837ed6bd423c89d802b44906df17_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfOTY4_661e766a-c6fa-4471-8ad1-b29ece80f8c5"
      unitRef="shares">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic438b74601344b28a5a621e09638dfa5_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTA0OA_552814b6-7048-48c5-a599-f21a0017f810"
      unitRef="usdPerShare">145.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ic438b74601344b28a5a621e09638dfa5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTA2Mg_f51142f9-bd0c-490f-b39e-73842ea982b2"
      unitRef="usd">955000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5e56837ed6bd423c89d802b44906df17_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTIwNg_4b07e495-1675-49f4-bc7b-f808ec978f71">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfDividendsPayableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk3Nw_a29c418f-3295-451c-80f6-28f821617c97">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quarterly cash dividends declared during 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/17/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/16/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/29/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/15/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/10/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/15/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/17/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/16/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/18/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/14/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDividendsPayableTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4bcd77a684aa4ecf8e6a62f0794f8418_D20220217-20220217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfMi00LTEtMS03MzI1Mw_4f25a377-5652-41bc-b521-14c47d6f1df9"
      unitRef="usdPerShare">1.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5e438a1448d44f418e9b8f452ccf2783_D20211029-20211029"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfMi0xMC0xLTEtNzMyNTM_b7f3d94c-d607-427b-a2d2-dce7341ade81"
      unitRef="usdPerShare">1.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2670f469a2ac4a459ccecfc909f364ee_D20210910-20210910"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfMy0xMC0xLTEtNzMyNTM_a8f02438-c7e2-467d-ab5c-412ecffb35a9"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i72db19201e77427a944de55507b7fe80_D20210617-20210617"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfNC0xMC0xLTEtNzMyNTM_9ca16ffc-57cc-49bd-9836-56032288399d"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i300fb3fc7b084fe1ae13da9f57c82d71_D20210218-20210218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjYxYWM2YTAwZTZhMzRhMWE5MGNlM2NlZWQ2YzFmYjM5L3RhYmxlcmFuZ2U6NjFhYzZhMDBlNmEzNGExYTkwY2UzY2VlZDZjMWZiMzlfNS0xMC0xLTEtNzMyNTM_00b22f3e-6b11-46ad-a647-6b77aee89359"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib694cd894894414da5c46138d815dd90_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTczNQ_179d288c-4c4b-4176-8afd-d7c1676d3c39"
      unitRef="shares">8000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib694cd894894414da5c46138d815dd90_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTc0OQ_ace58bd0-32f9-4b38-9b4a-feb688038a57"
      unitRef="usd">1100000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6bcc50f777fb4122a035380de5a8418a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTc3MA_472345c8-7d01-49d7-9aff-40e3e35ceb0e"
      unitRef="shares">5000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6bcc50f777fb4122a035380de5a8418a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTc4NA_c73e7f8e-8391-46a6-aed4-3648918de159"
      unitRef="usd">550000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMTg3MA_114f1288-7ee2-4d45-8e0e-35269d11d62a"
      unitRef="usd">1400000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2MQ_21423e4f-a9b1-4c84-bfca-b2a59f1c6fb0">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;br/&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30d113b6de524e999e45640992e7d5f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS0xLTEtMS03MzI1Mw_77f70682-aa47-4061-b81c-c1e5cc33936d"
      unitRef="usd">-570000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic307ce6fcfdb4b95a357b18194e6695a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS0zLTEtMS03MzI1Mw_ed9efadd-0b70-4c28-a654-3ba3fdffec44"
      unitRef="usd">-91000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied4482ed129142548aa3b7aba9e6e05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS01LTEtMS03MzI1Mw_87a60b0f-b93c-46cf-b77a-d210f3b60ade"
      unitRef="usd">-2546000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b80412b07c14765b60765c6863daf16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS05LTEtMS03MzI1Mw_fd66df94-3e37-4172-870b-7d694403bb60"
      unitRef="usd">308000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i305d5315aa3249959cf54167f51117a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMS0xMS0xLTEtNzMyNTM_3a7f76fd-01d7-4286-bce0-85eaa3e36fb7"
      unitRef="usd">-2899000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi0xLTEtMS03MzI1Mw_f8b1b970-28c1-417a-a13c-accc19b34ed4"
      unitRef="usd">-231000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi0zLTEtMS03MzI1Mw_0c196775-8afa-4e06-abd0-8ac9707cf0a9"
      unitRef="usd">142000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi01LTEtMS03MzI1Mw_4a1d6403-b50c-424e-a577-1329c647cf59"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi05LTEtMS03MzI1Mw_69274530-2b25-41b5-97d3-90492c5cfa64"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMi0xMS0xLTEtNzMyNTM_f3bb716e-6c7d-4a47-a30b-e74377f40787"
      unitRef="usd">-105000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy0xLTEtMS03MzI1Mw_1298a307-bcbc-447e-837b-437f76c494b4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy0zLTEtMS03MzI1Mw_f48164ac-7cd6-43fb-a521-ccce6d9a8f91"
      unitRef="usd">12000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy01LTEtMS03MzI1Mw_8b74cff2-1213-4912-a7bf-6b146f8edcb1"
      unitRef="usd">-43000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy05LTEtMS03MzI1Mw_dff79d81-9f2f-4fa0-8852-ca8568d86d3d"
      unitRef="usd">11000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfMy0xMS0xLTEtNzMyNTM_0d3dccb7-f5f7-44a2-b76a-5495135363eb"
      unitRef="usd">-20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC0xLTEtMS03MzI1Mw_298f64df-bbe7-4d83-94c3-58d32b8d3753"
      unitRef="usd">-231000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC0zLTEtMS03MzI1Mw_c5a2f653-636f-4547-9735-558b206f4855"
      unitRef="usd">130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC01LTEtMS03MzI1Mw_36f93c7f-07c3-4763-a333-e296a396fef9"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i222f710050af4ecca660d0fd445ff9ef_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC05LTEtMS03MzI1Mw_9347fb8c-cdfe-4372-aec8-e495ca7ef79c"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if6c2e6b413dd4c95ae4cc6fd40f6a699_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNC0xMS0xLTEtNzMyNTM_59ef415f-bb77-4dde-aec0-3ce5e3ee7249"
      unitRef="usd">-85000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38cbefbb7640470d8912c518f4d612c4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS0xLTEtMS03MzI1Mw_a2a27db3-fbc3-462c-a009-15a092e1779a"
      unitRef="usd">-801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d0749feb42e4416b8b7650f417a1131_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS0zLTEtMS03MzI1Mw_403a9201-0f5c-4205-aaec-a91ada04e201"
      unitRef="usd">39000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a8127b3ac3548c3890da55bf63f1701_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS01LTEtMS03MzI1Mw_b8a6180b-1cd5-4b51-a6f7-95aa62fc8592"
      unitRef="usd">-2518000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice36e374d1fe41cd885017f660510ca7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS05LTEtMS03MzI1Mw_92804cbc-58b0-4c67-a080-522492b6e035"
      unitRef="usd">296000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00bc0c90f91f4af0a5a3a88ab5477eaa_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOmZkZjc0Mzg2OGM4ZTQ5MjVhZjM0OWFiODhkNjEyMzY1L3RhYmxlcmFuZ2U6ZmRmNzQzODY4YzhlNDkyNWFmMzQ5YWI4OGQ2MTIzNjVfNS0xMS0xLTEtNzMyNTM_67f164da-e354-4460-bc13-a1dbc7015a90"
      unitRef="usd">-2984000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7ef7519873594295b569d2ed9d013d3b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjA2MQ_96e17760-55c4-44a9-8b63-0e567a6341da"
      unitRef="usd">-231000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5c66dc788a1430581c272b0c716b06a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjE0NA_20b09ab5-2c30-4c26-9dc1-3c6796bbc789"
      unitRef="usd">130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idba4be4766064887868cd838db3129a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS0xLTEtMS03MzI1Mw_fe7eb643-5c2e-48ff-b0d7-910749fc9116"
      unitRef="usd">583000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13ba96e9d518432f846efbdefd0568c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS0zLTEtMS03MzI1Mw_3b9c3c4c-629d-480e-a9bc-cb6e7730c1a9"
      unitRef="usd">-790000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfa61ba6e74c4671b7c09c21de67bea5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS01LTEtMS03MzI1Mw_8b1d9b67-75fc-4706-ac89-05607b6fe060"
      unitRef="usd">-3067000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85f7baaa43f94988beb4cab455519ed9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS05LTEtMS03MzI1Mw_9e210a6b-a8d7-4be0-bc23-ed4c54775cc6"
      unitRef="usd">157000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ef17bd343cf45f4a0064de2b7b25559_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMS0xMS0xLTEtNzMyNTM_a8bb977e-b28c-4f5b-bd9a-89e070581d08"
      unitRef="usd">-3117000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi0xLTEtMS03MzI1Mw_5091bf29-43bd-431d-a704-7fb9db81eccd"
      unitRef="usd">-677000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi0zLTEtMS03MzI1Mw_5ecb2c41-ded5-47c1-9456-044ed82eed49"
      unitRef="usd">377000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi01LTEtMS03MzI1Mw_720bf9b4-2c7c-4781-a199-6f2a90a3017d"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi05LTEtMS03MzI1Mw_171d1ad6-70f3-410b-a34f-f64b2ae56119"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMi0xMS0xLTEtNzMyNTM_f855eef1-8a36-4cf1-80be-dcabedf16dd4"
      unitRef="usd">-241000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy0xLTEtMS03MzI1Mw_61d391f1-9d0c-4152-97d2-7f8b158571d4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy0zLTEtMS03MzI1Mw_c55f480c-7b37-493b-bbd0-d437c39d8f64"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy01LTEtMS03MzI1Mw_235ef38a-f6ab-43fc-a4c1-c2fe8af5ebb3"
      unitRef="usd">-55000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy05LTEtMS03MzI1Mw_a2b03e6b-bf89-4c9e-b4b4-d852b838f644"
      unitRef="usd">-11000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfMy0xMS0xLTEtNzMyNTM_0e1bda45-a5a4-42c8-9cbb-929eefa3a23e"
      unitRef="usd">-63000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC0xLTEtMS03MzI1Mw_e14401c9-dfa9-476c-add1-c1dc16d322af"
      unitRef="usd">-677000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC0zLTEtMS03MzI1Mw_769e6d0e-35c3-4ef5-b0df-64cf7115895c"
      unitRef="usd">374000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC01LTEtMS03MzI1Mw_24867c57-01fa-4dbe-883f-fc6689a9ebf3"
      unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iacecdda3bbc54ee1b9906ba01da77d2e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC05LTEtMS03MzI1Mw_447e3161-da5c-40fa-9de3-8e0cbc174251"
      unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia0d08aebc5e649d9a475213ebb8a10ef_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNC0xMS0xLTEtNzMyNTM_eaf61c04-c54d-4a68-9187-d327530dadb2"
      unitRef="usd">-178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32fccc997a0749b1bb81108be62eb6e8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS0xLTEtMS03MzI1Mw_f0c16c0e-7b6e-4610-949b-0f71ce370d2e"
      unitRef="usd">-94000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i157ad54cc34c4b9e9f5f62ce15e5c956_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS0zLTEtMS03MzI1Mw_3a67128c-4e2c-48c8-81f2-2c6e5d5f69f3"
      unitRef="usd">-416000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcc473aa8ebe448e985aa0a29dcd7e8c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS01LTEtMS03MzI1Mw_5120133a-9fb5-43e1-9cbc-40d924229cf5"
      unitRef="usd">-2988000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ce7636b82d0488790d551ca1286a964_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS05LTEtMS03MzI1Mw_97434751-500e-4eec-939f-7edc8464e0d7"
      unitRef="usd">203000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe0c4dc2984f481b92d6852e941b91b9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjM4YTZkNTA4OWI5NzQ0N2ZhOWE1M2U1YzViMzdmNzRkL3RhYmxlcmFuZ2U6MzhhNmQ1MDg5Yjk3NDQ3ZmE5YTUzZTVjNWIzN2Y3NGRfNS0xMS0xLTEtNzMyNTM_a663df18-efbd-4f3f-973a-ce8748b0af62"
      unitRef="usd">-3295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4fde8fe6a5d44d7083e9b20d383298c0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjQ1Mw_414d4f41-8327-43fc-bdef-4a32becbc3fc"
      unitRef="usd">-677000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f16ffe755c541c08daeb711d76a9eed_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjUzNg_a7a98ad9-a4a8-4ce8-bb67-aa673c880201"
      unitRef="usd">374000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2OQ_f08f215e-185f-43d3-935f-b5ad69422b48">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the impact on AbbVie&#x2019;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions) (brackets&#160;denote&#160;gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension and post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial losses and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses (gains) on foreign currency forward exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on treasury rate lock agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on interest rate swap contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&#160;Amounts are included in interest expense, net (see Note 8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) Amounts are included in cost of products sold (see Note 8).&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy01LTEtMS03MzI1Mw_dcbb1f13-4991-4b76-b758-f7b88b8d660e"
      unitRef="usd">14000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy03LTEtMS03MzI1Mw_a9d9e243-873f-4eef-b19e-5939933a8100"
      unitRef="usd">4000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNC01LTEtMS03MzI1Mw_5f0e1514-67fc-4d20-8b08-68e5c6f4d4f1"
      unitRef="usd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNC03LTEtMS03MzI1Mw_77ebe8da-9685-4ffa-8526-61d7c89d48b8"
      unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i28e53bf29aba4d48b3d569bcdcfec9ec_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNS01LTEtMS03MzI1Mw_ec404f7b-1deb-4c78-884b-51df5958ad4e"
      unitRef="usd">12000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i156ab7fa7ed04946b0d67a6660158361_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNS03LTEtMS03MzI1Mw_7044b95b-6116-4e47-a277-d51285f3fb47"
      unitRef="usd">3000000</us-gaap:NetIncomeLoss>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy01LTEtMS03MzI1Mw_5de29469-8128-4032-a9fe-d194d6935866"
      unitRef="usd">-55000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy03LTEtMS03MzI1Mw_e0b01168-ad34-434d-9854-14c860bb3278"
      unitRef="usd">-69000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOC01LTEtMS03MzI1Mw_112200b5-9640-4d81-9fee-7db12d22b8a8"
      unitRef="usd">-12000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOC03LTEtMS03MzI1Mw_8f879815-e499-4e80-ade5-9e40fe45bc45"
      unitRef="usd">-14000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i19158d14e728497cbede5b260b0904be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOS01LTEtMS03MzI1Mw_9dd51b1c-5977-4e4e-8c01-6970958c10cf"
      unitRef="usd">-43000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iab1455b44d7b4ad7ae2afb21e3bdb861_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfOS03LTEtMS03MzI1Mw_d6e3f0b4-65bf-4b59-ba85-79044bab00a6"
      unitRef="usd">-55000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i115d67da01e8464594d5f3097915285d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNS0xLTEtNzMyNTM_c3509005-a607-426a-a140-90bfa6a40cdb"
      unitRef="usd">-8000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7d2a39cd4e914c2baf4e3f7f78e0e037_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNy0xLTEtNzMyNTM_da5e13a0-ba04-43e2-9ccc-697be415ecf8"
      unitRef="usd">12000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia93484cb8e084701be386a098217dd41_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNS0xLTEtNzMyNTM_5e757465-320d-4d59-890d-c8493a2521aa"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="iac58012cb8394749b3da275880c656bf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNy0xLTEtNzMyNTM_d33aba04-37d9-4799-8851-d1a29a61115b"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5f8aa0c8a5684d66952c25dc6e509fe7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNS0xLTEtNzMyNTM_f5d8bf1d-c1fd-4481-bde9-f036b794d7e1"
      unitRef="usd">-2000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if5ce39b3335d40a193f5da7859d3e742_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNy0xLTEtNzMyNTM_9dfa7b53-a718-428a-84f0-a2b6048d47ca"
      unitRef="usd">-7000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18c8e4e34cdc418dadb3f7f36b8d5041_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTQtNS0xLTEtNzMyNTM_d872b70e-3b25-442d-9a78-73c7d69c6ba0"
      unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie2761b85b027474db273e8bb0d34f65a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTQtNy0xLTEtNzMyNTM_5319d78c-a45b-46c7-b368-9e3013b38f0a"
      unitRef="usd">-2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i18c8e4e34cdc418dadb3f7f36b8d5041_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTUtNS0xLTEtNzMyNTM_ddf6dd7e-9a94-469b-b583-bf68b1b57af7"
      unitRef="usd">11000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie2761b85b027474db273e8bb0d34f65a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTUtNy0xLTEtNzMyNTM_b0b11797-29bf-4771-bf25-60dd8128fc4f"
      unitRef="usd">-11000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfODc2_3cffd7dd-37dd-4a84-81ee-af324be0a3e4">Income Taxes The effective tax rate was 9% for the three months ended March 31, 2022 compared to 8% for the three months ended March 31, 2021. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The increase in the effective tax rate for the three months ended March 31, 2022 over the prior year was primarily due to differences in the company&#x2019;s jurisdictional mix of earnings.Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company&#x2019;s gross unrecognized tax benefits balance may change within the next 12 months by up to $244&#160;million.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMzg_95480677-3953-4786-aa98-e1c16c06b125"
      unitRef="number">0.09</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMzg_a5d928bc-8853-4106-a13d-3adbe2389638"
      unitRef="number">0.09</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfNjQ_40a93071-68a4-4386-9aa8-1a8d760378c3"
      unitRef="number">0.08</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfNjQ_980de54f-ec99-47f6-ba90-1fb0e3b4ece4"
      unitRef="number">0.08</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMTYy_342774af-a098-4993-a192-a5e468b13e30"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfMTYy_9d4d592b-3622-4fbb-a18d-cdc5cfadda06"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184OC9mcmFnOmE2MWIyMDgyNjQ5MjQ5ZmU5NGEzNDljMzJhYzEyODA4L3RleHRyZWdpb246YTYxYjIwODI2NDkyNDlmZTk0YTM0OWMzMmFjMTI4MDhfODcz_24d67e30-c249-4f72-827e-f53b4c88b925"
      unitRef="usd">244000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMTU5MDQ_4c0ad276-1c33-4e3a-a63b-75138bffbe09">Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management&#x2019;s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie&#x2019;s consolidated financial position, results of operations or cash flows.Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Niaspan Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MDL No.&#160;2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney&#x2019;s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys&#x2019; fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott&#x2019;s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie&#x2019;s settlements with biosimilar manufacturers and AbbVie&#x2019;s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Humira (Adalimumab) Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices, and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#x2019; fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Namenda Indirect Purchaser Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States District Court for the Southern District of New York.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan&#x2019;s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#x2019; fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#x2019; fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Bystolic Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States District Court for the Southern District of New York.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,146 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 257 matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In March 2022, Allergan reached settlements with the States of Florida and Rhode Island and their political subdivisions. Allergan previously reached settlements with other plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the New Mexico Attorney General filed a lawsuit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico&#x2019;s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder and Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. One of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, a federal securities lawsuit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Holwill v. AbbVie Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Allergan plc Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The plaintiffs generally seek compensatory damages and attorneys&#x2019; fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability and General Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, a qui tam lawsuit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Silbersher v. Allergan Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District Court for the Northern District of Illinois against Alvotech hf. AbbVie alleges defendant&#x2019;s proposed biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court denied Defendant&#x2019;s motion to dismiss on jurisdictional grounds in the first case; a motion in the second case remains pending. The court has set a trial on a subset of patents for August 2022. The court order provides that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed. In March 2022, the parties settled the case and it was dismissed without prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.&lt;/span&gt;&lt;/div&gt;Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.</us-gaap:LegalMattersAndContingenciesTextBlock>
    <abbv:LossContingencyIndividualPlaintiffLawsuitsNumber
      contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjAzMw_5787628e-6f07-4264-aa30-ad6b14497e72"
      unitRef="lawsuit">4</abbv:LossContingencyIndividualPlaintiffLawsuitsNumber>
    <abbv:LossContingencyPurportedClassActionsNumber
      contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjA3MA_45995349-1a0a-47ca-8a77-5d7f5df40e8c"
      unitRef="class_action">2</abbv:LossContingencyPurportedClassActionsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjExMQ_33823b0e-1fc4-4c5c-a470-3d12bd22c315"
      unitRef="direct_purchaser">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="idfd179fad6a84747bceee1f796370db1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfMjE1NQ_f45633de-1c5d-4a3f-8084-0ef38c826c91"
      unitRef="end_payor_purchaser">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
      contextRef="ie9849c3641274f60b03fcb8763315cdc_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfNDY2NQ_aa25e41b-bf53-4a5a-a31b-8dc09404aab6"
      unitRef="company">3</abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws>
    <abbv:PutativeClassActionLawsuitIndividualNumber
      contextRef="i2876ad381a314d1492fed65c7ba60831_D20190301-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfNTMyOA_458b4390-3a4a-4239-a538-cf697171a444"
      unitRef="company">12</abbv:PutativeClassActionLawsuitIndividualNumber>
    <abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
      contextRef="i061f6899a2e64d8b9f6710d2ffdaa440_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfNzQ2Mg_4ba8e633-fc58-4bcc-8ee8-5bfffb5d90cc"
      unitRef="company">6</abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1b950ca2895a442093c6358346b89e00_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfODExNQ_3c84c455-296a-473b-8bf5-dee1996e950f"
      unitRef="claim">3146</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0d6b8a8607154239bab327083f4f2a16_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfODM4OQ_51a4d9ca-a094-49b5-ba2c-ed7909e16509"
      unitRef="claim">257</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5c041511930545c890fb52c2cac408df_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfOTIxMg_4b9a294a-6bd8-4bec-bd5e-925e4d42bbbf"
      unitRef="investment_fund">5</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="id8b1a9f1c7674ab7b5a46fc570730aa0_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfOTYzNA_d11b56cf-06d2-463c-b4f6-23ef529e8f4c"
      unitRef="investment_fund">3</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="ie49c8cbd1c924c69b51d6bd1f5088886_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185NC9mcmFnOjFhYjlkNGQwNzA2ODQwMWZiODdhNzE3NWE3NGE5ZDBkL3RleHRyZWdpb246MWFiOWQ0ZDA3MDY4NDAxZmI4N2E3MTc1YTc0YTlkMGRfOTc2MA_80e278f6-e0da-4ec5-bd0f-3f6921e4c321"
      unitRef="investment_fund">1</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RleHRyZWdpb246YWRmOWQwNjFjMDQxNDdhMmE4Y2FhYTcxYzA4NDk4YzFfMTIyNQ_a01029c1-acb2-4324-80fb-b0d9f3987bc5">Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details AbbVie&#x2019;s worldwide net revenues:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Humira&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Skyrizi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rinvoq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Hematologic Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Venclexta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Cosmetic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Juvederm Collection&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Therapeutic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vraylar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duodopa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ubrelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Qulipta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lumigan/Ganfort&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alphagan/Combigan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Key Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mavyret&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Creon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Linzess/Constella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RleHRyZWdpb246YWRmOWQwNjFjMDQxNDdhMmE4Y2FhYTcxYzA4NDk4YzFfMTIzMw_32c51bec-a861-4071-b236-e1875aa43e34">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details AbbVie&#x2019;s worldwide net revenues:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Humira&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Skyrizi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rinvoq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Hematologic Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Venclexta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Cosmetic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Juvederm Collection&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Therapeutic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vraylar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duodopa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ubrelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Qulipta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lumigan/Ganfort&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alphagan/Combigan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Key Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mavyret&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Creon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Linzess/Constella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3d814e2470641b7adca70c8dfd22826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNC02LTEtMS03MzI1Mw_36c3bfe8-9650-4555-9459-63295132e331"
      unitRef="usd">3993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7d8cd18e85b4007971cea988abe2864_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNC04LTEtMS03MzI1Mw_929fc5c8-0534-4b8b-938e-bdd8245084e9"
      unitRef="usd">3907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86efe50966f24c74849d1de4249000b9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNS02LTEtMS03MzI1Mw_2a24f481-424e-47e5-9c1b-e3ca9cea3416"
      unitRef="usd">743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf1053eda3554c3bb53ea7f9f667809a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNS04LTEtMS03MzI1Mw_85cb3600-69f7-4b65-9e45-70a17d0c09d7"
      unitRef="usd">960000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d8620bf3edb45e497398d57317e67ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNi02LTEtMS03MzI1Mw_54002b94-0bd4-4aeb-9b69-56bcf8c8c78f"
      unitRef="usd">4736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i151f76a6bb394b0e8dc33fbdabffeef4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNi04LTEtMS03MzI1Mw_2641a9b0-3ef3-4582-9bae-12c3a244bd2b"
      unitRef="usd">4867000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9dcf0e2a5bc4237a3420a8ed35591ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNy02LTEtMS03MzI1Mw_162044ff-fbc3-4ad8-b7f6-a72ff98ab7ab"
      unitRef="usd">781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a121fb3a1a74d08bb6b193989e4706a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNy04LTEtMS03MzI1Mw_ddf85b60-4824-4dfb-be36-190594c6950e"
      unitRef="usd">481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief7e3bfd63234b9987cf846478a441fd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOC02LTEtMS03MzI1Mw_6499a3b2-7c7c-4ece-8fc6-d9e76d451169"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8267ed584474c71a1ee8dbc54f58ef8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOC04LTEtMS03MzI1Mw_518c16b0-8dd8-4197-a15c-326ac85ac06c"
      unitRef="usd">93000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f415caa04a941a3b6c40335ad6d10f0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOS02LTEtMS03MzI1Mw_03042188-9aeb-4ba4-bc81-1b45d1cf0ea2"
      unitRef="usd">940000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f1c4e6bb026457da1f4cdf7df42c5f6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfOS04LTEtMS03MzI1Mw_5aa32436-4793-4e6b-8872-70789931b376"
      unitRef="usd">574000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia38c669542ad4085a09a271f057f90d9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTAtNi0xLTEtNzMyNTM_c4d69af5-a829-45a7-9540-b27d486d3df4"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0dfe507ba24433988668a7d003a378c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTAtOC0xLTEtNzMyNTM_f27b2299-fe4b-4669-ac44-b44a59de50bf"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia89a047a7f15451fae62f0586e4244bb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTEtNi0xLTEtNzMyNTM_e13db72e-fb4c-4316-b7a8-a4afbbabbf72"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa4d1ef4d3c3472f8587646493588ca3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTEtOC0xLTEtNzMyNTM_639016e5-e8f9-4c7b-885b-092f8deeeb6d"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06547d54c7744ec59245e1aabe7bb4a9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTItNi0xLTEtNzMyNTM_405092bf-3acd-4a29-ad37-567816952ead"
      unitRef="usd">465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68fecb4ba92b444e8e7c4082e3cacd88_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTItOC0xLTEtNzMyNTM_1da59748-41ab-49d1-b504-3de25de1a323"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63c7fad38a034510aef4faf293e98042_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTQtNi0xLTEtNzMyNTM_ee3ab9a4-ad1c-4adc-992a-83b79bd7611d"
      unitRef="usd">874000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2609235fb4a14a5fa8a9ae2ce41de85d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTQtOC0xLTEtNzMyNTM_6b42358a-937a-498b-9a59-fc2c81ec2c1b"
      unitRef="usd">999000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i83dd8a4923b14d1e9444794bdc3c9fa3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTUtNi0xLTEtNzMyNTM_066cbcc0-a381-4005-99e6-9245e4d8a1ad"
      unitRef="usd">299000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i839ac535845b43fe8878c6e026ae540d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTUtOC0xLTEtNzMyNTM_5a601b29-a36d-4b4f-9ebd-27ebc94578fd"
      unitRef="usd">269000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia88dc4f478b445c989df2931bf4129de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTYtNi0xLTEtNzMyNTM_0025c39e-a490-4bde-a247-823399e5217d"
      unitRef="usd">1173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8b31104dd4f4b588d5964c0a59fc7d9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTYtOC0xLTEtNzMyNTM_8bf4e65c-57ef-47f6-b085-265597b287be"
      unitRef="usd">1268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa0a5001dda54d03b17d99d99907ef72_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTctNi0xLTEtNzMyNTM_7bc08d4b-265a-45ec-999a-5880b7d81bc9"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc2f01f0a3bc4965baed776f9c1ee2ee_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTctOC0xLTEtNzMyNTM_60fce076-6160-4caf-87cc-e0583981aac1"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fd7e7447fe34c6287942f568429ef69_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTgtNi0xLTEtNzMyNTM_32389218-f067-4d6e-a580-742b7701a81a"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffd103eaea8d4b81b307a47031308a2b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTgtOC0xLTEtNzMyNTM_6b3d5f2e-fb4b-4d4b-b2b6-bf0adce3fbeb"
      unitRef="usd">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia21887679ab4450e9854e11b52987fd2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTktNi0xLTEtNzMyNTM_e7070f5d-8298-426c-9d71-7210a2f9e5fe"
      unitRef="usd">473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ca3b9d904a042d1be012441bfbfbbbc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMTktOC0xLTEtNzMyNTM_8dcef4d7-85d6-46b0-8db0-3b79fae3a350"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i646b3499eac046a9a4d0c7b552528647_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjEtNi0xLTEtNzMyNTM_73866265-4668-400d-a67d-f7f3f75076e2"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d51184fb925493e90b9ff271b8ba444_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjEtOC0xLTEtNzMyNTM_1ebd005b-4dfe-469b-b721-7756e7b20115"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cf374b782644e749678d1f567eb3bc1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjItNi0xLTEtNzMyNTM_c264426a-4684-4437-8182-33f8b7d452dd"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i231632e602304cbcbf663af9260ff447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjItOC0xLTEtNzMyNTM_442eaa2a-5bc1-4dfc-89fe-02ca33986c62"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d97cd1c204d47a0894f071baccfb3dc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjMtNi0xLTEtNzMyNTM_62291a29-fb33-4ea7-9dd3-9a1782f9abc2"
      unitRef="usd">641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i485c4f314f4d4d4887041a01bca64c2b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjMtOC0xLTEtNzMyNTM_fb739af8-6bba-45c1-8b11-01922c4a9043"
      unitRef="usd">477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia81395f4f3fa48e8826d79041d865c17_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjQtNi0xLTEtNzMyNTM_14e65d96-5742-4a2e-9353-b4dc242e06fc"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5523e96c483e4a5a83a81a78cfdec571_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjQtOC0xLTEtNzMyNTM_35fd73b2-36b4-4489-927b-418983fb98ba"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2bf9f5d90ff4778afcba822173f993c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjUtNi0xLTEtNzMyNTM_2d73675f-a4dc-4226-92b4-c014f5b1900f"
      unitRef="usd">262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8ccf536e0504054b9c01fbb9c17051f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjUtOC0xLTEtNzMyNTM_2529bfca-3120-4f0e-8b45-d5f9b3f0c389"
      unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68379647466f42ac98da932e0ae7ba56_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjYtNi0xLTEtNzMyNTM_ac4d593e-86fa-43a0-824d-f1199478a40b"
      unitRef="usd">410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b9a74c5d27b427db7df5b72e0ef9e71_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjYtOC0xLTEtNzMyNTM_78ed5b47-b125-4b62-9a16-7f43e4acb843"
      unitRef="usd">321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9886797304fd44789c0dae1792702122_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjctNi0xLTEtNzMyNTM_ab5f4c59-9bf0-4231-9769-bf405f746840"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1192611baa7144ae9f6aa9bd6469b73f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjctOC0xLTEtNzMyNTM_d1918ce4-e532-4150-b5d2-77cb324c8e5e"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f45042ba49947aea027157aa3e5005e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjgtNi0xLTEtNzMyNTM_b7b6576c-986f-4b54-a6da-7f46e2c52930"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6297715bc8540428f641904958468e5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjgtOC0xLTEtNzMyNTM_5b3719aa-af83-4077-bb5e-beb520b9439c"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i274365a0958a49bb88080cb48c332ccd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjktNi0xLTEtNzMyNTM_5041ce48-e13f-47ff-90fa-c05b5c89533c"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aeec465d3b44d6d836a7f5d22f41e34_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMjktOC0xLTEtNzMyNTM_d9223227-4083-4a32-9f50-44d714b8568d"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic117a05f0ad047458c3dfdf3d563d985_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzEtNi0xLTEtNzMyNTM_a14980a4-664b-4ea1-a6f0-365e6cae2a01"
      unitRef="usd">500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0aa0c6e5e8e4e86be8c148b66aedbb6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzEtOC0xLTEtNzMyNTM_627bf828-6065-419e-8192-900c0845bbd6"
      unitRef="usd">429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0f1b5410e4a4e8fb9abfa2219b13d78_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzItNi0xLTEtNzMyNTM_04926e6a-3715-4def-95f4-9f31abf1cac3"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic78f3e2ee61c499ba7cc0746a2385d47_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzItOC0xLTEtNzMyNTM_99f3b4f7-3e67-4b53-88c6-c3ffa1e86380"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdbacd087ccb4b378166217f2e6bac38_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzMtNi0xLTEtNzMyNTM_aae2e661-b438-44c1-9018-01ab05c80024"
      unitRef="usd">614000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b0f54b6f66490ea61e7105a06bbd5f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzMtOC0xLTEtNzMyNTM_e4a24f30-3a05-4de4-940b-12f67c67fb37"
      unitRef="usd">532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ff614778cc44cd498c6a9c8964075c2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzQtNi0xLTEtNzMyNTM_c1fed9b7-0dc1-4f1d-b68a-abcd334da6f1"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f19775fa7fb4454916890a2d18f7368_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzQtOC0xLTEtNzMyNTM_150c33ab-756c-4e02-a022-484ec30d7166"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3125d8c421f84befbfdc8c98d0f12733_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzctNi0xLTEtNzMyNTM_29b75ffb-0381-4970-a9d0-3ada4ae3b464"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1c196d5476444949e789bed861f1aa6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzctOC0xLTEtNzMyNTM_ee6fffc4-865e-4ab0-9b8e-12f2347b64d8"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d5f22d6d24942c5974fd185d2251f6a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzgtNi0xLTEtNzMyNTM_f566b25d-a465-4361-af44-536ea448062c"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdf4bed28ef04a34be1be2775ace098f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzgtOC0xLTEtNzMyNTM_4039c928-f5df-4024-8572-a3d4c85a5449"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia72f22aa56674f6ea95b38deaf7d7ef0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzktNi0xLTEtNzMyNTM_15774689-14f0-46bb-88e3-bf539fcf6d8a"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i639f02ea2ac340d384b27444a35f86c5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfMzktOC0xLTEtNzMyNTM_17afb34f-3f1b-43ab-9e86-ee9c63a5b746"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0f9dd7d8685493e9094a8411dc69ba7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDAtNi0xLTEtNzMyNTM_9e617e15-55ae-4d59-9a31-03d29b13479c"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb5cc0c791ad4deb82c1071bb2540517_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDAtOC0xLTEtNzMyNTM_66a757f9-b648-4d7c-a0a2-8538d53f748d"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3d3e94281d14e1ead6013f512d2ba56_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtNi0xLTEtODE2Njk_d7c0345b-c90d-419b-8d78-c1ffe16d4ba8"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18fd6150a38a4e9b9bd77ea967639212_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtOC0xLTEtODE2ODI_7783c6ab-c9ef-4120-86b6-49000195aeef"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i512cec6652ce4f19be4c4e4462feb4e8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtNi0xLTEtNzMyNTM_cb7d8987-e142-45dd-8a58-885b5bb0ff44"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b4fe39a35de44ecaa3535608505ded0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDMtOC0xLTEtNzMyNTM_da5c2922-dbcc-49f2-a7f1-d1a771183af7"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifeabc0e9b646406e88ddb1c5e1f12518_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDQtNi0xLTEtNzMyNTM_e8788858-d899-4db6-aaec-d06cb7ac880c"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia12ead842eee42f59b1937c152fb8415_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDQtOC0xLTEtNzMyNTM_d48e3d62-74d7-439f-b248-e3573767dac6"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia67b003e0c9d489a93fc432063b0605d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDUtNi0xLTEtNzMyNTM_c43e30b9-49b5-46cb-8317-dce2c66c88e2"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45a38522757a47f08bcaaed26cc95890_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDUtOC0xLTEtNzMyNTM_06e48134-5cae-4127-9f2a-bf7e134c4e92"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0b09878f9324ebc81010863a7bb2312_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDctNi0xLTEtNzMyNTM_d2318318-93b2-43da-a67c-dff3909d51a6"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67b43137ee1c4af9956280587d60c83c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDctOC0xLTEtNzMyNTM_5743eadd-4e20-403e-9863-6ff734eed9ca"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae85b406a18e40d7b2917cf2e17d0b83_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDgtNi0xLTEtNzMyNTM_8813f64c-9195-4893-8b43-b66f1fabd378"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i741797da087c4ef6a3b16e0b40c35175_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDgtOC0xLTEtNzMyNTM_ead8daed-e9d7-493f-af54-6132cade79db"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic34cab53f8594ff4979a946f5a3fc1f9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDktNi0xLTEtNzMyNTM_05fa9027-d0cd-4cac-af3b-f71ef87e9cca"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85cd48264009438ca440c693ab0cf2f1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNDktOC0xLTEtNzMyNTM_7c681d77-ec0a-41bd-aae3-fcd868aedb4c"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fc8282031784d8caeb6a4ef809f2f50_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTAtNi0xLTEtNzMyNTM_55d46e55-341d-43cf-a116-89b43801efcd"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a85e57b458b4094a0c62505b2a9799e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTAtOC0xLTEtNzMyNTM_7bab5c73-9f23-4dc2-9bbf-92388fa89089"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50fb763a0f1c482a9572f571170e440e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTEtNi0xLTEtNzMyNTM_3ea334ee-965e-4608-b89a-4f1eb2db06a3"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93307eafe6504d879af164c82b04eda8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTEtOC0xLTEtNzMyNTM_1d61a0e4-921f-41f1-9ad6-5ae9811519ca"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia46e3aeb263045cfbb0acf95c88c121b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTItNi0xLTEtNzMyNTM_16ef93fd-37c7-4688-9bdb-1a5f802b9c45"
      unitRef="usd">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a77a42b923942bfaff4dc08627c3225_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTItOC0xLTEtNzMyNTM_d1625484-50ed-43f3-be25-826a15d39bc7"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief85b551045345879ed1be64c67a8b4b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTMtNi0xLTEtNzMyNTM_53bc52e2-bd4c-4837-ba9c-3c40f70acda8"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cf3d5f2dfb344e59a6c9efc465d8f5b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTMtOC0xLTEtNzMyNTM_23e2c35f-3db4-4444-90a4-c3e8cb22efd3"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic62a015e1747449791ed3c131fc6f351_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTQtNi0xLTEtNzMyNTM_9a0403a8-91a7-4128-8b45-263a93987573"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bf8ded17cba43f7b08f7d24f7aed016_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTQtOC0xLTEtNzMyNTM_af7af429-cb8e-49fa-8159-b65ded5dbcd7"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea2c9be5775d49e7af0a83f0b14fce7f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTUtNi0xLTEtNzMyNTM_c60990e1-a2a2-4a02-9c3d-490abd0c4f47"
      unitRef="usd">246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ddf6b053a5d4cf1b48234a1c15b6c1a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTUtOC0xLTEtNzMyNTM_6cd9ac42-65ad-4642-a7e3-480dc3c682e2"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i882c0ed4b6454d5db18fd823a31bcb88_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTYtNi0xLTEtNzMyNTM_5e161b08-de8e-48dd-bd01-d3e88e3e176b"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf25850c2d1c4ceb840ecd9bfee2891c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTYtOC0xLTEtNzMyNTM_9c030a35-13fd-41e3-ab84-efff01f8f235"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife17341a39044007bd37eb3dcabab9af_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTctNi0xLTEtNzMyNTM_e39d9814-9d7e-4d3f-b4f6-bce26ad8cdb3"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i379b152b16b1407985df7a9d9e3ad633_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTctOC0xLTEtNzMyNTM_df937c43-3c35-433e-894d-b3729743f666"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6df2de6a1db84a14bc36698e3dbcbf51_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTgtNi0xLTEtNzMyNTM_b4fd3319-97ce-4b03-807b-e3e658087392"
      unitRef="usd">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58a92b2ecc5f4aaf9d8351f86caf7be5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNTgtOC0xLTEtNzMyNTM_be3abe21-d3be-4f9a-9602-efac9c5f0c15"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e933b76f7264c7cb306a5779cb4d526_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzAtNi0xLTEtNzMyNTM_9152e379-0fc6-4fad-a615-1c6f4467f1e7"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9bf38d011cc4cfd9351b1938594689b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzAtOC0xLTEtNzMyNTM_a54130ef-ff84-4355-8b13-997edee68873"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e746d238af04e0fba57b391911704b6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzEtNi0xLTEtNzMyNTM_d3f56cb5-c2bb-4377-ab28-cec53bc7ca50"
      unitRef="usd">211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59295dec623542dba93f26a4df9b7bf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzEtOC0xLTEtNzMyNTM_91db4c7b-8ed1-47f2-af88-8c71ffcac031"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieefe0806b5ac487fb58df139e942b4bf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzItNi0xLTEtNzMyNTM_137adc64-b240-4cbb-b982-d47ea1150d79"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic251b48766744736852af8a750fb5fa6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzItOC0xLTEtNzMyNTM_fa85162e-f767-4553-9b1c-6f8bf43889a0"
      unitRef="usd">415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife9748feec04436daefd70ed8fde5035_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzMtNi0xLTEtNzMyNTM_7a044198-cc03-4d41-a23a-b44a9e180167"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72ca6bfcb2a742d2a419a770b28a65e2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzMtOC0xLTEtNzMyNTM_3a9b6290-3743-46e7-b69d-aca39a7363c7"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2ecf09fad83434f8b75838cf1459dde_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzctNi0xLTEtNzMyNTM_d91db237-6306-41d3-9027-5189db05b88c"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6fb7ab9f9404aa4800b094182ef46f5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzctOC0xLTEtNzMyNTM_4a4787fe-8450-41e4-b2d5-92da5688cefa"
      unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9915235f3a844da69814226e5774c2d7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzgtNi0xLTEtNzMyNTM_0d3b281e-ab0d-45ea-ad80-489e3c75f266"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4538d383a2c14cac819e3ce9bc8a27c4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzgtOC0xLTEtNzMyNTM_e6536072-3b68-4589-857b-80abc79eac26"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i531f3349e8c348c39ad330ddd7567561_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzktNi0xLTEtNzMyNTM_27bd77ea-9059-44c3-8a2a-6c60a60af0ca"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a8b6f17bd484927bdf4246fdc7d2e83_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfNzktOC0xLTEtNzMyNTM_7ac3f90c-6936-448e-bf10-77b7a0ad14e7"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i092297541dd04ee2b04cfdcfbb71eef1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODQtNi0xLTEtNzMyNTM_0abc59f1-4597-4d34-8a52-4eafb5624a34"
      unitRef="usd">1211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i143c59ef117840e5b84f10e564ee91c4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODQtOC0xLTEtNzMyNTM_3f9e4b9b-f703-4708-be83-79598895c460"
      unitRef="usd">1476000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="icf2f690357b3411ab045058c62c6b838_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODUtNi0xLTEtNzMyNTM_3560e8c6-d560-4bf8-9af0-4748f93abd1e"
      unitRef="usd">13538000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY185Ny9mcmFnOmFkZjlkMDYxYzA0MTQ3YTJhOGNhYWE3MWMwODQ5OGMxL3RhYmxlOjI4MzRmNmMzNjNhMzRiYTliMWU4Yzg2MWMyZjk0OTliL3RhYmxlcmFuZ2U6MjgzNGY2YzM2M2EzNGJhOWIxZThjODYxYzJmOTQ5OWJfODUtOC0xLTEtNzMyNTM_b38b4100-48f5-49fb-81ff-dac7d1620595"
      unitRef="usd">13010000000</us-gaap:Revenues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at March 31, 2022 and December 31, 2021. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjMzNzFjODljMzFkYjQ3NGI5MTdlYjI1N2E0ZmI2OTcxXzI3NDg3NzkwNjk0NDQ_af625595-0582-4b93-a179-0e2dd45ed242"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjZiMTY3ZWQzNGFiYjRkNDdiMTA0MzIyMDkyZTJlNGZjXzI3NDg3NzkwNjk0NTA_9cccc2a8-86e2-48fe-9f89-53bbf7e6c0f0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_5d256177-b7e1-4915-a8f0-e491dbb9f298"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_5d256177-b7e1-4915-a8f0-e491dbb9f298"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NTA_04ada94e-64b7-459a-a5dd-adeb4f6ea353"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NTA_04ada94e-64b7-459a-a5dd-adeb4f6ea353"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NDQ_7949dad9-89a4-41ee-b66a-7fc7207216bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NDQ_7949dad9-89a4-41ee-b66a-7fc7207216bb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NjY_34203fed-736d-478f-9829-5ad6abaa8128"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NjY_34203fed-736d-478f-9829-5ad6abaa8128"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_2255b661-58b9-448c-a8da-5793bd88bc4d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_2255b661-58b9-448c-a8da-5793bd88bc4d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NTg_1139f260-ebf0-4997-a8bf-8e3e9c1797b3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NTg_1139f260-ebf0-4997-a8bf-8e3e9c1797b3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1OA_5d256177-b7e1-4915-a8f0-e491dbb9f298"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NTA_04ada94e-64b7-459a-a5dd-adeb4f6ea353"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0xLTEtMS03MzI1My90ZXh0cmVnaW9uOjM0NmYyMzM1ZDVmNDRhYWU5ZGJiNzc3ZDA4MTVlMTEzXzI3NDg3NzkwNjk0NDQ_7949dad9-89a4-41ee-b66a-7fc7207216bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NjY_34203fed-736d-478f-9829-5ad6abaa8128"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMjc0ODc3OTA5NTI1Mg_2255b661-58b9-448c-a8da-5793bd88bc4d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0xLTEtMS04MTA3OC90ZXh0cmVnaW9uOjhhOTdiMzJiNzRjNDQ3YjM5NDlmMWQ2MzEzNGY2ZTk5XzI3NDg3NzkwNjk0NTg_1139f260-ebf0-4997-a8bf-8e3e9c1797b3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMDY_84d7cab9-93ac-4fc8-a39f-7622c4e8652b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNS0xLTEtNzMyNTM_c3509005-a607-426a-a140-90bfa6a40cdb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNS0xLTEtNzMyNTM_c3509005-a607-426a-a140-90bfa6a40cdb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNy0xLTEtNzMyNTM_da5e13a0-ba04-43e2-9ccc-697be415ecf8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNy0xLTEtNzMyNTM_da5e13a0-ba04-43e2-9ccc-697be415ecf8"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2Ng_339b42bb-9e96-46ac-89bc-283f924a8cbd" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2Ng_339b42bb-9e96-46ac-89bc-283f924a8cbd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(c) Amounts are included in cost of products sold (see Note 8).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNS0xLTEtNzMyNTM_c3509005-a607-426a-a140-90bfa6a40cdb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2Ng_339b42bb-9e96-46ac-89bc-283f924a8cbd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTEtNy0xLTEtNzMyNTM_da5e13a0-ba04-43e2-9ccc-697be415ecf8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk2Ng_339b42bb-9e96-46ac-89bc-283f924a8cbd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy03LTEtMS03MzI1Mw_e0b01168-ad34-434d-9854-14c860bb3278"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy03LTEtMS03MzI1Mw_e0b01168-ad34-434d-9854-14c860bb3278"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy01LTEtMS03MzI1Mw_5de29469-8128-4032-a9fe-d194d6935866"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy01LTEtMS03MzI1Mw_5de29469-8128-4032-a9fe-d194d6935866"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwOA_4e00e857-6c03-4577-bf53-0941bd05ee5f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwOA_4e00e857-6c03-4577-bf53-0941bd05ee5f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy03LTEtMS03MzI1Mw_e0b01168-ad34-434d-9854-14c860bb3278"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwOA_4e00e857-6c03-4577-bf53-0941bd05ee5f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfNy01LTEtMS03MzI1Mw_5de29469-8128-4032-a9fe-d194d6935866"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMzAwOA_4e00e857-6c03-4577-bf53-0941bd05ee5f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy01LTEtMS03MzI1Mw_dcbb1f13-4991-4b76-b758-f7b88b8d660e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy01LTEtMS03MzI1Mw_dcbb1f13-4991-4b76-b758-f7b88b8d660e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNS0xLTEtNzMyNTM_f5d8bf1d-c1fd-4481-bde9-f036b794d7e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNS0xLTEtNzMyNTM_f5d8bf1d-c1fd-4481-bde9-f036b794d7e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNy0xLTEtNzMyNTM_d33aba04-37d9-4799-8851-d1a29a61115b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNy0xLTEtNzMyNTM_d33aba04-37d9-4799-8851-d1a29a61115b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNS0xLTEtNzMyNTM_5e757465-320d-4d59-890d-c8493a2521aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNS0xLTEtNzMyNTM_5e757465-320d-4d59-890d-c8493a2521aa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy03LTEtMS03MzI1Mw_a9d9e243-873f-4eef-b19e-5939933a8100"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy03LTEtMS03MzI1Mw_a9d9e243-873f-4eef-b19e-5939933a8100"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNy0xLTEtNzMyNTM_9dfa7b53-a718-428a-84f0-a2b6048d47ca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNy0xLTEtNzMyNTM_9dfa7b53-a718-428a-84f0-a2b6048d47ca"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(a)&#160;Amounts are included in interest expense, net (see Note 8)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy01LTEtMS03MzI1Mw_dcbb1f13-4991-4b76-b758-f7b88b8d660e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNS0xLTEtNzMyNTM_f5d8bf1d-c1fd-4481-bde9-f036b794d7e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNy0xLTEtNzMyNTM_d33aba04-37d9-4799-8851-d1a29a61115b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTItNS0xLTEtNzMyNTM_5e757465-320d-4d59-890d-c8493a2521aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMy03LTEtMS03MzI1Mw_a9d9e243-873f-4eef-b19e-5939933a8100"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RhYmxlOjRmODNjNjgzYzY2YjRhOTFhMWVlZmZhZDk3YTA5YjBiL3RhYmxlcmFuZ2U6NGY4M2M2ODNjNjZiNGE5MWExZWVmZmFkOTdhMDliMGJfMTMtNy0xLTEtNzMyNTM_9dfa7b53-a718-428a-84f0-a2b6048d47ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY184Mi9mcmFnOmY4Yjk1N2UzNWRmODRmZTI4MzcwZDJiYWYyMGVhMmI2L3RleHRyZWdpb246ZjhiOTU3ZTM1ZGY4NGZlMjgzNzBkMmJhZjIwZWEyYjZfMjk5NQ_4f394a68-56b5-40ba-85ee-31ba8f0a7a22"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjc2MzFmNTcxMzBkZTQyZjE4NmQ5MmEwNjk4ODM5MGM1XzI3NDg3NzkwNjk0NTA_6fba84dd-6dc2-4522-a73d-12e386424d43"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjc2MzFmNTcxMzBkZTQyZjE4NmQ5MmEwNjk4ODM5MGM1XzI3NDg3NzkwNjk0NTA_6fba84dd-6dc2-4522-a73d-12e386424d43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjgzM2JmZTkxZDBkZDQyMWE5NDI5NmQxMjEyNGE3M2MzXzI3NDg3NzkwNjk0NDQ_274ad924-0f34-4f79-977f-36dc21f67545"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjgzM2JmZTkxZDBkZDQyMWE5NDI5NmQxMjEyNGE3M2MzXzI3NDg3NzkwNjk0NDQ_274ad924-0f34-4f79-977f-36dc21f67545"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmI2ODBhMDkwNGJjZTQ2ZmViMjljYmVjY2Y1NGIzYzMyXzI3NDg3NzkwNjk0NTA_cef10409-9e56-4640-b348-5c474e51230b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmI2ODBhMDkwNGJjZTQ2ZmViMjljYmVjY2Y1NGIzYzMyXzI3NDg3NzkwNjk0NTA_cef10409-9e56-4640-b348-5c474e51230b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0yLTEtMS03MzI1My90ZXh0cmVnaW9uOmQ0MGEzNmJlOGMxYzRjM2RhOTE4ZWYwODI5MTZiYTcwXzI3NDg3NzkwNjk0NDQ_22cd617e-882f-4a62-a3a0-f377e022ebfd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0yLTEtMS03MzI1My90ZXh0cmVnaW9uOmQ0MGEzNmJlOGMxYzRjM2RhOTE4ZWYwODI5MTZiYTcwXzI3NDg3NzkwNjk0NDQ_22cd617e-882f-4a62-a3a0-f377e022ebfd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmMzYzcyMDAxZGQyNTQzNTRhYjBjZGRmMzEwOTkxMzQ0XzI3NDg3NzkwNjk0NTA_f621a23b-df7f-4771-a959-3f4a432c6de1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmMzYzcyMDAxZGQyNTQzNTRhYjBjZGRmMzEwOTkxMzQ0XzI3NDg3NzkwNjk0NTA_f621a23b-df7f-4771-a959-3f4a432c6de1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS03MzI1Mw_1e8fbd73-3e85-44c5-8cfb-b0e0822a4975"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS03MzI1Mw_1e8fbd73-3e85-44c5-8cfb-b0e0822a4975"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOjc2MzFmNTcxMzBkZTQyZjE4NmQ5MmEwNjk4ODM5MGM1XzI3NDg3NzkwNjk0NTA_6fba84dd-6dc2-4522-a73d-12e386424d43"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMS0yLTEtMS03MzI1My90ZXh0cmVnaW9uOjgzM2JmZTkxZDBkZDQyMWE5NDI5NmQxMjEyNGE3M2MzXzI3NDg3NzkwNjk0NDQ_274ad924-0f34-4f79-977f-36dc21f67545"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMy0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmI2ODBhMDkwNGJjZTQ2ZmViMjljYmVjY2Y1NGIzYzMyXzI3NDg3NzkwNjk0NTA_cef10409-9e56-4640-b348-5c474e51230b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfMi0yLTEtMS03MzI1My90ZXh0cmVnaW9uOmQ0MGEzNmJlOGMxYzRjM2RhOTE4ZWYwODI5MTZiYTcwXzI3NDg3NzkwNjk0NDQ_22cd617e-882f-4a62-a3a0-f377e022ebfd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNC0yLTEtMS04MTA4MC90ZXh0cmVnaW9uOmMzYzcyMDAxZGQyNTQzNTRhYjBjZGRmMzEwOTkxMzQ0XzI3NDg3NzkwNjk0NTA_f621a23b-df7f-4771-a959-3f4a432c6de1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RhYmxlOjlkZmVkOTU3OGIxNzQ1ZDJhMTJjNGJiNDY3N2UxODkzL3RhYmxlcmFuZ2U6OWRmZWQ5NTc4YjE3NDVkMmExMmM0YmI0Njc3ZTE4OTNfNS0yLTEtMS03MzI1Mw_1e8fbd73-3e85-44c5-8cfb-b0e0822a4975"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmM4OWYwNjMyMGY5YzRmNTdiMTljNTExODIyZjM2Y2FjL3NlYzpjODlmMDYzMjBmOWM0ZjU3YjE5YzUxMTgyMmYzNmNhY183MC9mcmFnOjNkYjc4MTIwZTI1NDQ0ZDQ4Y2UyNGJkMTMzZDUxZTYwL3RleHRyZWdpb246M2RiNzgxMjBlMjU0NDRkNDhjZTI0YmQxMzNkNTFlNjBfMTIxMTQ_721db4ae-4305-482d-b373-ec8b16aa1b8a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %QFIE0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !<9J94-05 +N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.NU8#U&7"XC3)B$Q"<0M2KPMHFFBQ*C=V].&K1."!^ 8^\_G
MSY);'83V$9^C#QC)8KH;7=<GH<.&G8B" $CZA$ZE<DKT4_/@HU,T/>,1@M(?
MZHA0<]Z 0U)&D8(96(2%R&1KM- 1%?EXP1N]X,-G[#+,:, .'?:4H"HK8'*>
M&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#JN<FW:HX&VW?<GK%K9/
MI'J-TZ]D!9T#;MAU\NOJX7'_Q&3-Z[K@ZX(W^ZH1:R[NJ_?9]8??3=AY8P_V
M'QM?!64+O^Y"?@%02P,$%     @ 7&:F5)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M?/5 0:47BZS4?\E#_=G0'Y!X62J1KQJ#@SPMZO_L<16(C0:^LZ6!NVK@?M>
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M$%F?-JYOE%CH [NW0BF1Z\LY9PF7U0?@_3L!(WIU4WU!<^;[^%]02P,$%
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M'97!7L1[KAEHA#ZE\ )QYARAM9]N_],HZ4/:1C,R,(TP:1G)=U=-V!>!\'/
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M&*&$WD?[C']A3R%M)^36_F*65<U?]-1BK1&*]Q5G>6L,$>1I<?@?_6B).#'
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MXC-TU9AD*K[W"14P>^!M#>D$-=$_Z#W_P*=B?D'DQZ4@\\5':I.3%\CU3Q;
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MCQ0A(;_K""AYA8%>++ZCS]3R3HOXE>28N!0SQ!,G6CQ$1$(^T!%1$F>BZY:
M8C'B1>W23DH<T*Y0LD@"H#MR2EYA)UOEV!HP6.MX(;L,DR[&#F:/U'P6\&C<
M\1 >Q_-2#S2'Z%-1T,<+=4R"W\ D33*SUJQ7LA6D3RO8Y8=AXD2-5VH1*#-P
M1R,X3B-'8"$3[Z0QIGZVP!E\VQG<7M@>]DBFN _;)S4/P>Y(!I-X>MK+;$M-
M7K*UYHM^D6+97@;]KYGT&$SJ%!A>L4"DXXZ1<)R1[FG1I%'HWAN0[T/OLE _
M=#PB22#:<4=3.$Y3\4H#N_R33/H5LD<H#51LN*,H'*>H]P=T@]C#/\GD("LV
MF'TTE>( ZHZF\.Q=:6C-*PK]Y)O34,<L.,XLMU)DC.4ORE%J#^O8)J(0U6:H
MF2Q1SE9^H[JT 4U7@*)QQQLXSAMW4%,\M\<RQS!L9-3*8*A@$-M(K J^L;V"
MWXZ>?@6(8M&WHRL6V CIN(3$>YHK,%3.JMP4&SSW@2-NDP(U!>ZG&J\8P0$O
M(QT'D3@''>5'+4&=>_F,E&G%O&A]Y)+.QGVT'K%9J-8D'0>1. <=>RID&Z@Z
MF<RXLMYJ04.)$?0#\I9>QR,T"V1&<G N]@H+'7CS_^W,B8=L<.KXB8^22,A-
M.DXB<4Z*IW;BL@GN9TF/S# -P.H8A\09Y_TYL@'LZ86FBUF_)O&)D606@MT1
M$HD3TM?UFF6VGV5/67V  S[ 4-9TQ. ,]GSPI;1Z@(H@4!,2EWQF_5UX^"ET
MUDDZ>B+Q+LH<PV;MX=.;X7HZ*#)U#I@\8@D)G3R2CNE(G.F6'I2?T8IM>&4.
M9VU9RR07_D3M4MUBYL:?*S5/0R4,Z0B1O*&1<I ST[A&,2^<<^[IV#GE]4@M
M9HZ'C XN7THF-_9.2B';2]<W%NVO[;W7A;WMZ?U^F9PLZ]NK;IKZ,NV&2C"%
M E9?PY3C+S-0HZSOI^H7+7;VBF<EM!:E?=PR"AG4",#WM1#ZY<4LT-X2GO\'
M4$L#!!0    ( %QFIE3@HT^5TP,  ,X(   8    >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&ULI591;]LV$/XK!PT8.B"3;#E=B\PV8*?M&A1MC7C='H8]T-1)
M8DN1&DG%\7[][BA9<08W&]"76*3NOOONN]-=YGOKOO@:,<!]HXU?)'4([566
M>5EC(WQJ6S3TIK2N$8&.KLI\ZU 4T:G163Z9_)0U0IED.8]W&[><VRYH97#C
MP'=-(]QAC=KN%\DT.5[<JJH.?)$MYZVH<(OA4[MQ=,I&E$(U:+RR!AR6BV0U
MO5I?LGTT^$WAWI\\ V>RL_8+'VZ*13)A0JA1!D80]'.'UZ@U Q&-OP;,9 S)
MCJ?/1_0W,7?*92<\7EO]NRI"O4A>)E!@*3H=;NW^+0[Y/&<\:;6/?V$_V$X2
MD)T/MAF<B4&C3/\K[@<=_H]#/CCDD7<?*+)\)8)8SIW=@V-K0N.'F&KT)G+*
M<%&VP=%;17YAN19>>; E;!QZ-$&P5O,L$#0;9'* 6?<P^5=@9O#>FE![>&T*
M+![[9T1IY)4?>:WS)P'?"Y?";'H!^23/G\";C7G.(M[L*W@?726,^CNF=P'7
MUGBK52'ZSC#%H_19CC?*"".5T+"E2Z0V#![^6.U\<-1(?S[!Z')D=!D977ZK
M\D_"\$=[Y5LA<9&T#.3N,#F/#>/M6T5]Y92D[!X9_%HC=$9TA0I8@#(!G6I
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MSRX*X'UIT2&'3730?R,M_@902P,$%     @ 7&:F5)=:4$-!"   "A@  !D
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M.7<';W(^TX93C.S-T$$G/1DF4?XAR$\.R)^SG[1RF64_J%2DF_)#8&D 36I
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MY=OZ6Q_),5[%;\BX0]]9HI^6'AA9AX9"F$3R7/XG. %-'XN9J9:P0.%1&A(
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M<#2?#MJALM]85?NGS4I9>BCY94DO4]1.@.[72MG]QAGHW[K+OP%02P,$%
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M2[/8<P+<YLFHCR>5-D=X>] =LE5^:!'_:)%>V[/SWZID329BL>N-D[V#=[Y
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M/,HE*[(0L#P.P-@<FZ*P2H<A3'NO,(9N.NRH/F/K<WZQL=7FU(Z5#/(MQI_
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MHLEI:<4QH/:3X]CIJ]K>)Y7X1S^F4S^P-?6G'W2 .:^; IT)]JN.7 D_8]Y
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M+.B'@-HYT/=<*;N;N W:7\SL-U!+ P04    " !<9J94AX\MZND(  ")&@
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MTX7J"T)152-4E*=RPWT1^0YZ@]%BGVF/>*$;?UB3%#MF6)6=RAMD;-U(GF:
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MV/IK8 =*#M+((-/'<VHB_ORG>11&/T!O-!!)C-^0=HYLP6?8G8*O<OVPCN-
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MDBEH8#9_D@*82A<))RX)IX-]TWL2"&*?P&@Q^0XD$'XG$D",?R0)4/;^/T@
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M$S"^TG"TN2$#[=>G\W\#4$L#!!0    ( %QFIE0=!==@H ,  !H(   9
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M\.=/]+2@<0]C4!%F[\$-^E87>@498L\Y8;$0>Y<-@0><AX;[]!Q+J0]C'U]
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MVNTF-#?PH7IK(L>E.Y2MU;3*R<ZN*1K!$J69RY&!#W<L$6C.EJ$E<+<E3/=
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MXAF/"V3!X.^!W_ L0TZ@QQ\5TT$C$PG;YS7W=]IX,&;"%+\1V6]I4LPO!M&
M)'S*RJSX)%8_\,H@'_G%(E/Z2%;5L_: Q*4JQ*(B!@T6:6[^V6/EB$,(G(K
MT7H;05K+-ZQ@E^=2K(C$IX$;GFA3-34HE^8X*W>%A+LIT!67[]*<Y7'*,O(^
M5X4LP>&%(BQ/R#N62O(KRTI./G*F2LD5&=ZS2<;5R?FH -G(8117<JZ-'&>/
M')=\%'DQ5^1MGO!DFWX$.C>*.[7BUTXOPX],GA*76L2Q':>'G]LXPM7\W'V.
MV)C[)E5Q)HS%OU]-P"T0.W_OD>$U,CPMP]LCX\Z$/A%3PA:BK#V=B9CI$(7Q
MA,OT@6&D*@(CQ9R36(#+<L43/%,B2Q-6P,6$93!SG.BY5UTSTJL,POU,+5G,
M+P: 9\7E Q]<WH.\J<@ JVD^(P7.=@78])^@$:JS3_.KR00P\]>_1 X-7ZN6
M(21M1=9+;#HS,?B@)T4SIJ^[AH9I#M#(,E!$G9#K-@\2LZ56$,(EGC?Q0M[P
MF"\F7-8C]$O)(#4 \'. JI0\C]?@/;EB,B'\,9ZS?*9-U0&D@%K!H]I0ID"$
MFI,I>)K,>3(#Y]Y*OF0I4B[1-<;# KPER1%Q(CCXE%S%L7'_DJWU[.!#+(YE
M"5RSE$W2+"U2(#XB 9+M",W!MC2'X"IP.@Z0[$6$>N/#Q>HY<5XW_X>(_TE+
M8DK!G!,O)-2OAC*1SUX57"ZV1'@-\Q]% 7'6%O"\08%+G.!P>YPQH2[D1M "
MM"82!!&U8LMO,JV[SCI8*TK"';'3#2RZO%I+ -/[7$M#%[U_+PI8$-JIZ(C0
M2,=3$.(17')$W)#TY$2_R8E^?TZ$.B,IP59((9"'7A7LL4DQ._DPZ7>TY+&8
MY9"G$HBQRL.Q6 #3.581.A'!-2=#2.[=:UBOJH=G3'T7#<!4UV'4#*HE9=2
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MK7>\"%C^&0W"O)6"0D4:P].5E7<08Y"D8H;I1J_Q8H*.U&YKWRSSUHTT7Y9
M?&5XW" \T%W\CQ*2>Z9Q"?VG98\Q@;B61W778 41A?^Z%_DH<KZNM"/3,D^,
MSXL4"J6$+X5*@0VU/,]O2+:O-$P4^KYJ#)WF5NOT+2A5K-O/4=LFH D=-\\\
M2:6;3(!]3R.^=6Y\7GGQB(16%%)CK#;:L]S0;1G[H15)O9D'.JW0:Q'N7O>H
MZFX,:IW>P'T(38P:#$.( &E68^I:$8V>-*'5L+%O>T>!>I;MTBWE3"M8T_PG
M0N_)GLY_!_K&5N@%.A ]'Z?,MYRQ_U+TM<#6A[L-*EJG';B#H@6Q!W_U0[U0
M<(+VOL4! '"\#>?V^0Y6J6TYCJ]]XU>^";8P]@*P0C&V!0?G,*C25D[S#X"J
M9T51^!2J9G@/5,?.=AYQ0S..)#T%P;@I",:'%@2J%:D9?^ 9<;LBMFN![Y>A
M$TH+\=,*W(LER]=_4]JAG0YK.V.E*[@L+C.= TI5]P2;5*7ZH7;V_#[P=DKX
MI.O8W_0K(<Q;#Z 7# Q9[RU\[Z!;"AUJ]NGXF+PB[FEP# ?[& :<XU?$P6MZ
M&AZ36RDFQDK33K*U3DZ8:,J<Q?,49B)!I2!Z >S0!&N&@,!C,J;'6Y=V+SLI
MUBS3OIRLP25)6O5SP\D)\8,-%SC=N02F_^ Q&KJ&3J;%5QE'@CVVZ^%Y^'0
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MM!PA%)A8A\#H\8B7*(0#(AJ_*LR@3ND"]]<[](]>.VE9,H.72GSGJ<W&P2"
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MP"G(A(\SX<'IC?\@LM#.Z=;?KJ5 MO($C"\U#!T>6,'V"]GY'U!+ P04
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M%84.KMY3?M,.?KMQN@G#MM2.1C<L:[HKT7@'^EYI[?8;GZ"_??,_4$L#!!0
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M6T=#F/F,&R7T6Z+]U/()"4;87H(U%F"3(X'![2-6B%!Y!SZ"E\TCN+VY S?
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MUZ1MIO#T(=(L@/FU@)"4'>.@>DR-_@%02P,$%     @ 7&:F5+TWA!.D!
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MHN,FZK:K?E%\7S4BSUSIMJ9ZW.E6E0ACH+]O.%=O+V:"MOE=_0=02P,$%
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MB@YJ9 R<"1UQ0Y3+!PY1]A>'=G'H7/P!OZB'I13F=F>J? YP_(]Z'IBSK5G
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M):C>;ACD0EUF0L$M0KG@EL5R*<!-/".SZOJA4K#0$KYH>0FM#&\Q/P*N\P'
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M1)0]KAF%G- -H'XIA'I^T0J*+S<F_P%02P,$%     @ 7&:F5-5;B6ZN P
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M&R:H2!GEY%9HHTJ,D-&$BHS<4*;(%\I+('= =:E DP_D#T6%7H/21*[)E=:
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M,!3^*T=1'UJI:T(@7"I *M!I>ZB$8-V>37(@5IV8VDX9^_6SG>"ED$9[V%[
M=L[YSG?NXP,7+S)%5/ S8[F<>*E2^WO?EW&*&9%W?(^Y_K+E(B-*7\7.EWN!
M)+%*&?/#(.C[&:&Y-QW;MZ68CGFA&,UQ*4 664;$<8:,'R9>QSL]K.@N5>;!
MGX[W9(=K5,_[I= WWZ$D-,-<4IZ#P.W$>^C<ST=&W@I\IWB0M3,83S:<OYC+
MUV3B!880,HR502#Z[PWGR)@!TC1>*TS/F32*]?,)_;/U7?NR(1+GG/V@B4HG
MWM"#!+>D8&K%#U^P\B<R>#%GTO["H9(-/(@+J7A6*6L&&<W+?_*SBD--0>,T
M*X250GBNT/M H5LI=*VC)3/KUH(H,AT+?@!AI#6:.=C86&WM#<U-%M=*Z*]4
MZZGIXVM!U1$^P5KQ^ 56N"]$G.JXP%+PG2 97"]0$<KDC19Z7B_@^NH&9$H$
M2J Y/%'&=#KD+5S5KV-?:7+&A!]71&8ED? #(EUXXKE*)3SF"2;O]7WME/,L
M/'DV"UL!GXBX@V[G%L(@#!OXS/]>O=-"I^L"W;5XW=9 W\*<$2F!;^&;;CI9
MB&,9^18+/6>A9RWT/K"P)$?=7@IT:Y\2)%PZDZ:,E'A]BV?:_6W:Z0V"L?]6
M#].ET& X<#+OF$:.:=3*=(5FOM!\5_*LT012J)0+^HN439[Q(E=-U*,&ZD'0
M3*OO:/5;:2TPQFR#0J>\,[QLB(<ZM99\#9RYP7^JB*&S,&QU:'U1!7"MF[0L
MCINFL)9X42VLP[-RN)2(FJ,^<B1'_[AL1Y>Y[P3G97LI%$7G]>'7YF:&8F?7
MB838%%TY:-RKVU@/=E"?O<_T)BL7SQ^8<@WJ,;*CN02&6PT9W UTY$2Y6LJ+
MXGL[G3=<Z5EOCZG>QBB,@/Z^Y5R=+L: V^_3WU!+ P04    " !<9J94!^./
M\I@%   $'0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6S-65UOVS84
M_2N$L8<6:&J1E&2K< PD;H<%6-J@7;=G6J)MK1+IDG32_/M1LB+:XD=B-$7V
MDDCRX=6YY.4YI#B[X^*;W%"JP(^Z8O)\M%%J^VX\EOF&UD2^Y5O*]"\K+FJB
M]*U8C^564%*TC>IJC*(H'=>D9*/YK'UV(^8SOE-5R>B- ')7UT3<7]**WYV/
MX.CAP>=RO5'-@_%\MB5K^H6JK]L;H>_&?92BK"F3)6= T-7YZ *^6\1M@Q;Q
M=TGOY,$U:%)9<OZMN;DJSD=1PXA6-%=-"*+_W=(%K:HFDN;QO0LZZM_9-#R\
M?HC^>YN\3F9))%WPZI^R4)OST70$"KHBNTI]YG=_T"ZAI(F7\TJV?\%=AXU&
M(-])Q>NNL690EVS_G_SH.N*@@8[C;H"Z!FC8(/8TP%T#W":Z9]:F]9XH,I\)
M?@=$@];1FHNV;]K6.IN2-</X10G]:ZG;J?F'[[M2W8,S<)'GNWI7$44+\$EM
MJ  +7NO*V#1#=DO!GUQ*\.H]5:2LY&O=X.N7]^#5;Z_!;Z!DX+JL*CTJ<C96
MFE03>IQW!"[W!)"'  ;7G*F-!!]808OC]F.=3)\1>LCH$@4#7A/Q%F#X!J (
M(0>?Q=.;PP =W'<P;N-A3[R+3XLK<,7R:E>4; UNN&C+]T(I42YWBBPK"A0'
M'SG+=3\(KOM1PZZ8HH)*]09\U%.9K\!?Y$> 3-R3B5LRL8?,)5V7C#4O6)**
ML)RZQFL?(FU#-"IP.X=)C-/9^/:P%QTH'&63'G7$+^GY)4%^^\++CPJOTH7G
MHKF/E!P0.)LF Y(.#)Q,W1S3GF,:Y*CK])$.3*VWPA3#>,#-@<(3C-WD)CVY
M29"<EC8M7$PKAQ"4Y?= "<*DGM6M9!;_:D'1&JQDH):F_:NF+U_864\F^_G"
MSNQJ2";18%AL4#+U# J,C,A&)]=UJ?NEIN!54]^OP9)J2Z;:&/.*2%FNRKP=
M,[>@1G8B",-!(BY4.O%,4'C@%S"82C-L#66JW6"MEPF:NR&MO6,E>*W-V9@)
M/V%.=^\^Y#P<GR#D."=D<D+/)CM=J,<ZWX'R=[[Q$HA_4GNZ ,>R&%GT'*@L
M]K SY@+#[M*41LENZ5YCP(86ZX9MNU(K54E#J@.-1<#DY74'&C> 83MXDO)
M6^S/,FM0'*!)YBMNXP@P; G/K#T3V[9B-,S$!F%O\1N_@=,75)ZI8ZE@Y>4
M^;S!.!<,6]=)XF.[DUYU#5G:(#SQ3&YD+ R%+>QQZ4&VX>!LP,V!.8MAZB%G
M3 F%3>FFVU<25H ME^J,UMN*W[<RM*2,KLK@D@<9IT#HY<4'&3] 83]XDO@@
MA]BC)!XNZ%TP'*6>:8N,*Z"P*SRO_G0O.YZGPV6_ X1\$\#X#@KO37ZI_"![
MIQ+C858V)DD\61G[0F'[.D5]D&U0:#HD:6,FF8>DL3 4MK G:(_M.+K&H<7.
M!<NFGATA,M:$PM:T('(#5I5N=M*B!QF30-G+ZPXV9H##9O DW<$./XB&(^(
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M4!7$M["C@,V#,X#_5TK9W8,;(#L6GOP&4$L#!!0    ( %QFIE3V=\6J"@(
M &8$   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;(5438_3,!#]*U9.
M($'=IBV@51JIW06QAT55*Y8#XN FD\1:?P1[TBS_'G^DV:Y$RR69L>>]>3,>
M.^NU>;(- ))G*91=)0UB>T.I+1J0S$YT"\KM5-I(ALXU-;6M 58&D!0TG4X_
M4,FX2O(LK&U-GND.!5>P-<1V4C+S9P-"]ZMDEIP6=KQNT"_0/&M9#7O [^W6
M.(^.+"67H"S7BABH5LEZ=K-9^/@0\,BAMV<V\94<M'[RSGVY2J9>$ @HT#,P
M]SO"+0CAB9R,WP-G,J;TP'/[Q/XEU.YJ.3 +MUK\X"4VJ^130DJH6"=PI_NO
M,-2S]'R%%C9\21]CE\N$%)U%+0>P4R"YBG_V//3A#)#.+@#2 9 &W3%14'G'
MD.69T3TQ/MJQ>2.4&M!.'%?^4/9HW"YW.,SW4+L6([E7\8!]I]Z3=5ER;S+Q
M:N/-'2#CPK[-*+K<GH$60YY-S)->R#,G#UIA8\EG54+Y&D^=YE%X>A*^2:\2
M/C S(?/9.Y).T]3&*J[0SL=^S /M_#_]V$&K#7)5DY_K@T7CIN?7%?K%2+\(
M](L+]-\Z>0!#=$7<M3(L)!C$VW\U-;(M YN_7\=\EM'CN0!Z=O823!TFW))"
M=PKC&(RKXR5:Q]EY"8\WT+6TYLH2 96#3B<?75X3ISHZJ-LP20>-;BZ#V;B'
M (P/</N5UGAR?(+Q:<G_ E!+ P04    " !<9J94K R-AR$+  "*4P  &0
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M\S1&87:@9S")*,<.U-,D4L/M0:8]M6JJLI_(B&LC27B#L*?P J7:@9[!*:(
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=J[3NM %(7A5XG\ $SV+< 1H:*A1;R
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M*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;9+.$0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U
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M>@502P$"% ,4    " !<9J94!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %QFIE0U!4 N[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( %QFIE297)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ 7&:F5"Z&=B.'!P  _RT  !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( %QFIE2@Q'Z_YP0  -D1   8              " @<L/  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !<9J94#R"(_LD#  #$#
M&               @('H%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ 7&:F5+[ZW'?P @  UP<  !@              ("!YQ@  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %QFIE2;1;<P-@8
M +(8   8              " @0T<  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " !<9J94'06V"IL"  #4!@  &               @(%Y
M(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 7&:F5(VZ
M,:YW!@  ER$  !@              ("!2B4  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( %QFIE3U?3?>S08  #$<   8
M  " @?<K  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !<
M9J94X*-/E=,#  #."   &               @('Z,@  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ 7&:F5%>O*Z?Q @  % <  !D
M         ("! S<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " !<9J94186O]N0#  #."0  &0              @($K.@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %QFIE1\E^ECV0,  "\)
M   9              " @48^  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ 7&:F5)=:4$-!"   "A@  !D              ("!5D(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !<9J94HD'C
M56@$  #W"@  &0              @('.2@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( %QFIE3V'CZ:9 0  ),+   9
M  " @6U/  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M7&:F5,O$T)]!$P  J$0  !D              ("!"%0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " !<9J94+!'G6^("  !N!@  &0
M            @(& 9P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( %QFIE2'CRWJZ0@  (D:   9              " @9EJ  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 7&:F5!T%UV"@ P
M&@@  !D              ("!N7,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " !<9J94H><WZ8$2   &.0  &0              @(&0
M=P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %QFIE3A
M+1+GF 8  '4/   9              " @4B*  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ 7&:F5!T"_\H3 P  U0<  !D
M     ("!%Y$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %QFIE0;<BHT70D  '<F   9              "
M@?>B  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 7&:F
M5"-1RRCR @  M08  !D              ("!BZP  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " !<9J94;L4CP+ &   M$P  &0
M        @(&TKP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( %QFIE1<0L!=O 0  &$+   9              " @9NV  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 7&:F5*,0-)AG @  B04
M !D              ("!CKL  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " !<9J94Q2<=#: #  !U#   &0              @($LO@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %QFIE0<5K8Q
MLP,  )@-   9              " @0/"  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ 7&:F5![R$:8+ P  6 D  !D
M ("![<4  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !<
M9J94O3>$$Z0$  !@$P  &0              @($OR0  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %QFIE0]WEN>FP(  )T&   9
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M970T,"YX;6Q02P$"% ,4    " !<9J94/UE07(,'   >,   &0
M    @(&LYP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M %QFIE0#OK\BL04  ,4A   9              " @6;O  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ 7&:F5-5;B6ZN P  M@L  !D
M             ("!3O4  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " !<9J94YY>@Q30%   0&0  &0              @($S^0  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( %QFIE3NW#)!^ (
M %T)   9              " @9[^  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ 7&:F5$(=%%93 P  / H  !D              ("!
MS0$! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !<9J94
M?H=G!88#  !D#0  &0              @(%7!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( %QFIE08^/B,+ ,  "0+   9
M      " @10) 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ 7&:F5,1NLPC( @  Z08  !D              ("!=PP! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !<9J94&Z!1[<("  #?!@
M&0              @(%V#P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( %QFIE0FE#)54P(  $H&   9              " @6\2 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 7&:F5*/VIKW$
M @  ZP<  !D              ("!^10! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " !<9J94!^./\I@%   $'0  &0
M@('T%P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( %QF
MIE3"Y%;#W04  "X<   9              " @<,= 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ 7&:F5*^">UY\ @  @P8  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( %QFIE3]M3K+KP0  ,$F   /
M  "  >H] 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !<9J94$R?LNN\!
M  "E(@  &@              @ '&0@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !<9J948B/G&-@!  !((@  $P
M@ 'M1 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0@!"  42  #V1@$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>415</ContextCount>
  <ElementCount>279</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>120</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Earnings (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Supplemental Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SupplementalFinancialInformation</Role>
      <ShortName>Supplemental Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements</Role>
      <ShortName>Licensing, Acquisitions and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111105 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/Collaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114106 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - Integration and Restructuring Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IntegrationandRestructuringPlans</Role>
      <ShortName>Integration and Restructuring Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Financial Instruments and Fair Value Measures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures</Role>
      <ShortName>Financial Instruments and Fair Value Measures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Post-Employment Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/PostEmploymentBenefits</Role>
      <ShortName>Post-Employment Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Legal Proceedings and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LegalProceedingsandContingencies</Role>
      <ShortName>Legal Proceedings and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Supplemental Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>Supplemental Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/EarningsPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Collaborations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CollaborationsTables</Role>
      <ShortName>Collaborations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/Collaborations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Integration and Restructuring Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IntegrationandRestructuringPlansTables</Role>
      <ShortName>Integration and Restructuring Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/IntegrationandRestructuringPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables</Role>
      <ShortName>Financial Instruments and Fair Value Measures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Post-Employment Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/PostEmploymentBenefitsTables</Role>
      <ShortName>Post-Employment Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/PostEmploymentBenefits</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2335308 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/Equity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/SegmentInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/BasisofPresentation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Supplemental Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SupplementalFinancialInformationDetails</Role>
      <ShortName>Supplemental Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/SupplementalFinancialInformationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/EarningsPerShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails</Role>
      <ShortName>Licensing, Acquisitions and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CollaborationsDetails</Role>
      <ShortName>Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/CollaborationsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Integration and Restructuring Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails</Role>
      <ShortName>Integration and Restructuring Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/IntegrationandRestructuringPlansTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Fair Value Measures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Post-Employment Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/PostEmploymentBenefitsDetails</Role>
      <ShortName>Post-Employment Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/PostEmploymentBenefitsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Equity - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityStockBasedCompensationDetails</Role>
      <ShortName>Equity - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Equity - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityStockOptionsDetails</Role>
      <ShortName>Equity - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails</Role>
      <ShortName>Equity - RSUs and Performance Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Equity - Cash Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityCashDividendsDetails</Role>
      <ShortName>Equity - Cash Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Equity - Stock Repurchase Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails</Role>
      <ShortName>Equity - Stock Repurchase Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Equity - Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/IncomeTaxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Legal Proceedings and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails</Role>
      <ShortName>Legal Proceedings and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/LegalProceedingsandContingencies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="abbv-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails</Role>
      <ShortName>Segment Information - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="abbv-20220331.htm">abbv-20220331.htm</File>
    <File>abbv-20220331.xsd</File>
    <File>abbv-20220331_cal.xml</File>
    <File>abbv-20220331_def.xml</File>
    <File>abbv-20220331_lab.xml</File>
    <File>abbv-20220331_pre.xml</File>
    <File>abbv-20220331xex101.htm</File>
    <File>abbv-20220331xex102.htm</File>
    <File>abbv-20220331xex103.htm</File>
    <File>abbv-20220331xex104.htm</File>
    <File>abbv-20220331xex105.htm</File>
    <File>abbv-20220331xex106.htm</File>
    <File>abbv-20220331xex311.htm</File>
    <File>abbv-20220331xex312.htm</File>
    <File>abbv-20220331xex321.htm</File>
    <File>abbv-20220331xex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>abbv-20220331_g1.jpg</File>
    <File>abbv-20220331_g2.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="945">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="56">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "abbv-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 31,
   "contextCount": 415,
   "dts": {
    "calculationLink": {
     "local": [
      "abbv-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abbv-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "abbv-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abbv-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abbv-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abbv-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd"
     ]
    }
   },
   "elementCount": 547,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 24,
   "keyStandard": 255,
   "memberCustom": 59,
   "memberStandard": 60,
   "nsprefix": "abbv",
   "nsuri": "http://www.abbvie.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.abbvie.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Supplemental Financial Information",
     "role": "http://www.abbvie.com/role/SupplementalFinancialInformation",
     "shortName": "Supplemental Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Earnings Per Share",
     "role": "http://www.abbvie.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements",
     "role": "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements",
     "shortName": "Licensing, Acquisitions and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111105 - Disclosure - Collaborations",
     "role": "http://www.abbvie.com/role/Collaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114106 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - Integration and Restructuring Plans",
     "role": "http://www.abbvie.com/role/IntegrationandRestructuringPlans",
     "shortName": "Integration and Restructuring Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Financial Instruments and Fair Value Measures",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures",
     "shortName": "Financial Instruments and Fair Value Measures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Post-Employment Benefits",
     "role": "http://www.abbvie.com/role/PostEmploymentBenefits",
     "shortName": "Post-Employment Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Equity",
     "role": "http://www.abbvie.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Income Taxes",
     "role": "http://www.abbvie.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
     "shortName": "Condensed Consolidated Statements of Earnings (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Legal Proceedings and Contingencies",
     "role": "http://www.abbvie.com/role/LegalProceedingsandContingencies",
     "shortName": "Legal Proceedings and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Segment Information",
     "role": "http://www.abbvie.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Supplemental Financial Information (Tables)",
     "role": "http://www.abbvie.com/role/SupplementalFinancialInformationTables",
     "shortName": "Supplemental Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.abbvie.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i9fe4ce1afbad40ee8b142ccdca3cbdf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Collaborations (Tables)",
     "role": "http://www.abbvie.com/role/CollaborationsTables",
     "shortName": "Collaborations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i9fe4ce1afbad40ee8b142ccdca3cbdf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Integration and Restructuring Plans (Tables)",
     "role": "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables",
     "shortName": "Integration and Restructuring Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ib2fa833e1b5a4350b5373871f1e0b8db_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables",
     "shortName": "Financial Instruments and Fair Value Measures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Post-Employment Benefits (Tables)",
     "role": "http://www.abbvie.com/role/PostEmploymentBenefitsTables",
     "shortName": "Post-Employment Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335308 - Disclosure - Equity (Tables)",
     "role": "http://www.abbvie.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Segment Information (Tables)",
     "role": "http://www.abbvie.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.abbvie.com/role/BasisofPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i101f1d797ff34ad09ebb8518ec09bdf3_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Supplemental Financial Information (Details)",
     "role": "http://www.abbvie.com/role/SupplementalFinancialInformationDetails",
     "shortName": "Supplemental Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.abbvie.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireOtherInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)",
     "role": "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails",
     "shortName": "Licensing, Acquisitions and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i72db22a233c742cb9fdaf4ec7205f2f1_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Collaborations (Details)",
     "role": "http://www.abbvie.com/role/CollaborationsDetails",
     "shortName": "Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i20abf2418b52449bbcdcb69db0df0b34_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i3ee167f36562471dab7b2f232caad9ae_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "id13caefd7d5a471aa354ceb296f2d670_I20220331",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Integration and Restructuring Plans (Details)",
     "role": "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
     "shortName": "Integration and Restructuring Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "id13caefd7d5a471aa354ceb296f2d670_I20220331",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i0ed7b475bcdf40e59be351b723196753_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i0ed7b475bcdf40e59be351b723196753_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Fair Value Measures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ia38e263f9b26407aad657967962464cc_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ie41be7ae9a7746e29ab56e1c3957336c_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ie41be7ae9a7746e29ab56e1c3957336c_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i95aad88173d14db798e85a935c24c68b_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:NumberOfPrincipalUSCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i95aad88173d14db798e85a935c24c68b_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:NumberOfPrincipalUSCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "if319dff6fb6d4c9b9e70b7590afec644_D20220101-20220131",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "if319dff6fb6d4c9b9e70b7590afec644_D20220101-20220131",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Post-Employment Benefits (Details)",
     "role": "http://www.abbvie.com/role/PostEmploymentBenefitsDetails",
     "shortName": "Post-Employment Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "ia5efb5d06f0c4acd9a7f96ddd5917965_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Equity - Stock-Based Compensation (Details)",
     "role": "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
     "shortName": "Equity - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Equity - Stock Options (Details)",
     "role": "http://www.abbvie.com/role/EquityStockOptionsDetails",
     "shortName": "Equity - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8391b17f0e1049f9be08ea7161a2487c_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i5e56837ed6bd423c89d802b44906df17_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)",
     "role": "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
     "shortName": "Equity - RSUs and Performance Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i5e56837ed6bd423c89d802b44906df17_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDividendsPayableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i4bcd77a684aa4ecf8e6a62f0794f8418_D20220217-20220217",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Equity - Cash Dividends (Details)",
     "role": "http://www.abbvie.com/role/EquityCashDividendsDetails",
     "shortName": "Equity - Cash Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDividendsPayableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i4bcd77a684aa4ecf8e6a62f0794f8418_D20220217-20220217",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Equity - Stock Repurchase Program (Details)",
     "role": "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails",
     "shortName": "Equity - Stock Repurchase Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i3ee167f36562471dab7b2f232caad9ae_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Equity - Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i30d113b6de524e999e45640992e7d5f9_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i19158d14e728497cbede5b260b0904be_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Income Taxes (Details)",
     "role": "http://www.abbvie.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "idfd179fad6a84747bceee1f796370db1_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:LossContingencyIndividualPlaintiffLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Legal Proceedings and Contingencies (Details)",
     "role": "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
     "shortName": "Legal Proceedings and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "idfd179fad6a84747bceee1f796370db1_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:LossContingencyIndividualPlaintiffLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Segment Information - Additional Information (Details)",
     "role": "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails",
     "shortName": "Segment Information - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)",
     "role": "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails",
     "shortName": "Segment Information - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i092297541dd04ee2b04cfdcfbb71eef1_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i8b2b4b8b78f645bdb160863ef2a3fb7a_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i6accb844205d4e909ea7d6f406d2b865_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "i5a942c6b68a54ff3b7a44fe6b3def08c_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.abbvie.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220331.htm",
      "contextRef": "icf2f690357b3411ab045058c62c6b838_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 120,
   "tag": {
    "abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Net Gain (Loss) From Net Investment Hedges",
        "label": "Accumulated Net Gain (Loss) From Net Investment Hedges [Member]",
        "terseLabel": "Net investment hedging activities"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromNetInvestmentHedgesMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing, Acquisitions, and Other Arrangements",
        "terseLabel": "Licensing, Acquisitions, and Other Arrangements"
       }
      }
     },
     "localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract",
     "nsuri": "http://www.abbvie.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for acquisitions, collaborations and other arrangements of the entity.",
        "label": "Acquisitions Collaborations and Other Arrangements Disclosure [Text Block]",
        "terseLabel": "Licensing, Acquisitions, and Other Arrangements"
       }
      }
     },
     "localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abbv_AestheticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Aesthetics, a key product portfolio of the entity.",
        "label": "Aesthetics [Member]",
        "terseLabel": "Aesthetics"
       }
      }
     },
     "localname": "AestheticsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AllerganIntegrationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Allergan integration plan.",
        "label": "Allergan Integration Plan [Member]",
        "terseLabel": "Allergan integration plan"
       }
      }
     },
     "localname": "AllerganIntegrationPlanMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AlphaganCombiganMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Alphagan/Combigan, a product of the entity.",
        "label": "Alphagan/Combigan [Member]",
        "terseLabel": "Alphagan/Combigan"
       }
      }
     },
     "localname": "AlphaganCombiganMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.",
        "label": "AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member]",
        "terseLabel": "AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al."
       }
      }
     },
     "localname": "AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_BotoxCosmeticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Botox Cosmetic, a product of the entity.",
        "label": "Botox Cosmetic [Member]",
        "terseLabel": "Botox Cosmetic"
       }
      }
     },
     "localname": "BotoxCosmeticMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_BotoxTherapeuticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Botox Therapeutic, a product of the entity.",
        "label": "Botox Therapeutic [Member]",
        "terseLabel": "Botox Therapeutic"
       }
      }
     },
     "localname": "BotoxTherapeuticMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_BystolicAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bystolic antitrust litigation.",
        "label": "Bystolic Antitrust Litigation [Member]",
        "terseLabel": "Bystolic antitrust litigation"
       }
      }
     },
     "localname": "BystolicAntitrustLitigationMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.",
        "label": "Collaborative Arrangement Milestone Method Payments Receivable",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestoneMethodPaymentsReceivable",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.abbvie.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.",
        "label": "Collaborative Arrangements Percentage Of Share Of Development Costs",
        "terseLabel": "Share of collaboration development costs responsible by the entity (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.",
        "label": "Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party",
        "terseLabel": "Share of collaboration development costs responsible by Janssen (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Cost of Goods And Services Sold From Collaborative Arrangements",
        "terseLabel": "Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)"
       }
      }
     },
     "localname": "CostofGoodsAndServicesSoldFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_CreonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Creon, a product of the entity.",
        "label": "Creon [Member]",
        "terseLabel": "Creon"
       }
      }
     },
     "localname": "CreonMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_December2018StockRepurchaseAuthorizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2018 Stock Repurchase Authorization",
        "label": "December 2018 Stock Repurchase Authorization [Member]",
        "terseLabel": "December 2018 Stock Repurchase Authorization"
       }
      }
     },
     "localname": "December2018StockRepurchaseAuthorizationMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.",
        "label": "Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit)",
        "negatedLabel": "Amortization of actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_DuodopaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Duodopa, a product of the entity.",
        "label": "Duodopa [Member]",
        "terseLabel": "Duodopa"
       }
      }
     },
     "localname": "DuodopaMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ElliottAssociatesL.P.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Elliot Associates, LP.",
        "label": "Elliott Associates, L.P. [Member]",
        "terseLabel": "Elliott Associates, L.P."
       }
      }
     },
     "localname": "ElliottAssociatesL.P.Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_EyeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Eye Care, a key product portfolio of the entity.",
        "label": "Eye Care [Member]",
        "terseLabel": "Eye Care"
       }
      }
     },
     "localname": "EyeCareMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_FloatingRateTermLoanTrancheDueMay2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Term Loan Tranche Due May 2025",
        "label": "Floating Rate Term Loan Tranche Due May 2025 [Member]",
        "terseLabel": "Floating rate notes due 2025"
       }
      }
     },
     "localname": "FloatingRateTermLoanTrancheDueMay2025Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Term Loan Tranche Due May 2025, Refinanced",
        "label": "Floating Rate Term Loan Tranche Due May 2025, Refinanced [Member]",
        "terseLabel": "Floating rate notes due 2025, refinanced"
       }
      }
     },
     "localname": "FloatingRateTermLoanTrancheDueMay2025RefinancedMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_GenentechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Inc. [Member]",
        "label": "Genentech, Inc. [Member]",
        "verboseLabel": "Genentech, Inc."
       }
      }
     },
     "localname": "GenentechInc.Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_HUMIRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to HUMIRA, a product of the entity.",
        "label": "H U M I R A [Member]",
        "terseLabel": "Humira"
       }
      }
     },
     "localname": "HUMIRAMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_HematologicOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity.",
        "label": "Hematologic Oncology [Member]",
        "terseLabel": "Hematologic Oncology"
       }
      }
     },
     "localname": "HematologicOncologyMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to lawsuits filed alleging that AbbVie\u2019s settlements with biosimilar manufacturers and AbbVie\u2019s Humira patent portfolio violated state and federal antitrust laws.",
        "label": "Humira Antitrust Litigation, In re: Humira (Adalimumab) Antitrust Litigation [Member]",
        "terseLabel": "Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation"
       }
      }
     },
     "localname": "HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ImbruvicaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Imbruvica, a product of the entity.",
        "label": "Imbruvica [Member]",
        "terseLabel": "Imbruvica"
       }
      }
     },
     "localname": "ImbruvicaMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Immunology, a key product portfolio of the entity.",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertains to the entity Janssen Biotech Inc.",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_JuvedermCollectionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Juvederm Collection, a product of the entity.",
        "label": "Juvederm Collection [Member]",
        "terseLabel": "Juvederm Collection"
       }
      }
     },
     "localname": "JuvedermCollectionMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_KeyProductPortfolioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information concerning the company's portfolios of key products.",
        "label": "Key Product Portfolio [Axis]",
        "terseLabel": "Key Product Portfolio [Axis]"
       }
      }
     },
     "localname": "KeyProductPortfolioAxis",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abbv_KeyProductPortfolioDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Information concerning the company's portfolios of key products.",
        "label": "Key Product Portfolio [Domain]",
        "terseLabel": "Key Product Portfolio [Domain]"
       }
      }
     },
     "localname": "KeyProductPortfolioDomain",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_LinzessConstellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Linzess/Constella, a product of the entity.",
        "label": "Linzess/Constella [Member]",
        "terseLabel": "Linzess/Constella"
       }
      }
     },
     "localname": "LinzessConstellaMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.",
        "label": "Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure",
        "verboseLabel": "Current portion of long-term debt and finance lease obligations, excluding fair value hedges"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.",
        "label": "Long Term Debt and Capital Lease Obligations Fair Value Disclosure",
        "verboseLabel": "Long-term debt and finance lease obligations, excluding fair value hedges"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_LossContingencyIndividualPlaintiffLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.",
        "label": "Loss Contingency Individual Plaintiff Lawsuits Number",
        "terseLabel": "Number of individual plaintiff lawsuits"
       }
      }
     },
     "localname": "LossContingencyIndividualPlaintiffLawsuitsNumber",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.",
        "label": "Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws",
        "terseLabel": "Number of generic companies with whom certain litigation related agreements were entered into"
       }
      }
     },
     "localname": "LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_LossContingencyPurportedClassActionsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purported class actions filed, pertaining to a loss contingency during the period.",
        "label": "Loss Contingency Purported Class Actions Number",
        "terseLabel": "Number of purported class actions"
       }
      }
     },
     "localname": "LossContingencyPurportedClassActionsNumber",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_LumiganGanfortMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Lumigan/Ganfort, a product of the entity.",
        "label": "Lumigan/Ganfort [Member]",
        "terseLabel": "Lumigan/Ganfort"
       }
      }
     },
     "localname": "LumiganGanfortMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_MAVYRETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to MAVYRET, a product of the entity.",
        "label": "MAVYRET [Member]",
        "terseLabel": "Mavyret"
       }
      }
     },
     "localname": "MAVYRETMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Neuroscience, a key product portfolio of the entity.",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_NiaspanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Niaspan, a product of the entity.",
        "label": "Niaspan [Member]",
        "terseLabel": "Niaspan"
       }
      }
     },
     "localname": "NiaspanMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_NumberOfPrincipalUSCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of principal U.S. customers of the entity.",
        "label": "Number of Principal US Customers",
        "terseLabel": "Number of principal customers"
       }
      }
     },
     "localname": "NumberOfPrincipalUSCustomers",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_OtherAestheticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Other Aesthetics products.",
        "label": "Other Aesthetics [Member]",
        "terseLabel": "Other Aesthetics"
       }
      }
     },
     "localname": "OtherAestheticsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax",
        "terseLabel": "Net investment hedging activities, net of tax expense (benefit) of $37 for the three months ended March 31, 2022 and $103 for the three months ended March 31, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Tax",
        "terseLabel": "Net investment hedging activities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeTax",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_OtherExpensesFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Other Expenses From Collaborative Arrangements",
        "terseLabel": "Global - AbbVie's share of other costs (included in respective line items)"
       }
      }
     },
     "localname": "OtherExpensesFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_OtherEyeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Other Eye Care products.",
        "label": "Other Eye Care [Member]",
        "terseLabel": "Other Eye Care"
       }
      }
     },
     "localname": "OtherEyeCareMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherKeyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to other key products of the entity.",
        "label": "Other Key Products [Member]",
        "terseLabel": "Other Key Products"
       }
      }
     },
     "localname": "OtherKeyProductsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Other Neuroscience products.",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other Neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to other products of the entity not specified anywhere.",
        "label": "Other Products [Member]",
        "terseLabel": "All other"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherRestructuringPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other restructuring plans.",
        "label": "Other Restructuring Plans [Member]",
        "terseLabel": "Other restructuring"
       }
      }
     },
     "localname": "OtherRestructuringPlansMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PotentialPaymentsUnderAgreementCertainMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.",
        "label": "Potential Payments under Agreement Certain Milestones",
        "terseLabel": "Potential payments under agreement certain milestones"
       }
      }
     },
     "localname": "PotentialPaymentsUnderAgreementCertainMilestones",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prescription Drug Abuse Litigation In State Courts",
        "label": "Prescription Drug Abuse Litigation In State Courts [Member]",
        "terseLabel": "Prescription drug abuse litigation in state courts"
       }
      }
     },
     "localname": "PrescriptionDrugAbuseLitigationInStateCourtsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PrescriptionDrugAbuseLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to prescription drug abuse litigation.",
        "label": "Prescription Drug Abuse Litigation [Member]",
        "terseLabel": "Prescription drug abuse litigation"
       }
      }
     },
     "localname": "PrescriptionDrugAbuseLitigationMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PrincipalUSCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal US Customers",
        "label": "Principal US Customers [Member]",
        "terseLabel": "Principal US customers"
       }
      }
     },
     "localname": "PrincipalUSCustomersMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents estimated probability of payment for royalties excluding approved indications.",
        "label": "Probability of Payment for Royalties Excluding Approved Indications [Member]",
        "terseLabel": "Probability of payment for royalties excluding early stage or approved indications"
       }
      }
     },
     "localname": "ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents probability of payment for royalties by indication.",
        "label": "Probability of Payment for Royalties by Indication [Member]",
        "terseLabel": "Probability of payment for royalties by indication"
       }
      }
     },
     "localname": "ProbabilityofPaymentforRoyaltiesbyIndicationMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProbabilityofPaymentforUnachievedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the probability of payment for unachieved milestones",
        "label": "Probability of Payment for Unachieved Milestones [Member]",
        "terseLabel": "Probability of payment for unachieved milestones"
       }
      }
     },
     "localname": "ProbabilityofPaymentforUnachievedMilestonesMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProjectedYearofPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents projected year of payments.",
        "label": "Projected Year of Payments [Member]",
        "terseLabel": "Projected year of payments"
       }
      }
     },
     "localname": "ProjectedYearofPaymentsMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PutativeClassActionLawsuitIndividualNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of the number of individual putative class action lawsuit.",
        "label": "Putative Class Action Lawsuit Individual Number",
        "terseLabel": "Number of individual putative class action lawsuits"
       }
      }
     },
     "localname": "PutativeClassActionLawsuitIndividualNumber",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_QuliptaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qulipta",
        "label": "Qulipta [Member]",
        "terseLabel": "Qulipta"
       }
      }
     },
     "localname": "QuliptaMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_RINVOQMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to RINVOQ, a product of the entity.",
        "label": "RINVOQ [Member]",
        "terseLabel": "Rinvoq"
       }
      }
     },
     "localname": "RINVOQMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of development milestone expense from research and development expense",
        "label": "Reclassification of development milestone expense from research and development expense",
        "terseLabel": "Reclassification of development milestone expense from research and development expense"
       }
      }
     },
     "localname": "ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&amp;D and milestones expense.",
        "label": "Reclassification of development milestone expense to IPR&amp;D and milestones expense",
        "terseLabel": "Reclassification of development milestone expense to IPR&amp;D and milestones expense"
       }
      }
     },
     "localname": "ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Research And Development Expense From Collaborative Arrangements",
        "terseLabel": "AbbVie's share of development costs (included in R&amp;D)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_RestasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Restasis, a product of the entity.",
        "label": "Restasis [Member]",
        "terseLabel": "Restasis"
       }
      }
     },
     "localname": "RestasisMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_RestrictedStockUnitsAndPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units And Performance Shares [Member]",
        "label": "Restricted Stock Units And Performance Shares [Member]",
        "terseLabel": "RSUs and Performance Shares"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceSharesMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_RestructuringReserveCashSettledRestructuringGainsLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.",
        "label": "Restructuring Reserve Cash Settled Restructuring Gains (Losses)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringReserveCashSettledRestructuringGainsLosses",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.",
        "label": "Restructuring Reserve Period Cash Settled and Other Adjustments",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_SKYRIZIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SKYRIZI, a product of the entity.",
        "label": "SKYRIZI [Member]",
        "terseLabel": "Skyrizi"
       }
      }
     },
     "localname": "SKYRIZIMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec0.750SeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "label": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "terseLabel": "Sec 0.750 Senior Notes Due 2027"
       }
      }
     },
     "localname": "Sec0.750SeniorNotesDue2027Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1.250SeniorNotesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.250 Senior Notes due 2031 [Member]",
        "label": "Sec 1.250 Senior Notes due 2031 [Member]",
        "terseLabel": "Sec 1.250 Senior Notes due 2031"
       }
      }
     },
     "localname": "Sec1.250SeniorNotesdue2031Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1.375SeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "label": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "terseLabel": "Sec 1.375 Senior Notes Due 2024"
       }
      }
     },
     "localname": "Sec1.375SeniorNotesDue2024Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1250SeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.250 Senior Notes Due 2024",
        "label": "Sec 1.250 Senior Notes Due 2024 [Member]",
        "terseLabel": "Sec 1.250 Senior Notes Due 2024"
       }
      }
     },
     "localname": "Sec1250SeniorNotesDue2024Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1500SeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.500 Senior Notes Due 2023",
        "label": "Sec 1.500 Senior Notes Due 2023 [Member]",
        "terseLabel": "Sec 1.500 Senior Notes Due 2023"
       }
      }
     },
     "localname": "Sec1500SeniorNotesDue2023Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2.125SeniorNotesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.125 Senior Notes due 2028 [Member]",
        "label": "Sec 2.125 Senior Notes due 2028 [Member]",
        "terseLabel": "Sec 2.125 Senior Notes due 2028"
       }
      }
     },
     "localname": "Sec2.125SeniorNotesdue2028Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2125SeniorNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.125 Senior Notes Due 2029",
        "label": "Sec 2.125 Senior Notes Due 2029 [Member]",
        "terseLabel": "Sec 2.125 Senior Notes Due 2029"
       }
      }
     },
     "localname": "Sec2125SeniorNotesDue2029Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2625SeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.625 Senior Notes Due 2028",
        "label": "Sec 2.625 Senior Notes Due 2028 [Member]",
        "terseLabel": "Sec 2.625 Senior Notes Due 2028"
       }
      }
     },
     "localname": "Sec2625SeniorNotesDue2028Member",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Selling, General And Administrative Expense From Collaborative Arrangements",
        "terseLabel": "AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_SeniorNotesDue2022At3.450PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2022 At 3.450 Percent",
        "label": "Senior Notes Due 2022 At 3.450 Percent [Member]",
        "terseLabel": "3.45% senior notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesDue2022At3.450PercentMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SupplementalFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Financial Information",
        "terseLabel": "Supplemental Financial Information"
       }
      }
     },
     "localname": "SupplementalFinancialInformationDisclosureAbstract",
     "nsuri": "http://www.abbvie.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abbv_SyndesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Syndesi",
        "label": "Syndesi [Member]",
        "terseLabel": "Syndesi"
       }
      }
     },
     "localname": "SyndesiMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "label": "Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months"
       }
      }
     },
     "localname": "TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_UbrelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ubrelvy, a product of the entity.",
        "label": "Ubrelvy [Member]",
        "terseLabel": "Ubrelvy"
       }
      }
     },
     "localname": "UbrelvyMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_VENCLEXTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to VENCLEXTA, a product of the entity.",
        "label": "VENCLEXTA [Member]",
        "terseLabel": "Venclexta"
       }
      }
     },
     "localname": "VENCLEXTAMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_VraylarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Vraylar, a product of the entity.",
        "label": "Vraylar [Member]",
        "terseLabel": "Vraylar"
       }
      }
     },
     "localname": "VraylarMember",
     "nsuri": "http://www.abbvie.com/20220331",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XCHI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHICAGO STOCK EXCHANGE, INC [Member]",
        "terseLabel": "CHICAGO STOCK EXCHANGE, INC"
       }
      }
     },
     "localname": "XCHI",
     "nsuri": "http://xbrl.sec.gov/exch/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "NEW YORK STOCK EXCHANGE, INC."
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r53",
      "r116",
      "r117",
      "r273",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r193",
      "r309",
      "r312",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r272",
      "r294",
      "r392",
      "r397",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r623",
      "r627",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r272",
      "r294",
      "r392",
      "r397",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r623",
      "r627",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r193",
      "r309",
      "r312",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r189",
      "r309",
      "r310",
      "r576",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r189",
      "r309",
      "r310",
      "r576",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r272",
      "r294",
      "r344",
      "r392",
      "r397",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r623",
      "r627",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r272",
      "r294",
      "r344",
      "r392",
      "r397",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r623",
      "r627",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r116",
      "r117",
      "r273",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r309",
      "r311",
      "r625",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r309",
      "r311",
      "r625",
      "r650",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r568",
      "r570",
      "r573",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "verboseLabel": "AbbVie's payable to Janssen"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r20",
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "AbbVie's receivable from Janssen"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r65",
      "r73",
      "r74",
      "r75",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Pension and post-employment benefits"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r228"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r56",
      "r65",
      "r73",
      "r74",
      "r75",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r75",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Cash flow hedging activities"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r62",
      "r64",
      "r65",
      "r607",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r65",
      "r73",
      "r74",
      "r75",
      "r119",
      "r120",
      "r121",
      "r464",
      "r628",
      "r629",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Supplemental Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r412",
      "r413",
      "r414",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r399",
      "r408",
      "r416"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Pre-tax compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "After-tax compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r105",
      "r214",
      "r221"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r75",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]",
        "terseLabel": "Net investment hedging activities"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r61",
      "r65",
      "r73",
      "r74",
      "r75",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r176",
      "r180",
      "r185",
      "r202",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r458",
      "r465",
      "r538",
      "r562",
      "r564",
      "r581",
      "r604"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r49",
      "r112",
      "r202",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r458",
      "r465",
      "r538",
      "r562",
      "r564"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r198",
      "r200",
      "r204",
      "r588"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r401",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r480",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r104",
      "r446"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r443",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Significant unobservable input for contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Book value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r107"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r102",
      "r107",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and equivalents, end of period",
        "periodStartLabel": "Cash and equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "verboseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r112",
      "r135",
      "r139",
      "r144",
      "r148",
      "r150",
      "r158",
      "r159",
      "r160",
      "r202",
      "r258",
      "r262",
      "r263",
      "r264",
      "r267",
      "r268",
      "r292",
      "r293",
      "r296",
      "r297",
      "r538",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r448",
      "r449",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/Collaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative and license agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r246",
      "r590",
      "r612"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityCashDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "verboseLabel": "Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,811,430,573 shares issued as of March 31, 2022 and 1,803,195,293 as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r84",
      "r596",
      "r618"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to AbbVie Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r83",
      "r456",
      "r457",
      "r469",
      "r595",
      "r617"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r82",
      "r455",
      "r469",
      "r594",
      "r616"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r193",
      "r535",
      "r536",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r193",
      "r535",
      "r536",
      "r634",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r193",
      "r535",
      "r536",
      "r634",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r164",
      "r165",
      "r193",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentrations risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r161",
      "r164",
      "r165",
      "r166",
      "r535",
      "r537",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r193",
      "r535",
      "r536",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r87",
      "r576"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Losses (gains) on foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r589",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "terseLabel": "Aggregate principal amount outstanding"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r111",
      "r118",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r560",
      "r582",
      "r583",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r269",
      "r288",
      "r289",
      "r558",
      "r560",
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Principal amount of unsecured senior notes"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt and Credit Facilities [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r111",
      "r118",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r111",
      "r118",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r299",
      "r300",
      "r301",
      "r302",
      "r557",
      "r558",
      "r560",
      "r561",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Debt and Credit Facilities [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term loan credit agreement term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Potential change in unrecognized tax benefits"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r105",
      "r113",
      "r427",
      "r432",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r322",
      "r360",
      "r379",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined benefit and other post-employment plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r322",
      "r358",
      "r377",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r322",
      "r326",
      "r357",
      "r376",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r355",
      "r374",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r324",
      "r356",
      "r375",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r105",
      "r226"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r484",
      "r574"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Foreign currency contracts",
        "verboseLabel": "Fair value - Derivatives in asset position"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r484",
      "r574"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Foreign currency contracts",
        "verboseLabel": "Fair value - Derivatives in liability position"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Derivative instrument net gains (losses) recognized in the consolidate statements of earnings"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r53",
      "r481",
      "r485",
      "r493",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r478",
      "r481",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r478",
      "r481",
      "r493",
      "r499",
      "r500",
      "r503",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Gain (loss) on derivatives"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount of derivative instruments"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r471",
      "r473",
      "r474",
      "r478",
      "r479",
      "r487",
      "r493",
      "r501",
      "r502",
      "r506",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Duration of forward exchange contracts"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "auth_ref": [
      "r514",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.",
        "label": "Derivatives and Fair Value [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measures"
       }
      }
     },
     "localname": "DerivativesAndFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivative instruments, notional amount and fair value"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed product rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of worldwide net revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r85",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r132",
      "r135",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r512",
      "r513",
      "r597",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Per share data"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicTwoClassMethodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Two Class Method [Abstract]",
        "terseLabel": "Basic EPS"
       }
      }
     },
     "localname": "EarningsPerShareBasicTwoClassMethodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r85",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r512",
      "r513",
      "r597",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Two Class Method [Abstract]",
        "terseLabel": "Diluted EPS"
       }
      }
     },
     "localname": "EarningsPerShareDilutedTwoClassMethodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r114",
      "r422",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and employee benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r157",
      "r203",
      "r298",
      "r303",
      "r412",
      "r413",
      "r414",
      "r428",
      "r429",
      "r511",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r628",
      "r629",
      "r630",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Carrying amount of investments in equity securities that do not have readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r278",
      "r288",
      "r289",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Approximate fair value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value, asset and liability measures",
        "verboseLabel": "Bases used to measure the approximate fair values of the financial instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of significant level 3 unobservable inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r515",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of book values, approximate fair values and bases used to measure certain financial instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r278",
      "r288",
      "r289",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r384",
      "r516",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r278",
      "r288",
      "r289",
      "r515",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r515",
      "r516",
      "r519",
      "r520",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r278",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r278",
      "r345",
      "r346",
      "r351",
      "r384",
      "r516",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r278",
      "r288",
      "r289",
      "r345",
      "r346",
      "r351",
      "r384",
      "r516",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant other observable inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r278",
      "r288",
      "r289",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r384",
      "r516",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant unobservable inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r521",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in fair value of Level 3 inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Transfers of liabilities into Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfers of liabilities out of Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfers of assets into Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]",
        "terseLabel": "Transfers of assets or liabilities between the fair value measurement levels"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfers of assets out of Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value recognized in net earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r278",
      "r288",
      "r289",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r384",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r525",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r215",
      "r217",
      "r220",
      "r223",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r220",
      "r578"
     ],
     "calculation": {
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r215",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r220",
      "r577"
     ],
     "calculation": {
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyGainLossMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).",
        "label": "Foreign Currency Gain (Loss) [Member]",
        "terseLabel": "Net foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r539",
      "r541",
      "r543",
      "r545"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Net foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r53",
      "r345",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) relating to components of the gain (loss) on the cash flow hedging instrument excluded from the assessment of cash flow hedge effectiveness. Recognized in earnings.",
        "label": "Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net",
        "terseLabel": "Amount excluded from the assessment of effectiveness for cash flow hedges"
       }
      }
     },
     "localname": "GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": {
     "auth_ref": [
      "r491",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.",
        "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net",
        "terseLabel": "Amount excluded from the assessment of effectiveness for fair value hedges"
       }
      }
     },
     "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r163",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r206",
      "r207",
      "r564",
      "r580"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r478",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D and milestones"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r176",
      "r179",
      "r181",
      "r184",
      "r187",
      "r579",
      "r591",
      "r599",
      "r620"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r230",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r423",
      "r425",
      "r426",
      "r430",
      "r436",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r130",
      "r131",
      "r175",
      "r421",
      "r431",
      "r437",
      "r621"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1": {
     "auth_ref": [
      "r481",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.",
        "label": "Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge",
        "terseLabel": "Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "terseLabel": "Income tax assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r150"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r213",
      "r218"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r174",
      "r556",
      "r559",
      "r598"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedLabel": "Interest expense, net",
        "negatedTerseLabel": "Gains on derivative amount excluded from effectiveness testing",
        "negatedTotalLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeAssetsAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.",
        "label": "Interest Rate Derivative Assets, at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateDerivativeAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.",
        "label": "Interest Rate Derivative Liabilities, at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateDerivativeLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap contracts",
        "verboseLabel": "Designated as fair value hedges"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueOrExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Revenue (Expense), Net [Abstract]",
        "verboseLabel": "Interest Expense, Net"
       }
      }
     },
     "localname": "InterestRevenueOrExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r205"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r48",
      "r564"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r205"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r205"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r89",
      "r173"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Money market funds and time deposits"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Proceedings and Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r112",
      "r202",
      "r538",
      "r564",
      "r585",
      "r610"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r112",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r459",
      "r465",
      "r466",
      "r538",
      "r562",
      "r563",
      "r564"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r277",
      "r287",
      "r288",
      "r289",
      "r583",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt obligations, gross"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt and finance lease obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term debt and finance lease obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Legal Proceedings and Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of plaintiff claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of parties to lawsuit (in investment funds)"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of healthcare benefit providers acting as plaintiff in lawsuit"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of claims pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Length of Time Hedged in Cash Flow Hedge",
        "terseLabel": "Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold"
       }
      }
     },
     "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r47",
      "r112",
      "r202",
      "r258",
      "r262",
      "r263",
      "r264",
      "r267",
      "r268",
      "r538",
      "r584",
      "r609"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Change in noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds and time deposits"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r102",
      "r103",
      "r106"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r67",
      "r70",
      "r75",
      "r80",
      "r106",
      "r112",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r146",
      "r176",
      "r179",
      "r181",
      "r184",
      "r187",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r513",
      "r538",
      "r592",
      "r614"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTotalLabel": "Total reclassifications, net of tax",
        "terseLabel": "Net earnings attributable to AbbVie Inc.",
        "totalLabel": "Net earnings attributable to AbbVie Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r70",
      "r75",
      "r130",
      "r131",
      "r461",
      "r468"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r132",
      "r133",
      "r147",
      "r150",
      "r176",
      "r179",
      "r181",
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Earnings available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r134",
      "r140",
      "r141",
      "r142",
      "r143",
      "r147",
      "r150"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Earnings available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r303",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument",
        "verboseLabel": "Not designated as hedges"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r176",
      "r179",
      "r181",
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating earnings"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r57",
      "r62",
      "r540",
      "r542",
      "r547"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments, net of tax expense (benefit) of $(7) for the three months ended March 31, 2022 and $(25) for the three months ended March 31, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r76",
      "r548",
      "r550",
      "r555"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r62"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months ended March 31, 2022 and $3 for the three months ended March 31, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Cash flow hedging activities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r62",
      "r483",
      "r489",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r55",
      "r63",
      "r544",
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r68",
      "r71",
      "r73",
      "r74",
      "r76",
      "r81",
      "r298",
      "r548",
      "r553",
      "r555",
      "r593",
      "r615"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Pension and post-employment benefits, net of tax expense (benefit) of $10 for the three months ended March 31, 2022 and $19 for the three months ended March 31, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r60",
      "r63",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedLabel": "Pension and post-employment benefits, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]",
        "terseLabel": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r480",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r318",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other post-employment plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other integration"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "terseLabel": "Earnings allocated to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted",
        "terseLabel": "Earnings allocated to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Acquisitions and investments",
        "negatedTerseLabel": "Cash outflows related to acquisitions and investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r317",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Defined benefit plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at fair value measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]",
        "terseLabel": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
        "label": "Postemployment Benefits Disclosure [Text Block]",
        "terseLabel": "Post-Employment Benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt, including capital lease obligations and mandatory redeemable capital securities.",
        "label": "Proceeds from (Repayments of) Long-term Debt and Capital Securities",
        "negatedTerseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Sales and maturities of investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r94",
      "r411"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "HUMIRA"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r67",
      "r70",
      "r75",
      "r101",
      "r112",
      "r122",
      "r130",
      "r131",
      "r176",
      "r179",
      "r181",
      "r184",
      "r187",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r455",
      "r460",
      "r462",
      "r468",
      "r469",
      "r513",
      "r538",
      "r599"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net earnings"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r227"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r229",
      "r564",
      "r600",
      "r611"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Significant amounts reclassified out of each component of AOCI"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r548",
      "r552",
      "r555"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "negatedTerseLabel": "Amortization of actuarial losses and other"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r76",
      "r548",
      "r552",
      "r555"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss",
        "negatedTotalLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r73"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
        "negatedTerseLabel": "Repayments of long-term debt and finance lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired IPR&amp;D and milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r233",
      "r236",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Integration and Restructuring Plans"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r232",
      "r235",
      "r241",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Integration related costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r232",
      "r235",
      "r241",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Charges associated with integration or restructuring plans"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r233",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Accrued balance end of the period",
        "periodStartLabel": "Accrued balance beginning of the period"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring reserve rollforward"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r303",
      "r415",
      "r564",
      "r608",
      "r631",
      "r633"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r203",
      "r412",
      "r413",
      "r414",
      "r428",
      "r429",
      "r511",
      "r628",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r317",
      "r318",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r317",
      "r318",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r447",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Collaboration revenues",
        "verboseLabel": "International - AbbVie's share of profits (included in net revenues)"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r171",
      "r172",
      "r178",
      "r182",
      "r183",
      "r189",
      "r190",
      "r193",
      "r308",
      "r309",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r78",
      "r112",
      "r171",
      "r172",
      "r178",
      "r182",
      "r183",
      "r189",
      "r190",
      "r193",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r538",
      "r599"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenues",
        "verboseLabel": "Total net revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r164",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r65",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of changes in balances of each component of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of profit and cost sharing relationship"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r481",
      "r493",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of amounts and location of derivatives on the condensed consolidated balance sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDividendsPayableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.",
        "label": "Schedule of Dividends Payable [Table Text Block]",
        "terseLabel": "Summary of quarterly cash dividends"
       }
      }
     },
     "localname": "ScheduleOfDividendsPayableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted earnings per share, impact of two-class method"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r399",
      "r407",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r215",
      "r219",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r215",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of definite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r222",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r241",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r237",
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of charges associated with integration plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r233",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Summary of cash activity in the restructuring reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r401",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r176",
      "r177",
      "r181",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair market value of awards vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of the stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r398",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r12",
      "r564",
      "r582",
      "r605"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r586",
      "r587",
      "r603"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShorttermDebtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.",
        "label": "Short-term Debt, Fair Value",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShorttermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r110",
      "r112",
      "r135",
      "r139",
      "r144",
      "r148",
      "r150",
      "r158",
      "r159",
      "r160",
      "r202",
      "r258",
      "r262",
      "r263",
      "r264",
      "r267",
      "r268",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r538",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r73",
      "r74",
      "r75",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r157",
      "r203",
      "r298",
      "r303",
      "r412",
      "r413",
      "r414",
      "r428",
      "r429",
      "r511",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r628",
      "r629",
      "r630",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r157",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r298",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation plans and other (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r303",
      "r400",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation plans and other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining share repurchase authorization amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r112",
      "r197",
      "r202",
      "r538",
      "r564"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r74",
      "r112",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r202",
      "r203",
      "r303",
      "r412",
      "r413",
      "r414",
      "r428",
      "r429",
      "r453",
      "r454",
      "r467",
      "r511",
      "r538",
      "r548",
      "r549",
      "r555",
      "r629",
      "r630",
      "r670"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryLockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.",
        "label": "Treasury Lock [Member]",
        "terseLabel": "Treasury rate lock agreements"
       }
      }
     },
     "localname": "TreasuryLockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r45",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r45",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Common stock held in treasury, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r298",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of treasury stock (in shares)",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r304",
      "r307"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common stock held in treasury, at cost, 44,557,588 shares as of March 31, 2022 and 34,857,597 as of December 31, 2021"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r298",
      "r303",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payment for shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r134",
      "r150"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average diluted shares outstanding (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r132",
      "r150"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average basic shares outstanding (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r664": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r665": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r666": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r667": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r669": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001551152-22-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001551152-22-000017-xbrl.zip
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M-J,1S=7->6Y/.-SX3M752&3 $"&"^)@=Y&@9D4<CG%W,>6Y/3!B*(Y3B@DF
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M)J2*1H:P*C P-_U+D?_HWH.?'OYKC*Q%1KH5JL3D 'P+2'.,F9(8X\FG7 ;
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MH]D+FO] \]KD.XY9Z;NG>IN6HZ2Q9OO 6Y]4;0&JB"&Z;$).$DW)?@1]SB9
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M$>GVN\2,0U@[G2 Y+I8TFB"*\YFJ 365&T6R1XM=SB_PQ)([CPZV O]!TF5
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M@_V@Z4.T,'P(1HUV.HO_#J2_O/24366H:]V&;F;[[8;M.)]5]NZ#!_R@0<\
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MY539\@/5=GMWKJCQVS:+M6X<7R-%/4J[.-$N7AY1:#Q2U@+EM(YV$7J@&>0
M*8J59%P%3V_L(IUKNUC;7:ON;27K-VW#.!>*/1?&N/]#OX;6..VE9],5BTE#
M&J":\[;3S8.<[\XCP'73I^X7F$7\=_8S.YR_?J=<UJDOZZ^T? Y"@1\ZK5:C
METKJ91\;39]%,V!\]]W40U\;>7&]],C!$]^<G=ZY/%+6$*7QC==*/7' ,$(!
M4U 0(JW1G*>RB0@0QC@;M=0O$#R=1E2WT3K.>ET[J.;Z0U:.CM'*R=GQ4J:;
M_?LNW=TMP?+L\DD[/)R>72[]-8<QZ*FKWZX_;O22P>]7XY6WIX+P2&+*";((
M<"(B51:& ^.0!(XK0306D4"+I=4U8[XV?+;5MBOWT>6%V96D8D4R]:!=R<=<
M0RM2/FRO\[&#Y0\;T,T6ZMW]4K4TXC1'DWN9-CW'S>[8I'?.BE+WT=C]&&KF
M*_G'QJ6V_5Q'LT[(NC]T,].]K'?F;2J4Z[)&.VOT>YFMYS&SGW'^>^> /&0.
M4BQA\@S, @]_N[D!9P*'4;\[W;,;7IJW,/@P:+_RH>/\>)RAESYQUNU\3_=9
MT+#@QX;9W.>')^\;U93J^VWK*GX/5S=W6X<G]?H!WL<'M0U4/?ET6JVE(B7[
M-]_Y&I_%VH>ULU9E<PL?KN]<'IQL1=@]@(>;AZWMS8\GA[7#>J6VCRNM'13?
M^_+P:QQC;2UE(\7_VOA.^]='(0@I4Z49Y%+ZO;04&,\8(!Q!@35-#6&65M=]
M4U_HKO]U1'&($+\0_#OY#J6./$5':OIRZZ9JM\WU9('I^ZR%?^NN\%OIO,%:
M@9#*\5'N&)#0$8""5,B$H(-12ZLD57T7#%'Q /%_N@&8%R.8PV[6Z6:=5, ]
M.SGO-GJN8?-X5+2*C=L0G7^L>ZS;C>O\][O&\.U P3U3N;6RN[*WDOG66;-S
M%>>R<4=OLW:NN'\6&@%Z&$AE]TGN,/OLQ6(F#\NRF#K(KCG7];W>S7\^QP&@
MA0389SEGY$@%SC2&"C#O4FT%*8!B0H((FMCZU.X<ZZ55E%4[W7X]^Z;/3WT$
M@VRWH]T<Q$KF2Y8^Q!^WN[7.Q6+RU&=)$CJBD5 2KCUP++GYUA"@./0 "6B,
MTT9I8I=6!W+T(34K.^Z,2M#RC$*B-^N5V\'MU,'D>[1YK]3[>-8^Y]51$ ZG
M!E9 $1OQP2 )-,,>*,V%)0)J%=C2ZE8S:EVGT1N'A!DMY9=.7*OF8>-LX$:^
MM76Z/H*1Z(84YY;*1Z(KJ0,R3B5(.NDT"1[A2'0YA)P"'LG,P\'[ <<%9L.X
M<BRO^:8_JW?:_EVQ^VH/S/V<HCPGZ['6]?I-2O#.U9&1G#J%($!:1 D.$61,
M<!A@Z;GTR'(MS-*J'/?1_IPFRGSN1._C2Q*X!7;"G[4R]$AS(X0/""@9C3K%
M"@+#20#&D4"$QQ@IO[2JHA<MU!.1I<!<C-$]V<DXLM5VR4GSF;G*;-W;TZR5
MTKHOZC[WB5.6QJWH\!_H)N.EKGM9:#2]RW2S&3^1LJ-Z\;__>][HQC_V.YGQ
M-Q^(-][SN5/](WLF^M*WLF>BJYT>$S\4'?!^P_>RC4M;U^UCGZW9?O+$4_9,
MYN+5]G'^T;.NMS[YRQG"69XWV<O^B#>-O"7KG=MZUJMW4L1ZF%72K^O^Z*M<
MZ+OC38,=?/GF;?Y<SG3;97_@6Z]L(ON)'S(G\872E_+/QV^FH=S<+.6-]?*1
MY"/5O7ZF8.;T56_ET=OZTR8-'\Z[W3C<07);?(=$!,][;T^UKX\\IYQ+98%@
MA@*J6:1W'"G O7!$:2U]2CH]\!.8W>.L[T-S(.$#<VMN\LT+9  /PXTL>L)S
M\.[T0;DO<XZJ"5DBJ+0:_7[$HDCL;+_;::=P7_,J\]]]]RK;2@Q31Q3][K-U
MW=>#!)H1O/UYC[/S;N\\W3I>V#UO^@&>4,@2FN[ZX_/!6=YL#]2R/])%\3<F
M>.7F _UZ(]_T.TN;?M/&W<&@?R"I[_TY?SAY:_;3Y-_ YIO#R7UXI VECDD#
M@DV;:%Q:( UT !/G-(/>6UKB9(F3T\')B$HZ:\;A^DQ;&W&RJQ/8)=3H)K(V
M\:]9%$(P\4*O%0$V/J4[I#\1.5KQW:^6$T&-MXM<+DW-<7;<[5STZ\/+*Y&J
M^GQLSH=&.\]?[B7<_.__DA%!_KYOA/EE]/?P8[_]P/WC&WXP\=.E>T:YE+(W
M?F(_P@;@[(9JW^;7*\\)>"Q,)A*!*X@5GS.D5B"1Q6<BT16">.&W17@%JH?=
M=G;)/;>K=DP?=&:3MY"X6?=#5.SC3O=J(5G"(%LA/O/TX-L!JUP?I^_ ZN;^
MY<'),3VXWF+;F]73RLG!Y4$K]0?9&LU6.#GXMEL_/#F]WLZ9Q0X\K'UL;*_7
M3RHGI_0 [UQ53U)CP8V+2E->C*7J("JPLY@":2$&U-GX$_804&*%8JE:$T5+
MJY]SG%V[!:/YQ#\[<^>!4CV IN)/O_W6JL,)C.9IKY4KWQ3S,!ZFCQ-6\#DO
M=3\"O=Q"T;\+RIV<CQ6K1DHU@U6; PVCKT+#]NYCDJ]*TZ9NU_-I?'_>BT_N
M]5[C6>"9FOUH[BMWS3XFBFDJ.9 .&4 9#=%Q,]'VDV M$M8JI7Y[EO@Q /N(
MQ+SGY?#-!PQL3/842Q!X# @,)W$SG\,/0V>[!(-G@<'5&!B(0+2USJ9BG]$'
MT%H#XXT "E),C"!*0/X(,'A(NB>9>?@K_"+,M)PU)D?'&F'2!D*^;1"Y6+N3
M1_W/>X,0513^086;"6?M.]W\6<VK]/"+1GQT?&S6]A<I_M7UWQN]/#35UFV;
M5#0N1SJBDC[<Z^NVTUW7RU)66,.-;#G<[/=FB/RA_YP8=)I22/1AT_[*(J*]
MNF\VAU*3_1%E(8]+#LYO/2 "^/@-EP/?FZN8]DSC^2\>T)\^STT"-<FRO0N-
M2^_B:S5[;S UBQU)%E= *P^\X1Y0X2C00D(@.'',46:A"+\M C=7<',KZ68
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M^PR(T=1T(EU]I&[,#)A+P'OS@!>1+" GE B!4.V@\L9(AF14&F5<&)0'1D/
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MKD_9$99&.$@)\)Q!0)$50!MG4YQ3:"JC'!"XM$K&5?^Q7NQ+A,M+@5PP@=R
MU9TCS$B4.H. 9<9&-Y61Z*%2"@*G$:F<CF04+ZW&97^Z3+X%-W6"U9MSPKH@
M-NL'(TVYVKO>-G6OUPAQ\M*@(]:5$/)H"!GU0RV63B.) '/8 \HT!EH&!&#
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M$JLD0BPB$5N&SZ_P66Y7S9\"%[==52KPC!1XM-M'(!@ZRX'AJ6,NE0)(H1F
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M,%5<0<=3$YUE)<<KSS\\JEK&,.90L9]..DK%GD/%'J$BV*NHV90#SD@>VH#
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MCJ@"VT; =CJFQT1G(XT*!:,)XB$8Y!R/R#KFE2!!6U[Z^:PP;!E)+AKI8O
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MQ@5;5S0W6R7Y"O&-:4=PX*73WJ"=#_BM'SMPY-=X&8'X_UVOCCSF27SY%>N
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M,$SJ\%OC6S3AA%J_G9U7X]O[LUX/X*1U 8.H_>O8]F.-.%@"&$[L;];.CYM
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M6AM5[?TU:M%FS4VJ145YT*1F52M\J_UY3:TPN8?*SV^UX^XY3$MO<X*3RA-
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M 7!FX^N?[?K73]\.3@)PW!<ZFX-[L/N%U4]V8"Q'[.#K&YJY^6#W^%M]=X<
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M073TV+B0V!W-VRLP>!$RL#))2F'=@V 2\6@CRIYFY#2.&&O"'$MK1085&#R
M"F!M A>4(%@N$ F)YXU5L4;!D-QZ('!/8VY'<K=*> ^E<60(9O-^,?,\JW9S
M:7$Y=C1K>C[55@)+Z+9RM97 E?4R4??^OO-YE)D D#:JC/_7,.6\:LZR]Q[&
M\.50L&2"%PXE3_-.P%HC&PU'D29EN0I!*K;J^PR,^:#P@7D[KA*9[O]P@_.M
M>VMZRZCG7/\XQD%__78?H&K+4+7\W0?8EI+W*T!8J%IB"S.]0G>]_1@W]]M_
MX35/+&?+K$*Y<<MN<Y\RA;+F8!7VJWA[)4<+^"&_U8HL_XD.846;D'[.B!N5
M03UT2XM7-4^STU3&A4?;?[1&]8CEUVMG[B?=[>2A75Y7AQA^+T5M^>J%O"T_
M@NIQ3_98_SFXO:GMJWSE.[>@>0@.OJ8)JOBBXHLYOKBK6_C*]OR>??GK2WC?
MWC^+=%G$L"PLJ>[S O=9TN8=92MWND7%:K+%[JV%K??AA ?L8O(,K=OO]_;_
MZL53VPRC%**)W4P>LU_#"_7OO]\K+[POW4LVX+_?*RT0 K%1X$"3D\1KC@W1
M$ENF':$T^.C% _I4COV^DU[C'/48K'OY[; ?_]O6ASU_V=A]3QM[7RX^['UJ
M[^]]X0WZUTGCW1OVX=U?K8.3-S_R9K.S_?CWOWX1C<LZKI_D=MWO1>/=P7%C
M[X@=P'CW]SP_^/I7N[[WANU__2OOM7(QTX\?"Q<X2QIQ@R/BWEFDO9 HZ*2)
M9P8S:S>VZ:-W?%KBCBL54+P6H&#:2*<TH2%O4\"%MC)&XBFE*7@1^.)M&"J@
M6!907,X A8S6<Q$$@N50.6LF)T$:BAP)>8<5(W20&]MBON7IBP+%0W2I^VBZ
MZZR/[7A?!MZ&Q>YEHM]PLZ:1J[8YKY=6H/LJ0#<DS7DD&@=FN33>)J6\2T%R
M'".6#^B6<BWH_G/D\Z^ =S'@I3/ R[P,U/. *!&Y&BKW5E%8($FQ$<%$K+C8
MV):KA;L55KP*K*!*@PU %:,I<BR\-0K,!.>MYI8Z<5.A0H45SX05; 8K*! ?
M!6L;69YK[;QCR' M$!><8<T25AJ#-;="6'&'!W"4B@.#C;>K9-69TV<N:4OV
M]7*M7EN#^2#_ZMT;U*\,GM_?O[INN]0_@3P3QFG*33*.>VQ=<MS)B(,()!&S
M+-VW<C@L*LL:G^<\D[DG9Y1<(N>$S#U'--(8!R2PH-*[W#9$K]A>]!6+ 8N1
MZ(*A+C=AXP$^>L8QD<E%+&32N/+IO1R+S?KT%"5!2LY1("P@GF1"CL: -$F"
M<AH24V!:$C[?FF$U>&P! ?X@I]X:*0$/=>K]]'B5&T6FQ(DD/JL$W#!A1%3,
M$R<]%63Y[K [2K J++L7ELVZR2R75CAE$-6*(LZL1SJ XI H3E8[9TRNYRS2
ME>EO*XIG/RL/<LHPC399Y0EG,5J2#/-"&FU9B"8MW\U4\> R>'#6_:0C3J!1
MY$V_J$"<4PK*NV(((!4 5.?VH&$5>?"G3$-;GJ]DC6*?'XI=F8H"GH>I0O>-
M7ZS,&R\"P\(:&:C&1#B>.VE[K(!IE92,44%-Y1UY*:AMCKTCO+X+YQX=8JVL
M=,8C0:)&7,2$+)4!L02(F_U93H"ZP]4*N?HK%@,JURE2'0T#70;DH]7*1*E4
M$)I$C-6R FH5BSV Q<;>D0^[=5+_>&BIX8GDCN8I;]"HF46.6XRDA*7S43AO
MY,8VF>\3MAHL5F4\S4C]JRTK'^L/><T(14D2*1G,.?%<*:-!E #5@UEFN+-F
M64I %?)_($K1*T6@_J-^=,@-6$$Q&)2,IHC;W,!(<X9DL8<O3D)J!XK BH+4
MS\IE&.2]B=Z[O#M*(-RQ**(!KB,ZVD"7E?E<>3R6S'ULDOL:'P^%(-QJR9&*
MTB+.N$3:LX DTUHEFZ+49FD>C^=+NWDMV2&-&W;BJE)"*M_S."5$4L=)##(Q
MSB5Q*42="&,LA62,K)P>+^_T&->@."^E"0I%9<$L8UXC8W% AE,>N%0R*=!U
MY/R^)55XYR59S 3IE>(Z.<UYTDPK0816TF?C0LO*Z;$*3H\ABWDO'5,8(T^C
MRTX/@1RQ%I%@I54!K$"B-K;IH\L-JHR0*B-D1>&*,^$8%H9:K[@*1ALOL%1:
M8YTB";CR@*R&!V0$60:4-65HMKRB1!Q+@@PU#D58/FD9LX&##497-8GMIV4S
M!5J<TE$I+SGVV"A@,!5)%-8*)D556[0:KHX1FR4JN6/!(E"U">*6$>0X#RAW
M^' .!\I23A9=)>5[27D=J^C9>'_+QE3+2.)81DBHNL<3W^,G\>(]0?NL-=+C
M*U_>_3?BH3A(+WPP1/! B"N<#I8J+B2E]*9=\A[H:*@B*H]6,S[\,>?CB]$$
MKIA'V$F/N!<&:2LP"MY23F6*T8I5S"&M^&^CF3?6\U38'/OBL(R.<:>),C'(
M$"PFRW7T5?RW#/Z;=0#R2(,REB( 3XZXL!SXCRJ46PL(3Z1Q"J\Z_U5>P,H+
M^.BX(%=2Y!Z()#E.<[9M(B*2A+5C2L@GJ NK<&L1W)KU O( 6$6#1%3G+;RT
M)<@2+Y P+#(7""?<;VP_NCU=I3$LE<LTEP0'X@(%<8.3,SIBS)F*5,O \+*J
MQ2LN>R"7S3H!K0/.\M0ABYT!+@L>&0I_A$Q,R\093\!ECZXZ>#X?X.HU[EF7
M,ZN)797.3:^A&G%N"\NJ$O%G3H\VAAD9HE#>@_(=''.6)2NYD=%HO.2DO,J1
M\/A>A%E-:.(?65V :RX:>_5#84 GB%PCJEP.$W*/M%8849^B$2(HEE.)5B\W
MNF+ C:9T3E'F=5#!<*&DI9%*90-V(>)0I>R]+*-=3#-:M)8Q)BW"EH)2[A(%
MTU>07!&D8=$$BP8O(V>O*E2L"A57!Z*2YHECYB0EBA,>C><J2QIXUYABJOJ8
MOS1,-6;T@>!MT$0+E)ASH ^D@)R2&F&-A6::"9_XQC91C\X@JG2!Y:;O&X8Q
M2]AK!;J 9(XHB2GW$7/&L%E65*]BM <SVHP^@ 7SG'N% !@IXM039*SE2!F<
MC$S461M7K''!0S.9AEL.EC?[E<'30_<LA[E&C+/N.VKN=0>V!6PUWEG[,>E.
MRYFM627L^=;HE>P4L?QY67<1HQUUW&F7VTUQX8(#'-*2Q40M2TY5?;E?3KR\
MG_/K@"(06<Q!'V<8X@$;I(.A0#OPV6J'DZ4@7O2R:L26BO%+W]"F KD*Y.[9
M:3A&(E5B4DC*%0G6*4<39=1;&XR-E4_M)4%N1H>V)!IK D?6RX"X,1Y90@)2
M8/B8I"TE)F2?VK)"W2L!<B^O2[[\""J@KX!^/;39RF'R4+"?]4PJPZFR+*"D
ML$)<&HQ<\AH1D,R>!QT4=P#V2ZMM7 FPKX"N KKUT&@KH'LPT,U&BCUF1M.(
M<,R;9"CBD*.,(\:#D=90Y0W;V&:O1ZDM_,I_'^3*A^W12S7.VD!:'KZ'YO?M
M?\"?T8NT;>^HV1F--[/+\)<\0%VHB4MA1(+OXD2:.?'K<1/FRL/[V69GT@=<
ML[U8ZY^YD^@'M4$WM_(?P$S!SSW;.8JYGW^_=MX<'-<&QW"#;AL&?5$DVJC?
M^K6B("3V3FTOQY4W)\^!]8&[=[J#6C<E,",G'CI,52OJ1R;"TL5C8'3E33HA
MEZAF-;Y3K&61W>=LRW8\#/@XP@VVQD14S'Y>DXPIS<Z9+2AM<CV&LR$X3-=I
MM]_,)_S:BZUB0+^=-\/@> 1:$U<-EP]?76(=C.9L</,E$\LLBF4N*.;JA@65
MPG*W[&D__CKZ\-LH>[/9*1:ON.BW:2+*R9<S%%I0<'GX:D!;N!S4, 8R?/+P
M\%9Q:(;KRF.&;6EA;CR,M\B-QVZ[+=LR_.8K)^]Z1^1FP1!+NQE"*TXOSBS'
M+XT+R8@+BSO]VAS Z?X>$C)K[[6WW5Z[1C#Z.*+G)8]I. )U[0AJ_UL;/;;9
M/JKU>_[_;ECGOJ.187%X1+>.FFFC9EN#FPY-,QD\^<=#:%?BTQ\;?Q^S\\UV
M_'(IP<>,8<L'Y!M)X?J%(&0&SN:%3OG[Q-_CWM64'$7D>M%^0S;!Z_QJ6^?V
MHI^G<Q*<8$4FD? F$+N!3[;_X7IY?::&6?R=@=Y2I6+*RY"\)\99KH.T7,3@
M,#>22N:I*%5 N":&G9PSZYD%^\@QQFW@1#%-(O?46HMQX,K[:X'V-@D[):1G
MZOL336"<,0'/XX18&); 0GM)O72:Z</=@L@))NC*PIY6-3_[XQC.6J!?_F'[
MQV];W?/_*=+-WW=\ZRS$\+ZSX_U9^ZR515>1CO4'B,9>/ ;!!D('3NNVXS^[
M_?Y>7MX]&-KOK:[_MI[Z:"O^SZ>+@Z_AU%$NZ_13LW%Y] .>UZJ??,&-W4_?
M&KO')W ?O-_^^*-^V?C6V'O;:IS\GG7+'_7=-X?8^)""Q2@*"X:SHP)9, )0
M8!)'AJ/5!H F@M9^F@FT=Q:?<8$;<?!^O+_1:)6KU;WGZE[N9&LA;\(+JYM4
MWD.>201:06ZLYKE(&A:8L[G5?4X%>0^4S@3*6/<\:[^ES@:KV2_TWZR1PA?0
MRG[4;+LL@NZFVA'HTOW:+RU8Y-C_6RWUNNU)+1<.PHN4&G0O^NY1!\83X.>R
MY4JA*(_II9;O\NL(6M=&9]1DRPCQ()WQ]F/<\/M>N1:56(M,JMR22KWLG"XR
M5GWST0=H]_<(XRQPZO*6U]Q'^RQ5R>=UO5VO3>X=]V*LM>&\XWXM@C$="MVM
M;GO^N,;(YI3_9;F&UTN\[B^ JG"W%NB>_;_=(Z_M14CH:<]\:'KBZM!LUL/N
MDY.XK&CP:Y@PL@@CKVX&Z]U:6O'";[L]^-JI^;->+W;\1:ZW/+>]W-'.'V=_
MY6*=*Y=$2*\*(9;%.$]RG[6O9[\GG3]!F\K%R]]6DJP?73:S,FM\_VCQ=:_V
MS/'>>[[3+XOL7YJD%C(F0YSEP5 3I)"2&DQ88%A>[Z"9#OUF)H%/LWZ;V[PQ
M4ZZZ=V# YQ]_CR!'XJ?H6[;?;R:8Q3SXG4[8LS]>1Z#XI$X.]CZ*QLD.;M O
MY_N7_Y^]-VUN:EG2A?^*PM$WWM,1+N\:LJ:]^W4$8.!RXDANP&S:_D+4B.5!
MXD@R8$?_^)NUY%&RP8-L)%&G>X.QEM:J597/4YE9.;P]:6^]ZG9>OZ7X#-$Y
MW&8[>X'AV+J3!\7MD[\/.AO[O+WQ5NQL/=_KE&:!']^49^+[!+ZS]_=AY^3O
MO>V/_\SMXZEB6L+(%&10Q.""$Z#1$R>"(R;A+T'+[#6LK$\'>$]I\0N42UQ)
M:IY)ZBY52+GA.8%T44;(SGO0F2>>K( ( +3A*';&4>SG<7B5FGXA-<%DMX^8
M%"ZJ(8S;1"!)0;QVC@C+,V<I!A;DRKI8AN3&Q5: >VG4ZIZ?O\RP6/NB:L&W
M2B2?HV*/LV?F&6B/MV?FZ>._2L\SIN?.=!E6QJFBFFMB+?X!1GAB0"HBDW6>
MQI0B%2OKAL]1A<A9T]!O"^\G5;PJO)\"WI/:%["8 R1*,EA+@&=*7'::1&N9
MS%;&3-$PM//4:^V^[L>KP<M7?9T+X7?_48NHB:[8LW16WFK>EEJ'NZL +<\.
MH- "HR8C%5 *AH-+V44MG)=&,FWE3!6\:GH_*OF_G]+M/ !N[P(-;J\<FMX
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M/<D%S5:[II[IPVLL5[*K9+?@9#>S+*=*=D]!=IT)S<Y[[[@$0:B30"!Q)+O
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M^;PPV7C#ZN?QWX7VQC\UW#?^\90]#W'@5S:V6Z["+U%V;S<#_^CV3E^Q>W"
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M&TJ^1BW,7#=D= VXGJ?;_O@S6*PY$#/5NV\,7%>W4<S&6M;C'A.86VF\;3=
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MVM_^^!;'_Q;:_&\<QTNZ??+VN'/XS_U&O]C8W9OV9;8_L:PYI=:4 FH>_S!
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M\ ZHI#8:&ZW45/.GA6D%Y^T/],?@_/:))9-]U(*(9"2:^4$2)%U//$W4<.[
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MD27A*9;6A0R(32$1S:-2PAK#J%U9-V)5R0>GV<T3_SV]NEP[9U4&GKM#A,K
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M81%A$70.N#)D!<VXKRF0,I>2( #TFWP>)P#7H05HW^T-)PM5I4,T\$<QC-H
M^. :@4Z.^CE,.D;_,B9:[!ZU!B7PE/I=+O5T;(B%.ROB-YBI5N:>KT!V0AQ;
M$]#]P7B=J+KAJT)B%"Q\P?;;&<5"[)R4$@?/D1?#)V=/"^G:L'1 [=^CZ]\(
MV^,27J%H#1=;*;.22\NTL=)P'B,S6 'GQMAB*G$P::QTE.IIU)[5N9OWX=:0
M_",=;.[NB9Q&Y:DFT0?$77) M@3.01",?) !?"(J@.IF2)ZM9G,!R:G=@T'O
M'A;]#,MC46@"%/9;?BJH%1*W,4@?N>')@=F6";!?1.Z\2&$2<J 3TUT*P?>@
M-EOEV>!"&/4O@@LO;'[W<!FX/O](89Y/=SX>)!I\Q)K"A%HPN4$+!$.?D +D
M=811AGG:V$JMKQ&= 9A-9GD\?5LE]A4PP=W-8GM0G-C^9,'\ @-*L)S#Z?)'
M\5MK4(K&(@AQ)RFI"=Y32QMK;A]$K8@*G"#AA05I,P:Y) **UB>;B;H2/T*3
M"X$KPBB"W2[-CRA=H*JM>5S,71#@I&/'E0Z)<>R=ECY%^)]@8'ZT)K>U-U=E
MI):'6\@#V=D^R%/'@,XA\--R:JZ*R/@DX$_LB4G, A[]0!XJ&F:+;CR](AM
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MJV?B)Y@S'P*S".81(\X,1I8)BVST.FAE<K6REZ#6:Q!%6:-DD.U.#Q[BO"P
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M0G-I13!4 W_2.L\EP3"7A('UL,%%RK21#%1VMO3US ?_R(4B2CH^/.H#*>K
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M=%Z.?_%'O^=CS+'?"K2O34,=47_>$?4?B\QU$:/16B(-U\E&;I5V01OO#!<
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M#,FE7.5I:L7L/$[X=JM?P(-7PYSQ?%QBI!@<]4;M4#[/D05_SN8YCV5G<AL
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M;TX"?.]\<6[=MYVQ3==MQS5;L<+2&EG7YGM%J6Y"\^L"[VVPI\HVVV^(?F\
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M\]*.%O7Y&/4KC$JZ^<+#RS2/6PG8SF[$J'5H6B+"^\KY]P4/;I\ATO3*K7O
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MK' 2 6E8-<2I],@$19 "@F%I,E&D?%+KW3,K>C=G#WWW!OJXM\R98#"WF--
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M/)L-XCC$<-W=\PV/!J_/8 SP*N< JW9Z-9B=31:C,'#Y&38,AN,\GC\7X\I
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M"FLSG K??&OF6#XUE:2FDFJ,+ VMB@C!:I0=;IH%K;G2",%42ILPO9Q4EE<
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M9:YXY>Q@!?":(3 C7"!,ZV%LSU^L/5O!RI4&#FX6? 089G[RZ&!L^5ED#SP
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M/O HY$?P#=_SS*.L002L=#)C#G+/Y"'5W;]?O-#[H5UZP80A52+</\#UR!H
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MDCR#JK 5/&B@3+ !;VD:P@)P8_G>]WXNR*&[V_\P/NHK9@!89'#0,%79]H:
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M:23<7)7P&8\43F4;G(F7JM[8^\,>VB!.8"#B %1C>"A&$P>!!\_&*$5<DS8
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MQR$($ 9(:G]]9RUKL<=(TD^WDS;ME4WC=K6T)8]V[0YT[0OS>1T]=\#.O[$
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MLUXWB2T16]H%X6;*EDCLJ=JF;2WV$%O:,UM:G94DD'Q($!MUXZB-Q8YT=A\
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M$>!HVB =, ]AN,T]*J91>^8ZW>&T*\(QK?M]J-3%5AV.MUPK.*()DIX/A?"
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MXV#8LWOW+E_;H%G0?<$WBA:?SX;/;%MB7'GT6=/&V@3J??@\R5P+:84$Z="
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M[F3>W>_*U>5!3Y;6ZE*L^#Y?8_M!&'4/G%R!,Q(TE4$0L+1T!V) O'&&J*R
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M.NKD;$*VH'P%;X+F40>3-?6CO9]6Z5[CU77N"N/!"J-S&;N 6T>V%K<.M/'
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M[2I:>[X:],=\ASH_N81=&'_Y8S74Y*O?G2QF*+R_CQ=GSR]QY1?H;5G)A%3
M2 Z6H^N6,D%?CA.P)@,88RSM% L_H,-2M45\@^I[;%6HF.JX?!.7':!^^:-,
MS(+Y[I=/.6X5PQT] EC<UJDB%CPEC#OF(A/&1]UIL^S^S&]0P5JRTF!:[+,8
M2VCJEL_T&A;/+V<S!#?2C(>D-"Z=QV4O/$$0%"-*.$T#:&:@69?@K:B^09VJ
M3E:#D;%K;.B$%V H&OS)[!+2J[$/XW.D".9KJ#%()K-'YH571&K-T"M/E+AD
MD^=*:<G:ZE4'D'^J674J*\Z?O>J< <O&R246/O/G!6:Z0);FBRL9K?;?![9?
M?&70%O4D9"N)E'Y94(KXO0-J;+%3NP7U*H#Y!E7N*#Q6G$R[Q+\Y"[D3[*!L
MS-PGXDTIOTLFXYMC!+$TH((Y3J5UG=3O< S?JM8-Q%J#J;0-LI&< !FL%X39
M,K@D1X^OC^<D@'%.<25M:%.[\&>V8N_C^LCJ\&BS%:4/T><8",4#H%RN*^(=
MC\11*YP/7%/0773ZSVS%/17BH6S%?8@Y6N99%Y#??+;B7DP>E()V" U'TQD;
MC8NI%# 8BD:H8H8$KY!AX= WQTT=1*><_Z>@*_MF*[97E7VD/U2V(@,IE&2!
M*%W<8UKZ*O@L2VO(Q)UF0;MN26U/+%MQ+RZZ9"ON(\A!LA6#%-9(1R)?-K]7
MEGBN(T'/('AN?1(^="+V"64K'DQJ7P$V*.G>W/P.:(C,ID D0SPR*$Y\J1Q2
ME#&//I]CP35Q@TZ]T>DA]F,]JAY!H],N</]L=%J!ZIXM*0_AZ3$T.O4",HB(
M>['T91HQOE_>XQD9P:)A96V@;:I-'X5:'=3H=$BMVH>>X1N=*A%URKYT>[4H
M"9\8L5)0HDHY@10B4-VF2^Z3;W2Z#ZW[-3K=AY/*C4ZO.[;\#:8?9_[3V3CZ
M\ZM7QF?+E XD@X72+% 3;QDE/ (Z=YQ[*CM5#W3R;[?"^,;-HGH456Z,^OXJ
MCGL;TLIQZ *J>BQM*YSA8V>5Z)JVDG7E@-EV<,D%;5U4Q#!TX*6(@:#;J(AC
MA@-W7(9N29./40%V!,2&Y'\?$5?D?9DQ,OLR^NW]2$FO4K21. >I7,4[XE,"
M$C2>9=ID&G?.EI]#_.'C]/./JT^\XGGUAR7-2X)OGC=LM*22X*>]I-:@ PX>
M6[^MS1H+R7A'.;'"H^W!\<VRFF6BHE$96%8AM1D>>PO$4V:UKTR'*,XMN?N_
MC]%.F:27DP5:**4$:3E;=G[WSZ]AT:-X][ ']2[NK;"^.\6_V<50&BYDZY.D
M&AR/+G GL].66>I'ASVRWVO[HH@&7J&=>>^9KZZ3"Z*G/I9L JN%+ Z%)+C'
M<)(%Y59;B<=.FT9W7=#UW;AV/.-OL^E\CDX:I"0-(XI#:;237,F+542HR$4T
M3OE&J2T/(1O>OZVN+7=WO*ID-#CE=N![%N/EQ>4Y&FKIV<5TMAC_S[*(?R0=
MDY&G0)1S96AV0'&$4HDI(5/+\"R(;9H8[H_UVU*H&H0UB+7M0(R[_LCY+(7"
M@Y]*I@E:>8'XS!11(H 7UIFD.B4EU50GQ/5MJ<Z^1#2X/WHY60EY,\+KVK.U
M43$"RY,/&:E%XZ/@+86Z)A!19F-+RX*.;6HF]D5Z@JK4E*P&=:X;S][[*(/"
M=5.40?#&$QF9)4$H1T1.#E\%@;LF-%*I+OA.4I&J$]-D=L:][?(^1@7.\%#R
M-SS-94Z@(XC9$U1P=).H!%"MNMT_C.X;4)W>I#0H)KVY(=DACJN;#V6T#4&A
M8C,%1&90Q)82"LXSC>A= Y6M>X,_A'&H0H+FJM.(EF,G_G>0WT]??O7_/9T]
M/_?S^=5T4T=5DAH50R?<68U+Q(EH"8V,Q0@ZTT8)7GN //[]9ETUZ6Z7]Z)K
M6%_N!NBM!,DN<)LF>>T)^#A)7LT4H+NB56/O$2A=D#GD8"+QW#(B9<K$<<5)
M9$DF+\'1V,:*?Q3*]D#JUV/5M7U(:Z!CJX)72!\@GDVFY]./7]Z-/YXMUK=5
M"G)*C =B$N#^3KD@%K(DF@;K@_,B-(J9/P#L4=GU_8F=MF.E0?#\U3B6MV[R
M\;I.8 U,)&M]SFE9S$.DH BLQ-)"L":&0(/RG>:N[JTN6R&=MJ+486*(:V84
M!7R\:H?L)^D=S-$AB(O+&6)_>^[[3$'K^,F]+Y(/6<&=FV.3F<M!:\E4EIQZ
MYUE,F<O$&4L&_*CC,_HVO[OUL:6!W[/EHV#V&6[<3!\D6 6.J&4K,R-HZ4 :
MB #EF=3!T&X37O9^D[N@JQ>>^.IIRR<M[Y&6C3!OAE*Q')"FI$C)O4%A*$%"
M&2'DG,M49FK5W>*]ZC&*3D"'W^RJZ]+VD$5]JIK.#_L*[DHD/WVYJD HF&\@
M^Z15X"H3KTN[?L\T<1XL,<'C=B%4XLU;;G0&^^UH6#7*&ECM'5^*980&[4$\
M;;(A(J -(#7:&#YF133W9>A$0%^G3:/_/4 .%6!]++O5WL0\E@CK/8MDZ2]S
MX%D!=\2(S,L$,WPOK/8E4]+'( UHW2:6NA'.\:.FE;F_U["V+P<-=J1[H%;.
M31=830.A6X =)^!9@;J'E*&'W =4BV2"YC1YXC*ZNS)PCO#07H,,65D7-!5M
M$LL'58<'0I+#:<,^XJ[=$.79^3G,/OK)+=>V(%N%*7B.*7(:B78N(K(R=@QB
M&="2HS;>4B[50P& AQ]S9*OU4":F3<18NRG*LL7U_5#%"EE,W%(5/9$EH"ZE
MD<0QJHB2(5@E4:MIZD3PSL>< ,'UQ/@8PGD]ZD2Z?G3S@%Z76A#IM/.N]&V'
MB&X@=5%R*ZE*@F7KO'PPHE>G^J.38R-H2IGI2(+4>+(H(4MP6)',;>9:,@.-
MJC^&".GML+E+)]>X^IZ-LHXIF2R(+5VC)$7/#E]00V32S-#LHY8#2&$'PD<:
M8ME'>W;:);7(:1"]VX'SY2261N?+[T<L:$6#4;BK.SQDE[.28FEFE[WA/BEJ
M;)L^&1T!?ELJ=# UK1V>E0#>3<_/7TQGO_M9&AECG%$N$P2F\1QW:*B%A%_P
M] A:4 BY3;;C \!.76-Z4M&@[F,3O!&N1_@<.-KQ"NUXE4J1L70D 2A0AB,J
M-9AZ'%DG^E+601WVDG=MQW@3H.=^?O8>%HMS^-I4_!M*;_YJ.I_#'%V!D*D-
MI5X2G0LII2@U 930H%P*$KT]TVU0Q8$ 3D,M!J.@]H3$39C?PFP\3;>0XUZZ
M]">?I?^^G"^N9A4P2F,27)-D&?J1&4$[I37Q3F;<7LNX\7RPWG1!<.**4YV$
M)G,/-VR"W-CD'3ABK45,7)8$) -H=/,<@X[2^C;WSP\?.FVO1C.^PB$H0:@M
MMS"E!M0:SXBT!M]AP3EC;<SXIWHUVL<<:T7,X[X:I5GJ:!DG(@9\HW0PZ-IJ
M2TS)S3,23%)M$B*?[-7H7MQWNAK=AX,![\"ZP/K6KT;WHJ[C9=@A<A]0+71,
M$A02AD<O17@2B*<RD,0HBRKZX!U_^NIPT-5H"VW81]S#7HU2[:74*9*4C"/2
M24N"IWC8!E^ZS#)M^$E=C>[%1/>KT7W$./35J'-..T>B=;Z<=.AX"!%QZ28Y
MQ"@IF$X$/Y&KT8,)KB?&UOOXUX;S56-/GAP-Z.(977Q,$(H$026)/'K'K,M9
M#^!=W0?V3=F"/7EI$/Z]RBK^"N2Z;V\'8$WMPJW0'H%EV)?(C1-%:K'0;#K-
M)H"!&JLR;GO+OO/2N$@LMPF/N<Q]9L S;W.3-+!Z[&,I#J8=^PB_@5;\<O'I
M?/H%X#U\AIF?1%B/4G(..%.*P++;%(A G%2!J!R%I%%JYMI4@&\!-+SM48FR
M:7UY-TA7N&\7K7&EX).QI:24E?L)A=]I47+,G6=*ELG$LHD>;$-T*HI01>(-
M-H27DSB]@.ON\J_*/RCB+3L@VM4^&B:)9*#+>DT9C8Y&5-:Y-#B43K3JS[45
MU*D;G[7X:-(2<".TU<O1!5Q3XW,GO.,8H-7([*8D/9@8;F=9@61).NF8($9I
MP&T/?6^ON2$B@7>X%2:7VU2)'T%-'C!$CZ,E^Q#09)[8?/$FO_?GL([&N&!8
MX)X20,L:32)JRA4APZTS<YVCAFC:F![WH QO<U2DZMZ,L#YR;I,I"_B!9WAR
MKIK5E!679-[)?&T=!R$M&,F)==:5WG"46*4M$LBX1K-(IMPL2_8A<*>D'+6Y
M:%&P#N?G)8<*)N@_G2/09^D")8XFV'(TV@KK6K>U$^A (;7H6J%NTUA*X"(C
MROEDG7 97*.6H/O /"45:L?/UM!IQ6*D%^,).N5C?_YR4HSZ9::5GZ07?CS[
M/_[\$M\!/[^<P7S3[_4H5*KQV-Y%3-77?J? 2;E J;>:X;DBK:1E%Q$4SQY0
MWC'N1C4 ].UA-QM_7NKI_/JIKZYSEB@#Q2 HDC)^D2$X$F0I#?"X\0ET]L&T
MJ??9":M_W[[UA[^>+FO+SI]=E!%B(RLE2.X-,5FI,J;*X):?%6$Q1ADC1Z>V
M30;Y-D3#;Y/U].%^7[X*4F]@C=W@^@"SB]*L9H([=T1<(LI$P:.3BY D4X[8
MK#()4>(;K%.RW<8L]M"&KQ&=IC;TD'H#8^M7_\?XXO+B%4P^+L[>Y _HPOX'
MI(^E'6')3GYQ/OU]^6=6\MBIXSH1D65$)T*AVBK*";<T\! C1<^TB7ITAGA*
M^M*&EP9WTS]#6-R<TB]\A-4VET,RD1D@ HU*(B/ZFZXX%8$"M5R&%!O5SFY#
M=$KJ447J#0+&I?"EU+V\0%D\GUY\FDZ*Z78U<@)2^6EI;CJ?%]2X"=[6Y%]R
MAEAD-<&_+[.6P#IM=$@D>&>)+&VU;,G:L1 X17,R&-]FPZFXB%/2N6-QVV!6
MS7Y+N9;CYK4P=&*S"IK0)' MMG21U-Z2S#T-RDA&99O05<U5?+N*6I'=!L-Q
M;J1TC?--OOGALE7T*%&A&<N1T!P%8DP&A84OET(+DFLJE-*MW=;MZ$Y)LZJS
M<5]C=&.->37V87P^7GP92243E]P2)P)'G$(3SQ4C-C$N6,H*7)OSM2O";TAS
M#F/EOO:8BM&!96(#M4J&K-$SY25\"Q+A>(.4ZIP#1)X#;5-A<@?(4*6-@T0
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M'H=)58G.;8K3DXN6-M4M:'QM[N':C.*Y))L#D5PF$B!E$AR74H!P3K6)2^\
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MJ,'FD?:B/3V-:BSWV(SVH:A!J/ZYG\V^X'G^#CXA:$A70M@.UV5G@\5W2J1
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M3#2Y^[B+[I<_/D%<0'H'B\O9Y,VD_.QJ[,W(R1 E=[AXN8SN.$6\88PPSAF
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M$[_:)M<M$),*@3).LEJ6^N Q[*+.Q,KH;0H0/&---.(A9,,;OG4XO%O16Y.
M!@'H-XLSF)6KH-GUZK\Z1S=!EMYHEVTBWF5.9$:A>(B!H#$77/'ON&Z3.G4
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MBS1=7JM97+.9I9*X*<\O6.6#4;C"O,SEX1J#5C1C&93V1%L>?4RVB3"> /8
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MV(O+S9'',\UJBKNK):O:.?V_I@O\:P0S"1\NPVU45-,D2?:X>Q4-#9F 9SR
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M:Q=.D1*CPL&A+=!BJEVS7\#13IN9Z5+$RB@3EV;34R0C2D2*8ZY,'];X\U2
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MJB9$^L/O21KF XT-E!0'<BNALBIIRMAW43<<Q4R"W7!2TLS3T^[5U5#,PTD
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M%G/QHN<W>Z'$)F63X;W#4&"F+3['Q=X]L46B\TJ,UFG,6?&/^[CS62+:[LT
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M?UVP&_<.?6Z @GJ[Y8$ZIA!&<"0 %=Z1.]\-&PLC; O#(EPLE!A^ %)?O3X
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M.#EA9  3 (0  $56=^_Q]-#4W<'&T39(:Z*JNN#CZ&1RCB8Y8)*<KU5D@G2
MF;&XQN'DZ>OM\-_BZ.;H[>/EZN+EZN#BZ.+DZ>7H[!<K5(..I <=2?___P
M                     "'_"TY%5%-#05!%,BXP P$!   A^00      "P
M    9  3   (_P S"!Q(L&!! P(,*BPX(,#"AQ C2IQ(,<,%# <J"L1@P8#&
MCP(9 "@ LJ3 BP ^8L PP&1%E"Y!PM2XLF5,B0P()+@YT$&$!PT@+)PIT"=0
MH0IK$C0:E.=$ID@7%E! 8*55"P N>!R(,D " !:LKD2@H(##@34''*@J%NL"
MCP8L6,@X<8%< Q<L,"#H%0 "L59'$A3 %G!;DB<Q( AK6"R"A!L5-P9\(0.#
ME0LD)EBY]Z*"@0,83UY9.4, Q@<:$AR0@+'-BRLM7+ I,,  NQRWBCW 8*M
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M0(MU(>I%*&6:H3"''$=<69^1@"1D$N9YGLJ,L93DZ8"M[$5"S72_NZG\4TK
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M4D8!8CB%-$D0%($40:[^+0.G=*2S(\Z-DK8"@TH)Z<8_Y_&UXQZOJ(W,.SW
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MP&\R^^JA: K$69')L.4RSZA8OQ,(BBRA@) ",L01AS SJH3E3]:E<4^O:G?
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MEJL<KWUZ\][_'Y(L%MMV4*0X!C"$%! >Y8"1,(%Y&,&DU*IY:=#GTCCQ('*
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M334KU)P:;682S&J^68'STI"S:^3:1";OJN\5XQO6;V,/N2G$BX06I6"Y+.(
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M(+C4[=S)"#1A.).80/?-JPO$G%Q'#<K1M,FX5B'F+"$L$[LJ>;%-B@)@&(=
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MOJ55P]DJYRB$.(, 02KH+DM3@,HX!11E(44\SY/"\"SO0H]+X[=>X-:%3Z6
M[T256^-&JA#4K0ZF)WR7L-<]YG.(J/>SOB&82MJ@$S?8R^ORP$\3&L>G?I=Z
MG?GH3Q.$T_,_W1=M0V_J[>X;WSZ\WWSGS:YSF@^)8)RX &F11[)">@0*AA-A
M7J5)1(H$L8R;!=V<=K(TBE$R NF"*XRGO92F439GP-0CD&LA\LP9 W3>:Z!C
M$5 SKK[C4)HS'<T<1#.NZFGXS,2SUR:TD>U^*M_6F]9IEG+"Q6Z* PZ9,#)"
MF *2% Q $H4A*E,4IT8G,F,=+6WBOWO:[F.FRWK[)][*B\/V'%X&1RNA#8E@
M%&0],G !G6=".(AX$T@A)7J]F#Z2U)P'PE-^FA>=O5)JFO,JCV>E&7G>\G)P
M?/_SYOEW_%_U]NT:-TT;H\MBEA)$ 8N@8(Z$(T!*E@&.Q.:$L)RGV,A_TJ#O
MI9%)*SKX,')$0)X#)7^@%+"*Y#49&,TK.C]P^[YY<XFT^26:.69N[\8,^I_W
MRLL<F).;+(LF;+-NO<R4\[Z/ /PL#"]A%-SN=MN*/.WD3=FW6AY^2WJMUZ+1
MN_>RDK"PRE8EY6$,TT*6BX\!S!-A.:4D R2'91:7+(H@,2D<[T8L(VJ<H:S\
M-]E'P)4^IGFYG Q3GD*8$&'@LC+$TC6%@8*78L$J<![F<51PB%9MX?NO.[S=
M+76P7HKH;\C>\+MJHTHS$KR6"3]>9=R2*"9Y&H6 B]$#,.4QP"0C( II*69=
M$85IU(W;+QNV[%'K!?0W9J*'UQXPS1./V8? ]QG)F:QY-\%>J:#3*ABJ)6N>
M'BL6])JYS++G$FG':?B<B#9SGCZ7<)XF\G/:^C4!Z]_PC\[OM*OIL8(<1B5)
M<Y"FN;!THBP#.",4X"A'88Q9GH5&9T0C_2QM5]?%8<ML>YU+N4V<^ADX49*B
MN& @RZ L=YN& $4A 07E,2E0&LD"!-_YEM0S CKLSZ,U>, R^*DK9JN96^82
MJGK+CP.D/*\GW5<GD>K=\G]Z<PDIR_#_41P\A/^?]O4*X?^C"I\/_Q]_W(Y@
M>]<!Y5,ENMARW/!WO/WOBB4A2^.<@IQF(8 A%CN5E N:+5!29B7/P\CH0&VR
MMZ61[:_UEE=WFZ!U,Z//P6Z+-\VZ/:/'[+^>K*[FI@'7HPQG,'HFCE[.FRZ$
MIQ<U^*D7UB%_:('BE$6F>YR52[24?\DH>B_9\<HMI2H;\!=.>:7\NS_RW=O6
M85-F6RYPBE+ (YD^/BQB@+(D W&4A@BQG$;4*-W05&=+8Y5>5ID*N1/V)MCP
M\5V6.;P<%B'/4@[BDF<"WDRZM!,&.,-1D@K6+EAD9LVY G@>DVZ?6O  <>MB
M]#\$?S=\XQ!J/;YV!9]GNMY_FE\&GR8N=S+X<KVN_Y3G./)F.GB[Y:S:!3(U
M[TW0Z>&.R'70<LKCDQW.2N,ZJK]D<:UWKG<(?=\T3_(#^%1^J#=W\HKW'2>[
M549)6(:0 K$CEXGSJ3 .DZ2M/H2*$F%!]+8>H>>[7!JA'WLQ5IW,T@UA+:1N
M7968D-O>'W0$>CWN<0NH9P8ZQO+] ,L/>RS?36%YE5/H-#S>O$)'NGTUM]!I
M&*;\0B^\:4="<I61OB35YD[NPMZN<?4@Z_D^B*G&V<<G%7064QHRRC*0I04'
M$(<4D(PBD#.29BG!&2N-'$5U.ET:$;52J8H<0EPA>UD&5 D>L%YR,Q+2@EZ/
MAEP#ZIF(I+C!0-Z;H)4XV(M\$[1"NZ,B$XB<DI%6Q[/2D0D4+PG)Z-TKBZ2U
M]R)OZX?'>B./@I2S$\8<(TQ3$,4A!!"*_RE"EH,HIS',.,PR:G1H-MG;TDBH
MJ]%U$-*N2L0DP+K7NHY@\TPUQHC9%S>;0L)/4;.S/;Y.,;,IY4>+F$V^9'TR
M]O3PM)95KM3!FVQ\R^_YIE'%;^0AOZ2P-GEE"2.80UJ"M,PS8=<08=>4$0><
MH2*/DB+AW&A[9=+YTJAE('MWGGPD?=!=4QT5H3+D':.QT3[[\8*X_[,@AV#;
MG $9H^;Z3$A?@+G/B(RA.7-F9-[&E<F]#CD'FWU^?)H6.(5I!DI2I "6*00X
MBQDH$Y3'"4<Y9;E5DJXSG2V-S@9Y-@?26I<@F,19CZI<H>>9FNR!LT]1-8&(
MGU13YSI\G911$ZJ/IGZ:>L?6$:R/._PF&E#; "H8HL1E E+,"( L"P$J.04<
M)92S%-*P-+*-3KM8&F4<) RDB%9;JS- ZK'#=?!XY@1#9"R<D\:4=^R7=-+-
MS"Y)8VJ>>B.-/FFY+5)Q-?V]*DU#7(2D!%E;8!ZGH(B0^)^2YTF*4,Y#;!+)
M<M2ZT;2>+2"E3S%FDR;I&#S-C8DM)+YW'DHN'_?*YQ1VNVDXZF'>7<$YY4[,
M_K,/V=:]_+RMV1,])%+D."TRL1*7,<ED\&T!<)G%@(=AE&5AG$0D,BMP>=S!
MTA;CV_7:))7W*&[3L]4%&IXG;'L\T(MW.3>B'BRFQ2+MX9FI*N07+K;8C3K@
MK3:J<+5R)'WDVQVN5&S;KNZJ-3[V6-9EFV-JLY-'Q+(,I*R$6I459P'>//\I
M'N9.ZS2>1_%R0<87[\U<>?&\U*<E%D>>L\Q?4C7X[F[+[]0X?BJ_\.]\\\3;
ML\$XSF%48 Q@7N8 AFD$",4$A$C\L]BTY&EHE'U\JK.E$>.QK/(;[J2U.Y.=
MQ%G/U'&%GF<BM0?./)^)!B)N<YI,=3AO7A,-U4]RF^B\XZH4G&CG7?T@UH15
MS$M:4A*"D,1B%Y2J$P["00++-,]9CE.$KZL'M^]K:21RIMQ9N[%OQ;VZ--P!
M9#T*<02=9P:Q1LU!J;@3/#S7BSOT]\I%XTX4OUPY[O055U$6_68LRHHLA 5@
M"(6".9(<X#0-01&GG!4L*TNDM1F[U-'2:,-7=(51;GL78/D^9#EU]?>0U/X2
M$)Z]^%\CG?TEE2][[U^U.5%[G:'S[>V&O<6/E3S$E%%=G\BZ:HV8YLQES2K%
M4<)H 4'.4"1H@Z4 $1J!**,$YA"C.-:,'+I.$).9,D],T8<C7WY5EJRL-LH[
M?:U"&NN#0C<R;6.7:V-0.^F>LSNN>;![Y3AJG"G-,C:>64SJT"9]?-</2J='
MH!0)!IH$9Z^-9QD-@Z.L649E_@,O>8@UF GX07*>W.#B_1E7ER<H:.XYWP6L
M*T:*U^L7830WP9_W%;T/JJ:=B3)'6R4>>P[N\7<YXQ[P[FG;%K]BLB\5OU9O
M>/#,\?:0M_U<?]N \.=:?$7R@?J12XM-M$B?J30CJC:BAV]O O*T&\QQ^?1C
MFQ)%J;KE,A=\5TN-R6,]PH.NKN&?U>Z^VASD$7W*US?R/' ]T6?PN'YJ MI]
MW2>4HU1M.U+=/-1;\?L]'O34 G%>=5=GB%=_OI,GC?:MSW<>>34"1Z>6U[=F
M[VVQ$>/\_)'O5D5*Q%0G&4 I*P$,RP(4+,X 37"&<%%B,?U-_2SZQI>V?^AE
MJW07ZK.(Q:&PE B/05Y @1A+&2!Q!@$O&!&_$49A:')[;8W8#)?7;A#3VUC9
MXN#9#-F+=1-\G-AJ6CF=O%37N;O)OH/9'4U>JG;.Q>3D&3,^8[Q:_:(NSWZM
MUKP+6,M0EL2"N0##J=CDQ#P'*(1<['DR3@@K>%IHQ>><:WQI?-;*%T@!+\6K
M709N>I)>"X?G26J A/9$G5+YS$1M./W+7?W]W\5K[1P5/ZBIJ2;EV<9FF913
M:O23<O*9*SW#6[<48=],5PP5#WRL-]NC J(?J@U_O^,/S8J'D)9QS$ 2RE2Z
M.<: R&-/'E&4<2IO2XRL%*?2+8T6?MWOQ6Y:?S.U=UYW"CX'#ZU^MM6=G0QH
M@N(P@CP$.<F%$<4+!(C8\0&69'$:X3!E,#;+8O-J0SK/$9603^QYGYIVR]D-
MH=KPX<?';?VC>I";W,,V?+_U;@^RQ"9:;*:;W?;)(JN9VZ'7LP9?;3@]KU3#
M4MY=$0$Y.R]7]99/#35LRWP'?Y=*!DI+'Z$1+M'W$TOA1,+7";YP">YHM(;3
M3JZ,J/]4_MJST>>ZJ52:X3Z*"4<HIEF:@R26I;I)A@%.2@X*E$09Y0R*_[<*
MK)_H=&DK]UYF2=Y[J8->;.OP,:T!T.-EU[!ZIEL'B-I'Y&M Y"<P?ZKCUXG/
MUX!B-$Q?YUT[8AH+C^V2P[[M<L-^DZEA16^RXPW[=D@4^QNN-C*4]G9;-8(T
MWSU)ZORL2C!\Y$+N;_C'*N5QQF@2@A!A)'B-2TH+$U 4'$4L#W$4&D7!SB#S
MTFA1-U>O<@91=N^YM-_R#__R4_ZS2G(H+>.=F'P\>*@WN_LFX!LF+*[?Q2=T
M'R3132 O*)3-]2\_Q:G^.Y$9,<_Q >KQ^L(^*\_+PL6D!S=!_]'UF@<#U=6'
M,5 ^D-KWZ1(Z!((6@J#%0!T>RR]0X.!NI9EQT)PN5'/(/>LZ-^- O%PFY^S:
MPEWIZ]/CXUHMXWB]7\;?'T)D#K>:>T.401H+FQ^+=5+6A881!(27&8@+3%$8
M(UF>7CO6S+S_I:U^0PT&)NQ !P,_%XOAT' W\@NR[RV"/;YF_A/V*$TZ3E@T
M.Y_'A+W.1ZX25S1CMS/XY>%Q73]S_I5OOU>4?[W'6RZ/8)ED6D&SJM>/M8J3
MY^Q6EG-N5*3W\.]OZV;WL=[];[[[PFE]MZG^R9DJO/3I4;EVK"!-F:H0"$F1
M TAS" J28)"*O0%$<8R*W&AO,(O42^/'O\I3JT[.@ X4$;],U#=[Q6'7L\@7
M-YB^>5@J"(C4,/B,G]6AS>UV*PNDRY]O@KVN@5+V)FAUN FDDN*ON^!9V-@'
M/6^"6^6*Z,[>GG5(G%K<\T@^J\T]ZV"\M+KG[=QL#6NVNU47#/UIVPFH4@$1
M6B*8T!R0$,KEAF& ,!36=5KR$!,:<ACK+#=C'2QM9>AD5+OU3DRCK$JC0$X3
MN MX/'.M!3+:9'E)_2E>$^\..$W\]I+/1AN?A7HNJ=:SQ,7G[(Q26?H#-_>B
MY>\5X^S-\U\;6;R\,X@W=[=B>_]=7?"U*;*?Q+]]:IW.!9OL-W0\*\,L21-
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M46948&:LHZ7QW4'.-O.0E-32*VD46UWK['K$O)MC-F!9F%_32#BVMT8ZF]G
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M>+M[_B@^T&XKPB/.> $+P',2 YB2$! 2(U"FA$<XIYSA4-?;0[O7I?'@4,I
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M5IJXJ/1+GKC\@GF^A]_Q?]7;MT_-KGX0\T]5Z\)I7/(<%_*04<9]%@4@F$>
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M:@?DM%3/R*EX^&U;/^.UJDXO!6G33:H9S+HY*UJ7D=(L>-H(;NUB</?"U)M
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M_[RMOXLM-GOS_%=AJ[W??'K\_ZM[U][(<2U+]/O\"@)S,9T%F#622%%D#S"
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M9;B0RJ0J9%G6V=K4EEN-L:!.C))/0#;F!@ZXW1#[,6TTX :FSA:SUE#06CK
M4L<+DZBLUMWBJ#3EY?QSWO&[*?Q ZEU5/,DRUOUBOI.=\NEQO5KSN5O#W.28
M,IRE"<R%EA G[L#;)#ED1&;:%)IFPJO CU]S4Z.2VF)0F[R?505VS/8_M/)
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M;6_F^*ULS RL!/(<1;]O\Q)L7F*]>;U>+TOQN'9!YBY8\!EV[\]A%UX>Y 1
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M'D((!31G(9+KET1J<QOT*$GCEL%V#>-AU-C%I-/[E^E70MNV/[J6F$)OHBG
M1(VAK3#@K4;@Y"RQY!AJT^9YW>XTCEL@VS5F&RFZ Z-ZG[-7*57G?T5RQ^G7
M39,+]$D+D\BKS_7IA!,)/ L"3/ Q&I\]VC89O5VHZ^WE^S#(>!: 1ZJI4_OY
M9OZ5A+Y8TL:=)&YY"!1:8@RV^O06HL\%I"Q9Q8C>BS9!V9-D]?;,_41P.U0Q
MG>+LW1*_A&F^S"MN/1#RK#?>R3;O3?Z(T9O99;R.X*ESL0-]"2B9J.^T28IM
M'I,>1F]O;^=/A,S!5=DI9"\-_KOPK5I[8I"^LSRG]:YGY4V*T[GV,(,4.0/%
MHH*@;0$EZE5-T9++-ATJ#Z.WMU?X)SZ[!U-EEX[DU64-7C*Z:3=PX]LW?)<B
M1>'*UU'PK#ZFX(7\=.T@.B>TRD:&1DUZCZ.[M^?])_,&&JFV R#O7MDT,2D)
MC(:DJ )Q5F1],$FG2M:6%<,=LF":@'9W&L=U5SNH$FNDS@X&&#_"6?745WL(
MEQ?.<LF&O'E!ITL4'D*6"$Z1>T_AI,NBS8.N8>CO9NS>2:J!6RJW ]M+A\DF
M _AQL;W1V/CP%TQO?C"Q3B?M/8')^3I\+F?RB@A;!9E,.ILH2YNZQF=)Z[(>
MMRE>[KZL&%1Y741A]U@B^9+0UM_>S<)\37Y[?3"WN8:;*"<YZCI5-01##I8)
M$#6Y6H4;%5PNVH@V$VUVI[%+7V!4A ZCSCZA^FM8_A,W3WL_8#I?7K@X+B>?
MD,059"$7)]&YY!DJB@J"3I(5G5B;BK"=R!OW+.\1H$<KL0]L+A<),:]^)IE_
M"#/B:EUY^48[[O5B-L.TD6"-'Z_/"DFQH4P^UQ[YM29>QIJQ8Q!<DCP+YS-K
MD\DZ@-AQTU@]X+:Q@CMR37]>+&]R>\/'N1U,UBME9V*&HE0"Q:V%8#/)U'OA
MT:I21)N:E#T)'3>#U0-V&RJVG]YNNPMZDJQV(C@&=(Q88M!$\-XD\"(E+YPP
MME%/M]UI'+=*L /0-E)GOUFM[3CZW5.&4DJ,SH/V,8!B*5P,J2?/W1NC162I
M63OS >@?UZ,X=5:KI7)[<!UN'"NUU1WQBF_++XOY)[+OGW_$N)XXI7@11H$V
MN399T@QBQ%H)*:W4$5'&1MF#9VGK,J_5%#%/.+<#J*\#0+['+UNGYS8?U5V_
MN#>\$6V*A,5C(5GQ.L*Z4*#I.6HHA@R *:9$TZ8*9A\JNTQMG1*DS53:CPO[
M[HK!JU;S$[39T%ED(,?:"C1(7Z?X". L:J.+*D:U ><#Q'29O3JIH3Q207WD
MJJ[#0=I3Y\MT%E987T)>#368A!0QQR1!FMHW*M4Z6T,N?&+919VM2[IY:/\(
M;5UFHL; X$#JZP.2-[-KE86W7S8"^^D/7*8IB7CB7"#(D!E/)2+YY,@A*A&
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MPRFL ]3=%UYX6%[;3<65M1K1@M7UJ6O.!6(4'CPZ'S$PSW6;SB9[$CJNQS4
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M"?;2XV)@H8X-C+_AG"1S0?Y?M_2KX$O@<?.>FAP#-!$\TD[*K/!@G72<\9U
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M^9+VU+M9F!]4Z?+L9PY0U+(?W0/5K]Q:YE5=]B+<3.OIUTV_I^M6 ):A-*J
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MZ"RUG.42&PV@:FB\KJ]'KG?-#?F_F5]=V&V&2UTHZ-UB-:W:?6!K*;01A<S
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M%41W##%PS(;B;0(G*5)3VCM*1W5]T,O0EV"3R:W#Z!<UR>@@W1\RR>@0170
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MP:&#X*J%.*J?6SNXBR1+I&3. DO"@/+)U#=F%KA$+D31)LJ78QPW?'5B&SU
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MYR][<O'KV331GZU'.2]FY<-D\?<S/)IXZFO/^!!B;^[/\;@A>).*TW1F!VY
M)5ZO&C5%DHJ<M5"IA-AX7WV#QPUW)%S%NRF<I9R1HP?.*J\8"OCD&1%'\0DW
M7DO6J,5L)SV=E'%.1<6##K+3A=]!%>8!%S]\_P&GZ?.7,/_[ZHY>1)*1UO55
M7MW"I&T&Q[D%(1D*7;3%TN:$?HZR<6$UA/:? ]0IJN@26EMN-G=8*GL7HPN
M48FZTUE"1&,HH_(40!LG*(H^$[3N4M89M$["P;,@.T$I'8#L55IMO*S/>G&R
M>O6[N<C,UB8FD5R[]0E4#((LD?(H;[@LF1EM&\W2>HRBWD!UBMYG#930 9@^
MADLD)K[A] K?XG+#A)),%!<2E.!U;>L5M?7;0-!,H_8I"=,FG-I)SKCY9U,8
MG2[^#C"TPWM?+Y(63C-?5Q3Z$ABHK#/)Q6I Y;-E(O%LSG7@71/5&9Z:A%%'
M*:!'+-U:=6A=5(')##95_\J\ H^I@&4L.6:5E?Y,<7DO^]L'4_RSB=YQ6N@
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M<P&5:UBM*?5BLJ9<*4DA]WM*/1!!8W>7M8+F:$KKU*V^Q>5[).[R)-VZ5+[
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M04QR]P[%"Y>4-9G.'L\IH H<?/0", 3I@["84IN(_"]Y<7H0%)Z\.#U$+QV
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M5@;6IBFP/6]=E(':.-X>T-"7?6SMOS;;_GPY^\?*[*\E\233VE%8EQ$A2)]
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M.'@]^Q(K)QL6A!4Y4]8)DN(1"E5J^YGE"; $(;%$F\5^_G_WY^\'@I=2TQM
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M\@4SX>57<:B7)$/;S/KBL_YJEV=]A*?79MX?;MY?FFPLQOF;$__0EL,&8;K
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MJL4_4'1-W(/9Y:VQS;EJ5$ELIY8DI7 ;F 0P0&KH#NZC"(8L)D8\(X<#($O
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MUKIYQ^7D_(G%21>OO+JX4[UEK01C'73(7H?>FKW4I+IJ8:0E[1GS3G?RCGA
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MQI1UM&#T^'E4.::PK%9Y$NM\&_;>3XT:Y9:8]68>O YJB*]L3SQ;4FCESQW
M%'ME3F+E>ATI%)68GV^-X!K3,57MF(^P'9&4B.O(:S'NDK*^=2E$DE'W2=P]
MLN8@'%H28^-3ZE'M1-"^,((P3?O@ YR7>E5$SZU-=RC8%V!SHY=\DSK3)I[E
M'/,D0FW7M9TCR1&[5$><MK_! A"/D--<@ZP &5<2MH"/Z"A213R))V]#34$
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MR[];85!8%I1GABI@^'FO24V*J:58]U!99V-<_Z89F9SGXC4!(?B9) >,>\6
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M8AX\*8%#VI;:>+]7Y!#A@N<"!\S,<(1Y!OP*Y/695)/Z0X,A4Q.F03R9@.<
MDXT0"2N]FCI.8,V@TXR)@H%$ZF;F-C9/FO&BC]3H.^&I9P38 B<$*VKF128J
M-Z/!0L3$"+))Z'EN?%(/%U?TM%4-8-G@)JRE-$"!4=A4FS8 D4;GL-3-GE>.
M,-VU5V.B01D)GA+I_",0OIW<>&]JU7T7!S3'9?TR5SF%6K@B6-[V(9TY.OO:
MH^",3'0@);+X<DBC,BP0&O98$S&M\\Q&I+MJD9LG%S,RYNV^<QQ\X%2]:=S
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ME5":F&11\T%F9^P;""<39/7L=F.M$V5\7DH_ PG#/J/,E<2=L8U#<)-58$F
M7_7%XB.RZU3G%.)$3HKA\+<865;"9S1!_X))8;.1.6;0U"JK/,4D)P4\-=7+
M8;!3Q1T!P\>^24]JZQ[D55KP5AF!?9D23#B*1Z,XK)C)"?<:[.GKK$)0S[1'
M4F5V&TX11]CI;"&K/\QU%)=9SE_%:C20..H1GVO,+N#V+EA*R6"F_$=MKI^/
M$";HU139A&"81$([POG%,#JJ251MWR"!#U;8K:^#_]4JH;XR8'*FR,B2$.:,
MR@610S>;)IK2!WPB."'C; F[AZ2M_.:_E'[ &4 Q&FH$1:/ZNI&_/B-)X3/5
MY\$RA;_L28YU,O7F:H*Z7J7R#;C$X.6>U93IH"J0VY+YXP3/SC6IAG"*Q='D
M!;G1$F6LV!^WY2E:E!5&$+EU>!&.P>9X1O,Y</$(UOY>KI;;1:'F0NO"EU-:
M :<+GIMVIQ-2)85$A4;Z6IMFK+8%5\F!:$/@2AO].]3^FAL>@^(+=J,JZ)5[
M0A+G-RH+0MAGHPJ$IB?.@?Y2XYYVAP<33YN3 2N<XA*=BC4^+#_[32%F^$!U
MCCUK:.%>(RGR,N!PJ;/EA9[@*F,D UVQS3X4[-NIQR_,\:(;2K.P:_0-<9.'
M(XZA)F,PRM(@*1Q8!)2/E]@/MFA7<1\Z!K>AH"0WVSV+!>@%DRPOB4RBA]4O
M^27C \ BK29#W0D/>.R;[L)!D? 0^W>5E:[6#.VW?V7Y%VG%?BRTN,](4Y-U
M-=%P!X8GQB-VFIE<V,Q<*T3OCD&$FDA#;6H14Q*EX]SIE6[A"%K"!C8BX)@B
MK&Y@/S^CV3=>T*4N R*9*9$2[H::!U[1G#RCR;@@6%0<"CD,GWI&E"*-'"^6
MZ+T1U5H_M8,K2\8/BKCT]\ NI*.82ANELL"=_$G,.T GV37C^:Y4G%B2:>ZF
M@I.![#=%(-^_UD.+7ZO?@Q*!=ZW,IXAZ3"]W$CTJ?SQX!1-!-XK)./EQ9^_-
MM+RS:5Y,4N^:86*A%%1M&M[TW^);>Q$E"P*?9$5)4388V2!-*P*R3N$$#K9^
M0@S%WN[./[=K"_6PFSP8E^6TH %0T0K]8SWIOAH.0>CZ(6:5X8-"ASNC.,&.
MN>N1@%TWB5U-R>SR$ONV_^K5(B)+>-MBC)7GUNW )AJ"$+ R_'_1A"19MFD)
M55$ U"L/(;$G78X!OZX;,G3A6T7RJ8C'7==4?+MXX'$L(C+@;O>TO-CYD1CW
M]G?W#E!X$-4!GAF;> XLLBJEMC(CVL+[$<2-5G$8,JQ<$D_X'*P'*@1\9Y#X
M_W5Q-C@ZQJ.<B.VP^V+''JB*O@9O+_*$'R=\9YJHKH80CU/X[[HAU7?KQJ4%
M'_]+X8:JV.R!A]T#[3#.HXA/'&*=C,WOMQP"-<RNM(?$90 O>HA$#8"5E!3'
MP;/U.H_+DDJI*,H(%SXS&3S^JL.*-J7/NM'ST[V]X$A/RW[PV\LW/_>"]TET
MV0\&GP]>[.SW@KW@E$@]?U?5%XT$[V>9BGKRQ\-Q'*K+K!><? A>[>Z^>M$+
M?CT?4+#M)D#JT@3%]L/%R=_^^NK%.V>H/,J(VI*8PL^_G'PX^?SYY/3XSC'0
M&S#9HZ-7V)1</):2BZ>GB<X^?1R</KFF81LFU3K+_9J4 CSL4@QJI39<ZQNG
M85)%>B7&%C&IQ&7%X[FF?,ZBA"K$@"EOPWHJF^K<<ODAE,K$_;%TNU9N F=O
M.-9,H$'J&ZD_/6(/TQH-B4*IMZ(V+*'PN'A237@46%6/CT-VL#R2('NHXRF7
MG*"KY]_5(Q'!6X$%HJ]0M9M>Y@04)!;2.K=0&FB5)S<[7;<:,<7/S;2# .2Q
M*ZP-,Z#/#"BM^TQ3O-78/+5B-4E)M?O-<FH*V=[J]HD)<*QB63V6O!I>ID<I
MM5 PNM(Q J/!6&I&-!Z(Z^TYPHT(]F!8,D8"V1WD-YP,O X,KRA7UVE039G"
M8C*I4F0P]7KHT/9NM&*\:\J5;[5^!NFE^D.5%;6B*.))B?U!]@_>O$N1C%46
M&W.L*4*1_X1)PDM5H$(,%QQFANU*UKI"C!9XU!.XR\'+O7<Q3 H1*R6EBU3H
MGN0U0WC4R[?O\KAG'LK?*N.8?GKYSEQ ^"^\!<U_4*C*+@98KXW1! 5_+1C%
MJ'8C^!-^%[^DL7=*17?*5'Y/@KGD$MQ;X&/)<9AU3^+)4&$'F43_R1/Y*,^:
M9=V 7\^?7NO@C1=0#R50FZ8\N#!-A&S+IF?D%*SB59?M9N>1?'?$/8X]D+EC
M+YJB<U"6C/ G7%F6^S&.N$ F01-*,?@^!JU%M< +/9(,<QC.6544L7I&:U6S
M^1!I9C!ZEIX-S1K7?(S;J#GF>\E]B7>&I%O"H_GL9G( KIK,&;>?KM=RVHYN
MD4Z0&J.#AZTYR^2HAF%6<3"4@H#]\V<TI2WA;+8'C+%W,W%38.AU[JPQ/<4X
MNT8>46+J3;, ?DY+CJG6EZZY-&T*BKDK^>PU2<ST?&TM+=-L/2OX.\?->;Y2
M*?T@)A!*>^8^R]ZW0/'7W&1[4G&0[\W^G/E=,<^\CHH;B^WA]J[KQCK-L\FT
MI HU61>O[2:7N^'15FOKZ:QL9VZUM2<2_% C']AX05CE6/-\8]4V<9N;R.F?
M&/]5Z1>G5+$\P-2RF-HY W@F/G2OG(,X6@EUR!1+"7< I3 1ECO&(4&HDRP$
MK6,&I$T= E='<GO/RTK83Y^17)SJF)2SS_.:FG3GB+CN+9$U:FMKY" #O2#3
MB=T5[DRZ?*I3Q47S'>+3;FZAXJ3*=6OMO'53UW>L&Q9;CN<0(SD?_'IT$@S.
M!N^?7*1D"9*H$U>P>\_@PQGQPE6=![4NA;:9 EIU137\PRN8_/_;N];>MI$K
M^E>(%BAD0.LF\6;C8($%%%O9"%DKJ>,DW7X;B53,AB)54K2C_OK>U[Q(6;$=
MUY1$?NDVMD4-YW'GOLXYCFG$T'X:$76/Q\:L\^\5HF47-_8'E_1.U (WJ# ;
MWP? T_S&N^LY&XU_'[Q_=S[<Q7>]YR'[!WCS,![<)^]A>\#"#[]%X&NTJV*_
M%4>;<U]U%RU&6A%<(.)\J&;,1%:^MHXB, \NE"RG)B*7]J9G+XYZ3P]ZLP.3
MFG.(UL%&O"Z7)?IN [ OO9-+M4#.G&?'+_O!LR=/?@F&X>&!IVO_V$6=&RBE
M7@^:6$N9[(.6;5^K#U%8>0C60+()XB0+!;SN"$<HYOO7'?B60^TL2R,23QM(
MNP;YMQ]@7ZL%\B<(Q1,^6ZX[[DH1YU9CE<H%2LL4&0J\F0>Y1X?4F7 \B1%U
M,E_2HE4<$(T=O#@266 K3;G$.3.Z58XY@J.%LZ2U)[3]Z?J!]Z<?^"^_845(
MV#WLZ8R(4DWD0XB:J-*B8M5%(FI+Z;N\P'VWL%.X/JNYBIZ_,)<0;#(-3;1T
MS8XUT0P&2!YE*91)%0KB7Y*37IKTAY.@=LA$O#J3.?0>:S*'U5*J)%+CS4^O
M..+UI_=A $0;P ^3@BA_A69SJM[LYN;6WOE[U/7ZYV@T"DYC:6U^BF%_J/_5
M^QGNY$P2!2JU$WS\Y,"9X6;!^'=URM]]O'@3#%Z?CT[V+?CMV@0JJKR2[*.&
MHBP)WEGUMBX6>=22$>IF4DZW6&![FLX@<NX/;6@U_6<2M5-9.S<706G;DL#?
M6Q@RU+;=N1UZD[$$W1\9.*_!8);#-+=H.PY$=''#RFA)^%G.MW*R\L17N=NT
MUK=";@IV7*)>P=I,-U<]D;.MP"RY2X1&511V2DETSJ^QK"VM1/!-3/H&)\62
M17.=9;GQ!5NTW#M1W.A+#8KCV-HJ[8U+LE=E\/V1"FV/-1BE-7OI7H.IJPC)
M!]/'\;@:X?>F[_I!UBZ/J8(2"?5SW3B'QT-[%/?A\'CY8D<IN9HX&=M! O:C
M=?F&S\;MAC]I_&P<'_YRW/';["2_S5UYG';02_02!N0P$<A ;ER%FM(K/:=,
MC&-OX"I%CG=]WYHK)]@3"IFF4CP4XG(_L.$R9Z)S F ;A6^BT0C)[2$"\[EB
ME7:CUH" <@[?LF"A<O"0XP4VEU0P):;U+UTB5G!M)+94WTSHC<Z8EOGVR/J=
MSI:U#UE0^1O<!7R: WMGAO$O!/S.S+#LB-V^HEV*YNZ:3W\_&(UW\3V[1/IM
MH]:!#8$T5?]I7$R1V  .!EQZ8X6]'16E,BZ C;/@$U-\^Q*QNT75]HI:F,'V
M>_6^2J2(>4"ZD#S#Y1 &N:;+"RL=^@G_JI-/;*]D\@]<ZFYV#AL^RC3&[HM<
MD0@&O/:RC)=964@F%N80$W=824 0H.P^[GB"W<5]C&N3I@[,A-28A+M>:]P8
M!CX]&$2F5%.$@N#"5##%\5F>M(V@W=S/>-DCNCQ>.AI+HB'@\R\P4(YKS\0V
M@7H4I;2/X:+"D0DY <Y^'LP^M["9$CT8I#2;@_<D^A86"3J)I:[OK-M-&5[Z
M.OC?+QD>X(DJXC;EPT_0,$E5HV*SUIY*/DN8R]*G2U9Q\^HY'TT=,%\3\^Q"
M5' +WJ ST\AJN&CG*<K?*;HM-"G0.LZDGA0T3%?;][<\,W)[R&IB!@FY72Y
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M@0+W 13X__C==EV"?T>R-_C/Y7*>_/8_4$L#!!0    ( %UFIE1+J!>G,WX
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M^Z_6:BT&NW=;B:,LHI_?('@!=QKLFJ@*2YC+G^]M7-.D//ZY?'/'N6Q)KKW
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M:C"M,;W9DFQ;@]62;:V29<N($H@0*(*4XF=8WS@RX0/Q_158@B:.Q=)3)[S
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MO2Z2%*E5MND/5F92.AKO:4"2?%]DF23F3*=$55'HLKA-,YL>* ^O/;> @24
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M;^3GP%WC>G.*VL:CX.@MP5#PIAD6E6;7'L,@@ZO[=4^<?&IBA&R1#L& J7P
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M&\,L5](8:G%N???I$K4>/.LSC!(.AH^8L*RK\I7HLLL:TU6S$G5(S6ZJ88(
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M/N>R(J>X/JM%EE./QMU;VWX2[BTIJ8>1*SCD^CB0RM9+D5^9FD:D1;?@X3[
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MZD6OI&^YG74W!_BK;)C'% OM%HB+H]].8$V^VK9;Z4M\/#E_^^'\_>#LZ"2
MGT\_'%\$@[/CP/_[[R<7EZ=GOP;G)__]Z?3\Y/W)V>7%0S@7*XSS(6%HJ&9$
MU(M0).*(H:B>Z450HYX%P^\BG.BH2C@[[.=H:]CW^G;+:O6U*T;9K3* ?%F;
M00(-F.("1OK$QG1L,$*&V71H.&7PE.OY!L5\:$"7SIM;#7^[?OK>F_1W:7AQ
M4>H9O^!'G1._+WHS'XF7I[C7CMRF/9=->ZZ+IKJT!G9MV]BF**ATKK&#!(D*
M7C*=*L97#G6276^PUL'M$QS@O U589,R+>95%>&2:T3U$UB$JL01E9%KVXKI
MY..%:3F$G]J]:.QFKZROO55I!]-@#F\=C-F+L,38?I=&@2THB!NBK/+4#NGR
MXMP.::EA])C_LPCS>.B5/[45I?=-HXE\1@U#>+OQ\H5;TVS#PJKJ,,N9I)O0
MM!V*FRB^E&$5Y;9,#YZ/J_6Z0"T*WRJI+,+J>*P5VX.Y(X;(7\P/K[&M0J)N
M?HE3F@'ZTFM0,6/0RG(PO(#INM)85JL2&2P-DC\6??WR5?_PY<^HLDL89QF9
M!XLV[Y,V_[&,VI\]>]G_^?#5W(_W^P=S/UMTVY?[_5<_'2YUVQ]IR#QLF)@"
MMNS__N'9#XVYH[D%T<$*F#@*C #*IV4VZ_A0UN67P]F7X*#>@83]A-;$9K,5
MN0Z^56+E3&;NOI.2\_V?[)RUMW]MYC9,KA8=TUN)6FZV_DNE%9:['>P=ZU!/
MAV 8/#OH!8?[AX?W$"U1X'.G:Q-$[W!YT?NZZ=H8T21Q?-82T.=M ?V1S(FU
M=L9O,X>_WS#ICEW-I>;$*]G]>2RIZ*_RX< _:_EEJ!(WV#OY@WF:B_A+>;,W
M0I=RY^6+W29I,W8.L14$--5=CF.=QHH*2&QM^=SU8*=4E1UWW.!E:78],/-H
MVZIUQ ]P-IGBM^C1+TS1C9S(OPX&'^E/TA;,.?:M,$>:(B.Q#7)@.TW84C9V
M< .?!$P[W;(L^H]<BUPNJ3(6;H,ZG8*6N-%4> 3P,,;"+KP-WZ(GK"VP!;I]
M_'OY[37W?P^6YN>?[Q*;'.2Q2N9-YOY2DQD_T.Y=9BE?U^;CX!6^.BXD;*3_
M]^!Y_]D^YES&U% C-UN&.8G\Y8*K#_?W_XVRW/>>^1?]PX/O/?-K//4'^POG
M^^"KY_NG_O-GWWV^UWC"]U\LG/ 7,M\8D_R*.?_^VN5J#:><(MW+S/K^OWVK
MFH(5GI2=!QMCA)J'IJ$YD:G!^+<H R(T]3Z5/XF6)A/2IGLSKFVN6?C8!FF*
M!VXA/8@#-<RN-/?.[#YZP8FFDFW;;J YVAI/K!W#%%8SGB4>#4I:D?4#Z^G(
MS'+$-,(E$7*Z2Y%AJI%2NQ1>),K5](*;6"="D.]22\T[[N#7)9$S,!?11S:G
MP[W69(R5&':216)Y)#I.WPIW3S'M>ID"D^+\'D_&?$ZS=9/5^[B\AVO_5DO$
MI&[U>"\OSJV7NX?!%3]U2-\P5U"9*^PEOZ'/A)O'J!2+VOSFP-ZCC ABZ:U!
M4)O.,CJ6KX"]_.]_>?;J]<?@(XC<5(6ZHF!4+W@38R>0">,[WL4CN!*)(6 ;
MGH(D?C'@F+-_7)P$@SQ4C1N8J]*@'E8ZM/1,,9;Q,FID5@U!0)*;/6RTRVVJ
MY"T3!?L3N_SY3NYAEW7O;TE^]I&9(;,G-]AMO5\TH6NB;XDF^/I:C15RK<R[
M7T<T;OTUVC)^ZO)Q%K?[<;<W-4#]4UF8AFQOL$R_->VLYH1C8-)ZI$&)[C$4
MOBNFPAK'*8=LRBS\C,#X4-O#FK2KM&CW/P==UHRL'%C4A6:\P%?>[_D&+^>E
MG'G&/A=Y][IQ-43?LT+A[VS^V97=RT9[<F!.5?Y9EPXOJKK)PAZCIFF9%"3E
MN:,R:DZ9;U3<-T3&9S8Q''MD3#4K^-;8V1;0V UHO'-,$1%$KV]!&>VQ)_P=
MHP!J;8( /_=?_H0O;^@.<0-,J?T6FLL'+X)9%A,K*'JG1N' EED4)?C_#E_<
M)1BVGDLT?"Q+M'^_);I3O'(]ERA<FR4ZV.\?/IN_1O?;10=/8!<]5"KT6^\B
MNT(2>EIJA?;,"BT?A%[/5=*/9)4.[K=,<!P] 7-VR: PSP?;N7&Q9!RX;IW>
M,R!\GQ!ML[\O6=7UWB#+8/:_>GE75K2( .W!\?')V?&G]P].0[8BIA.O$Z*1
MI-O;[-3$I.<5XM?KA(@ZDRH-2 0[;KNRD,'A2D,&-/%M.F9I ![5>9F;C7YB
M/(B8.M\4B-;["'EM1+^VE=!V?;ZJW=-M*[7:CD_SNZ9\RU90Z]&$=^V:0#U>
MFX=.1<H.<)4ZSQ=FQ52M:MV2P#1Z\% ^T%2PJXZ3Y5[5TFN>(2:RM$_G'SZ>
M#,Z"3V>G'\Y<?><GFW>G?1#8ZTZ./IQ]>']Z% S.3P;N^I.!_<+1AT]GE^>G
M)Q>]X.*/T\O_.3E_AXP*^/_PD,N3X^#OIV>_'G]8RGQ9,Z[U921Q$4O:L2H5
MR%)\I<('ZBNVW%YAV(BS@US;G%S/$H4M("ZDJO7@H,TA(#K:$"C=M63S,:WF
M#W_[Z/6TD+,'E:MMG1WAFL($EC)A?(XT[2CAR\$&&W3X&A9WNP2QX9!W1F]+
M67\TSR0YVC':CIS;77N\8*DJCZ7'[3N*@O$W$7=.&&GJ6.;1(MF6T.@TV4.U
M_K2.\76?=495DH@M,Q;X7N-1_L%MLBN)'L.Y-\6#3!*4UO];-(RN7O"4/S?=
MW&_8LF [M]Y?I=6KQ_5-7]##M]WBQWX-#A\TK3SK(B/'Q)O3>TT8F@'2UP]/
M.>Q=@JWX%@RR'PRH1='D%BTT&CV@,=U;J3$-@N'-D%!'^,M8%X5Z1YGZ0E6%
MOL-JU6@'N*'98^P[LB2=KC^)/A.>M>?OM3-1XI$'(@AU3@Q]1AV#36]<'.GZ
M2H$@ML^'V/^C[I1P%S>A]?0V3PH680\>,27?%;LK]6 D*D[,KSQ>4**S"7I>
M',CJ!9&T'1G&.=+S%!DY4X4.*VSLV*-.7,@PZ'2N&:ZX-!(1VX%GT"?H@#CE
MQI_NPHU5 C/4"QB\J1*Z^9_9,"B1O[A'C&@24J.V7CG(:I87DWB&9U'2+(LA
M(C8XTNWD4]L[\,O@C0DZ@.8RCA-N/C5MQ^7^Z,:$JICL!K!OTA*;ZF''E8BZ
MZV$(+L&?D!D"_ZU2_HDFH"I-TT#;'ZFI,T?J*LM[]ACP=#_(IAJ;[68. 9!2
M"2U:+TMLU <.&\PUO.=8%;Y*6*4:M& ^.J_;Y\I0.V)%.4OM+L2%9S6(*\O-
MNL#\&55)SP283:MWA%8%EW6!6WJW$^!(A13]E4Y-"2*A7;375Z]IQ&$(4<@=
MEQAWD+I:?G$]N%V7E&YK(X8!D?@3O6%=Y+CQO4CDG8V&%;(Z__ W&KK6= B:
MUEW<W"@;PA&B3+B!E%EI"#9A](66]D=%1T7<%I)R5XZMQW>R>S8/;;D2VP61
M PGBD6?5>%)C7P4YPR)-[T]<N<G-O*1[5I*-XY"/5[I]5.$A0S1"M:YR%J8X
MHN9[<3CIV.G7I#%$18EJ*"?4X(O/73HYN?6MG-$^,6\M%(1TI\[_H[Y@E/AR
M <)^\^F22F/:V1B_=LW X2[P:I:/52IPNB!+P1XA?8NZQ_3ZS"F'1>J&F6Q'
MC?)9RN@9+26]:!O^D>MEVN$MT8=DEBCBPK4W9;WLNOOAZX(QP<2NHC[OI/&>
MMLE[+Z.6MY#Q&QJGVC1+QXS]GA8ZN=(VG!SGZ/O%24R) -7E.W<=8?.%@TXQ
M;;+A7^'_WMNRI_-^5.5<5-$](=Q(SUD7U&&WL"3<=S<S<O,>]YHB^_(Q<AZ3
M+COYS\OSP?%)\#9.P0I&-^ HR[&%-A@5%SJ_HDZKIVG8MSV#O75<3ZM57FD=
M[%73>M3V678>E9.+FY:;V5M>$K&^3Y9P1]PC^S!N)J[3L0!X6?A<*\K%,2FV
MC6%62(KA7S*-"TSHP::*R;\2VYL3?-9=._G4"TY.!KW@ A[U+YTGU!+0I)C@
MNK^#Y$5P=^(]+S3;Y'(6&^_W.LN32"#%PMXKWZ:NF7",O;E3;*36HI:GN_TN
MTD$6/."L*,B=IJ@)\G[':3UBTCK&>XOBE;W6(?AP9KJ_O5'XZ#P&^U37PCT=
MT5.7J^,C7+M3<[&H>+%"2E2!X,(-4/%@^$.:XAI'?XX+S4W7F/5^F&>?]9R]
M0M)+O<3;&CD1_$2DR2#WXPLJE#=J=G^N18+M[8Q>;TK-Q'9H9G$A/G?L$5S;
M6!B7D=[8'(?A)<?AS+*2+3I?]%K1-["I*"\8EG,E@//!OU4@)\&Y+K(J1TW-
M.I^F;C <_AZ[ZYM7'FN<3ZJ_"OZ8Z-0*1RX4F,UC#+=+U^A[ON:Z^S$J?CM:
MK7DVR_%@"0HU GM5Y5'1U47WY!.J@#1"W,P1.MHP35@I<I1@CS\8CY4;\@_1
M1&6R?S;7,8DO=J[*X9W'@K:J"T!]>4T;!MHTWNA<U?(#+L_3M4%K6 L_@ -^
M2Z\E*J E>4OC8=1S>7'R:5%&9;VX Y7KHM'0TAAD=)',YM;K!>!T%-A*J/T)
MP@1SP9# IYY?V;Z61 T\,M.3O7E%A[BII,@ZWHJS+SU4G&/"+]9ZHBLY"L"[
M [T4PT80)(KXGXO&2$<:<NH7KO%TF!7PK+K^@>NNP>G\+JIH7B@>P]S7^@JC
MU]9:(O>3.E/C8<-M;W(]J@IQTHUJ:27N6F%]G'YL((!NL(!2*$SLX6*L4L&C
M$;WQ:]( A&4Q9S?^-@5+@:P%MESHJ@6!I\>^A_GHN.\!D&(D)44I237+,VCP
MQGHU_$-3;X )@XP6S7Q5K+280Z6$G8K=J>&:H3N\5 :#D]OVV)]S :)<*QP$
MLRTC3S0]88J/;HQ/S@!P<8L;N'3:0&;AX65A/C;NWXP&6_L)GVT?B$<BV,\X
MJUEZ,X5UP=<K,B?!=BI#V%)N.K% TH'H:(CQXSY)[H@9&KS[]>3\=/"8W_B^
M30YU*?DO5-Q'JK@M??[ ()[@+"MQ!]HDF@'M/&]C=L1=9D7K\#XMVGN+0T#K
M#S.,OE5O04&'K0?T/(5NXIX%S9=U7@VZ1%&Z$$[7&_ZB_F):1]'HKN/"<=.X
MK)-HP6^^T[;YB3OF)]9  YW_>G)V>7JVF3J(TA08\3S+G+6]4D6TN8C\,X_Y
MA\M-4K&I>,EN2"M+G"1WS#R@!D<Z9Q2$\'EE[#(PHP6HQ GZSZ@Z!_F88ED/
M501^UWE^*MCGP:>+R_/!NR=KR?SPMX,52TRCU?CW'\0B1?HF)[<$[)%WZGJK
M/E>C/AOV*RA 3(^/FU;H;;T$&Q$MLC\EZ""@M<CVUN/2#_PT3%0\):4[U*D>
M@?NWX\+[)FJ3Q-.XE,R?>+ED2>WZ[44E6!\W.OO:N*:Y_W56)5$P1H11CE:N
MA.2-('Y4>1D<'O>M=6T2A@1&&(0E\O0>!#M'Y62WUVG.T_? ?QU06,LW^3WH
M DPW-O_F8B?/9Z<"+@)2T$L7_!$'YCBZ ".7>)?_6E]?3KM:-;DZ6OQ'H"8'
M%::F,-P3?$";)3C.P@JWX%9EKDMQ]-SFGLU /RRE]$SG[\U;6HKR>26[\93B
M[13V<'#J&4.O/75-%O &KPWU=8W,)&+8T(*_X "ZBA6OAX *KO604L>8^RS+
M&7>^HV E_:<J^IKX._MA-J6_D&NP-TO41A>IO[F17N,FX$M2MZA<0^IF1S$6
MA;;#N]C!F'>%CA;OBT=^SCW;GG/SS[E+]24X==IM>[JM##MIK6FD>IG)+W#"
ML&EZ40V1P)*LW5?/!GM'CL@UQ&H=7,<!(8Q(":/1?/#SSS^QT5QC-5XO:!T,
M="U@=<Q#600[#=(4GU@AM4[&(R -N&-4Z,W@M_/!Z=D3C0EM(\N/1Q,B7X6U
M[*-,%QRT$.IY-!PCZG7($!3T]3FJ;#QTMYRP8=^H20[&>H_BTW2SN'ZO%$O\
M,DN"UOGM#5Z.@<,[QD51=: =.?79#@IQO&FH#722\J$>%A,1Q(C#JSBKW$;C
M;NZDGQ+N0E^A3%),3U8 (1B\""C,S!C':>:MH*(%A9.C!+4E4]8MK<TZ=/*%
M4,O8(DJ)HG(1<F.6Z:H)PL,$56\H_!HW]2%@$9'YT\)1$Q>,-!BMU>/2,1/?
MY5Q9$,9Y:**3VQ4F2U&JY9*;-I*3)GJ*2">"1/,4M@Z*%+1-*(7<L+0JMX2,
M%I%GE)UW=( M/LV82*JPJXT5>Q05IT"[<(XYDOGZ'1#@K=T^YK)TY@KS8,5+
MW&J#E_]R89Q#H<4@40Z9990*+B?42*L64=D]@C=!._@[F3(<C?2SS0@PSI00
MGM13YNG9_>>#_SE]MX%F_SLUA&WV3EV#/V>$:>7Q_3I8F86:"WW0F&(M85"K
MO6 GWB7E]4;R40[PWDDAVZ#A4[G PBVK+'+FZ9QI$+%T0XK<X6Z-&N067MN5
MR3+1\TXL0UO\>#IR"6YNHAF=C'_SRC&;3\6OP9/ET3$'1FQ!A724B*EJID=L
M2_!X_^$=+('3*C4EPW0C]\@GIPF.!F>#XRTH9".CP'6$+Q^@VP#(X\*&]!S-
MYR*4B%5NC-NS;KH!+9/)9(4@V.'*4>O)>-AF(C]:?S6XQ4#<5RN<ZT(E&LNJ
M3)':&AE'<'Y3X64I=HGO8-G2W&H&!W?AE%N-E]A0M>!?P'D'8>3^LUPJK&;4
M0Z%F3-D-90TM,:!PFES0P3Y^"[Y?8_#]0F%KQS.QC*H0DA_/DSQ2J8I439:$
M*#MVU#3SO$LO>H3F,".B6<Z]/X=5GH/P@EIVD&G\)K[J/[+\<W!!MS^1VW>4
M!CXJE;Q-UR]0R2?IF%C2W\%*5[!IMT;:ZDC A("GC49SP2D.2,4EEPAC0:?^
M,B,:S6M<10O*\8PX!9_A488=7Y#:73 X18](E$.)=TDH &NQ-9J)Q$HM<6I$
M_"+6-N4XHJ2ZO,P-QJ<Q])@+IQ48ES8D*:%'^8VO[%$:)U?7*1RH:/F)%#YM
M ;BC^_Q.%U8DL$0W355<%"0/5QDM?#S^][\</GOV.DA4D/./$8=88/%@5<>)
M0AP=<JS!RO(%> .R^3$9Q+1,L*)Q\,\*;1:0O<HA[T &OO"WPJJ4K\/U5P3.
M2U/Y2Z")&"&4 1#+W)]5%(>QBCGR75) !3\E,E22!3&?*BL<(JW&9J&/X4N'
MSU_C546%"#_Y?<'K/'+O875]=A_!476F2B&]^!6)#[8GU<I.JJZ&!T4UFQE.
M8U/>_%.KNKF[Q<&CVJ-O.Z@B)11\2U"YSOAHBKL1/ *V?R[M5F)V&I6]=ZOG
M#$>:#8T",PO!T6H[3!D:$*K_!D,_8BA+8:CRQ+YPS'X4PXYBJJ0T!>@>-T:=
M%]2.0ES6PMUXAU.@"9HC,GBFJ'#]CLP;&@+ ZXFF?"5\CO$@3 H@&UF51M+.
M.4ZO8-$C-B.\$A]O5AV7$E*)WO;V$LKBO,"\.+U]R5JA%#]%[L3)%#ZT. 6P
MVP<YX)>W R#BH*@#Y5)[?NTI]3+].4)EJ7>0!-R'NW@)"28*,2(E$D6K0"*U
MOA#.2T](CF&HZX#G9">Z.;)ZA9Q9:R2X1=(B[!A%?4S$T@ZX\7N_13<AI YZ
MG!%ZP]((X4JZ<C-/Y LA%RN(8+L05$>-@U_X\9C6)4X1Y./QSAO1(5.]8D8_
MJ6=#QIG:>+]6!!&N@N<%A]7,<(0T!_P5I"::5M/Z0X,ADRRF03R=@D<"DXWX
M!BO-FMIT8 &@TY2)@H%$ZF;NMC9/FO.BC]QX/.4E8)C7$B<'*W F029V.J/9
M0@2V"%Q)&(9N?"(1%\ORM%@-9=E@6ZSE#4"Q49!5FUX)D4;GL]3-9F*.1=[U
MKV/J1!D)GA[IXJ,1OIW<>&]JCX$NPF>.XOJUJW(ZM<!!L,SMPSMS'/^U1\'9
MF>A ZE[QY9"Z95@@WNNQ9SM:YYV-8W<5&C=/-B:;S-L-_CC(P?ETT^6"[]=2
MP"PS3B_XV@(-#.SJ5R74*R@ MSFR9S3>[:N5:\^\)Q'4-=3.O&)JK7**I-2+
MJGDV\FPO)_O/*&>K)?V)0L;;H1YE KC@7BDF!NPU7YEG>F+PR)F:.]1(I[6[
MX\)9][L$=V:#PG^GCE= 4C.=%@)Q0%J.K"C-ZZR_N-\5X_#;Z;N3NP]\?=[W
MGKXX]=X#J?MH@*9;;WR]O'%2B]*$T-&-/>MVR!]Y@@<G@;DP:Z<(QII9F<E1
M0I'(R![5RL!ZYU=['-'1C:8HAKVUHB[8[=O(9K"HZT?-8GCK5,/YF+/C(#VZ
M<,II#JV]CW^A(!T?TGS"C%P+64\ =TV? SRVZ"988IQ1B7$6_*H1+I<$YU6"
M3TRS?O#LV4M+ZX'+HU(V*8O"G#CXD6L6\%[EGS4#^I[TLO#D11H!WD0GZHDR
M2G^]]("#,]01[:8A]UG>=0%:&_"BM0OOO JVIT7.U@N35;L[&@RG5S-),'KP
MA@M\789E;E$0WPH%\8C$FPJ5K"J7AEJLA V)LJASGUO#ZO!Z=49;F"E/.D\<
MO:UC"?3OJGM(\I^T NK0$(XC:JC]3=T\>%5!/KMTT;A9./'4P:J891PZFZ/#
MS+H_ZI/X[K[(1C)YOA6Y,W@E[KB0)5B+L<F@XSF^@=F58SQ5YW0Z6=AB,:Z'
M.9A?PO1/=;TDLUGB;GBN[9;'C9FJ-6W,1&-;Y;)9_@C;MY8*/^,4.Q3QU%'Y
M'V;L7,R&/1'7L"S+:\U*&KV[I>T\V#A^:/5I=Y_OJ(/"6:/>QQYJ4KHKW0+T
MI0)!:22@J$.JOHJSJDAN3.M>R_<'/S)8LQ)&;V,^-)H6MO#"_>!T5%LU5FZ%
MA,P;5]]&V^27,_HWQ6"V;;FD6K7Y':A53E^FL"IMB#,(9;UIGNUFX#=GNC)Y
MA69#&[<L>&,:CH$B2==F>W.X1E"Q)L=AWJ(??)I1K-T+%3=FQY8HV!Y2!NZM
M'.1[(3N!=)\\>+6/^29NW<S&XR3+,84M2:R.=E6R%XF3(!BT>E:U#C.C)R\&
M;T_\GFW>*NX:Z?2CX^2<<U]-4..L!P@ZK!)=&* ?33;K8U'RL-%2<B/=VG;3
MQF]>K*T+^.%E;?UMQ1(&*D -"5WK-6#%;<')RTJ5GC\2HJ80V+^GD+QLE'<3
M:D?7T.HH:"2T?!L,6.65%%QFJ6E>ULA1[+HNDX['C>_M=B/U*9&V9B3EWDCH
MVZ9,WNA#4^<I3?',".V!Q7F3CC.HQY9_[1R+P&RA%$TS9<?#,ARSTN(',2!,
MR-KJ*BM.0:KZP5ONG6;3-YPSG9<VKFVKBMAFSV&XN>G74)^A1F()]ZW9_8*[
MQ;D0?@"O<;O+8X-:*2>4R';F6^?VMHH,IF:D8\F3>1 /HY:T EL9M[4 0>8I
M)1CK8T])UDX4KSM3YS%H=:-H7Z)(T.;JAJJDHC5MK2W>Q%2RPZ4:BG.$R+M@
ME+<T6;>\-%8CM/2J289;W!7').;L3>HHE9;MEW(O8(A=;.%=QQO94N9Y]4;M
M\U\DQW;BD\.3&DG)2S9?;'$W13!1\33#*:68LF6A:92&;_#!<^Q+I<%5= @G
MP@]4W)HY5'*?^A=],*:21.44X&5ER85 X4U0MPJ=46H5\P;/_FE#+<Q9 .I*
ML<3LS^WYVD6I:O(I=4.UQ*H)Y=\U&*KTL\]^Q3:=WX7+O4.6M\2F0:E%R1BY
MVW;EOV;EZ_MLD9?6<LUB0X*69B;<+0 HBG,*,9'KK.@?.I0O@8MSXP1T.GXC
MS V#PD4/!LNOZ7O6)NU\==]O:.@0L8Q:9Y_7DG*3.=CF>+I#,,T8-V/F<914
MH?3(Q.8&G^&2\EH+T(V@/][*Y#Z#FU?B2?Q$QGI(I4+'2JNLM-GNS<, OA:A
M4QH/JPZ.ENT:UOLO=_M)KF&$;_L+X)65+K+!%TL9@DZCFPYP%97"Q(@C(PNM
M%@YI]I7LV)+>D*Q7M%W7Y6)GTK#6.IC>7.+9#+X8S+E0]K&'9C'/B)&;H8S4
M';M%'N?]W+%M)GS-^0#\AF=FYZ>FT<RHK0&LJP\;VP1#&&Y98$AA1+Q>!+6,
MJ6ZW(,1MS>B3(IF,1+<%:8Y3. "(6+ B( FS>!$$U7B).J4XE1\/;P# /;X8
MAPFVWV^Z%]@XUI4"==R]AAMO,W]Q#*6C_3KJ,Z16Q-(+&S_K=;0BXEB,'ZU9
M-BQ+$:9>+;S4U ;K'TBY:X+YP[L/[]\\V3YOV]K3]3^G?5!Z9\GIP?Z2-:=/
M0V87V2YHL-3;#@_0600M=W#XRG5&2[+I$%NT,'_E419)X8+E522UQG2-IE&9
MZ6ON$Y^3V9FEHK[-D/ZC,#6&X#6K_$926/;\JE%04CZ0H8$]!@+Y]76LR77D
M^Z->_4TK/: 2YCMFSC.;G$CH/<V;]"1V6?!(Z+XCQ"1I[Y(KQ13^E+>(]#05
MR-A,W8 YC=W8O^"O14;1WS@MJIP.([*WT8LRYX,9MO,.:#1[9G[5E (X7,AA
M0WHW>#2M_VGR]>T2D#QUVSMFU5K6"R/<0F'NH1F,%O'Q>+9)[T0GD8_.VUDO
MT,\YCSD+SL"')A!3I(/?%0P'GGH#JBPNLA7S5^[B,O0<<KI&%.^Q*9IVR!*S
ML8A8NT(;+-=G&?->MDH3BPFU$Y5RSC*OM" W/G-=M(]6[<"9-F=V;17T'<W]
MXY.S]X/SOS]1RVEA#S,4C["DY"F!MS[,Z C?'DBK*FS_5JTZY8/<-S/8Z:>;
M[1SK=*KRS[LMW->Q2A'((U)!T0>N^#W'@5+X]V.5AQ.J \XI=D/-.\@L%3VM
MR[!OM,^)*\T]]TISJ0Q!3;F^C!$A_Z72"K$P![W@</_@YS7F[?#W2K N?=BV
M+5BW+5C7=9+OWH)UHJZXZD5@RK NH@H6:S;C=L>I:+*>.)FQU^2A \C6W-*W
MZZ<G9P:]/3U[-S@[WD SZ ^0 @3(2VGTI?JR=RZ!BE,0J]6:0RT2)<MKCUSS
M$@U\U0H&-EGO>]WE+)P2]XM:WG()!F<,6E/A\C,X)O)W#>\]LMJ['$A'2Y Q
MP3=,> R4X[4::R]CPT&AP@2"NF F^ SN"H7!+/[:M;=Z4UU.LJCPH)^.ZKR-
M\9-(&3$V\:<66_OT=O?YX.SHJ3)X;)N4+)G4L6?OUL-;61)#2JLDZFCJJ)QV
M>HOHI(GE8:)(X]1CG!K>F/Q&$;SK!X>'+_8.?OYI[X"!S_J??=2/],'>P?[>
MBY_I[_;WES9O),_Q>E>%E!-QAL_Z*\%MBY(M'_ZC5PA;/ORG+0!WM-2V?/C?
MC0]_BQY</7KPCKOCMP]GOP9_A_]L79E--%NV_1;7QG1YJ'Z+V_:*6]_EM@[4
M,\E)>B576RVPHMK!GL4X,MM)SZ_/DJ*M9BA7>$6*^$LPA4=,+"6 (]-L9H>\
MXI0)I9Z+B<<U3:PF-31^%!<(D202<F2JP("Q#,R68E-)>/QEC\8 EZ58DLV$
M#,WA/')]LNT-N$"?G+[_^.'\<G!V&9Q]N#QU4?*M*OFNK_['X/SL].Q79FJ^
M% N"W-%F<DL,!;$B>G4;PN"?.3LTQ4X[,7+%MK$/EN2JHX<#MV=@XT*G JUQ
M/4^D'@9;:ZBJG&1Y7))U\ANR._X]\QC@-V\=+QM91L.S@P0W?!;H+QAQ+K"=
M0&68]PQQOUD<1B&6EMQZ@R?TM)&YG6!(CTC#JB$*\!"+O:2@KNS8-PJ1M 56
M[MO=T&(*(V1H-L0=0MC_&68 4HKPC#31OJJ$EC!\[$?AMO?@(B@$IN2WY]^J
MDX-PA(FMZI$)NR-+JI(0_T2AXKF,7HRP,'S-BZJ&7*LHKC8"UYV;)<W4#<>$
M.4-I#[@GB9(X/3O>R++/<Y\?[-RK[5TM]*EF24C"*_$9^SS.1^+C$P31 EZO
MCBIJ!OT85F]=JWQN<NOU@R4*VE>IPFK%]*M<O7F%_-@=@[F9-)@4DN5JE>![
M994C%2<(7VD2C[AB]@5<B)O$BP[*Z\/9R<5&*K C)@IDRDK"#-?PP2[5O+5M
MU@,!WNYCU'!)L#M.C*0;%@JNF.E)F.2RC.MA7-+:8A ,LQL_@_'?USIO=^TS
M()A$0# <.Z!Q%DW:#XPENF?Q&0(/D_9[<B2A589Z"G6?3L?,1$R-?3$^8.A#
M;+G!4!5,78D%P6=9/SA\CA<=[N__C'\],[#<MXD:]RQ4IP?GCJ*Y&^#H\/'V
MRD$*3[1YE7@JO $X*Q\-TSI"O<ZMB@QVJ+LD!VH?0=KD3K4Z"UN[@13ILOJS
M4BG(5%E]#MYC$Z9XJHSJ*.(@4@D8#6\4N-SXY_$XCQ_:)KIC,5(_. 9)@W>8
MFM%/XJ%"8MP\IHT57,#HITBU-%2E@FTV2".%5X]YA^%KEK!U)O"WZ5"%"KZ*
M=YOBUV &LL\HK'OR;W #4@C'>OY9P1#3(.*'\S/C- YV;N"#JA? ]/ZITC^Q
M5OHC7 />S%BIM$<W?W=Y^C&X5)]UI';YAA&&AF+U&>](4SZL37G/O1WX+Y6*
MS7.;HRMQ48=5R<_A]975+>-(?:;[I"4^\K-6PP*>8F]"PX<WB^#!.8[D$TQ4
M.M[C?\S^+-6D2GF+EG*G-]1]6\$NY#A)3P0&MRS,*'40PST^KH*_:_R]@)D(
M8#$J6@:[2^'KGVFZ<@3LXD^R98.=S[J$SV":X 6'<0F7/>:M.L=^N3@?G+S;
M0./E,H>!81/V/$?/8^5M)N=U*[A?$XF[M(*H/7@1J34]L3/D4:=X[L%=&JU[
MO78BS4:].Z".R@ZZ[ 81JG5M.JBQ2UE+L#!.BUSI)$!%-6[3'_KEK2( II83
M!C+D@1C)H#RG*721(8*+2[6(I?I"TV/R':"M*([CU\7LZ/ZXWW-FPJFE;C'A
MG=TZ2;9/^PKWW@D[QF/[:?!XII)<H06PW]Y!4DZ1ASN->;?%Q]D0RR7I"U=$
M7OB56FN+3'QTR,3W@W>7F^AZUR%Y1VK%/G;0*I@T19+/VT62-8HJ1[C68DYI
M%5/ZM F6DNUP3J+:G(-U0)NAN,4@/H)4N(!2]'$/XY#@AE+M\>U'UR:%N=Z?
M_)_3HP^/^84W%_[[]6$^6ZSFLXFL6.',2U-TTM[?K0>A87UIVLZU\!DC9J-,
M E ^66$::$? DGM35F-;=T95_7$;'+"LK2D"+@@&9*HUW:PC%(/;U/RSTFA0
M6PR&E=2YTVY< 3/K-G=#4*+W^DL<2F,+7L0ZFW%OKG!TWB<NNL6/.E-I(=78
MX 5_8V*Q<BASNS,&HQF_<.E-WMR^CD\4!H<>,SE;"W>^Y/A=;S6"G>& B\5[
M]VY2Q#V;C;_Y#<9M"IM]7(*G@T+L9]SB";7/\:N<[_LRQF&E]A]9A$74PER-
MYAZ6-D]]=)09N#\,;Y\+_*P5*\![!:77J:QQN^;UKD5TG4R6D\U8+0D7QGF;
M=!Q?QYNU>5 /;XX=J\V=9F_] XK;DHE[EWM_ <>%,E8H#$CE0AV*03AU6FQ)
M:-?$SG#'"A;^CE.XC\2VOH$I27P_#+4P2L3U/4.IX.1JC&P_.7'#ANP-6P9M
MT61>87GG*$:YG$9765*E)=[:W@O<93=(W1IB&YQSFQY<V#K!:]6PP2(V**CZ
MY9ZMD^>W,,7J.SI._9,<+["!U+N[.XQCINY/S,?,G2R(03U60^S\L^E>R95*
M*EU/L>#61N2:K^-CT?&AI^.I#VL<28/D,)OI9<P)@P8E"K&M5UCG[UD(OS6<
M9QG1=7"JJ+8>MW'Y%_I*4YX&"1(X6T9;+]=1A5EI;+6'&Y#(FG,$Y]N$3B\8
M9FE5<+N<=+QG/E?HMB*G/PR"1 +).TR37Z\7@(1&BQBF$5[!W9;Q-/C^9-I_
M"9.J0+R5Z]U7-(Z,Q8[I4[5'MR5WRS=#."-&FM6&\5:Y6I<NGI364NR&Y[X-
M9&[6I[6;%=AL[[E\2&EQ-_&8L,5Z'^=MTXY4'O#LC4J9&QX+$MPW,0P;4U$0
M6V4J;=#R8WDN9JIM9P2[W?M!X-%<]VZSX5QVQH+FZC _,V\>%8!]J-_<T1L
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MB2BO]0M[K8?6>L3G5[<L_Z%R+(98IX$NZ'_%^2/;]U%L,HSS][C2!C1Z:>*
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MYZ=FT"F#V_D'#)8@/,$ M';7,?8T"C@E4/#(^NPZ#@D> CP%].64L]J4%9M
M)I%$M8NSBQ!]$JU,:U?6DMQX ARV@#RQ12B?+%[>:3ZCE\]QZ>GLV=ZZ_3"-
M?F9Y>W>L"_.[D0<F! [&>12F'H3@U),->=:BAEK;P?"D$=:V^27S!T;7H_/A
M8'M%:':"KZ46UP8(OC9M<SWX.)T>]S_O"$Y;A5V\9]K?E)2_O8VX<^JDC1;Y
ME>NDE4IQ*P4\E)?!N8NP'Q(F-(OXQ7K9XO4=799T!81>!P5/</#6@<_QUSYG
M^95,0]MV4S>ZO3232WP**#5 :'718<*> BUN-UAV2 E0Q:E8IN,LL1W6@W?O
M/KH>ZJRDHR,I<L'R.JQ*1%4O2ZK56XT>W]XPR.<% YS_2#77JSU7W,Y6-1'*
M2-T&!)YBTI9+;X" B0A?Y9EM,W-J'0'>H*-[%STV?&7JK#V+2F9,?+R8L+RT
MT^]"@1&<YW4[QH0[QD@=%$-*");TK/#A'A_>*OE]]"Y#*#,#\NTOYT3%X>6F
MK+6^\[.[_?% *D&R=[D7$PH7W_*Q,<N6G[XN4['AETX7.64>X3"WQWM09A(T
M!"EAH)^ETOC6Q?SGQZ<'@^&CJQIL@._8I="[%/KQC]-P,.H?D5Y/U#\9G!Z,
M^F>M/%N[Q+%1SK8^2UN?86>=64H:D16][P;7"3Z9.U3FS-$R\&@2VBK77$+O
M/,=X2DBC"J?P.:-9HH-<C>&K#>P9793@G"[C\>:+?W3.I%3HNUUCD.=1Y'H1
M95*^VA3.A9U$"S5 N\RTF1C.Y\;+;FA'*69H\4:QC%Z(@.5*09:[";(@"">@
MI Y#+PRW!5F5W<ZB>('D"6"A<$S1)L[^"UJ\Q(-IN6@39YK+-GY@T'EL2H/*
M3!WU,[*>G;@LLNAS'V9=RJT@!)_&JEH- FBSF/_M>VRL.^)#=9:H\*R5A*C+
MHQM<GZ6-J#T5ER'FI)F$'@X!764B:=_."/F*3\P,#1UA'OO$1,'<Q?BWH\58
M&2064_G<8@#[PE8!+]_H)+NFUPF:9UOVZV:#^*L)D%_,]34!"?GQ\3A@D"<A
M"A(AFG"AVLP85KUZ0Y!A=H^^3; _"0./!\-?CGX[V>0;W]%;?6T,_#MG1 (I
M?]I)B5Y4 E<[I.Z]@<QXX!'PXL?8:\V'D#<=,L8J[+?YNYF]GMSI!,PF>$M+
MM[6,&&U_%YZ9!_I1-^#2\T364EW&64TA+J+H:3;?NS_*FHD?/X!W.%%_PI<O
MW232*<[0+U L8__5F^@0UB]+BX;B8#Z<G!XV 083=4KE$V)[]%,&)=(3R(1N
ML%KB_MYV]3E?U$^*K&H5,D?TP.,95UI?>^X'7:;-PC=\[7E0%PH+]O2D:L?1
M6:<EY8]./US.<>:'/VQF4IOO&^M+E4SQK33,=ZU,[$"1]!WK/P>_A'O]<?;9
MU@4-U3*G%!,UD:1U4?J]ZED4;)(</!4B@7,46!/B7<A#S026KZ-8S% J#:E6
M,YGE<B7._<Z5TU([[YWU[IP8/&#6B^>O]U^P36<Z[#WVA5C"=/F82:ES-,>N
MA;OXH!+KB.1$>&\0,I[<Z3Z_=)-,3DC<4KB3,,66CC\\."S88(*'<B0H58(;
M5MR/IQ=:VD5Z_5,4*SA3!'^1)3GNT=<NM<+.B#2S$35,5WQA;O#^<BSF2DVY
MRND2ZV*2F[&C6<XFL,!"2>298)BDQE\Q_B:VMDOSF$)>59M^RMQU"?T2=?'<
MDN *,;T O5XL+*G5S-6,7!\=3C%&*Q5%Q"^0KJ#H2\K/W!;%JQTK;@!RVAOC
MK]@,N/+H,FDK!7=B[YJW 9>VR(SLD%6;B:SZ[JVOL18ZF3Y3*.!16,8=D[*R
M*F\;DX[AN%A[&,2,]W:*'<[W15YHSU&)W:ADH<M$=%I_^:"LWZ46[O)?YP=E
MZ!X,1EX74XH$*C#'I4)'J=EB"?)>3#&:^QJ_T>K$9GL=ZX[4:+V>9+(HA&[M
M,%$FW76C&I!%5"D*5Q88R.$*M4:5B"ZDK423&:M475#GJ<BF$,\H$? -/Z8P
MEB&V.C1!]*\U:FY(EB?3/'0-Y)$L#S0SWB'5,W]_7)HO[;I9:W@?181>9+G"
M?1=UUO I@5%#UPJW@?(4F9"(AL-Q>]3=<C>19 7=7VS@:Q:6J<1Y W>!+=Z+
MYY8GFBDZRT2,E;Z*,&7%Z$5BMQ%NE<'RN@'7<Y.AXUV*JG5YNVVTTWE@[?OC
MH#\:'FQKT7N'*-I&1%$S,JD?<784_G,Y3Y.W_P)02P,$%     @ 76:F5+8N
MV41L'P  :OD  !<   !A8F)V+3(P,C(P,S,Q>&5X,3 S+FAT;>U=6W/3R+9^
M/[^B-U-G=G+*<>) @ 'V5(7$0.I H!(S4W->3K6E=MR#+'FWI!C/K]_KTBVU
M9#D7!I""PP.$6));W>N^OK76BW\<OS\:_?%A**;9+!(?/KY\>W(D'NSL[O[^
M\&AW]WAT+-Z,WKT5C_I[ S$R,DYUII-81KN[P],'XL$TR^;/=G<7BT5_\;"?
MF(O=T=DN/NK1;I0DJ>J'6?C@UQ?X&_A;R?#7_WKQCYT=<9P$^4S%F0B,DID*
M19[J^$+\'JKTD]C9L5<=)?.ET1?33.SO[>^+WQ/S25]*_CS36:1^=<]YL<O_
M?[%+7_)BG(3+7U^$^E+H\%\/],&3<"^0P=/PR=[>HT>/]\?CQT\&:OQP/SQX
M>B#'!___\"&L<A>NYYO2;!FI?SV8Z7AGJG !SY[LS[/G"QUFTV>#O;W_?E"Y
M+E.?LQT9Z8OX&2T7/ITD\'+VXR")$O/LISWZ\QP_V9G(F8Z6S_YY!'>-C?YG
M+X6MW4F5T1.^(-5_*?@F^%+Z[\*N NZ/=*S<J@:#?5C*\/-4CW4F!GO]AR]V
M\7KW+BMOY*TT@&U3YN9+'>F92L6I6HBS9";C=4L>W&C)AR]?_G8R%">G1_WJ
MBCNXUM/WISO#=Q_>OO]C.!3')V?#H]'[,W$V/!^=G1R-AL?B?/3^Z'_%Q].3
MD3A\?38<OAN>CF[]5D"SYM>;W/5GGF9ZLGQ.O])Q" ]Y]O!)_]'\%F3WA?OS
MJ+X_^P>P/^]CD4UU*MSBO^X:]J\[(UK#SS\]WGM.?[T^.SP=B>/#T5!LO7M_
M.GHCCH][X@_XLPV?[S^GO[[36IOW:RN;*O'S3T_W]_>>?^-UT!.?Z0PH)[C!
MREZ#@,_$,0CD-O>'MF;P?+OWC4[I9E1].![_II4XB8.^Z.Z)'26SN8R7;6Z4
M.RXQ54:-E^("B2@56=(1@?#JY.Q\)$X/WPT]_B\_?GNX\FF;N]EA6CO61@59
M8CI!;%*<J30S.D#C\3Q+@D_B8PPVT.%"FK##FTCKZ\0.)I..,.CH_>CPK3A_
M<P@FE2#U/3SN"#.:DL92HK$<:"SM,'DA#Z2=("^CYK![8)RB7X?[Q8X<J 60
M(DI?*B%CH?Z=RTC$^6RL#!+D^53"32*)@;_3N0KT1,/6'ZL(KC=+LDQNY"]T
MSD8>P0:P: )#F30D^KRP,$-[\\$D\,L9; E=D.;C/T'4XF;AIW.37.H4W.X4
M]\B[OE>Y&2[#/<ORM/I[&8(?JX&098;;;O)(P15R/@>2DN-("6M$B'D"O]'T
M(:P#'P'NR2RE_P5)')+K#ZM3F9@D)IL*;2W_PPNC%+KA_3;M1M&JO7@2TXZI
M2XQJP#'AANH8MBV%K5=QL!1REEA6J!^HOX6]+SUR=V97'_N5#Q?I5$81GG5F
MDNCK<-K?\VL?M\JQC>1OMXRY&<25D"FP0Q0EB_3GGPZ>/O\*[WKUGLUE&()0
MW8G4A.]Z?LV3=P9/O\,V-JOYP3<2"3?Y]N>5G?JE_^0 M^%838 OZ"S;E!<;
M+"I'K-: 0E%6QDDF0CP3T(CH0NJX)P(Y)Y/G+_@=,R%+IJD$28;WIG*FQ$S)
M&*T+8$ =^W+LBR471GE;DC=;<KM=BN _W3)G"ZW8KDGK2?4-Y%8T3]8XVRMV
MW]]@N%LH/4K&K#ZY+<X=WW/N:K!(9O*>:5M[_2-E,@E*<:Y,BNE:4)#@LLTD
MFCU"CI,\(WWI0GJ@>*-0C)?T2^<..H?B/!^G.M02''!XAEA,=3"MWDT.1:C0
M-327.H ?MO3$\S"W>^@*13ERL-@:YZST(SW3*%"R9+OR. PA#)X\3T4,2KXG
MI@FH>N!^HU*VQ3,5J?DTB94-'/2$FDD=N6MZ(I290C-]K,%)[8DT"33L0*J"
MW.ALV1-SF:9S<& %+#V!;S9"HS#2$U@M;9![;BHC>.L>+(23WG3WG\E84+*Y
M1SZ>#5G0!EHKQ&X@+$3!(43D,J#U0BY#BM^*-_(WX_?"LR@7#NZ^?9K$*U6(
MAE <P.O"3_/<!%.9XH^7((SQWSSFG^@]\BS-8'=PA^TR5O9S(B\3>"L\1'(#
M<S-/4MHIH#=Y0:84[*]S'('RK+]ZK5EU"^E\=\5\T+:8[YB$KY/7F8OX4<"A
M=>$O1DT\$*D+D 47.?"7EG$I ?CWIO(*WX'>.^R/A&V3>P>M&BL(6Z?MS35L
M*)#.J?E#4)J@)$EGH7]".++]O<%#3-JC7KU4UEGYBF&!NZN^5.O\W"U>'BD#
M=@Y9=O?\W-KK'U)\SYZ#F)ADYIP(LE/14#9*@@\#+D7A0H1*9E/4W49EH.#1
M>-X6"YVQ6_(RP<@\6+5.^1<Q>]^S08.\\&RT2EM1]BT%Y??[U9PJ;0BY'M,D
MPISD&5Y\'QYO3\6%[GC0ETV)%:QK2$GC:.E<,TKX8\X8_\..;^RYZ,Z?-.#N
MR25E>VU2N7#>Y22S66@7Y.,T5RS2')["7Q#)>4H>8YI+ZZDJNE \$F,5)0NQ
MI21<+;L)BZA0>Q?@$1M,WA^,Q@"$I4+_8&Z;/KW#)MF@W93/P'>QVJ(&6D1%
M%'&2#V.#8Y!3MC)$I@@&\I233)EZ,'9UA5!D1(27-TSB"%0_HQMDD"'R: 63
MQ,_#T!J%"Q4%1<ED2%.5K1@2L&:4CKX= 43\RWHB_L$#98-V\R%W@:SG:.YF
M'/<6ETFF?#W=1,=$4$C+WYZH_%JG><*E7L^,BB@:MK;Z:9QD63)[ME?>(L=I
M$N79ZBUK%^'_/37EBUVHG3'(@4\[9*4\D]%"+M,'MRK2NN8[.\]3>T]:#3[3
MU[?-4[2(QIS&B@0GH]6RTT(#WXU5'4\I0SQ,2KEX4#BF<^2\1,R4N5 &](!1
MB;F0L?Z+_%.G4S2\G32,]5O!0W[/=$D7Z).,NO/J#AOU[]PZYJ0SHR0 ;1O)
M14\T2$9W=(%,I^BF\&V,#;8/A'?&'%W(&< 088UZG+.G,I<Z1'?E*@>INXCM
M8_MF8@A;=BDC?/<N>"ABBQ,CV53&WO;#H55W'T[79E:U6K&/V!&=R25RH4[3
M'-0>Q6G@H.:67LB XJ,#6^M2FRQ7#D#+H/MT'NFL!X;;;&P#13W[B5L7QX(*
MU!A=L^UHA[!B%FR&U)/$Y:_)8T;\V$20_TJPEH5"5"<OBK6O37"'F(U> -L;
MI&.):6S1='Z6KL<5IQN6Z#*O8Q6KB<[<;A7L4-^:*[:=N2Q(3,CO4&;FDP!.
M@_SWBG/OX;TK3E>OC!Q4$0$$:S43Q3GZ@I,P@PQR+L6L/# LG%J8T_MY7U P
M>O'8>FBA?!Z9YA1>"#?8*7Z%* K.QQ,3 :W#;F+ROXQKUH7J41*J,@RS]\MA
MSU&\(_;B1/@TRHJ*@F2LM'7\UDC,\- &S(=.'7:A+&2 W[GU[+N85(!/"4%;
M+A7\%>8%J #COJOP=Z2M\MO ZT+P!E+@%;S T:UKE< &D]=H5>D2WX'\*@RH
M4'$DGAF63JLXBT:Z<-85;OUM4FM=M6R:8^4/^Q7A=1\3;XV 65\4JG621]'2
M8J%0A5ME6M:P7ZVZ2PW4X"7 CZFRVFKKX?:6W.Z)K?$VF__@B[F8-[Q^A-==
MJFC),K:3-F97"+BP+7/0'!&K*FDBK2@>3(:+.T;K6X4J#4#0*\+6E:<B'L&1
MH"* 0_GJHJ?+88#6(L:5,$";48!2$J!;88-J:1(!@ZO/ 3@K%\CK8#C :>%/
M&38MFBAC"$0)U@I][G!?"YVB<YFBX84YXXV%.#)YM1:Y]<FK3>HZQ%!_&-HF
M5T4]LD,)^IXNP9[GRF3+=9ZMO3M(0.NH E[-Q$M9#?@TC[*OX>SV2KU8"W95
M/"]R?^E-UM> ,NR[L:KWUKBIO?[!P9V&3G4I^-JVU&W.9Q1.8*6RO\#%SUVV
MESQ:1<K;PN&E)<H0J2Q$;Q7XR:"W5Z]$<+<OF<4F"IP[&2%?$.#!<:<7@? 8
M-9(+)GSF(J<D*N[TCQFJ76UGAD;8H[YX2V@..(8.&(:#-CV;0:N>S<!Y-A49
MS=S%@!LD6^>H3W)#5#Y)3$!$KR83E/,%=FM-Z+M4#"KC:,W<!N"<[6T5 !>Q
MX\W6^"9(3Z^#F)Y!5S ] ]^K^5O5_U55^3U?8;]=),I^^QJ.UN#!@<7PLL5>
M)G9'6MV+ DM835 465=OLSC*4G8%*PC_:Y2_M,84W<&QM"G9CMA2TC%88M66
M,)NIIQU/4*3**,S.H"TK5O:I&GHL X[<'0B; H'1G!/:H.%N3)T42C<H/K5M
M>?@A5NF@'TF(!\JFZ+3HI '7CQ XGX."/%,7><22[>>?!H^?/!>#/N:+=AYN
MZ>VM@UM%T+[8O^N"_4M!R(.^^!V\" 03XOZ/Y&=U']7O0%H*PWDI4&DZ8<3E
MQ_YY'\W<.(EWZ.>JV]>SH)(F[R_#,Q72:&HJ3D4ER'W4=ZW2OXEC]E&3.R1L
MKKY XI?MZ7P8?"U[.5[>32OP/KIL,6984FA8+OMPI*^&ZKT/Z7[O'0#_V3G$
M!2S)RG_'T(6$L/\'OAX7G,^A+2>9:E":A:=)0.I\)_#WAN-TNRU$[X/%I1"U
M_&3CPJ&U8F.;Q"V031RH&LO@D\M:6$Y=ZUQN6 *BM5X,71'B5A8C3;G\E;K4
M29YB24] @?Q"FEN!+\4KJ8UX)\TGE8G?9)0KSC%\UC.P'^'&"L)8SI*<3;JQ
M%>LJN@+6=)?S NM3/$Y!UKHM,D;,-B>V;?YEGDT3PQT:DU*CUE6I/;C&RM,K
M[&B$=E3!C&7=#'YY#6M:EH;C0K"[%3678I]W!2>YS:LLFS!A<DG%*5]>.A1,
M$1P2KZV]QUZWO42F#N,,HDVE*;;*LK4 R5S'-N=5RV@5O@[L-+OPZ+7TJC!/
MW'/?QDC&0"E<B]"6WVA%0IO2X&32:,YQG31L8PFEK9-C"?IHL/&J!UQ'N]HT
M)5Q'?#%6*G:)?\J>Y%%#)_/FPL2K4O0WZ:Y]AT&6S0=ZFF1XB$4',TY'&761
MP/]ZB,ZOGX:WA8ZU!X_!V7&,-G1IWL/ MM0NJ04.JI!7/'<,/Y\ID!SA6L39
M 3Y<CA,X^CR.L!<=WI1SX(#XU^=3^S"-"7#@686=]P*+DZX*+PHT3$F"8,<U
MB:!&&0)-8OHO"%"^X ,Q9@B" 6..::\$YB("W[T=B4=E97>)YK55 ;PM+-EX
M=35T706^?4"EK95RIC*1F*<W]HF:Y-4=IM[FB.+COCA-N&<&;@M&<76,<N&<
M.YEL0'2Q>6/:CBY63 K7SG(EF367!IA3SUG]UX@>'H% E[*4W,)>-(YN R.4
M"WGO9-#OET=MQOSHV]OU5FD)V!:UUA6@L  YI *R:ZKGI;?ZQ<7_/[JSR@35
M5L#1)Z@6Z0D(:0*D4X!LRCX[V,K*Z8C Z@@G;ES/J]7^$O3/I)G2KHJ,_-AX
M92:UMD)M79%=I(0F6*U:""<YUMBF^ :-2LC[L#@.U:P9'57*C,@P@Z7_F!&1
M9O/E"=EU1U8SV!HC,O,VP*+K:KZ8Y^Z$B6+#C.='$WDVJW G<0ML<HGN+_MQ
M\[7.YGO)Y=F;7# *#OG4NIW81][S$+U*W92L8.K!BBJ-3P*!J7$DS86J!-B\
MHRE=0C"DLP7&4>K-&7UIM,&G\"K/<F-)/J4P"+65MSND3>. JEY1T&A!1VD2
M48U38 KX?25B\.,ZYD_[" Z6P-CZ4@:M3LG]*GKS'A#RW;?@@Y>C\&)<Q5R-
M$.EK;I+,!LXPHL?Q1E<;C,59< 'F!=R$!5>3N!9?6SR>R!=C$$5>P?40*3*D
M]A9_W%_)Y-6BKEL&/S8XPS!JVBOPTG&0".SESS\]>O(<[08*0N/.V5#^#0^]
M>KZ8.Y)<S($:EL:QF,*2AR>7AZ3NCZ@HU;3(UZT%9B1=VBQL#+)O]VK4?U6X
M[MMXSH.]IQT1[0QNUUT M[>*Z+Y,HARL6Z,)0_ I3A94'9[V.-GBTJ\2#=ZT
MB<'S5-V"RZ6?;^%!A[=L[7@-"=UE8NP$-;9)C 6<(F5J 4&EY]KU7[+.*U!;
MDJ8TXXIHSR@:\E6A.Y)S\ 1*$BJD59/$.BB]7 QX\Q HO^&4QNK<&8_K[M5&
M0.'SBPE1M[8B?'0&M_,'09UJC#EYO$*BW/&)!5,4(MW9/-?:.$XOD]N#N5O,
MF()6==E(?\)XXXN,U51&$S+VQ-@DGW!Q;N/ _34AO:JM0UY,+;B@@F&G/>>&
M2@2T]*NA"ZA2%?IR@Y:1&P[Y_$9RL&/N5B>PVJT:=84]/%9E^93M!E!P66*<
M&L96+FS^@9$WR:.> _PX3JU,LZ\@0*S>+N1E(6349Y!6*88*O0%YWTX\;K %
M?VQ]9V<_T;ED\A/L?"0#S$F8)+^8^EH,]QH+@KQ?X13HE* R)K1(O2BYT %;
M;_3X,$?ARR"K" /%AB1GB?HJ\6+5 9?6^RZHK<#CH8DXX:F1-!:2 0)VPJ3?
M7$7ZB*X5Y"*OT13U>>G:V8T$!.(J)'@7_.9 W9-.03K8B,?N8-&64!DT=>#0
MD%EG^B_'GA:S55CGA&NM#@"EJ X(%CL#Q7LZ]IK,X]5PC+>6@IA2I-[6ZL@[
M<$HCQT-%1#J@37(HL>J\U(+6_9;;/+6!- "*8CZTU)J&)'WID2OV+#ZW$-JV
M15+-?*1F2.YDFP)F[FR_3)YO6$;^OOJE 4?/&LVY.<Z]:9 >#9;&>J(E8T.Y
MOKU?X)#5#:*&2<]4LH[Y_P;[JS;<F>PUUYVF^K+H1R%PP+?'J#=?FM5K\NP:
MO^CU[TTI(+I4^4$#:T-CC33W[R93RLW]7B3FNQ2W=%E2=:*FJFVBJ80N>C[0
M!]MI*A-@J827E" X15JZ9BO!]FL28^5   X*^?5%U\%HO]?0Y<'>+_W]07MM
M9SH1"VTU&)J,*:Y)/I:96<E?A.#59W2]XQ(MB:KF;R%O:R=^MZFG$^33:EX'
M;UO:; T"E#+L]ZLO;*1<8O,>&2S;H9Z.IV&Z0#QMT@[ZE2IE(PG!;1?&VJ'Y
M/*2F,Q*'CL^(ID+E^ID:,09#ZQ-8I6(+37J,BW/-52W<L[U"=%=F_S:'\"XW
MG.Z2.?I_G):+U 6.IJ2IUU=CB1*S"B7BR!5:6;9TJ?0VJ6]T+:5VO;]58%VN
M"I5\Q3#)W0$=WLRJ!B]:45^+PI[.V%EC4WK,P&5LAESUB+W0KYDG!K$_TQQ6
MA_'?)#<!%=?C%E]=&MQ-%XPPD5NJ+:[?[X"E2VOXB&5"3NE4:S9J%>@E#,4Z
M7\!W2%)!GO% )_2V".;JX"N4Z1=;KH:(>QKX'1;<=13KJ>?<JRVXBV%J10,#
MU]+0_0+OQQ)Y3][@3 ^VY(LR_.)U&B)?U:R:YW1>7: 9-P[+JFP(95JNR:R
MOZMIB^)DX14_3PB"W1<5KB:OEXK5JQ AW),I0>!3#++HLES4];]8C^1;*7*?
M2!W5SGO)Z0A++RHL3C#Q3K8O5F1!1^5G,VC[%ZJZ.0RI\N@,="&G]6BN3R<0
MW.W(JK;K;HHX+5L53)0.TY/)SSUKMR#EZAB8D:"R=(H]N,.X>7"EO/A4(H*
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MTU"VWL=O]4E>)2PEYJ9&*2'1B@BHZXC46LU'![:YUIN[Z$-LTV/D^#L.<7[
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MT<,>Z(+))"[0#^N:3-#)*B1/<I2K*NJ#7ACJ/_],: J#C.(&HQ)U,>B4%'Q
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M<J-,%[+2Q"EDNQO@@DLD[1);:J3(;G"M32#-AU?P];Y?;I>@)S -*5"<8]N
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MU3ZT-S3RY%^-R\KW[5-F'&-]!N)'Q5=#K1TN+M=3''.4V)KIJ2I6">0\5AF
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M.BK>;!$S3FVZP(;W9V#A"TJPJ'13*3CD!MSWUHK>![]Y7NT%)Q-CLU!+.=+
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M9/A8Z^A/LW3WORL8"&&&SJE+E( N6FBRI5]BXRS3;D_DI$[;-C<U74/#UW9
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M+')=_#B[T=3; 3Y)LP!^)HI66*GZRC:7JEWZOG!EW7ZL^SR&IJRE ^3IU@^
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M_QM<!1@7RLTG$!<0A.,O>C)]XJ" 3=0!;2,P1D8*7#FB VA&@?#4/WCVIK7
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MH@I8-UH#^'S+E^%X/QJK).V:^BK'B'M9*9KE=![-=($335<9X;]1UJ.]'*[
MO87;#]:BK$$1FF<6NJQ3RJJ,BWS:?:^CI%3#)$VJ^?[:%NU;&8\K&0I[2;*N
M=!@]OPI"63,T_:N*;7\O?9*J:]"PV86Z8/W:$*\>[/H"=&PZ9PUJ?NMA$H6N
M'.I,CY.J*6-X.8E4B18NB11H]>0*Y*/GRQU<-C1FRO4D :$#AQP.B!FX(!3Z
MMYK]9F6QHJ/^]0SEC7',G_Z  C=:EV-.C[]O65_=,:?A+#""UQ1LHB%5ZPRV
M\1JM*]A&3S]WN]@>&XM\%8I8*% 1,:@L/G5@*)14AO^NN-._)"SA0]QG.2/\
M?RIT2@G)A:#W85Y5^?2GI^XK:ECF:5VUO[)P$/Z_D\*]V(5^@@[*Y1,U!G_E
M)Y5>JWD9/OXF;/X-SWP@>BZ^;SUW2U6S89KO2%7J6VB:S9BES3B<EA]%NJ@4
M&$%@@Y58)A2X0FJ8UU5H.DUTV@K18F 1?K7F#GZJ*K&DRO#[>QAML";>OA=B
MC/;:(<;];GL^ ^7;BR8Y*%U0!06J9@)IZ%3/)GFF!4*%QAQX">8:L!=510I]
MF!35I!>5^0B=/_ .ZX)LOYDJRUE>5-9 C-A#',-H:4+,?4N5PFOV8"!<7$7?
M_C,?1E34U",C4,!;-&'BWLN$]3#<#0,CYP>#XH2!**WU2$_&YU826("31>ZF
M\$H=8ZHW&\'KPD^SNAA-5(D_7NFRPO_6&?]$[U%7Z(#1#,LP6O,Y5E=YX<QF
MN",<$313(%_J@I+%,+\&^ *2)GB;.R2.@R@=*N\';]KJ>W>E;JMDK;N[4[4;
MI&H'O-]!RQ15,JI!@Y!"ZH4*,@$]!?H5C*F2@U&H$J8Z!A6$$123*",'>3:9
ME_AWW.>H*%!]@X9)"M8:J(1!3X ;#)XVHME(ITK$!)5!K!4XL!@,:U^5JI+0
MB#!@#!4G69W7)1X321[CL$A1H^:EL,S!LV@*5TU@\(QG974S0A5=Z%FJ1N+"
MLT=>RIW=[13>#1]9)I_E5@+CQ#R72V(9U!B7 +U%X-\Y?."%>*(/*0S(QT._
M/3^B/[KJI1QO"_=-E@:?X.%Q#NN/K\J+ELSP!!$U:F[;XX!4":<6KJD:C>C4
MD&-1I3#%,QP2H0-)#W?."-R5@PS+1^0-9-6@PE?+@&Z8XAUOFN)M)UW6J6]V
M'GU7%HP*>S6:9*#DAFR\#G5UK776"N7Y)JU! =M;(GRN @-ICIISG=& 3=ZB
M%YNZ1:UB/3.%&10\8<3*IHBM'62J+^!LOZC!^$_@)+'N"?^]"%YA:R6.0+)[
MDW4%FADAO#'&-@WGEQRLJS,R)=>)7-XL-V03H-RPR?/1J"X*#6Z\L?+%MK7(
MN&B4%*-ZBN[[")Z-V:9F/,;9AY]G% >Y+C"31OB#DG$"'1BMS<U>K@Y]4V!P
M7V04FD%;.[[2B)P8@3-R82WT3%5U 0Y6.<IGE/6#J:SJQ3EG$QCO1:J&N8:I
M%'B&Y*HEPXRQ$7B"'H^QEBR9HG<&YCCFM\&=*4QUV:$=RV%.=3\!GLZL)@6[
M%#^UX8Y$UPHSE+>X/YX-8Y@2+A\$_ZH>PG:@G"7%G8*[CT O4" G)PMFZ5>_
M CQK@W/FJTJ=>*(-N,,BBQ'F=:8:B BN!BQ\H$E+"EDM5)QISDJ1#5[WFV[(
MB%D0\S2=2KU<K,>Z0(O7OY_XUGAY]^<S*5P+T3 LMB!Q)9;C1;&:V\U$L55R
MA(/[)(ARTCOQ(?$AM05373,P;%$X5F49U@$/%:*F*=(<[9%P63!@J.;&A?Y/
M3960L!8@(;CR^U+><VLEA=]SI4+LW8#:PGA4EW]SBY5]O$#LJ]OJ!0KC-S>R
M7?<\JTL#3)EK53CPB8V2<:6XK&'P/<D0F,_L_5U-=' Y1:;:D#=ON"8K0",)
MY4B/=&Q2 ?2QN5%3J';['\1DN91T2P6L<U+-GPQI\\$VQ*S0E0Y5[!YI7=BV
MS >1SPC?W\."BX(!=DW.B-X"%HF>\RR#!_N/VV<Z H[<@H$ 5Q J2LJQ*P>*
MVL$75H O;)B0-B$P,X2()\;[0+&9&?X$L%O1CKU2::TE_8H!^N6GRTX1H"*X
MM1TI&1@Z=3F-H!N>@METUSH=8S&]22OTX,A.< ULG@&7"G8O[&_81O!6.OL3
M;A&WP+NW,!F<,1F>)%:,@A/%"1></?29X\=86G#4$]^+OT?O(5_T<BNHJ,A@
M3I,Q#K*L"W2?>R:'UC,Y&<IH2ZX&H:0V?X0?7"G.^#-<>">P(K&@I/.16NJ]
MD-7*GB2=:9']!N4CX:R8YH7FK.'SEQ$,USG6-]QN=8F\)<K[,2]<0]<T3#V8
MP'Q( " 5X?E>CD'?YYCNL D36AN!W6/YA#?MGNE2EO64CP'Z)BDJ"_;W:5C0
M4$%UA@E-(A*&9W^42IF7WP(EO3HDY9MG2Y(=2-H-1[!%FQ4[WI"\IL ?!I)U
MQ&V'1 &TGYX]/7B.W*CB*C!KP ZH!=OKS]WV\L2(842M8OJU3,UZ<5D4S20K
M$8]'KP!H+(A, 6/M.:PJLA 4F@-MUGCQ\; (Z^RL_]G"^84I\:1-B" 0;D:Q
M2512.0<R"7,6-T/<8D<@/UYQ1;XHK@O^'X+6X&;CKII-S^%@"C=O77D$Z%P,
MI0@MEN(S-',P1T0V$%6)3J?PF%1=X^4)2TCEO0S'0>Y?KZY!BW:3I#[KAP24
M-+>$3I[D*;J!9WCQNCC":(A;3):(QD%LE@=3,KQ9!#U.?GHZ-R%;8F9%C\SF
M;W(?@V@@Y^ US-2< *?-H#*%R^A/AJ>(J44RS@3Q U(U*PE47M9*P.QB[[^
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M>C4T[.2)!)<JY?#&(7MC2?9F)AVF9>/#WM19JHH+'03//4W@ C\@!-4U[L=
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MBH)BOE87VLNX<2RP-/&_+A@0/H/[EV$,D[]V[:W>5%>3/"Z]D@-'0-_&GDJ
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M0.V.+"FZ0IP/A407=I)B)(%AZUY6%.5Z37$Q%;CNW&UIIN8<^^1,G#W@NM$
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MH&3I)5.7DC#!G&^O<*;HGY3YE&"-1/H[QOG&V#ZJ5U2)CU<R\3;_K55*[8K
MR,J0F24E2!>5<R+E<3Y+-:5$^"!R,LL9(/8322GZ;: II8(3B%(YU @B1RTY
ME[]NL>#QT>[S9YE";78Q)SJ=>7,WQ2-&9?(-N,3 T[9Z"G54ET@MRKQT4A_
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M=)!CAUH.P4:-1G6!Q<MSHC.H,3J&/*LF1O871OI4AI5!$6L>1+R;L@U3A69
MML32[E4L$.,K =>8Y2CEWJ@4'\!"0O#:$;:;YB.5V@%I ZWGND-N?'I1"Y?J
MNFD1=4+Y)I_)-3.9J#&QXEM*:PPOVB:[R%4O"&7B;X5[$[/23&>**]([EK3=
M24$E:5WHUGQZ<ZFNR_X&R?/7/'99 +=84PQ <F0.D[*L3<]J4]=FA2W6*7*R
M=7 7-V>= N^R\<5R_]3_N,53W!+>9KMPF"6J?"XP(+E\%ID7;9)?(V<_=<W(
M\@A^SBI.*(=+V5RJMMY>NK)60>\63R:$*:_;3J5,NPTLP]\91,#SETGI,%'2
M):RE/>;J;8K ?1Q\.CJ)!F>#-X\V#G<+=K035X?_C3"R"Z+5Z]YB03-8VV\&
M-UM9#__TZIX]NPT#1"--S& !\;S)"C4XY?TZS;><63Y4,Q1<(7'?KGUX<OK+
MX,/[L^.'_,YWW(3_!Y0NC OEY@.("PC"\6<-CM%V TPV2@5PI+5MKR3(2H0+
M1Y0PS?@L.C7/GKYNK2_]_> U^(&RS*8W@T#UGOWP?.]@?V^\;P/!7N\)T"4_
MUU6-Y_L ]-#>X43-D,'KV:L?>]&SIT^_CX[C_GZTYPU@7:G(!01X/P_6N;8R
M^?M;+MZNI4[I.NIP^SF7KDCS6,@HO%X[BENDF,(3QPSY+L\TM3X<"/J( @8?
M0>[5#&E5A) .[RW')H.L)%I@:OKJ&7;M*G-LSVAOY&\M:HR'XTEM/SW[D"U>
MU0&1=<)$(-\-(L7J"N?0MA#TU!=L09PUT[['SW )78Q;7TT4@M*SA[BQ&E >
MU])'$WRGYS-8]_Q$5>E;3U;9O?S!JCD8EBD"=<3BGCP:[@ID,W-DW]2RK1YR
MO_C*1@D]C]9CIPGR9E9L GYOCG1)2I;HMY??O6$2MN_>@P$0003?3!*__ A#
M)]8\.^S98.S$#]AT[_^>G)Q$1XD P0\P$A>;W_9>@-;/)78'/IZ=X%=/][T9
M_NI6Y:X&8F.-ZO>?SG^-!C^?G1P^5N=V!S*YH0>V9!H(OI:GT7O7L'+G6VQ$
M! ];#%.BJ9PA2-*D4#CY@2=6,_]ALT<C65,_!D&YI)I(#3;8!6B)Y9E[A4WP
M#=:-J?F8@^$;#<8%+/ENFZZ+O)3,T"62&LE'XX)MPW0>].]F3'@+#4;&,N*A
ML;]+9PJ4@_-(25EB^M3G=Z24-]M+U&\T3(AWYL$U/(DY+4&#."I_3HI72U]P
MBY?_063!>P(@8/^\M6J/SM1[U)BGQ]==>GNUQTG6TK?^D9[YS81Y(X?E>:/+
M++].=7SA*J)NSP^X ;2 Y%IO"NW/?<$&;D_[<_"T__R'+^<%_(IT9YVKAZ1-
M#WS-AQNSYCNJIT=#]?25=\_&F%=!9((L"ZJ%D2-(P9$VFYN)9$(H=R0UJ:&"
M\VQECJCHD5 EK3NF1+XCX\%L#P1ND$"$ Z!LBD2E)7/*Q&0/4..#J;JDRB?;
M'08)%-@/RJ.9*L"D3&:(8FF40%D =%9AB6RG2U.IS]:G12L%E1F6Z0;-/SP(
M3>=-9I0_AR,1[^;1/'!'@@LB.LCML-R(?4#3@XK@?QB<G&[$P'<Q^+LZ9@-G
MS9MF'$=).4+J#1!E.*-.%<(Y&BT5.2-YFD>_,]M^V&UZ8XF4EB[4&RK! .T=
M)&(;S@^&QNA("52.QWOE*YW 4_*(4L+#2KZQ^3147W \^X$JQ'3468( BT)1
M^QMX_:I.JKPN)4@)<XDQ+$P^8-6I2".#GD#:&/+8&4_T@,+4STW:2I@N6)9#
MT@P&L<7-:)E@]#%*2BYJ7J3;WBO!GKAX?",M0E)Y7=JDW4=(*,*E$0P6(!H5
M;"E3"Z(,%QFV4LRQ8K;@8#48U68Q%:"PLGP*=I&TJ'&ER,-$@!C>.BX*?M+C
MX-^+'#?V4)7)-H>.#U&!24*@H=LZ=RWO-0SCF-TGJ[I\-;VO9E[YQCKGW2_)
M0]%<T(%JK:OCE^./L%^GHE/&T%YUL8+M22[  MUNWA),9A^4_A,%3LP(N@C;
MGRB"9W%3J*J'N1PT!DSB8%872 501GO,JD;53UAE0R'%D><=[8<\D=2E"S2S
MJLH<K]_BG7B28>0S81?RIHT(RE64HT6[#35CLYK^[!#.+=.[QFW2,MRE:(](
MUUSA3V:3KIK42^.]U!@''.;4&$LR0LD<&KGC%K/-$>"($^HGS?E![SMC _$S
MPS-OJ"LK=. BEJ)\&,5FTUI9C06M,+2KO*O'\N,PI,BB=#QD F1T>M<'@UM,
MGSLRK3>-V+^%K*X]FNE:.D09%>ZHMUO,@B-8%*IVIKB(IZ!,S 56;ZS)7#"I
M9RKL2@-RV%:#OHBSRC@8-:6Z/M1C<-4T0[<\,+FYH@\^]S@?MUBOG"_<O/9D
M=D1WJI36E'@@2,R#S"VWNW5+:TCY8XOIEV,<QGU*X!@:B;_CLW'*%B;1NMM>
MW6$Z-T-5[3+>JQ'QT@EVB"V:=QGO!TZ>)8!%6DQ3*&7-$(5-SL=$,0X_EFRZ
M@%7>5)0]T91\0H]=&!LN\L4F*4.[?*R2PE( $Z@^Z>N^'52LRUD2YTQ2@LE-
M;1&#'"OY"'X!,7*Z\I0';BS=5RNI1Z&!=IB;3=) 9I>ZVAVW/**&N"Z[9_2*
MITX:^U==]\AT8U>*BK915Y')C7^3/XG>,5\#S5%@ZSHID;+M=QNQ[H J$*F.
M8] E<2TA;?3L2%FY/%U@46+ E4+=5[IA#[;39<OBY]3YVY;^9?;M)IH"NE[%
MGPU\;!:*_# '7S?YQ]^?O7C^.HM.U2BAU&"LT^B=+D8*%#4X[[\K&-]Z236C
M/2,@GL+P@+=3> ^,\N[W3"QO'L'@<6WP= )?KJXH4.6Q"A#+@(6$/&C,YVUS
MHG\<'QW?(2FZ.2]\Q]/F#]B&R-5#A%'@BZO/3\XT5]&>5'JZWH(>4GCC/$WS
M:Q%-*4MDVZVL9S,)2)C0R*M6:.2.@,1O_:Y_2)2%DC1&]RJ_YMD/$MOHO D/
MSSE*P(&<AF['NEA8]W),_7,2CCG;-7>U6^3O^ *0H "T;.+%4]V,0!HNO#(8
M.PS'#,!&C2K7[H>(FDQ-;AA?71;^]UZR)</+#'=O1@F39;J'KS*Q>)9CCLI.
M8?!N5)?;&LOF6^ZWUIPGY_]]?/9V<'JTA>IS,=?1>A6G*S7Q<8U9D-1QIJ#M
M(2%;CK;46JW^=<[>7K+OF4@-8@IE"!$HSHV6,!;+/'\9@8HL]7_ZMB@>U%D9
M_0P.?0'F(Y*J@'KXV1)2?$0ZBM%]69 /89(WLH84%NCC1A#)]**]!,10<#!L
MHZ=S1-5P.R<=TV9V!Z?P/<AUKG8##VPXDOX"A26 2E  6RMU#/6,/$(+[%IE
MSO,VR @6 58!SWGR9XT[B_FQ)!4GMH<5=&"9$J?-ULZL8=AQ[#NL ;ENB" \
M>3SO5)_1RP.<>MI[!G9@ODP%B'FQO1)K78!>Y# ;W@%C3Q3F]P/#U3$=.<JD
M#=6V)Z?O-D+;/CJC_/S3Z<GC;0*T:\T;I+\>0&O>!R1WM]YI9[\=__LAO_"7
M>[Z;XO5N;Y[J$R6:SNOBTB::@DC50E)OY:CQNSI?@,^ F@%OK.=;/+_GDZ!!
MA_"<( DZ%G1:<#4^[=]Y<2E5MB8;TXNN)\EH@JN /3L(C2V]&3#D3I/;\Z8=
MK&+L[%#.I\,\-0G(P9LWO]L48Q9PZXN76#+E/G<JH,"/875R/3RW2$$YT_@$
MZQNFFL.YCJQLIZLV$>A(P7B$I:+?4DCHG&"+"&[EPN DLVUOO'3\GNY?]%GQ
MA1Q&^P:SS(CYN!YQFVS;TP,[]6 %J968Q)>81$*!:%6!4:"STED\O'F;).O1
MFQR!S@S7-T\NB'#!M: PVKKSNSOYN"67'>F[PG7E\B??$&,QW9&K]PTYL?"F
MX[H@X]LO'W9P"#+.O7P9V<ST6(H.;Y/9^^FWL\')Z5<GUM]!A#?]5-WYUYOH
M7S]T;7)Z<GY\1!USHN-W)V>#\^./#UF9[ESJQV&&M*MHV]7KW)6/W&GD:S^V
M)>N$NRPLG#.SA Q<TH6ZRF:>T&ZIT-(4FJ;2]D/+J 9K4*@AW#H!F=%E@ .U
MOJ!37_S0BKF@T*JQ64.NXY'Q(CPE'.T4]H6IX/,[IO68##)-V-,=SGN^'B5K
M:HL%Q7!H(7268RAY82OO//>$$);:-TK1$1%(5GZ=17&-M F@H;"\TX04W VV
M>(I/QF$X*\XU![1<H:4]L<E!##DZVGMD.8%NV,?5>87,@%285A6\&YM]=!!Y
MF\?\NTO <4<4Y\1P\PQ'K$A0O"*ZPOF9&U_#,6$EQ&*4B>EAH=--#I+MDPR?
M4O==DJ&B([#D,7%0,+TN?G94#U6")%^JJ QX\%AX*N#/5SK-9_1WPO29?/ZR
MHB*^-2'YRTK/"('(R\=EE)X'B?!)Q';"0'62,1Y[L4"08K9+OU5.)9N!OYV<
M_G+T_MU#?O$=L=5=;> /[!$)%GV])19K7J< $F[QQ2O#KU';(!3'<0^T<D(^
MKSBXJRVP,FLJOL\(-"(<A(9#:QXQ K\+X\P<!\A:/W%TC"TOEO%58S!YR##*
MJOW5D=?,K_@K*/YWZD^X^=Q6)YTAK4"-+2J>OWH='<)&S^$]#/[EUW=GA[:Z
M<B^(!Q"5H,/;!^PG8-I?H?MO/]_O1V&_*I66>7/&<\M\P(#]2ZUGC@Q!ATQ(
M>,%=9T-=*(Q1TXC;:VA6?DZ.@>T]+ZN8NW( 8W*V*KZ&>J+2,?5NQO*NF4IB
M"X6C>RS_'CP)Y_W+YOO1G@;-^)5$B33Q7O6B9-S:M4IZ,"/^L\">7L)N"@Y&
M,H+IVU/</T]<R*E6F53WV-C5\[U+V[X+6VYWUI -F ;BX,?G+WA',[WP/NL9
MC$U90SN94K*DPD"]';P78K/<8-+K[<2G .E433>])//-$=D22A+Z3I+DAH5#
M3QPM=VR%@&T24&!%^3B^G;F9I!^?1K&"/4417IF2W_ITV[E6F R0_"UB16G$
M%\D5OE^!43H)%C9)3F)=CL#G-C0]43Z""1:.'D>-PJPM;L3X3,SF!A5ZPN;4
MJH?)[;B$CX@25W9*<(:XX)S^7M:&Y2FSP0";.H9=C"=!HPG?#2PDV'!BRFMN
MHIW-) WGO-B?B?$IQK5I+%TNF13O3<Q;^_W&28VX$$RIT_$3A13TI2$R2:;<
M$I(?GDR',.EF5WGGSLJJ=8_= 6F0L6\9FJY46NN0WTOKFZ=[^;L:G,"7UB5)
M,2^(7=%N!Q))CK7"J4)UJUGN!;4K&QJ51HLV9K'I\7C5\XXL97DGN+0NA<7J
M,%7)=(O-]74'JQ<SORUT 4AM2\E^D]_+9P-$E1FKJ;J@P'29C^%45-)YU/^:
MPA.12,!0!=%O2_H1(0>95 +0&(ADT!#$,I$8<L#R_>.@-JUG:SCA.K(K7'?8
M!J58M+>$IP64&F9WX36023X7;D:_L&:?@M_V)=*\I/>+P2?+:L. 8$\#.\ M
MEL5/AD"VW>R\%785!IX83Y'8"L*U2C#ZEL#1<Y7CP3N7=KRAN#WH0^>6H;'?
M3X[/3P=?/2:VPUML@I6QPUL\$+S%5YWR5[<K/EL)Z_&M/]LL/?(=EAC"?R;5
M-/W7_P]02P,$%     @ 76:F5)O%$D\'<P  F9(# !<   !A8F)V+3(P,C(P
M,S,Q>&5X,3 V+FAT;>V]ZW;;1K8N^O\\!7;WV+VD/6C&DAW'B7OW&+2D)#JQ
M96]93G:O/V<4B:*(& 38N$AFGO[,6]T D*)DRZ1$]EC+L4D0*%3-FC4OW_SF
M/__'\;NCBW^_/XDFU32-WG]\_>;T*/K;D^^^^^/9T7??'5\<1[]>O'T3/>\_
M/8@N"I65297DF4J_^^[D[&_1WR95-?OIN^^NKZ_[U\_Z>7'YW<7Y=WBKY]^E
M>5[J?ES%?_O7/_$3^%.K^%__SS__QY,GT7$^JJ<ZJZ)1H56EXZ@ND^PR^B/6
MY:?HR1.YZBB?S8OD<E)%AT\/#Z,_\N)3<J7X^RJI4OTO<Y]_?L?__N=W])!_
M#O-X_J]_QLE5E,3_^V_)L^_C'^(7SUZ,7_[X_7/]\H=A/'[Z]/F+@Q<_QB\/
MQ^.7_]^S9S#*[^!Z_E%9S5/]O_\V3;(G$XT#^.F'PUGUZCJ)J\E/!T^?_L^_
M!==5^G/U1*7)9?83#1>^'>?P<O+U*$_SXJ>_/Z7_O<)OGHS5-$GG/_W7$?QJ
M6"3_U2MA:I^4NDC&?$&9_*7A2?!0^N>UC )^GR:9-J,Z./@>AG+R>9(,DRHZ
M>-I_\<_O\'KS+JTW\D8Z@FG3Q>I#O4BFNHS.]'5TGD]5MFC(!RL->?#Z]>^G
M)]'IV5$_'/$&CO7\Y,/%^>G1Q<EQ].'BW=%OT<>STXMH\,OYR<G;D[.+UOAY
ME""#Q;]6>;<_Z[)*QO-7]%&2Q?"J/SW[H?]\=@LQNN/[/F^^[R&^[[LLJB9)
M&9G!?]TQ'-XTYS2&?_S]Q=-7],<OYX.SB^AX<'$2[;U]=W;Q:W1\W(O^#?_;
MA^\/7]$?]S/4U:8KVJLF.OK'WU\>'CZ]IX'8.:,[_I14(#FC%8;V"RCL*CH&
M!;O.":*I.7BUWXL&P^'OB8Y.LU%_@V?M*)_.5#;?A"F+)KK0PWETB0M91E6^
M(9ORY]/S#Q?1V>#MR8;LP<V8EC>#S9J5S=UC)]-9FL_U1NBE2$7GNJR*9(2&
MZ(<J'WV*/F9@3PVN51%O\"32^#9B!O/QANS BW<7@S?1AU\'8+1%9#J<'&_(
M9BR<C)4D8S7(6+G!XH5[H-P(\2KT#&8/#&/T$7&^V"F$X[#0(YU<Z4AED?Y/
MK=(HJZ=#7:! ?I@H^%&49["_RYD>)>,$IOY8IW!],2>K:"7?8^/L\PN8 %9-
M8*2398#^,PRLH+EY7^3PX12FA"XHZ^&?>D23A=_.BOPJ*<&%+W&.O.M[P8_A
M,IRSJB[#SU4,/G$"@JPJG/:B3C5<H68S$"DU3'4DQE,TR^&3A+Z$<> MP(&;
MEO2O49[%%$: T>DJ&N=%-8D2\3H&EX76Z-+WOXU&6;!;[TF?K;;"IQG-F+["
M" DL$TYHDL&TE3#U.AO-(S7-92LT%]2?PMY=E]RLV?)E7WKSJ)RH-,6UKHH\
M_3H[[<M\ZA?KV+$'A[)C.\5?IHQW,ZBK2)6P'=(TOR[_\??O7[[Z"N^Z?,YF
M*HY!J3Y)]9A_]>J&.S\Y>'F;:1P4B4KOO!5I\@[N21'<'/PY_)^O@OFA-S_6
M8]@*M'QK4A$T*^O2CO3PM6E'WDU\DH%0HGK,\BJ*<4W@$$1O.<EZT4C-R,KY
M"S[C?<?*:*) >>%O2S75T52K# T*V'-)YJNNQ<HJ$ <*"7_=[7+/%IVZ;ZFY
MU7C"S?4CSI,]N>Y9OFXY;X$NWH2I^V81CV_Z\%7-7S!Q%CCL+=MQ4W?P725Q
MN,D[N/_#]SA51ZHN];?8,C=8\#0.T?RHZTG%LW4%8^ZAWH\U'@]T=@SG]+WQ
M7^!$0.^\S,&GB9-R5&@\\I<;9<%L'#Q]N8)P'3[O/WMVGR?$TCE*OI%I=;/L
M\":;@D^.!F,T++0:3<R:F&"A,9>7F=+F6HP='/SPJHPT?<#>$/A0:1W3X@]K
M-AW29)J@%JGRK[BLZW$U:$GW!OO1BM-XE,?T]]>8>]=E"1]D<3VJ0,A__)I"
M?C=GY.#Y\\Y;?_-Y_?$Y3NOKE:>U)8'V GL\17GAR27[R&J$ DJ^_FT68/DL
M/=SY/MJ':9E.DQ)C"UU3#?H<I@S_-BY4'?=@0H?ZK[]2.\'P@W&%>ARF-],C
MU!+1=5)-NA<IKJL$HX6%\05&>5V4BQ?5+=]NM?ZU=[P?71=Y=CFN4SHMT[RL
M"]VU;*7&HQ3#1B-0.3SCL$#C!%4%;JXD&^<%;#5<+JNH^$R&2^D_8SJ:/]3#
M,HD35<"ZT1K ]UN^#"?[T5@E:=?45SE&@LM*T2RG\VBF"YQHNLH(_XVR'NWE
M< 7N+=Q^L!9E#8K0/+/099U2C'Y<Y-/N>QTGI1HF:5+-]]>U: NL_C6M69+L
MF]B\1#1F:))6%=ND7F@]5=>@Y;)+=<DZKK'$/=AY!>BY=,Y:S/RKAP%VNG*H
M,SU.JN8ZX^6TK"5:2+2LH%F3*UBCGK_V<-G0F K7DP06'APQ4-(S,(TI+&RU
MZ\T;]LL<M*\6VMP$O^[I#R &H_Y"<VQ-)CH-:YU>' U@;9%&>OJ%DV6KP!8M
M$_F3"C9*#!N7]1\,A;8V_'<G[^',QGU,P*HMEZ\C750*5"YH_!)!U8'QHX8Y
M^*B!HI[HM!6H,*DZJUWQ:U6)XB[#&^RA@V%/E'W/(X[VVA[Q?O<1GH&4]Z))
M#M(-(E?@'J!!Z%3/)GFF)0>/9P<8!N8:.)[ ?\*=,TR*:M*+RGR$]AX8A'5!
M1\U,E>4L+RI['D5L%(YAM#0CYKZE2N$U>S 0QJ+3K__,AQ%AP'MTYDCVGV9,
M+'J9L1Y&?6!@9.]@;(BR;Z4]K.C)^-Q*? G8PG(WA5?J&!,,V0A>%_ZV<#OZ
MN/%9SK#YGPJ=4@9U(9)\F%=5/OWIJ?N)&I9Y6E?MGRS4"?Z?D\*IATO]!#W7
M3T_4&!S9GU1ZK>;EWVX%>+_AF1NCC9;NNEE=C":JQ-6[TF6%_ZTS_AN)7EVA
MF4R;0B2GM07&ZBHOG&$%=X3U(N&&T:E+RBK!EC!I<QBG9.N_2H;I\1T'>G/"
MVGPL;$S^B8;CG*8M/S 'K+3AJ"BJ9%3#,4"G2B\\Y1(X;."4!%U7<A !]?I4
MQW".H.=K@O[D5,TF\Q(_QYV/VAX/83@FDH)5/YZDH.S!=0+O#-$Q=#"*IXOJ
M(=8*G!X,8K2O2E5)Z"88,(;XDJS.ZQ(/^R2/<5ATVN+Q2>[TP6$TA:LF,'A&
MM;$"&N$Y6^A9JD;B]K$75\J=W>T4W@T?62:?Y58""]M+]KW N0&=,!C_#0*)
M+N +SS6/WJ<P(!^9^.;BF#YT6/X<;POW398&#>#A<0[KCZ_*BY;,T P0Q6IN
MV^- 0@FF!ZZI&HWHZ"<E.M$JA2F>X9 (;42:N7-&X*[LF"X?D3>0G2/:V&'C
M?D>\>LNUSH6O7%P0GVK2-)J7L->';(D/=76M==:*@OCFN;'8[2T1@%*!Y3!'
M!;).%W*M::U;"NIEO[W#SPU.F(SL>Y3:U>0FNNA20ZF^A$/FL@97(@&59IT=
M_KP(7F&GG<(9G?3O&_=RRP']DL/9>TZ&QF:9C)L%6;I7);[B$;+N$R0?C>JB
MT-E(&Y-4##$+28E&23&JI^A]CN#9&$YOAH"<,?-Y1I&7ZP)3!93D+)LG]:TJ
MDC<R12*8A@1KM$H8",6"T"Z,KS1F9\&/SRZM-9FIJB[ &2A'^8RR&C"35;TX
MKV5B++U(U3#5,).2 I9\F&2QT+.')^CQ&.LHDBEZ$F Z8@X-3._"9&^.[%B.
M<L*\!W@3LY@475/\U(;I'%TKS,#<XOYX?(QA2KC@!7R!>@A;D7(R%.@*[CX"
M+45AB)S,C*4__0H0D(>;ES-")TY3(Z.ZR*J#:9VI1M*5"V$*/Y?=$D)6"A4G
MTK)21(.7_:8;,E -I#Q-IU(J$NNQ+M J]>\G;B!>WOW]3&HVPH0[2RT(7(F5
M*.!IS^U>HE@N^6S!?1($4NB=]*#TD-*"F:X9>K(HE*BR#.O6A@JQBA38CO9(
MMBS<*%1RXT+_IZ8:(%@*$!!<^'W!L-]:1>'O'!Z>'1!06A@YZ7)!;K&P7\TD
MW;1UO;JM5J"D07,;VV7/L[HT6?>Y5H7+K-MP#A<VRA(&OY-\A/G.WM\5 P:7
M4PBEC:GQAFL"VC224(ST2,<FBDU?FQLU96HG)'O+9:1;)F"5DVK^9$@[#_8@
M9J"N=*A>]TCCPI[E N)\1M#7'F*<"\;O-(N,>PO*CGO.[PP>[#]NGVMG.< (
MM@%<08 /J4*L6G@/9U@AFC$Q-BP.869*4,'\07/H2J6UEK0AQB27JZF=2.U=
MW=H:D9 S*6^.F^J&N6F6[UJG8RP^-''4'FC^!%? !E9QH4 .0%+ 8H:WTMF?
M<(NXA3*[Q<GC3))0(UDA"C23$RW08?2=*S!>BNKNB0'/OZ/WD!]ZP604>3*[
MTF2,@RSK EVPGDD:]$P0FI)Z$IQ&O)4-F.,75XKSU(QKVR6&5T@,/][=*ML5
MUC4?J:4. %E^[(O1T1#97U#V"53N-"\TYXB>?1_!<)UK>L/M5M^.M\1B/E:K
M_2II>GT-<PGF+Q\29D=%>$J68SCI<@SJV[0 +8U@8Q'C[,VZ9P"493WE Y!^
M24K:(G+]&GX\[E&58_:*F!+AV1\$SO[]BO'A+UJO=20%[AIBO*^"ILT(,=YR
M,@1KLL./KC7L*VGV@:3U<,=C\2IMY<.G!\^0#4]L?:YDO1$B=,.&1)6ZN9F?
MN^[L/^^[5/&6X[E@" FJX=T&6]OK#R@T2<8ZGM1>L<)8X)P" MIS0%>LY"TT
MA\VL&>6C:1$3VEFKL(7S"U/B2;H44R/,B2*-J+1R#DL2UBENQJO%I$&>I^**
M @*X+OA_"):"FXV[:KP\OX^IB+QUY1&@CS>4@IE8"F70XL)\#YEC5%4VG<)C
M4G6-ER<L(97W,AS8N'\]NP;SMILF[[ ?TI_1W!*T>9*GZ(V?X\5KI7S;8M(O
M-!9BLSR47\&](LASBI:D<Q. )6H^= UM+B;WH6\&K@[^RTS-">?8#!&3JT\?
M&2H-KJ+/.*O##TC5K"1T<UDK <*+Y_$<ME^:7T=[5 FM-I/ ,!#V32 RW&+I
M?N^''X*%N2W1V0.P;9>>J7MJ?[V'>J '@O.TDF8,6,G&204Y&%3)2X>1U"4:
MB4]KCVLKS]*YH)\Q)8"IJ!9U)]\/:S"H%,B=YJHL=55V& B=U=]?0Q0V4*96
M6]*]85BK%2ZK*RB&:;_**^T?$EWKR-% 6,OMGM31@@*XE@C3D2GS>9VPA=S@
M754QO@R9L!YE)H?]&90SU<4EU6 7.B\N59;\I22]1YM*H/'$"=KB3;UM8=$W
M6K&-LXN[SZ8/X5(AP$(\1-(^&(]/N?J^2VT/U>C399'#/GHB Q[3_U[)OY[1
M_^[Q8&?2F AF%O-2L<OLQLC8F@QK"\W1(Q A"4*MTQB8J21&4W.9<>LS39A7
M8W">]U:E4(K4!KL7GA5L$1M<2UG6\.[-C#0=)CP..'>NDJ*J+4"3$^;E+$VJ
M'OJ30W$=>_*-/^6@"PSKI&3/-U)88$I2[:==>;8+K-7-0J6%60AFP#=,F920
M\GXK\T8%$#S7?+?KO,9"940O9&#GD4D!O@@>1[2JUTEIUP-ET2^Y1*='ZBGM
M>C:J<<GI\:;>EXA]0CUB>F:8YY\P60N375FMC&^)Z1M$-PG6Q4/EQ-B.*J;,
M,8F)BF8@?E4^=8\S.3G4$5<J]48D]LVB@?$O>6;(-AIBG8C9"52=E5==!.;T
M.Y%A>T./\=LN$\%)X=K6'28JYJ<MF'(*L? 4QS?-;S\:E"0"O-)8-ML:B3!#
M-Z:N=),KSPA6B&4+*9 K?ICOMAI!@_'3Q\U-[/FLM-(T+*['">:LZ07O&5 =
MYMV"ZK&;5O,:3&):/'RZLY0-@Q0-B#48W5MP=@/'HXTWU!IY[&9@$,P*3--Z
MP*T "HY<6)D 1<&@ML -F@^)?7K3U,'#0_28."OPZ09ZH6M7BP/#9=0\,QMF
M7!.D N-+)20":X +@W) NE)]UJ5/WV,WEK>9EJS$O;]RM!BB<D>#;LN1+3?:
ML_<HY2OV%1BW3WY4N:"BQCJQGK]4-\ME(L(^AD442<-2+HPJQ7LA=F)9:P)S
MN=^*(%MP;BPY$1JFHWL1[S! .X3X.E(Y^QHH..Q2@(!GO#6=S)0W(A\O;S&!
MN(8C\U!76*M;3<7BZ#BBW#A:;[DANF"CY/4L[Y &LZ9L.A5^A#LO;N0Z:R[+
M$M<";^4, ECX'(PL#K9C*1<%RS%=92/I]%WPM GU<S RZ<7)<N\7-G0O'"0L
MNLY&!%^?++/$.$P[46D/Z^>&VX! YC0AX\B:2TW'GJB\;$;CZ8^#7H.)SYW>
M;-*Z-D(V/R,5&,9C;/L+>0<E 3D0QN#VK&<SED.3VAFAAQ&K0@#YOH$*THAB
MG+,)[UGCE,(NEMJ].P'J3K\%^S;+7:#/\H1[U1%F,99KJ-NDES<U:M:=37[6
M#U*'NZSQVK+&ZWQ[9T0V/*5N.]"!5\OH!:FJ'SB3W(\\>Q0#1;#',K'7,/@A
MJ0QP#)#J^3/7Q,5(NHAUP?BW"KN3<W%C+YJ!9KW4+A9*$2?0B'@^$%G.GO'<
MKG0JE;(;F<.^_RVVVCK;7GQ@VR8I'Y*J2!,\<=#R0HO(ANLX1Q'K<@0'$%LN
M2#YL%O[YGMKO17M#81$:[5.MQ\V8Y@>L,:EQT?-^](80%3!/&Z ZM[V/E)?V
ML3KI^UZHEAX/.&'%G*?JSEM\@RW"F'70Y^J2=LB%SWETO]+9/9;MI2OY@Y)$
M+8^%_QYW\GPW,1F]3FP9AM7"\!/9RHPS@^_7.>.4@IDDV(@QRQ">5&(AI0SV
M%VRSRJ#)^V_8N]HB-4!4ZT68;0!6V5/GOK&!T!A4Z&AFD$KOB>2Y\$X@I11W
M(8&,I4649\60E^[N+I:,145[D1J;50HZ$;? ;YN%UU@';&F=I\TQDG>N]XQ9
M>WU2(/PLR58=NQ#E@MI5OS8@YE)S(D1U'81YK[5VR)ZE3B;J<XKCTM]*CICE
M4PZ^E%Y*E+/<M#^1*IR!@G1^R+U2=5TR!TXYDA1#  U8JV[LU@G(Y9 CS4+9
MZ+&,%;LY^+88V:8(LU1"V+H+A:_:"Y8H#L3YD6F4%<&UHS5K%$L)L#-='Z9*
M<RMXHQ+[!ENZ0YX>%2"S.[3\?;_-4+"++Z_EU4\S%])CIL .'D*+T4,037'%
MU.64\&[SOLA9C0 E9#A#,FYF6M>%QKAL80CJ,!M/_;P->&HCX[,?[/N>T 1L
M0ID1!<R98:)G()@,427.=!\SR##'3 BI?!)Y9AUK\C0UFJY:!GMJB,%I^(ET
MVNW\@1 1.6?* D)Z+J,V(C &W"*#>5$R3HOJ&V$>7C#S[CDA6(54+/U0M5I"
M;^$>%G1@0U0=,_]*LM(1T;GA;&UM_MT:=*_!ZO-O>219(=_HE&$\5] JPN5)
M6P8Y':5QQ%!?)AFAN[VV$3YQT%"/D7^H0_$+<)@WXW5.>?'PMX[:N/LT8 L(
MPP#7Q& )6D)5[6;<>W)H-&=O7WI@F$X?KF* >W]CA*?KOC:JB3_W*+Q[VRN?
MJ^QMY!^R2;ZE&]U:SJM&#[98,Z#'TH&4M/E068FRQ@")]A!+!\]@=PO1+.ZB
MJWTSTS<6@^V0NIOAZ+SH1R?,V8MP-.D&^%K%T6"T%3P,W;.RWOTXL,4MU+2H
MT%=)7I=PF!FWW\8!0E2QPWGZ)V"3XYW[]S+EKS39Y=(7Y%6%,ZU&>DTZO23[
M(, S&VV #0<:=09G&L88X+G8;QLY;8)^V53OJTUB+M;87 3[9%U/-!V2\ 6^
M73BTSV@2:.H]H (K@NP1+)VZ(0GH,[<\2A@'"<@/_>AG!VZ".2=IV8+=NHFG
M9S,^<:-%W""&\FQ&IC<(*JM#U-)POPNOM,ZY[WFE>$UD^Z+<)OGLE-_D@&-@
MIW62/3G-9KI8$ ETK OA*6U4U34**Q>T9^I'T6GHRZB&0D(0M(RG[1-X"X=+
MR@8_ZD/FYH3-*4UC<QSNE19B";MLO>!N4S6G  3%>5'#.JV*W5[QWBV>'&S,
MA\*$"2@?TK#@V*"&@#,9Y)V2Q8MDD]+0V"^88\C-(P?+/UE]Z]CI;\/T@RO?
M7_L>5J.1GC$30B/@X,IS1Y^R_)IPG5(4FS3V?N#X-DXZN!;M2ZS*=!7]0_@2
MDX;[O6Z!M?AOBCS)XZ2"@ZON>W[]$"XL_7,!/9G0D(GC#=,6*U?(:UD&HKW-
MBG#J_GU5C*XF'3TVE+3/ F<C5TSKIX,^F!(GOL3>"!E&,Z\,/(9Z @F1AESO
MDUO9)=@7_U44DE$2'K$-%XG LTL<F6>"!<4"UQBP"0PI"L4\7M/H93_ZPZN!
MO< :V)UAM)ZP0E#)Y"B A'??Q<E1Y="1%)RO#>6+&07FNV95]K'_H<^J-7M"
M?Q]K- ?2'G$P@J/!>\D517IUT%P8721E4*%^20@[TYO6Z?^T"S%MZ^?,\>@.
M3G]#-TI.A_-[@?-N#OCAFX%W%R H\;2C5N<*<S@34QRWG)_KP<_Z-P.Q+>B)
MJ:Y,^;/EO1$=;/:$W62&4H1:P,GF8=/4;.Y&$JW!:/!05_(6A%]6ABV9!A5\
MDYT.;D\F)K<-?[#-C^6++8Z(&UHJ//CIBM>+J%OGII.]@W+"!YSG\*D1E1G'
MCG[GBG7BSRHIHK>J^ 1NW.^<6$?NE\\$A( ?AHV^F$: MRIM0YT^BFK2Q;BM
M!78V>V'DVI<$"4%WBAMV_L7*R^J[IJ*39>IDP%UB*&"4IUI@/^'# ^/):T#4
MT>6S762^[SJ$L.@$+;Z:-!*</6V,O<>NNUP"+K_00X%RTB65+8BO:N+$[2XF
MUIBCU!+6E*-9U@MKY-FA=2= /@1)85;"+2XT.!UW'K9<40#3Z'@(FN+H2E$[
M3N!P@9N!,.2*$E"4)880.B^*'M5I!W58-T=KHU WS/J&O)+^KM@\W?-ERWB6
M5[ATE@5-@G#Z,J=68LTH6L@%97.P+R@J+-=*63)F[WH-&8'EL5JJ+LWSIAKT
M1;RH4C9Z2<4K%->K,\)9$72._2':M?[NE)LEA+("Y02G2C+J]/?(?YJ0WN >
MHWAJ24MEX6.C=M384YJ:C7*;M28\R^696&/[@8^$(VVDA$B?\>BZZFG,7+X4
M[C0O@^UBT'6YLIW:I:5V%%>/*W'^8S\ZR[E? 4H%PDZPUV$L^Q7UU1;$G38Q
M?7[1Z%[6X-MRC1Q5 >HIF2F_.[+9]G'.N$3+)BX1]20#&0=3FSEM'FHTYZ:)
M_/&Y!'.8.C+S(]^&2IUS\BFKN4DR6ZDH][&Z[SQA0Z+)',-94\_RL-NV1^GF
M=T8U"22ZJJL3#9/E=4[CX_3L>29'^[S38"X]^BS3Z_1F0GXR+4WFMGO[>R(M
MG,*57^__@*>TJ91I2@^>PH&E#&"$JLG7HZ1I-&MRWNC9ZSJ=Z.'M3+--.XAS
MM#CE;'MU<O;YL1X^T@E5[0<',M(_E$C F903.'NOP'C-*MCKB ]OY(T2XL=V
M*5$)1V0L_13&L7S6TSPF/KU>I+@_(GJGY8RSYNA-+X1_>$KCL9YJLA+4VL.1
M?",V+X>+",-O6"X)!VARXB/JXD+3XS=>L9&E5ON*<4U+0UNA]/:";?\-RY<F
MNO:^LC<S O+:NY8#$GC/'H$ST)=NDEK2PS0"4V;4<R:U,:N9*A]LQFC%)87S
ME?WED8"^F]@M61%B[>9E<8 3L:B3HK/"JN=1W<?--O&+($Z/?+KC?=P7$PEI
M"/U_*[Z%6PNM'M(]:"7R-B(*X%05ESH(V7K[RH4;8-JK:RT\QGY+R= $>M23
MK1N=B&!6_=/"<_M@.4*W[Y'/S'C?2QC:UHLMBGE+@[A%W&,\0<D^IEL*1?6=
M9#94V""!<%@2$7 H^4;:A.EW/R4,Q'?]1OTO"LKMNFC[4OHJ0Z.+C3*2F+V8
M<I3/%I<S=7CI1FM_HPYEZVC5ONK:)OL"V',:UM0X$G$R+"4NI+"^Y&%:[+::
M8=%K/^"]8280%>A"$<SR8LJF'A9SC-# :F872Y7BUC(P>,E5>4E,L/OJBE'B
MF,6DI4(,=#JJI5D9Y6A-WV5,&2(%JS1&\AKLXC=QG<5P%5@>8&U,D[)$B!@(
MP)-\_$3VJ$$)P9Z;Y&F"/81GB,8>YEE=XDY,<U@3<S%5=<.'1EXH#&8:.E/!
MIT['N&^-\=H+0)_R* ,4SW)!#Y<3:LP#DSJ7OD6$;V>,?#"%,'$]%WSC,XQ2
M/-C[&"8*S=>PW?$M@DJ/]_"[W/?< J$5"+O6+&IQ6V?HA'.MTTAEIJ<A]A(:
MV4Y-(ZZ=JV[0M ]^&B?[@D/RRB]"S"2(]"A5R;2C=T53%<1J2K5H'&)'1*8.
M.P:U6@D%"/M&)<TU'--ECFIAOV7S1DE1Z*L<<W5X/3),Z+)E);?"B!8HP<TS
MZ+5L.RP:+X=BI0.>=U6"6Z]F5*M:W.AFE\[;#+D>Y36?:B2BA+CYLX;UC1F7
MX#JSX)IGS(30P[7%DX=ROB#L2.==Y%DRXGQVHZ+$\8P$@FD3S *P\ 75//5:
M$0"PV^@+MQB!BK0GB2R@CU<A)4VG!O]E@T&.O,_V^0GJ9BC)5\-F0J@"+9MA
M<<?)5)D#2.'^%F^1\ =$1<0M4V%%U2?]!&N\*&9H[H"%/HDD+6[N:/O@5^)/
ML ]U(E5Q3K%FBTT.)_PX3ZFV1N'(\CD$![47(A?H&6BJE$!XE''CBK:I5XG)
M8B$V4.=O%.-=$&52H6UJ>V\:-C4#IESVA%[SG,(;C--Z9(H O8L1EXDE"F5T
MG*=@$_[C[\]_>,75"MQA;T3&,4QM9OL,1,52JM:'(SK=O/0'!WVL+U2P29,K
M-5H7AU7(1_^ 9WEQ=<9[#W/JH9>8^A3;3>(JS(J\$D@48K5XP[E&@SV\ '&>
MIG6GK_"ZH1;F]K3(<!@ZG&C#/[$_\9D+W?XQP?X[@3JV&#%ZT357L<X214PY
MI((PHT)Q0*^B>L5%#]>7;&,F%4'#!Y%^" "4Y#W:*':1]&Z)S-,')1MM6#=<
MV%9AW>5RK7+AK8G3'AB;SP_I^UGR'H-&38C%Y,O;XDP$)RO+=,##SJR0-UMT
M#YOO>-6U0/8G4PQ1\FP5&G9W0HO@LKP](I^%V9:Y+S21#07S3HP#< ?*$SI_
MRF5[$9#6:[7H3F CD%%&T4-S=$@E(/5ORM2EB>O<ZLSP:RLXU #;$GQN'<@*
M;5PC)X(LL!O8G' WGFA&"U.@W]FD%E7<I&9HO<A0@SD]IJ,]&A;Y)W9'#$\%
M-I; 5Y7VS41QWBJQI3GG&G**+71:PF'AR@IL7P^)(/AAU%S:@W:H':5IDUR0
M<ABD\1#7PN<*G![C.NV9,)L1"IMQZDH<.TXE#GYQGJD,'[:'?K4]I?;9O1;]
M:O>UW0R.ND#V\?UNXRVV*X[%HC?G'*T+QBLBP^]9Y/7EQ->V.-=85^]]--4P
MA)#Z-LTODQ&?LG3[N*9<,I7RI'-N#YHJK_FGJTH*^MH:G\"*JJWZ(C0MMK2L
MP$Y%VY'@V!J\9/R'1UFH_+JA5GT<C['0E[6@E8UPM$2("D^XF!]S2C$6GNQ$
MQXI./I.(O]=A5!=X),.BX6:=)G^9[2DU0M:*HO Z+>78]/(F7Y,82NC\].Z.
MZ;,Z:SN)WEBL,)4HO6LC5]Z 5;HP>\BL"0:>A>7?H]QM.MAY<:FRY"\Q1C*#
MHT15;!JAL E#VI=NV;*[\+Y6:4O*M6'FX+K;E>URX\W:WDV?/[X@S6@_NOBJ
M9[ U5(V!VK&O.L[@Q<M)QW 0 [VE2?U5[0PT@L9UP49N\*H4P)^'1@ZU:RVK
M)E^%C/!.+[\S,4!>2^T[?6*88E";V\Z3B8%UZ3AAUWGQF(D$$.WIQ]N8VL^#
MBV/[8%V,,-GMQ<<$=V2-^5;<YX88+1M4./.&DJRRU 4W5:KMLM";AUIC64KV
MHWQ(<1*RA8NI:"(;TM*?T44".]6H(U1]WP:MMLG3AA%"_.U<XGX(^JL0-I5<
M2LQ)(1.>&LV_9-X>0? .)@K-/.JB/>'ZULM"CK]Z%A.5&I7&,'0!B9P->F<(
M^OT3]LHE((XCMVQX7_NM&=X%31.DRI\Q[A$G#]FQ4\$Q+<^W-? %UH%F]9]P
M 8ZS\ @GV A$WFSEV'S0,L/]7HWV0),</'UY9Y6T1C:AD+M0:^+GLD=_Q483
MG_I#KI1"GE%88\\J8%S I(8!84@BKPL$=;(16CQ$&VHUYDHLXOB(> NCF]HE
MOZLZ#,V*2IL0$DN+RML_ZU&-EJJ85@1",(DD+H+?,R@6<C24S]1DKK/ 0#_Z
MWZP:#,/\J[S ?K-:X [WB%I4LG>Y";X;HM0\_0)#$_O$XC:#WC8-[S*,Z7IR
MOI2,@:P?N&N"<&]7#AXL%L7Y;HCK@>'-\*0LO_:H7A@2W ^-=C*_B9JG57@+
M R9(-[HR'MFRX?A:G-UN4?J,59(V9%% I"+W!)]GZ<J+CE9B=@=OR.Y>C3OE
MX) :&!#;^'NU+5PI&\G1.UF1@9YQ;]V[2X#R(8M\2,#JO!6"UGHH.O@9IQ?)
M0Z5V8<P?-4F&20<Y.1N0U+"+"B9$T7:H_ Y-UT43(>J+,K1(AGBE4H, O$1$
M9T:64@"3D51"#OIOF,?SF]2.#'GDAHQ002K;$,HKY&SSN:Y:05%SX#68/2.,
M-20=;5Z'-5*/8X. +1;N00KG3"93<HMN"[>6=<F/8]52ES@2:Y@V-(=RL=^B
M!]-A'*A7$59@$R.!QR=/E?:NDUWGP(+"B( IK=? GPOH]C*YTL&<T Y@( ?#
MM(C=CR"Q^,8@7;7K/;$$?[#_$,W2%0^N9WV&J,+1_AZSI[NC:XU'5XL\Q;B_
M?HGGD%HSU,,4443CL3#FCDT:.=$W6HU;/<=./2!;(TYN60^%B);Q4)<N<D#,
M^QPG@H.4N"3JTL-N)?"$R](9\'RH>RMAU _^?4\()QUE:0,2Z9IEF(S20H%H
M%+A3)T/&#AC'<ME0'K$^>]YWG*'2.7/7+F--U@KRZE@:%<L)O9P>R@8SR#^>
MFV[: 0*F74M2I[J%B7G$0OY]GY28'SX8N.EY8P!"YVXR-F(+/."%6$SIY9\H
M ;&F5>[6\,3Z8*:G]D&H2TC39]()NADKHMIB;S]PHQ@&DU7<U<RI?82KT&E%
M :6])OK7.^UVV=0-K^D-F.2%&=VG:?:_WQ<6JW:4T6G+&1*J^)PN996//CF]
M2@6"#M?8!%P9%#6"<#$$^B A$"N&[]>'CJ;G@RI71<SF(R^5DK*FR0VTH8B+
M;7*A&=H,4".@#K#I(DA2+RKS$99/@6=<"P_)3,W!@$KY:Q/YRC/#:.Z!\=7G
M)P8<RQ1##:CL[<B*43@I@Y@&!W]'5TRI,6]VLNR.C TI-T)!L5F!H0HLRT4:
MLN:-#<5>I4<34_T>UTWNM\['[$FOO'NV^^B.JW<<O(#U.9<5.<7U6:<P2^O
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MC%"2\+F"Z>7!,3;2J?5Z3O\E&[W$[")HO80</7$".-MH_<:3C[WHY&30BS[
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MC2"X&-N$;_$8I=G(2)6.'V64E_"L4/\@M;40KMZ[*EJ4%," ^[6F9A[67*(
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M5TE<JS2\ V*]M=O'7"O/)&8>PGB%6VWQ\E\LC7/XE/ RRR@57/NID>\M)BX
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M%8S9LT"ZK;$6-[S6<A[XW"[V$ BK9-J20HGG16OMR:7M:7!;54)B]9#%XKX
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MWKJU+KGX]>0<RWT^;*%&^4,A$R UO?%R;-SC;HM3%4&ZX!KGJ SZUHM]*T0
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M<R7ZOLI][T^B"8%=3K"*WKJ;V%-& !!6Q/\/6KHDZC:;IFJ*QWN%1;0KZ.C
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ME."L6YD))=H1@JPS7$/N*$.'+5$\L\A3Q;%MK$Y\$S&9&,0./U6?J(;!MM#
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M[I[1*YXZ:>Q?==TCVX5]"2KT1EU%-B=^)A^)WC$_ \U18+\NJ2NR+4<;T?B
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M_IVISJSPCBB.X#)%=(7S,S<6M:/R28A")1/3P\(;FTP&VR<9/D7HVR1#14>
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M^.')= B[PJ@]ST1:^>S;8_=4&E#L6UJ;*Y76.F2MTOKF_;#\70TZXTMK6:0
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MP5[TEKP.*F;/SX9IN#=JS'3-J:FR)(Y_[KFM![-2U@;/4\CO7[V8+6&&79J
M"'Y>9TZEGF?MR(444F4[L?M-+24HR9*+3?9LCERYXL_Z&LT?:*9XZ3=H_B=#
M+ C+?:X]U#WD%[QF'?0DM6"/+RN><_-T)QG'TT$:IK?A?AEH@99EJO=5)>_!
M];WTFS-E>,D+8L,37J^47A$\?2$?+>)D N_#=^$\A'>LL*B];Y+!*'ZTF \U
M'%+9V(3]$4Q\R[#[\1AD":9B\(ZHG-1,!V>7@FW@L#"6DL;Q0V7%MU)S^$4U
M3VHH9%U[96'-3>6T?+,B"H&*#;QEC51.Q\,\_\ 9G-1%"+MVT].=29K&T[E<
M-J3>N*]D^AQ0SDNIEFU(QL$;**5R4AO$*"FPFF(0G!)55#!(^KY $PTE%[A^
MA0$]L%+8,I@&4E,XOBPJ4I\SK.S+)=?:XKT)PP/M4/3]\2=]>"MSS&\X#.&4
MHP0F^O"!%RBF(EPM2=V'E[PF-:[84ZQPI@I.!)PA7%<2_/GSBK.RW>O()98,
MIKJX:*W0A\)5$WQINB@W$JX3UN+:FX)-U;Y5FK0Y<7-WN^=>4=='.D&U1Y/I
M Y?EAE"*C340K#398(SAY.1P]%YMLB"9--^N$7TY6'>3Y]ZMV\\%&JD-U7(E
M,&X+](>PL7,53XI]7G'%;,O7UGJZ#?IDL$M:N1BGR6B7=E_EW3B\BL'6 <G^
M8(BFWY_:"+F?(:W9IMV*\LI-.MO>]-%7K?W#>2W]6Z_Q&LO#TO=>+$6&H "*
MJ\[VG4LQ5=&GC6+:>J]OR40(0#;$A,F(A ;=J?N.J[Q*4A1(W=3I4AAWK81W
MOKQ.[ML)'#YP%BV).L=9T,@F&SG3&Y(+UE%SJ2A3 ;I D$:SK'N94JX;0389
MKYU!'=.TE95+8^32BIM>V&)3$-'B<A ]N1TW1VDX'B1VXC0(TM#NX'88#=TP
M&AFZ3=N?A/OQU\EQF%S1(B?;RT<---KQ16_0NQ.26=I<0G([U&V4WE7"X_]^
M0>J4?+HSW)MJ]]SN&%?.O8>RK4>MOU%7T%)P"AWN?VD)%/*=S?"?5'_TVCUD
MW_]?&>:4;&#L![%MO2)7?+[YO[W', T?@D9<V'XD=F;TN/#-@>,4@1. 834"
MP9;C;A_:<8)"OH&M/PL53G8YP_V-DA?<CKLXUMT<H&UDK3FVL-P.)FW30TEW
M]Y0K57-=>0'WG(IQBN'8Y1!J6<*JP16+E6GS4+WM/FZ^<_G12'_[DRDF,+DN
MV-9UR'4!==TMOF8A.5;1E=EF^8<;E/;I[W/<S=+!7U!+ 0(4 Q0    ( %UF
MIE3+$4U2.%8" .1R'P 1              "  0    !A8F)V+3(P,C(P,S,Q
M+FAT;5!+ 0(4 Q0    ( %UFIE032T]E?!(  -7#   1              "
M 6=6 @!A8F)V+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( %UFIE1:4I7[:R$
M +9) 0 5              "  1)I @!A8F)V+3(P,C(P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    " !=9J94 \$[PQ=H   P?P0 %0              @ &PB@(
M86)B=BTR,#(R,#,S,5]D968N>&UL4$L! A0#%     @ 76:F5"IZ"95X.@
M*3L  !0              ( !^O(" &%B8G8M,C R,C S,S%?9S$N:G!G4$L!
M A0#%     @ 76:F5 7XYDWQ @  [ (  !0              ( !I"T# &%B
M8G8M,C R,C S,S%?9S(N9VEF4$L! A0#%     @ 76:F5(A*TLX;#@$ 4K8*
M !4              ( !QS # &%B8G8M,C R,C S,S%?;&%B+GAM;%!+ 0(4
M Q0    ( %UFIE2[8[T4YY<  'WH!@ 5              "  14_! !A8F)V
M+3(P,C(P,S,Q7W!R92YX;6Q02P$"% ,4    " !=9J94'V/INKZ"  #8!P0
M%P              @ $OUP0 86)B=BTR,#(R,#,S,7AE>#$P,2YH=&U02P$"
M% ,4    " !=9J942Z@7IS-^  "&R0, %P              @ $B6@4 86)B
M=BTR,#(R,#,S,7AE>#$P,BYH=&U02P$"% ,4    " !=9J94MB[91&P?  !J
M^0  %P              @ &*V 4 86)B=BTR,#(R,#,S,7AE>#$P,RYH=&U0
M2P$"% ,4    " !=9J94XE_ND_]Q   T>0, %P              @ $K^ 4
M86)B=BTR,#(R,#,S,7AE>#$P-"YH=&U02P$"% ,4    " !=9J94,8'J6ZQQ
M   <E , %P              @ %?:@8 86)B=BTR,#(R,#,S,7AE>#$P-2YH
M=&U02P$"% ,4    " !=9J94F\423P=S  "9D@, %P              @ %
MW 8 86)B=BTR,#(R,#,S,7AE>#$P-BYH=&U02P$"% ,4    " !=9J94HD0O
M1* '  #)(P  %P              @ %\3P< 86)B=BTR,#(R,#,S,7AE>#,Q
M,2YH=&U02P$"% ,4    " !=9J94:K%0W<@'  "X(P  %P
M@ %15P< 86)B=BTR,#(R,#,S,7AE>#,Q,BYH=&U02P$"% ,4    " !=9J94
MA08G^<H$  "!$@  %P              @ %.7P< 86)B=BTR,#(R,#,S,7AE
M>#,R,2YH=&U02P$"% ,4    " !=9J94X1K!\M($  "T$@  %P
M    @ %-9 < 86)B=BTR,#(R,#,S,7AE>#,R,BYH=&U02P4&     !( $@#
)!   5&D'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
